focis program may 2005

Phot

ogra

ph b

y Pe

ter V

ande

rwar

ker

20052005200520052005ANNUAL MEETINGMay 12-16, 2005 • Westin Copley Place, Boston, MassachusettsFINAL PROGRAM

• Satellite Programs• Exhibit Hall• Poster Hall• Thematic Symposia• Oral Abstract

Session

• Plenary Session• Thematic Symposia• Oral Abstract

Sessions

• Industry Tutorials• Oral Abstract

Session• Speaker Ready

Room

20052005200520052005ANNUAL MEETING

1

May 12-16, 2005 • Westin Copley Place, Boston, MassachusettsFINAL PROGRAM

TT TTTABLE O

F CO

NTEN

TSA

BLE OF C

ON

TENTS

ABLE O

F CO

NTEN

TSA

BLE OF C

ON

TENTS

ABLE O

F CO

NTEN

TS

TTTTTable of Contentsable of Contentsable of Contentsable of Contentsable of ContentsWestin Copley Place ......................................................................... inside coverSupporting Organizations ................................................................................ 2Mission Statement & Strategic Plan .................................................................... 3Member Societies ........................................................................................... 5FOCIS Centers of Excellence ............................................................................ 6Steering Committee ......................................................................................... 7FOCIS Committees and Executive Office Staff ..................................................... 8Faculty ........................................................................................................ 11General Information ...................................................................................... 16CME Information .......................................................................................... 16Program-At-a-Glance .................................................................................... 18Satellite Symposia ........................................................................................ 19Industry Tutorials ........................................................................................... 34Business Meetings ........................................................................................ 38Program Schedule ........................................................................................ 39Exhibitor Information ..................................................................................... 58Travel Award Recipients ................................................................................. 66Abstracts in Order of Presentation ................................................................... 67CME Self-Reporter ...................................................................................... 133

Future MeetingsFuture MeetingsFuture MeetingsFuture MeetingsFuture MeetingsFOCIS 2006FOCIS 2006FOCIS 2006FOCIS 2006FOCIS 2006June 1-5, 2006San FranciscoMarriott

FOCIS 2007FOCIS 2007FOCIS 2007FOCIS 2007FOCIS 2007June 7-11, 2007Sheraton San DiegoHotel & Marina

FOCISFOCISFOCISFOCISFOCIS555 East Wells StreetSuite 1100Milwaukee, WI 53202Phone (414) 918-3192Fax (414) [email protected]


2

Supporting OrganizationsSupporting OrganizationsSupporting OrganizationsSupporting OrganizationsSupporting Organizations

FOCISFOCISFOCISFOCISFOCIS gratefully acknowledges the continued support of its funders. This support allows FOCISto continue to fulfill its mission to foster interdisciplinary approaches to both understand and treatimmune-based diseases, and ultimately, to improve human health through immunology.

Thank you to the 2005 IndustrThank you to the 2005 IndustrThank you to the 2005 IndustrThank you to the 2005 IndustrThank you to the 2005 Industry Liaison Council...y Liaison Council...y Liaison Council...y Liaison Council...y Liaison Council...

Thank you to the FOCIS 2005 Major Supporters...Thank you to the FOCIS 2005 Major Supporters...Thank you to the FOCIS 2005 Major Supporters...Thank you to the FOCIS 2005 Major Supporters...Thank you to the FOCIS 2005 Major Supporters...

Thank you to the FOCIS 2005 Contributing Supporters...Thank you to the FOCIS 2005 Contributing Supporters...Thank you to the FOCIS 2005 Contributing Supporters...Thank you to the FOCIS 2005 Contributing Supporters...Thank you to the FOCIS 2005 Contributing Supporters...

National Institutes of HealthNational Institutes of HealthNational Institutes of HealthNational Institutes of HealthNational Institutes of Health

20052005200520052005ANNUAL MEETING

3


Mission StatementMission StatementMission StatementMission StatementMission Statement

Federation of Clinical Immunology Societies, Inc. (FOCIS) has been created to engender cross-fertilization among the many specialty societies that are included in the broad field of clinicalimmunology. A major role of the Federation is to organize an annual meeting involving clinicianscientists from many different constituent societies, which share an interest in clinical immunology.An additional principal purpose of the Federation is to educate the community, physicians, train-ees, and patients in the broad discipline of clinical immunology as well as to promote anunderstanding of the field of clinical immunology.

FOCIS Annual MeetingFOCIS Annual MeetingFOCIS Annual MeetingFOCIS Annual MeetingFOCIS Annual Meeting

The FOCIS Annual Meeting provides a scientific forum to foster the cross-disciplinary approachrequired to understand and treat immune-based diseases. The evolution of clinical immunology isa reflection of the shared pathophysiology of many diseases including: autoimmune diseases,cancer, allergy/asthma, infectious diseases, immune deficiency, and transplant rejection. Whileclinicians necessarily remain linked to diseases associated with their own specialty, the immuno-logical sciences underlying recent advances in diagnosing and treating these diversediseases are multi-disciplinary and cut across traditional clinical boundaries.The ultimate goal of the FOCIS Annual Meeting is to create a better understanding of the sharedpathophysiological underpinnings of clinical immunology and the new therapeutic approachessuggested by these novel relationships, including the increasingly widespread use of biologics intherapy. In addition to highlighting the best science in the field, the FOCIS Annual Meeting is anincubator for developing scientists and practitioners alike to meet with one another and represen-tatives of the relevant biotech and pharmaceutical industries whose combined support is invalu-able to the success of the field of clinical immunology.


4

2005-2008 Strategic Plan2005-2008 Strategic Plan2005-2008 Strategic Plan2005-2008 Strategic Plan2005-2008 Strategic Plan

Core Purpose:Core Purpose:Core Purpose:Core Purpose:Core Purpose:To improve human health through immunology.

Mission:Mission:Mission:Mission:Mission:To foster interdisciplinary approaches to both understand and treat immune-based diseases.

Core VCore VCore VCore VCore Values:alues:alues:alues:alues:InterdisciplinarInterdisciplinarInterdisciplinarInterdisciplinarInterdisciplinary:y:y:y:y:Believing in the importance of interdisciplinary approaches in education, research, and patientcare; translating new knowledge from basic science into multiple clinical disciplines.

Leadership:Leadership:Leadership:Leadership:Leadership:Embracing active and committed leadership to ensure a successful future.

Collaboration:Collaboration:Collaboration:Collaboration:Collaboration:Strengthening relationships by proactively reaching out to related groups.

TTTTTraining and Education:raining and Education:raining and Education:raining and Education:raining and Education:Supporting basic and clinical scientists to perform the best research, to create new tools andprovide new insights.

GoalsGoalsGoalsGoalsGoals

I.I.I.I.I. Education of Clinical TEducation of Clinical TEducation of Clinical TEducation of Clinical TEducation of Clinical Trainees and Investigatorsrainees and Investigatorsrainees and Investigatorsrainees and Investigatorsrainees and InvestigatorsCreate educational programs that maintain, develop and increase the knowledge, under-standing, skills and professional performance of trainees and investigators in the broad fieldof clinical immunology.

II.II.II.II.II. Education of Basic ScientistsEducation of Basic ScientistsEducation of Basic ScientistsEducation of Basic ScientistsEducation of Basic ScientistsEnable basic scientists to understand the pathogenesis of immunological disease and theprinciples of clinical research.

III.III.III.III.III. FOCIS Centers of Excellence (FCE)FOCIS Centers of Excellence (FCE)FOCIS Centers of Excellence (FCE)FOCIS Centers of Excellence (FCE)FOCIS Centers of Excellence (FCE)Establish a variety of diverse of FCE that are fully functional as interdisciplinary “umbrella”programs that bring a unique approach to research and patient care.

IVIVIVIVIV..... Annual MeetingAnnual MeetingAnnual MeetingAnnual MeetingAnnual MeetingEstablish the FOCIS Annual Meeting as the premier venue for clinical immunology in theworld.

VVVVV..... EndowmentEndowmentEndowmentEndowmentEndowmentEstablish an ample endowment to support the FOCIS infrastructure, Annual Meeting, educa-tional, and research initiatives.

VI.VI.VI.VI.VI. Committee StructureCommittee StructureCommittee StructureCommittee StructureCommittee StructureDevelop and appoint membership to committees designed to support FOCIS mission.

20052005200520052005ANNUAL MEETING

5


Member SocietiesMember SocietiesMember SocietiesMember SocietiesMember Societies

American Academy of Allergy, Asthma, and Immunology (AAAAI)American College of Rheumatology (ACR)American Society for Blood and Marrow Transplantation (ASBMT)American Society for Histocompatibility and Immunogenetics (ASHI)American Society of Transplantation (AST)American Uveitis Society (AUS)America’s Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)Association of Medical Laboratory Immunologists (AMLI)Clinical Immunology Society (CIS)Crohn’s and Colitis Foundation of America (CCFA)Immunology of Diabetes Society (IDS)International Complement Society (ICS)International Cytokine Society (ICS)International Society for Interferon and Cytokine Research (ISICR)International Society for Neuroimmunology (ISNI)International Society for the Biological Therapy of Cancer (ISBTC)Society for Investigative Dermatology (SID)Society for Mucosal Immunology (SMI)

Affiliate SocietiesAffiliate SocietiesAffiliate SocietiesAffiliate SocietiesAffiliate Societies

Australasian Society of Clinical Immunology and Allergy (ASCIA)Clinical Immunology Chapter of the Sociedad Mexicana de InmunologiaCommonwealth of Independent States Society of Allergology and Clinical ImmunologyIsrael Association of Allergy and Clinical ImmunologyThe Italian Society of Allergology and Clinical ImmunologyPan American Group for ImmunodeficiencySection of Clinical Immunology and Allergy of the Royal Society of MedicineThe International Society for NeuroImmunoModulationWorld Allergy Organization (WAO)


6

FOCIS Centers of ExcellenceFOCIS Centers of ExcellenceFOCIS Centers of ExcellenceFOCIS Centers of ExcellenceFOCIS Centers of Excellence

Albert Einstein College of MedicineAlbert Einstein College of MedicineAlbert Einstein College of MedicineAlbert Einstein College of MedicineAlbert Einstein College of MedicineDirector: Chaim Putterman

Baylor College of MedicineBaylor College of MedicineBaylor College of MedicineBaylor College of MedicineBaylor College of MedicineDirector: David P. Huston

Brigham & WBrigham & WBrigham & WBrigham & WBrigham & Women’omen’omen’omen’omen’s Hospitals Hospitals Hospitals Hospitals HospitalDirector: Paul Anderson

Children’Children’Children’Children’Children’s Hospital Bostons Hospital Bostons Hospital Bostons Hospital Bostons Hospital BostonDirector: Raif S. Geha

Cincinnati Children’Cincinnati Children’Cincinnati Children’Cincinnati Children’Cincinnati Children’s Hospitals Hospitals Hospitals Hospitals HospitalDirector: Alexandra H. Filipovich

Cleveland Clinic FoundationCleveland Clinic FoundationCleveland Clinic FoundationCleveland Clinic FoundationCleveland Clinic FoundationDirector: Brian Mandell

Columbia UniversityColumbia UniversityColumbia UniversityColumbia UniversityColumbia UniversityDirector: Betty Diamond

Dartmouth Medical SchoolDartmouth Medical SchoolDartmouth Medical SchoolDartmouth Medical SchoolDartmouth Medical SchoolDirector: Lloyd H. Kasper

Duke University Medical SchoolDuke University Medical SchoolDuke University Medical SchoolDuke University Medical SchoolDuke University Medical SchoolDirector: E. William St. Clair

EmorEmorEmorEmorEmory Clinicy Clinicy Clinicy Clinicy ClinicDirector: Jorg Josef Goronzy

FOCIS Center of SeattleFOCIS Center of SeattleFOCIS Center of SeattleFOCIS Center of SeattleFOCIS Center of SeattleDirector: Keith B. Elkon

Hospital for Special SurgerHospital for Special SurgerHospital for Special SurgerHospital for Special SurgerHospital for Special SurgeryyyyyDirector: Mary K. Crow

Mayo ClinicMayo ClinicMayo ClinicMayo ClinicMayo ClinicDirector: Hirohito Kita

McGill UniversityMcGill UniversityMcGill UniversityMcGill UniversityMcGill UniversityDirector: Emil Skamene

Robarts Research InstituteRobarts Research InstituteRobarts Research InstituteRobarts Research InstituteRobarts Research Institute& W& W& W& W& Westeresteresteresterestern Universityn Universityn Universityn Universityn UniversityDirector: Joaquin Madrenas

RoberRoberRoberRoberRobert Wt Wt Wt Wt Wood Johnsonood Johnsonood Johnsonood Johnsonood Johnson

Medical SchoolMedical SchoolMedical SchoolMedical SchoolMedical SchoolDirector: Alice B. Gottlieb

University of Alabama -University of Alabama -University of Alabama -University of Alabama -University of Alabama -BirminghamBirminghamBirminghamBirminghamBirminghamDirector: Robert P. Kimberly

University of California -University of California -University of California -University of California -University of California -Los AngelesLos AngelesLos AngelesLos AngelesLos AngelesDirector: Bevra Hahn

University of California -University of California -University of California -University of California -University of California -San DiegoSan DiegoSan DiegoSan DiegoSan DiegoDirector: Arthur Kavanaugh

University of ChicagoUniversity of ChicagoUniversity of ChicagoUniversity of ChicagoUniversity of ChicagoDirector: Stephen Hanauer

University of Colorado HealthUniversity of Colorado HealthUniversity of Colorado HealthUniversity of Colorado HealthUniversity of Colorado HealthSciences CenterSciences CenterSciences CenterSciences CenterSciences CenterDirector: George S. Eisenbarth

University of FloridaUniversity of FloridaUniversity of FloridaUniversity of FloridaUniversity of FloridaDirector: John F. Valentine

University of IowaUniversity of IowaUniversity of IowaUniversity of IowaUniversity of IowaDirector: Elizabeth H. Field

University of MiamiUniversity of MiamiUniversity of MiamiUniversity of MiamiUniversity of MiamiDirector: Jay Skyler

University of North CarolinaUniversity of North CarolinaUniversity of North CarolinaUniversity of North CarolinaUniversity of North CarolinaDirector: Dhavalkumar D. Patel

University of PennsylvaniaUniversity of PennsylvaniaUniversity of PennsylvaniaUniversity of PennsylvaniaUniversity of PennsylvaniaMedical SchoolMedical SchoolMedical SchoolMedical SchoolMedical SchoolDirector: Arnold I. Levinson

University of PittsburghUniversity of PittsburghUniversity of PittsburghUniversity of PittsburghUniversity of PittsburghDirector: Scott Plevy

University of Rochester MedicalUniversity of Rochester MedicalUniversity of Rochester MedicalUniversity of Rochester MedicalUniversity of Rochester Medical CenterCenterCenterCenterCenterDirector: Christopher H. Ritchlin

University of California -University of California -University of California -University of California -University of California -San FranciscoSan FranciscoSan FranciscoSan FranciscoSan FranciscoDirector: Jeffrey A. Bluestone

University of Southern CaliforniaUniversity of Southern CaliforniaUniversity of Southern CaliforniaUniversity of Southern CaliforniaUniversity of Southern CaliforniaDirector: Chaim Oscar Jacob

Stanford UniversityStanford UniversityStanford UniversityStanford UniversityStanford UniversityMedical CenterMedical CenterMedical CenterMedical CenterMedical CenterDirector: C. Garrison Fathman

YYYYYale Universityale Universityale Universityale Universityale UniversityDirector: Jordan S. Pober

WWWWWashington Universityashington Universityashington Universityashington Universityashington UniversityDirector: Wayne M. Yokoyama

International FCEGhent University HospitalGhent University HospitalGhent University HospitalGhent University HospitalGhent University HospitalDirector: Eric Veys

Giannina Gaslini InstituteGiannina Gaslini InstituteGiannina Gaslini InstituteGiannina Gaslini InstituteGiannina Gaslini InstituteDirector: Lorenzo Moretta

Institute of Immunology of CentralInstitute of Immunology of CentralInstitute of Immunology of CentralInstitute of Immunology of CentralInstitute of Immunology of CentralUniversity Medical School, VUniversity Medical School, VUniversity Medical School, VUniversity Medical School, VUniversity Medical School, VenezuelaenezuelaenezuelaenezuelaenezuelaDirector: Nicolas E. Bianco

Institute of ImmunologyInstitute of ImmunologyInstitute of ImmunologyInstitute of ImmunologyInstitute of ImmunologyCzech Republic (pending)Czech Republic (pending)Czech Republic (pending)Czech Republic (pending)Czech Republic (pending)Director: Jirina Bartunkova

Oxford Radcliffe HospitalsOxford Radcliffe HospitalsOxford Radcliffe HospitalsOxford Radcliffe HospitalsOxford Radcliffe HospitalsDirector: Helen M. Chapel, MD

Rostov-on-Don StateRostov-on-Don StateRostov-on-Don StateRostov-on-Don StateRostov-on-Don StateMedical UniversityMedical UniversityMedical UniversityMedical UniversityMedical UniversityDirector: Lyudmila P. Siziakina, MD

Shiraz University ofShiraz University ofShiraz University ofShiraz University ofShiraz University ofMedical SciencesMedical SciencesMedical SciencesMedical SciencesMedical SciencesDirector: Sara Kashef

University Hospital of FreiburgUniversity Hospital of FreiburgUniversity Hospital of FreiburgUniversity Hospital of FreiburgUniversity Hospital of FreiburgDirector: Hans-Hartmut Peter

Universite Libre de BruxellsUniversite Libre de BruxellsUniversite Libre de BruxellsUniversite Libre de BruxellsUniversite Libre de BruxellsHopital ErasmeHopital ErasmeHopital ErasmeHopital ErasmeHopital ErasmeDirector: Michael Goldman

20052005200520052005ANNUAL MEETING

7


Steering Committee Steering Committee Steering Committee Steering Committee Steering Committee

Grant J. AnhaltGrant J. AnhaltGrant J. AnhaltGrant J. AnhaltGrant J. AnhaltJohns Hopkins University School of MedicineSociety for Investigative Dermatology (SID)

Jack PJack PJack PJack PJack P. Antel. Antel. Antel. Antel. AntelMontreal Neurology Hospital & InstituteInternational Society for Neuroimmunology (ISNI)& America’s Committee for Treatment andResearch in Multiple Sclerosis (ACTRIMS)

Richard S. BlumbergRichard S. BlumbergRichard S. BlumbergRichard S. BlumbergRichard S. BlumbergBrigham & Women’s HospitalCrohn’s and Colitis Foundationof America (CCFA)

Jeffrey A. BluestoneJeffrey A. BluestoneJeffrey A. BluestoneJeffrey A. BluestoneJeffrey A. BluestoneUniversity of California-San FranciscoTrialNet

MarMarMarMarMary K. Crowy K. Crowy K. Crowy K. Crowy K. CrowHospital for Special SurgeryAmerican College of Rheumatology (ACR)

Charlotte Cunningham-RundlesCharlotte Cunningham-RundlesCharlotte Cunningham-RundlesCharlotte Cunningham-RundlesCharlotte Cunningham-RundlesThe Mount Sinai Medical CenterClinical Immunology Society (CIS)

Mohamed R. DahaMohamed R. DahaMohamed R. DahaMohamed R. DahaMohamed R. DahaLeiden University Medical CenterInternational Complement Society (ICS)

LLLLLynn K. Gordonynn K. Gordonynn K. Gordonynn K. Gordonynn K. GordonJules Stein Eye Institute-UCLAAmerican Uveitis Society (AUS)

Vijay KuchrooVijay KuchrooVijay KuchrooVijay KuchrooVijay KuchrooHarvard Medical SchoolInternational Society for Neuroimmunology (ISNI)

Peter E. LipskyPeter E. LipskyPeter E. LipskyPeter E. LipskyPeter E. LipskyFederal Liaison

Michael TMichael TMichael TMichael TMichael T. Lotze. Lotze. Lotze. Lotze. LotzeUniversity of PittsburghInternational Society for the Biological Therapyof Cancer (ISBTC)

TTTTT. Mohanakumar. Mohanakumar. Mohanakumar. Mohanakumar. MohanakumarWashington University-School of MedicineInternational Cytokine Society (ICS)

William J. MurphyWilliam J. MurphyWilliam J. MurphyWilliam J. MurphyWilliam J. MurphyUniversity of North Virginia Medical SchoolAmerican Society for Blood and Marrow Trans-plantation (ASBMT)

Maurice R.G. O’GormanMaurice R.G. O’GormanMaurice R.G. O’GormanMaurice R.G. O’GormanMaurice R.G. O’GormanThe Children’s Memorial HospitalAssociation of Medical Laboratory Immunologists(AMLI)

Charles G. OroszCharles G. OroszCharles G. OroszCharles G. OroszCharles G. OroszOhio State UniversityAmerican Society for Histocompatibility andImmunogenetics (ASHI)

Lanny J. RosenwasserLanny J. RosenwasserLanny J. RosenwasserLanny J. RosenwasserLanny J. RosenwasserNational Jewish Medical Research CenterAmerican Academy of Allergy, Asthma andImmunology (AAAAI)

Daniel RotrosenDaniel RotrosenDaniel RotrosenDaniel RotrosenDaniel RotrosenNational Institute of Allergy and InfectiousDiseasesFederal Liaison

Kendall A. SmithKendall A. SmithKendall A. SmithKendall A. SmithKendall A. SmithCornell University Medical CollegeInternational Society for Interferon and CytokineResearch (ISICR)

WWWWWarren Stroberarren Stroberarren Stroberarren Stroberarren StroberSociety for Mucosal Immunology

Matthias G. VMatthias G. VMatthias G. VMatthias G. VMatthias G. Von Herrathon Herrathon Herrathon Herrathon HerrathLa Jolla Institute Allergy & ImmunologyImmunology of Diabetes Society (IDS)

Adriana ZeeviAdriana ZeeviAdriana ZeeviAdriana ZeeviAdriana ZeeviUniversity of Pittsburgh Medical CenterAmerican Society of Transplantation (AST)


8

FOCIS Executive CommitteeFOCIS Executive CommitteeFOCIS Executive CommitteeFOCIS Executive CommitteeFOCIS Executive Committee

ChairChairChairChairChairC. Garrison FathmanC. Garrison FathmanC. Garrison FathmanC. Garrison FathmanC. Garrison FathmanStanford University

Vice-ChairVice-ChairVice-ChairVice-ChairVice-ChairDavid A. HaflerDavid A. HaflerDavid A. HaflerDavid A. HaflerDavid A. HaflerHarvard Medical School

SecretarSecretarSecretarSecretarSecretary/Ty/Ty/Ty/Ty/TreasurerreasurerreasurerreasurerreasurerJonathan BraunJonathan BraunJonathan BraunJonathan BraunJonathan BraunUCLA Medical Center

FOCIS Centers of ExcellenceFOCIS Centers of ExcellenceFOCIS Centers of ExcellenceFOCIS Centers of ExcellenceFOCIS Centers of ExcellenceChairChairChairChairChairDavid PDavid PDavid PDavid PDavid P. Huston. Huston. Huston. Huston. HustonBaylor College of Medicine

Education CommitteeEducation CommitteeEducation CommitteeEducation CommitteeEducation CommitteePaul J. Utz, ChairPaul J. Utz, ChairPaul J. Utz, ChairPaul J. Utz, ChairPaul J. Utz, ChairStanford University School of Medicine

Abul K. Abbas, Vice-ChairAbul K. Abbas, Vice-ChairAbul K. Abbas, Vice-ChairAbul K. Abbas, Vice-ChairAbul K. Abbas, Vice-ChairUniversity of California-San Francisco

International CommitteeInternational CommitteeInternational CommitteeInternational CommitteeInternational CommitteeStefan MeuerStefan MeuerStefan MeuerStefan MeuerStefan Meuer, Chair, Chair, Chair, Chair, ChairUniversity of Heidelberg

Research CommitteeResearch CommitteeResearch CommitteeResearch CommitteeResearch CommitteeDhaval Patel, ChairDhaval Patel, ChairDhaval Patel, ChairDhaval Patel, ChairDhaval Patel, ChairUniversity of North Carolina

Bill St. ClairBill St. ClairBill St. ClairBill St. ClairBill St. Clair, V, V, V, V, Vice-Chairice-Chairice-Chairice-Chairice-ChairDuke University Medical Center

Development CommitteeDevelopment CommitteeDevelopment CommitteeDevelopment CommitteeDevelopment CommitteeLanny J. RosenwasserLanny J. RosenwasserLanny J. RosenwasserLanny J. RosenwasserLanny J. Rosenwasser, Chair, Chair, Chair, Chair, ChairNational Jewish Medical Research Center

Emil Skamene, Vice-ChairEmil Skamene, Vice-ChairEmil Skamene, Vice-ChairEmil Skamene, Vice-ChairEmil Skamene, Vice-ChairMcGill University Health Centre

Accreditation CommitteeAccreditation CommitteeAccreditation CommitteeAccreditation CommitteeAccreditation CommitteeGeorge S. Eisenbarth, ChairGeorge S. Eisenbarth, ChairGeorge S. Eisenbarth, ChairGeorge S. Eisenbarth, ChairGeorge S. Eisenbarth, ChairUniversity of Colorado Health Science Center

Communication AdvisorsCommunication AdvisorsCommunication AdvisorsCommunication AdvisorsCommunication AdvisorsLLLLLynn K. Gordonynn K. Gordonynn K. Gordonynn K. Gordonynn K. GordonJules Stein Eye Institute-UCLA

Andrew SaxonAndrew SaxonAndrew SaxonAndrew SaxonAndrew SaxonUCLA School of Medicine

FOCIS Committee ChairsFOCIS Committee ChairsFOCIS Committee ChairsFOCIS Committee ChairsFOCIS Committee Chairs

20052005200520052005ANNUAL MEETING

9


2005 Program Committee2005 Program Committee2005 Program Committee2005 Program Committee2005 Program Committee

ChairsChairsChairsChairsChairsRichard S. BlumbergRichard S. BlumbergRichard S. BlumbergRichard S. BlumbergRichard S. BlumbergBrigham & Women’s Hospital

Vijay KuchrooVijay KuchrooVijay KuchrooVijay KuchrooVijay KuchrooHarvard Medical School

Megan SykesMegan SykesMegan SykesMegan SykesMegan SykesMassachusetts General Hospital

MembersMembersMembersMembersMembersAbul K. AbbasAbul K. AbbasAbul K. AbbasAbul K. AbbasAbul K. AbbasUniversity of California-San Francisco

Jeffrey A. BluestoneJeffrey A. BluestoneJeffrey A. BluestoneJeffrey A. BluestoneJeffrey A. BluestoneUniversity of California-San Francisco

MarMarMarMarMary K. Crowy K. Crowy K. Crowy K. Crowy K. CrowHospital for Special Surgery

Thomas A. FleisherThomas A. FleisherThomas A. FleisherThomas A. FleisherThomas A. FleisherNational Institutes of Health

LLLLLynn K. Gordonynn K. Gordonynn K. Gordonynn K. Gordonynn K. GordonJules Stein Eye Institute-UCLA

Norma Sue Kenyon, PhDNorma Sue Kenyon, PhDNorma Sue Kenyon, PhDNorma Sue Kenyon, PhDNorma Sue Kenyon, PhDUniversity of Miami

Gerald TGerald TGerald TGerald TGerald T. Nepom. Nepom. Nepom. Nepom. NepomVirginia Mason Research CenterBenaroya Research Institute

John D. RiouxJohn D. RiouxJohn D. RiouxJohn D. RiouxJohn D. RiouxWhitehead Institute

Lanny J. RosenwasserLanny J. RosenwasserLanny J. RosenwasserLanny J. RosenwasserLanny J. RosenwasserNational Jewish Medical Research Center

WWWWWarren Stroberarren Stroberarren Stroberarren Stroberarren StroberNational Institutes of Allergy and Infectious Dis-eases/National Institutes of Health

Paul J. UtzPaul J. UtzPaul J. UtzPaul J. UtzPaul J. UtzStanford University

Matthias G. VMatthias G. VMatthias G. VMatthias G. VMatthias G. Von Herrathon Herrathon Herrathon Herrathon HerrathLa Jolla Institute Allergy & Immunology

Adriana ZeeviAdriana ZeeviAdriana ZeeviAdriana ZeeviAdriana ZeeviUniversity of Pittsburgh Medical Center


10

2005 Program Committee2005 Program Committee2005 Program Committee2005 Program Committee2005 Program Committee

Abstract Review CommitteeAbstract Review CommitteeAbstract Review CommitteeAbstract Review CommitteeAbstract Review CommitteeAbul K. AbbasAbul K. AbbasAbul K. AbbasAbul K. AbbasAbul K. AbbasUniversity of California-San Francisco

Deborah AndersonDeborah AndersonDeborah AndersonDeborah AndersonDeborah AndersonBrigham and Women’s Hospital

Jack PJack PJack PJack PJack P. Antel. Antel. Antel. Antel. AntelMontreal Neurology Hospital & Institute

Ken BeamanKen BeamanKen BeamanKen BeamanKen BeamanRosalind Franklin University Medical Center

Jeffrey A. BluestoneJeffrey A. BluestoneJeffrey A. BluestoneJeffrey A. BluestoneJeffrey A. BluestoneUniversity of California-San Francisco

Richard S. BlumbergRichard S. BlumbergRichard S. BlumbergRichard S. BlumbergRichard S. BlumbergBrigham & Women’s Hospital

Jonathan BraunJonathan BraunJonathan BraunJonathan BraunJonathan BraunUCLA Medical Center

Rachel CaspiRachel CaspiRachel CaspiRachel CaspiRachel CaspiNational Institutes of Health

MarMarMarMarMary K. Crowy K. Crowy K. Crowy K. Crowy K. CrowHospital for Special Surgery

Charlotte Cunningham-RundlesCharlotte Cunningham-RundlesCharlotte Cunningham-RundlesCharlotte Cunningham-RundlesCharlotte Cunningham-RundlesThe Mount Sinai Medical Center

Mohamed R. DahaMohamed R. DahaMohamed R. DahaMohamed R. DahaMohamed R. DahaLeiden University Medical Center

Raif S. GehaRaif S. GehaRaif S. GehaRaif S. GehaRaif S. GehaChildren’s Hospital Boston

LLLLLynn K. Gordonynn K. Gordonynn K. Gordonynn K. Gordonynn K. GordonJules Stein Eye Institute-UCLA

David PDavid PDavid PDavid PDavid P. Huston. Huston. Huston. Huston. HustonBaylor College of Medicine

Vijay KuchrooVijay KuchrooVijay KuchrooVijay KuchrooVijay KuchrooHarvard Medical School

Thomas S. KupperThomas S. KupperThomas S. KupperThomas S. KupperThomas S. KupperBrigham and Women’s Hospital

Michael TMichael TMichael TMichael TMichael T. Lotze. Lotze. Lotze. Lotze. LotzeUniversity of Pittsburgh

TTTTT. Mohanakumar. Mohanakumar. Mohanakumar. Mohanakumar. MohanakumarWashington University-School of Medicine

CathrCathrCathrCathrCathryn Nagleryn Nagleryn Nagleryn Nagleryn Nagler-Anderson-Anderson-Anderson-Anderson-AndersonMassachusetts General Hospital

Maurice R.G. O’GormanMaurice R.G. O’GormanMaurice R.G. O’GormanMaurice R.G. O’GormanMaurice R.G. O’GormanThe Children’s Memorial Hospital

TTTTTrevor Owensrevor Owensrevor Owensrevor Owensrevor OwensMcGill University

Jerome RitzJerome RitzJerome RitzJerome RitzJerome RitzHarvard Medical School

Kendall A. SmithKendall A. SmithKendall A. SmithKendall A. SmithKendall A. SmithCornell University Medical College

TTTTTerrerrerrerrerry Stromy Stromy Stromy Stromy StromBeth Israel Deaconess Medical Center

Megan SykesMegan SykesMegan SykesMegan SykesMegan SykesMassachusetts General Hospital

Dale UmetsuDale UmetsuDale UmetsuDale UmetsuDale UmetsuStanford University School of Medicine

Paul J. UtzPaul J. UtzPaul J. UtzPaul J. UtzPaul J. UtzStanford University School of Medicine

Matthias G. VMatthias G. VMatthias G. VMatthias G. VMatthias G. Von Herrathon Herrathon Herrathon Herrathon HerrathLa Jolla Institute Allergy & Immunology

FOCIS Executive Office StaffFOCIS Executive Office StaffFOCIS Executive Office StaffFOCIS Executive Office StaffFOCIS Executive Office StaffGail L. BastGail L. BastGail L. BastGail L. BastGail L. BastExecutive Director

Megan M. KelleyMegan M. KelleyMegan M. KelleyMegan M. KelleyMegan M. KelleyMeetings Manager

Sarah J. KrauseSarah J. KrauseSarah J. KrauseSarah J. KrauseSarah J. KrauseProgram Manager

Jennifer D. WJennifer D. WJennifer D. WJennifer D. WJennifer D. WarpoolarpoolarpoolarpoolarpoolProgram Coordinator

555 East Wells Street, Suite 1100Milwaukee, WI 53202Phone (414) 918-3192Fax (414) [email protected]

20052005200520052005ANNUAL MEETING

11


Abul Abbas, MDAbul Abbas, MDAbul Abbas, MDAbul Abbas, MDAbul Abbas, MDDepartment of Pathology, University of California—San Francisco

Salvatore Albani, MD PhDSalvatore Albani, MD PhDSalvatore Albani, MD PhDSalvatore Albani, MD PhDSalvatore Albani, MD PhDProfessor of Medicine and Pediatrics, University of CaliforniaSan DiegoDisclosure: Scientific Founder, Androclus Therapeutics

Jack Antel, MDJack Antel, MDJack Antel, MDJack Antel, MDJack Antel, MDMcGill University, Montreal

K. Frank Austen, MDK. Frank Austen, MDK. Frank Austen, MDK. Frank Austen, MDK. Frank Austen, MDAstraZeneca Professor of Respiratory and Inflammatory Diseases,Harvard Medical School; Director, Inflammation & Allergic Dis-eases Research Section, Brigham and Women’s Hospital

Jean Francois Bach, MD DScJean Francois Bach, MD DScJean Francois Bach, MD DScJean Francois Bach, MD DScJean Francois Bach, MD DScProfessory of Immunology, Rne Descartes Paris V University; Head,Laboratory Immunology

Tim Behrens, MDTim Behrens, MDTim Behrens, MDTim Behrens, MDTim Behrens, MDProfessor of Medicine, University of Minnesota Medical School

Nina Bhardwaj, MD PhDNina Bhardwaj, MD PhDNina Bhardwaj, MD PhDNina Bhardwaj, MD PhDNina Bhardwaj, MD PhDProfessor of Medicine, Director, Tumor Vaccine Program, NYUCancer Institute

Christine A. Biron, PhDChristine A. Biron, PhDChristine A. Biron, PhDChristine A. Biron, PhDChristine A. Biron, PhDEsther Elizabeth Britzenhoff Professor of Medical Science; Chair-person, Department of Molecular Microbiology & Immunology;Brown University

Jeffrey Bluestone, PhDJeffrey Bluestone, PhDJeffrey Bluestone, PhDJeffrey Bluestone, PhDJeffrey Bluestone, PhDA.W. and Mary Clausen Distinguished Professor of Medicine,Pathology, Microbiology & Immunology; Director, Diabetes CenterDisclosure: Potential financial gain from topics discussed, IP andCo-Founder of XCYTE Therapies.

Richard S. Blumberg, MDRichard S. Blumberg, MDRichard S. Blumberg, MDRichard S. Blumberg, MDRichard S. Blumberg, MDAssociate Professor of Medicine, Brigham and Women’s Hospital

Jonathan Braun, MD PhDJonathan Braun, MD PhDJonathan Braun, MD PhDJonathan Braun, MD PhDJonathan Braun, MD PhDDepartment of Pathology and Lab Medicine, David GeffenSchool of Medicine at UCLADisclosure: Equity in Santarus Corporation (San Diego, CA) andPrometheus Corporation (San Deigo, CA)

2005 Faculty2005 Faculty2005 Faculty2005 Faculty2005 Faculty

Jane BucknerJane BucknerJane BucknerJane BucknerJane Buckner, MD, MD, MD, MD, MDAssistant Member, Benaroya Research Institute; Clinical AssistantProfessor, University of Washington, Department of Medicine

Michael Carroll, PhDMichael Carroll, PhDMichael Carroll, PhDMichael Carroll, PhDMichael Carroll, PhDProfessor of Pediatrics (Pathology), Harvard Medical School

RoberRoberRoberRoberRobert Cart Cart Cart Cart Carterterterterter, MD, MD, MD, MD, MDProfessor of Medicine, Division of Clinical Immunology & Rheu-matology, Department of Medicine, University of Alabama Bir-minghamDisclosure: Paid consultant for Genentech.

Andrew C. Chan, MD PhDAndrew C. Chan, MD PhDAndrew C. Chan, MD PhDAndrew C. Chan, MD PhDAndrew C. Chan, MD PhDVice President, Research Immunology, Genentech, South SanFrancisco, CADisclosure: Employee of Genentech

Lieping Chen, MD PhDLieping Chen, MD PhDLieping Chen, MD PhDLieping Chen, MD PhDLieping Chen, MD PhDJohns Hopkins University School of Medicine

Chris Contag, PhDChris Contag, PhDChris Contag, PhDChris Contag, PhDChris Contag, PhDAssistant Professor, Departments of Pediatrics, Radiology andMicrobiology and Immunology

Cathleen CooperCathleen CooperCathleen CooperCathleen CooperCathleen Cooper, MD, MD, MD, MD, MDScientific Review Administrator, Transplantation, Tolerance, andTumor Immunology Study Section and Referral; Officer, Divisionof Receipt and Referral, Center for Scientific Review

Michael Croft, PhDMichael Croft, PhDMichael Croft, PhDMichael Croft, PhDMichael Croft, PhDLa Jolla Institute for Allergy and Immunology, Division of Mo-lecular Immunology

MarMarMarMarMary K. Crowy K. Crowy K. Crowy K. Crowy K. Crow, MD, MD, MD, MD, MDHospital for Special Surgery

Chella S. David, PhDChella S. David, PhDChella S. David, PhDChella S. David, PhDChella S. David, PhDMayo Clinic College of Medicine

Glen Dranoff, MDGlen Dranoff, MDGlen Dranoff, MDGlen Dranoff, MDGlen Dranoff, MDAssociate Professor of Medicine, Dana-Farber Cancer Institute,Harvard Medical School


12

David Fiorentino, MD PhDDavid Fiorentino, MD PhDDavid Fiorentino, MD PhDDavid Fiorentino, MD PhDDavid Fiorentino, MD PhDAssistant Professor; Director, Cutaneous Autoimmunity Clinic,Stanford University School of Medicine, Department of Derma-tology

Alexander Flugel, MDAlexander Flugel, MDAlexander Flugel, MDAlexander Flugel, MDAlexander Flugel, MDLaboratory for Cellular and Molecular Neuroimmunology, Max-Planck Institute for Neurobiology, Martinried/Munich

Stephen J. Galli, MDStephen J. Galli, MDStephen J. Galli, MDStephen J. Galli, MDStephen J. Galli, MDProfessor of Pathology and of Microbiology and Immunology,Stanford University School of Medicine

Raif Geha, MDRaif Geha, MDRaif Geha, MDRaif Geha, MDRaif Geha, MDJ. Gambles Professor of Pediatrics, Harvard Medical School;Chief, Division of Immunology, Children’s Hospital Boston

Ronald N. Germain, MD PhDRonald N. Germain, MD PhDRonald N. Germain, MD PhDRonald N. Germain, MD PhDRonald N. Germain, MD PhDDeputy Chief, Laboratory of Immunology; Chief, LymphocyteBiology Section, Laboratory of Immunology, National Institute ofAllergy and Infectious Diseases, National Institutes of Health

Joan Goverman, PhDJoan Goverman, PhDJoan Goverman, PhDJoan Goverman, PhDJoan Goverman, PhDDepartment of Immunology, University of Washington, Seattle

David A. HaflerDavid A. HaflerDavid A. HaflerDavid A. HaflerDavid A. Hafler, MD, MD, MD, MD, MDJack, Sadie and David Breakstone Professor of Neurology, De-partment of Neurology, Brigham and Women’s Hospital,Harvard Medical School

MarMarMarMarMartin Hemlertin Hemlertin Hemlertin Hemlertin Hemler, PhD, PhD, PhD, PhD, PhDProfessor, Department of Pathology, Harvard Medical School,and Department of Cancer, Immunology, and AIDS, DanaFarber Cancer Institute

Steve Jacobson, PhDSteve Jacobson, PhDSteve Jacobson, PhDSteve Jacobson, PhDSteve Jacobson, PhDChief, Viral Section, National Institutes of Health

Dan KastnerDan KastnerDan KastnerDan KastnerDan Kastner, MD PhD, MD PhD, MD PhD, MD PhD, MD PhDChief, Genetics and Genomics Branch, National Institute of Ar-thritis and Muscoloskeletal and Skin Diseases

Juha Kere, MD PhDJuha Kere, MD PhDJuha Kere, MD PhDJuha Kere, MD PhDJuha Kere, MD PhDProfessor, Karolinska Institute, Stockholm, SwedenDisclosure: Member of Board of Directors of Geneos Ltd, a com-pany holding patent applications on the use of GPRA, an asthmacandidate gene that is the subject of this speaker’s presenta-tion. Speaker is one of the inventors of these patent applicationsand a minority shareholder of Geneos Ltd.

Samia KhourSamia KhourSamia KhourSamia KhourSamia Khouryyyyy, MD, MD, MD, MD, MDCo-Director, Partners MS Center; Associate Professor of Neurol-ogy, Harvard Medical School

Hirohita Kita, MDHirohita Kita, MDHirohita Kita, MDHirohita Kita, MDHirohita Kita, MDProfessor of Medicine, Mayo Clinic College of Medicine

Lars Klareskog, MD PhDLars Klareskog, MD PhDLars Klareskog, MD PhDLars Klareskog, MD PhDLars Klareskog, MD PhDRheumatology Unit, Department of Medicine, Karolinska Insti-tute, StockholmDisclosure: Served as an expert consultant to several pharmaceu-tical companies, with no financial interest in these companies

Dwight Kono, MDDwight Kono, MDDwight Kono, MDDwight Kono, MDDwight Kono, MDAssociate Professor, The Scripps Research Institute, Departmentof Immunology

Art Krieg, MDArt Krieg, MDArt Krieg, MDArt Krieg, MDArt Krieg, MDChief Scientific Officer, Coley Pharmaceutical GroupDisclosure: Founder and stockholder of Coley PharmaceuticalGroup

Matthew Krummel, PhDMatthew Krummel, PhDMatthew Krummel, PhDMatthew Krummel, PhDMatthew Krummel, PhDAssistant Professor, Department of Pathology, UCSF

Vijay K. Kuchroo, PhD DVMVijay K. Kuchroo, PhD DVMVijay K. Kuchroo, PhD DVMVijay K. Kuchroo, PhD DVMVijay K. Kuchroo, PhD DVMProfessor of Neurology, Brigham and Women’s Hospital, HarvardMedical School

Eric LanderEric LanderEric LanderEric LanderEric Lander, PhD, PhD, PhD, PhD, PhDDirector, Broad Institute of MIT and Harvard Medical School

Antonio Lanzavecchia, MDAntonio Lanzavecchia, MDAntonio Lanzavecchia, MDAntonio Lanzavecchia, MDAntonio Lanzavecchia, MDInstitute for Research in Biomedicine


20052005200520052005ANNUAL MEETING

13


David Lee, MD PhDDavid Lee, MD PhDDavid Lee, MD PhDDavid Lee, MD PhDDavid Lee, MD PhDDivision of Rheumatology, Immunology, and Allergy, Brighamand Women’s Hospital, Harvard Medical School

Andrew Lichtman, MD PhDAndrew Lichtman, MD PhDAndrew Lichtman, MD PhDAndrew Lichtman, MD PhDAndrew Lichtman, MD PhDAssociate Professor of Pathology, Brigham and Women’s Hospi-tal and Harvard Medical School

Peter LipskyPeter LipskyPeter LipskyPeter LipskyPeter Lipsky, MD, MD, MD, MD, MDChief, Autoimmunity Branch, National Institute of Arthritis andMusculoskeletal and Skin Diseases, National Institutes of Health

YYYYYoun-Jun Liu, MD PhDoun-Jun Liu, MD PhDoun-Jun Liu, MD PhDoun-Jun Liu, MD PhDoun-Jun Liu, MD PhDProfessor and Chairman, Department of Immunology; Director,Center for Cancer Immunology Research, M.D. Anderson Can-cer Center

Roy Lobb, PhDRoy Lobb, PhDRoy Lobb, PhDRoy Lobb, PhDRoy Lobb, PhDAdvisor, Abingworth VenturesDisclosure: Consultant to Biogen IDEC on VLA-4

Michael TMichael TMichael TMichael TMichael T. Lotze, MD. Lotze, MD. Lotze, MD. Lotze, MD. Lotze, MDUniversity Pittsburgh Molecular Medicine Institute

Andrew LusterAndrew LusterAndrew LusterAndrew LusterAndrew Luster, MD PhD, MD PhD, MD PhD, MD PhD, MD PhDChief, Division of Rheumatology, Allergy and Immunology, Mas-sachusetts General Hospital

Ann Marshak-Rothstein, PhDAnn Marshak-Rothstein, PhDAnn Marshak-Rothstein, PhDAnn Marshak-Rothstein, PhDAnn Marshak-Rothstein, PhDProfessor of Microbiology, Boston University School of Medicine

Diane Mathis, PhDDiane Mathis, PhDDiane Mathis, PhDDiane Mathis, PhDDiane Mathis, PhDHead, Section on Immunology and Immunogenetics; Joslin Dia-betes Center/ Professor of Medicine; Harvard Medical School

Stephan MeuerStephan MeuerStephan MeuerStephan MeuerStephan MeuerChairman, Department of Immunology, University of Heidelberg

Stephen D. MillerStephen D. MillerStephen D. MillerStephen D. MillerStephen D. Miller, PhD, PhD, PhD, PhD, PhDCong. John E. Porter Professor of Biomedical Sciences, Depart-ment of Microbiology-Immunology, Northwestern University Medi-cal School, Chicago

Branch MoodyBranch MoodyBranch MoodyBranch MoodyBranch Moody, MD, MD, MD, MD, MDDepartment of Medicine, Brigham and Women’s Hospital,Harvard Medical School

Lorenzo Moretta, MDLorenzo Moretta, MDLorenzo Moretta, MDLorenzo Moretta, MDLorenzo Moretta, MDFull Professor of General Pathology and Pathophysiology, Uni-versity of Genova; Scientific Director, Giannina Gaslini Institute,Genova, Italy

GarGarGarGarGary Nabel, MD PhDy Nabel, MD PhDy Nabel, MD PhDy Nabel, MD PhDy Nabel, MD PhDDirector of Vaccine Research Center, National Institutes of Health

Robert Negrin, MDRobert Negrin, MDRobert Negrin, MDRobert Negrin, MDRobert Negrin, MDProfessor of Medicine, Stanford University School of Medicine

Lindsay B. Nicholson, MD PhDLindsay B. Nicholson, MD PhDLindsay B. Nicholson, MD PhDLindsay B. Nicholson, MD PhDLindsay B. Nicholson, MD PhDClinical Sciences, Pathology and Microbiology, University of Bristol

Hans Ochs, MDHans Ochs, MDHans Ochs, MDHans Ochs, MDHans Ochs, MDProfessor of Pediatrics; University of Washington, School ofMedicine; Department of Pediatrics

John O’Shea, MDJohn O’Shea, MDJohn O’Shea, MDJohn O’Shea, MDJohn O’Shea, MDMolecular Immunology and Inflammation Branch, National In-stitutes of HealthDisclosure: CRADA with Pfizer

Drew Pardoll, MD PhDDrew Pardoll, MD PhDDrew Pardoll, MD PhDDrew Pardoll, MD PhDDrew Pardoll, MD PhDSeraph Professor; Co-Director, Cancer Immunology & Hemato-poiesis Program

Virginia Pascual, MDVirginia Pascual, MDVirginia Pascual, MDVirginia Pascual, MDVirginia Pascual, MDAssociate Investigator, Baylor Institute for Immunology Research

Dhaval Patel, MD PhDDhaval Patel, MD PhDDhaval Patel, MD PhDDhaval Patel, MD PhDDhaval Patel, MD PhDDirector, Thurston Arthritis Center; Chief, Rheumatology, Allergyand Immunology; Professor of MedicineUniversity of North Carolina at Chapel Hill

Karl PeggsKarl PeggsKarl PeggsKarl PeggsKarl PeggsSenior Lecturer, Royal Free and University College, London Medi-cal School; Visiting Investigator, MSKCC, NY

J. Theodore Phillips, MD PhDJ. Theodore Phillips, MD PhDJ. Theodore Phillips, MD PhDJ. Theodore Phillips, MD PhDJ. Theodore Phillips, MD PhDClinical Associate Professor, Department of Neurology, Univer-sity of Texas Southwestern Medical Center, Dallas, Texas

Shiv Pillai, MBBS PhDShiv Pillai, MBBS PhDShiv Pillai, MBBS PhDShiv Pillai, MBBS PhDShiv Pillai, MBBS PhDAssociate Professor of Medicine, Massachusetts General Hospi-tal and Harvard Medical School



14

Jeffrey VJeffrey VJeffrey VJeffrey VJeffrey V. Ravetch, MD PhD. Ravetch, MD PhD. Ravetch, MD PhD. Ravetch, MD PhD. Ravetch, MD PhDTheresa and Eugene Lane Professor; Head, Laboratory of Mo-lecular Genetics and Immunology, The Rockefeller University

Paul RidkerPaul RidkerPaul RidkerPaul RidkerPaul Ridker, MD, MD, MD, MD, MDBrigham and Women’s Hospital

John D. Rioux, PhDJohn D. Rioux, PhDJohn D. Rioux, PhDJohn D. Rioux, PhDJohn D. Rioux, PhDDirector, Inflammatory Disease Research, Broad Institute of MITand Harvard; Assistant Professor of Medicine, Harvard Medi-cal School, Brigham and Womens Hospital; Associate ProfessorMedicine, University of Montreal, Montreal Heart Instutite

Jerome Ritz, MDJerome Ritz, MDJerome Ritz, MDJerome Ritz, MDJerome Ritz, MDProfessor of Medicine, Dana-Farber Cancer Institute, HarvardMedical School

William Robinson, MD PhDWilliam Robinson, MD PhDWilliam Robinson, MD PhDWilliam Robinson, MD PhDWilliam Robinson, MD PhDDivision of Immunology and Rheumatology, Stanford UniversitySchool of Medicine, GRECC, Palo Alto VA Health Care System

Kenneth Rock, MDKenneth Rock, MDKenneth Rock, MDKenneth Rock, MDKenneth Rock, MDProfessor and Chair, Department of Pathology, UMass MedicalSchool

DerrDerrDerrDerrDerry Roopenian, PhDy Roopenian, PhDy Roopenian, PhDy Roopenian, PhDy Roopenian, PhDSenior Staff Scientist, The Jackson Laboratory

Alexander RudenskyAlexander RudenskyAlexander RudenskyAlexander RudenskyAlexander Rudensky, PhD, PhD, PhD, PhD, PhDProfessor and Investigator, HHMI/University of Washington

David Sachs, MDDavid Sachs, MDDavid Sachs, MDDavid Sachs, MDDavid Sachs, MDDirector, Transplantation Biology Research Center, Massachu-setts General Hospital; Professor of Surgery (Immunology),Harvard Medical School

Steve Sacks, MD PhDSteve Sacks, MD PhDSteve Sacks, MD PhDSteve Sacks, MD PhDSteve Sacks, MD PhDHead of the Department of Nephrology & Transplantation, Guy’sKings’ & St. Thomas School of Medicine, Kings College London

Shimon Sakaguchi, MD PhDShimon Sakaguchi, MD PhDShimon Sakaguchi, MD PhDShimon Sakaguchi, MD PhDShimon Sakaguchi, MD PhDProfessor, Institute for Frontier Medical Sciences, Kyoto University

Federica SallustoFederica SallustoFederica SallustoFederica SallustoFederica SallustoInstitute for Research in Biomedicine

Jane Salmon, MDJane Salmon, MDJane Salmon, MDJane Salmon, MDJane Salmon, MDProfessor of Medicine, Weill Medical College, Cornell Univer-sity, Attending Physician and Senior Scientist, Hospital for Spe-cial Surgery

Mohamed Sayegh, MDMohamed Sayegh, MDMohamed Sayegh, MDMohamed Sayegh, MDMohamed Sayegh, MDBrigham and Women’s Hospital

Kathy Siminovitch, MD FRCPKathy Siminovitch, MD FRCPKathy Siminovitch, MD FRCPKathy Siminovitch, MD FRCPKathy Siminovitch, MD FRCPProfessor, Department of Medicine, University of Toronto, MountSinai Hospital/University Health Network

Arlene H. Sharpe, MD PhDArlene H. Sharpe, MD PhDArlene H. Sharpe, MD PhDArlene H. Sharpe, MD PhDArlene H. Sharpe, MD PhDHarvard Medical School

Grace ShenGrace ShenGrace ShenGrace ShenGrace ShenDirector, Ocular Immunology Program, Division of ExtramuralResearch, National Eye Institute

Kendall A. Smith, MDKendall A. Smith, MDKendall A. Smith, MDKendall A. Smith, MDKendall A. Smith, MDCornell University Medical College

Jean-Paul Soulillou, PhDJean-Paul Soulillou, PhDJean-Paul Soulillou, PhDJean-Paul Soulillou, PhDJean-Paul Soulillou, PhDNantes UniversityDisclosure: Member of Scientific Board of TcLAND

LarrLarrLarrLarrLarry Steinman, MDy Steinman, MDy Steinman, MDy Steinman, MDy Steinman, MDStanford University School of Medicine

Ralph Steinman, MDRalph Steinman, MDRalph Steinman, MDRalph Steinman, MDRalph Steinman, MDRockefeller University

Megan Sykes, MDMegan Sykes, MDMegan Sykes, MDMegan Sykes, MDMegan Sykes, MDMassachusetts General Hospital, Harvard Medical School

Cox TCox TCox TCox TCox Terhorst, PhDerhorst, PhDerhorst, PhDerhorst, PhDerhorst, PhDChief, Division of Immunology, Beth Israel Deaconess MedicalCenter; Professor of Medicine, Harvard Medical School


20052005200520052005ANNUAL MEETING

15


Angus Thomson, PhD DSc FRCPathAngus Thomson, PhD DSc FRCPathAngus Thomson, PhD DSc FRCPathAngus Thomson, PhD DSc FRCPathAngus Thomson, PhD DSc FRCPathProfessor of Surgery and Immunology, University of Pittsburgh,Director of Transplant Immunology, Starzl Transplant InstituteDisclosure: Member, Scientific Advisory Board, Therakos

John TJohn TJohn TJohn TJohn Todd, PhDodd, PhDodd, PhDodd, PhDodd, PhDProfessor of Medical Genetics, Cambridge Institute for MedicalResearch; Director, JDRF/WT Diabetes and Inflammation Labo-ratory

Shannon J. TShannon J. TShannon J. TShannon J. TShannon J. Turleyurleyurleyurleyurley, PhD, PhD, PhD, PhD, PhDAssistant Professor, Department of Cancer, Immunology andAIDS, Dana Farber Cancer Institute; Assistant Professor, Depart-ment of Pathology, Harvard Medical School

Dale TDale TDale TDale TDale T. Umetsu, MD PhD. Umetsu, MD PhD. Umetsu, MD PhD. Umetsu, MD PhD. Umetsu, MD PhDThe Prince Turki al Saud Professor of Pediatrics, Childrens Hos-pital Boston, Harvard Medical School

Paul J. Utz, MDPaul J. Utz, MDPaul J. Utz, MDPaul J. Utz, MDPaul J. Utz, MDStanford University

Inder VInder VInder VInder VInder Verererererma, MSc PhDma, MSc PhDma, MSc PhDma, MSc PhDma, MSc PhDSalk Institute for Biological Sciences

Matthias von Herrath, MDMatthias von Herrath, MDMatthias von Herrath, MDMatthias von Herrath, MDMatthias von Herrath, MDAssociate Professor with Tenure, Division of Developmental Im-munology, La Jolla Institute for Allergy and Immunology, SanDeigo, CA


Sander J. van DeventerSander J. van DeventerSander J. van DeventerSander J. van DeventerSander J. van Deventer, MD, MD, MD, MD, MDLaboratory of Experimental Internal Medicine

Edward WEdward WEdward WEdward WEdward Wakeland, PhDakeland, PhDakeland, PhDakeland, PhDakeland, PhDDirector, Center for Immunology, University of Texas MedicalCenter

Hanspeter WHanspeter WHanspeter WHanspeter WHanspeter Waldneraldneraldneraldneraldner, PhD, PhD, PhD, PhD, PhDBrigham and Women’s Hospital and Harvard Medical School

Howard WHoward WHoward WHoward WHoward Weinereinereinereinereiner, MD, MD, MD, MD, MDRobert L. Kroc Professor of Neurology, Harvard Medical School

David S. Wilkes, MDDavid S. Wilkes, MDDavid S. Wilkes, MDDavid S. Wilkes, MDDavid S. Wilkes, MDCalvin H. English Professor of Medicine, Microbiology and Im-munology; Director, Center for Immunobiology

David WDavid WDavid WDavid WDavid Wofsyofsyofsyofsyofsy, MD, MD, MD, MD, MDProfessor of Medicine and Microbiology/Immunology, Univer-sity of California, San FranciscoDisclosure: Consultant for Genentech, Aspreva, Bristol-MyersSquibb, Serono

John B. WJohn B. WJohn B. WJohn B. WJohn B. Wong, MD Fong, MD Fong, MD Fong, MD Fong, MD FACDACDACDACDACDProfessor of Medicine; Chief, Division of Clinical Decision Mak-ing, Tufts-New England Medical Center, Tufts University Schoolof MedicineDisclosure: Grants NIH National Library of Medicine; Schering-Ploegh, Honoraria for speaking, Schering-Ploegh, Centocor

KathrKathrKathrKathrKathryn Wyn Wyn Wyn Wyn Wood, PhDood, PhDood, PhDood, PhDood, PhDProfessor of Immunology, University of Oxford

Anette ZieglerAnette ZieglerAnette ZieglerAnette ZieglerAnette Ziegler, MD, MD, MD, MD, MDProfessor of Internal Medicine, Ludwig-Maximilians University,Munich; Senior Physician, Internal Medicine, Schwabing Hos-pital; Director, Immunology and Diabetes Department, Diabe-tes Research Institute


16

General InformationGeneral InformationGeneral InformationGeneral InformationGeneral Information

• Dates:Dates:Dates:Dates:Dates: The meeting begins Thursday, May 12 and adjourns Monday, May 16, 2005.• VVVVVenue:enue:enue:enue:enue: Westin Copley Place

10 Huntington AvenueBoston, Massachusetts 02116www.westin.com

Registration InformationRegistration InformationRegistration InformationRegistration InformationRegistration Information

Name badges will be mailed to pre-registrants prior to the meeting. Final programs andregistration bags will be distributed at the registration desk, located at the Westin Copley Place.Registration will be open during the following hours:

33333rdrdrdrdrd Floor- Essex Foyer: Floor- Essex Foyer: Floor- Essex Foyer: Floor- Essex Foyer: Floor- Essex Foyer:Thursday, May 12 8:00 am-8:00 pm

44444ththththth Floor- America Foyer: Floor- America Foyer: Floor- America Foyer: Floor- America Foyer: Floor- America Foyer:Friday, May 13 7:00 am-5:00 pmSaturday, May 14 7:00 am-5:00 pmSunday, May 15 7:00 am-5:00 pm

CME InformationCME InformationCME InformationCME InformationCME Information

TTTTTarget Audience:arget Audience:arget Audience:arget Audience:arget Audience:The target audience for this meeting is a multi-disciplinary group of individuals with an interest inclinical immunology:• Researchers• Clinical investigators• Clinicians• Postdoctoral fellows• Pre-doctoral students• Graduate students

Learning Objectives:Learning Objectives:Learning Objectives:Learning Objectives:Learning Objectives:At the completion of the meeting, participants should be able to:• Discuss the current research and/or clinical topics relevant to the session topics.• Demonstrate a gained level of insight into the methods being used by researchers and practitioners.• Describe a personal exposure to several stimulating areas of inquiry with faculty and presenters.

Accreditation Statement:Accreditation Statement:Accreditation Statement:Accreditation Statement:Accreditation Statement:The Clinical Immunology Society is accredited by the Accreditation Council for Continuing MedicalEducation (ACCME) to provide continuing medical education for physicians.

Credit Designation:Credit Designation:Credit Designation:Credit Designation:Credit Designation:The Clinical Immunology Society (CIS) designates this educational activity on an hour-for-hourbasis in Category 1 credit toward the Physicians Recognition Award of the American MedicalAssociation. Each physician should only claim those hours of credit he/she actually spends in theeducational activity.


18

7:00 a.m. Industry Tutorials Industry Tutorials

7:30 a.m

8:00 a.m.

8:30 a.m. Planary Session Planary Session Planary Session

9:00 a.m.

9:30 a.m.

10:00 a.m. Break Break Break Break

10:30 a.m Concurrent Thematic Symposia

11:00 a.m.

11:30 a.m.

12:00 p.m.

12:30 p.m. Lunch, Industry Tutorials Lunch, Industry Tutorials Lunch

1:00 p.m.

1:30 p.m.

2:00 p.m.

2:30 p.m.

3:00 p.m. Break Break Break

3:30 p.m. Concurrent Oral Abstract Sessions

4:00 p.m.

4:30 p.m.

5:00 p.m.

5:30 p.m. Poster Session 2 Poster Session 2

6:00 p.m.

6:30 p.m.

7:00 p.m.

7:30 p.m.

8:00 p.m.

8:30 p.m.

9:00 p.m

Program At-a-GlanceProgram At-a-GlanceProgram At-a-GlanceProgram At-a-GlanceProgram At-a-GlanceThursday Friday Saturday Sunday Monday

Concurrent Thematic Symposia(10:30 am - 12:30 pm)

Plenary Session(8:30-10:00 am)

Welcome Reception(7:00 - 9:00 pm)

NIH GrantsInformation Session(12:30 - 2:00 pm)

Concurrent Oral Abstract Sessions(3:30 - 5:30 pm)

MemberSocietySatellitePrograms

Poster Session 1(7:30-8:30 am)

Industry Symposia(1:30 - 3:00 pm)

Poster Session 2(5:30-7:30 pm)

20052005200520052005ANNUAL MEETING

19


Satellite SymposiaSatellite SymposiaSatellite SymposiaSatellite SymposiaSatellite Symposia

ThursdayThursdayThursdayThursdayThursday, May 12, 2005, May 12, 2005, May 12, 2005, May 12, 2005, May 12, 2005American Academy of AllergyAmerican Academy of AllergyAmerican Academy of AllergyAmerican Academy of AllergyAmerican Academy of Allergy, Asthma and Immunology, Asthma and Immunology, Asthma and Immunology, Asthma and Immunology, Asthma and ImmunologyEosinophil Biology in Health and DiseaseEosinophil Biology in Health and DiseaseEosinophil Biology in Health and DiseaseEosinophil Biology in Health and DiseaseEosinophil Biology in Health and Disease1:15-4:30 pm1:15-4:30 pm1:15-4:30 pm1:15-4:30 pm1:15-4:30 pm Essex North-East, 3rd FloorEssex North-East, 3rd FloorEssex North-East, 3rd FloorEssex North-East, 3rd FloorEssex North-East, 3rd FloorModerator: Lanny J. Rosenwasser, MD FAAAAICo-Moderator: Peter F. Weller, MD FAAAAI

1:15-1:20pm IntroductionLanny J. Rosenwasser, MD FAAAAI and Peter F. Weller, MD FAAAAI

1:20-2:00 pm Hypereosinophilic SyndromesPeter F. Weller, MD FAAAAI

2:00-2:40 pm Eosinophils in AsthmaCriag Gerard, MD PhD

2:40-3:10 pm Break

3:10-3:50 pm Eosinophil Biology in Animal ModelsJames J. Lee, PhD

3:50-4:30 pm GI in Eosinophilia: Basic and Clinical MechanismsMarc Rothenberg, MD PhD FAAAAI

American College of RheumatologyAmerican College of RheumatologyAmerican College of RheumatologyAmerican College of RheumatologyAmerican College of RheumatologyRheumatoid Arthritis Scientific Forum:Rheumatoid Arthritis Scientific Forum:Rheumatoid Arthritis Scientific Forum:Rheumatoid Arthritis Scientific Forum:Rheumatoid Arthritis Scientific Forum:A Forum to Identify Opportunities for Advances in Rheumatoid Arthritis ResearchA Forum to Identify Opportunities for Advances in Rheumatoid Arthritis ResearchA Forum to Identify Opportunities for Advances in Rheumatoid Arthritis ResearchA Forum to Identify Opportunities for Advances in Rheumatoid Arthritis ResearchA Forum to Identify Opportunities for Advances in Rheumatoid Arthritis Research8:00 am-5:00 pm8:00 am-5:00 pm8:00 am-5:00 pm8:00 am-5:00 pm8:00 am-5:00 pm Essex NorEssex NorEssex NorEssex NorEssex North-Centerth-Centerth-Centerth-Centerth-Center, 3rd Floor, 3rd Floor, 3rd Floor, 3rd Floor, 3rd Floor

8:00-8:30 am WelcomeIntroduction and Overview of RA Scientific Forum GoalsOpportunities and Challenges in RA ResearchSpeakers:Michael Brenner, MDHarvard Medical School, Boston, MADavid Fox, MDUniversity of Michigan, Ann Arbor, MI

Session ISession ISession ISession ISession IEpidemiology and Genetics: Defining Environmental and Inherited Risk Factors for RAEpidemiology and Genetics: Defining Environmental and Inherited Risk Factors for RAEpidemiology and Genetics: Defining Environmental and Inherited Risk Factors for RAEpidemiology and Genetics: Defining Environmental and Inherited Risk Factors for RAEpidemiology and Genetics: Defining Environmental and Inherited Risk Factors for RA8:30-8:50 am Epidemiology of RA: What Questions Can We Answer

in the Next Decade?Alan J. Silman, MDUniversity of Manchester, Manchester England

8:50-9:10 am Strategies to Define Links Between EnvironmentalTriggers and Autoimmunity in RALars Klareskog, MDKarolinska Hospital, Stockholm Sweden


20


American College of Rheumatology (Session 1 continued...)American College of Rheumatology (Session 1 continued...)American College of Rheumatology (Session 1 continued...)American College of Rheumatology (Session 1 continued...)American College of Rheumatology (Session 1 continued...)9:10-9:30 am Genetics of RA: MHC and Non-MHC Loci

Peter Gregerson, MDBiology I Human Genetics, North Shore Univ. Hospital

9:30-9:50 am Genetic Determinants of Lymphocyte Function in RAShimon Sakaguchi, MDKyoto University, Institute for Frontier Medical Sciences

9:50-10:20 am Panel Discussion, Question and AnswerPeter Gregerson, MDLars Klareskog, MDShimon Sakaguchi, MDAlan Silman, MD

10:20-10:40 am Break

Session IISession IISession IISession IISession IISynovium, Cartilage and Bone in RA: Identifying Molecular Control Points of DiseaseSynovium, Cartilage and Bone in RA: Identifying Molecular Control Points of DiseaseSynovium, Cartilage and Bone in RA: Identifying Molecular Control Points of DiseaseSynovium, Cartilage and Bone in RA: Identifying Molecular Control Points of DiseaseSynovium, Cartilage and Bone in RA: Identifying Molecular Control Points of DiseaseProgression and Novel Therapeutic TProgression and Novel Therapeutic TProgression and Novel Therapeutic TProgression and Novel Therapeutic TProgression and Novel Therapeutic Targetsargetsargetsargetsargets

10:40-11:00 am Synovial Fibroblasts: Instigators or Targets?Gary Firestein, MDUniversity of California – San Diego

11:00-11:20 am Development of the Synovial Lining and its Role in Inflammatory ArthritisMichael Brenner, MD

11:20-11:40 am Synovial Angiogenesis – How Can it Be Reversed?Alisa Koch, MDUniversity of Michgan, Ann Arbor, MI

11:40 am-12:00 pm Events at the Interface of Pannus with Cartilage and BoneSteffen Gay, MDCenter of Experimental Rheumatology, Zurich, Switzerland

12:00-12:20 pm The Response of Cartilage and Bone to Synovitis: How Can Repair ofDamaged Joints be Promoted?Steven Goldring, MDBeth Israel Deconess Medical Center, Boston, MA

12:20-1:00 pm Panel Discussions, Question and AnswerWilliam Arend, MD, University of Colorado, Denver, COGary Firestein, MDSteffen Gay, MDSteven Goldring, MDAlisa Koch, MD

1:00-2:00 pm Lunch on your own

20052005200520052005ANNUAL MEETING

21



American College of Rheumatology (continued...)American College of Rheumatology (continued...)American College of Rheumatology (continued...)American College of Rheumatology (continued...)American College of Rheumatology (continued...)Session IIISession IIISession IIISession IIISession IIIRedefining the Contributions of Innate and Adaptive Immune Mechanisms to RARedefining the Contributions of Innate and Adaptive Immune Mechanisms to RARedefining the Contributions of Innate and Adaptive Immune Mechanisms to RARedefining the Contributions of Innate and Adaptive Immune Mechanisms to RARedefining the Contributions of Innate and Adaptive Immune Mechanisms to RA2:00-2:20 pm Understanding Lymphocyte Function in RA

Cornelia Weyand, MDEmory University, Atlanta, GA

2:20-2:40 pm Autoantibodies and the Joint – Unique Immune andInflammatory MechanismsDiane Mathis, MDHarvard Medical School, Boston, MA

2:40-3:00 pm Cytokine Networks in RA SynoviumIain McInnes, MD, University of Glasgow, Glasgow, United Kingdom

3:00-3:20 pm Reversing the Roles of Innate and Adaptive Immune Components in RADavid Fox, MD

3:20-3:40 pm Panel Discussion, Question and AnswerCornelia Weyand, MDDiane Mathis, MDPeter Lipsky, MD, National Institute of Arthritis Musculoskeletal and SkinDiseasesMichael Holers, MD, University of Colorado, Denver, CO

3:40-4:00 pm Break

Session IVSession IVSession IVSession IVSession IVAchieving and Measuring Remission and Cure of RAAchieving and Measuring Remission and Cure of RAAchieving and Measuring Remission and Cure of RAAchieving and Measuring Remission and Cure of RAAchieving and Measuring Remission and Cure of RA4:00-4:20 pm Developing Better Approaches to Measuring the Clinical Activity of RA

and the Utility of Novel TherapeuticsDavid Felson, MDBoston University School of Medicine, Boston, MA

4:20-4:40 pm Measuring and Mitigating the Total Impact of RA: Medical,Economic and Social AspectsEdward Yelin, MDUniversity of Texas, Houston, TX

4:40-5:00 pm Defining Better Targets and Better Strategies for Treating RAWilliam Arend, MD

5:00-5:25 pm Panel Discussion, Question and AnswerDavid Felson, MDEdward Yelin, MDWilliam Arend, MDJames O’Dell, MD, University of Nebraska, Omaha, NEWilliam St. Clair, MD, Duke University Medical Center, Durham, NC

5:25-5:30 pm Concluding Remarks and AdjournmentMichael Brenner, MDDavid Fox, MD


22


American Uveitis SocietyAmerican Uveitis SocietyAmerican Uveitis SocietyAmerican Uveitis SocietyAmerican Uveitis SocietyBench to Bedside: TBench to Bedside: TBench to Bedside: TBench to Bedside: TBench to Bedside: Translational approaches to ocular Inflammationranslational approaches to ocular Inflammationranslational approaches to ocular Inflammationranslational approaches to ocular Inflammationranslational approaches to ocular Inflammation WWWWWebster/Courierebster/Courierebster/Courierebster/Courierebster/Courier,,,,,An American Uveitis Society Sponsored MeetingAn American Uveitis Society Sponsored MeetingAn American Uveitis Society Sponsored MeetingAn American Uveitis Society Sponsored MeetingAn American Uveitis Society Sponsored Meeting 7th Floor 7th Floor 7th Floor 7th Floor 7th FloorOrganizers: Reza Dana, LOrganizers: Reza Dana, LOrganizers: Reza Dana, LOrganizers: Reza Dana, LOrganizers: Reza Dana, Lynn Gordon, Roberynn Gordon, Roberynn Gordon, Roberynn Gordon, Roberynn Gordon, Robert Nussenblatt for the AUSt Nussenblatt for the AUSt Nussenblatt for the AUSt Nussenblatt for the AUSt Nussenblatt for the AUS

Despite significant research efforts and advances in diagnostic and therapeutic capabilities, ocu-lar inflammatory diseases remain a significant cause of ocular morbidity and legal blindness. Thepurpose of this symposium is to explore some of the major concepts in pathogenesis of ocularinflammatory disease and discuss new approaches to understanding immune regulation as itrelates to the eye. The format is a combined short presentation followed by open discussion.

Specific aspects of the ocular microenvironment will be considered throughout the symposium. Thissymposium is presented in three parts. First, an overview of the current models of ocular inflamma-tory diseases will be presented followed by an active discussion regarding the strengths andweaknesses of these models. Second, aspects of innate and adoptive immunity will be consid-ered as they relate to ocular inflammatory diseases. Finally, concepts relating to immune regula-tion or modulation, including soluble and cellular mediators will be discussed.

The goal of this meeting is to maximize discussion. The presentations by our speakers will set thestage for an active discussion which will be stimulated by questions which will be posed to theaudience. The discussions will have three goals: understanding the current state of the art, identi-fication of important future directions, and development of strategic goals in investigation of ocu-lar inflammatory disease.

1:00-1:05 pm Welcome

1:05- 2:00 pm Animal Models- Anterior and PosteriorRobert Hendricks and Rachel Caspi

2:00-2:20 pm Break

2:20-3:20 pm Innate and Adaptive ImmunityRalph Levinson and Howard Weiner

3:20-3:40 pm Break

3:40-4:40 pm ImmunoregulationAndrew Tayler and Arlene Sharpe

4:40-5:00 pm Wrap Up

20052005200520052005ANNUAL MEETING

23



Clinical Immunology SocietyClinical Immunology SocietyClinical Immunology SocietyClinical Immunology SocietyClinical Immunology SocietyEmerging Lab TEmerging Lab TEmerging Lab TEmerging Lab TEmerging Lab Technologiesechnologiesechnologiesechnologiesechnologies9:00 am-12:30 pm9:00 am-12:30 pm9:00 am-12:30 pm9:00 am-12:30 pm9:00 am-12:30 pm Essex Nor Essex Nor Essex Nor Essex Nor Essex North-Wth-Wth-Wth-Wth-West, 3rd Floorest, 3rd Floorest, 3rd Floorest, 3rd Floorest, 3rd Floor

CME ACME ACME ACME ACME Availablevailablevailablevailablevailable Program OrganizersProgram OrganizersProgram OrganizersProgram OrganizersProgram OrganizersRegistration fee: $15.00 Jonathan Braun, MD PhDOn-Site Registration Available Matthias G. Von Herrath, MD

William Robinson, MD PhD

9:00 am Introduction and OverviewJonathan Braun, UCLA

9:05 am Multibead Array Analysis of HLAs and KIRs in TransplantationElaine Reed, UCLA

Proteomic Analysis of Signal TProteomic Analysis of Signal TProteomic Analysis of Signal TProteomic Analysis of Signal TProteomic Analysis of Signal Transduction Pathways:ransduction Pathways:ransduction Pathways:ransduction Pathways:ransduction Pathways:9:25 am Reverse Phase Protein Array Analysis of Phospho-proteins

Steven Chan, Stanford University

Imaging TImaging TImaging TImaging TImaging Technologies:echnologies:echnologies:echnologies:echnologies:9:45 am PET: Anti-Tumor T Cell Marking

Jonathan Braun, UCLA

Glycomics:Glycomics:Glycomics:Glycomics:Glycomics:10:05 am Mass Spectrometry Identification of Immunostimmulatory Oligosaccharides

Rudolf Grimm, Agilent Technologies

Human Proteome Arrays:Human Proteome Arrays:Human Proteome Arrays:Human Proteome Arrays:Human Proteome Arrays:10:25 am Human Proteome Array Analysis of Autoimmune Disease and Cancer

Paul Predki, Invitrogen

10:45 am Break

TTTTTechnologies to Characterize the Specificity of Immune Responses:echnologies to Characterize the Specificity of Immune Responses:echnologies to Characterize the Specificity of Immune Responses:echnologies to Characterize the Specificity of Immune Responses:echnologies to Characterize the Specificity of Immune Responses:11:00 am Antigen Microarray Analysis of Antibody Responses in Infection and Autoimmunity

William Robinson, Stanford University

11:20 am Peptide:MHC Microarray for Profiling T Cell Specificity and FunctionDaniel Chen, Stanford University

11:40 am Flow Cytometry Analysis of Antigen-Specific T Cell ResponsesAmit Bar-Or, Montreal Neurologic Institute

The Road Ahead:The Road Ahead:The Road Ahead:The Road Ahead:The Road Ahead:12:00 pm Roundtable Discussion: Translating Diagnostic Technologies Into the Clinic:

Promise and PitfallsVicki Seyfert, Immune Tolerance NetworkThomas Fleisher, NIHBruce Sands, Massachusetts General Hospital


24

20052005200520052005ANNUAL MEETING

25



Clinical Immunology SocietyClinical Immunology SocietyClinical Immunology SocietyClinical Immunology SocietyClinical Immunology SocietyPrimarPrimarPrimarPrimarPrimary Immunodeficiency Diseases Consory Immunodeficiency Diseases Consory Immunodeficiency Diseases Consory Immunodeficiency Diseases Consory Immunodeficiency Diseases Consortium Conferencetium Conferencetium Conferencetium Conferencetium Conference8:00 am-5:00 pm (Reception to follow)8:00 am-5:00 pm (Reception to follow)8:00 am-5:00 pm (Reception to follow)8:00 am-5:00 pm (Reception to follow)8:00 am-5:00 pm (Reception to follow) Staffordshire, 3rd Floor Staffordshire, 3rd Floor Staffordshire, 3rd Floor Staffordshire, 3rd Floor Staffordshire, 3rd Floor

CME ACME ACME ACME ACME Availablevailablevailablevailablevailable Program OrganizersProgram OrganizersProgram OrganizersProgram OrganizersProgram OrganizersRegistration Fee $25.00 Charlotte Cunningham-Rundles, MD PhDOn-Site Registration Available Kathleen E. Sullivan, MD PhD

Helen Chapel, MDJordan Orange, MD PhD

This intensive one-day conference will provide an opportunity to capitalize on the diagnosis andtreatment of primary immunodeficiency diseases in a setting that encourages interactive participa-tion amongst presenters and attendees that will facilitate the exchange of information.

The target audience for this conference is a multi-disciplinary group of individuals with an interestin clinical immunology focusing on Primary Immune Deficiency. Themes of the day will include:• Antibody Deficiency Diseases: Cases/ Diagnosis/ Molecular Defects in B Cell Differentiation/

Isotype Switch, Somatic Hypermutation, etc.• Combined Immune Defects: Cases/ Diagnosis/ Molecular Defects/ Signaling Pathways/

Treatment Strategies• Pathways in Innate Immunity: Natural Killer Cells• Monocyte Neutrophil Disorders: Analysis/ Treatment• Cytokine and Signaling Defects: Common Themes, Infections, Toll Receptors and Signaling• Laboratory Evaluation of Primary Immunodeficiency• Immune Reconstitution: Gene Therapy Strategies/ Stem Cell/ Bone Marrow/ Measures of Term

Reconstitution• Use of Standard and Novel Therapies: Cytokines, Immune Modulation, Monoclonal Antibodies

Both research and case-based presentations will be made. The sessions will start with a keynotepresenter, giving details of the latest research work in their respective fields. Following this, asecond block will include the research presentations given by new investigators, fitting into thethemes just introduced. These sessions will be laboratory based but in each case, elucidatingfacets of the Primary Immune Deficiencies. Laboratory Investigations will include data handlingand genetics.


26


Federation of Clinical Immunology SocietiesFederation of Clinical Immunology SocietiesFederation of Clinical Immunology SocietiesFederation of Clinical Immunology SocietiesFederation of Clinical Immunology SocietiesBasic Immunology for Clinicians: Update 2005Basic Immunology for Clinicians: Update 2005Basic Immunology for Clinicians: Update 2005Basic Immunology for Clinicians: Update 2005Basic Immunology for Clinicians: Update 20058:00am-5:00 pm8:00am-5:00 pm8:00am-5:00 pm8:00am-5:00 pm8:00am-5:00 pm Conference Center at Har Conference Center at Har Conference Center at Har Conference Center at Har Conference Center at Harvard Medical School, Rotundavard Medical School, Rotundavard Medical School, Rotundavard Medical School, Rotundavard Medical School, Rotunda

Sponsored by Abbott Laboratories (www.abbott.com)

This one-day course will review fundamental principles of adaptive immunity and immunologicaltolerance, with an emphasis on recent advances. Topics to be discussed include: antigen process-ing and presentation (including dendritic cell biology); T lymphocyte activation and homeostasis(including costimulation and apoptosis); innate immunity (including Toll receptors and the biologyof NK cells); cytokines and helper T Cell subsets; and self-tolerance and its breakdown. Ampletime will be scheduled for discussions and interactive exchanges with the faculty. Outlines oflectures and illustrations will be provided in a course syllabus and on CD-ROM for each student.

FacultyFacultyFacultyFacultyFacultyAbul K. Abbas, MDUniversity of California - San FranciscoSan Francisco, CA

Hidde L. Ploegh, PhDHarvard Medical SchoolBoston, MA

ScheduleScheduleScheduleScheduleScheduleLecture 1: Innate ImmunityLecture 2: Antigen PresentationLecture 3: Activation and Regulation of T LymphocytesLecture 4: Effector Mechanisms of Cell-Mediated ImmunityLecture 5: Lymphocyte DevelopmentLecture 6: Tolerance and Autoimmunity

Shuttles will run from the Westin Copley Place to the ConferenceCenter from 7:00 - 8:00 am, returning at 5:00 pm.

20052005200520052005ANNUAL MEETING

27



Federation of Clinical Immunology SocietiesFederation of Clinical Immunology SocietiesFederation of Clinical Immunology SocietiesFederation of Clinical Immunology SocietiesFederation of Clinical Immunology SocietiesFOCIS Centers of Excellence TFOCIS Centers of Excellence TFOCIS Centers of Excellence TFOCIS Centers of Excellence TFOCIS Centers of Excellence Trainee Satellite Symposiumrainee Satellite Symposiumrainee Satellite Symposiumrainee Satellite Symposiumrainee Satellite Symposium8:00 am- 5:00 pm8:00 am- 5:00 pm8:00 am- 5:00 pm8:00 am- 5:00 pm8:00 am- 5:00 pm Essex Center & Essex South, 3rd Floor Essex Center & Essex South, 3rd Floor Essex Center & Essex South, 3rd Floor Essex Center & Essex South, 3rd Floor Essex Center & Essex South, 3rd Floor

7:00 -8:00 am Continental Breakfast

8:00-8:15 am WelcomeDavid P. Huston, MD, Baylor College of Medicine

8:15-9:00 am The Expanding Scope of Clinical Immunology - Cardiovascular DiseaseKeynote Speaker: Cornelia Weyand, MD, PhD, Emory University

9:05-10:20 am Trainee Abstract Minisymposium

9:05-9:20 am Antibodies to Citrulline-Modified Proteins Enhance Tissue Injury inInflammatory ArthritisKristine Kuhn, University of Colorado

9:20-9:35 am B-Cell and Dendritic Cell Perturbations in the Fingerprinting of SLEMeghavi Kosboth, MD, University of Florida

9:35-9:50 am Presence of Interferon-a in Systemic Lupus Erythematosus Plasma is HighlyCorrelated with Expression of Interferon Target Genes in SLE PBMCJing Hua, MD PhD, Hospital for Special Surgery

9:50-10:05 am Plasma Cell Differentiation of CD27- and CD27+ Human B CellsJennifer Huggins, MD, University of Rochester

10:05-10:20 am Characterization of an Immunodeficient Patient with TLR7, 8, 9 DefectsDouglas McDonald, MD PhD, Children’s Hospital Boston

10:20-10:35 am Break

10:35-11:35 am Plenary Session

10:35-11:05 am FMF and Beyond: Misadventures in the Genomics of InflammationDan Kastner, MD PhD, NIH/NIAMS

11:05-11:35 am New Insights into the Mechanism of Disease and Targets for Treatmentof the Antiphospholipid SyndromeJane Salmon, MD, Hospital for Special Surgery

11:35 am-1:15 pm Lunch & Poster Presentations with Authors Present

1:30-2:30 pm Plenary Session1:30-2:00 pm Genetic Control of Autoimmunity by Aire

Mark Anderson, MD PhD, University of California – San Francisco

2:00-2:30 pm Mast Cells and Inflammatory ArthritisDavid Lee, MD PhD, Brigham & Women’s Hospital

2:35-3:50 pm Trainee Abstract Minisymposium

2:35-2:50 pm Targeting of Antigen-Specific T Cells With Macromolecular ConjugatesTarek Fahmy, PhD, Yale University


28


Federation of Clinical Immunology Societies (continued...)Federation of Clinical Immunology Societies (continued...)Federation of Clinical Immunology Societies (continued...)Federation of Clinical Immunology Societies (continued...)Federation of Clinical Immunology Societies (continued...)2:50-3:05 pm High-Throughput Analysis of Autoantibodies Recognizing Myelin Anti-

gens in Acute Disseminated Encephalomyelitis.Kevin O’Connor, PhD, Brigham & Women’s Hospital

3:05-3:20 pm De Novo Generation of Antigen-Specific CD4+CD25+ Regulatory T Cellsfrom Human CD4+CD25- CellsMindi Walker, PhD, Benaroya Research Institute

3:20-3:35 pm Differential Expression of Phosphorylated NF-kB/RelA in Normal andPsoriatic Epidermis and Downregulation of NF-kB in Response to Treatment with Etanercept.Paul Lizzul, MD, PhD, Robert Wood Johnson

3:35-3:50 pm Binding of the Green Tea Polyphenol, Epigallocatechin Gallate, to theCD4 Receptor on Human CD4+ T Cells Resulting in Inhibition of HIV-1-gp120-BindingChristina Nance, PhD, Baylor College of Medicine

3:50-4:00 pm Break

4:00-4:30 pm Closing Plenary: The Intersection of Science and ArchitecturePeter Vanderwarker

4:30-4:40 pm Closing RemarksDavid Huston

20052005200520052005ANNUAL MEETING

29



International Complement SocietyInternational Complement SocietyInternational Complement SocietyInternational Complement SocietyInternational Complement SocietyComplement in Health and DiseaseComplement in Health and DiseaseComplement in Health and DiseaseComplement in Health and DiseaseComplement in Health and Disease8:00 am-12:00 pm8:00 am-12:00 pm8:00 am-12:00 pm8:00 am-12:00 pm8:00 am-12:00 pm WWWWWebster/Courierebster/Courierebster/Courierebster/Courierebster/Courier, 7th Floor, 7th Floor, 7th Floor, 7th Floor, 7th Floor

Chairs: John Lambris and Moh DahaOrganized by: International Complement Society

Sponsored by Biovista (www.biovista.com)

8:00-8:30 am Novel Elisa-Based Methods for the Diagnostic Assessment of ComplementMohamed R. DahaLeiden University Medical CenterLeiden, The Netherlands

8:30-9:00 am Cleaning the Bloodstream: A Complement-Erythrocyte Dependent ProcessAnne Nicholson – WellerHarvard Medical School and Beth Israel Deaconess Medical CenterBoston, USA

9:00-9:30 am Protective Role of Innate Immunity in Autoimmune DiseaseMarat AlimzhanovCBR Institute for Biomedical Research and Dept. of Pediatrics,Harvard Medical SchoolBoston, USA

9:30-10:00 am Gastrointestinal and/or Myocardial Schemia/Reperfusion Models in MiceGregory L. StahlBrigham and Womens Hospital and Harvard Medical SchoolBoston, USA

10:00-10:30 am Coffee Break

10:30-11:00 am Signaling of Human T Cells Through CD46John AtkinsonWashington University School of MedicineSt. Louis, USA

11:00-11:30 am From Atoms to Systems: a Multidisciplinary Approach toStudy Complement FunctionsJohn LambrisUniversity of PennsylvaniaPhiladelphia, USA

11:30 am-12:00 pmExtended Discussion


30


International Society for Neuroimmunology - Immunology of Diabetes SocietyInternational Society for Neuroimmunology - Immunology of Diabetes SocietyInternational Society for Neuroimmunology - Immunology of Diabetes SocietyInternational Society for Neuroimmunology - Immunology of Diabetes SocietyInternational Society for Neuroimmunology - Immunology of Diabetes SocietyEarly Clinical TEarly Clinical TEarly Clinical TEarly Clinical TEarly Clinical Trials in Multiple Sclerosis and Trials in Multiple Sclerosis and Trials in Multiple Sclerosis and Trials in Multiple Sclerosis and Trials in Multiple Sclerosis and Type 1 Diabetes: A Look Down the Pipelineype 1 Diabetes: A Look Down the Pipelineype 1 Diabetes: A Look Down the Pipelineype 1 Diabetes: A Look Down the Pipelineype 1 Diabetes: A Look Down the Pipeline8:00am-5:00 pm8:00am-5:00 pm8:00am-5:00 pm8:00am-5:00 pm8:00am-5:00 pm St. George, 3rd FloorSt. George, 3rd FloorSt. George, 3rd FloorSt. George, 3rd FloorSt. George, 3rd Floor

9:00-11:45 am9:00-11:45 am9:00-11:45 am9:00-11:45 am9:00-11:45 am Antigen Specific InterAntigen Specific InterAntigen Specific InterAntigen Specific InterAntigen Specific Interventions and Tventions and Tventions and Tventions and Tventions and T-/or B-Cell T-/or B-Cell T-/or B-Cell T-/or B-Cell T-/or B-Cell Targeted Approachesargeted Approachesargeted Approachesargeted Approachesargeted ApproachesChairs: Amit Bar-Or and George EisenbarthChairs: Amit Bar-Or and George EisenbarthChairs: Amit Bar-Or and George EisenbarthChairs: Amit Bar-Or and George EisenbarthChairs: Amit Bar-Or and George Eisenbarth

Speakers:Speakers:Speakers:Speakers:Speakers:9:00 – 9:15 am Introduction: Questions that Mice Pose to the Clinician

Matthias von Herrath

9:15 – 9:35 am Antigen Specific DNA Vaccine and Altered Peptide Ligands in MS and T1DHideki Garren

9:35 – 9:55 am Anti-CD25 Therapy/Daclizumab and Deletion of Aggressive T Cell with ECDIStephen Miller

9:55 – 10:35 am Autoantibodies in MS and Anti-CD20/B Cell Targeted TherapyKevin O’ConnorAmit Bar-Or

10:35 – 10:45 am Break

10:45 – 11:00 am The European Anti-CD3 ResultsLucienne Chatenoud

11:00 – 11:15 am Statins in the Treatment of AutoimmunityScott Zamvil

11:15 – 11:45 Two selected abstract presentations from FOCIS submissions

11:45 am– 1:00 pm Lunch (provided)

1:00 – 4:30 pm1:00 – 4:30 pm1:00 – 4:30 pm1:00 – 4:30 pm1:00 – 4:30 pm Systemic Immune Modulators, Combination Therapies and Failed TheraSystemic Immune Modulators, Combination Therapies and Failed TheraSystemic Immune Modulators, Combination Therapies and Failed TheraSystemic Immune Modulators, Combination Therapies and Failed TheraSystemic Immune Modulators, Combination Therapies and Failed Therapies in Tpies in Tpies in Tpies in Tpies in Type 1 Diabetes and MSype 1 Diabetes and MSype 1 Diabetes and MSype 1 Diabetes and MSype 1 Diabetes and MSChairs: Kevan Herold and JerrChairs: Kevan Herold and JerrChairs: Kevan Herold and JerrChairs: Kevan Herold and JerrChairs: Kevan Herold and Jerry Palmery Palmery Palmery Palmery Palmer

Speakers:Speakers:Speakers:Speakers:Speakers:1:00 – 1:20 pm Introduction: Clinical Caveats When Using Systemic Immune Modulation

David Harlan

1:20 – 1:40 pm CTLA-4-Ig/Costimulatory BlockadeSamia Khoury

1:40 – 2:00 pm Islet Regeneration Therapy – Novel AvenuesJacob Petersen

2:00 – 2:20 pm Anti-VLA-4/Adhesion Molecules/TraffickingBenoit Lapointe

2:20 – 2:40 pm The Trial Net ExperienceJerry Nepom

2:40 – 3:00 pm Break

20052005200520052005ANNUAL MEETING

31



International Society for Neuroimmunology - Immunology of Diabetes SocietyInternational Society for Neuroimmunology - Immunology of Diabetes SocietyInternational Society for Neuroimmunology - Immunology of Diabetes SocietyInternational Society for Neuroimmunology - Immunology of Diabetes SocietyInternational Society for Neuroimmunology - Immunology of Diabetes Society(continued...)(continued...)(continued...)(continued...)(continued...)3:00 – 3:30 pm Combination Therapies in MS and T1D

Peter CalabresiKevan Herold

3:30 – 3:50 pm Lessons from Negative Trials – MSJack Antel

3:50 – 4:10 pm Lessons from Negative Trials – Type 1 DiabetesGeorge Eisenbarth

4:10 – 5:00 pm Panel Discussion: Future Avenues and StrategiesGeorge Eisenbarth, Jack Antel, David Harlan, David Hafler, CarlaGreenbaum, Jerry Nepom, Vicki Seyfert, Jerry Palmer, Dick Insel

Idea, Goals and Synopsis:Idea, Goals and Synopsis:Idea, Goals and Synopsis:Idea, Goals and Synopsis:Idea, Goals and Synopsis:The idea for this symposium was jointly conceived by the International Neuroimmunology andDiabetes Societies. This event is organized in a similar fashion as last year’s joint-symposium,which was focused on more basic aspects of pathogenesis and was successful and well-received.The focus this year is on agents already introduced into early phase studies in patients, especiallythose, where human immune-monitoring and mechanistic data are available. The morning sessionis focused on antigen specific therapies and interventions that directly target T- and B-cells. In theafternoon, the aspects of systemic immune modulation and possible combinatorial therapies willbe discussed. We will close with two talks highlighting past failures, which directly lead into apanel discussion that will suggest and debate future avenues and optimal strategies. We believethat this topic is highly relevant for refining future immune based interventions in multiple sclerosis(MS) and type 1 diabetes (T1D) and several other autoimmune disorders. Identifying parallels aswell as differences between MS and T1D will allow us to better to fully realize the potential ofnovel treatments. The symposium, which already features international experts, will also serve asa forum for the most outstanding abstracts to be chosen from work submitted to ICI/FOCIS 2004.In summary, bridging the knowledge and experience across two disciplines is timely and a goodstrategy to further our understanding into autoimmune disease mechanisms and prospective thera-peutics. Sharing data during the early phase trials in both diseases will allow us to identifyparallels and differences and help to optimally design future interventions. Furthermore, lessonslearned from one disease might be helpful for the other and vice versa. Clinicians, basic scientists,pharmaceutical industry and, ultimately, patients, will all profit from this satellite meeting.


32


International Society for NeuroimmInternational Society for NeuroimmInternational Society for NeuroimmInternational Society for NeuroimmInternational Society for NeuroimmunologyunologyunologyunologyunologyImmune-Mediated Disease in Non-Human Primates: Critical Models for Preclinical StudiesImmune-Mediated Disease in Non-Human Primates: Critical Models for Preclinical StudiesImmune-Mediated Disease in Non-Human Primates: Critical Models for Preclinical StudiesImmune-Mediated Disease in Non-Human Primates: Critical Models for Preclinical StudiesImmune-Mediated Disease in Non-Human Primates: Critical Models for Preclinical StudiesPRIMOCID (non human PRimate MOdels of Chronic ImmPRIMOCID (non human PRimate MOdels of Chronic ImmPRIMOCID (non human PRimate MOdels of Chronic ImmPRIMOCID (non human PRimate MOdels of Chronic ImmPRIMOCID (non human PRimate MOdels of Chronic Immune Disorders)une Disorders)une Disorders)une Disorders)une Disorders)2:00-5:00 pm2:00-5:00 pm2:00-5:00 pm2:00-5:00 pm2:00-5:00 pm Essex NorEssex NorEssex NorEssex NorEssex North-Wth-Wth-Wth-Wth-West, 3rd Floorest, 3rd Floorest, 3rd Floorest, 3rd Floorest, 3rd Floor

Organized by the Biomedical Primate Research Centre (BPRC), Rijswijk, NetherlandsAn EU-Sponsored Research Infrastructure

Chairpersons: Dr. Sandra Amor and Dr. Margreet Jonker

Invited Speakers:Invited Speakers:Invited Speakers:Invited Speakers:Invited Speakers:Dr. Sandra Amor Preclinical Models of Multiple Sclerosis in Non-Human PrimatesDr. Marc de Beats Myastenia Gravis Model in Rhesus MonkeysProf. Stuart Knechtle Non-Human Primate Models of TransplantationDr. Mark de Boer Costimulation Blockade: The Benefits of Non-Human Primate ModelsProf. Avi Ben-Nun A New Model of Optic Neuritis in Rhesus MonkeysDr. Thomas Hanke Pre-Clinical Therapy Evaluation for ArthritisDr. Margreet Jonker Summing Up

This symposium will highlight the non-human primate models of immune disorders as essentialsteps toward the clinical development of new therapies and drugs. The BPRC offers the opportu-nity to the EU research community to use the institutes animals and scientific expertise for studiesrequiring non-human primates, an activity which sponsored by the EU as Research Infrastructure.

Contact InfContact InfContact InfContact InfContact Information:ormation:ormation:ormation:ormation:DrDrDrDrDr. Sandra Amor or Dr. Sandra Amor or Dr. Sandra Amor or Dr. Sandra Amor or Dr. Sandra Amor or Dr. Margreet Jonker. Margreet Jonker. Margreet Jonker. Margreet Jonker. Margreet JonkerBiomedical Primate Research CentrePO Box 33062280GH [email protected]@bprc.nl


34

IndustrIndustrIndustrIndustrIndustry Ty Ty Ty Ty Tutorialsutorialsutorialsutorialsutorials

FridayFridayFridayFridayFriday, May 1, May 1, May 1, May 1, May 133333Cytometric Bead Array Cytokine and Gene Expression Profiling of Host Immune Responses toCytometric Bead Array Cytokine and Gene Expression Profiling of Host Immune Responses toCytometric Bead Array Cytokine and Gene Expression Profiling of Host Immune Responses toCytometric Bead Array Cytokine and Gene Expression Profiling of Host Immune Responses toCytometric Bead Array Cytokine and Gene Expression Profiling of Host Immune Responses toEmerging Infectious DEmerging Infectious DEmerging Infectious DEmerging Infectious DEmerging Infectious DiseasesiseasesiseasesiseasesiseasesDavid Kelvin, PhDDavid Kelvin, PhDDavid Kelvin, PhDDavid Kelvin, PhDDavid Kelvin, PhD12:30-1:30 pm12:30-1:30 pm12:30-1:30 pm12:30-1:30 pm12:30-1:30 pm Adams Room, 7th Floor Adams Room, 7th Floor Adams Room, 7th Floor Adams Room, 7th Floor Adams Room, 7th FloorLunch served

Presented by BD Biosciences

Severe acute respiratory syndrome (SARS) is a notable example of a recently-emerging infectiousdisease. The highly variable pathogenesis of SARS may be the result of unabated proinflammatoryhost responses against the SARS coronavirus (CoV). To model host gene expression during SARSCoV infection, we collected longitudinal samples from mild and critical care SARS patients fromthe onset of symptoms through convalescence or, in some cases, death. Using Cytometric BeadArray (CBA) system (BD Bioscience) and high-density cDNA microarray analysis of peripheralblood RNA, we uncovered multiple gene pathways whose expression patterns associated withdifferent disease courses of SARS. For example, persistent increased expression of the chemokineCXCL10 in the periphery and lungs was linked to uncontrolled immune responses against theSARS CoV. Moreover, signatures of other interferon-associated genes identified deviated adap-tive immune responses in patients who were at risk for poor outcome in SARS. In this regard, CBAand gene expression analysis may represent a powerful prognostic tool in differentiating patientson the basis of their host immune responses and immune-mediated injury due to serious infections.

Clinical Genomics - IT Strategies to Enable TClinical Genomics - IT Strategies to Enable TClinical Genomics - IT Strategies to Enable TClinical Genomics - IT Strategies to Enable TClinical Genomics - IT Strategies to Enable Translational Researchranslational Researchranslational Researchranslational Researchranslational Research12:30-1:30 pm12:30-1:30 pm12:30-1:30 pm12:30-1:30 pm12:30-1:30 pm Flying Cloud Room, 7th Floor Flying Cloud Room, 7th Floor Flying Cloud Room, 7th Floor Flying Cloud Room, 7th Floor Flying Cloud Room, 7th Floor

Presented by IBM

The healthcare and pharmaceutical industries have been buzzing with the promise of personal-ized medicine since the inception of the human genome project. As this decade unfolds, contin-ued advances in science, technology and information technology will accelerate the translation ofresearch discoveries into clinical practice. In order to achieve this goal of information basedmedicine, an advanced information infrastructure will be required across the healthcare con-tinuum. This presentation will explore the factors and technologies enabling the move towardsinformation based medicine. Specifically, it will explore the emerging area of Clinical Genomics,where the integration of phenotypic and genotypic data will present a host of opportunities foridentifying and validating novel disease markers, enabling more focused clinical research andultimately transforming the delivery of healthcare.

20052005200520052005ANNUAL MEETING

35



SaturdaySaturdaySaturdaySaturdaySaturday, May 14, May 14, May 14, May 14, May 14Advances in Immune Monitoring and Epitope DiscoverAdvances in Immune Monitoring and Epitope DiscoverAdvances in Immune Monitoring and Epitope DiscoverAdvances in Immune Monitoring and Epitope DiscoverAdvances in Immune Monitoring and Epitope Discovery: A SARS Case Studyy: A SARS Case Studyy: A SARS Case Studyy: A SARS Case Studyy: A SARS Case StudyKurKurKurKurKurtis Braytis Braytis Braytis Braytis Bray, Ph.D., Director, Ph.D., Director, Ph.D., Director, Ph.D., Director, Ph.D., Director, Research and Development, Beckman Coulter, Research and Development, Beckman Coulter, Research and Development, Beckman Coulter, Research and Development, Beckman Coulter, Research and Development, Beckman Coulter, Inc., Inc., Inc., Inc., Inc.7:00-8:00 am7:00-8:00 am7:00-8:00 am7:00-8:00 am7:00-8:00 am WWWWWebster Room, 7th Floorebster Room, 7th Floorebster Room, 7th Floorebster Room, 7th Floorebster Room, 7th FloorBreakfast Served

Presented by Beckman Coulter

Objective: SARS is a severe infectious disease caused by a virus identified through gene sequenc-ing and serological analysis as a new strain of human Coronavirus. SARS coronovirus (SARS-CoV)causes severe acute respiratory symptoms in patients and results in a high mortality rate. Antigenicpeptides recognized by SARS virus specific CTL’s are useful tools for studying the CTL responsesduring infection enabling researchers to better monitor disease and develop T-Cell mediatedvaccines. In order to identify potential immunogenic epitopes from the SARS N protein, we usedBeckman Coulter’s iTopia™ Epitope Discovery System to analyze the protein across 8 MHC ClassI alleles. This technology identifies and ranks candidate epitopes across 8 class I alleles based ontrue experimental binding, affinity and off rate determinations in an in vitro 96-well format

Results: Identification of SARS candidate epitopes were as follows: 6 epitopes for HLA*A0101,30 epitopes for HLA*A0201, 18 epitopes for HLA*A0301, 28 epitopes for HLA*A1101, 37epitopes for HLA*A2402, 18 epitopes for HLA*B0702, 7 epitopes for HLA*B0801 and 27epitopes for HLA*B1501. Based on iTopia rankings of candidate epitopes, SARS iTAg™ MHCTetramers for two of the candidate epitopes of the A1101 allele were manufactured and used tostain cryopreserved PBMC’s from an A1101+ convalescent SARS patient. Both tetramers showedstrong staining, confirming the biologic activity of these two epitopes.

Conclusion: Using the iTopia Epitope Discovery System, the SARS N protein (422 amino acids)was screened and potential immunogenic epitopes were identified based on true experimentalbinding, affinity and off rate determinations. SARS results demonstrate the capacity of the iTopiasystem to screen large number of MHC Class I restricted peptides and prioritize the epitopes withgreatest potential for producing an immune response. Biologic activity of two of the identifiedepitopes was confirmed by in vitro staining with MHC tetramers of cells from a convalescent SARSpatient.


36


A Method for Analyzing Gene Expression Using RNA Isolated From Whole BloodA Method for Analyzing Gene Expression Using RNA Isolated From Whole BloodA Method for Analyzing Gene Expression Using RNA Isolated From Whole BloodA Method for Analyzing Gene Expression Using RNA Isolated From Whole BloodA Method for Analyzing Gene Expression Using RNA Isolated From Whole Blood12:30-1:30 pm12:30-1:30 pm12:30-1:30 pm12:30-1:30 pm12:30-1:30 pm Adams Room, 7th Floor Adams Room, 7th Floor Adams Room, 7th Floor Adams Room, 7th Floor Adams Room, 7th FloorLunch Served

Presented by Agilent Technologies

With the recent advances of diagnostic tools such as microarray analysis and quantitative ampli-fication technologies, including real-time reverse transcriptase – polymerase chain reaction (RT-PCR), there is an increasing need for rapid and inexpensive methods to purify high quality RNA.Agilent Technologies has developed a “whole solution” platform for the analysis of differentialgene expression experiments, and RNA isolation is often the critical first step for these applica-tions. In many research and clinical assays whole blood is the desired source of cellular RNA.However, isolation of RNA from blood is frequently compromised by instability of the mRNA profileand the presence of interfering compounds such as hemoglobin and heparin. We have devel-oped a method for isolating high- purity, intact cellular RNA from whole blood by combining ourTotal RNA Isolation Mini Kit with PreAnalytiX PAXgeneâ blood collection tubes. PAXgene tubesenable the collection and stabilization of whole blood samples. Agilent’s RNA isolation technol-ogy ensures purification of total cellular RNA that is essentially free of interfering components,including genomic DNA, and does not require the use of toxic chemicals such as phenol orchloroform. In preliminary experiments using the RNA as input in Agilent’s Low RNA Input Fluores-cent Linear Amplification Kit, ample yield of high specific activity cRNA was synthesized. Thelabeled cRNAs were further utilized in hybridizations to Agilent Human 1A Oligo Microarrays.

Multiplex Serum Cytokine Analysis for Immunogenicity and Immune CompetenceMultiplex Serum Cytokine Analysis for Immunogenicity and Immune CompetenceMultiplex Serum Cytokine Analysis for Immunogenicity and Immune CompetenceMultiplex Serum Cytokine Analysis for Immunogenicity and Immune CompetenceMultiplex Serum Cytokine Analysis for Immunogenicity and Immune CompetenceMeeta Patnaik, MD, Vice President, Pathway DiagnosticsMeeta Patnaik, MD, Vice President, Pathway DiagnosticsMeeta Patnaik, MD, Vice President, Pathway DiagnosticsMeeta Patnaik, MD, Vice President, Pathway DiagnosticsMeeta Patnaik, MD, Vice President, Pathway Diagnostics12:30-1:30 pm12:30-1:30 pm12:30-1:30 pm12:30-1:30 pm12:30-1:30 pm W W W W Webster Room, 7th Floorebster Room, 7th Floorebster Room, 7th Floorebster Room, 7th Floorebster Room, 7th FloorLunch Served


20052005200520052005ANNUAL MEETING

37



Fine Mapping Solutions to the MHC and BeyondFine Mapping Solutions to the MHC and BeyondFine Mapping Solutions to the MHC and BeyondFine Mapping Solutions to the MHC and BeyondFine Mapping Solutions to the MHC and BeyondSarah Shaw-MurraySarah Shaw-MurraySarah Shaw-MurraySarah Shaw-MurraySarah Shaw-Murray, PhD, PhD, PhD, PhD, PhD12:30-1:30 pm12:30-1:30 pm12:30-1:30 pm12:30-1:30 pm12:30-1:30 pm Flying Cloud Room, 7th Floor Flying Cloud Room, 7th Floor Flying Cloud Room, 7th Floor Flying Cloud Room, 7th Floor Flying Cloud Room, 7th Floor

Presented by Illumina

For almost 20 years, researchers have been using genome-wide linkage analysis to search forgenes conferring susceptibility to inflammatory diseases. The results of these linkage studies havebeen difficult to replicate. One exception is linkage of most inflammatory disorders to the MHCregion. Unfortunately, the MHC region is also one of the most difficult regions to fine map in orderto determine the associated gene and the underlying etiologic variant conferring susceptibility todisease. Illumina has developed two high density SNP genotyping products that overcome thesechallenges. The Illumina MHC panel consists of two multiplexes, each with ~1,200 SNPs that aredesigned for use with Illumina’s GoldenGate® assay and can be used either independently or inconjunction with one another. The first multiplex is “exon-centric” and contains SNPs within 10 kbof coding sequences of genes in the MHC region spanning from ret finger protein (RFP) to motilin(MLN). The second multiplex consists of SNPs evenly spaced across the region with an emphasison tag SNPs. For genome-wide fine mapping studies, Illumina’s new InfiniumTM assay provides awhole genome genotyping solution that enables investigators to more precisely identify inflamma-tory disease susceptibility genes.

SundaySundaySundaySundaySunday, May 15, May 15, May 15, May 15, May 15Monitoring VMonitoring VMonitoring VMonitoring VMonitoring Vaccine Response: Standardization of Functional Cell Assaysaccine Response: Standardization of Functional Cell Assaysaccine Response: Standardization of Functional Cell Assaysaccine Response: Standardization of Functional Cell Assaysaccine Response: Standardization of Functional Cell AssaysEnrique Rabellino, MD, Medical OfficerEnrique Rabellino, MD, Medical OfficerEnrique Rabellino, MD, Medical OfficerEnrique Rabellino, MD, Medical OfficerEnrique Rabellino, MD, Medical Officer, Beckman Coulter, Beckman Coulter, Beckman Coulter, Beckman Coulter, Beckman Coulter, Inc., Inc., Inc., Inc., Inc.7:00-8:00 am7:00-8:00 am7:00-8:00 am7:00-8:00 am7:00-8:00 am W W W W Webster Room, 7th Floorebster Room, 7th Floorebster Room, 7th Floorebster Room, 7th Floorebster Room, 7th FloorBreakfast Served



38

Business MeetingsBusiness MeetingsBusiness MeetingsBusiness MeetingsBusiness Meetings

Clinical Immunology Society Council MeetingClinical Immunology Society Council MeetingClinical Immunology Society Council MeetingClinical Immunology Society Council MeetingClinical Immunology Society Council MeetingWednesday, May 114:00 -11:00 pmFlying Cloud Room

FOCIS Centers of Excellence Directors MeetingFOCIS Centers of Excellence Directors MeetingFOCIS Centers of Excellence Directors MeetingFOCIS Centers of Excellence Directors MeetingFOCIS Centers of Excellence Directors MeetingFriday, May 135:30-7:00 pmAdams Room

FOCIS InterFOCIS InterFOCIS InterFOCIS InterFOCIS International Advisornational Advisornational Advisornational Advisornational Advisory Committee Meetingy Committee Meetingy Committee Meetingy Committee Meetingy Committee MeetingFriday, May 1311:30 am-12:30 pmAdams Room

FOCIS 2006 Organizing Committee MeetingFOCIS 2006 Organizing Committee MeetingFOCIS 2006 Organizing Committee MeetingFOCIS 2006 Organizing Committee MeetingFOCIS 2006 Organizing Committee MeetingSaturday, May 145:30-7:30 pmAmbassador Suite

Clinical Immunology Society Annual Business MeetingClinical Immunology Society Annual Business MeetingClinical Immunology Society Annual Business MeetingClinical Immunology Society Annual Business MeetingClinical Immunology Society Annual Business MeetingSaturday, May 146:30-7:45 pmTurner’s Fisheries

FOCIS Steering Committee MeetingFOCIS Steering Committee MeetingFOCIS Steering Committee MeetingFOCIS Steering Committee MeetingFOCIS Steering Committee MeetingMonday, May 161:00-3:00 pmWebster/CourierLunch served @ 12:30

20052005200520052005ANNUAL MEETING

39


Program ScheduleProgram ScheduleProgram ScheduleProgram ScheduleProgram Schedule

FridayFridayFridayFridayFriday, May 13, 2005, May 13, 2005, May 13, 2005, May 13, 2005, May 13, 20057:00 am-5:00 pm Registration Open

7:30-8:30 am Poster Session 1Poster Session 1Poster Session 1Poster Session 1Poster Session 1 St. George, 3rd FloorSt. George, 3rd FloorSt. George, 3rd FloorSt. George, 3rd FloorSt. George, 3rd Floor

8:30-10:00 am PlenarPlenarPlenarPlenarPlenary Sessiony Sessiony Sessiony Sessiony Session America Ballroom, 4th FloorAmerica Ballroom, 4th FloorAmerica Ballroom, 4th FloorAmerica Ballroom, 4th FloorAmerica Ballroom, 4th FloorRegulation of T Cell DifferentiationRegulation of T Cell DifferentiationRegulation of T Cell DifferentiationRegulation of T Cell DifferentiationRegulation of T Cell Differentiation

Chair: Vijay K. Kuchroo, DVM PhDChair: Vijay K. Kuchroo, DVM PhDChair: Vijay K. Kuchroo, DVM PhDChair: Vijay K. Kuchroo, DVM PhDChair: Vijay K. Kuchroo, DVM PhD

Signals for T and B Cell ActivationAntonio Lanzavecchia, MD

Antigen Specific Control of the Immune System by Dendritic CellsRalph Steinman, MD

10:00-10:30 am Break

10:30 am-12:30 pm Concurrent Thematic SymposiaConcurrent Thematic SymposiaConcurrent Thematic SymposiaConcurrent Thematic SymposiaConcurrent Thematic SymposiaI. RegulatorI. RegulatorI. RegulatorI. RegulatorI. Regulatory T Cells in Ty T Cells in Ty T Cells in Ty T Cells in Ty T Cells in Transplant & Autoimmunityransplant & Autoimmunityransplant & Autoimmunityransplant & Autoimmunityransplant & Autoimmunity America North, 4th FloorAmerica North, 4th FloorAmerica North, 4th FloorAmerica North, 4th FloorAmerica North, 4th Floor

Chair: Shimon Sakaguchi, MD PhDChair: Shimon Sakaguchi, MD PhDChair: Shimon Sakaguchi, MD PhDChair: Shimon Sakaguchi, MD PhDChair: Shimon Sakaguchi, MD PhD

Preventing Rejection with Alloantigen Reactive Regulatory T CellsKathryn Wood

Generation of Regultory T Cells: Induction and Isolation of Antigen Specific TRJane Buckner, MD

Naturally Arising CD25+CD4+ Regulatory T Cells in Immunologic ToleranceShimon Sakaguchi, MD PhD

Foxp3 as a Dedicated Genetic Mechanism of Dominant ToleranceAlexander Rudensky, PhD

(OR-01) Distinct Regulatory Functions are Defined by HLA-DR Expression on Human CD4+CD25 T RegCellsC.M. Baecher-Allan

II. FCR and ComplementII. FCR and ComplementII. FCR and ComplementII. FCR and ComplementII. FCR and Complement America CenterAmerica CenterAmerica CenterAmerica CenterAmerica Center, 4th Floor, 4th Floor, 4th Floor, 4th Floor, 4th FloorChair: Michael Carroll, PhDChair: Michael Carroll, PhDChair: Michael Carroll, PhDChair: Michael Carroll, PhDChair: Michael Carroll, PhD

Blockade of Locally Acting Complement in Renal TransplantationSteve Sacks

The Antiphospholipid Syndrome Revisited: A Disorder Initiated by InflammationJane Salmon, MD

FC Receptor Function in Immunity and ToleranceJeffrey V. Ravetch, MD PhD

Functions of the Novel MHC Class I Like Fc Receptor, FcRnDerry Roopenian, PhD


40


FridayFridayFridayFridayFriday, May 13, 2005, May 13, 2005, May 13, 2005, May 13, 2005, May 13, 2005 (continued)(continued)(continued)(continued)(continued)III. Dendritic Cells (TIII. Dendritic Cells (TIII. Dendritic Cells (TIII. Dendritic Cells (TIII. Dendritic Cells (Transplant)ransplant)ransplant)ransplant)ransplant) America South, 4th FloorAmerica South, 4th FloorAmerica South, 4th FloorAmerica South, 4th FloorAmerica South, 4th Floor

Chair: MarChair: MarChair: MarChair: MarChair: Mary K. Crowy K. Crowy K. Crowy K. Crowy K. Crow, MD, MD, MD, MD, MD

Dendritic Cells as Modulators of Transplant OutcomeAngus Thomson, PhD DSc FRCPath

Dendritic Cells and the Modulation of ImmunityNina Bhardwaj, MD PhD

GM-CSF Based Cancer VaccinesGlen Dranoff, MD

Dendritic Cells and ImmunityYoun-Jun Liu, MD PhD

(OR-02) CNS Dendritic Cells Drive Naïve T Cell Proliferation and Epitope Spreading in RelapsingExperimental Autoimmune EncephalomyelitisS.D. Miller

IVIVIVIVIV. Antibodies in Disease Pathogensis and Therapy. Antibodies in Disease Pathogensis and Therapy. Antibodies in Disease Pathogensis and Therapy. Antibodies in Disease Pathogensis and Therapy. Antibodies in Disease Pathogensis and Therapy Staffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd FloorChair: Paul J. Utz, MDChair: Paul J. Utz, MDChair: Paul J. Utz, MDChair: Paul J. Utz, MDChair: Paul J. Utz, MD

Role of Autoimmunity in the Pathogenesis of Lung Allograft RejectionDavid S. Wilkes, MD

Overcoming Natural Antibodies in XenotransplantationDavid Sachs, MD

B Cell Immunity After Allogeneic Stem Cell TransplantationJerome Ritz, MD

Natural History of Islet Autoimmunity in Type 1 DiabetesAnette Ziegler, MD

(OR-03) A New Spontaneous Mouse Model for Human Devic’s DiseaseE. Bettelli

12:30-1:30 pm LunchLunchLunchLunchLunchIndustrIndustrIndustrIndustrIndustry Ty Ty Ty Ty Tutorials presented by BD Biosciences and IBM (see page 34)utorials presented by BD Biosciences and IBM (see page 34)utorials presented by BD Biosciences and IBM (see page 34)utorials presented by BD Biosciences and IBM (see page 34)utorials presented by BD Biosciences and IBM (see page 34) 77777ththththth Floor Floor Floor Floor FloorPoster Session 1 (continued)Poster Session 1 (continued)Poster Session 1 (continued)Poster Session 1 (continued)Poster Session 1 (continued) St. George, 3rd FloorSt. George, 3rd FloorSt. George, 3rd FloorSt. George, 3rd FloorSt. George, 3rd Floor

20052005200520052005ANNUAL MEETING

41


FridayFridayFridayFridayFriday, May 13, 2005, May 13, 2005, May 13, 2005, May 13, 2005, May 13, 2005 (continued)(continued)(continued)(continued)(continued)1:30-3:00 pm IndustrIndustrIndustrIndustrIndustry Symposium Presented by Biogen IDECy Symposium Presented by Biogen IDECy Symposium Presented by Biogen IDECy Symposium Presented by Biogen IDECy Symposium Presented by Biogen IDEC America Ballroom, 4th FloorAmerica Ballroom, 4th FloorAmerica Ballroom, 4th FloorAmerica Ballroom, 4th FloorAmerica Ballroom, 4th Floor

This session is programmed by FOCIS and supported by an unrestricted educational grant from Biogen IDEC.

Selective Adhesion Molecule Inhibition in Autoimmune DiseaseSelective Adhesion Molecule Inhibition in Autoimmune DiseaseSelective Adhesion Molecule Inhibition in Autoimmune DiseaseSelective Adhesion Molecule Inhibition in Autoimmune DiseaseSelective Adhesion Molecule Inhibition in Autoimmune DiseaseModerator: Roy Lobb, PhDModerator: Roy Lobb, PhDModerator: Roy Lobb, PhDModerator: Roy Lobb, PhDModerator: Roy Lobb, PhD

How Does VLA-4 Work? Mechanistic Insights—Past, Present, and FutureMartin Hemler, PhD

Clinical Results of Selective VLA-4 Blockade with Natalizumab in Relapsing Multiple SclerosisJ. Theodore Phillips, MD PhD

Speaker TBA

3:00-3:30 pm Break

3:30-5:30 pm Concurrent Oral Abstract SessionsConcurrent Oral Abstract SessionsConcurrent Oral Abstract SessionsConcurrent Oral Abstract SessionsConcurrent Oral Abstract SessionsI. Antibodies and B CellsI. Antibodies and B CellsI. Antibodies and B CellsI. Antibodies and B CellsI. Antibodies and B Cells America North, 4th FloorAmerica North, 4th FloorAmerica North, 4th FloorAmerica North, 4th FloorAmerica North, 4th Floor

Chair: Shiv Pillai, MBBS PhDChair: Shiv Pillai, MBBS PhDChair: Shiv Pillai, MBBS PhDChair: Shiv Pillai, MBBS PhDChair: Shiv Pillai, MBBS PhD

(OR-04) Elucidating the Mechanism of Anti-MOG Antibody –Mediated Demyelination.C. B. Marta

(OR-05) Synovial Intracellular Citrullinated Proteins Colocalizing with Peptidyl Arginine Deiminase arePathophysiologically Relevant Antigenic Determinants of Rheumatoid Arthritis-Specific Humoral Autoimmunity.L. De Rycke

(OR-06) Antibodies to Citrulline-Modified Proteins Enhance Tissue Injury in Inflammatory Arthritis.K. A. Kuhn

(OR-07) T to B Epitope Spreading is Responsible for the Diversification of Autoantibody ResponsesWithin the Small Nuclear Ribnucleoprotein Complex.U. S. Deshmukh

(OR-08) In Sjogren’s Syndrome Serum Autoantibodies Recognize Tear Lipocalin and Alpha-Fodrin.Riccardo Navone

(OR-09) Microarray Profiling of Anti-Lipid Antibodies in MS.J. L. Kanter

(OR-10) High-Throughput Analysis of Autoantibodies Recognizing Myelin Antigens in Acute Disseminated Encephalomyelitis.K. C. O’Connor

(OR-11) Role of CD38 in Human B Cells: Evidence of a Functional and Physical Association with CD 19.S. Deaglio



42

FridayFridayFridayFridayFriday, May 13, 2005 (continued), May 13, 2005 (continued), May 13, 2005 (continued), May 13, 2005 (continued), May 13, 2005 (continued)II. Innate Immune System Regulating DiseaseII. Innate Immune System Regulating DiseaseII. Innate Immune System Regulating DiseaseII. Innate Immune System Regulating DiseaseII. Innate Immune System Regulating Disease America CenterAmerica CenterAmerica CenterAmerica CenterAmerica Center, 4th Floor, 4th Floor, 4th Floor, 4th Floor, 4th Floor

Chair: Hanspeter WChair: Hanspeter WChair: Hanspeter WChair: Hanspeter WChair: Hanspeter Waldneraldneraldneraldneraldner, PhD, PhD, PhD, PhD, PhD

(OR-12) Toll-Like Receptor 2 Regulates Cellular Responses to Axonal Degeneration in the CentralNer vous System.A. A. Babcock

(OR-13) Linking Innate Immunity to Autoimmunity Through the Role of TLRs and the MyD-88 SignalingPathway.P. P. Ho

(OR-14) Transcription Factor T-Bet Regulates Inflammatory Arthritis Through Linking the Innate andAdaptive Immunity.J. Wang

(OR-15) Three Different TLR9 CpG Stimulants Exhibit Diverse Effects in Murine Graft-Versus Host Disease(GVHD).R. A. Puliaev

(OR-16) HSP60 Inhibits Th1-Mediated Hepatitis Model Via Innate Regulation of Th1/Th2 TranscriptionFactors and Cytokines.Alexandra Zanin-Zhorov

(OR-17) Toll Receptor Ligands Potently and Broadly Enhance the Immune Response of ImmunodepressedCutaneous T-Cell Lymphoma Patients.M. Wysocka

(OR-18) Beta-Adrenergic and Toll-Like Receptor 2 Signalling in Epidermal Keratinocytes Drive the SkinImmune Response to a Soluble Protein.Georges J.M. Maestroni

III.III.III.III.III. T Regs and Regulation of Immune ResponseT Regs and Regulation of Immune ResponseT Regs and Regulation of Immune ResponseT Regs and Regulation of Immune ResponseT Regs and Regulation of Immune Response America South, 4th FloorAmerica South, 4th FloorAmerica South, 4th FloorAmerica South, 4th FloorAmerica South, 4th FloorChair: Joan Goverman, PhDChair: Joan Goverman, PhDChair: Joan Goverman, PhDChair: Joan Goverman, PhDChair: Joan Goverman, PhD

Oral Anti-CD3 Suppresses Autoimmunity by Inducing TGF-b Dependent LAP+ Regulatory T CellsHoward Weiner, MD

(OR-19) Regulatory Function Is Deficient in CD4+CD25+ T Cells from Patients with Systemic LupusErythematosus.M. I. Vargas-Rojas

(OR-20) IL-2 Mediates Expansion but Not Maintenances of TGF Induced T Regs in Inflammation: ANovel Role of IL-10.M. C. Fantini

(OR-21) Identification of Important Functional Domains of FOXP3 by Analysis of Mutations Present inPatients with IPEX Syndrome.T. R. Torgerson

(OR-22) GRAIL Expression Is Associated with the Biological Activity of CD25+ T Regulatory Cells.D. A. MacKenzie


20052005200520052005ANNUAL MEETING

43



FridayFridayFridayFridayFriday, May 13, 2005 (continued), May 13, 2005 (continued), May 13, 2005 (continued), May 13, 2005 (continued), May 13, 2005 (continued)IVIVIVIVIV. New Pathways of Immune Regulation. New Pathways of Immune Regulation. New Pathways of Immune Regulation. New Pathways of Immune Regulation. New Pathways of Immune Regulation Staffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd Floor

Chair: Marie WChair: Marie WChair: Marie WChair: Marie WChair: Marie Wahren, MD PhDahren, MD PhDahren, MD PhDahren, MD PhDahren, MD PhD

(OR-27) Requirement for the Adipocyte Fatty Acid Binding Protein aP2 in Allergic Airway Inflammation.B. Shum

(OR-28) Transcriptional Regulation of Autoimmune Diseases by Tumor Suppressor p53.Xiaochun Wan

(OR-29) The Sjögren’s Syndrome Associated Autoantigen Ro52 Is a RING-Dependent E3 Ligase ThatSuppresses Cellular Proliferation.A. Espinosa

(OR-30) Graft-Versus-Leukemia Target Antigens in Chronic Myelogenous Leukemia (CML) are Expressedon Myeloid Progenitor Cells.J. Wu

(OR-31) BAFF-but Not LT-Dependent B Cell Expansion Contributes to the Suppression of Lethal IntestinalInflamation.Yasuyo Shimomura

(OR-32) Increased Constitutive Activation of NF-B in Patients with Multiple Sclerosis.J. Yan

(OR-33) Control of Macrophage Activation Via Myeloid CD200R Signaling During ExperimentalAutoimmune Uveoretinitis.J. Calderm

(OR-34) Role of Fgl2 Prothrombinase/Fibroleukin in Experimental and Human Allograft Rejection.Qin Ning


44

FridayFridayFridayFridayFriday, May 13, 2005 (continued), May 13, 2005 (continued), May 13, 2005 (continued), May 13, 2005 (continued), May 13, 2005 (continued)VVVVV. NK and NK T Cells. NK and NK T Cells. NK and NK T Cells. NK and NK T Cells. NK and NK T Cells WWWWWebster/Courierebster/Courierebster/Courierebster/Courierebster/Courier, 7th Floor, 7th Floor, 7th Floor, 7th Floor, 7th Floor

Chair: TBAChair: TBAChair: TBAChair: TBAChair: TBA

(OR-35) Glycolipid Mediated Activation of iNKT Cells is Sufficient to Induce Airway HyperreactivityIndependent of Conventional CD4 T Cells.E. H. Meyer

(OR-36) The Involvement of CD1-Restricted NKT Cells in the Pathogenesis of Collagen-Induced andAntibody-Induced Arthritis.S. Kaieda

(OR-37) Effects of Natural Killer (NK) Cells on Allogeneic Bone Marrow Transplantation.Swati Bhattacharyya

(OR-38) - NK-Mediated Protection in CFA-Injected NOD Mice igI.F. Lee

(OR-39) Microsomal Triglyceride Transfer Protein Regulation of CD1d-Mediated Glycolipid AntigenPresentation.S. K. Dougan

(OR-40) Exogenous IL-2 Promotes IL-5 Production by Human CD4+ NKT Cell Clones: The Role of IL-2 inthe Immune Regulation.K. Sakuishi

(OR-41) - Specificity of NK T Cells Against GD3 Ganglioside.Dianna Y. Wu

(OR-42) CD4+ Invariant T Cell Receptor+ NKT Cells and the Development of Bronchial Asthma in Humans.Omid Akbari

5:30-7:30 pm Poster Session 2 (WPoster Session 2 (WPoster Session 2 (WPoster Session 2 (WPoster Session 2 (Wine and Cheese Serine and Cheese Serine and Cheese Serine and Cheese Serine and Cheese Served)ved)ved)ved)ved) St. George, 3rd FloorSt. George, 3rd FloorSt. George, 3rd FloorSt. George, 3rd FloorSt. George, 3rd Floor

7:00-9:00 pm WWWWWelcome Receptionelcome Receptionelcome Receptionelcome Receptionelcome Reception Essex Ballroom, 3rd FloorEssex Ballroom, 3rd FloorEssex Ballroom, 3rd FloorEssex Ballroom, 3rd FloorEssex Ballroom, 3rd FloorOpen to all delegatesOpen to all delegatesOpen to all delegatesOpen to all delegatesOpen to all delegates


20052005200520052005ANNUAL MEETING

45



SaturdaySaturdaySaturdaySaturdaySaturday, May 14, 2005, May 14, 2005, May 14, 2005, May 14, 2005, May 14, 20057:00 am-5:00 pm Registration Open

7:00 am-8:00 am IndustrIndustrIndustrIndustrIndustry Ty Ty Ty Ty Tutorials presented by Beckman Coulter (see page 35)utorials presented by Beckman Coulter (see page 35)utorials presented by Beckman Coulter (see page 35)utorials presented by Beckman Coulter (see page 35)utorials presented by Beckman Coulter (see page 35) 77777ththththth Floor Floor Floor Floor Floor

7:30-8:30 am Poster Session 1Poster Session 1Poster Session 1Poster Session 1Poster Session 1 St. George, Essex, 3rd FloorSt. George, Essex, 3rd FloorSt. George, Essex, 3rd FloorSt. George, Essex, 3rd FloorSt. George, Essex, 3rd Floor

8:30-10:00 am PlenarPlenarPlenarPlenarPlenary Sessiony Sessiony Sessiony Sessiony Session America Ballroom, 4th FloorAmerica Ballroom, 4th FloorAmerica Ballroom, 4th FloorAmerica Ballroom, 4th FloorAmerica Ballroom, 4th FloorGenetics & Gene TherapyGenetics & Gene TherapyGenetics & Gene TherapyGenetics & Gene TherapyGenetics & Gene Therapy

Chair: Megan Sykes, MDChair: Megan Sykes, MDChair: Megan Sykes, MDChair: Megan Sykes, MDChair: Megan Sykes, MD

Edward Wakeland, PhD

Gene Therapy: Medicine of the 21st CenturyInder Verma

10:00-10:30 am Break

10:30 am-12:30 pm Concurrent Thematic SymposiaConcurrent Thematic SymposiaConcurrent Thematic SymposiaConcurrent Thematic SymposiaConcurrent Thematic SymposiaI. Genetics of Immune-Mediated Diseases & TI. Genetics of Immune-Mediated Diseases & TI. Genetics of Immune-Mediated Diseases & TI. Genetics of Immune-Mediated Diseases & TI. Genetics of Immune-Mediated Diseases & Transplantationransplantationransplantationransplantationransplantation America North, 4th FloorAmerica North, 4th FloorAmerica North, 4th FloorAmerica North, 4th FloorAmerica North, 4th Floor

Chair: Jack PChair: Jack PChair: Jack PChair: Jack PChair: Jack P. Antel, MD. Antel, MD. Antel, MD. Antel, MD. Antel, MD

Towards a Taxonomy of Type 1 DiabetesJohn Todd

Inflammatory Bowel Disease-A Genetics Success StoryKathy Siminovitch, MD FRCP

GPRA, A Susceptibility Gene for Allergy and AsthmaJuha Kere, MD PhD

The SLAM Family of Cell Surface Receptors Controls Immune Responses to Viruses and BacteriaCox Terhorst, PhD

(OR- 43) TIM-1 Induces T Cell Activation and Inhibits the Development of Peripheral Tolerance.S. E. Umetsu

II. TLR, NK, Innate ImmunityII. TLR, NK, Innate ImmunityII. TLR, NK, Innate ImmunityII. TLR, NK, Innate ImmunityII. TLR, NK, Innate Immunity America CenterAmerica CenterAmerica CenterAmerica CenterAmerica Center, 4th Floor, 4th Floor, 4th Floor, 4th Floor, 4th FloorChair: Stephan MeuerChair: Stephan MeuerChair: Stephan MeuerChair: Stephan MeuerChair: Stephan Meuer, MD, MD, MD, MD, MD

Checkpoints in Human NK Cell Activation and FunctionLorenzo Moretta, MD

Endogenous TLR Ligands and Systemic Autoimmune DiseaseAnn Marshak-Rothstein, PhD

Danger Signals and the Initiation of Immune ResponsesKenneth Rock, MD

Active Control of CDI Antigen Processing in Human Dendritic CellsBranch Moody, MD

(OR-44) In Vivo Homeostatic Proliferation of Naive CD4+ T-Cells Restrains the TCR Repertoire in HealthyHuman Adults.S. Kohler


46


SaturdaySaturdaySaturdaySaturdaySaturday, May 14, 2005 (continued), May 14, 2005 (continued), May 14, 2005 (continued), May 14, 2005 (continued), May 14, 2005 (continued)III. Immunodysregulation and ImmunoreconstitutionIII. Immunodysregulation and ImmunoreconstitutionIII. Immunodysregulation and ImmunoreconstitutionIII. Immunodysregulation and ImmunoreconstitutionIII. Immunodysregulation and Immunoreconstitution America South, 4th FloorAmerica South, 4th FloorAmerica South, 4th FloorAmerica South, 4th FloorAmerica South, 4th Floor

Chair: Matthias vonHerrath, MDChair: Matthias vonHerrath, MDChair: Matthias vonHerrath, MDChair: Matthias vonHerrath, MDChair: Matthias vonHerrath, MD

Immunodysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX): A Model of Foiled PeripheralSelf-ToleranceHans Ochs, MD

Innate AutoimmunityMichael Carroll, MD

Immune Deficiency Due to Defects in Isotype SwitchingRaif Geha, MD

Alemtuzumab in Allogeneic Transplantation: Between Scylla and CharybdisKarl Peggs, MD

(OR-45) Intragraft Foxp3 Expression is Associated with Rejection and is Suppressed by CsA.K. G. Haanstra

20052005200520052005ANNUAL MEETING

47


SaturdaySaturdaySaturdaySaturdaySaturday, May 14, 2005 (continued), May 14, 2005 (continued), May 14, 2005 (continued), May 14, 2005 (continued), May 14, 2005 (continued)IVIVIVIVIV. Disease Regulation: Role of Antigens, Cytokines, Chemokines. Disease Regulation: Role of Antigens, Cytokines, Chemokines. Disease Regulation: Role of Antigens, Cytokines, Chemokines. Disease Regulation: Role of Antigens, Cytokines, Chemokines. Disease Regulation: Role of Antigens, Cytokines, Chemokines Staffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd Floor

Chair: Andrew LusterChair: Andrew LusterChair: Andrew LusterChair: Andrew LusterChair: Andrew Luster, MD PhD, MD PhD, MD PhD, MD PhD, MD PhD

Fevers, Genes, and Pathways: The Systemic Autoinflammatory DiseasesDan Kastner, MD PhD

Chemokines and Lipid Chemoattractants in DiseaseAndrew Luster, MD PhD

Cytokine Signal: Basic and AppliedJohn O’Shea, MD

Cytokines in Viral InfectionsChristine A. Biron, PhD

(OR-46) Insulin with Native B:9-23 Sequence is an Essential Autoantigen in the NOD Mouse.M. Nakayama

12:30-1:30 pm LunchLunchLunchLunchLunchIndustrIndustrIndustrIndustrIndustry Ty Ty Ty Ty Tutorials presented byutorials presented byutorials presented byutorials presented byutorials presented byAgilent TAgilent TAgilent TAgilent TAgilent Technologies, Beckman Coulterechnologies, Beckman Coulterechnologies, Beckman Coulterechnologies, Beckman Coulterechnologies, Beckman Coulter, Illumina (see page 36), Illumina (see page 36), Illumina (see page 36), Illumina (see page 36), Illumina (see page 36) 77777ththththth Floor Floor Floor Floor FloorPoster Session 1 (continued)Poster Session 1 (continued)Poster Session 1 (continued)Poster Session 1 (continued)Poster Session 1 (continued) St. George, Essex, 3rd FloorSt. George, Essex, 3rd FloorSt. George, Essex, 3rd FloorSt. George, Essex, 3rd FloorSt. George, Essex, 3rd Floor

1:30-3:00 pm IndustrIndustrIndustrIndustrIndustry Symposium Presented by Centocory Symposium Presented by Centocory Symposium Presented by Centocory Symposium Presented by Centocory Symposium Presented by CentocorThis session is programmed by FOCIS and supported by an unrestricted educational grant from Centocor.

Immune-Mediated InflammatorImmune-Mediated InflammatorImmune-Mediated InflammatorImmune-Mediated InflammatorImmune-Mediated Inflammatory Disorders: Elucidating Pattery Disorders: Elucidating Pattery Disorders: Elucidating Pattery Disorders: Elucidating Pattery Disorders: Elucidating Patterns in Immune Disease Concomitancyns in Immune Disease Concomitancyns in Immune Disease Concomitancyns in Immune Disease Concomitancyns in Immune Disease Concomitancyandandandandand Connectivity Connectivity Connectivity Connectivity Connectivity America Ballroom, 4th FlooorAmerica Ballroom, 4th FlooorAmerica Ballroom, 4th FlooorAmerica Ballroom, 4th FlooorAmerica Ballroom, 4th FlooorModerator: John B. WModerator: John B. WModerator: John B. WModerator: John B. WModerator: John B. Wong, MDong, MDong, MDong, MDong, MD

Patterns of Immune Disease: Exploring the Biologic UnderpinningsAbul Abbas, MD

The Gastroenterology PerspectiveSander J. van Deventer, MD

The Clinical Immunology PerspectiveSpeaker TBA

Current Implications and Future DirectionDavid F. Fiorentino, MD, PhD

Closing

3:00-3:30 pm Break

3:30-5:30 pm Oral Abstract SessionsOral Abstract SessionsOral Abstract SessionsOral Abstract SessionsOral Abstract SessionsI. Genetics and GenomicsI. Genetics and GenomicsI. Genetics and GenomicsI. Genetics and GenomicsI. Genetics and Genomics America North, 4th FloorAmerica North, 4th FloorAmerica North, 4th FloorAmerica North, 4th FloorAmerica North, 4th Floor

Chair: John Rioux, PhDChair: John Rioux, PhDChair: John Rioux, PhDChair: John Rioux, PhDChair: John Rioux, PhD

(OR-47) Differential Transcript Profiling Identifies Candidate Genes in the New Zealand Model ofSystemic Lupus Erythematosus, Including the B-Cell Transcription Factor, Bach2.R. J. Rigby



48

SaturdaySaturdaySaturdaySaturdaySaturday, May 14, 2005 (continued), May 14, 2005 (continued), May 14, 2005 (continued), May 14, 2005 (continued), May 14, 2005 (continued)(OR-48) Impact of the Lupus Susceptibility Locus, Sle1 on B Cell Tolerance.K. Raman

(OR-49) Insulin-VNTR Modulate Functional Phenotypes of T-Cell Responses to Proinsulin in HLA-DRB1*04Positive Subjects with and without Type 1 Diabetes.I.Durinovic-Bello

(OR-50) A Toll Receptor Pathway Polymorphism Affects Susceptibility to Inflammatory Bowel Disease.P. L. De Jager

(OR-51) Finally Found: Human BAFF-R Deficiency Causes Hypogammaglobulinemia.K. Warnatz

(OR-52) Polymorphisms in CTLA4 and CD28 Are Associated with SLE.D. S. Cunninghame Graham

(OR-53) Building an Admixture Map for Disease Gene Discovery in African Americans.A.Waliszewska

II. ImmunodiagnosisII. ImmunodiagnosisII. ImmunodiagnosisII. ImmunodiagnosisII. Immunodiagnosis America CenterAmerica CenterAmerica CenterAmerica CenterAmerica Center, 4th Floor, 4th Floor, 4th Floor, 4th Floor, 4th FloorChair: TBAChair: TBAChair: TBAChair: TBAChair: TBA

(OR-54) Detection of Allergen-Antibody Complexes on Murine B Cells Using Flow Cytometry.P. A. Wachholz

(OR-55) Novel Candidate Markers for Multiple Sclerosis Using Phage cDNA Display.V.Somers

(OR-56) Phenotypic and Functionnal Ex Vivo Profiling of Human CMV Specific CD8+ T-Cell ResponsesAfter Allo-HSCT.V.Bajzik

(OR-57) A Compliant Solution for Monitoring Proteins Using a Lab-on-a-Chip Instrument.P. Barthmaier

(OR-58) Correlation of Clinical Outcome with Immunophenotype in Islet Transplant Recipients.N. S. Kenyon

(OR-59) Autoimmunity in Children with Atypical Type 1 and Type 2 Diabetes.L. K. Gilliam

(OR-60) Development of a Clinical Assay Evaluating Toll-Like Receptor Function.R. P. Deering

(OR-122) Identification of Disease Profiles for Rheumatoid Arthritis Using Antibody and Antigen Arrays.D. Hirschberg


20052005200520052005ANNUAL MEETING

49



SaturdaySaturdaySaturdaySaturdaySaturday, May 14, 2005 (continued), May 14, 2005 (continued), May 14, 2005 (continued), May 14, 2005 (continued), May 14, 2005 (continued)III. TIII. TIII. TIII. TIII. Toleranceoleranceoleranceoleranceolerance America South, 4th FloorAmerica South, 4th FloorAmerica South, 4th FloorAmerica South, 4th FloorAmerica South, 4th Floor

Chair: Stephen D. MillerChair: Stephen D. MillerChair: Stephen D. MillerChair: Stephen D. MillerChair: Stephen D. Miller, PhD, PhD, PhD, PhD, PhD

(OR-61) Tolerance to Inhaled Proteins Does Not Develop in the Presence of Proteinase-Activated Receptor-2 (PAR-2) Activation.C. Ebeling

(OR-62) Nasal Vaccination with a Proteosome-Based Adjuvant and Glatiramer Acetate Clears Alzheimer’sAmyloid in an Antibody-Independent Fashion.Dan Frenkel

(OR-63) Collaboration between Central Tolerance and Peripheral Regulation to Control Autoimmunity.Z. Chen

(OR-64) Mechanisms of Retinal Immune Privilege.C. H. Lau

(OR-65) - Treatment with a Donor-Specific Transfusion and Anti-CD154 mAb Induces Non-Responsiveness in a Population of T Cells That Recognize Alloantigen Via Indirect Antigen Presentation.N. E. Phillips

(OR-66) Successful Induction of Mixed Chimerism and Tolerance with Non-Myeloablative Conditioningin Mice Presensitized with Fully Mismatched Skin Grafts.P. D. Bardwell

IVIVIVIVIV. Dendritic Cells and Regulation of Disease. Dendritic Cells and Regulation of Disease. Dendritic Cells and Regulation of Disease. Dendritic Cells and Regulation of Disease. Dendritic Cells and Regulation of Disease Staffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd FloorChair: Shannon TChair: Shannon TChair: Shannon TChair: Shannon TChair: Shannon Turleyurleyurleyurleyurley, PhD, PhD, PhD, PhD, PhD

(OR-67) Dendritic Cell Response to Necrosis is Defective in Atopy.H. Kandil

(OR- 68) CD150 (SLAM) Modulates TLR and CD40 Pathways in Monocyte-Derived Dendritic Cells.B. Rethi

(OR-69) Activation of Human NK Cells by Plasmacytoid DC and Its Modulation by CD4+ T Cells andCD25hi T Regulatory Cells.C. Romagnani

(OR-70) Hepatitis C Virus Core Protein Induced, Monocyte-Mediated Mechanisms of Reduced IFN andPlasmacytoid Dendritic Cells Loss in Patients with Chronic HCV Infection.A.Dolganiuc

(OR-71) Delayed IL-10 Induced Human Tolerogenic DC Inhibit Naive T Cell Proliferation by MechanismsOther Than Their Exaggerated PD-L1/2 Induction.F. Li

(OR-72) Induction of Heme Oxygenase-1 (HO-1) Inhibits Dendritic Cell Differentiation and AdaptiveImmunity.J. J. Listopad

(OR-73) Donor-Specific Allograft Tolerance by Administration of Recipient-Derived Immature DendriticCells and Suboptimal Immunosuppression.G. Beriou


50


SaturdaySaturdaySaturdaySaturdaySaturday, May 14, 2005 (continued), May 14, 2005 (continued), May 14, 2005 (continued), May 14, 2005 (continued), May 14, 2005 (continued)(OR-74) - Impact of Plasmacytoid Dendritic Cell (PDC) Recovery on Outcome after Allogeneic Stem CellTransplantation (allo-SCT).M. Mohty

VVVVV. Immunodeficiency. Immunodeficiency. Immunodeficiency. Immunodeficiency. Immunodeficiency WWWWWebster/Courierebster/Courierebster/Courierebster/Courierebster/Courier, 7th Floor, 7th Floor, 7th Floor, 7th Floor, 7th FloorChair: Dale Umetsu, MD PhDChair: Dale Umetsu, MD PhDChair: Dale Umetsu, MD PhDChair: Dale Umetsu, MD PhDChair: Dale Umetsu, MD PhD

(OR-75) Functional Interaction of Common Gamma Chain and Growth Hormone Receptor SignalingApparatus.M. Adriani

(OR-76) Novel Humoral Immunodeficiency in Humans Associated with Deleterious Homozygous Mutation in CD19.D. Castano

(OR-77) Mutations in TACI Are Associated with Immunodeficient Phenotypes in Humans.U. Salzer

(OR-78) Expansion of Maternally Derived Monoclonal T Cells with a CD3 + CD8 + TCR Phenotype inTwo Children with Severe Combined Immunodeficiency.E. Hodges

(OR-79) Semi-Nested Degenerate rtPCR Allows Rapid Identification of TCR-beta Rearrangement on theSingle Cell Level.Dun Zhou

5:30-7:30 pm Poster Session 2 (WPoster Session 2 (WPoster Session 2 (WPoster Session 2 (WPoster Session 2 (Wine and Cheese Serine and Cheese Serine and Cheese Serine and Cheese Serine and Cheese Served)ved)ved)ved)ved) St. George, Essex, 3rd FloorSt. George, Essex, 3rd FloorSt. George, Essex, 3rd FloorSt. George, Essex, 3rd FloorSt. George, Essex, 3rd Floor

SundaySundaySundaySundaySunday, May 15, 2005, May 15, 2005, May 15, 2005, May 15, 2005, May 15, 20057:00am-5:00 pm Registration Open

7:00-8:00 am IndustrIndustrIndustrIndustrIndustry Ty Ty Ty Ty Tutorials presented by Beckman Coulter (see page_)utorials presented by Beckman Coulter (see page_)utorials presented by Beckman Coulter (see page_)utorials presented by Beckman Coulter (see page_)utorials presented by Beckman Coulter (see page_) 77777ththththth Floor Floor Floor Floor Floor

8:30-10:00 am PlenarPlenarPlenarPlenarPlenary Sessiony Sessiony Sessiony Sessiony Session America Ballroom, 4th FloorAmerica Ballroom, 4th FloorAmerica Ballroom, 4th FloorAmerica Ballroom, 4th FloorAmerica Ballroom, 4th FloorTTTTTracking Pathogenic & Therapeutic Immune Responsesracking Pathogenic & Therapeutic Immune Responsesracking Pathogenic & Therapeutic Immune Responsesracking Pathogenic & Therapeutic Immune Responsesracking Pathogenic & Therapeutic Immune Responses

Chair: Richard Blumberg, MDChair: Richard Blumberg, MDChair: Richard Blumberg, MDChair: Richard Blumberg, MDChair: Richard Blumberg, MD

Imaging Inflammation in Type-1 DiabetesDiane Mathis, PhD

Imaging Cell Fates and Function NoninvasivelyChris Contag

10:30 am-12:30 pm Concurrent Thematic SymposiaConcurrent Thematic SymposiaConcurrent Thematic SymposiaConcurrent Thematic SymposiaConcurrent Thematic SymposiaI. I. I. I. I. In VivoIn VivoIn VivoIn VivoIn Vivo Imaging Imaging Imaging Imaging Imaging America North, 4th FloorAmerica North, 4th FloorAmerica North, 4th FloorAmerica North, 4th FloorAmerica North, 4th Floor

Chair: Jeffrey Bluestone, PhDChair: Jeffrey Bluestone, PhDChair: Jeffrey Bluestone, PhDChair: Jeffrey Bluestone, PhDChair: Jeffrey Bluestone, PhD

Multicellular Synapse Dynamics In VivoMatthew Krummel, PhD

Trafficking of Immune Populations with BiolumenescenceRobert Negrin, MD

20052005200520052005ANNUAL MEETING

51


SundaySundaySundaySundaySunday, May 15, 2005 (continued), May 15, 2005 (continued), May 15, 2005 (continued), May 15, 2005 (continued), May 15, 2005 (continued)II. Costimulation and TII. Costimulation and TII. Costimulation and TII. Costimulation and TII. Costimulation and Toleranceoleranceoleranceoleranceolerance

Chair: TBAChair: TBAChair: TBAChair: TBAChair: TBAHigh Resolution Dynamic Visualization of Immune Cell Function In Vivo in Health and DiseaseRonald N. Germain, MD PhD

Live Imagine of Autoaggressive T Cells Attacking the CNSAlexander Flugel, MD

(OR-80) Expanded T Cells from Human Type 1 Diabetic Pancreatic Draining Lymph Nodes React withInsulin A Chain 1-15.S. C. Kent

The Roles of the New Negative T-Cell Costimulatory Pathways in Regulating AutoimmunitySamia Khoury, MD

CD137 and HVEM in the Control of Transplantation ToleranceLieping Chen, MD PhD

OX40: OX4OL in T Cell Immunity and DiseaseMichael Croft, PhD

Novel T Cell Costimulatory Pathways in TransplantationMohamed H. Sayegh, MD

(OR-81) Anti-CD28 Antibodies-Induced Transplant Tolerance Involving TCR- Class II- CD80/86+ Regulatory Cells and Tryptophan Degradation.F. Haspot

III. Mast Cell, Eosinophils, Allergic ReactionsIII. Mast Cell, Eosinophils, Allergic ReactionsIII. Mast Cell, Eosinophils, Allergic ReactionsIII. Mast Cell, Eosinophils, Allergic ReactionsIII. Mast Cell, Eosinophils, Allergic Reactions America South, 4th FloorAmerica South, 4th FloorAmerica South, 4th FloorAmerica South, 4th FloorAmerica South, 4th FloorChair: Stephen J. Galli, MDChair: Stephen J. Galli, MDChair: Stephen J. Galli, MDChair: Stephen J. Galli, MDChair: Stephen J. Galli, MD

Mast Cells as Effector and Potential Immunoregulatory Cells in Acquired Immune ResponsesStephen J. Galli, MD

Mast Cells and Inflammatory ArthritisDavid Lee, MD PhD

Homing/Recruitment and Function of Peripheral Tissue Mast CellK. Frank Austen, MD

Role of Eosinophils in Innate Immunity and Allergic InflammationHirohita Kita, MD

IVIVIVIVIV. Living with the Bugs: Good or Bad. Living with the Bugs: Good or Bad. Living with the Bugs: Good or Bad. Living with the Bugs: Good or Bad. Living with the Bugs: Good or Bad Staffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd FloorChair: Kendall A. Smith, MDChair: Kendall A. Smith, MDChair: Kendall A. Smith, MDChair: Kendall A. Smith, MDChair: Kendall A. Smith, MD

Immunopathology in HTLV-I Associated Neurologic DiseaseSteve Jacobson, PhD

How Viruses Enhance or Abrogate Type 1 DiabetesMatthias von Herrath, MD

Infection and Immunity in AtheroclerosisAndrew Lichtman, MD PhD



52

SundaySundaySundaySundaySunday, May 15, 2005 (continued), May 15, 2005 (continued), May 15, 2005 (continued), May 15, 2005 (continued), May 15, 2005 (continued)How Did Infections Protect Us from Allergic and Autoimmune Diseases?Jean Francois Bach

(OR-82) - Immature Myeloid Dendritic Cells Induce Intestinal Granulomas under Certain EnvironmentalConditions.K. Sugimoto

12:30-1:30 pm LunchLunchLunchLunchLunchPoster Session 1 (continued)Poster Session 1 (continued)Poster Session 1 (continued)Poster Session 1 (continued)Poster Session 1 (continued) St. George, Essex, 3rd FloorSt. George, Essex, 3rd FloorSt. George, Essex, 3rd FloorSt. George, Essex, 3rd FloorSt. George, Essex, 3rd Floor

1:30-3:00 pm IndustrIndustrIndustrIndustrIndustry Symposia Presented by Genentechy Symposia Presented by Genentechy Symposia Presented by Genentechy Symposia Presented by Genentechy Symposia Presented by Genentech America Ballroom, 4th FloorAmerica Ballroom, 4th FloorAmerica Ballroom, 4th FloorAmerica Ballroom, 4th FloorAmerica Ballroom, 4th FloorThis session is programmed by FOCIS and supported by an unrestricted educational grant from Genentech.

Linking B Cells and Autoimmune DiseasesLinking B Cells and Autoimmune DiseasesLinking B Cells and Autoimmune DiseasesLinking B Cells and Autoimmune DiseasesLinking B Cells and Autoimmune DiseasesModerator: Dhaval Patel, MD PhDModerator: Dhaval Patel, MD PhDModerator: Dhaval Patel, MD PhDModerator: Dhaval Patel, MD PhDModerator: Dhaval Patel, MD PhD

Pathways of B Cell ActivationRobert Carter, MD

B Cells and AutoimmunityPeter E. Lipsky, MD

Therapeutic Targeting of B CellsDhaval Patel, MD PhD

3:00-3:30 pm Break

3:30-5:30 pm Oral Abstract SessionsOral Abstract SessionsOral Abstract SessionsOral Abstract SessionsOral Abstract SessionsI.New Animal Models: Defining Antigens Recognition by Animal ModelsI.New Animal Models: Defining Antigens Recognition by Animal ModelsI.New Animal Models: Defining Antigens Recognition by Animal ModelsI.New Animal Models: Defining Antigens Recognition by Animal ModelsI.New Animal Models: Defining Antigens Recognition by Animal Models America North,America North,America North,America North,America North,

Chair: Chella David, PhDChair: Chella David, PhDChair: Chella David, PhDChair: Chella David, PhDChair: Chella David, PhD 4th Floor4th Floor4th Floor4th Floor4th Floor

(OR-83) HLA-A11/KboDbo Transgenic Mice are Susceptible to PLP41-60 Induced Experimental Autoimmune Encephalomyelitis (EAE).A.K. Mangalam

(OR-84) Fibrinogen-Induced Arthritis in Mice as a Novel Model for Rheumatoid Arthritis.P. P. Ho

(OR-85) Murine Model of Mixed Connective Tissue Disease in HLA-DR4 Transgenic Mice Induced withU1-70kD Small Nuclear Ribonucleoprotein Autoantigen.R. W. Hoffman

(OR-86) Proteoglycan-Induced Arthritis: A New and Unique TCR Transgenic Arthritis Model.S. E. Berlo

(OR-87) BDC 12-4.1 (Anti-Insulin B:9-23) T Cell Receptor Transgenic Mice Are Lymphopenic but EntrainEarly Insulitis and Can Cause Early Diabetes Modified by Insulin 2 Gene Expression.J. M. Jasinski

(OR-88) Implication for the Pathogenesis and Immunoregulation in a Murine Model of Sarcoidosis.B.Wei

(OR-89) A New Model of Endogeneous AML Following Irradiation and Allogeneic Bone Marrow Trans-plantation.B.Van Wijmeersch


20052005200520052005ANNUAL MEETING

53


SundaySundaySundaySundaySunday, May 15, 2005 (continued), May 15, 2005 (continued), May 15, 2005 (continued), May 15, 2005 (continued), May 15, 2005 (continued)II.II.II.II.II. CostimulationCostimulationCostimulationCostimulationCostimulation America CenterAmerica CenterAmerica CenterAmerica CenterAmerica Center, 4th Floor, 4th Floor, 4th Floor, 4th Floor, 4th Floor

Chair: Arlene Sharpe, MD PhDChair: Arlene Sharpe, MD PhDChair: Arlene Sharpe, MD PhDChair: Arlene Sharpe, MD PhDChair: Arlene Sharpe, MD PhD

(OR-90) Monoclonal Antibody Targeting of TIRC7 Results in Significant Therapeutic Effects on T and BCell Response in Collagen-Induced Arthritis in Mice.N. Utku

(OR-91) Transgenic Expression of Program Death Ligand 1 Protects Islets from Autoimmune Diabetes inNonobese Diabetic Mice.Huey-Kang Sytwu

(OR-92) PD-L1/PD-L2 Expression Protects Against the Development of Autoimmune Diabetes.Mary E. Keir

(OR-93) ICOS Engagement of CD4 T-Cells Following Pulmonary Influenza Infection: Evidence for Negative Regulation of T-Cell Effector Function.M. E. Dahl

(OR-94) Tim-4 Is the Ligand for Tim-1, and the Tim-1/Tim-4 Interaction Regulates T Cell Expansion.J. Hartt Meyers

(OR-95) Evidence for Early Anergy Followed by Rapid Peripheral Deletion of Donor-Specific CD8 T Cellsafter Non-Myeloablative BMT with Anti-CD154: In Search of a Tolerogenic Donor Cell.T. Fehr

(OR-96) TIM-3 Mediated Enhancement of Anti-Tumor Immune Responses.Brian K. Helmich

III.III.III.III.III. ImmunotherapyImmunotherapyImmunotherapyImmunotherapyImmunotherapy America South, 4th FloorAmerica South, 4th FloorAmerica South, 4th FloorAmerica South, 4th FloorAmerica South, 4th FloorChair: TBAChair: TBAChair: TBAChair: TBAChair: TBA

(OR-97) Apoptosis Induction as a Therapeutic Intervention To Eliminate Encephalitogenic T Cells; AntisenseXIAP (AEG35169) in Murine Models of EAE.S. P. Zehntner

(OR-98) Blockade of TNF Preferentially Inhibits Proliferation of Anti - CD3, Recall - Antigen Responsiveand Autoreactive Human VLA-1+CD45RO+CD4+ T Cells.S. Ben-Horin

(OR-99) An Immunization Strategy for Generation of T Cell Receptor Mimics.Vaughan P. Wittman

(OR-100) Differential Expression of Phosphorylated NF-kB/RelA in Normal and Psoriatic Epidermis andDownregulation of NF-kB in Response to Treatment with Etanercept.P. F. Lizzul

(OR-101) Anti-IL-2R Therapy: An Alternative Strategy for Regulating CD40L Expression.J. Shen

(OR-102) Prophylactic Administration of Abatacept (CTLA4-Ig; BMS-188667) Prevents Disease Induction and Bone Destruction in a Rat Model of Collagen-Induced Arthritis.B.Kliwinski



54

SundaySundaySundaySundaySunday, May 15, 2005 (continued), May 15, 2005 (continued), May 15, 2005 (continued), May 15, 2005 (continued), May 15, 2005 (continued)(OR-103) Abatacept (CTLA4Ig) Modulates Human T-Cell Proliferation and Cytokine Production but DoesNot Affect TNF Production by Monocytes.P. M. Davis

(OR-104) Essential Role of IL-10 in Restricting Immunity during a Chronic Viral Infection.Mette Ejrnaes

IVIVIVIVIV..... TTTTTrafficking and Adhesionrafficking and Adhesionrafficking and Adhesionrafficking and Adhesionrafficking and Adhesion Staffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd FloorChair: TBAChair: TBAChair: TBAChair: TBAChair: TBA

(OR-105) Effects of Natalizumab (anti-VLA-4 Antibody) on Immune Cell Adhesion and Migration inPatients with MS.Masaaki Niino

(OR-106) Molecular Imaging of Adhesion Molecules in Experimental Autoimmune Encephalomyelitis(EAE).R. A. Linker

(OR-107) Immunotherpy of Relapsing Experimental Autoimmune Encephalomyelitis (EAE) by Neutralization of CD4+ T Cell Chemoattractant Cytokine IL-16.D. S. Skundric

(OR-108) High Resolution Dynamic Visualization of Immune Cell Function In Vivo in Health and Disease.R. N. Germain

(OR-109) Migration Matters: Regulatory T Cell Compartmentalization Determines Suppressive Activity InVivo.K. Siegmund

(OR-110) The Anti-Inflammatory Action of Methotrexate is Not Mediated by Lymphocyte Apoptosis, butby the Suppression of Activation and Adhesion Molecules.A.Johnston

(OR-111) Conditional Deletion of Alpha (v) Integrins Causes Inflammatory Bowel Disease.A.Lacy-Hulbert

VVVVV. Cytokine Mediated Immunoregulation. Cytokine Mediated Immunoregulation. Cytokine Mediated Immunoregulation. Cytokine Mediated Immunoregulation. Cytokine Mediated Immunoregulation WWWWWebster/Courierebster/Courierebster/Courierebster/Courierebster/Courier, 7th Floor, 7th Floor, 7th Floor, 7th Floor, 7th FloorChair: Lindsay B. Nicholson, MD PhDChair: Lindsay B. Nicholson, MD PhDChair: Lindsay B. Nicholson, MD PhDChair: Lindsay B. Nicholson, MD PhDChair: Lindsay B. Nicholson, MD PhD

(OR-112) Phenotype of Cytokine Expressing Cells in Peanut Allergen-Primed Mice.P. A. Wachholz

(OR-113) Foxp3+ Regulatory T Cells Can Be Induced from CD4+CD25- TGF Transgenic Cells and AreAble To Condition Dendritic Cells To Suppress Naïve T Cells.Y. Carrier

(OR-114) Atorvastatin Prevents the Th1 Differentiation of Myelin-Reactive T Cells During EAE by Interfering with the Prenylation of Ras and the Activation of ERK.S. E. Dunn


20052005200520052005ANNUAL MEETING

55


SundaySundaySundaySundaySunday, May 15, 2005 (continued), May 15, 2005 (continued), May 15, 2005 (continued), May 15, 2005 (continued), May 15, 2005 (continued)(OR-115) Regulation of T Cell Differentiation by IL-4R-Chain Single Nucleotide Polymorphisms.A. Skapenko

(OR-116) Diverging Roles for the IL-12 Family in T Cell Immunity: IL-12 and IL-27-EBI3 Have SimilarContributions to Pathogen Responses While IL-23 Is Unique to Certain Autoimmune Pathways.Jacqueline M. Benson

(OR-117) IL-4 Can Be a Key Positive Regulator of Inflammatory Arthritis.Koichiro Ohmura

(OR-118) IL-12/23-Deficient Genotype Reveals Two Distinct Pathways Leading to Arthritis in Mice.H. Hess

(OR-119) Systemic Onset Juvenile Idiopathic Arthritis is an IL-1 Mediated Disease.F. Allantaz

5:30-7:30 pm Poster Session 2Poster Session 2Poster Session 2Poster Session 2Poster Session 2 St. George, Essex, 3rd FloorSt. George, Essex, 3rd FloorSt. George, Essex, 3rd FloorSt. George, Essex, 3rd FloorSt. George, Essex, 3rd Floor

MondayMondayMondayMondayMonday, May 16, 2005, May 16, 2005, May 16, 2005, May 16, 2005, May 16, 20058:30-10:00 am Distinguished Lecture: Genetics and GenomicsDistinguished Lecture: Genetics and GenomicsDistinguished Lecture: Genetics and GenomicsDistinguished Lecture: Genetics and GenomicsDistinguished Lecture: Genetics and Genomics America Ballroom, 4th FloorAmerica Ballroom, 4th FloorAmerica Ballroom, 4th FloorAmerica Ballroom, 4th FloorAmerica Ballroom, 4th Floor

Chair: David A. HaflerChair: David A. HaflerChair: David A. HaflerChair: David A. HaflerChair: David A. Hafler, MD, MD, MD, MD, MD

HIV Vaccines Epitope Diversity and T Cell MemoryGary Nabel, MD PhD

Genomic Information: Implications for MedicineEric Lander, PhD

10:00- 10:30 am Break

10:30 am-12:30 pm Concurrent Thematic SymposiaConcurrent Thematic SymposiaConcurrent Thematic SymposiaConcurrent Thematic SymposiaConcurrent Thematic SymposiaI. Therapeutic VI. Therapeutic VI. Therapeutic VI. Therapeutic VI. Therapeutic Vaccinesaccinesaccinesaccinesaccines America North, 4th FloorAmerica North, 4th FloorAmerica North, 4th FloorAmerica North, 4th FloorAmerica North, 4th FloorIntroductionIntroductionIntroductionIntroductionIntroduction

Chair: Lucienne Chatenoud, MD PhDChair: Lucienne Chatenoud, MD PhDChair: Lucienne Chatenoud, MD PhDChair: Lucienne Chatenoud, MD PhDChair: Lucienne Chatenoud, MD PhD

Enhancing Tumor Vaccination Through In Vivo Plasmacytoid Dendritic Cell Activation Via TLR9Art Krieg, MD

Breaking Tumor-Induced Tolerance with Therapeutic IntentDrew Pardoll, MD PhD

The Quest for Antigen Specific Therapy for Autoimmune DiseaseLarry Steinman, MD

Modulation of Adaptive Immunity in Rheumatoid ArthritisSalvatore Albani, MD PhD



56

MondayMondayMondayMondayMonday, May 16, 2005 (continued), May 16, 2005 (continued), May 16, 2005 (continued), May 16, 2005 (continued), May 16, 2005 (continued)II. Development of Immune-Based TherapeuticsII. Development of Immune-Based TherapeuticsII. Development of Immune-Based TherapeuticsII. Development of Immune-Based TherapeuticsII. Development of Immune-Based Therapeutics America CenterAmerica CenterAmerica CenterAmerica CenterAmerica Center, 4th Floor, 4th Floor, 4th Floor, 4th Floor, 4th Floor

Chair: Michael Lotze, MDChair: Michael Lotze, MDChair: Michael Lotze, MDChair: Michael Lotze, MDChair: Michael Lotze, MD

B Cell ImmunotherapyAndrew C. Chan, MD PhD

On the Horizon: Better Therapies for Systemic Lupus ErthematosusDavid Wofsy, MD

Monoclonar Antibody and Cellular Therapy in Type 1 DiabetesJeffrey Bluestone, PhD

Molecular Pathogensis of RA and Mode of Action of TNF-Blocking and Other Target TherapiesLars Klareskog, MD PhD

(OR-120) - A High Affinity, Soluble T Cell Receptor for Targeting Tumours Expressing NY-ESO and HLA-A2.R. Ashfield.

III. Roles of Interferons in Defense & DiseaseIII. Roles of Interferons in Defense & DiseaseIII. Roles of Interferons in Defense & DiseaseIII. Roles of Interferons in Defense & DiseaseIII. Roles of Interferons in Defense & Disease America South, 4th FloorAmerica South, 4th FloorAmerica South, 4th FloorAmerica South, 4th FloorAmerica South, 4th FloorChair: Tim Behrens, MDChair: Tim Behrens, MDChair: Tim Behrens, MDChair: Tim Behrens, MDChair: Tim Behrens, MD

Role of Interferon-alpha in Systemic Lupus ErythematosusVirginia Pascual, MD

The Interferon Pathway and Human LupusTim Behrens, MD

The Role of Interferons in Systemic AutoimmunityDwight Kono, MD

Control of T-Cell Immunity by Dendritic CellsFrederica Sallusto

IVIVIVIVIV. Immunodiagnostic Disease Predictors. Immunodiagnostic Disease Predictors. Immunodiagnostic Disease Predictors. Immunodiagnostic Disease Predictors. Immunodiagnostic Disease Predictors Staffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd FloorStaffordshire, 3rd FloorChair: Jonathan Braun, MD PhDChair: Jonathan Braun, MD PhDChair: Jonathan Braun, MD PhDChair: Jonathan Braun, MD PhDChair: Jonathan Braun, MD PhD

Proteomic Analysis Reveals Molecular Subtypes of Rheumatoid ArthritisWilliam Robinson

Molecular and Microbial Disease Markers in Inflammatory Bowel DiseaseJonathan Braun, MD PhD

Paul Ridker, MD

Can We Detect Tolerance Following Allograft Transplantation?Jean-Paul Soulillou

(OR-121) GAD65- and Proinsulin-Specific CD4+ T-Cells Detected by MHC Class II Tetramers in thePeripheral Blood of Type 1 Diabetic Patients and Prediabetic Subjects.V. Oling


20052005200520052005ANNUAL MEETING

57



MondayMondayMondayMondayMonday, May 16, 2005 (continued), May 16, 2005 (continued), May 16, 2005 (continued), May 16, 2005 (continued), May 16, 2005 (continued)12:30-2:00 pm NIH Grants Information SessionNIH Grants Information SessionNIH Grants Information SessionNIH Grants Information SessionNIH Grants Information Session America North, 4th FloorAmerica North, 4th FloorAmerica North, 4th FloorAmerica North, 4th FloorAmerica North, 4th Floor

This session will inform applicants about the NIH peer review and program funding processes. Thesession is directed at all academic investigators. The topics will include the receipt and referral process,the review process, as well as the funding mechanisms and NIH program initiatives available to clinician-scientists.

Dr. Cathleen CooperScientific Review Administrator, Transplantation, Tolerance, and Tumor Immunology Study Section andReferral; Officer, Division of Receipt and Referral, Center for Scientific Review

Dr. Grace ShenDirector, Ocular Immunology Program, Division of Extramural Research, National Eye Institute


58

Exhibit Hall - Essex Ballroom, 3rd Floor

Booth #Booth #Booth #Booth #Booth # CompanyCompanyCompanyCompanyCompany1-2 Agilent Technologies3-4 DakoCytomation5-6 DynalBiotech ASA7-8 Whatman/Schleicher & Schuell9 National Institute of Allergy and Infectious Diseases10 Journal of Experimental Medicine11-12 Centocor, Inc.13 Immune Tolerance Network14 Elsevier15 American Autoimmune Related Diseases Association16-18 Grifols International SA19-23 Beckman Coulter, Inc.24 BD Biosciences25 Autoimmun Diagnostika GMBH/Cell Technology, Inc.26 Biacore, Inc.27 Cellular Technology, Ltd. CTL

28 EFORE (USA), Inc.29 ALPCO Diagnostics30 BioLegend, Inc.31 Jackson ImmunoResearch Laboratories, Inc.32 KRONUS, Inc.33 LINCO Research, Inc.34 Luminex Corporation35 Miltenyi Biotec, Inc.36 ProImmune, Inc.37 Bristol-Myers Squibb38 SeraCare Life Sciences39 THERAKOS40 Upstate41 Blackwell Publishing42 IgG America

20052005200520052005ANNUAL MEETING

59


Exhibit HallExhibit HallExhibit HallExhibit HallExhibit Hall

Exhibit Hall HoursExhibit Hall HoursExhibit Hall HoursExhibit Hall HoursExhibit Hall HoursFriday, May 13 Opening Reception 7:00-9:00 pmSaturday, May 14 7:00 am-7:30 pmSunday, May 15 7:00 am-7:30 pm

Exhibit Hall hours are designed to correspond with Poster Sessions also being held in the Essex Ballroom. Poster viewing hours are7:30-8:30 am, 12:30-1:30 pm, and 5:30-7:30 pm. However, the Exhibit Hall and poster areas will be accessible from 7:30 amto 7:30 pm.

1313131313ththththth International Congress of Immunology International Congress of Immunology International Congress of Immunology International Congress of Immunology International Congress of ImmunologySociedade Brasileira de ImunologiaApuiar 44Sao PauloBrasil

The 13th International Congress of Immunology, sponsored bythe International Union of Immunological Societies (IUIS), theBrazilian Society of Immunology (SBI) and the Latin AmericanSociety of Immunology (ALAI) will be held in Rio de Janeiro,August 12th-17 th, 2007. The Scientific Program will be outstand-ing; there will be a full social program to allow delegates toexperience the charm of Rio de Janeiro, one of the most beauti-ful cities in the world, nicknamed “Cidade Maravilhosa” (Won-derful City).

American Autoimmune RelatedAmerican Autoimmune RelatedAmerican Autoimmune RelatedAmerican Autoimmune RelatedAmerican Autoimmune RelatedDiseases AssociationDiseases AssociationDiseases AssociationDiseases AssociationDiseases Association22100 Gratiot Ave.E. Detroit, MI 48021Booth Number: 15Booth Number: 15Booth Number: 15Booth Number: 15Booth Number: 15

Agilent TAgilent TAgilent TAgilent TAgilent Technologiesechnologiesechnologiesechnologiesechnologies2850 Centerville RoadWilmington, DE 19808Booth Number: 1-2Booth Number: 1-2Booth Number: 1-2Booth Number: 1-2Booth Number: 1-2Agilent Technologies is a leading supplier of life science tech-nologies, providing solutions for gene expression, proteomicsand informatics that optimize sensitivity and workflow productiv-ity. Key products include: whole genome and custom microarrays,scanners; HPLC, LC/MS/MS and HPLC-Chip/MS; ion trap andTOF mass spectrometers; lab-on-a-chip products; reagents; anddata analysis software.

ALPCO DiagnosticsALPCO DiagnosticsALPCO DiagnosticsALPCO DiagnosticsALPCO DiagnosticsPO Box 451Windham, NH 03087Booth Number: 29Booth Number: 29Booth Number: 29Booth Number: 29Booth Number: 29ALPCO Diagnostics offers a comprehensive range of over 600high-quality immunoassay kits to both the research and clinicallaboratory communities. ALPCO is featuring kits in the areas ofAllergy Research, Autoimmunity, Rheumatology, Thyroid Func-tion, and Hepatology. Please visit us to receive our full productcatalog, Immunoassay Kits Beyond the Ordinary.

AutoImmun Diagnostika GMBH/Cell TAutoImmun Diagnostika GMBH/Cell TAutoImmun Diagnostika GMBH/Cell TAutoImmun Diagnostika GMBH/Cell TAutoImmun Diagnostika GMBH/Cell Technologyechnologyechnologyechnologyechnology,,,,,Inc.\Cell TInc.\Cell TInc.\Cell TInc.\Cell TInc.\Cell Technologyechnologyechnologyechnologyechnology, Inc., Inc., Inc., Inc., Inc.8980 Old Annapolis RoadSuite LColumbia, MD 21045Booth Number: 25Booth Number: 25Booth Number: 25Booth Number: 25Booth Number: 25Cell Technology, Inc. (www.celltechnologyinc.com) is the NorthAmerican Distributor of Image Analyzers (for EliSpot / ViralPlaque/ IFA assay) and test kits manufactured by AutoImmunDiagnostika, Strassberg, Germany (www.aid-diagnostika.com).Additionally, Cell Technology Inc. provides storage and distri-bution services for biological materials.

BD BiosciencesBD BiosciencesBD BiosciencesBD BiosciencesBD Biosciences2350 Qume DriveSan Jose, CA 95131Booth Number: 24Booth Number: 24Booth Number: 24Booth Number: 24Booth Number: 24BD Biosciences, a business segment of BD (Becton, Dickinsonand Company), has four business units: Clontech, DiscoveryLabware, Immunocytometry Systems, and Pharmingen. As oneof the largest companies supporting the life sciences, BD Bio-sciences provides integrated, high value products and servicesfor genomics, proteomics, drug discovery and development, andcell analysis.


60


Beckman CoulterBeckman CoulterBeckman CoulterBeckman CoulterBeckman Coulter7330 Carroll RoadSan Diego, CA 92121Booth Number: 19-23Booth Number: 19-23Booth Number: 19-23Booth Number: 19-23Booth Number: 19-23From Epitope Discovery to Patient Monitoring. Your ImmuneMonitoring Partner: Beckman Coulter. Come see the latest solu-tions from Beckman Coulter that help you innovate, simplify andautomate your immune monitoring processes. From our revolu-tionary iTopia Epitope Discovery System and iTAg MHC Tetram-ers to the IC 100 cellular imaging system, Quanta and FC 500Series flow cytometry systems, as well as the A2 MicroArraySystem, Beckman Coulter delivers complete Immune Monitoringsolutions. Learn more by visiting our booth.

Biacore, Inc.Biacore, Inc.Biacore, Inc.Biacore, Inc.Biacore, Inc.200 Centennial Ave, Suite 100Piscataway, NJ 08854Booth Number: 26Booth Number: 26Booth Number: 26Booth Number: 26Booth Number: 26Biacore supplies analytical systems that improve productivity ofresearch and development in the life science and pharmaceuti-cal markets. Unique data on protein interactions give insightsinto protein functionality, the role of proteins in normal and dis-eased states, and the influence of potential drug candidates.The company also provides ready-to-use solutions to determinefood quality and safety. For more information, visitwww.biacore.com

BioLegend, Inc.BioLegend, Inc.BioLegend, Inc.BioLegend, Inc.BioLegend, Inc.8395 Camino Sante Fe, Suite ESan Diego, CA 92121Booth Number: 30Booth Number: 30Booth Number: 30Booth Number: 30Booth Number: 30At BioLegend, we are committed to providing world-class qual-ity research reagents and outstanding value. BioLegend fea-tures antibodies/conjugates against human, mouse, and ratcovering the areas of cell immunophenotyping, cytokines andchemokines, adhesion, phosphorylation, cancer research, cell-cycle analysis, and apoptosis. BioLegend reagents’ applicationsinclude flow cytometry, ELISA, ELISPOT, immunoprecipitation,Western blotting, immunofluorescence microscopy, immunohis-tochemistry, and in vitro/in vivo functional assays. BioLegendoffers a wide range of custom conjugation services to meet ourcustomers’ specific needs.

Blackwell PublishingBlackwell PublishingBlackwell PublishingBlackwell PublishingBlackwell PublishingBooth Number: 41Booth Number: 41Booth Number: 41Booth Number: 41Booth Number: 41

Blackwell Publishing is one of the world’s leading medical pub-lishers, representing the very best in academic research, profes-sional development and student learning. Our Immunologyportfolio contains some of the leading journals in the field, in-cluding Immunological Reviews, the official journals of the Brit-ish Society for Immunology: Clinical and Experimental Immunol-ogy and Immunology , and the Scandinavian Journal of Immu-nology. Visit us at booth# 41, or browse our websiteat: www.blackwellimmunology.com

Bristol-Myers SquibbBristol-Myers SquibbBristol-Myers SquibbBristol-Myers SquibbBristol-Myers Squibb345 Park AveNew York, NY 10154Booth Number: 37Booth Number: 37Booth Number: 37Booth Number: 37Booth Number: 37

Bristol-Myers Squibb welcomes you to Boston! We invite you tovisit our exhibit and learn more about T-Cell Co-Stimulation. Bristol-Myers Squibb is a pharmaceutical and related health care prod-ucts company whose mission is to extend and enhance humanlife.

Cellular TCellular TCellular TCellular TCellular Technologyechnologyechnologyechnologyechnology, Ltd.-CTL, Ltd.-CTL, Ltd.-CTL, Ltd.-CTL, Ltd.-CTL10515 Carnegie Ave.Cleveland, OH 44106Booth Number: 27Booth Number: 27Booth Number: 27Booth Number: 27Booth Number: 27From academic roots, CTL has grown to become the world leaderin ELISPOT development and automated image analysis. Weprovide scientifically validated ELISPOT products for all needsand budgets including the ImmunoSport Analyzer line,ImmunoSpot Software with dual color, scanning, and analysisservices, and contracted research. Seeing is believing! Visit ourbooth and witness how CTL’s products can be an asset to yourlaboratory. www.immunospot.com

20052005200520052005ANNUAL MEETING

61


CentocorCentocorCentocorCentocorCentocor, Inc., Inc., Inc., Inc., Inc.200 Great Valley ParkwayMalvern, PA 19355Booth Number: 11-12Booth Number: 11-12Booth Number: 11-12Booth Number: 11-12Booth Number: 11-12Centocor, a wholly owned subsidiary of Johnson & Johnson,creates, acquires and markets biomedicines that benefit patientsand the healthcare community. Centocor is dedicated to re-searching and developing treatments for a wide range of im-mune mediated inflammatory disorders (I.M.I.D.) to help physi-cians deliver innovative treatments to improve health and re-store quality of life.

Clinical Immunology SocietyClinical Immunology SocietyClinical Immunology SocietyClinical Immunology SocietyClinical Immunology Society555 E. Wells StreetSuite 1100Milwaukee, WI 53202Booth Number: FoyerBooth Number: FoyerBooth Number: FoyerBooth Number: FoyerBooth Number: FoyerThe Clinical Immunology Society (CIS) is the key inter-disciplin-ary organization for the field of clinical immunology with themission to support and advance the community of immunologicscholars and physicians in education, research, and patient care.Established in 1986, CIS is devoted to fostering developmentsin the science and practice of clinical immunology. CIS is aninternational professional organization which includes 700 cli-nicians, investigators, and trainees. CIS has various program-ming objectives and is known worldwide for Educational Resi-dential Seasonal Schools.

DakoCytomationDakoCytomationDakoCytomationDakoCytomationDakoCytomation4850 Innovation DriveFort Collins, CO 80525Booth Number: 3-4Booth Number: 3-4Booth Number: 3-4Booth Number: 3-4Booth Number: 3-4

DakoCytomation A/S, headquartered in Copenhagen, Denmark,is a leading cancer diagnostics company with a focus on per-sonalized medicine. DakoCytomation offers systems solutions forclinical laboratories and life science researchers, providing testsand instruments so that physicians can link diagnostic results tospecific therapies and optimize patient care. The privately heldcompany has significant R&D and manufacturing activities inDenmark, UK and USA, with operations in 20 countries, dis-tributors in 50+ countries and more than 1,300 employees.www.dakocytomation.com


Dynal Biotech ASADynal Biotech ASADynal Biotech ASADynal Biotech ASADynal Biotech ASAUllernchausjeen 52N-0379 OS6NorwayBooth Number: 5-6Booth Number: 5-6Booth Number: 5-6Booth Number: 5-6Booth Number: 5-6Dynal Biotech is the leading supplier of basic and clinical re-search grade magnetic beads for human and mouse cell sepa-ration and expansion. By coupling your own antibodies, youcan also isolate or deplete cells from a variety of samples.Dynabeads bridge the gap from basic research methods, throughresearch & validation to routine applied ex-vivo immunotherapy.Clinical-grade Dynabeads are versatile tools in clinical researchto separate viable cell populations. Come and see us at ourbooth.

EFORE (USA), Inc.EFORE (USA), Inc.EFORE (USA), Inc.EFORE (USA), Inc.EFORE (USA), Inc.6029 W. Campus Circle DriveIrving, TX 75063Booth Number: 28Booth Number: 28Booth Number: 28Booth Number: 28Booth Number: 28EFORE (USA), Inc. is the distributor for Bio-Sys Bioreader andBiocount(r) in the United States and Canada. Bioreader’s areused for counting Elispot and Colony Forming Units (CFU) aswell as Plaque Assays. [email protected]:* Diagnosis of genetic defects* Allergic diseases* Autoimmune diseases* Transplantation* Cancer research* Acute inflammation, acute infectious diseases and septic shock

ElsevierElsevierElsevierElsevierElsevier655 Avenue of the AmericasNew York, NY 10010Booth Number: 14Booth Number: 14Booth Number: 14Booth Number: 14Booth Number: 14Elsevier publishes journals, books and reference works acrossimmunology. Come to the booth to: Claim conference discountson key book titles such as Measuring Immunity or the new edi-tion of Mucosal Immunology; Discover the benefits to authors ofpublishing in our prestigious journals, such as Clinical Immunol-ogy; Human Immunology or Cytokine and pick up a free sampleof Trends in Immunology or Current Opinion in Immunology.


62

Grifols International SAGrifols International SAGrifols International SAGrifols International SAGrifols International SADepartment of Inflammation200 Cambridge Park DriveCambridge, MA 02140Booth Number: 16-18Booth Number: 16-18Booth Number: 16-18Booth Number: 16-18Booth Number: 16-18Grifols has been working for health since 1940 creating inno-vative products and services based on the values of ethics andresponsibility. The Bioscience Division develops quality plasma-derived therapies with outstanding records of safety and effi-cacy. Grifols’ plasma derivative production uses the most ad-vanced technology by a highly-qualified team— and all of thiswith complete traceability of the entire process. Grifols plasmaderivatives are accompanied by PediGri: a commitment of com-pletely transparent information to health professionals.

IgG AmericaIgG AmericaIgG AmericaIgG AmericaIgG America34 Flint StreetMarblehead, MA 01445Booth Number: 42Booth Number: 42Booth Number: 42Booth Number: 42Booth Number: 42IgG America is a national specialty pharmacy that providesimmune globulin (IgG) services. IgG America provides immuneglobulin, supplies, pump/pole, pharmacy clinical monitoring,and all nursing services required to administer IgG in the homeand or alternate site settings. Please visit us atwww.iggamerica.com or call toll-free 877-674-9700.

Immune TImmune TImmune TImmune TImmune Tolerance Networkolerance Networkolerance Networkolerance Networkolerance NetworkSuite 3004800 Montgomery LaneBethesda, MD 20814Booth Number: 13Booth Number: 13Booth Number: 13Booth Number: 13Booth Number: 13The Immune Tolerance Network (ITN) aims to accelerate thedevelopment of immune tolerance therapies in kidney, liver andislet transplantation, autoimmune diseases and allergy & asthma.The ITN solicits proposals for clinical trials and associated toler-ance assay studies from academic and industry-based research-ers in a year-round, open call for proposals. The ITN is jointlysponsored by the NIAID, NIDDK and JDRF. More informationmay be found at www.immunetolerance.org


Jackson ImmunoResearch Laboratories, Inc.Jackson ImmunoResearch Laboratories, Inc.Jackson ImmunoResearch Laboratories, Inc.Jackson ImmunoResearch Laboratories, Inc.Jackson ImmunoResearch Laboratories, Inc.872 West Baltimore PikePO Box 9West Grove, PA 19390Booth Number: 31Booth Number: 31Booth Number: 31Booth Number: 31Booth Number: 31Affinity-purified secondary antibodies (many absorbed againstother species for multiple labeling) (see also our new anti-mouseIgG subclass specific antibodies), anti-digoxin, anti-biotin, anti-FITC, streptavidin, and purified immunoglobulins are conjugatedwith fluorophores (including Cy2, Cy3, and Cy5), enzymes, Bi-otin-SP , colloidal gold, phycoerythrin, and allophycocyanin.Monovalen Fab fragments are available for blocking endog-enous Ig and for lableing two antibodies from the same host.

Journal of Experimental MedicineJournal of Experimental MedicineJournal of Experimental MedicineJournal of Experimental MedicineJournal of Experimental Medicine1114 First AveNew York, NY 10021Booth Number: 10Booth Number: 10Booth Number: 10Booth Number: 10Booth Number: 10

The Journal of Experimental Medicine provides broad cover-age in all research areas encompassing the host’s response todisease. The topics covered include: hematopoiesis; infectiousdisease; inflammation; microbial pathogenesis; oncology; stemcells; vaccines; vascular biology; and virology. With a high im-pact factor of 15.302 (2003 ISI® Journal Citation Reports®),the JEM is a leading life sciences journal in two ISI categories:Immunology and Research & Experimental Medicine. The JEMnow has a free open archive of full-text, searchable PDF ver-sions of all articles dating back to 1896, a new design, andnew features including In This Issue overview and commentar-ies/news.

KRONUS, Inc.KRONUS, Inc.KRONUS, Inc.KRONUS, Inc.KRONUS, Inc.12554 W. Bridger St.Suite 108Boise, ID 83713Booth Number: 32Booth Number: 32Booth Number: 32Booth Number: 32Booth Number: 32

KRONUS will be showcasing a variety of immunoassay test kitsfor use by clinical and research laboratories to aid in the differ-ential diagnosis and management of various autoimmune dis-eases in the areas of Type 1 Diabetes, Celiac Disease, Addison’sDisease, thyroid autoimmunity (including Grave’s Disease) andMyasthenia Gravis/Lambert-Eaton Myasthenic Syndrome. Pleasevisit our exhibit to learn more about the complete line of KRONUSproducts!

20052005200520052005ANNUAL MEETING

63


LINCO Research, Inc.LINCO Research, Inc.LINCO Research, Inc.LINCO Research, Inc.LINCO Research, Inc.14 Research Park DriveSaint Charles, MO 63304Booth Number: 33Booth Number: 33Booth Number: 33Booth Number: 33Booth Number: 33LINCO Research is a recognized leader in the developmentand commercialization of multiplexed immunoassays for theLuminex xMAP platform. LINCOplex multi-analyte panels areavailable for cytokines/chemokines, as well as biomarkers forthe study of metabolic diseases (diabetes, obesity, cardiac dis-ease). Several specialty panels are also available for analytesrelated to bone, sepsis/apoptosis and skin. LINCO is also awell known provider of traditional RIA and ELISA kits for diabe-tes and obesity.

Luminex CorporationLuminex CorporationLuminex CorporationLuminex CorporationLuminex Corporation12212 Technology Blvd.Austin, TX 78727Booth Number: 34Booth Number: 34Booth Number: 34Booth Number: 34Booth Number: 34

Luminex Corporation develops, manufactures and markets pro-prietary biological testing technologies, with applications through-out the life-sciences industry. This industry depends on a broadrange of tests, known as “bioassays,” to discover new drugs,identify new genes or simply monitor blood cholesterol levels.The experts at Luminex have developed an innovative approachto bioassays, known as xMAP technology. This groundbreakingtechnology, enables companies and laboratories to perform bio-assays more quickly and cost-effectively than with other systems,without sacrificing accuracy.

Miltenyi Biotec, Inc.Miltenyi Biotec, Inc.Miltenyi Biotec, Inc.Miltenyi Biotec, Inc.Miltenyi Biotec, Inc.251 Auburn Ravine RoadSuite 208Auburn, CA 95603Booth Number: 35Booth Number: 35Booth Number: 35Booth Number: 35Booth Number: 35

Miltenyi Biotec, manufacturer of MACS Separation Technology,supplies equipment and reagents for the immunomagnetic isola-tion of specific cell types, organelles, and molecules from hetero-geneous samples. The CliniMACS system, approved in the Euro-pean Union since December of 1997, is indicated for the purifi-cation of stem cells for the use in bone marrow transplantation.


National Institute of Allergy and Infectious Dis-National Institute of Allergy and Infectious Dis-National Institute of Allergy and Infectious Dis-National Institute of Allergy and Infectious Dis-National Institute of Allergy and Infectious Dis-eases/National Institutes of Healtheases/National Institutes of Healtheases/National Institutes of Healtheases/National Institutes of Healtheases/National Institutes of Health4900 Seminary RoadSuite 1100Alexandria, VA 22311Booth Number: 9Booth Number: 9Booth Number: 9Booth Number: 9Booth Number: 9

With nationwide responsibility for improving the health and wellbeing of all Americans, the Department of Health and HumanServices, (DHHS), oversees the biomedical research programsof the National Institutes of Health, (NIH), and those of NIH’sresearch Institutes. NIAID is the second largest of 27 Institutesand Centers of the world-renowned National Institutes of Health,DHHS, the U.S. Government’s premier biomedical research in-stitution. The 317-acre NIH campus is located in Bethesda,Maryland.

ProImmune, Inc.ProImmune, Inc.ProImmune, Inc.ProImmune, Inc.ProImmune, Inc.Oxford BioBusiness CenterLittlemore ParkLittlemore, Oxford OX4 4SSBooth Number: 36Booth Number: 36Booth Number: 36Booth Number: 36Booth Number: 36

ProImmune is a leading provider of products and services formonitoring the state of the immune system, including recombi-nant Pro5TM MHC Pentamers, custom peptide libraries andantibodies. Pro5TM MHC Pentamers can be used to evaluate Tcell immunity in disease and in response to therapy, enablinginvestigators to accelerate their research and the discovery anddevelopment of new biopharmaceutical drugs in areas of ma-jor unmet need, such as cancer, infectious diseases, autoimmu-nity, and in transplantation.

SeraCare Life SciencesSeraCare Life SciencesSeraCare Life SciencesSeraCare Life SciencesSeraCare Life Sciences1935 Avenida DeloroSuite FOceanside, CA 92056Booth Number: 38Booth Number: 38Booth Number: 38Booth Number: 38Booth Number: 38SeraCare offers a broad range of biological based materialsand services, including clinical specimens used for target iden-tification, culture and media components, blood-derived basematrices, positive and negative control sera, and various puri-fied proteins. Products featured will include our extensive bankof specimens obtained from apparent ADR cases, with poten-tial use in toxicogenomic and protein identification, and viable,well-characterized cryopreserved human PBMC’s.


64

THERAKOSTHERAKOSTHERAKOSTHERAKOSTHERAKOS437 Creamery WayExton, PA 19341Booth Number: 39Booth Number: 39Booth Number: 39Booth Number: 39Booth Number: 39

THERAKOS, Inc., an immune cell therapy company, is a world-wide leader in extracorporeal disease management. THERAKOSPhotopheresis, including the UVAR ® XTS ™ System and UVADEX® Methoxsalen Sterile Solution, IS approved for the palliativetreatment of skin manifestations in Cutaneous T-Cell Lymphoma,and is currently being studied in other immune mediated dis-eases.

UpstateUpstateUpstateUpstateUpstate706 Forest StreetCharlottesville, VA 22903Booth Number: 40Booth Number: 40Booth Number: 40Booth Number: 40Booth Number: 40Upstate is a leading provider of cell signaling products andservices for research and drug discovery. Products include anti-bodies, enzymes, siRNA and assay kits for signaling pathwayanalysis, as well as a complete offering of cytokine, chemokineand growth factor multiplex kits for the Luminex System.


Whatman/Schleicher & Schuell BioScience, Inc.Whatman/Schleicher & Schuell BioScience, Inc.Whatman/Schleicher & Schuell BioScience, Inc.Whatman/Schleicher & Schuell BioScience, Inc.Whatman/Schleicher & Schuell BioScience, Inc.PO Box 201210 Optical AvenueKeene, NH 03431Booth Number: 7-8Booth Number: 7-8Booth Number: 7-8Booth Number: 7-8Booth Number: 7-8Whatman/Schleicher & Schuell BioScience will feature thecompany’s full line of protein array products and services, in-cluding the new S&S Two-Color Labeling and Fluorescent De-tection Kit. FAST Quant protein array kits and software for multi-plex cytokine quantification, FAST Slides and protein arrayingkits, and a complete menu of protein arraying, processing andscanning services.

20052005200520052005ANNUAL MEETING

65


FOCIS 2005 TFOCIS 2005 TFOCIS 2005 TFOCIS 2005 TFOCIS 2005 Travel Aravel Aravel Aravel Aravel Award Recipientsward Recipientsward Recipientsward Recipientsward Recipients

Biogen IDECBiogen IDECBiogen IDECBiogen IDECBiogen IDECDaniel BandariHalima El-MouslimanySteve BrassRitika JainiAnjali ShahOlaf StuveGreg Wu

Boehringer IngelheimBoehringer IngelheimBoehringer IngelheimBoehringer IngelheimBoehringer IngelheimPhillip BardwellS. Ben-HorinGilles BenichouSwati BhattacharyyaClaudia CalderV. Cotta-de-AlmeiP. DavisCory EbelingAlexander EspinosaMassimo Claudio FantiniThomas FehrDan FrenkelR. GorczyskiBrian HelmichS. KaiedaC. KliwinskiChun LauI-Fang LeeD. MacKenzieEverett MeyerQin NingN. PhillipsJ. ShenYasuyo ShimomuraB. ShumPhillipe StockTroy TorgersonM. Vargas-RojasXiaochun WanVaughan WittmanDianna WuJun YanSimone Zehntner

Bristol-Myers SquibbBristol-Myers SquibbBristol-Myers SquibbBristol-Myers SquibbBristol-Myers SquibbRobert AxtellAlicia BabcockEstelle BettelliTarek FahmyLisa GilliamPeggy HoJing HuaJennifer HugginsMeghavi KosbothKristi KuhnPaul LizzulDouglas McDonaldMaki NakayamaChristina NanceMindi WalkerKefei Yu

Dana FoundationDana FoundationDana FoundationDana FoundationDana FoundationRebecca AshfieldClare Baecher-AllenK. HaanstraFabienne HaspotSally KentSiegfried KohlerStephen MillerVivetka OlingKen SugimotoDale Umetsu

FOCISFOCISFOCISFOCISFOCISMarsilio AdrianiFlorence AllantazJacqueline BensonGaelle BeriouYijun CarrierD. CastanoMiguel de La FuenteScott DeGregorioF. DolganiucS. DunnAnna ErikssonRonald Germain

Anjelica GonzalezXiaonan HanHenry HessAli JabbariAndrew JohnstonH. KandilSonja KiersteinBrent KoehnSubramaniam KrishnanAdam Lacy-HulbertF. LiJulie LinRalf LinkerJ. ListopadPeng LiuDalam LyEmma MastellerLaurie MinnsMohamad MohtyKoichiro OhmuraGeorgios PapachristouB. RethiKhaja RhemanChiara RomagnaniPedro RuizMichael ShakarijanNicole SherryAlla SkapenkoDusanka SkundricJason SongPeter SziglietiHenrik Toft-HansenYue WangBo WeiKristy Wolniak


66

FOCIS 2005 TFOCIS 2005 TFOCIS 2005 TFOCIS 2005 TFOCIS 2005 Travel Aravel Aravel Aravel Aravel Award Recipientsward Recipientsward Recipientsward Recipientsward Recipients

Juvenile DiabetesJuvenile DiabetesJuvenile DiabetesJuvenile DiabetesJuvenile DiabetesResearch FoundationResearch FoundationResearch FoundationResearch FoundationResearch FoundationDamien BressonChristopher MooreYu Feng PengGovinda Rajagopalan

National InstitutesNational InstitutesNational InstitutesNational InstitutesNational Institutesof Healthof Healthof Healthof Healthof HealthV. BajzikPeter BarthmaierS. BerloD. Cunningham-GrahamSilvia DeaglioRaquel DeeringPhillip DeJagerLeen DeRyckeUmesh DeshmukhIvana Durinovic-BelloR. HoffmanJean JasinskiJennifer KanterNorma Sue KenyonGeorges MaestroniCecilia MartaRiccardo NavoneRoman PuliaevK. RamanRobert RigbyVeerle Anne-Marie SomersW. WalchholzJ. WangKlau WarnatzMaria WysockaAlexandra Zanin-Zhorov

National Multiple Sclerosis SocietyNational Multiple Sclerosis SocietyNational Multiple Sclerosis SocietyNational Multiple Sclerosis SocietyNational Multiple Sclerosis SocietyAlexandra DegenhartSusan GauthierAdil JavedSalvatore Napoli

Immune TImmune TImmune TImmune TImmune Tolerance Networkolerance Networkolerance Networkolerance Networkolerance NetworkOmid AkbariMartin DahlStephanie DouganJ. Harrt MeyersMary KeirMasaaki NiinoHuey-Kang SytwuNalan UtkuBart Van WijmeerschC. Wu

NovartisNovartisNovartisNovartisNovartisElena YarmolaLinda Wu

TTTTTevaevaevaevaevaElizabeth HodgesAshutosh MangalamKevin O’ConnorDaniel LiK. SakuishiU. SalzerAlicja WaliszewskaDun Zhou

FOCIS 2005 ParFOCIS 2005 ParFOCIS 2005 ParFOCIS 2005 ParFOCIS 2005 Participation Aticipation Aticipation Aticipation Aticipation Award Recipientsward Recipientsward Recipientsward Recipientsward Recipients

Jeffrey Modell FoundationJeffrey Modell FoundationJeffrey Modell FoundationJeffrey Modell FoundationJeffrey Modell FoundationClara BuenoEva CarmonaAudrey Chen

20052005200520052005ANNUAL MEETING

67


=====Poster of Distinction. Scored in TPoster of Distinction. Scored in TPoster of Distinction. Scored in TPoster of Distinction. Scored in TPoster of Distinction. Scored in Top 10% of Poster Submissions.op 10% of Poster Submissions.op 10% of Poster Submissions.op 10% of Poster Submissions.op 10% of Poster Submissions.

Poster Session 1Poster Session 1Poster Session 1Poster Session 1Poster Session 1FridayFridayFridayFridayFriday, May 13, 2005, May 13, 2005, May 13, 2005, May 13, 2005, May 13, 2005

7:30 am - 1:30 pm7:30 am - 1:30 pm7:30 am - 1:30 pm7:30 am - 1:30 pm7:30 am - 1:30 pm

Allergy/AsthmaAllergy/AsthmaAllergy/AsthmaAllergy/AsthmaAllergy/AsthmaF1.01 - Prevalence of Aeroallergens in Allergic Rhinitis.F1.01 - Prevalence of Aeroallergens in Allergic Rhinitis.F1.01 - Prevalence of Aeroallergens in Allergic Rhinitis.F1.01 - Prevalence of Aeroallergens in Allergic Rhinitis.F1.01 - Prevalence of Aeroallergens in Allergic Rhinitis.Mohammad Amin Kashef,1 Sara Kashef,2 Fardin Eghtedari.3

1Allergy Research Center, Shiraz University of Medical Sciences,Shiraz, Fars, Islamic Republic of Iran; 2Immunology and Allergy,Shiraz University of Medical Sciences, Shiraz, Fars, Islamic Re-public of Iran; 3Otolaryngology, Shiraz University of MedicalSciences, Shiraz, Fars, Islamic Republic of Iran.

F1.02 - Modulation of Immunological Functions of Mast CellsF1.02 - Modulation of Immunological Functions of Mast CellsF1.02 - Modulation of Immunological Functions of Mast CellsF1.02 - Modulation of Immunological Functions of Mast CellsF1.02 - Modulation of Immunological Functions of Mast Cellsby Heat Shock.by Heat Shock.by Heat Shock.by Heat Shock.by Heat Shock.E. Mortaz, F. A. Redegeld, M. W. Heijden, F. P. Nijkamp, H. R.Wong, F. Engels. 1Dept. Pharmacology & Pathophysiology,Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht,Netherlands; 2Dept. Pharmacology & Pathophysiology, Institutefor Pharmaceutical Sciences (UIPS), Utrecht, Netherlands; 3Dept.Pharmacology & Pathophysiology, Institute for PharmaceuticalSciences (UIPS), Utrecht, Netherlands; 4Dept. Pharmacology &Pathophysiology, Institute for Pharmaceutical Sciences (UIPS),Utrecht, Netherlands; 5Critical Care, Division of Critical CareMedicine, Children’s Hospital Medical Center and Children’sHospital, Cincinnati, OH, USA; 6Dept. Pharmacology & Patho-physiology, Institute for Pharmaceutical Sciences (UIPS), Utrecht,Netherlands.

F1.03 - Naive CD4+ T Cell Activation by Antigen-Present-F1.03 - Naive CD4+ T Cell Activation by Antigen-Present-F1.03 - Naive CD4+ T Cell Activation by Antigen-Present-F1.03 - Naive CD4+ T Cell Activation by Antigen-Present-F1.03 - Naive CD4+ T Cell Activation by Antigen-Present-ing Airing Airing Airing Airing Airway Eosinophils.way Eosinophils.way Eosinophils.way Eosinophils.way Eosinophils.H. Wang,1 P. F. Weller.1 1Division of Allergy and Inflammation,Beth Israel Deaconess Medical Center, Harvard Medical School,Boston, MA, USA.

F1.04 - TF1.04 - TF1.04 - TF1.04 - TF1.04 - Transforransforransforransforransforming Growth Factor Beta-1 May Up Regulateming Growth Factor Beta-1 May Up Regulateming Growth Factor Beta-1 May Up Regulateming Growth Factor Beta-1 May Up Regulateming Growth Factor Beta-1 May Up RegulateInterferon Gamma Production by Peripheral Blood Mono-Interferon Gamma Production by Peripheral Blood Mono-Interferon Gamma Production by Peripheral Blood Mono-Interferon Gamma Production by Peripheral Blood Mono-Interferon Gamma Production by Peripheral Blood Mono-nuclear Cells from Asthmatics and Normal Controls.nuclear Cells from Asthmatics and Normal Controls.nuclear Cells from Asthmatics and Normal Controls.nuclear Cells from Asthmatics and Normal Controls.nuclear Cells from Asthmatics and Normal Controls.J. Joseph,1 S. Benedict,1 M. Joseph,2 B. Al-Ramadi.3 1InternalMedicine, Faculty of Medicine & Health Sciences, Al Ain,Abudhabi, United Arab Emirates; 2Pediatrics, Al Ain Hospital,Al Ain, Abudhabi, United Arab Emirates; 3Microbiology & Im-munology, FAculty of Medicine & Health Sciences, Al Ain,Abudhabi, United Arab Emirates.

F1.05 - Increased Experession in CD30+ and CD57+ Mol-F1.05 - Increased Experession in CD30+ and CD57+ Mol-F1.05 - Increased Experession in CD30+ and CD57+ Mol-F1.05 - Increased Experession in CD30+ and CD57+ Mol-F1.05 - Increased Experession in CD30+ and CD57+ Mol-ecules on CD4+ T Cells in Atopic Asthmatic Children: A Pre-ecules on CD4+ T Cells in Atopic Asthmatic Children: A Pre-ecules on CD4+ T Cells in Atopic Asthmatic Children: A Pre-ecules on CD4+ T Cells in Atopic Asthmatic Children: A Pre-ecules on CD4+ T Cells in Atopic Asthmatic Children: A Pre-liminarliminarliminarliminarliminary Repory Repory Repory Repory Report.t.t.t.t.N. E. Martinez-Jimenez,1 E. Rojas-Ramos,1 Y. B. Garfias,2 E. G.Zenteno,2 R. L. Lascurain.2 1Clinical Immunology and Allergy,ISSSTE, Mexico, Mexico City, Mexico; 2Biochemistry, INER, SSA,Mexico, Mexico City, Mexico.

F1.06 - CCR3 Expressed on CD4+ T Cells Correlations withF1.06 - CCR3 Expressed on CD4+ T Cells Correlations withF1.06 - CCR3 Expressed on CD4+ T Cells Correlations withF1.06 - CCR3 Expressed on CD4+ T Cells Correlations withF1.06 - CCR3 Expressed on CD4+ T Cells Correlations withIL-4 Production in Allergic Rhinitis Patients. PreliminarIL-4 Production in Allergic Rhinitis Patients. PreliminarIL-4 Production in Allergic Rhinitis Patients. PreliminarIL-4 Production in Allergic Rhinitis Patients. PreliminarIL-4 Production in Allergic Rhinitis Patients. Preliminary Re-y Re-y Re-y Re-y Re-port.port.port.port.port.E. Rojas-Ramos,1 M. N. Martinez-Jimenez,1 E. G. Zenteno,2 Y.B. Garfias,2 R. L. Lascurain.2 1Clinical Immunology and Allergy,ISSSTE, Mexico, Mexico City, Mexico; 2Biochemistry, INER,SSA,Mexico, Mexico City, Mexico.

F1.07 - Mugwort-Pollen Allergy Represents an Ideal Candi-F1.07 - Mugwort-Pollen Allergy Represents an Ideal Candi-F1.07 - Mugwort-Pollen Allergy Represents an Ideal Candi-F1.07 - Mugwort-Pollen Allergy Represents an Ideal Candi-F1.07 - Mugwort-Pollen Allergy Represents an Ideal Candi-date for Peptide Immunotherapydate for Peptide Immunotherapydate for Peptide Immunotherapydate for Peptide Immunotherapydate for Peptide Immunotherapy.....B. Jahn-Schmid,1 G. F. Fischer,2 B. Bohle,1 F. Ferreira,3 C. Ebner.11Dept. of Pathophysiology, Medical University of Vienna, Vienna,Austria; 2Dept. of Blood Serology, Medical University of Vienna,Vienna, Austria; 3Department of Immunology and Allergology,University of Salzburg, Salzburg, Austria.

F1.08 - Characterization of Human Cord Blood-Derived InF1.08 - Characterization of Human Cord Blood-Derived InF1.08 - Characterization of Human Cord Blood-Derived InF1.08 - Characterization of Human Cord Blood-Derived InF1.08 - Characterization of Human Cord Blood-Derived InVitro Generated Mast Cells: Hemopoietic Antigens,Vitro Generated Mast Cells: Hemopoietic Antigens,Vitro Generated Mast Cells: Hemopoietic Antigens,Vitro Generated Mast Cells: Hemopoietic Antigens,Vitro Generated Mast Cells: Hemopoietic Antigens,Chemokine Receptors, Activation Markers, TChemokine Receptors, Activation Markers, TChemokine Receptors, Activation Markers, TChemokine Receptors, Activation Markers, TChemokine Receptors, Activation Markers, Tetraspanins.etraspanins.etraspanins.etraspanins.etraspanins.I. Mirkina, T. Schweighoffer. 1RD-ADV, Novartis Institutes forBiomedical Research, Vienna, Austria.

F1.09 - IL-4Ra Single Nucleotide Polymorphisms in Aller-F1.09 - IL-4Ra Single Nucleotide Polymorphisms in Aller-F1.09 - IL-4Ra Single Nucleotide Polymorphisms in Aller-F1.09 - IL-4Ra Single Nucleotide Polymorphisms in Aller-F1.09 - IL-4Ra Single Nucleotide Polymorphisms in Aller-gic Bronchopulmonargic Bronchopulmonargic Bronchopulmonargic Bronchopulmonargic Bronchopulmonary Aspergillosis.y Aspergillosis.y Aspergillosis.y Aspergillosis.y Aspergillosis.Alan P. Knutsen,1 Barbara Kariuki,1 Manoj R. Warrier.2 1Al-lergy/Immunology, Saint Louis University, St. Louis, MO, USA;2Allergy/Immunology, Cincinnati Children’s Hospital, Cincinnati,OH, USA.

Abstracts in Order of PresentationAbstracts in Order of PresentationAbstracts in Order of PresentationAbstracts in Order of PresentationAbstracts in Order of Presentation


68=====Poster of Distinction. Scored in TPoster of Distinction. Scored in TPoster of Distinction. Scored in TPoster of Distinction. Scored in TPoster of Distinction. Scored in Top 10% of Poster Submissions.op 10% of Poster Submissions.op 10% of Poster Submissions.op 10% of Poster Submissions.op 10% of Poster Submissions.

F1.10 - House Dust Mite Allergen (Der p1 and Blo t5) LevelsF1.10 - House Dust Mite Allergen (Der p1 and Blo t5) LevelsF1.10 - House Dust Mite Allergen (Der p1 and Blo t5) LevelsF1.10 - House Dust Mite Allergen (Der p1 and Blo t5) LevelsF1.10 - House Dust Mite Allergen (Der p1 and Blo t5) Levelsin Asthmatics’ Home in Hong Kong.in Asthmatics’ Home in Hong Kong.in Asthmatics’ Home in Hong Kong.in Asthmatics’ Home in Hong Kong.in Asthmatics’ Home in Hong Kong.Baoqing Sun, Adrian Wu, Nanshan Zhong. 1Dept of Medi-cine, Guangzhou Institute of Respiratory Deseases, Guangzhou,GuangDong, China; 2Dept of Medicine, The University ofHongKong, HongKong, Hong Kong; 3Dept of Medicine,Guangzhou Institute of Respiratory Deseases, Guangzhou,GuangDong, China.

F1.11 - House Dust Mite Allergen Der f Increase BronchialF1.11 - House Dust Mite Allergen Der f Increase BronchialF1.11 - House Dust Mite Allergen Der f Increase BronchialF1.11 - House Dust Mite Allergen Der f Increase BronchialF1.11 - House Dust Mite Allergen Der f Increase BronchialEpithelial Cell Cytokine Expression.Epithelial Cell Cytokine Expression.Epithelial Cell Cytokine Expression.Epithelial Cell Cytokine Expression.Epithelial Cell Cytokine Expression.Baoqing Sun, Nanshan Zhong. 1Dept of Medicine, GuangzhouInstitute of Respiratory Diseases, Guangzhou, GuangDong,China; 2Dept of Medicine, Guangzhou Institute of RespiratoryDiseases, Guangzhou, GuangDong, China.

F1.12 - F1.12 - F1.12 - F1.12 - F1.12 - D. pteronyssinus D. pteronyssinus D. pteronyssinus D. pteronyssinus D. pteronyssinus Extract-TExtract-TExtract-TExtract-TExtract-Treated Confluent A549 Cellsreated Confluent A549 Cellsreated Confluent A549 Cellsreated Confluent A549 Cellsreated Confluent A549 Cells(cA549) Secrete Mediators That Stimulate Human Pulmonar(cA549) Secrete Mediators That Stimulate Human Pulmonar(cA549) Secrete Mediators That Stimulate Human Pulmonar(cA549) Secrete Mediators That Stimulate Human Pulmonar(cA549) Secrete Mediators That Stimulate Human PulmonaryyyyyFibroblasts TFibroblasts TFibroblasts TFibroblasts TFibroblasts To Increase Secretion of Vo Increase Secretion of Vo Increase Secretion of Vo Increase Secretion of Vo Increase Secretion of Vascular Endothelialascular Endothelialascular Endothelialascular Endothelialascular EndothelialGrowth Factor (VEGF).Growth Factor (VEGF).Growth Factor (VEGF).Growth Factor (VEGF).Growth Factor (VEGF).A. Capetandes,1 M. Frieri.1 1Dept of Pathology, Division ofAllergy Immunology, Nassau University Medical Center, EastMeadow, NY, USA.

F1.13 - Skin Reactivity for Aeroallergens and Peripheral Eosi-F1.13 - Skin Reactivity for Aeroallergens and Peripheral Eosi-F1.13 - Skin Reactivity for Aeroallergens and Peripheral Eosi-F1.13 - Skin Reactivity for Aeroallergens and Peripheral Eosi-F1.13 - Skin Reactivity for Aeroallergens and Peripheral Eosi-nophilia in Children with Otitis Media with Effusion.nophilia in Children with Otitis Media with Effusion.nophilia in Children with Otitis Media with Effusion.nophilia in Children with Otitis Media with Effusion.nophilia in Children with Otitis Media with Effusion.Fardin Eghtedari,1 Hossein Mohammadi-Nik,1 Sara Kashef,1

Mohammad Hadi Imanieh,1 Farhad Handjani,1 EskandarKamali-Sarvestani,1 Marzieh Orouj.1 1Allergy Research Cen-ter, Shiraz University of Medical Sciences, Shiraz, Fars, IslamicRepublic of Iran.

F1.14 - Recurrent Angioedema by Blastocystis Hominis Suc-F1.14 - Recurrent Angioedema by Blastocystis Hominis Suc-F1.14 - Recurrent Angioedema by Blastocystis Hominis Suc-F1.14 - Recurrent Angioedema by Blastocystis Hominis Suc-F1.14 - Recurrent Angioedema by Blastocystis Hominis Suc-cessfully Tcessfully Tcessfully Tcessfully Tcessfully Treated with Paromomycin.reated with Paromomycin.reated with Paromomycin.reated with Paromomycin.reated with Paromomycin.D. Micheloud,1 J. Jensen,1 E. Fernandez-Cruz,1 J. Carbone.1

1Clinical Immunology Unit, University Hospital Gregorio Maranon,Madrid, Spain.

F1.15 - Exposure to Monomeric Human Myeloma IgE in theF1.15 - Exposure to Monomeric Human Myeloma IgE in theF1.15 - Exposure to Monomeric Human Myeloma IgE in theF1.15 - Exposure to Monomeric Human Myeloma IgE in theF1.15 - Exposure to Monomeric Human Myeloma IgE in theAbsence of Known Specific Antigen Can Enhance ChemokineAbsence of Known Specific Antigen Can Enhance ChemokineAbsence of Known Specific Antigen Can Enhance ChemokineAbsence of Known Specific Antigen Can Enhance ChemokineAbsence of Known Specific Antigen Can Enhance ChemokineProduction in Production in Production in Production in Production in In VitroIn VitroIn VitroIn VitroIn Vitro-Derived Human Mast Cells.-Derived Human Mast Cells.-Derived Human Mast Cells.-Derived Human Mast Cells.-Derived Human Mast Cells.Adrian M. Piliponsky,1 Kentaro Matsuda,1 Motoyasu Iikura,1Toshiaki Kawakami,2 Evelyn Wang,1 Mindy Tsai,1 Stephen J.Galli.1,3 1Pathology, Stanford University School of Medicine,Stanford, CA, USA; 2Division of Cell Biology, La Jolla Institute forAllergy and Immunology, San Diego, CA, USA; 3Microbiologyand Immunology, Stanford University School of Medicine,Stanford, CA, USA.

F1.16 - Comparison of the Efficacy of Intranasal PhototherapyF1.16 - Comparison of the Efficacy of Intranasal PhototherapyF1.16 - Comparison of the Efficacy of Intranasal PhototherapyF1.16 - Comparison of the Efficacy of Intranasal PhototherapyF1.16 - Comparison of the Efficacy of Intranasal Phototherapyand Fexofenadine Hydrochloride for the Tand Fexofenadine Hydrochloride for the Tand Fexofenadine Hydrochloride for the Tand Fexofenadine Hydrochloride for the Tand Fexofenadine Hydrochloride for the Treatment of Sea-reatment of Sea-reatment of Sea-reatment of Sea-reatment of Sea-sonal Allergic Rhinitis.sonal Allergic Rhinitis.sonal Allergic Rhinitis.sonal Allergic Rhinitis.sonal Allergic Rhinitis.A. Koreck, Zs Csoma, M. Boros-Gyevi, L. Kemeny. 1Departmentof Dermatology and Allergology, University of Szeged, Szeged,Hungary..F1.17 - Inhibition of the Peptidyl-prolyl Isomerase (PPIase)F1.17 - Inhibition of the Peptidyl-prolyl Isomerase (PPIase)F1.17 - Inhibition of the Peptidyl-prolyl Isomerase (PPIase)F1.17 - Inhibition of the Peptidyl-prolyl Isomerase (PPIase)F1.17 - Inhibition of the Peptidyl-prolyl Isomerase (PPIase)Pin1 Induces Caspase-3-Mediated Apoptosis of Human Pe-Pin1 Induces Caspase-3-Mediated Apoptosis of Human Pe-Pin1 Induces Caspase-3-Mediated Apoptosis of Human Pe-Pin1 Induces Caspase-3-Mediated Apoptosis of Human Pe-Pin1 Induces Caspase-3-Mediated Apoptosis of Human Pe-ripheral Blood Eosinophils.ripheral Blood Eosinophils.ripheral Blood Eosinophils.ripheral Blood Eosinophils.ripheral Blood Eosinophils.Z. J. Shen,1 S. J. Esnault,1 J. S. Malter.1 1Pathology and Labora-tory Medicine, Waisman Center for Developmental Disabilities,University of Wisconsin, Madison, WI, USA.

F1.18 - Natural CD25F1.18 - Natural CD25F1.18 - Natural CD25F1.18 - Natural CD25F1.18 - Natural CD25+++++CD4CD4CD4CD4CD4+++++ Regulator Regulator Regulator Regulator Regulatory Cells Inhibit Pro-y Cells Inhibit Pro-y Cells Inhibit Pro-y Cells Inhibit Pro-y Cells Inhibit Pro-liferation of CD25liferation of CD25liferation of CD25liferation of CD25liferation of CD25-----CD4CD4CD4CD4CD4+++++ Cells from Naive or Immunized BALB/ Cells from Naive or Immunized BALB/ Cells from Naive or Immunized BALB/ Cells from Naive or Immunized BALB/ Cells from Naive or Immunized BALB/c Mice When Stimulated by Dendritic Cells Pulsed with Fel dc Mice When Stimulated by Dendritic Cells Pulsed with Fel dc Mice When Stimulated by Dendritic Cells Pulsed with Fel dc Mice When Stimulated by Dendritic Cells Pulsed with Fel dc Mice When Stimulated by Dendritic Cells Pulsed with Fel d1 or Major Fel d 1 T Cell Epitopes.1 or Major Fel d 1 T Cell Epitopes.1 or Major Fel d 1 T Cell Epitopes.1 or Major Fel d 1 T Cell Epitopes.1 or Major Fel d 1 T Cell Epitopes.F. R. Hentges,1 C. A. Leonard,1 C. P. Le Pogam.1 1Laboratory ofImmunogenetics and Allergology, CRP-Sante, Luxembourg, Lux-embourg.

F1.19 - Omalizumab Improves Asthma Outcomes Irrespec-F1.19 - Omalizumab Improves Asthma Outcomes Irrespec-F1.19 - Omalizumab Improves Asthma Outcomes Irrespec-F1.19 - Omalizumab Improves Asthma Outcomes Irrespec-F1.19 - Omalizumab Improves Asthma Outcomes Irrespec-tive of Leukotriene Receptor Antagonist (Ltive of Leukotriene Receptor Antagonist (Ltive of Leukotriene Receptor Antagonist (Ltive of Leukotriene Receptor Antagonist (Ltive of Leukotriene Receptor Antagonist (LTRA) Use.TRA) Use.TRA) Use.TRA) Use.TRA) Use.M. Massanari,1 Y. Deniz,2 R. Maykut,1 C. Reisner,3 G. Geba.1

1US Clinical Development and Medical Affairs, Novartis Phar-maceuticals Corporation, East Hanover, NJ, USA; 2Clinical De-velopment, Genentech, South San Francisco, CA, USA; 3Clini-cal Development, Novartis Pharmaceuticals, East Hanover, NJ,USA.

20052005200520052005ANNUAL MEETING

69



F1.20 - Administration of Chitin Down-Regulate Serum IgEF1.20 - Administration of Chitin Down-Regulate Serum IgEF1.20 - Administration of Chitin Down-Regulate Serum IgEF1.20 - Administration of Chitin Down-Regulate Serum IgEF1.20 - Administration of Chitin Down-Regulate Serum IgELevels and Lung Eosinophilia in Ova-Albumin Allergic Mouse.Levels and Lung Eosinophilia in Ova-Albumin Allergic Mouse.Levels and Lung Eosinophilia in Ova-Albumin Allergic Mouse.Levels and Lung Eosinophilia in Ova-Albumin Allergic Mouse.Levels and Lung Eosinophilia in Ova-Albumin Allergic Mouse.C.-L. Kao,1 C.-R. Shen,1,2 C.-J. Lin,1 J.-K. Chen,3 M.-L. Kuo,2 C.-L.Liu.4 1Graduate Institute of Medical Biotechnology, Chang GungUniversity, Kweishan, Taoyuan, Taiwan; 2Graduate Institute ofBasic Medical Sciences, Chang Gung University, Kweishan,Taoyuan, Taiwan; 3Department of Environment and Biotechnol-ogy, Refine and Manufacture Research Center, Chinese Petro-leum Company, Chiayi, Chiayi, Taiwan; 4Graduate Institute ofEngineering and Department of Biochemical Engineering, Ming-Chi University of Technology, Taishan, Taipei, Taiwan.

F1.21 - Allergic /TF1.21 - Allergic /TF1.21 - Allergic /TF1.21 - Allergic /TF1.21 - Allergic /Toxic Manifestations Associated with In-oxic Manifestations Associated with In-oxic Manifestations Associated with In-oxic Manifestations Associated with In-oxic Manifestations Associated with In-gestion of Stir-Fried/ Cooked Mushrooms.gestion of Stir-Fried/ Cooked Mushrooms.gestion of Stir-Fried/ Cooked Mushrooms.gestion of Stir-Fried/ Cooked Mushrooms.gestion of Stir-Fried/ Cooked Mushrooms.M. Ishaq, I. M. Sameera, M. Taj. 1Allergy/Pulmonology, Al-Junaid Hospital, Nowshera, Pakistan.

F1.22 - Effects of TF1.22 - Effects of TF1.22 - Effects of TF1.22 - Effects of TF1.22 - Effects of Tacrolimus Upon Tacrolimus Upon Tacrolimus Upon Tacrolimus Upon Tacrolimus Upon T-L-L-L-L-Lymphocyte, NK Cell,ymphocyte, NK Cell,ymphocyte, NK Cell,ymphocyte, NK Cell,ymphocyte, NK Cell,and Eosinophil Activation.and Eosinophil Activation.and Eosinophil Activation.and Eosinophil Activation.and Eosinophil Activation.C. N. Huynh,1 E. S. Lee,1 Q. N. Chung,1 M. A. Gibson,1 R. L.Roberts.1 1Department of Pediatrics, David Geffen School ofMedicine at UCLA, Los Angeles, CA, USA.

F1.23 - Hemopoietic Cells Accumulate in Murine Lungs inF1.23 - Hemopoietic Cells Accumulate in Murine Lungs inF1.23 - Hemopoietic Cells Accumulate in Murine Lungs inF1.23 - Hemopoietic Cells Accumulate in Murine Lungs inF1.23 - Hemopoietic Cells Accumulate in Murine Lungs inResponse to Ectopic Grafts of Lung Tissue from Allergic andResponse to Ectopic Grafts of Lung Tissue from Allergic andResponse to Ectopic Grafts of Lung Tissue from Allergic andResponse to Ectopic Grafts of Lung Tissue from Allergic andResponse to Ectopic Grafts of Lung Tissue from Allergic andfrom IL-5 Tfrom IL-5 Tfrom IL-5 Tfrom IL-5 Tfrom IL-5 Transgenic Donors.ransgenic Donors.ransgenic Donors.ransgenic Donors.ransgenic Donors.M. I. Gaspar-Elsas, E. S. Maximiano, T. Q. Souza-Pinto, D. Jo-seph, B. B. Vargaftig, P. Xavier Elsas. 1Pediatrics, InstitutoFernandes Figueira - FIOCRUZ, Rio de Janeiro, RJ, Brazil; 2Im-munology, Inst. Microbiol. Prof. Paulo de Goes - UFRJ, Rio deJaneiro, RJ, Brazil; 3Pharmacology, Instituto de CienciasBiomedicas - USP, Sao Paulo, SP, Brazil; 4Unite Pharmacol.Cellulaire - U485 INSERM, Institut Pasteur Paris, Paris, Ile-de-France, France.

F1.24 - Intracellular Stores of Interleukin-4 (IL-4) Receptor aF1.24 - Intracellular Stores of Interleukin-4 (IL-4) Receptor aF1.24 - Intracellular Stores of Interleukin-4 (IL-4) Receptor aF1.24 - Intracellular Stores of Interleukin-4 (IL-4) Receptor aF1.24 - Intracellular Stores of Interleukin-4 (IL-4) Receptor aL. A. Spencer,1 R. C.N. Melo,1,2 S. A.C. Perez,1 A. M. Dvorak,3P. F. Weller.1 1Department of Medicine, Beth Israel DeaconessMedical Center, Boston, MA, USA; 2Department of Biology, Fed-eral University of Juiz de Fora, Juiz de Fora, MG, Brazil; 3De-partment of Pathology, Beth Israel Deaconess Medical Center,Boston, MA, USA.

F1.25 - Anaphylaxis to Intravenous and Oral Cyclosporin inF1.25 - Anaphylaxis to Intravenous and Oral Cyclosporin inF1.25 - Anaphylaxis to Intravenous and Oral Cyclosporin inF1.25 - Anaphylaxis to Intravenous and Oral Cyclosporin inF1.25 - Anaphylaxis to Intravenous and Oral Cyclosporin ina Child and Successful Desensitization.a Child and Successful Desensitization.a Child and Successful Desensitization.a Child and Successful Desensitization.a Child and Successful Desensitization.Sara Kashef,1 Mojhgan Kiani,2 Habib Nourani-Khojasteh,3 ManiRamzi.3 1Allergy Research Center, Pediatric Immunology & Al-lergy, Shiraz University of Medical Sciences, Shiraz, Fars, Is-lamic Republic of Iran; 2Pediatric Immunology & Allergy, ShirazUniversity of Medical Sciences, Shiraz, Fars, Islamic Republic ofIran; 3Department of Hematology & Oncology, Shiraz Universityof Medical Sciences, Shiraz, Fars, Islamic Republic of Iran.

F1.26 - Skin Reactivity to Aeroallergens Is Not Related to theF1.26 - Skin Reactivity to Aeroallergens Is Not Related to theF1.26 - Skin Reactivity to Aeroallergens Is Not Related to theF1.26 - Skin Reactivity to Aeroallergens Is Not Related to theF1.26 - Skin Reactivity to Aeroallergens Is Not Related to theNasal Polyp Tissue Eosinophil Inflammation.Nasal Polyp Tissue Eosinophil Inflammation.Nasal Polyp Tissue Eosinophil Inflammation.Nasal Polyp Tissue Eosinophil Inflammation.Nasal Polyp Tissue Eosinophil Inflammation.Fardin Eghtedari,1 Seyed Reza Cheraghzadeh,2 Sara Kashef,3

Ahmad Monabati,4 Elham Shoraka.5 1Allergy Research Cen-ter, Department of Otolaryngology, Shiraz University of Medi-cal Sciences, Shiraz, Fars, Islamic Republic of Iran; 2Depart-ment of Otolaryngology, Shiraz University of Medical Sciences,Shiraz, Fars, Islamic Republic of Iran; 3Allergy Research Center,Pediatric Immunology & Allergy, Shiraz University of MedicalSciences, Shiraz, Fars, Islamic Republic of Iran; 4Department ofPathology, Shiraz University of Medical Sciences, Shiraz, Fars,Islamic Republic of Iran; 5Department of Obstetrics & Gynecol-ogy, Shahid Beheshti Hospital, Shiraz, Fars, Islamic Republic ofIran.

F1.27 - Superior Safety of Polymerized Allergen VF1.27 - Superior Safety of Polymerized Allergen VF1.27 - Superior Safety of Polymerized Allergen VF1.27 - Superior Safety of Polymerized Allergen VF1.27 - Superior Safety of Polymerized Allergen Vaccines:accines:accines:accines:accines:Zero Systemic Reactions during 55,000 Injections of Polymer-Zero Systemic Reactions during 55,000 Injections of Polymer-Zero Systemic Reactions during 55,000 Injections of Polymer-Zero Systemic Reactions during 55,000 Injections of Polymer-Zero Systemic Reactions during 55,000 Injections of Polymer-ized Ragweed and Grass Vized Ragweed and Grass Vized Ragweed and Grass Vized Ragweed and Grass Vized Ragweed and Grass Vaccines in 500 Allergy Patients.accines in 500 Allergy Patients.accines in 500 Allergy Patients.accines in 500 Allergy Patients.accines in 500 Allergy Patients.S. Kagen, J. Zondlo, R. Muthiah, M. Kagen. 1Allergy - Immu-nology, Kagen Allergy Clinic, Appleton, WI, USA.

F1.28 - TF1.28 - TF1.28 - TF1.28 - TF1.28 - Trans Fatty Acid and Atopic Eczema/Derrans Fatty Acid and Atopic Eczema/Derrans Fatty Acid and Atopic Eczema/Derrans Fatty Acid and Atopic Eczema/Derrans Fatty Acid and Atopic Eczema/Dermatitis Syn-matitis Syn-matitis Syn-matitis Syn-matitis Syn-drome: The Relationship with a Free Radical cis-trans Isomer-drome: The Relationship with a Free Radical cis-trans Isomer-drome: The Relationship with a Free Radical cis-trans Isomer-drome: The Relationship with a Free Radical cis-trans Isomer-drome: The Relationship with a Free Radical cis-trans Isomer-ization of Membrane Lipids Tization of Membrane Lipids Tization of Membrane Lipids Tization of Membrane Lipids Tization of Membrane Lipids Trans LIPIDS in Atopic Derrans LIPIDS in Atopic Derrans LIPIDS in Atopic Derrans LIPIDS in Atopic Derrans LIPIDS in Atopic Dermatitis.matitis.matitis.matitis.matitis.L. Chini,1 F. Angelini,1 C. Chatgilialoglu,2 S. Dellonte,2 V.Moschese,1 S. Corrente,1 R. Iannini,1 M. Chianca,1 P. Rossi,1 C.Ferreri.2 1Pediatrics, Policlinico Tor Vergata, University of RomeTor Vergata, Rome, Italy; 2ISOF, Consiglio Nazionale delleRicerche, Bologna, Italy.



F1.29 - ProinflammatorF1.29 - ProinflammatorF1.29 - ProinflammatorF1.29 - ProinflammatorF1.29 - Proinflammatory Cytokines and Nitric Oxide in Ex-y Cytokines and Nitric Oxide in Ex-y Cytokines and Nitric Oxide in Ex-y Cytokines and Nitric Oxide in Ex-y Cytokines and Nitric Oxide in Ex-haled Breth Condensate in Monitoring of Exacerbationhaled Breth Condensate in Monitoring of Exacerbationhaled Breth Condensate in Monitoring of Exacerbationhaled Breth Condensate in Monitoring of Exacerbationhaled Breth Condensate in Monitoring of ExacerbationAsthma in Children.Asthma in Children.Asthma in Children.Asthma in Children.Asthma in Children.Boleslaw Kalicki,1 Anna Jung,1 Wanda Stankiewicz,2 MarekDabrowski,2 Janusz Zuber.1 1Paediatric, Military Medical Insti-tute, Warsaw, Poland; 2Immunology, Institute of Hygiene andEpidemiology, Warsaw, Poland.

F1.30 - Combined Skin Prick, Immediate Patch and Specific-F1.30 - Combined Skin Prick, Immediate Patch and Specific-F1.30 - Combined Skin Prick, Immediate Patch and Specific-F1.30 - Combined Skin Prick, Immediate Patch and Specific-F1.30 - Combined Skin Prick, Immediate Patch and Specific-IgE TIgE TIgE TIgE TIgE Testing in the Diagnosis of Peanut Allergy in Children.esting in the Diagnosis of Peanut Allergy in Children.esting in the Diagnosis of Peanut Allergy in Children.esting in the Diagnosis of Peanut Allergy in Children.esting in the Diagnosis of Peanut Allergy in Children.B. K. Wainstein,1 A. Yee,1 M. Ziegler,1 D. Jelley,1 J. B. Ziegler.1

1Immunology and Infectious Diseases, Sydney Children’s Hospi-tal, Sydney, New South Wales, Australia.

F1.31 - Cow’F1.31 - Cow’F1.31 - Cow’F1.31 - Cow’F1.31 - Cow’s Milk Allergy in Infantile Colic.s Milk Allergy in Infantile Colic.s Milk Allergy in Infantile Colic.s Milk Allergy in Infantile Colic.s Milk Allergy in Infantile Colic.Mohammad Hadi Imanieh,1 Hosein Moravej,1 Sara Kashef,1Farhad Handjani,1 Eskandar Kamali-Sarvestani,1 FardinEghtedari,1 Marzieh Orouj.1 1Allergy Research Center, ShirazUniversity of Medical Sciences, Shiraz, Fars, Islamic Republic ofIran.

F1.32 - 5-Lipoxygenase Locolization to Cytosolic Lipid Bod-F1.32 - 5-Lipoxygenase Locolization to Cytosolic Lipid Bod-F1.32 - 5-Lipoxygenase Locolization to Cytosolic Lipid Bod-F1.32 - 5-Lipoxygenase Locolization to Cytosolic Lipid Bod-F1.32 - 5-Lipoxygenase Locolization to Cytosolic Lipid Bod-ies in Rat Basophil Leukemia Cells.ies in Rat Basophil Leukemia Cells.ies in Rat Basophil Leukemia Cells.ies in Rat Basophil Leukemia Cells.ies in Rat Basophil Leukemia Cells.Z. Jin,1 D. Wan,1 H. B. Wang,1 I. Ghiran,1 R. J. Soberman,2 P. F.Weller.1 1Division of Allergy and Inflammation, Beth-Israel Dea-coness Medical Center, Harvard Medical School, Boston, MA,USA; 2Massachusetts General Hospital, Harverd Medical School,Boston, MA, USA.

F1.33 - Approaches to Immunogenicity of Human ProteinF1.33 - Approaches to Immunogenicity of Human ProteinF1.33 - Approaches to Immunogenicity of Human ProteinF1.33 - Approaches to Immunogenicity of Human ProteinF1.33 - Approaches to Immunogenicity of Human ProteinProducts.Products.Products.Products.Products.H. S. Ko.1 1Division of Hematology, Office of Blood Researchand Review, Center for Biologics Evaluation and Research, Foodand Drug Administration, Rockville, MD, USA.

F1.34 - Plasma Concentration of Soluble IL-4 Receptor inF1.34 - Plasma Concentration of Soluble IL-4 Receptor inF1.34 - Plasma Concentration of Soluble IL-4 Receptor inF1.34 - Plasma Concentration of Soluble IL-4 Receptor inF1.34 - Plasma Concentration of Soluble IL-4 Receptor inAsthma Patients during Specific Bronchial Challenge withAsthma Patients during Specific Bronchial Challenge withAsthma Patients during Specific Bronchial Challenge withAsthma Patients during Specific Bronchial Challenge withAsthma Patients during Specific Bronchial Challenge withDermatophagoides Pteronyssinus(Dp) Allergen.Dermatophagoides Pteronyssinus(Dp) Allergen.Dermatophagoides Pteronyssinus(Dp) Allergen.Dermatophagoides Pteronyssinus(Dp) Allergen.Dermatophagoides Pteronyssinus(Dp) Allergen.K. Kowal,1 A. Pampuch,1 L. M. DuBuske,2 A. Bodzenta-Lukaszyk.1 1Department of Allergology and Internal Medicine,University Medical School of Bialystok, Bialystok, Poland; 2Im-munology Research Institute of New England, Gardner, MA,USA.

F1.35 - Interleukin-4 and Its AlterF1.35 - Interleukin-4 and Its AlterF1.35 - Interleukin-4 and Its AlterF1.35 - Interleukin-4 and Its AlterF1.35 - Interleukin-4 and Its Alternatively Spliced Vnatively Spliced Vnatively Spliced Vnatively Spliced Vnatively Spliced Variantariantariantariantariant(IL-4(IL-4(IL-4(IL-4(IL-4δ2) δ2) δ2) δ2) δ2) in Healthy Donors and Patients with Atopic Asthma.in Healthy Donors and Patients with Atopic Asthma.in Healthy Donors and Patients with Atopic Asthma.in Healthy Donors and Patients with Atopic Asthma.in Healthy Donors and Patients with Atopic Asthma.A. A. Babakhin,1 E. I. Bateneva,1 S. M. Andreev,1 M. R. Khaitov,1D. Y. Trofimov,1 L. P. Alekseev,1 L. M. DuBuske.2 1National Re-search Center, Institute of Immunology, Moscow, Russian Fed-eration; 2Immunology Research Institute of New England,Gardner, MA, USA.

F1.36 - B Epitope Assay of hIL-4F1.36 - B Epitope Assay of hIL-4F1.36 - B Epitope Assay of hIL-4F1.36 - B Epitope Assay of hIL-4F1.36 - B Epitope Assay of hIL-4δ2, δ2, δ2, δ2, δ2, an Alternative Splicingan Alternative Splicingan Alternative Splicingan Alternative Splicingan Alternative SplicingVVVVVariant of hIL-4.ariant of hIL-4.ariant of hIL-4.ariant of hIL-4.ariant of hIL-4.S. M. Andreev,1 I. V. Dubinkin,1 A. O. Petrukhina,1 A. M. Vasiliev,2I. V. Kosarev,2 N. V. Tokhtamysheva,2 G. Y. Puchkova,2 A. A.Babakhin,1 L. M. DuBuske.3 1NRC Institute of Immunology,Moscow, Russian Federation; 2Institute of Immunological Engi-neering, Lyubuchany, Moscow Region, Russian Federation; 3Im-munology Research Institute of New England, Gardner, MA,USA.

F1.37 - LPS Differentially Modulates Th2 Cell Responses toF1.37 - LPS Differentially Modulates Th2 Cell Responses toF1.37 - LPS Differentially Modulates Th2 Cell Responses toF1.37 - LPS Differentially Modulates Th2 Cell Responses toF1.37 - LPS Differentially Modulates Th2 Cell Responses toAntigen during Acute and Relapse Allergic Asthma in Mice.Antigen during Acute and Relapse Allergic Asthma in Mice.Antigen during Acute and Relapse Allergic Asthma in Mice.Antigen during Acute and Relapse Allergic Asthma in Mice.Antigen during Acute and Relapse Allergic Asthma in Mice.M. Zerbs,1 R. Bankoti,1 G. Dekan,2 G. Stingl,1 M. M. Epstein.1

1Dermatology, Medical University of Vienna, Vienna, Austria;2Clinical Pathology, Medical University of Vienna, Vienna, Aus-tria.

F1.38 - Differential Th2 Immune Responses in C57BL/6 andF1.38 - Differential Th2 Immune Responses in C57BL/6 andF1.38 - Differential Th2 Immune Responses in C57BL/6 andF1.38 - Differential Th2 Immune Responses in C57BL/6 andF1.38 - Differential Th2 Immune Responses in C57BL/6 andBALB/c Mice in a Novel Model of Milk-Induced AllergicBALB/c Mice in a Novel Model of Milk-Induced AllergicBALB/c Mice in a Novel Model of Milk-Induced AllergicBALB/c Mice in a Novel Model of Milk-Induced AllergicBALB/c Mice in a Novel Model of Milk-Induced AllergicAsthma.Asthma.Asthma.Asthma.Asthma.M. Zerbs,1 G. Dekan,2 G. Stingl,1 M. M. Epstein.1 1Dermatol-ogy, Medical University of Vienna, Vienna, Austria; 2ClinicalPathology, Medical University of Vienna, Vienna, Austria.

F1.39 - Response of Older Patients with Asthma toF1.39 - Response of Older Patients with Asthma toF1.39 - Response of Older Patients with Asthma toF1.39 - Response of Older Patients with Asthma toF1.39 - Response of Older Patients with Asthma toOmalizumab: A Pooled Analysis across 5 Clinical TOmalizumab: A Pooled Analysis across 5 Clinical TOmalizumab: A Pooled Analysis across 5 Clinical TOmalizumab: A Pooled Analysis across 5 Clinical TOmalizumab: A Pooled Analysis across 5 Clinical Trials.rials.rials.rials.rials.R. J. Maykut,1 Y. Deniz,2 M. Massanari,1 C. Reisner,3 F. Kianifard,1G. P. Geba.1 1&2Clinical Development, Genentech, Inc., SouthSan Francisco, CA, USA; 3CRD, Novartis Pharmaceuticals Cor-poration, East Hanover, NJ, USA.

F1.40 - Development of a CD154-Dependent Model of IL-13F1.40 - Development of a CD154-Dependent Model of IL-13F1.40 - Development of a CD154-Dependent Model of IL-13F1.40 - Development of a CD154-Dependent Model of IL-13F1.40 - Development of a CD154-Dependent Model of IL-13Producing B Cells.Producing B Cells.Producing B Cells.Producing B Cells.Producing B Cells.O. Hajoui,1 J. Guay,1 S. Al-Tamemi,1,2 B. D. Mazer.1,2 1MeakinsChristie Laboratories, McGill University, Montreal, QC, Canada;2Division of Allergy and Immunology, Montreal Children’s Hos-pital, Montreal, QC, Canada.

20052005200520052005ANNUAL MEETING

71



F1.41 - Daclizumab Does Not Alter the Function of HealthyF1.41 - Daclizumab Does Not Alter the Function of HealthyF1.41 - Daclizumab Does Not Alter the Function of HealthyF1.41 - Daclizumab Does Not Alter the Function of HealthyF1.41 - Daclizumab Does Not Alter the Function of HealthyHuman CD4Human CD4Human CD4Human CD4Human CD4+++++CD25CD25CD25CD25CD25+++++ Regulator Regulator Regulator Regulator Regulatory T Cell In Vy T Cell In Vy T Cell In Vy T Cell In Vy T Cell In Vitro.itro.itro.itro.itro.T. Sornasse,1 Y. Zhang,1 W. Hong,1 D. Polakoff,1 V. V. Vexler.1

1Research, Translational Medicine, Protein Design Labs, Inc.,Fremont, CA, USA.

F1.42 - RespiratorF1.42 - RespiratorF1.42 - RespiratorF1.42 - RespiratorF1.42 - Respiratory Exposure to OVy Exposure to OVy Exposure to OVy Exposure to OVy Exposure to OVA Induce Functional Ef-A Induce Functional Ef-A Induce Functional Ef-A Induce Functional Ef-A Induce Functional Ef-fector CD4 T Cells.fector CD4 T Cells.fector CD4 T Cells.fector CD4 T Cells.fector CD4 T Cells.B. Chiu,1 V. R. Stolberg,2 S. W. Chensue.1,2 1Pathologh, Univer-sity of Michigan Medical School, Ann Arbor, MI, USA; 2Pathol-ogy and Laboratory Medicine, VA Ann Arbor Healthcare Sys-tem, Ann Arbor, MI, USA.

F1.43 - A-317491 Inhibits the Activation of Guinea-Pig Pul-F1.43 - A-317491 Inhibits the Activation of Guinea-Pig Pul-F1.43 - A-317491 Inhibits the Activation of Guinea-Pig Pul-F1.43 - A-317491 Inhibits the Activation of Guinea-Pig Pul-F1.43 - A-317491 Inhibits the Activation of Guinea-Pig Pul-monarmonarmonarmonarmonary Vy Vy Vy Vy Vagal Sensoragal Sensoragal Sensoragal Sensoragal Sensory Nery Nery Nery Nery Nerve Tve Tve Tve Tve Terererererminals by minals by minals by minals by minals by α,β−α,β−α,β−α,β−α,β−methylene-methylene-methylene-methylene-methylene-AAAAATPTPTPTPTP.....A. Pelleg,1 B. J. Undem.2 1&2Asthma Center, Johns HopkinsUniversity, Baltimore, MD, USA.

F1.44 – Abstract WithdrawnF1.44 – Abstract WithdrawnF1.44 – Abstract WithdrawnF1.44 – Abstract WithdrawnF1.44 – Abstract Withdrawn

F1.45 - Sodium Sulfite Activates Mast Cells and BasophilsF1.45 - Sodium Sulfite Activates Mast Cells and BasophilsF1.45 - Sodium Sulfite Activates Mast Cells and BasophilsF1.45 - Sodium Sulfite Activates Mast Cells and BasophilsF1.45 - Sodium Sulfite Activates Mast Cells and Basophilsthrough Induction of Oxidative Stress.through Induction of Oxidative Stress.through Induction of Oxidative Stress.through Induction of Oxidative Stress.through Induction of Oxidative Stress.C. R. Collaco,1 D. J. Hochman,1 R. M. Goldblum,1 E. G. Brooks.11Pediatrics, The University of Texas Medical Branch, Galveston,TX, USA.

F1.46 - Structural Basis for Epitopes Sharing between GroupF1.46 - Structural Basis for Epitopes Sharing between GroupF1.46 - Structural Basis for Epitopes Sharing between GroupF1.46 - Structural Basis for Epitopes Sharing between GroupF1.46 - Structural Basis for Epitopes Sharing between Group1 Allergens of Cedar Pollen.1 Allergens of Cedar Pollen.1 Allergens of Cedar Pollen.1 Allergens of Cedar Pollen.1 Allergens of Cedar Pollen.T. Midoro-Horiuti,1 C. H. Schein,2 V. Mathura,2 W. Braun,2 E.W. Czerwinski,2 A. Togawa,1 Y. Kondo,1 T. Oka,3 M.Watanabe,4 R. M. Goldblum.1 1Pediatrics, University of TexasMedical Branch, Galveston, TX, USA; 2Human Biological Chem-istry and Genetics, University of Texas Medical Branch,Galveston, TX, USA; 3Oka Pharmacy, Tamano, Okayama, Ja-pan; 4Tokyo Research Laboratories, Kowa Co., Ltd., Noguchi,Tokyo, Japan.

F1.47 - Food Allergy Related Hospitalizations New YF1.47 - Food Allergy Related Hospitalizations New YF1.47 - Food Allergy Related Hospitalizations New YF1.47 - Food Allergy Related Hospitalizations New YF1.47 - Food Allergy Related Hospitalizations New York Stateork Stateork Stateork Stateork StateHospitals from 1994-2003.Hospitals from 1994-2003.Hospitals from 1994-2003.Hospitals from 1994-2003.Hospitals from 1994-2003.L. R. Forbes,1 R. Y. Lin.2 1Pediatrics, St. Vincent’s Medical Cen-ter Manhattan, New York, NY, USA; 2Medicine, St. Vincent’sMedical Center Manhattan, New York, NY, USA.

F1.48 - Vitamin E Supplementation Augments the Levels ofF1.48 - Vitamin E Supplementation Augments the Levels ofF1.48 - Vitamin E Supplementation Augments the Levels ofF1.48 - Vitamin E Supplementation Augments the Levels ofF1.48 - Vitamin E Supplementation Augments the Levels ofEndogenous Antioxidants and Improves Lung Function in Asth-Endogenous Antioxidants and Improves Lung Function in Asth-Endogenous Antioxidants and Improves Lung Function in Asth-Endogenous Antioxidants and Improves Lung Function in Asth-Endogenous Antioxidants and Improves Lung Function in Asth-matic Patients.matic Patients.matic Patients.matic Patients.matic Patients.Ahmed Nadeem, Sunil K. Chhabra, Hanumanthrao G. Raj.1Department of Biochemistry, Vallabhbhai Patel ChestInstitute,University of Delhi, Delhi, India; 2Department of Cardio-respiratory Physiology, Vallabhbhai Patel Chest Institute,Universityof Delhi, Delhi, India.

Bone Marrow or Stem Cell TBone Marrow or Stem Cell TBone Marrow or Stem Cell TBone Marrow or Stem Cell TBone Marrow or Stem Cell Transplantationransplantationransplantationransplantationransplantation

F1.49 - RecoverF1.49 - RecoverF1.49 - RecoverF1.49 - RecoverF1.49 - Recovery of CD4 and CD8 Ly of CD4 and CD8 Ly of CD4 and CD8 Ly of CD4 and CD8 Ly of CD4 and CD8 Lymphocyte Subsets andymphocyte Subsets andymphocyte Subsets andymphocyte Subsets andymphocyte Subsets andTheir Impact on Acute Graft-vs. Host Disease (GVHD) afterTheir Impact on Acute Graft-vs. Host Disease (GVHD) afterTheir Impact on Acute Graft-vs. Host Disease (GVHD) afterTheir Impact on Acute Graft-vs. Host Disease (GVHD) afterTheir Impact on Acute Graft-vs. Host Disease (GVHD) afterReduced Intensity Conditioning (RIC) Allogeneic Stem CellReduced Intensity Conditioning (RIC) Allogeneic Stem CellReduced Intensity Conditioning (RIC) Allogeneic Stem CellReduced Intensity Conditioning (RIC) Allogeneic Stem CellReduced Intensity Conditioning (RIC) Allogeneic Stem CellTTTTTransplantation (allo-SCT).ransplantation (allo-SCT).ransplantation (allo-SCT).ransplantation (allo-SCT).ransplantation (allo-SCT).M. Mohty,1 D. Blaise,1 C. Faucher,1 D. Olive,1 B. Gaugler.1

1Immunologie des Tumeurs, Insitut Paoli-Calmettes, Marseille,France.

F1.50 - Cross-Presentation of Minor Histocompatibility Anti-F1.50 - Cross-Presentation of Minor Histocompatibility Anti-F1.50 - Cross-Presentation of Minor Histocompatibility Anti-F1.50 - Cross-Presentation of Minor Histocompatibility Anti-F1.50 - Cross-Presentation of Minor Histocompatibility Anti-gens Requires Dendritic Cells and Immunoproteasomes.gens Requires Dendritic Cells and Immunoproteasomes.gens Requires Dendritic Cells and Immunoproteasomes.gens Requires Dendritic Cells and Immunoproteasomes.gens Requires Dendritic Cells and Immunoproteasomes.T. M. Hill,1 L. Van Kaer,1 J. W. Yewdell,2 D. C. Roopenian,3 S.Joyce.1 1Microbiology and Immunology, Vanderbilt UniversitySchool of Medicine, Nashville, TN, USA; 2Laboratory of ViralDiseases, National Institute of Allergy and Infectious Diseases,National Institutes of Health, Bethesda, MD, USA; 3The JacksonLaboratory, Bar Harbor, ME, USA.

F1.51 - Permanent Mixed Chimerism in Mice by Short, LowF1.51 - Permanent Mixed Chimerism in Mice by Short, LowF1.51 - Permanent Mixed Chimerism in Mice by Short, LowF1.51 - Permanent Mixed Chimerism in Mice by Short, LowF1.51 - Permanent Mixed Chimerism in Mice by Short, LowTTTTToxicityoxicityoxicityoxicityoxicity, Radiation Free T, Radiation Free T, Radiation Free T, Radiation Free T, Radiation Free Treatment Allows Myoblast Allograftreatment Allows Myoblast Allograftreatment Allows Myoblast Allograftreatment Allows Myoblast Allograftreatment Allows Myoblast AllograftTTTTTolerance across Fully MHC-Mismatched Barriers.olerance across Fully MHC-Mismatched Barriers.olerance across Fully MHC-Mismatched Barriers.olerance across Fully MHC-Mismatched Barriers.olerance across Fully MHC-Mismatched Barriers.L. Stephan,1 J. P. Tremblay.2 1Human Genetic, CRCHUL, Que-bec, QC, Canada; 2Human Genetic, CRCHUL, Quebec, QC,Canada.

F1.52 - Neonatal CD4+ CD25+ T Cells – Age Restricted De-F1.52 - Neonatal CD4+ CD25+ T Cells – Age Restricted De-F1.52 - Neonatal CD4+ CD25+ T Cells – Age Restricted De-F1.52 - Neonatal CD4+ CD25+ T Cells – Age Restricted De-F1.52 - Neonatal CD4+ CD25+ T Cells – Age Restricted De-velopment of Immune Tvelopment of Immune Tvelopment of Immune Tvelopment of Immune Tvelopment of Immune Tolerance.olerance.olerance.olerance.olerance.R. Reibke,1 B. Arnold,2 G. J. Hammerling.2 1Dept. of InternalMedicine III, University of Munich, Klinikum Grosshadern,Munich, Germany; 2Molecular Immunology, German CancerResearch Center, Heidelberg, Germany.



F1.53 - In Vivo Neutralization of Both Interferon Gamma (IFN-F1.53 - In Vivo Neutralization of Both Interferon Gamma (IFN-F1.53 - In Vivo Neutralization of Both Interferon Gamma (IFN-F1.53 - In Vivo Neutralization of Both Interferon Gamma (IFN-F1.53 - In Vivo Neutralization of Both Interferon Gamma (IFN-g) and Interleukin-2 (IL-2) Accelerates Anti-Host Cytotoxic Tg) and Interleukin-2 (IL-2) Accelerates Anti-Host Cytotoxic Tg) and Interleukin-2 (IL-2) Accelerates Anti-Host Cytotoxic Tg) and Interleukin-2 (IL-2) Accelerates Anti-Host Cytotoxic Tg) and Interleukin-2 (IL-2) Accelerates Anti-Host Cytotoxic TLLLLLymphocyte (CTL) Development and Acute Graft-Vymphocyte (CTL) Development and Acute Graft-Vymphocyte (CTL) Development and Acute Graft-Vymphocyte (CTL) Development and Acute Graft-Vymphocyte (CTL) Development and Acute Graft-Versus-Hostersus-Hostersus-Hostersus-Hostersus-HostDisease (GVHD) in the Parent-Into-F1 Model.Disease (GVHD) in the Parent-Into-F1 Model.Disease (GVHD) in the Parent-Into-F1 Model.Disease (GVHD) in the Parent-Into-F1 Model.Disease (GVHD) in the Parent-Into-F1 Model.I. A. Puliaeva,1 R. A. Puliaev,1 F. D. Finkelman,2 C. S. Via.1

1Pathology, Uniformed Services University of Health Sciences,Bethesda, MD, USA; 2Medicine, University of Cincinnati Col-lege of Medicine, Cincinnati, OH, USA.

F1.54 - Role of Apoptotic Cells in the Induction of RegulatorF1.54 - Role of Apoptotic Cells in the Induction of RegulatorF1.54 - Role of Apoptotic Cells in the Induction of RegulatorF1.54 - Role of Apoptotic Cells in the Induction of RegulatorF1.54 - Role of Apoptotic Cells in the Induction of RegulatoryyyyyT Cells.T Cells.T Cells.T Cells.T Cells.Kim A. Campbell,1 Amy Krutsick,1 Janine Huber,1 David Peritt.1

1Research & Clinical Development, Therakos, Inc., Exton, PA,USA.

F1.55 - Distribution of CD4+25+ Cells in Fetal Sheep Early inF1.55 - Distribution of CD4+25+ Cells in Fetal Sheep Early inF1.55 - Distribution of CD4+25+ Cells in Fetal Sheep Early inF1.55 - Distribution of CD4+25+ Cells in Fetal Sheep Early inF1.55 - Distribution of CD4+25+ Cells in Fetal Sheep Early inGestation.Gestation.Gestation.Gestation.Gestation.Alireza Torabi,1 John S. Pixley,2 Jessica Chase, Esmail D.Zanjani.1 1Department of Animal Biotechnology and Depart-ment of Medicine, University of Nevada, Reno, Reno, NV, USA;2VA Medical Center, University of Nevada, Reno, Reno, NV,USA.

F1.56 - Clinical Relevance of Recipient Leukocyte InfusionF1.56 - Clinical Relevance of Recipient Leukocyte InfusionF1.56 - Clinical Relevance of Recipient Leukocyte InfusionF1.56 - Clinical Relevance of Recipient Leukocyte InfusionF1.56 - Clinical Relevance of Recipient Leukocyte Infusion(RLI) Therapy(RLI) Therapy(RLI) Therapy(RLI) Therapy(RLI) Therapy.....T. I. Saito,1 M. Sykes.1 1TBRC/BMT Section, MassachusettsGeneral Hospital, Boston, MA, USA.

F1.57 - Anti-Mouse Thymocyte Globulin Administration Pre-F1.57 - Anti-Mouse Thymocyte Globulin Administration Pre-F1.57 - Anti-Mouse Thymocyte Globulin Administration Pre-F1.57 - Anti-Mouse Thymocyte Globulin Administration Pre-F1.57 - Anti-Mouse Thymocyte Globulin Administration Pre-vents Acute Graft-versus-Host Disease in a Murine Model.vents Acute Graft-versus-Host Disease in a Murine Model.vents Acute Graft-versus-Host Disease in a Murine Model.vents Acute Graft-versus-Host Disease in a Murine Model.vents Acute Graft-versus-Host Disease in a Murine Model.M. C. Ruzek,1 J. S. Waire,1 A. Vitsky,2 J. Williams,3 S. M.Richards,1 R. D. Garman.1 1Immunology and Clinical Labora-tory Sciences, Genzyme Corporation, Framingham, MA, USA;2Pathology, Genzyme Corporation, Framingham, MA, USA; 3Im-mune Mediated Diseases, Genzyme Corporation, Framingham,MA, USA.

F1.58 - IFN-Gamma Promotes LF1.58 - IFN-Gamma Promotes LF1.58 - IFN-Gamma Promotes LF1.58 - IFN-Gamma Promotes LF1.58 - IFN-Gamma Promotes Lymphohematopoietic GVH Re-ymphohematopoietic GVH Re-ymphohematopoietic GVH Re-ymphohematopoietic GVH Re-ymphohematopoietic GVH Re-actions while Attenuating GVHD in Murine Allogeneic He-actions while Attenuating GVHD in Murine Allogeneic He-actions while Attenuating GVHD in Murine Allogeneic He-actions while Attenuating GVHD in Murine Allogeneic He-actions while Attenuating GVHD in Murine Allogeneic He-matopoietic Cell Tmatopoietic Cell Tmatopoietic Cell Tmatopoietic Cell Tmatopoietic Cell Transplantation Models.ransplantation Models.ransplantation Models.ransplantation Models.ransplantation Models.Hui Wang,1 Shumei Wang,1 Megan Sykes,1 Yong-GuangYang.1 1Bone Marrow Transplantation Section, TransplantationBiology Research Center, Boston, MA, USA.

F1.59 - Distinct Effects of Early and Delayed CTLA4-BlockadeF1.59 - Distinct Effects of Early and Delayed CTLA4-BlockadeF1.59 - Distinct Effects of Early and Delayed CTLA4-BlockadeF1.59 - Distinct Effects of Early and Delayed CTLA4-BlockadeF1.59 - Distinct Effects of Early and Delayed CTLA4-Blockadeafter Murine miHC-Disparate Allogeneic Bone Marrow Tafter Murine miHC-Disparate Allogeneic Bone Marrow Tafter Murine miHC-Disparate Allogeneic Bone Marrow Tafter Murine miHC-Disparate Allogeneic Bone Marrow Tafter Murine miHC-Disparate Allogeneic Bone Marrow Trans-rans-rans-rans-rans-plantation: Graft-Vplantation: Graft-Vplantation: Graft-Vplantation: Graft-Vplantation: Graft-Versus-Host Disease Versus-Host Disease Versus-Host Disease Versus-Host Disease Versus-Host Disease Versus Auto-Immunityersus Auto-Immunityersus Auto-Immunityersus Auto-Immunityersus Auto-Immunity.....S. Fevery,1 P. Vandenberghe,2 B. Sprangers,1 O. Rutgeerts,1 C.Lenaerts,1 J. Goebels,1 C. Segers,1 W. Landuyt,3 L. Boon,6 A.Kasran,4 C. De Wolf-Peeters,5 M. Waer,1 A. D. Billiau.1 1Lab.Experimental Transplantation, University of Leuven, Leuven, Bel-gium; 2Center of Human Genetics; 3Lab. Experimental Radio-therapy; 4Lab. Experimental Immunology; 5Dep. Pathology, Uni-versity of Leuven, Leuven, Belgium; 6Bioceros NV, Amsterdam,Netherlands.

F1.60 - Successful Bone Marrow TF1.60 - Successful Bone Marrow TF1.60 - Successful Bone Marrow TF1.60 - Successful Bone Marrow TF1.60 - Successful Bone Marrow Transplantation in a Patientransplantation in a Patientransplantation in a Patientransplantation in a Patientransplantation in a Patientwith WHIM Syndrome.with WHIM Syndrome.with WHIM Syndrome.with WHIM Syndrome.with WHIM Syndrome.Y. Kamachi,1 Y. Nakamura,1 A. Hama,1 K. Kudo,1 A. Yoshimi,1

N. Watanabe,1 I. Tsuge,2 S. Kojima.1 1Pediatrics, NagoyaUniversity Graduate School of Medicine, Nagoya, Aichi, Ja-pan; 2Pediatrics, Fujita Health University, Toyoake, Aichi, Japan.

F1.61 - Characterization and Depletion of Human PBMNCF1.61 - Characterization and Depletion of Human PBMNCF1.61 - Characterization and Depletion of Human PBMNCF1.61 - Characterization and Depletion of Human PBMNCF1.61 - Characterization and Depletion of Human PBMNCReactive with Murine Stimulator Cells.Reactive with Murine Stimulator Cells.Reactive with Murine Stimulator Cells.Reactive with Murine Stimulator Cells.Reactive with Murine Stimulator Cells.L. D. Fast,1 G. DiLeone,1 M. Chuck.1 1Department of Medicine,Rhode Island Hospital/Brown University, Providence, RI, USA.

Poster Session 2Poster Session 2Poster Session 2Poster Session 2Poster Session 2FridayFridayFridayFridayFriday, May 13, 2005, May 13, 2005, May 13, 2005, May 13, 2005, May 13, 2005

3:30 pm - 7:30 pm3:30 pm - 7:30 pm3:30 pm - 7:30 pm3:30 pm - 7:30 pm3:30 pm - 7:30 pm

Reproductive ImmunologyReproductive ImmunologyReproductive ImmunologyReproductive ImmunologyReproductive Immunology

F2.01 - Cytokines in the Placenta of Pakistani Newborns withF2.01 - Cytokines in the Placenta of Pakistani Newborns withF2.01 - Cytokines in the Placenta of Pakistani Newborns withF2.01 - Cytokines in the Placenta of Pakistani Newborns withF2.01 - Cytokines in the Placenta of Pakistani Newborns withand without Intrauterine Growth Retardation.and without Intrauterine Growth Retardation.and without Intrauterine Growth Retardation.and without Intrauterine Growth Retardation.and without Intrauterine Growth Retardation.M. Hahn-Zoric,1 S. Amu,1,2 A. Malik,2 R. Asraf,3 S. Zaman,4 I.Kjellmer,5 H. Hagberg,6 L. Padyukov,1 L. A. Hanson.1 1Depart-ment of Clinical Immunology, Gothenburg University/SahlgrenskaUniversity Hospital, Gothenburg, Sweden; 2Department of Ob-stetrics and Gynecology, King Edward Medical College, Lahore,Pakistan; 3Department of Social and Preventive Pediatrics, KingEdward Medical College, Lahore, Pakistan; 4Department ofSocial and Preventive Pediatrics, Fatima Jinnah Medical Col-lege/Sir Ganga Ran Hospital, Lahore, Pakistan; 5Perinatal Cen-ter, Department of Pediatrics, Gothenburg University, Gothenburg,Sweden; 6Department of Obstetrics and Gynecology,Gothenburg University, Gothenburg, Sweden.

20052005200520052005ANNUAL MEETING

73



F2.02 - Setup of IgG MAR Methods and Determination of theF2.02 - Setup of IgG MAR Methods and Determination of theF2.02 - Setup of IgG MAR Methods and Determination of theF2.02 - Setup of IgG MAR Methods and Determination of theF2.02 - Setup of IgG MAR Methods and Determination of thePrevalence of Ant isperm Ant ibodies in Semen ofPrevalence of Ant isperm Ant ibodies in Semen ofPrevalence of Ant isperm Ant ibodies in Semen ofPrevalence of Ant isperm Ant ibodies in Semen ofPrevalence of Ant isperm Ant ibodies in Semen ofImmunoinfertile.Immunoinfertile.Immunoinfertile.Immunoinfertile.Immunoinfertile.Abdolreza Esmaeilzadeh, Mehri Ghasemi, SudabehEsmaeilzadeh. 1Immunology, Zanjan Medicall Collage, Zanjan,Zanjan, Islamic Republic of Iran; 2Zanjan University of MedicalScienc, Zanjan, Zanjan, Islamic Republic of Iran; 3Azad Uni-versity of Bonab, Bonab, Azerbaijan e Shargi, Islamic Republicof Iran.

F2.03 - Sildenafil Does Not Influence Natural Killer Cell Ac-F2.03 - Sildenafil Does Not Influence Natural Killer Cell Ac-F2.03 - Sildenafil Does Not Influence Natural Killer Cell Ac-F2.03 - Sildenafil Does Not Influence Natural Killer Cell Ac-F2.03 - Sildenafil Does Not Influence Natural Killer Cell Ac-tivity in Wtivity in Wtivity in Wtivity in Wtivity in Women with a Historomen with a Historomen with a Historomen with a Historomen with a History of Recurrent Spontaneousy of Recurrent Spontaneousy of Recurrent Spontaneousy of Recurrent Spontaneousy of Recurrent SpontaneousAbortion.Abortion.Abortion.Abortion.Abortion.M. Jerzak,1 M. Kniotek,2 N. Stachowicz,3 A. Gorski,2 W.Baranowski.1 1Department of Gynecology, Military Institute ofMedicine, Warsaw, Poland; 2Department of Clinical Immunol-ogy, Transplantation Institute, University School of Medicine,Warsaw, Poland; 31st Department of Gynecology, UniversityMedical School, Lublin, Poland.

F2.04 - IgE Is Distributed on Macrophages Both in HumanF2.04 - IgE Is Distributed on Macrophages Both in HumanF2.04 - IgE Is Distributed on Macrophages Both in HumanF2.04 - IgE Is Distributed on Macrophages Both in HumanF2.04 - IgE Is Distributed on Macrophages Both in Humanand Murine Tand Murine Tand Murine Tand Murine Tand Murine Terererererm Placentae.m Placentae.m Placentae.m Placentae.m Placentae.J. Wang,1 X. Cui.2 1Department of Immunology and Cell Biol-ogy, School of Animal Health Science, Hebei Agricultural Uni-versity, Baoding, Hebei, China; 2Department of Medicine, Hos-pital Affiliated to Xuanhua Iron and Steel Company Ltd,Xuanhua, Hebei, China.

F2.05 - Complement Activation as a Mediator of RecurrentF2.05 - Complement Activation as a Mediator of RecurrentF2.05 - Complement Activation as a Mediator of RecurrentF2.05 - Complement Activation as a Mediator of RecurrentF2.05 - Complement Activation as a Mediator of RecurrentImmunologically-TImmunologically-TImmunologically-TImmunologically-TImmunologically-Triggered Miscarriages.riggered Miscarriages.riggered Miscarriages.riggered Miscarriages.riggered Miscarriages.G. Girardi,1 E. Chan,1 P. Redecha,1 J. M. Thurman,2 V. M.Holers,2 J. Salmon.1 1Department of Medicine, Hospital forSpecial Surgery-Weill Medical College, Cornell University, NewYork, NY, USA; 2Departments of Medicine and Immunology,University of Colorado HSC, Denver, CO, USA.

F2.06 - Prolonged Preterm Rupture of Fetal MembranesF2.06 - Prolonged Preterm Rupture of Fetal MembranesF2.06 - Prolonged Preterm Rupture of Fetal MembranesF2.06 - Prolonged Preterm Rupture of Fetal MembranesF2.06 - Prolonged Preterm Rupture of Fetal Membranes(PPROM), Is Associated with an Increased Maternal Anti-Fe-(PPROM), Is Associated with an Increased Maternal Anti-Fe-(PPROM), Is Associated with an Increased Maternal Anti-Fe-(PPROM), Is Associated with an Increased Maternal Anti-Fe-(PPROM), Is Associated with an Increased Maternal Anti-Fe-tal Ttal Ttal Ttal Ttal T-Cell Responsiveness.-Cell Responsiveness.-Cell Responsiveness.-Cell Responsiveness.-Cell Responsiveness.A. Steinborn,1 C. Seidl,2 E. Schmitt,3 Y. Stein,1 A. Klee,4 M.Gonser,4 E. Seifried,2 C. Sohn.5 1Depart. Obstet. Gynecol.,University of Frankfurt, Frankfurt/Main, Germany; 2Institute ofTransfusion Medicine and Immunohaematology, Blood Transfu-sion Center of German Red Cross, Frankfurt/Main, Germany;3Institute of Immunology, University of Mainz, Mainz, Germany;4Depart. Obstet. Gynecol., Dr. Horst-Schmidt Hospital,Wiesbaden, Germany; 5Depart. Obstet. Gynecol., Universityof Heidelberg, Heidelberg, Germany.

F2.07 - STF2.07 - STF2.07 - STF2.07 - STF2.07 - STAAAAAT3 Knock Down Reduces the Invasion of Chorio-T3 Knock Down Reduces the Invasion of Chorio-T3 Knock Down Reduces the Invasion of Chorio-T3 Knock Down Reduces the Invasion of Chorio-T3 Knock Down Reduces the Invasion of Chorio-carcinoma Cells.carcinoma Cells.carcinoma Cells.carcinoma Cells.carcinoma Cells.Tobias G. Poehlmann,1 Anja Meissner,2 Tobias Wengenmayer,1Karlheinz Friedrich,2 Ekkehard Schleussner,1 Udo R. Markert.1

1Obstetrics, Friedrich Schiller University, Jena, Germany; 2Bio-chemistry, Friedrich Schiller University, Jena, Germany.

F2.08 - Evaluation of Four Different Methods of Sperm Sur-F2.08 - Evaluation of Four Different Methods of Sperm Sur-F2.08 - Evaluation of Four Different Methods of Sperm Sur-F2.08 - Evaluation of Four Different Methods of Sperm Sur-F2.08 - Evaluation of Four Different Methods of Sperm Sur-face Antigens Extraction Using Biotinilated Sperm Due to Find-face Antigens Extraction Using Biotinilated Sperm Due to Find-face Antigens Extraction Using Biotinilated Sperm Due to Find-face Antigens Extraction Using Biotinilated Sperm Due to Find-face Antigens Extraction Using Biotinilated Sperm Due to Find-ing a Better Method for ELISA Ting a Better Method for ELISA Ting a Better Method for ELISA Ting a Better Method for ELISA Ting a Better Method for ELISA Technique.echnique.echnique.echnique.echnique.Asghar Talebian, Mohammad Reza Sadeghi. 1ReproductiveEndocrinology, Avesina Research Center, Tehran, Tehran, IslamicRepublic of Iran; 2Reproductive Endocrinology, Avesina ResearchCenter, Tehran, Tehran, Islamic Republic of Iran.

F2.09 - The Changes of T LF2.09 - The Changes of T LF2.09 - The Changes of T LF2.09 - The Changes of T LF2.09 - The Changes of T Lymphocyte CD Markers in Patientsymphocyte CD Markers in Patientsymphocyte CD Markers in Patientsymphocyte CD Markers in Patientsymphocyte CD Markers in PatientsExposed to Mustard Gas.Exposed to Mustard Gas.Exposed to Mustard Gas.Exposed to Mustard Gas.Exposed to Mustard Gas.Minoo K. Adib,1 Fariborz Mokarian,2 Mohammad R. Azizy.1

1Immunology, Medical School.Isfahan University of Medical Sci-ences, Isfahan, Isfahan, Islamic Republic of Iran; 2Oncology,Omid Hospital.Isfahan University of Medical Sciences, Isfahan,Isfahan, Islamic Republic of Iran; 3Immunology, MedicalSchool.Isfahan University of Medical Sciences, Isfahan, Isfahan,Islamic Republic of Iran.

F2.10 - Binding of Phage Displaying Multimeric CD147 onF2.10 - Binding of Phage Displaying Multimeric CD147 onF2.10 - Binding of Phage Displaying Multimeric CD147 onF2.10 - Binding of Phage Displaying Multimeric CD147 onF2.10 - Binding of Phage Displaying Multimeric CD147 onU937 Cell Conducts Apoptotic Signal.U937 Cell Conducts Apoptotic Signal.U937 Cell Conducts Apoptotic Signal.U937 Cell Conducts Apoptotic Signal.U937 Cell Conducts Apoptotic Signal.Nutjeera Intasai,1 Watchara Kasinrerk,1 Sabine Mai,2 ChatchaiTayapiwatana.1 1Clinical Immunology, Fac of Associated Medi-cal Sciences, Chiang Mai, Thailand; 2The Genomic Centre forCancer Research & Diagnosis, Manitoba Institute of Cell Biol-ogy, Manitoba, Winnipeg, Canada.



F2.11 - Sensitivity of Soil Bacteria towards Cadmium MetalF2.11 - Sensitivity of Soil Bacteria towards Cadmium MetalF2.11 - Sensitivity of Soil Bacteria towards Cadmium MetalF2.11 - Sensitivity of Soil Bacteria towards Cadmium MetalF2.11 - Sensitivity of Soil Bacteria towards Cadmium Metaland Its Effect on Moung Bean Plant.and Its Effect on Moung Bean Plant.and Its Effect on Moung Bean Plant.and Its Effect on Moung Bean Plant.and Its Effect on Moung Bean Plant.Rafia Azmat, Aliya Hayat, Tanveer Khanum. 1Chemistry, JinnahUniversity for Women, Karachi, Sindh, Pakistan; 2Microbiology,Jinnah University for Women, Karachi, Sindh, Pakistan; 3Micro-biology, Jinnah University for Women, Karachi, Sindh, Pakistan.

F2.12 - Surgical TF2.12 - Surgical TF2.12 - Surgical TF2.12 - Surgical TF2.12 - Surgical Trauma and the Mannan-Binding Lectin (MBL)rauma and the Mannan-Binding Lectin (MBL)rauma and the Mannan-Binding Lectin (MBL)rauma and the Mannan-Binding Lectin (MBL)rauma and the Mannan-Binding Lectin (MBL)Pathway of Innate ImmunityPathway of Innate ImmunityPathway of Innate ImmunityPathway of Innate ImmunityPathway of Innate Immunity.....H. Ytting,1 I. J. Christensen,1 S. Thiel,2 J. C. Jensenius,2 H. J.Nielsen.1 1Dept. of Surgical Gastroenterology, Hvidovre Uni-versity Hospital, Hvidovre, Denmark; 2Institute of Medical Micro-biology and Immunology, University of Aarhus, Aarhus, Den-mark.

F2.13 - The TheorF2.13 - The TheorF2.13 - The TheorF2.13 - The TheorF2.13 - The Theory of Hemaimmune Reaction Road Map.y of Hemaimmune Reaction Road Map.y of Hemaimmune Reaction Road Map.y of Hemaimmune Reaction Road Map.y of Hemaimmune Reaction Road Map.Guo Feng. 1Department of Blood Transfusion, Chang Hai Hos-pital Second Military Medical University, Shanghai, China.

F2.14 - A Novel CD70+ APC Imprints a Unique Pattern of NKF2.14 - A Novel CD70+ APC Imprints a Unique Pattern of NKF2.14 - A Novel CD70+ APC Imprints a Unique Pattern of NKF2.14 - A Novel CD70+ APC Imprints a Unique Pattern of NKF2.14 - A Novel CD70+ APC Imprints a Unique Pattern of NKReceptors on Gut Mucosal CD8 T Cells.Receptors on Gut Mucosal CD8 T Cells.Receptors on Gut Mucosal CD8 T Cells.Receptors on Gut Mucosal CD8 T Cells.Receptors on Gut Mucosal CD8 T Cells.A. Laouar,1 V. Haridas,1 R. A.W. van Lier,2 H. Yagita,3 N.Manjunath.1 1Dept. of Pediatrics, Harvard Medical School,CBR Institute for Biomedical Research, Boston, MA, USA; 2Dept.of Pediatrics, Harvard Medical School, CBR Institute for Biomedi-cal Research, Boston, MA, USA; 3Dept. of Laboratory Immunol-ogy, Academic Medical Center, Amsterdam, Amsterdam, Neth-erlands; 4Dept. of Medicine, Juntendo University, Tokyo, Tokyo,Japan; 5Dept. of Pediatrics, Harvard Medical School, CBR Insti-tute for Biomedical Research, Boston, MA, USA.

F2.15 - CAUSAL Protein Signaling Networks Derived fromF2.15 - CAUSAL Protein Signaling Networks Derived fromF2.15 - CAUSAL Protein Signaling Networks Derived fromF2.15 - CAUSAL Protein Signaling Networks Derived fromF2.15 - CAUSAL Protein Signaling Networks Derived fromMultiparameter Single-Cell Data.Multiparameter Single-Cell Data.Multiparameter Single-Cell Data.Multiparameter Single-Cell Data.Multiparameter Single-Cell Data.O. D. Perez,1 K. Sachs,2 D. Pe’er,3 D. Lauffenburger,2 G. P.Nolan.1 1Department of Microbiology and Immunology, StanfordUniversity School of Medicine, Stanford, CA, USA; 2BiologicalEngineering Division, Massachusetts Institute of Technology, Cam-bridge, MA, USA; 3Department of Genetics, Harvard MedicalSchool, Boston, MA, USA.

F2.16 - Don’t Judge a Cell by Its Surface Only: Combina-F2.16 - Don’t Judge a Cell by Its Surface Only: Combina-F2.16 - Don’t Judge a Cell by Its Surface Only: Combina-F2.16 - Don’t Judge a Cell by Its Surface Only: Combina-F2.16 - Don’t Judge a Cell by Its Surface Only: Combina-tion with Functional Assays.tion with Functional Assays.tion with Functional Assays.tion with Functional Assays.tion with Functional Assays.D. T. Montag,1 M. T. Lotze.1,2,3 1Bioengineering, University ofPittsburgh, Pittsburgh, PA, USA; 2Surgery, University of Pittsburgh,Pittsburgh, PA, USA; 3Molecular Genetics and Biochemistry,University of Pittsburgh, Pittsburgh, PA, USA.

F2.17 - Cigarette Smoke Extract Impairs CD40 Ligand-InducedF2.17 - Cigarette Smoke Extract Impairs CD40 Ligand-InducedF2.17 - Cigarette Smoke Extract Impairs CD40 Ligand-InducedF2.17 - Cigarette Smoke Extract Impairs CD40 Ligand-InducedF2.17 - Cigarette Smoke Extract Impairs CD40 Ligand-InducedMaturation of Human Dendritic Cells.Maturation of Human Dendritic Cells.Maturation of Human Dendritic Cells.Maturation of Human Dendritic Cells.Maturation of Human Dendritic Cells.T. W. Barnes,1 P. R. Kroening,1 H. Kita,2 R. Vassallo.1 1Pulmo-nary and Critical Care Medicine, Mayo Clinic College of Medi-cine, Rochester, MN, USA; 2Division of Allergic Diseases, MayoClinic College of Medicine, Rochester, MN, USA.

F2.18 - Isolation of Lactobacilli, Bacillus and PsuedomonasF2.18 - Isolation of Lactobacilli, Bacillus and PsuedomonasF2.18 - Isolation of Lactobacilli, Bacillus and PsuedomonasF2.18 - Isolation of Lactobacilli, Bacillus and PsuedomonasF2.18 - Isolation of Lactobacilli, Bacillus and Psuedomonasfrom Yfrom Yfrom Yfrom Yfrom Yogurogurogurogurogurt and Tt and Tt and Tt and Tt and To Detero Detero Detero Detero Determine Their Bacteriocin Activitymine Their Bacteriocin Activitymine Their Bacteriocin Activitymine Their Bacteriocin Activitymine Their Bacteriocin ActivityAgainst VAgainst VAgainst VAgainst VAgainst Various Clinical Isolates.arious Clinical Isolates.arious Clinical Isolates.arious Clinical Isolates.arious Clinical Isolates.Tanveer Khanum, Nadia Noor, Nasra Jalil, Sadaf Hedayat.1Microbiology, Jinnah University for Women, Karachi, Sindh,Pakistan; 2Microbiology, Jinnah University for Women, Karachi,Sindh, Pakistan.

F2.19 - Dendritic Cells Overexpressing FasL Induce Anti-TF2.19 - Dendritic Cells Overexpressing FasL Induce Anti-TF2.19 - Dendritic Cells Overexpressing FasL Induce Anti-TF2.19 - Dendritic Cells Overexpressing FasL Induce Anti-TF2.19 - Dendritic Cells Overexpressing FasL Induce Anti-Tu-u-u-u-u-moral Tmoral Tmoral Tmoral Tmoral T-Cell Response In V-Cell Response In V-Cell Response In V-Cell Response In V-Cell Response In Vivo.ivo.ivo.ivo.ivo.Sofia Buonocore, Najate Ouled Haddou, Fabrice Moore,Marianne Laporte, Frederic Paulart, Francoise Flemal, KrisThielemans, Michel Goldman, Veronique Flamand. 1Labora-tory of Experimental Immunology, Institut d’ImmunologieMedicale (IMI), Brussels, Belgium; 2Dermatology Department,Erasme Hospital, Brussels, Belgium; 3Laboraory of Physiology,Vrije Universiteit Brussel, Brussels, Belgium.

F2.20 - CD8aa + TF2.20 - CD8aa + TF2.20 - CD8aa + TF2.20 - CD8aa + TF2.20 - CD8aa + T-Cells Represent a Long-Lived Memor-Cells Represent a Long-Lived Memor-Cells Represent a Long-Lived Memor-Cells Represent a Long-Lived Memor-Cells Represent a Long-Lived MemoryyyyyTTTTT-Cell Subset in Patients with Melanoma Undergoing Epitope--Cell Subset in Patients with Melanoma Undergoing Epitope--Cell Subset in Patients with Melanoma Undergoing Epitope--Cell Subset in Patients with Melanoma Undergoing Epitope--Cell Subset in Patients with Melanoma Undergoing Epitope-Based TBased TBased TBased TBased Tumor Vumor Vumor Vumor Vumor Vaccination.accination.accination.accination.accination.I. Magalhaes,1 N. K. Vudattu,1 K. Freitag,1 J. Karbach,2 A.Kumar,3 Z. Zhu,3 K. Kuus-Reichel,3 M. Juelch,4 C. Castelli,5 E.Jaeger,2 M. Maeurer.1 1Dept. of Medical Microbiology, Univer-sity of Mainz, Mainz, Germany; 2Dept. of Hematology/Oncol-ogy, Krankenhaus Nordwest, Frankfurt, Germany; 3ImmunomicsOperation, Beckman Coulter Inc., San Diego, CA, USA; 4ThymedGmbH, Mainz, Germany; 5Dept. of Immunotherapy of HumanTumors, Istituto Tumori, Milano, Italy; 6Microbiology and TumorBiology Center, Karolinska Institute, Solna, Sweden.

20052005200520052005ANNUAL MEETING

75



F2.21 - Human Adipocyte and Its Participation inF2.21 - Human Adipocyte and Its Participation inF2.21 - Human Adipocyte and Its Participation inF2.21 - Human Adipocyte and Its Participation inF2.21 - Human Adipocyte and Its Participation inInnate ImmunityInnate ImmunityInnate ImmunityInnate ImmunityInnate Immunity.....Laurence Hoareau,1 Marie-Paule Gonthier,1 Regis Roche,1 FranckFesty,1 Christian Lefebvre D Hellencourt,1 Maya Cesari,1 Jean-Pierre Riviere,2 Marie-Amedee Dijoux,2 Sandrine Bes-Houtmann.11University of Reunion, LBGM, Saint Denis, Reunion, France;2Laboratoire d’anapathologie, CHD Felix Guyon, Saint Denis,Reunion, France.

F2.22 - HDL-Reverse Cholesterol TF2.22 - HDL-Reverse Cholesterol TF2.22 - HDL-Reverse Cholesterol TF2.22 - HDL-Reverse Cholesterol TF2.22 - HDL-Reverse Cholesterol Transporransporransporransporransport and Signal Tt and Signal Tt and Signal Tt and Signal Tt and Signal Trans-rans-rans-rans-rans-duction in Tduction in Tduction in Tduction in Tduction in T-Cells.-Cells.-Cells.-Cells.-Cells.T. Fulop,1 A. Larbi,1 A. Khalil,1 N. Douziech,1 C. Fortin,1 G.Dupuis.2 1Research Center on Aging, Universite de Sherbrooke,Sherbrooke, QC, Canada; 2Deapartment of Biochemistry,Universite de Sherbrooke, Sherbrooke, QC, Canada.

F2.23 - The Effect of TF2.23 - The Effect of TF2.23 - The Effect of TF2.23 - The Effect of TF2.23 - The Effect of Treatment Recurrent Herpes Simplex withreatment Recurrent Herpes Simplex withreatment Recurrent Herpes Simplex withreatment Recurrent Herpes Simplex withreatment Recurrent Herpes Simplex withLarifan.Larifan.Larifan.Larifan.Larifan.Evita Niedrite,1 Ingmars Mikazans,1 Guna Feldmane,2 ArijaVolrate.2 1Dept. of Dermatovenereology, Riga Stradin’s Univer-sity, Riga, Latvia; 2Institute of Microbiology and Virology, Riga,Latvia.

F2.24 - Multidimensional Liquid Phase Separations of IntactF2.24 - Multidimensional Liquid Phase Separations of IntactF2.24 - Multidimensional Liquid Phase Separations of IntactF2.24 - Multidimensional Liquid Phase Separations of IntactF2.24 - Multidimensional Liquid Phase Separations of IntactProteins as an Alternative to 2D Gel Electrophoresis forProteins as an Alternative to 2D Gel Electrophoresis forProteins as an Alternative to 2D Gel Electrophoresis forProteins as an Alternative to 2D Gel Electrophoresis forProteins as an Alternative to 2D Gel Electrophoresis forProteomics.Proteomics.Proteomics.Proteomics.Proteomics.A. Apffel,1 A. Adler,1 T. Sana,1 J. Garcia,1 R. Kincaid,1 S.Udiavar.1 1Molecular Technologies Laboratory, Agilent Labora-tories, Palo Alto, CA, USA.

F2.25 - Screening of ImmunostimulatorF2.25 - Screening of ImmunostimulatorF2.25 - Screening of ImmunostimulatorF2.25 - Screening of ImmunostimulatorF2.25 - Screening of Immunostimulatory Oligosaccharidesy Oligosaccharidesy Oligosaccharidesy Oligosaccharidesy Oligosaccharidesby Using a New HPLC-Chip/MS Tby Using a New HPLC-Chip/MS Tby Using a New HPLC-Chip/MS Tby Using a New HPLC-Chip/MS Tby Using a New HPLC-Chip/MS Technologyechnologyechnologyechnologyechnology.....R. Grimm,1 H. Yin,1 M. Ninonuevo,2 K. Killeen,1 C. Lebrilla.2

1Integrated Biology Solutions, Agilent Technologies, Palo Alto,CA, USA; 2Department of Biomedicine, UC Davis, Davis, CA,USA.

F2.26 - The Role of Mannose-Binding Lectin in Natural IgMF2.26 - The Role of Mannose-Binding Lectin in Natural IgMF2.26 - The Role of Mannose-Binding Lectin in Natural IgMF2.26 - The Role of Mannose-Binding Lectin in Natural IgMF2.26 - The Role of Mannose-Binding Lectin in Natural IgMMediated Ischemia/ReperMediated Ischemia/ReperMediated Ischemia/ReperMediated Ischemia/ReperMediated Ischemia/Reperfusion Injurfusion Injurfusion Injurfusion Injurfusion Injuryyyyy.....M. Zhang,1 K. Takahashi,4 E. M. Alicot,6 T. Vorup-Jensen,1 B.Kessler,2 J. Christian Jensenius,5 R.A. B. Ezekowitz,4 F. D. Moore,3M. C. Carroll.1 1CBR Institute of Biomedical Research, HarvardMedical School, Boston, MA, USA; 2Dept. of Pathology, HarvardMedical School, Boston, MA, USA; 3Surgery, Brigham andWomen’s Hospital, Boston, MA, USA; 4Dept. of Pediatrics, Mas-sachusetts General Hospital, Boston, MA, USA; 5Dept. of Medi-cal Microbiology and Immunology, University of Aarhus, AarhusC, Denmark; 6DecImmune Therapeutics, Boston, MA, USA.

F2.27 - Effect of Plaferon LB on the Damaged Peripheral NerF2.27 - Effect of Plaferon LB on the Damaged Peripheral NerF2.27 - Effect of Plaferon LB on the Damaged Peripheral NerF2.27 - Effect of Plaferon LB on the Damaged Peripheral NerF2.27 - Effect of Plaferon LB on the Damaged Peripheral NerveveveveveRegeneration.Regeneration.Regeneration.Regeneration.Regeneration.T. Chikovani,1,2 M. Kvezereli,2 G. Burkadze,1 T. Giorgadze,2 V.Bakhutashvili.2 1Microbilogy, Virology & Immunology, Tbilisi StateMedical University, Tbilisi, Georgia; 2Biomedicine, Institute ofMedical Biotechnology, Tbilisi, Georgia.

F2.28 - Activation of the Lectin Pathway of Complement inF2.28 - Activation of the Lectin Pathway of Complement inF2.28 - Activation of the Lectin Pathway of Complement inF2.28 - Activation of the Lectin Pathway of Complement inF2.28 - Activation of the Lectin Pathway of Complement inIgA NephropathyIgA NephropathyIgA NephropathyIgA NephropathyIgA Nephropathy.....M. R. Daha,1 M. P. Rastaldi,2 M. A. Seelen,1 J. W. Eijgenraam,1B. D. Oortwijn,1 D. J. Van Gijlswijk - Janssen,1 M. C. Faber -Krol,1 N. Calvaresi,2 M. Matsushita,3 T. Fujita,4 C. Van Kooten,1A. Roos.1 1Department of Nephrology, Leiden University Medi-cal Center, Leiden, Netherlands; 2Renal Immunopathology Cen-ter, Milan, Italy; 3Institute of Glycothechnology and Departmentof Applied Biochemistry, Tokai University, Hiratsuka, Japan; 4De-partment of Biochemistry, Fukushima Medical University,Fukushima, Japan.

F2.29 - Characterisation of Antibody Titres in an IntravenousF2.29 - Characterisation of Antibody Titres in an IntravenousF2.29 - Characterisation of Antibody Titres in an IntravenousF2.29 - Characterisation of Antibody Titres in an IntravenousF2.29 - Characterisation of Antibody Titres in an IntravenousImmunoglobulin Concentrate (Flebogamma®).Immunoglobulin Concentrate (Flebogamma®).Immunoglobulin Concentrate (Flebogamma®).Immunoglobulin Concentrate (Flebogamma®).Immunoglobulin Concentrate (Flebogamma®).M. Lopez,1 J. I. Jorquera.1 1R&D Area, Instituto Grifols, S.A.,Parets del Valles, Barcelona, Spain.

F2.30 - FLEBOGAMMA® Intravenous Immunoglobulin; Evalu-F2.30 - FLEBOGAMMA® Intravenous Immunoglobulin; Evalu-F2.30 - FLEBOGAMMA® Intravenous Immunoglobulin; Evalu-F2.30 - FLEBOGAMMA® Intravenous Immunoglobulin; Evalu-F2.30 - FLEBOGAMMA® Intravenous Immunoglobulin; Evalu-ation of Neutralizing Antibodies to Vation of Neutralizing Antibodies to Vation of Neutralizing Antibodies to Vation of Neutralizing Antibodies to Vation of Neutralizing Antibodies to Vaccinia Vaccinia Vaccinia Vaccinia Vaccinia Virus.irus.irus.irus.irus.H. Biescas,1 R. Gajardo,1 A. Vandermeeren,2 M. Esteban,2 J. I.Jorquera.1 1Research and Development Area, Instituto Grifols,Barcelona, Spain; 2Centro Nacional de Biotecnologia, CSIC,Campus Universidad Autonoma, Madrid, Spain.



F2.31 - Compatibility Study of TF2.31 - Compatibility Study of TF2.31 - Compatibility Study of TF2.31 - Compatibility Study of TF2.31 - Compatibility Study of Two Intravenous Immunoglo-wo Intravenous Immunoglo-wo Intravenous Immunoglo-wo Intravenous Immunoglo-wo Intravenous Immunoglo-bulin Preparations with Plastic Containers.bulin Preparations with Plastic Containers.bulin Preparations with Plastic Containers.bulin Preparations with Plastic Containers.bulin Preparations with Plastic Containers.M. Lopez,1 M. Costa,1 J. I. Jorquera.1 1R&D Area, Instituto Grifols,S.A., Parets del Valles, Barcelona, Spain.

F2.32 - Peripheral Blood LF2.32 - Peripheral Blood LF2.32 - Peripheral Blood LF2.32 - Peripheral Blood LF2.32 - Peripheral Blood Lymphocyte Immunological Profileymphocyte Immunological Profileymphocyte Immunological Profileymphocyte Immunological Profileymphocyte Immunological Profileof Patients with Autoimmune Hepatitis in Different Stages ofof Patients with Autoimmune Hepatitis in Different Stages ofof Patients with Autoimmune Hepatitis in Different Stages ofof Patients with Autoimmune Hepatitis in Different Stages ofof Patients with Autoimmune Hepatitis in Different Stages ofImmunosuppressive TherapyImmunosuppressive TherapyImmunosuppressive TherapyImmunosuppressive TherapyImmunosuppressive Therapy.....K. Gutkowski, M. Hartleb, A. Pluta, D. Gutkowska. 1Physio-therapy Institute, Rzeszow’s University, Rzeszow, Poland;2Gastroenetology Department, Medical University of Silesia,Katowice, Poland; 3Physiotherapy Institute, Rzeszow’s Univer-sity, Rzeszow, Poland; 4Epidemiology Department, Center forDisease Control and Prevention, Rzeszow, Poland.

F2.33 - Identifying Common “Innate Signature” from GeneF2.33 - Identifying Common “Innate Signature” from GeneF2.33 - Identifying Common “Innate Signature” from GeneF2.33 - Identifying Common “Innate Signature” from GeneF2.33 - Identifying Common “Innate Signature” from GeneExpression Profile in Innate vs. Adaptive LExpression Profile in Innate vs. Adaptive LExpression Profile in Innate vs. Adaptive LExpression Profile in Innate vs. Adaptive LExpression Profile in Innate vs. Adaptive Lymphocytes.ymphocytes.ymphocytes.ymphocytes.ymphocytes.T. Yamagata,1 C. Benoist,1 D. Mathis.1 1Section on Immunologyand Immunogenetics, Joslin Diabetes Center, Boston, MA, USA.

F2.34 - Different O-glycosylated Structures Are Expressed inF2.34 - Different O-glycosylated Structures Are Expressed inF2.34 - Different O-glycosylated Structures Are Expressed inF2.34 - Different O-glycosylated Structures Are Expressed inF2.34 - Different O-glycosylated Structures Are Expressed inT Cell Activation.T Cell Activation.T Cell Activation.T Cell Activation.T Cell Activation.Marisela Linares,1 Ma.Carmen Jimenez-Martinez,1 BlancaOrtiz,2 Edgar Zenteno,2 Ricardo Lascurain.3 1Research Unit,Institute of Ophthalmology, Fundacion Conde de Valenciana,Mexico, D.F., Mexico, D.F., Mexico; 2Biochemistry, InstitutoNacional Enfermedades Respiratorias, Mexico, D.F., Mexico,D.F., Mexico; 3Biochemistry, Universidad Nacional Autonomade Mexico, Mexico, D.F., Mexico, D.F.

F2.35 - ShorF2.35 - ShorF2.35 - ShorF2.35 - ShorF2.35 - Short-Tt-Tt-Tt-Tt-Terererererm Atorm Atorm Atorm Atorm Atorvastatin Tvastatin Tvastatin Tvastatin Tvastatin Treatment Enhances Specificreatment Enhances Specificreatment Enhances Specificreatment Enhances Specificreatment Enhances SpecificAntibody Production Following TAntibody Production Following TAntibody Production Following TAntibody Production Following TAntibody Production Following Tetanus Tetanus Tetanus Tetanus Tetanus Toxoid Voxoid Voxoid Voxoid Voxoid Vaccinationaccinationaccinationaccinationaccinationin Healthy Vin Healthy Vin Healthy Vin Healthy Vin Healthy Volunteers.olunteers.olunteers.olunteers.olunteers.P. Y. Lee,1 P. O. Scumpia,1 J. A. Byars,1 K. M. Kelly,1 H. Zhuang,1D. Theriaque,1 J. Shuster,1 P. W. Stacpoole,1 M. S. Segal,1 W.H. Reeves,1 M. L. Brantly.1 1General Clinical Research Center,University of Florida, Gainesville, FL, USA.

F2.36 - An Immunology Syllabus to Student’F2.36 - An Immunology Syllabus to Student’F2.36 - An Immunology Syllabus to Student’F2.36 - An Immunology Syllabus to Student’F2.36 - An Immunology Syllabus to Student’s Medicine.s Medicine.s Medicine.s Medicine.s Medicine.Osmel Gaspar Guerra Segura. 1Immunology Lab, Teach. andGen. Hosp. Dr. A. Neto, Guantanamo, Guantanamo, Cuba.

F2.37 - Use of C1 Inhibitor Concentrate for TF2.37 - Use of C1 Inhibitor Concentrate for TF2.37 - Use of C1 Inhibitor Concentrate for TF2.37 - Use of C1 Inhibitor Concentrate for TF2.37 - Use of C1 Inhibitor Concentrate for Treatment of An-reatment of An-reatment of An-reatment of An-reatment of An-gioedema Attacks in Patients with C1 Inhibitor Deficiencygioedema Attacks in Patients with C1 Inhibitor Deficiencygioedema Attacks in Patients with C1 Inhibitor Deficiencygioedema Attacks in Patients with C1 Inhibitor Deficiencygioedema Attacks in Patients with C1 Inhibitor Deficiency.....SurSurSurSurSurvey of 1102 Infusions in 503 Patients.vey of 1102 Infusions in 503 Patients.vey of 1102 Infusions in 503 Patients.vey of 1102 Infusions in 503 Patients.vey of 1102 Infusions in 503 Patients.A. Zanichelli,1 L. C. Zingale,1 B. Cicardi,1 L. Maggioni,1 E.Pappalardo,1 M. Cicardi.1 1Internal Medicine, University ofMilan, Hospital S. Giuseppe, Milan, Milan, Italy.

F2.38 - Immunonutritional Assessment of Special Plasma’F2.38 - Immunonutritional Assessment of Special Plasma’F2.38 - Immunonutritional Assessment of Special Plasma’F2.38 - Immunonutritional Assessment of Special Plasma’F2.38 - Immunonutritional Assessment of Special Plasma’sssssDonors.Donors.Donors.Donors.Donors.Osmel Gaspar Guerra Segura, Nerys Noa Rdguez. 1Immunol-ogy Lab, Teach.and Gen. Hosp. Dr. A.Neto, Guantanamo,Guantanamo, Cuba; 2Quality Control, Provincial Blood Bank,Guantanamo, Guantanamo, Cuba.

F2.39 - Presentation of the Human Hepatitis B Surface Anti-F2.39 - Presentation of the Human Hepatitis B Surface Anti-F2.39 - Presentation of the Human Hepatitis B Surface Anti-F2.39 - Presentation of the Human Hepatitis B Surface Anti-F2.39 - Presentation of the Human Hepatitis B Surface Anti-gen – Loop by the Cpn10 Scaffold Induces a Specific Anti-gen – Loop by the Cpn10 Scaffold Induces a Specific Anti-gen – Loop by the Cpn10 Scaffold Induces a Specific Anti-gen – Loop by the Cpn10 Scaffold Induces a Specific Anti-gen – Loop by the Cpn10 Scaffold Induces a Specific Anti-body Response in Mice by Genetic Immunization.body Response in Mice by Genetic Immunization.body Response in Mice by Genetic Immunization.body Response in Mice by Genetic Immunization.body Response in Mice by Genetic Immunization.S. Neckermann,1 J. Lohrmann,2 W. Zimmermann.1 1Tumor Im-munology Laboratory, Department of Urology, University ClinicGrosshadern, Ludwig-Maximilians-University, Munich, Germany;2GENOVAC GmbH, Freiburg, Germany.

F2.40 - Angioedema without Urticaria in 929 Italian Patients:F2.40 - Angioedema without Urticaria in 929 Italian Patients:F2.40 - Angioedema without Urticaria in 929 Italian Patients:F2.40 - Angioedema without Urticaria in 929 Italian Patients:F2.40 - Angioedema without Urticaria in 929 Italian Patients:Proposal for a Diagnostic and Therapeutic Approach.Proposal for a Diagnostic and Therapeutic Approach.Proposal for a Diagnostic and Therapeutic Approach.Proposal for a Diagnostic and Therapeutic Approach.Proposal for a Diagnostic and Therapeutic Approach.L. C. Zingale,1 L. Beltrami,2 A. Zanichelli,1 M. Cicardi.1 1Dpt ofInternal Medicine, University of Milan, Milan, Italy; 2Dpt of Car-diology, University of Milan, Milan, Italy.

F2.41 - Dynamic Control of T Cell Homing by Gut and Pe-F2.41 - Dynamic Control of T Cell Homing by Gut and Pe-F2.41 - Dynamic Control of T Cell Homing by Gut and Pe-F2.41 - Dynamic Control of T Cell Homing by Gut and Pe-F2.41 - Dynamic Control of T Cell Homing by Gut and Pe-ripheral Dendritic Cells.ripheral Dendritic Cells.ripheral Dendritic Cells.ripheral Dendritic Cells.ripheral Dendritic Cells.J. R. Mora,1 G. Cheng,1 D. Picarella,2 M. Briskin,2 N. Buchanan,2U. H. von Andrian.1 1CBRI, Harvard Medical School, Boston,MA, USA; 2Millennium Pharmaceuticals, Cambridge, MA, USA.

F2.42 - Isoation and Characterization of WF2.42 - Isoation and Characterization of WF2.42 - Isoation and Characterization of WF2.42 - Isoation and Characterization of WF2.42 - Isoation and Characterization of Water Isolates forater Isolates forater Isolates forater Isolates forater Isolates forBacteriocinogenic ActivityBacteriocinogenic ActivityBacteriocinogenic ActivityBacteriocinogenic ActivityBacteriocinogenic Activity.....Hina Waheed, Nazish Aziz, Tanveer Khanum, Kishwar Jabeen,Saba Ali Imama, Hina Rahat, Aliya Hayat. 1Microbiology, JinnahUniversity for Women, Karachi, Sindh, Pakistan; 2Microbiology,Same, Karachi, Sindh, Pakistan; 3Microbiology, Same, Karachi,Sindh, Pakistan; 4Microbiology, Same, Karachi, Sindh, Pakistan;5Microbiology, Same, Karachi, Sindh, Pakistan.

20052005200520052005ANNUAL MEETING

77



F2.43 - Inhibition of Pericardic Adhesions by the AmoebianF2.43 - Inhibition of Pericardic Adhesions by the AmoebianF2.43 - Inhibition of Pericardic Adhesions by the AmoebianF2.43 - Inhibition of Pericardic Adhesions by the AmoebianF2.43 - Inhibition of Pericardic Adhesions by the AmoebianAnti-InflammatorAnti-InflammatorAnti-InflammatorAnti-InflammatorAnti-Inflammatory Pentapeptide (MLIF). Preliminary Pentapeptide (MLIF). Preliminary Pentapeptide (MLIF). Preliminary Pentapeptide (MLIF). Preliminary Pentapeptide (MLIF). Preliminary Results.y Results.y Results.y Results.y Results.J. A. Gimenez-Scherer,1 C. Riera-Kinkel,2 R. Silva-Garcia,1 M.G. Rico Rosillo,1 J. Garcia,3 E. Foyo,3 E. Tena,3 R. Arguero,2 R.R. Kretschmer.1 1Unidad de Investigacion Medica enInmunologia, H. Pediatria, Centro Medico Nacional Siglo XXI,IMSS, Mexico, DF, Mexico; 2Hospital de Cardiologia, CentroMedico Nacional Siglo XXI, IMSS, Mexico, DF, Mexico; 3Bioterio,Centro Medico Nacional Siglo XXI, IMSS, Mexico, DF, Mexico.

F2.44 - Attenuation of the GAA-Specific Immune Response inF2.44 - Attenuation of the GAA-Specific Immune Response inF2.44 - Attenuation of the GAA-Specific Immune Response inF2.44 - Attenuation of the GAA-Specific Immune Response inF2.44 - Attenuation of the GAA-Specific Immune Response in66666neoneoneoneoneo/6/6/6/6/6neoneoneoneoneo GAA Knockout Mice, a Model of Pompe Disease. GAA Knockout Mice, a Model of Pompe Disease. GAA Knockout Mice, a Model of Pompe Disease. GAA Knockout Mice, a Model of Pompe Disease. GAA Knockout Mice, a Model of Pompe Disease.K. J. Munroe,1 S. M. Richards,1 R. D. Garman,1 A. M. Joseph.1

1&, Framingham, MA, USA.

F2.45 - The Effect of Electro Active Dental Metal Fillings Re-F2.45 - The Effect of Electro Active Dental Metal Fillings Re-F2.45 - The Effect of Electro Active Dental Metal Fillings Re-F2.45 - The Effect of Electro Active Dental Metal Fillings Re-F2.45 - The Effect of Electro Active Dental Metal Fillings Re-placement on Lplacement on Lplacement on Lplacement on Lplacement on Lymphocyte Activity in Patients with Oral Dis-ymphocyte Activity in Patients with Oral Dis-ymphocyte Activity in Patients with Oral Dis-ymphocyte Activity in Patients with Oral Dis-ymphocyte Activity in Patients with Oral Dis-comfort.comfort.comfort.comfort.comfort.J. Prochazkova,1 S. Podzimek,1 M. Miksovsky,1 J. Bartova,1 K.Hana.2 1Clinical Department, The Institute of Dental Research,1st Medical Faculty and GUH, Charles University, Prague, CzechRepublic; 2Research Department, The Institute of Biomedical Engi-neering, Czech Technical University, Prague, Czech Republic.

F2.46 - A Review of the Allergic /TF2.46 - A Review of the Allergic /TF2.46 - A Review of the Allergic /TF2.46 - A Review of the Allergic /TF2.46 - A Review of the Allergic /Toxic Adverse Reactions tooxic Adverse Reactions tooxic Adverse Reactions tooxic Adverse Reactions tooxic Adverse Reactions toAnti-TAnti-TAnti-TAnti-TAnti-Tuberculous Drugs(Auberculous Drugs(Auberculous Drugs(Auberculous Drugs(Auberculous Drugs(ATD), A 10 YTD), A 10 YTD), A 10 YTD), A 10 YTD), A 10 Years Therapeutic Surears Therapeutic Surears Therapeutic Surears Therapeutic Surears Therapeutic Surveyveyveyveyvey.....M. Ishaq, Taj M. , I. M. Sameera. 1Allergy/Pulmonology, Al-Junaid Hospital, Nowshera, Pakistan.

F2.47 - Defective Intrathymic T Cell Development and EarlyF2.47 - Defective Intrathymic T Cell Development and EarlyF2.47 - Defective Intrathymic T Cell Development and EarlyF2.47 - Defective Intrathymic T Cell Development and EarlyF2.47 - Defective Intrathymic T Cell Development and EarlyOnset of IBD in Mice Devoid of WOnset of IBD in Mice Devoid of WOnset of IBD in Mice Devoid of WOnset of IBD in Mice Devoid of WOnset of IBD in Mice Devoid of WASP and N-WASP and N-WASP and N-WASP and N-WASP and N-WASPASPASPASPASP.....V. Cotta-de-Almeida,1,3 D. Onaldi,1 M. Maillard,1,4 F. W. Alt,2S. B. Snapper.1 1Dept of Medicine, Massachusetts GeneralHospital/Harvard Medical School, Boston, MA, USA; 2Dept ofGenetics, Children’s Hospital/Harvard Medical School, Boston,MA, USA; 3Dept of Cell Biology, Oswaldo Cruz Foundation, Riode Janeiro, RJ, Brazil; 4Lausanne University Hospital, Lausanne,Switzerland.

F2.48 - FF2.48 - FF2.48 - FF2.48 - FF2.48 - FAS Induced Apoptosis – A Model System for BiFAS Induced Apoptosis – A Model System for BiFAS Induced Apoptosis – A Model System for BiFAS Induced Apoptosis – A Model System for BiFAS Induced Apoptosis – A Model System for BiFARARARARARTMTMTMTMTM

Implementation.Implementation.Implementation.Implementation.Implementation.H. Kalinski, A. Chajut, A. Khan, R. Skaliter. 1Research andDevelopment, Quark Biotech, Inc., Fremont, CA, USA.

F2.49 - Protective Effect of Thalidomide in Rats with Granu-F2.49 - Protective Effect of Thalidomide in Rats with Granu-F2.49 - Protective Effect of Thalidomide in Rats with Granu-F2.49 - Protective Effect of Thalidomide in Rats with Granu-F2.49 - Protective Effect of Thalidomide in Rats with Granu-loma in the Cerebral Amygdala and Pentylenetetrazole-In-loma in the Cerebral Amygdala and Pentylenetetrazole-In-loma in the Cerebral Amygdala and Pentylenetetrazole-In-loma in the Cerebral Amygdala and Pentylenetetrazole-In-loma in the Cerebral Amygdala and Pentylenetetrazole-In-duced Epilepsyduced Epilepsyduced Epilepsyduced Epilepsyduced Epilepsy.....L. Aguirre-Cruz,1 M. Martinez-Moreno,1 G. Palencia,1 N.Mendez-Mar,1 J. Manjarrez,2 R. Alvarado,2 E. Flores,3 M.Pacheco,3 P. Salgado,3 L. Rodriguez-Fragoso,4 J. Sotelo.1

1Neuroimmunology Department, National Institute of Neurologyand Neurosurgery (INNN), Mexico City, Mexico; 2Reticular For-mation Physiology Laboratory, INNN, Mexico City, Mexico;3Magnetic Resonance Unity, INNN, Mexico City, Mexico; 4Phar-macy Faculty, Autonomous University of Morelos, Cuernavaca,Morelos, Mexico.

F2.50 - Self-Limitation of Th1-Mediated Inflammation byF2.50 - Self-Limitation of Th1-Mediated Inflammation byF2.50 - Self-Limitation of Th1-Mediated Inflammation byF2.50 - Self-Limitation of Th1-Mediated Inflammation byF2.50 - Self-Limitation of Th1-Mediated Inflammation byIg!õIg!õIg!õIg!õIg!õM. Feuerer, K. Eulenburg, A. Hamann, J. Huehn. 1Exp. Rheu-matology, Charite Universitaetsmedizin Berlin, Berlin, Germany.

F2.51 - Origin and Generation of Distinct CD4F2.51 - Origin and Generation of Distinct CD4F2.51 - Origin and Generation of Distinct CD4F2.51 - Origin and Generation of Distinct CD4F2.51 - Origin and Generation of Distinct CD4+++++ Regula- Regula- Regula- Regula- Regula-tortortortortory T Cell Subsets.y T Cell Subsets.y T Cell Subsets.y T Cell Subsets.y T Cell Subsets.C. Siewert,1 K. Siegmund,1 M. Feuerer,1 L. Klein,2 A. Hamann,1J. Huehn.1 1Experimental Rheumatology, ChariteUniversitaetsmedizin Berlin, Berlin, Germany; 2IMP/IMBA,Vienna, Austria.

F2.52 - Correlation between Histamine and Mast Cells andF2.52 - Correlation between Histamine and Mast Cells andF2.52 - Correlation between Histamine and Mast Cells andF2.52 - Correlation between Histamine and Mast Cells andF2.52 - Correlation between Histamine and Mast Cells andPresence of IgE.Presence of IgE.Presence of IgE.Presence of IgE.Presence of IgE.Mandana Sattari,1 Shidehmehr Mofakham,1 Saeed Khalili.1

1Immunology, Shaheed Beheshti University, Medical School,Tehran, Islamic Republic of Iran.

F2.53 - Neutrophil Chemotaxis and Dental Caries.F2.53 - Neutrophil Chemotaxis and Dental Caries.F2.53 - Neutrophil Chemotaxis and Dental Caries.F2.53 - Neutrophil Chemotaxis and Dental Caries.F2.53 - Neutrophil Chemotaxis and Dental Caries.Mandana Sattari,1 Saeed Khalili,1 Maryam Basirat.1 1Immu-nology, Shaheed Beheshti University Medical Science, Tehran,Islamic Republic of Iran.

F2.54 - Correlation between Neuropeptides ConcentrationF2.54 - Correlation between Neuropeptides ConcentrationF2.54 - Correlation between Neuropeptides ConcentrationF2.54 - Correlation between Neuropeptides ConcentrationF2.54 - Correlation between Neuropeptides Concentrationand Different Parts of Human Gingiva and the Effects of Neu-and Different Parts of Human Gingiva and the Effects of Neu-and Different Parts of Human Gingiva and the Effects of Neu-and Different Parts of Human Gingiva and the Effects of Neu-and Different Parts of Human Gingiva and the Effects of Neu-ropeptides on Neutrophil Death.ropeptides on Neutrophil Death.ropeptides on Neutrophil Death.ropeptides on Neutrophil Death.ropeptides on Neutrophil Death.Mandana Sattari,1 Saeed Khalili.1 1Immunology Dept, ShaeedBeheshti University of Medical Science, Tehren, Islamic Republicof Iran.



F2.55 - Human MyD88s Is the Result of MyD88 Splicing likeF2.55 - Human MyD88s Is the Result of MyD88 Splicing likeF2.55 - Human MyD88s Is the Result of MyD88 Splicing likeF2.55 - Human MyD88s Is the Result of MyD88 Splicing likeF2.55 - Human MyD88s Is the Result of MyD88 Splicing likeThat Reported in the Mouse.That Reported in the Mouse.That Reported in the Mouse.That Reported in the Mouse.That Reported in the Mouse.A. Dominguez,1 J. L. Ventura,2 A. Zentella,2 R. Kretschmer,1 J. R.Velazquez.1 1Investigation in Medical Immunology, InstitutoMexicano del Seguro Social CMNSXXI, Mexico City, DF, Mexico;2Biochemestry, Instituto Nacional de Nutricion Salvador Zubiran,Mexico City, DF, Mexico.

F2.56 - Relationship of School Attendance with Quality ofF2.56 - Relationship of School Attendance with Quality ofF2.56 - Relationship of School Attendance with Quality ofF2.56 - Relationship of School Attendance with Quality ofF2.56 - Relationship of School Attendance with Quality ofLife, Physical Function, Disease Activity and Damage in Pe-Life, Physical Function, Disease Activity and Damage in Pe-Life, Physical Function, Disease Activity and Damage in Pe-Life, Physical Function, Disease Activity and Damage in Pe-Life, Physical Function, Disease Activity and Damage in Pe-diatric Systemic Lupus Erdiatric Systemic Lupus Erdiatric Systemic Lupus Erdiatric Systemic Lupus Erdiatric Systemic Lupus Erythematosus.ythematosus.ythematosus.ythematosus.ythematosus.L. N. Moorthy,1 M. G. Peterson,2 M. J. Harrison,2 K. B. Onel,3

M. J. Baratelli,1 D. R. Mohan,1 Thomas Lehman.2 1Robert WoodJohnson University, New Brunswick, NJ; 2Hospital for SpecialSurgery, New York, NY; 3La Rabida Children’s Hospital, Chi-cago, IL.

F2.57 - Improvement of Antimycobacterial Therapy Due to IL-F2.57 - Improvement of Antimycobacterial Therapy Due to IL-F2.57 - Improvement of Antimycobacterial Therapy Due to IL-F2.57 - Improvement of Antimycobacterial Therapy Due to IL-F2.57 - Improvement of Antimycobacterial Therapy Due to IL-10 Activity Blockage Is Strain Dependent.10 Activity Blockage Is Strain Dependent.10 Activity Blockage Is Strain Dependent.10 Activity Blockage Is Strain Dependent.10 Activity Blockage Is Strain Dependent.S. Roque,1,2 C. Nóbrega, R. Appelberg,1 M. Correia-Neves.1,3

1Laboratory of Microbiology and Immunology of Infection, Insti-tute for Molecular and Cell Biology (IBMC), Porto; 2Mestradode Imunologia Clinica, Universidade da Beira Interior; 3InstitutoSuperior de Saude do Alto Ave (ISAVE), Fontarcada, Portugal.

F2.58 - Quality Control of DNA with the Agilent 2100F2.58 - Quality Control of DNA with the Agilent 2100F2.58 - Quality Control of DNA with the Agilent 2100F2.58 - Quality Control of DNA with the Agilent 2100F2.58 - Quality Control of DNA with the Agilent 2100Bioanalyzer for Oligonucleotide Array CGH (aCGH).Bioanalyzer for Oligonucleotide Array CGH (aCGH).Bioanalyzer for Oligonucleotide Array CGH (aCGH).Bioanalyzer for Oligonucleotide Array CGH (aCGH).Bioanalyzer for Oligonucleotide Array CGH (aCGH).Samar Lightfoot,1 Hans Brunnert,2 Carsten Buhlmann,2 PaigeAnderson.1 1Agilent Technologies, Palo Alto, USA; 2Agilent Tech-nologies, Waldbronn, Germany.

F2.59 - Improvement of Antimycobacterial Therapy Due to IL-F2.59 - Improvement of Antimycobacterial Therapy Due to IL-F2.59 - Improvement of Antimycobacterial Therapy Due to IL-F2.59 - Improvement of Antimycobacterial Therapy Due to IL-F2.59 - Improvement of Antimycobacterial Therapy Due to IL-10 Activity Blockage is Strain Dependent10 Activity Blockage is Strain Dependent10 Activity Blockage is Strain Dependent10 Activity Blockage is Strain Dependent10 Activity Blockage is Strain DependentS. Roque,1,2 C. Nóbrega, R. Appelberg,1 M. Correia-Neves.1,3

1Laboratory of Microbiology and Immunology of Infection, Insti-tute for Melecular and Cell Biology (IBMC), Porto; 2Mestradode Imunologia Clínica, Universidade da, Beira Interior; 3InstitutoSuperior, de Saúde do Alto Ave, Fontarcada, Portugal.

F2.60 - Somatostatins in Clinical Immunology: An OverF2.60 - Somatostatins in Clinical Immunology: An OverF2.60 - Somatostatins in Clinical Immunology: An OverF2.60 - Somatostatins in Clinical Immunology: An OverF2.60 - Somatostatins in Clinical Immunology: An OverviewviewviewviewviewP.M. Van Hagen, V. Dalm, L.J. Hofland Dept. Internal Medicineand Immunology, Erasmus MC, Rotterdam, The Netherlands

Poster Session 1Poster Session 1Poster Session 1Poster Session 1Poster Session 1SaturdaySaturdaySaturdaySaturdaySaturday, May 14, 2005, May 14, 2005, May 14, 2005, May 14, 2005, May 14, 2005


Autoimmune Neurologic DiseasesAutoimmune Neurologic DiseasesAutoimmune Neurologic DiseasesAutoimmune Neurologic DiseasesAutoimmune Neurologic Diseases

Sa1.01 - Receptor-Modified T Cells as Novel TherapeuticSa1.01 - Receptor-Modified T Cells as Novel TherapeuticSa1.01 - Receptor-Modified T Cells as Novel TherapeuticSa1.01 - Receptor-Modified T Cells as Novel TherapeuticSa1.01 - Receptor-Modified T Cells as Novel TherapeuticApproach for Multiple Sclerosis.Approach for Multiple Sclerosis.Approach for Multiple Sclerosis.Approach for Multiple Sclerosis.Approach for Multiple Sclerosis.I. Moisini, T. L. Geiger. 1Pathology, St. Jude Children’s ResearchHospital, Memphis, TN, USA; 2Pathology, University of Tennes-see Health Science Center, Memphis, TN, USA.

Sa1.02 - The Role of Leukemia InhibitorSa1.02 - The Role of Leukemia InhibitorSa1.02 - The Role of Leukemia InhibitorSa1.02 - The Role of Leukemia InhibitorSa1.02 - The Role of Leukemia Inhibitory Factor (LIF) in Ex-y Factor (LIF) in Ex-y Factor (LIF) in Ex-y Factor (LIF) in Ex-y Factor (LIF) in Ex-perimental Autoimmune Encephalomyelitis (EAE).perimental Autoimmune Encephalomyelitis (EAE).perimental Autoimmune Encephalomyelitis (EAE).perimental Autoimmune Encephalomyelitis (EAE).perimental Autoimmune Encephalomyelitis (EAE).R. A. Linker,1 A. Wieczarkowiecz,1 S. Weikard,2 N. Kruse,1 C.Kleinschnitz,2 B. Holtmann,3 M. Sendtner,3 R. Gold.1 1Insitutefor Multiple Sclerosis Research, University of Goettingen andGemeinnuetzige Hertie-Stiftung, Goettingen, Germany; 2Dept.of Neurology, Clinical Research Group for Multiple Sclerosis,University of Wurzburg, Wuerzburg, Germany; 3Institute forNeurobiology, University of Wurzburg, Wuerzburg, Germany.

Sa1.03 - Novel Immunotoxin: A Fusion Protein Consisting ofSa1.03 - Novel Immunotoxin: A Fusion Protein Consisting ofSa1.03 - Novel Immunotoxin: A Fusion Protein Consisting ofSa1.03 - Novel Immunotoxin: A Fusion Protein Consisting ofSa1.03 - Novel Immunotoxin: A Fusion Protein Consisting ofGelonin and an Acetylcholine Receptor Fragment as a Poten-Gelonin and an Acetylcholine Receptor Fragment as a Poten-Gelonin and an Acetylcholine Receptor Fragment as a Poten-Gelonin and an Acetylcholine Receptor Fragment as a Poten-Gelonin and an Acetylcholine Receptor Fragment as a Poten-tial Immunotherapeutic Agent for the Ttial Immunotherapeutic Agent for the Ttial Immunotherapeutic Agent for the Ttial Immunotherapeutic Agent for the Ttial Immunotherapeutic Agent for the Treatment of reatment of reatment of reatment of reatment of Myasthe-Myasthe-Myasthe-Myasthe-Myasthe-nia gravisnia gravisnia gravisnia gravisnia gravis.....M. Hossann,1 Z. Li,2 Y. Shi,2 U. Kreilinger,1 J. Buettner,1 P. D.Vogel,1 Y. Jingming,2 J. G. Wise,1 W. E. Trommer.1 1Chemistry,TU Kaiserslautern, Kaiserslautern, Germany; 2Biotechnology,Shanxi University, Taiyuan, China.

Sa1.04 - Fumarate Therapy Ameloriates Chronic Experimen-Sa1.04 - Fumarate Therapy Ameloriates Chronic Experimen-Sa1.04 - Fumarate Therapy Ameloriates Chronic Experimen-Sa1.04 - Fumarate Therapy Ameloriates Chronic Experimen-Sa1.04 - Fumarate Therapy Ameloriates Chronic Experimen-tal Autoimmune Encephalomyelitis (EAE).tal Autoimmune Encephalomyelitis (EAE).tal Autoimmune Encephalomyelitis (EAE).tal Autoimmune Encephalomyelitis (EAE).tal Autoimmune Encephalomyelitis (EAE).S. Schilling,1 S. Goelz,2 R. A. Linker,1 F. Luhder,1 R. Gold.1 1In-stitute for Multiple Sclerosis Research, University of Goettingenand Gemeinnuetzige Hertie-Stiftung, Goettingen, Germany;2Biogen Idec, Cambridge, USA.

Sa1.05 - Beneficial Autoimmunity Restrains Destructive Immu-Sa1.05 - Beneficial Autoimmunity Restrains Destructive Immu-Sa1.05 - Beneficial Autoimmunity Restrains Destructive Immu-Sa1.05 - Beneficial Autoimmunity Restrains Destructive Immu-Sa1.05 - Beneficial Autoimmunity Restrains Destructive Immu-nity in a Regulatornity in a Regulatornity in a Regulatornity in a Regulatornity in a Regulatory Mannery Mannery Mannery Mannery Manner.....Nathan Karin,1 Yaniv Zohar,1 Uri Weinberg,1 Rachel Anunu,1Gizi Wildbaum.1 1Immunology, Rappaport Faculty of Medi-cine, Technion, Haifa, Israel.

20052005200520052005ANNUAL MEETING

79



Sa1.06 - CD4Sa1.06 - CD4Sa1.06 - CD4Sa1.06 - CD4Sa1.06 - CD4+++++CD25CD25CD25CD25CD25+++++FoxP3FoxP3FoxP3FoxP3FoxP3+++++ Regulator Regulator Regulator Regulator Regulatory T Cells Are a Highlyy T Cells Are a Highlyy T Cells Are a Highlyy T Cells Are a Highlyy T Cells Are a HighlyApoptosis Sensitive T Cell Population with an Impaired Sup-Apoptosis Sensitive T Cell Population with an Impaired Sup-Apoptosis Sensitive T Cell Population with an Impaired Sup-Apoptosis Sensitive T Cell Population with an Impaired Sup-Apoptosis Sensitive T Cell Population with an Impaired Sup-pressive Function in Multiple Sclerosis.pressive Function in Multiple Sclerosis.pressive Function in Multiple Sclerosis.pressive Function in Multiple Sclerosis.pressive Function in Multiple Sclerosis.B. Fritzsching,1,2 N. Oberle,1 N. Eberhardt,1 J. Haas,2 M.Korporal,2 B. Wildemann,2 P. H. Krammer,1 E. Suri-Payer.1 1De-partment of Immunogenetics, German Cancer Research Center,Heidelberg, Germany; 2Section of Molecular Neuroimmunology,Department of Neurology, University of Heidelberg, Heidelberg,Germany.

Sa1.07 - Accumulation of CD4+CD25+ RegulatorSa1.07 - Accumulation of CD4+CD25+ RegulatorSa1.07 - Accumulation of CD4+CD25+ RegulatorSa1.07 - Accumulation of CD4+CD25+ RegulatorSa1.07 - Accumulation of CD4+CD25+ Regulatory T Cellsy T Cellsy T Cellsy T Cellsy T Cellsin the CNS during Recoverin the CNS during Recoverin the CNS during Recoverin the CNS during Recoverin the CNS during Recovery from EAE.y from EAE.y from EAE.y from EAE.y from EAE.M. J. McGeachy,1 L. A. Stephens,1 S. M. Anderton.1 1Instituteof Immunology and Infection Research, University of Edinburgh,Edinburgh, United Kingdom.

Sa1.08 - The Pathology of Progressive Multiple Sclerosis.Sa1.08 - The Pathology of Progressive Multiple Sclerosis.Sa1.08 - The Pathology of Progressive Multiple Sclerosis.Sa1.08 - The Pathology of Progressive Multiple Sclerosis.Sa1.08 - The Pathology of Progressive Multiple Sclerosis.A. E. Kutzelnigg,1 C. Lucchinetti,2 W. Brueck,3 M. Schmidbauer,4H. Lassmann.1 1Department of Neuroimmunology, Brain Re-search Center, Medical University Vienna, Vienna, Austria; 2De-partment of Neurology, Mayo Clinic, Rochester, MN, USA; 3In-stitute of Neuropathology, University of Goettingen, Goettingen,Germany; 4Department of Neurology, Municipal Hospital Lainz,Vienna, Austria.

Sa1.09 - Endoneural CD34+ Fibroblasts: Putative RegulatorsSa1.09 - Endoneural CD34+ Fibroblasts: Putative RegulatorsSa1.09 - Endoneural CD34+ Fibroblasts: Putative RegulatorsSa1.09 - Endoneural CD34+ Fibroblasts: Putative RegulatorsSa1.09 - Endoneural CD34+ Fibroblasts: Putative Regulatorsof Macrophage Activation in the Peripheral Nerof Macrophage Activation in the Peripheral Nerof Macrophage Activation in the Peripheral Nerof Macrophage Activation in the Peripheral Nerof Macrophage Activation in the Peripheral Nerve?ve?ve?ve?ve?A. Kroner,1 B. D. Kohl,1 I. Kobsar,1 R. Martini,1 M. Maeurer.1

1Experimental Developmental Neurobiology, Julius MaximiliansUniversity, Wuerzburg, Bavaria, Germany.

Sa1.10 - Decreased TSa1.10 - Decreased TSa1.10 - Decreased TSa1.10 - Decreased TSa1.10 - Decreased T-Cell Immunity to Epstein-Barr V-Cell Immunity to Epstein-Barr V-Cell Immunity to Epstein-Barr V-Cell Immunity to Epstein-Barr V-Cell Immunity to Epstein-Barr Virus inirus inirus inirus inirus inMultiple Sclerosis.Multiple Sclerosis.Multiple Sclerosis.Multiple Sclerosis.Multiple Sclerosis.M. P. Pender, A. Lenarczyk, J. M. Burrows, J. Harness, S. R.Burrows. 1Medicine, The University of Queensland, Brisbane,QLD, Australia; 2Queensland Institute of Medical Research,Brisbane, QLD, Australia.

Sa1.11 - HLA-DR2 Is Associated with Chronic InflammatorSa1.11 - HLA-DR2 Is Associated with Chronic InflammatorSa1.11 - HLA-DR2 Is Associated with Chronic InflammatorSa1.11 - HLA-DR2 Is Associated with Chronic InflammatorSa1.11 - HLA-DR2 Is Associated with Chronic InflammatoryyyyyDemyelinating Polyradiculoneuropathy (CIDP) in Females, butDemyelinating Polyradiculoneuropathy (CIDP) in Females, butDemyelinating Polyradiculoneuropathy (CIDP) in Females, butDemyelinating Polyradiculoneuropathy (CIDP) in Females, butDemyelinating Polyradiculoneuropathy (CIDP) in Females, butNot Males.Not Males.Not Males.Not Males.Not Males.P. A. McCombe,1 P. A. Csurhes,1 M. A. Alizart,1 J. M. Greer.1

1School of Medicine, University of Queensland, Brisbane,Queensland, Australia.

Sa1.12 - Antibodies Specific for Myelin Proteolipid Pro-Sa1.12 - Antibodies Specific for Myelin Proteolipid Pro-Sa1.12 - Antibodies Specific for Myelin Proteolipid Pro-Sa1.12 - Antibodies Specific for Myelin Proteolipid Pro-Sa1.12 - Antibodies Specific for Myelin Proteolipid Pro-tein Are of Potential Pathogenic Relevance in Myelintein Are of Potential Pathogenic Relevance in Myelintein Are of Potential Pathogenic Relevance in Myelintein Are of Potential Pathogenic Relevance in Myelintein Are of Potential Pathogenic Relevance in MyelinOpsonization in Multiple Sclerosis.Opsonization in Multiple Sclerosis.Opsonization in Multiple Sclerosis.Opsonization in Multiple Sclerosis.Opsonization in Multiple Sclerosis.J. M. Greer,1 M. P. Pender.1 1School of Medicine, University ofQueensland, Brisbane, Queensland, Australia.

Sa1.13 - Autoantigen Specific T Cells Inhibit Glutamate Up-Sa1.13 - Autoantigen Specific T Cells Inhibit Glutamate Up-Sa1.13 - Autoantigen Specific T Cells Inhibit Glutamate Up-Sa1.13 - Autoantigen Specific T Cells Inhibit Glutamate Up-Sa1.13 - Autoantigen Specific T Cells Inhibit Glutamate Up-take in Astrocytes by Decreasing Expression of Astrocytictake in Astrocytes by Decreasing Expression of Astrocytictake in Astrocytes by Decreasing Expression of Astrocytictake in Astrocytes by Decreasing Expression of Astrocytictake in Astrocytes by Decreasing Expression of AstrocyticGlutamate TGlutamate TGlutamate TGlutamate TGlutamate Transporransporransporransporransporter GLAST – A Mechanism Mediated byter GLAST – A Mechanism Mediated byter GLAST – A Mechanism Mediated byter GLAST – A Mechanism Mediated byter GLAST – A Mechanism Mediated byTTTTTumor Necrosis Factorumor Necrosis Factorumor Necrosis Factorumor Necrosis Factorumor Necrosis Factor-a.-a.-a.-a.-a.T. Korn,1 T. Magnus,2 S. Jung.1 1Department of Neurology,Universitaet des Saarlandes, Homburg, Germany; 2Stem CellSection, Laboratory of Neurosciences, National Institute on Ag-ing, National Institutes of Health, Baltimore, MD, USA.

Sa1.14 - The MHC Is the Major Determinant for the Require-Sa1.14 - The MHC Is the Major Determinant for the Require-Sa1.14 - The MHC Is the Major Determinant for the Require-Sa1.14 - The MHC Is the Major Determinant for the Require-Sa1.14 - The MHC Is the Major Determinant for the Require-ment of B7.1/7.2-Costimulation in the Induction of Experi-ment of B7.1/7.2-Costimulation in the Induction of Experi-ment of B7.1/7.2-Costimulation in the Induction of Experi-ment of B7.1/7.2-Costimulation in the Induction of Experi-ment of B7.1/7.2-Costimulation in the Induction of Experi-mental Autoimmune Encephalomyelitis (EAE).mental Autoimmune Encephalomyelitis (EAE).mental Autoimmune Encephalomyelitis (EAE).mental Autoimmune Encephalomyelitis (EAE).mental Autoimmune Encephalomyelitis (EAE).B. Greve,1 C. Jabs Mansell,1 R. A. Sobel,2,3 A. H. Sharpe,4 V.K. Kuchroo.1 1Center for Neurologic Diseases, Harvard Insti-tutes of Medicine, Brigham and Women’s Hospital, Boston, MA,USA; 2Laboratory Service, Veterans Affairs Medical Center, PaloAlto, CA, USA; 3Department of Pathology, Stanford UniversitySchool of Medicine, Stanford, CA, USA; 4Department of Pathol-ogy, Harvard Medical School, Boston, MA, USA.

Sa1.15 - Anti-CTLA4 scFvSa1.15 - Anti-CTLA4 scFvSa1.15 - Anti-CTLA4 scFvSa1.15 - Anti-CTLA4 scFvSa1.15 - Anti-CTLA4 scFv, a Single-Chain Antibody, a Single-Chain Antibody, a Single-Chain Antibody, a Single-Chain Antibody, a Single-Chain Antibody, Attenu-, Attenu-, Attenu-, Attenu-, Attenu-ated Host Humoral Immune Responses during Repeated DNAated Host Humoral Immune Responses during Repeated DNAated Host Humoral Immune Responses during Repeated DNAated Host Humoral Immune Responses during Repeated DNAated Host Humoral Immune Responses during Repeated DNAVVVVVaccination in Immune Competent Animals.accination in Immune Competent Animals.accination in Immune Competent Animals.accination in Immune Competent Animals.accination in Immune Competent Animals.An-Bang Liu,1 Steve R. Roffler.2 1Neuromuscular Research, TzuChi Neuro-Medical Scientific Center, Tzu Chi Medical Center,Hualien, Taiwan; 2Institute of Biomedical Science, AcademiaSinica, Taipei, Taiwan.

Sa1.16 - MemorSa1.16 - MemorSa1.16 - MemorSa1.16 - MemorSa1.16 - Memory CD4+ T Cells and EAE.y CD4+ T Cells and EAE.y CD4+ T Cells and EAE.y CD4+ T Cells and EAE.y CD4+ T Cells and EAE.W. Elyaman,1 T. Chitnis,1 J. Imitola,1 M. H. Sayegh,2 S. J. Khoury.11Center for Neurologic Diseases, Brigham and Women’s Hospi-tal, Boston, MA, USA; 2Transplantation Center, Brigham andWomen’s Hospital and Children’s Hospital, Boston, MA, USA.

Sa1.17 - Therapeutic Effects of Glycosylated Sa1.17 - Therapeutic Effects of Glycosylated Sa1.17 - Therapeutic Effects of Glycosylated Sa1.17 - Therapeutic Effects of Glycosylated Sa1.17 - Therapeutic Effects of Glycosylated β β β β β InterferonInterferonInterferonInterferonInterferon(((((βββββIFN)IFN)IFN)IFN)IFN) on Childhood Adrenoleukodystrophy (ALDCCER)on Childhood Adrenoleukodystrophy (ALDCCER)on Childhood Adrenoleukodystrophy (ALDCCER)on Childhood Adrenoleukodystrophy (ALDCCER)on Childhood Adrenoleukodystrophy (ALDCCER)G. A. Moviglia,1 A. E. Pereyra,1 G. S. Shuster,2 C. Ruggilo.2

1Immunotherapy, Regina Mater Foundation, Buenos Aires, Ar-gentina; 2MRI, Medical Image, Buenos Aires, Argentina.



Sa1.18 - Anti-Myelin Antibodies as an Immune-ModulatorSa1.18 - Anti-Myelin Antibodies as an Immune-ModulatorSa1.18 - Anti-Myelin Antibodies as an Immune-ModulatorSa1.18 - Anti-Myelin Antibodies as an Immune-ModulatorSa1.18 - Anti-Myelin Antibodies as an Immune-ModulatoryyyyyMarker for IVIG TMarker for IVIG TMarker for IVIG TMarker for IVIG TMarker for IVIG Treatment in Patients with Progressive Mul-reatment in Patients with Progressive Mul-reatment in Patients with Progressive Mul-reatment in Patients with Progressive Mul-reatment in Patients with Progressive Mul-tiple Sclerosis.tiple Sclerosis.tiple Sclerosis.tiple Sclerosis.tiple Sclerosis.Sarah B. Kelley, Isaac Melamed, David Barr-Or. 1Immunology,1st Immunology and Infusion Center, Englewood, CO, USA; 2Im-munology, 1st Immunology and Infusion Center, Englewood, CO,USA; 3Trauma Research Department, Swedish Medical Center,Englewood, CO, USA.

Sa1.19 - T Cell TSa1.19 - T Cell TSa1.19 - T Cell TSa1.19 - T Cell TSa1.19 - T Cell Tolerance Induced by Cross-Reactive TCRolerance Induced by Cross-Reactive TCRolerance Induced by Cross-Reactive TCRolerance Induced by Cross-Reactive TCRolerance Induced by Cross-Reactive TCRLigands Can Be Broken by Superagonist Ligand Resulting inLigands Can Be Broken by Superagonist Ligand Resulting inLigands Can Be Broken by Superagonist Ligand Resulting inLigands Can Be Broken by Superagonist Ligand Resulting inLigands Can Be Broken by Superagonist Ligand Resulting inAnti-InflammatorAnti-InflammatorAnti-InflammatorAnti-InflammatorAnti-Inflammatory Cytokine Production.y Cytokine Production.y Cytokine Production.y Cytokine Production.y Cytokine Production.Z. Illes,1,2 H. Waldner,1 J. Reddy,1 E. Bettelli,1 L. B. Nicholson,1,3

V. K. Kuchroo.1 1Center for Neurologic Diseases, HarvardMedical School, Brigham and Women’s Hospital, Boston, MA,USA; 2Department of Neurology, University of Pecs, Pecs, Hun-gary; 3School of Medical Sciences, Bristol, United Kingdom.

Sa1.20 - Agonistic Anti-CTLA4 Antibody Inhibits T CellsSa1.20 - Agonistic Anti-CTLA4 Antibody Inhibits T CellsSa1.20 - Agonistic Anti-CTLA4 Antibody Inhibits T CellsSa1.20 - Agonistic Anti-CTLA4 Antibody Inhibits T CellsSa1.20 - Agonistic Anti-CTLA4 Antibody Inhibits T CellsExpansion, Cytokine Production and Development of Autoim-Expansion, Cytokine Production and Development of Autoim-Expansion, Cytokine Production and Development of Autoim-Expansion, Cytokine Production and Development of Autoim-Expansion, Cytokine Production and Development of Autoim-munitymunitymunitymunitymunity.....K. Miyamoto,1,3 L. Vijayakrishnan,1 E. Greenfield,1 B. Carreno,1A. Sharpe,2 V. Kuchroo.1 1Center for Neurolosic Diseases, BWH,Harvard Medical School, Boston, MA, USA; 2Pathology, BWH,Harvard Medical School, Boston, MA, USA; 3Neurology, KinkiUniversity, Osaka-Sayama, Osaka, Japan.

Sa1.21 - TSa1.21 - TSa1.21 - TSa1.21 - TSa1.21 - Tumor Necrosis Factorumor Necrosis Factorumor Necrosis Factorumor Necrosis Factorumor Necrosis Factor-----α α α α α Gene Polymorphism inGene Polymorphism inGene Polymorphism inGene Polymorphism inGene Polymorphism inIranian Patients with Multiple Sclerosis.Iranian Patients with Multiple Sclerosis.Iranian Patients with Multiple Sclerosis.Iranian Patients with Multiple Sclerosis.Iranian Patients with Multiple Sclerosis.M. Izad,1 A. A. Amirzargar,1 D. Fathi,2 M. H. Niknam,1 M.Vodjgani.1 1Dep.of Immunology, Faculty of Medicine, TehranUniversity of Medical Sciences, Tehran, Islamic Republic of Iran;2Dep. of Neurology, Shariati Hospital, Tehran University of Medi-cal Sciences, Tehran, Islamic Republic of Iran.

Sa1.22 - Corticotropin-Releasing Hormone Contributes to theSa1.22 - Corticotropin-Releasing Hormone Contributes to theSa1.22 - Corticotropin-Releasing Hormone Contributes to theSa1.22 - Corticotropin-Releasing Hormone Contributes to theSa1.22 - Corticotropin-Releasing Hormone Contributes to thePeripheral InflammatorPeripheral InflammatorPeripheral InflammatorPeripheral InflammatorPeripheral Inflammatory Response in Experimental Autoim-y Response in Experimental Autoim-y Response in Experimental Autoim-y Response in Experimental Autoim-y Response in Experimental Autoim-mune Encephalomyelitis.mune Encephalomyelitis.mune Encephalomyelitis.mune Encephalomyelitis.mune Encephalomyelitis.Y. Wang,1 C. Benou,1 J. Imitola,1 L. VanVlerken,2 C. Chandras,2K. P. Karalis,2 S. J. Khoury.1 1Center for Neurologic Diseases,Brigham and Women’s Hospital and Harvard Medical School,Boston, MA, USA; 2Division of Endocrinology, Children’s Hospi-tal and Harvard Medical School, Boston, MA, USA.

Sa1.23 - Individual Statins Differ in ImmunomodulatorSa1.23 - Individual Statins Differ in ImmunomodulatorSa1.23 - Individual Statins Differ in ImmunomodulatorSa1.23 - Individual Statins Differ in ImmunomodulatorSa1.23 - Individual Statins Differ in Immunomodulatory Po-y Po-y Po-y Po-y Po-tential and Capability Ttential and Capability Ttential and Capability Ttential and Capability Ttential and Capability To To To To To Treat Th1-Mediated CNS Autoim-reat Th1-Mediated CNS Autoim-reat Th1-Mediated CNS Autoim-reat Th1-Mediated CNS Autoim-reat Th1-Mediated CNS Autoim-mune Disease.mune Disease.mune Disease.mune Disease.mune Disease.M. J. Goldstein,1 M. S. Weber,2 S. E. Dunn,1 T. Prod’homme,2 L.Steinman,1 S. S. Zamvil,2 S. Youssef.1 1Neurology, StanfordUniversity, Stanford, CA, USA; 2Neurology, University of Califor-nia, San Francisco, CA, USA.

Sa1.24 - FMRI Correlates of Strategic Planning in MultipleSa1.24 - FMRI Correlates of Strategic Planning in MultipleSa1.24 - FMRI Correlates of Strategic Planning in MultipleSa1.24 - FMRI Correlates of Strategic Planning in MultipleSa1.24 - FMRI Correlates of Strategic Planning in MultipleSclerosis.Sclerosis.Sclerosis.Sclerosis.Sclerosis.J. J. Randolph,1 H. A. Wishart,1 R. M. Roth,1 B. C. McDonald,1

J. W. MacDonald,1 J. D. West,1 N. S. Koven,1 A. C. Mamourian,2L. H. Kasper,3 A. J. Saykin.1 1Department of Psychiatry, DartmouthMedical School, Lebanon, NH, USA; 2Department of Radiol-ogy, Dartmouth Medical School, Lebanon, NH, USA; 3Sectionof Neurology, Dartmouth Medical School, Lebanon, NH, USA.

Sa1.25 - A New Clinically Relevant Approach TSa1.25 - A New Clinically Relevant Approach TSa1.25 - A New Clinically Relevant Approach TSa1.25 - A New Clinically Relevant Approach TSa1.25 - A New Clinically Relevant Approach To Expando Expando Expando Expando ExpandMyelin Specific T Cells.Myelin Specific T Cells.Myelin Specific T Cells.Myelin Specific T Cells.Myelin Specific T Cells.Nathalie Arbour,1 Rejean Lapointe,2 Philippe Saikali,1 Jack P.Antel.1 1Neuroimmunology Unit, Montreal Neurological Insti-tute McGill University, Montreal, QC, Canada; 2Department ofMedicine, Faculty of Medicine, University of Montreal (HospitalCentre Notre-Dame), Montreal, QC, Canada.

Sa1.26 - IL-15 and IL-2 Fusion Proteins Attenuate Experimen-Sa1.26 - IL-15 and IL-2 Fusion Proteins Attenuate Experimen-Sa1.26 - IL-15 and IL-2 Fusion Proteins Attenuate Experimen-Sa1.26 - IL-15 and IL-2 Fusion Proteins Attenuate Experimen-Sa1.26 - IL-15 and IL-2 Fusion Proteins Attenuate Experimen-tal Autoimmune Encephalomyelitis.tal Autoimmune Encephalomyelitis.tal Autoimmune Encephalomyelitis.tal Autoimmune Encephalomyelitis.tal Autoimmune Encephalomyelitis.C. Gutierrez,1 T. Chitnis,1 M. H. Sayegh,2 X. X. Zheng,3 S. J.Khoury. 1Center for Neurologic Diseases, Brigham and Women’sHospital, Boston, MA, USA; 2Transplantation Center, Brighamand Women’s Hospital and Children’s Hospital, Boston, MA,USA; 3Immunology, Beth Israel Deaconess Medical Center, Bos-ton, MA, USA.

Sa1.27 - Dendritic Cells from the Mesenteric LSa1.27 - Dendritic Cells from the Mesenteric LSa1.27 - Dendritic Cells from the Mesenteric LSa1.27 - Dendritic Cells from the Mesenteric LSa1.27 - Dendritic Cells from the Mesenteric Lymph Nodesymph Nodesymph Nodesymph Nodesymph Nodesof OVof OVof OVof OVof OVA Fed Animals Stimulate Naïve T Cells In VA Fed Animals Stimulate Naïve T Cells In VA Fed Animals Stimulate Naïve T Cells In VA Fed Animals Stimulate Naïve T Cells In VA Fed Animals Stimulate Naïve T Cells In Vitro Titro Titro Titro Titro To Ex-o Ex-o Ex-o Ex-o Ex-press Latency-Associated Peptide.press Latency-Associated Peptide.press Latency-Associated Peptide.press Latency-Associated Peptide.press Latency-Associated Peptide.Kaiyong Yang,1 Ana Faria,2 Howard L. Weiner.1 1Center forNeurologic Diseases, Brigham and Women’s Hospital, Boston,MA, USA; 2Departamento de Bioquimica e Imunologia,Universidade Federal de Minas Gerais, Brazil.

20052005200520052005ANNUAL MEETING

81



Sa1.28 - Immature Dendritic Cells Can Reduce ExperimentalSa1.28 - Immature Dendritic Cells Can Reduce ExperimentalSa1.28 - Immature Dendritic Cells Can Reduce ExperimentalSa1.28 - Immature Dendritic Cells Can Reduce ExperimentalSa1.28 - Immature Dendritic Cells Can Reduce ExperimentalAutoimmune Encephalomyelitis in the Mouse.Autoimmune Encephalomyelitis in the Mouse.Autoimmune Encephalomyelitis in the Mouse.Autoimmune Encephalomyelitis in the Mouse.Autoimmune Encephalomyelitis in the Mouse.M. I. Iruretagoyena,1 S. E. Sepulveda,1 A. M. Kalergis.1

1Departamento de Genetica Molecular y Microbiologia,Pontificia Universidad Catolica de Chile, Santiago, Chile.

Sa1.29 - CD4+CD25+ RegulatorSa1.29 - CD4+CD25+ RegulatorSa1.29 - CD4+CD25+ RegulatorSa1.29 - CD4+CD25+ RegulatorSa1.29 - CD4+CD25+ Regulatory T Cells Mediate Recovery T Cells Mediate Recovery T Cells Mediate Recovery T Cells Mediate Recovery T Cells Mediate Recoveryyyyyfrom Experimental Autoimmune Encephalomyelitis in Asso-from Experimental Autoimmune Encephalomyelitis in Asso-from Experimental Autoimmune Encephalomyelitis in Asso-from Experimental Autoimmune Encephalomyelitis in Asso-from Experimental Autoimmune Encephalomyelitis in Asso-ciation with LAP+TGF ciation with LAP+TGF ciation with LAP+TGF ciation with LAP+TGF ciation with LAP+TGF β β β β β Secreting Cells.Secreting Cells.Secreting Cells.Secreting Cells.Secreting Cells.H. Ochi,1,2 X. Zhang,1,2 J. Reddy,1 D. Frenkel,1 V. K. Kuchroo,1

H. L. Weiner.1 1Center for Neurologic Diseases, Department ofNeurology, Brigham and Women’s Hospital, Harvard MedicalSchool, Boston, MA, USA; 2Contributed Equally.

Sa1.30 - Genetic Markers of Disease Risk, Prognosis andSa1.30 - Genetic Markers of Disease Risk, Prognosis andSa1.30 - Genetic Markers of Disease Risk, Prognosis andSa1.30 - Genetic Markers of Disease Risk, Prognosis andSa1.30 - Genetic Markers of Disease Risk, Prognosis andTTTTTreatment Response in Multiple Sclerosis.reatment Response in Multiple Sclerosis.reatment Response in Multiple Sclerosis.reatment Response in Multiple Sclerosis.reatment Response in Multiple Sclerosis.A. Foti,1 D. Lichter,1 J. Parekh,1 J. Bryce,3 G. Ginsburg,1 J. Lekstrom-Himes,1 D. Hafler,2 P. DeJaeger,2 R. Roubenoff,1 S. Khoury,2 H.Weiner,2 A. Parker.1 1Department of Molecular Medicine, Mil-lennium Pharmaceuticals, Inc., Cambridge, MA, USA; 2Depart-ment of Neurology, Harvard Medical School, Boston, MA, USA;3Department of Clinical Operations, Millennium Pharmaceuti-cals, Inc., Cambridge, MA, USA.

Sa1.31 - Investigating Anti Human MOG Antibodies in Mul-Sa1.31 - Investigating Anti Human MOG Antibodies in Mul-Sa1.31 - Investigating Anti Human MOG Antibodies in Mul-Sa1.31 - Investigating Anti Human MOG Antibodies in Mul-Sa1.31 - Investigating Anti Human MOG Antibodies in Mul-tiple Sclerosis Using Stably MOG Ttiple Sclerosis Using Stably MOG Ttiple Sclerosis Using Stably MOG Ttiple Sclerosis Using Stably MOG Ttiple Sclerosis Using Stably MOG Transduced Cell Lines.ransduced Cell Lines.ransduced Cell Lines.ransduced Cell Lines.ransduced Cell Lines.Rajneesh Srivastava,1 Dun Zhou,1 Stefan Nessler,1 SabineCepok,1 Hans-Peter Hartung,1 Bernhard Hemmer.1 1Departmentof Neurology, Heinrich-Heine-University Dusseldorf, Dusseldorf,NRW, Germany.

Sa1.32 - Role of CD46 in Multiple Sclerosis.Sa1.32 - Role of CD46 in Multiple Sclerosis.Sa1.32 - Role of CD46 in Multiple Sclerosis.Sa1.32 - Role of CD46 in Multiple Sclerosis.Sa1.32 - Role of CD46 in Multiple Sclerosis.A. L. Astier,1 D. A. Hafler.1 1Center for Neurologic Diseases,Brigham and Women’s Hospital, Boston, MA, USA.

Sa1.33 - Myelin-Specific Cytokine Responses Show a Dra-Sa1.33 - Myelin-Specific Cytokine Responses Show a Dra-Sa1.33 - Myelin-Specific Cytokine Responses Show a Dra-Sa1.33 - Myelin-Specific Cytokine Responses Show a Dra-Sa1.33 - Myelin-Specific Cytokine Responses Show a Dra-matic Gender Bias in Multiple Sclerosis (MS).matic Gender Bias in Multiple Sclerosis (MS).matic Gender Bias in Multiple Sclerosis (MS).matic Gender Bias in Multiple Sclerosis (MS).matic Gender Bias in Multiple Sclerosis (MS).I. M. Moldovan,1 A. C. Cotleur,1 N. Zamor,1 J.-C. Lee,3 R. A.Rudick,2 C. M. Pelfrey.1 1Neurosciences, NC30, Cleveland ClinicFoundation, Cleveland, OH, USA; 2Mellen Center for MS Treat-ment and Research, Cleveland Clinic Foundation, Cleveland,OH, USA; 3Biostatistics, Cleveland Clinic Foundation, Cleveland,OH, USA.

Sa1.34 - Intrathymic Expression of TSa1.34 - Intrathymic Expression of TSa1.34 - Intrathymic Expression of TSa1.34 - Intrathymic Expression of TSa1.34 - Intrathymic Expression of Torpedo Acetylcholine Re-orpedo Acetylcholine Re-orpedo Acetylcholine Re-orpedo Acetylcholine Re-orpedo Acetylcholine Re-ceptor Alpha Subunit.ceptor Alpha Subunit.ceptor Alpha Subunit.ceptor Alpha Subunit.ceptor Alpha Subunit.D. Song,1 Y. Zheng,1 A. I. Levinson.1 1Allergy/Immunology Sec-tion, University of Pennsylvania School of Medicine, Philadel-phia, PA, USA.

Sa1.35 - The Cytokine Pattern of Glatiramer Acetate ReactiveSa1.35 - The Cytokine Pattern of Glatiramer Acetate ReactiveSa1.35 - The Cytokine Pattern of Glatiramer Acetate ReactiveSa1.35 - The Cytokine Pattern of Glatiramer Acetate ReactiveSa1.35 - The Cytokine Pattern of Glatiramer Acetate ReactiveCD8+ T Cell Lines Derived from MS Patients and Healthy VCD8+ T Cell Lines Derived from MS Patients and Healthy VCD8+ T Cell Lines Derived from MS Patients and Healthy VCD8+ T Cell Lines Derived from MS Patients and Healthy VCD8+ T Cell Lines Derived from MS Patients and Healthy Vol-ol-ol-ol-ol-unteers.unteers.unteers.unteers.unteers.A. Dressel,1 A. Vogelgesang,1 S. Peters,1 F. Weber.2 1Depart-ment of Neurology, University Greifswald, Greifswald, Germany;2Section of Neurology, Max-Planck-Institute of Psychiatry, Munich,Germany.

Sa1.36 - An Exploration of the Role of TLR2 and TLR4 in CD14+Sa1.36 - An Exploration of the Role of TLR2 and TLR4 in CD14+Sa1.36 - An Exploration of the Role of TLR2 and TLR4 in CD14+Sa1.36 - An Exploration of the Role of TLR2 and TLR4 in CD14+Sa1.36 - An Exploration of the Role of TLR2 and TLR4 in CD14+Cells in Multiple Sclerosis.Cells in Multiple Sclerosis.Cells in Multiple Sclerosis.Cells in Multiple Sclerosis.Cells in Multiple Sclerosis.P. L. De Jager, C. S. Wolfish, V. Viglietta, J. Flores, H. L. Weiner,D. A. Hafler, S. J. Khoury. 1Neurology, Brigham and Women’sHospital, Center for Neurologic Diseases, Harvard MedicalSchool, Boston, MA, USA;

Sa1.37 - Regula t ion of Express ion of Matr ixSa1.37 - Regula t ion of Express ion of Matr ixSa1.37 - Regula t ion of Express ion of Matr ixSa1.37 - Regula t ion of Express ion of Matr ixSa1.37 - Regula t ion of Express ion of Matr ixMetalloproteinases in CNS Inflammation VMetalloproteinases in CNS Inflammation VMetalloproteinases in CNS Inflammation VMetalloproteinases in CNS Inflammation VMetalloproteinases in CNS Inflammation Versus CNS Injurersus CNS Injurersus CNS Injurersus CNS Injurersus CNS Injuryyyyy.....H. Toft-Hansen,1 A. A. Babcock,1 R. K. Nuttall,2 D. R. Edwards,2

T. Owens.1,3 1Neuroimmunology, Montreal Neurological Insti-tute, McGill University, Montreal, QC, Canada; 2School of Bio-logical Sciences, University of East Anglia, Norwich, Norfolk,United Kingdom; 3Medical Biotechnology Center, University ofSouthern Denmark, Odense, Denmark.

Sa1.38 - Searching for Biomarkers in Multiple Sclerosis: TheSa1.38 - Searching for Biomarkers in Multiple Sclerosis: TheSa1.38 - Searching for Biomarkers in Multiple Sclerosis: TheSa1.38 - Searching for Biomarkers in Multiple Sclerosis: TheSa1.38 - Searching for Biomarkers in Multiple Sclerosis: TheNeed for Natural HistorNeed for Natural HistorNeed for Natural HistorNeed for Natural HistorNeed for Natural History Studies.y Studies.y Studies.y Studies.y Studies.Vissia Viglietta,1 Bonnie Glanz,1 Guy Buckle,1 Howard L.Weiner,1 Samia J. Khoury.1 1Neurology, Brigham and Women’sHospital, Boston, MA, USA.

Sa1.39 - Protection in a Rodent Model of Multiple SclerosisSa1.39 - Protection in a Rodent Model of Multiple SclerosisSa1.39 - Protection in a Rodent Model of Multiple SclerosisSa1.39 - Protection in a Rodent Model of Multiple SclerosisSa1.39 - Protection in a Rodent Model of Multiple Sclerosisby Carbon Monoxide Release.by Carbon Monoxide Release.by Carbon Monoxide Release.by Carbon Monoxide Release.by Carbon Monoxide Release.M. V. George,1 S. Iyer,2 L. Gao,3 T. Fong,4 R. Buelow,5 D. J.Matthes.1 1Biological Sciences, San Jose State University, SanJose, CA, USA; 2Development Sciences, Genentech, South SanFrancisco, CA, USA; 3Research, Genzyme Corporation,Framingham, MA, USA; 4Research, Cellerant Therapeutics, PaloAlto, CA, USA; 5Research, Therapeutic Human Polyclonals,Mountain View, CA, USA.



Sa1.40 - IFNSa1.40 - IFNSa1.40 - IFNSa1.40 - IFNSa1.40 - IFNγ−γ−γ−γ−γ−Dependent Regulation of the Neutrophil-Dependent Regulation of the Neutrophil-Dependent Regulation of the Neutrophil-Dependent Regulation of the Neutrophil-Dependent Regulation of the Neutrophil-Activating Cytokines IL-17 and IL18 in EAE.Activating Cytokines IL-17 and IL18 in EAE.Activating Cytokines IL-17 and IL18 in EAE.Activating Cytokines IL-17 and IL18 in EAE.Activating Cytokines IL-17 and IL18 in EAE.R. D. Wheeler,1 L. M. Kelly,1 S. L. Carter,1 T. Owens.1,2

1Neuroimmunology Unit, Montreal Neurological Institute,Montreal, QC, Canada; 2Medical Biotechnology Center, Uni-versity of Southern Denmark, Odense, Denmark.

Sa1.41 - Differential Reactivity Against Solid-Phase and Liq-Sa1.41 - Differential Reactivity Against Solid-Phase and Liq-Sa1.41 - Differential Reactivity Against Solid-Phase and Liq-Sa1.41 - Differential Reactivity Against Solid-Phase and Liq-Sa1.41 - Differential Reactivity Against Solid-Phase and Liq-uid-Phase Myelin/Oligodendrocyte Glycoprotein in Multipleuid-Phase Myelin/Oligodendrocyte Glycoprotein in Multipleuid-Phase Myelin/Oligodendrocyte Glycoprotein in Multipleuid-Phase Myelin/Oligodendrocyte Glycoprotein in Multipleuid-Phase Myelin/Oligodendrocyte Glycoprotein in MultipleSclerosis and Experimental Allergic Encephalomyelitis.Sclerosis and Experimental Allergic Encephalomyelitis.Sclerosis and Experimental Allergic Encephalomyelitis.Sclerosis and Experimental Allergic Encephalomyelitis.Sclerosis and Experimental Allergic Encephalomyelitis.T. Menge,1 H.C. von Budingen,2 P. H. Lalive,1 S. L. Hauser,1 C.P. Genain.1 1Department of Neurology, University of CaliforniaSan Francisco, San Francisco, CA, USA; 2Neurologische Klinik,Universitat Zurich, Zurich, Switzerland.

Sa1.42 - Characterization of B Cell Immunoglobulin VSa1.42 - Characterization of B Cell Immunoglobulin VSa1.42 - Characterization of B Cell Immunoglobulin VSa1.42 - Characterization of B Cell Immunoglobulin VSa1.42 - Characterization of B Cell Immunoglobulin VariableariableariableariableariableRegion Genes Derived from Muscle Tissue of Subjects withRegion Genes Derived from Muscle Tissue of Subjects withRegion Genes Derived from Muscle Tissue of Subjects withRegion Genes Derived from Muscle Tissue of Subjects withRegion Genes Derived from Muscle Tissue of Subjects withInclusion Body Myositis.Inclusion Body Myositis.Inclusion Body Myositis.Inclusion Body Myositis.Inclusion Body Myositis.E. M. Bradshaw,1 L. Bregoli,1 A. A. Amato,2 D. A. Hafler,1 S. A.Greenberg,2 K. C. O’Connor.1 1Department of Neurology,Center for Neurologic Diseases, Brigham and Women’s Hospi-tal, Boston, MA, USA; 2Department of Neurology, Division ofNeuromuscular Disease, Brigham and Women’s Hospital, Bos-ton, MA, USA.

Sa1.43 - Analysis of Genomic DNA from Human Single CellsSa1.43 - Analysis of Genomic DNA from Human Single CellsSa1.43 - Analysis of Genomic DNA from Human Single CellsSa1.43 - Analysis of Genomic DNA from Human Single CellsSa1.43 - Analysis of Genomic DNA from Human Single CellsUsing Multiple Displacement Amplification: Application to B-Using Multiple Displacement Amplification: Application to B-Using Multiple Displacement Amplification: Application to B-Using Multiple Displacement Amplification: Application to B-Using Multiple Displacement Amplification: Application to B-and Tand Tand Tand Tand T-Cell Receptor V-Cell Receptor V-Cell Receptor V-Cell Receptor V-Cell Receptor Variable Region Genes.ariable Region Genes.ariable Region Genes.ariable Region Genes.ariable Region Genes.L. Bregoli, K. O’Connor, D. A. Hafler. 1Center for NeurologicDiseases, Brigham and Women’s Hospital, Harvard MedicalSchool, Boston, MA, USA.

Sa1.44 - Characterization of B Cell Immunoglobulin VSa1.44 - Characterization of B Cell Immunoglobulin VSa1.44 - Characterization of B Cell Immunoglobulin VSa1.44 - Characterization of B Cell Immunoglobulin VSa1.44 - Characterization of B Cell Immunoglobulin VariableariableariableariableariableRegion Genes Derived from Lesions of Patients with MS.Region Genes Derived from Lesions of Patients with MS.Region Genes Derived from Lesions of Patients with MS.Region Genes Derived from Lesions of Patients with MS.Region Genes Derived from Lesions of Patients with MS.K. C. O’Connor,1 N. H. Moore,1 L. Bregoli,1 E. Bradshaw,1 K.Wucherpfennig,2 D. A. Hafler.1 1Department of Neurology,Harvard Medical School, Brigham and Women’s Hospital, Bos-ton, MA, USA; 2Department of Cancer Immunology and AIDS,Dana Farber Cancer Institute, Harvard Medical School, Boston,MA, USA.

Sa1.45 - Genetic Resistance to Autoimmunity Is MediatedSa1.45 - Genetic Resistance to Autoimmunity Is MediatedSa1.45 - Genetic Resistance to Autoimmunity Is MediatedSa1.45 - Genetic Resistance to Autoimmunity Is MediatedSa1.45 - Genetic Resistance to Autoimmunity Is Mediatedby Autoantigen-Specific CD4+CD25+ Regulatorby Autoantigen-Specific CD4+CD25+ Regulatorby Autoantigen-Specific CD4+CD25+ Regulatorby Autoantigen-Specific CD4+CD25+ Regulatorby Autoantigen-Specific CD4+CD25+ Regulatory Cells.y Cells.y Cells.y Cells.y Cells.J. Reddy, Z. Illes, X. Zhang, J. Encinas, J. Pyrdol, L. Nicholson,R. Sobel, K. Wucherpfennig, V. Kuchroo. 1Center for Neuro-logic Diseases, Brigham and Women’s Hosp/Harvard MedicalSchool, Boston, MA, USA; 2Cancer Immunology and AIDS,Dana-Farber Cancer Institute, Boston, MA, USA; 3Pathology,Stanford University School of Medicine, Stanford, CA, USA.

Autoimmune Rheumatologic DiseasesAutoimmune Rheumatologic DiseasesAutoimmune Rheumatologic DiseasesAutoimmune Rheumatologic DiseasesAutoimmune Rheumatologic Diseases

Sa1.46 - A 20 YSa1.46 - A 20 YSa1.46 - A 20 YSa1.46 - A 20 YSa1.46 - A 20 Year Old with Knee Arear Old with Knee Arear Old with Knee Arear Old with Knee Arear Old with Knee Arthritis Develops Multiplethritis Develops Multiplethritis Develops Multiplethritis Develops Multiplethritis Develops MultipleOrgan Dysfunction: Think Zebras, Not Horses.Organ Dysfunction: Think Zebras, Not Horses.Organ Dysfunction: Think Zebras, Not Horses.Organ Dysfunction: Think Zebras, Not Horses.Organ Dysfunction: Think Zebras, Not Horses.P. B. Pinho,1 M. Rodriguez,1 D. Menasha,1 B. Suri,1 M. Youseff-Bessler,1 B. Suri,1 R. K. Messo,2 L. Bielory.1 1Internal Medicine,UMDNJ-NJMS, Newark, NJ, USA; 2Internal Medicine, StatenIsland University Hospital, Staten Island, NY, USA.

Sa1.47 - Differential Expression of Co-StimulatorSa1.47 - Differential Expression of Co-StimulatorSa1.47 - Differential Expression of Co-StimulatorSa1.47 - Differential Expression of Co-StimulatorSa1.47 - Differential Expression of Co-Stimulatory Moleculesy Moleculesy Moleculesy Moleculesy Moleculeson PBMCs from Patients with Active Systemic Lupus Eron PBMCs from Patients with Active Systemic Lupus Eron PBMCs from Patients with Active Systemic Lupus Eron PBMCs from Patients with Active Systemic Lupus Eron PBMCs from Patients with Active Systemic Lupus Erythe-ythe-ythe-ythe-ythe-matosus and Rheumatoid Arthritis.matosus and Rheumatoid Arthritis.matosus and Rheumatoid Arthritis.matosus and Rheumatoid Arthritis.matosus and Rheumatoid Arthritis.E. Rojas-Ramos,1 N. E. Martinez-Jimenez,1 Y. B. Garfias,2 E. G.Zenteno,2 R. L. Lascurain.2 1Clinical Immunology and Allergy,ISSSTE, Mexico, Mexico City, Mexico; 2Biochemistry, INER, SSA,Mexico, Mexico City, Mexico.

Sa1.48 - Effects of TSa1.48 - Effects of TSa1.48 - Effects of TSa1.48 - Effects of TSa1.48 - Effects of Taxus Yaxus Yaxus Yaxus Yaxus Yunnanensis for the Pain on Patientsunnanensis for the Pain on Patientsunnanensis for the Pain on Patientsunnanensis for the Pain on Patientsunnanensis for the Pain on Patientswith Rheumatoid Arthritis.with Rheumatoid Arthritis.with Rheumatoid Arthritis.with Rheumatoid Arthritis.with Rheumatoid Arthritis.Testuroh Okano,1 Koya Kubo,1 Yutaka Tajima,2 OsamuNakajima,3 Takahiro Nobukawa.4 1Immunology/AHS, KitasatoUniv, Sagamihara, Kanagawa, Japan; 2Infectiom Control Sci-ences, Juntendo Univ, Bunkyo, Tokyo, Japan; 3Rheumatology,Institute of Chem. Therapy, Chiba, Chiba, Japan; 4Med. Res.Institute, Kanazawa Med. Univ., Kanazawa, Isikawa, Japan.

Sa1.49 - Protection from Collagen-Induced Arthritis bySa1.49 - Protection from Collagen-Induced Arthritis bySa1.49 - Protection from Collagen-Induced Arthritis bySa1.49 - Protection from Collagen-Induced Arthritis bySa1.49 - Protection from Collagen-Induced Arthritis byComplement Receptor CR2/CR1 DeficiencyComplement Receptor CR2/CR1 DeficiencyComplement Receptor CR2/CR1 DeficiencyComplement Receptor CR2/CR1 DeficiencyComplement Receptor CR2/CR1 Deficiency.....K. A. Kuhn,1 V. M. Holers.1 1Immunology and Medicine, Uni-versity of Colorado Health Sciences Center, Denver, CO, USA.

Sa1.50 - Leptin Modulates Autoimmune Reactivity in (NZB xSa1.50 - Leptin Modulates Autoimmune Reactivity in (NZB xSa1.50 - Leptin Modulates Autoimmune Reactivity in (NZB xSa1.50 - Leptin Modulates Autoimmune Reactivity in (NZB xSa1.50 - Leptin Modulates Autoimmune Reactivity in (NZB xNZW)FNZW)FNZW)FNZW)FNZW)F11111 Lupus Mice. Lupus Mice. Lupus Mice. Lupus Mice. Lupus Mice.A. La Cava, F. M. Ebling, B. H. Hahn. 1Medicine/Rheumatol-ogy, University of California Los Angeles, Los Angeles, CA, USA.

20052005200520052005ANNUAL MEETING

83



Sa1.51 - Hyperhomocysteinemia in Hughes Syndrome.Sa1.51 - Hyperhomocysteinemia in Hughes Syndrome.Sa1.51 - Hyperhomocysteinemia in Hughes Syndrome.Sa1.51 - Hyperhomocysteinemia in Hughes Syndrome.Sa1.51 - Hyperhomocysteinemia in Hughes Syndrome.J. Carbone,1 A. Rodriguez-Huertas,2 E. Dulin,3 M. Rabadan,2

E. Sarmiento,1 D. Micheloud,1 R. Mora,1 E. Fernandez-Cruz.11Clinical Immunology Unit, University Hospital Gregorio Maranon,Madrid, Spain; 2Hematology Department, University HospitalGregorio Maranon, Madrid, Spain; 3Biochemistry Department,University Hospital Gregorio Maranon, Madrid, Spain.

Sa1.52 - Atherosclerosis in Murine SLE.Sa1.52 - Atherosclerosis in Murine SLE.Sa1.52 - Atherosclerosis in Murine SLE.Sa1.52 - Atherosclerosis in Murine SLE.Sa1.52 - Atherosclerosis in Murine SLE.Zhongjie Ma,1 Marc Monestier,2 Robert Eisenberg.1 1Depart-ment of Medicine, University of Pennsylvania, Philadelphia, PA;2Department of Microbiology and Immunology, Temple Univer-sity, Philadelphia, PA.

Sa1.53 - Association of a Single Nucleotide PolymorphismSa1.53 - Association of a Single Nucleotide PolymorphismSa1.53 - Association of a Single Nucleotide PolymorphismSa1.53 - Association of a Single Nucleotide PolymorphismSa1.53 - Association of a Single Nucleotide Polymorphismof PTPN22 (1858C/T) with Rheumatoid Factor Positivity in aof PTPN22 (1858C/T) with Rheumatoid Factor Positivity in aof PTPN22 (1858C/T) with Rheumatoid Factor Positivity in aof PTPN22 (1858C/T) with Rheumatoid Factor Positivity in aof PTPN22 (1858C/T) with Rheumatoid Factor Positivity in aHealthy Population.Healthy Population.Healthy Population.Healthy Population.Healthy Population.K. D. Deane,1 L. A. Parrish,1 D. S. Majka,1 J. H. Buckner,2 V.Gersuk,2 P. Concannon,2 J. M. Norris,3 V. M. Holers.1 1Divisionof Rheumatology, University of Colorado Health Sciences Cen-ter, Denver, CO, USA; 2Benaroya Research Institute at VirginiaMason, Seattle, WA, USA; 3Deparment of Preventive Medicineand Biometrics, University of Colorado Health Sciences Center,Denver, CO, USA.

Sa1.54 - Anti C1q, Anti Histone Antibodies and C1q Depos-Sa1.54 - Anti C1q, Anti Histone Antibodies and C1q Depos-Sa1.54 - Anti C1q, Anti Histone Antibodies and C1q Depos-Sa1.54 - Anti C1q, Anti Histone Antibodies and C1q Depos-Sa1.54 - Anti C1q, Anti Histone Antibodies and C1q Depos-its in Silent Lupus Nephritis.its in Silent Lupus Nephritis.its in Silent Lupus Nephritis.its in Silent Lupus Nephritis.its in Silent Lupus Nephritis.M. E. Zabaleta-Lanz,1 L. E. Munoz,1 R. E. Vargas-Arenas,1 F. J.Tapanes,1 N. E. Bianco.1 1Institute of Immunology, Central Uni-versity School of Medicine, Caracas, DF, Venezuela.

Sa1.55 - Modulation of Inflammation in RefractorSa1.55 - Modulation of Inflammation in RefractorSa1.55 - Modulation of Inflammation in RefractorSa1.55 - Modulation of Inflammation in RefractorSa1.55 - Modulation of Inflammation in RefractoryyyyyRheumathoid Arthritis by Granulocyte Apheresis: First Euro-Rheumathoid Arthritis by Granulocyte Apheresis: First Euro-Rheumathoid Arthritis by Granulocyte Apheresis: First Euro-Rheumathoid Arthritis by Granulocyte Apheresis: First Euro-Rheumathoid Arthritis by Granulocyte Apheresis: First Euro-pean Prospective Multicenter Open Pilot Studypean Prospective Multicenter Open Pilot Studypean Prospective Multicenter Open Pilot Studypean Prospective Multicenter Open Pilot Studypean Prospective Multicenter Open Pilot Study.....R. Sanmarti,1 R. Lafuente,2 J. Gratacos,3 J. Valverde,4 S. Marsal,5E. Casado,3 D. Reina,4 J. Rodriguez,1 A. Erra.5 1Rheumatol-ogy, Hospital Clinic i Provincial, Barcelona, Spain; 2IntensiveCare Unit, Hospital De L´Hospitalet, Barcelona, Spain;3Rheumathology, Hospital Parc Tauli, Sabadell, Barcelona, Spain;4Rheumathology, Hospital de Bellvitge, Hospitalet de Llobregat,Barcelona, Spain; 5Rheumathology, Hospital Vall d´Hebron,Barcelona, Spain.

Sa1.56 - Interferon-alpha Pathway Activation Identifies a Sub-Sa1.56 - Interferon-alpha Pathway Activation Identifies a Sub-Sa1.56 - Interferon-alpha Pathway Activation Identifies a Sub-Sa1.56 - Interferon-alpha Pathway Activation Identifies a Sub-Sa1.56 - Interferon-alpha Pathway Activation Identifies a Sub-group of Systemic Lupus Ergroup of Systemic Lupus Ergroup of Systemic Lupus Ergroup of Systemic Lupus Ergroup of Systemic Lupus Erythematosus Patients with Anti-ythematosus Patients with Anti-ythematosus Patients with Anti-ythematosus Patients with Anti-ythematosus Patients with Anti-bodies against RNA-Binding Proteins, Renal Disease, andbodies against RNA-Binding Proteins, Renal Disease, andbodies against RNA-Binding Proteins, Renal Disease, andbodies against RNA-Binding Proteins, Renal Disease, andbodies against RNA-Binding Proteins, Renal Disease, andLow Complement.Low Complement.Low Complement.Low Complement.Low Complement.K. A. Kirou,1 C. Lee,1 S. George,1 K. Louca,1 M. G.E. Peterson,1M. K. Crow.1 1Mary Kirkland Center for Lupus Research andDepartment of Medicine, Hospital for Special Surgery and WeillMedical College of Cornell University, New York, NY, USA.

Sa1.57 - The Rheumatic Joint Contains Hyperreactive CD28Sa1.57 - The Rheumatic Joint Contains Hyperreactive CD28Sa1.57 - The Rheumatic Joint Contains Hyperreactive CD28Sa1.57 - The Rheumatic Joint Contains Hyperreactive CD28Sa1.57 - The Rheumatic Joint Contains Hyperreactive CD28nullnullnullnullnull

CD4CD4CD4CD4CD4+++++ T Cells. T Cells. T Cells. T Cells. T Cells.A. E.R. Fasth,1 A.-K. Ulfgren,1 L. Klareskog,1 C. Trollmo,1 V.Malmstrom.1 1Rheumatology Unit, Department of Medicine,Karolinska Institutet, Stockholm, Sweden.

Sa1.58 - Absence of B Cells Decreases Both ProliferationSa1.58 - Absence of B Cells Decreases Both ProliferationSa1.58 - Absence of B Cells Decreases Both ProliferationSa1.58 - Absence of B Cells Decreases Both ProliferationSa1.58 - Absence of B Cells Decreases Both Proliferationand Cytokine Secretion.and Cytokine Secretion.and Cytokine Secretion.and Cytokine Secretion.and Cytokine Secretion.T. Wallerskog,1 L. Klareskog,1 V. Malmstrom,1 C. Trollmo.1 1Rheu-matology Unit, Department of Medicine, Karolinska Institutet,Stockholm, Sweden.

Sa1.59 - Synovial Fluid NKT Cells Display Different Proper-Sa1.59 - Synovial Fluid NKT Cells Display Different Proper-Sa1.59 - Synovial Fluid NKT Cells Display Different Proper-Sa1.59 - Synovial Fluid NKT Cells Display Different Proper-Sa1.59 - Synovial Fluid NKT Cells Display Different Proper-ties Compared to Peripheral Blood NKT Cells in Rheumatoidties Compared to Peripheral Blood NKT Cells in Rheumatoidties Compared to Peripheral Blood NKT Cells in Rheumatoidties Compared to Peripheral Blood NKT Cells in Rheumatoidties Compared to Peripheral Blood NKT Cells in RheumatoidArthritis.Arthritis.Arthritis.Arthritis.Arthritis.L. Linsen, V. Somers, M. Thewissen, P. Geusens, J. Raus, P.Stinissen. 1Biomedisch Onderzoeksinstituut (BIOMED), LimburgsUniversitair Centrum (LUC)/Transnational University Limburg (tUL),Diepenbeek, Belgium.

Sa1.60 - Regulation of Myeloid Cell Function and MHC ClassSa1.60 - Regulation of Myeloid Cell Function and MHC ClassSa1.60 - Regulation of Myeloid Cell Function and MHC ClassSa1.60 - Regulation of Myeloid Cell Function and MHC ClassSa1.60 - Regulation of Myeloid Cell Function and MHC ClassII Expression by TNFII Expression by TNFII Expression by TNFII Expression by TNFII Expression by TNF.....R. B. Mueller,1 A. Skapenko,1 M. Grunke,1 J. Wendler,1 B.Stuhlmuller,2 J. R. Kalden,1 H. Schulze-Koops.1 1Department ofInternal Medicine III, University of Erlangen, Erlangen, Germany;2Department of Rheumatology, Charite University Hospital, Ber-lin, Germany.



Sa1.61 - Isolated TSa1.61 - Isolated TSa1.61 - Isolated TSa1.61 - Isolated TSa1.61 - Isolated Type 5 Antimitochondrial Autoantibodiesype 5 Antimitochondrial Autoantibodiesype 5 Antimitochondrial Autoantibodiesype 5 Antimitochondrial Autoantibodiesype 5 Antimitochondrial AutoantibodiesAssociated with HistorAssociated with HistorAssociated with HistorAssociated with HistorAssociated with History of Thrombocytopaenia and Foetaly of Thrombocytopaenia and Foetaly of Thrombocytopaenia and Foetaly of Thrombocytopaenia and Foetaly of Thrombocytopaenia and FoetalLoss.Loss.Loss.Loss.Loss.Alvarez Silvia, Sanchez-Ramon Silvia, Rodriguez-MahouMargarita, Carbone Javier, Gil Juana, Micheloud Dariela,Fernandez-Cruz Eduardo. 1Immunology, University GeneralHospital Gregorio Maranon, Madrid, Spain.

Sa1.62 - FOXP3+ RegulatorSa1.62 - FOXP3+ RegulatorSa1.62 - FOXP3+ RegulatorSa1.62 - FOXP3+ RegulatorSa1.62 - FOXP3+ Regulatory T Cells in the Rheumatic Joint:y T Cells in the Rheumatic Joint:y T Cells in the Rheumatic Joint:y T Cells in the Rheumatic Joint:y T Cells in the Rheumatic Joint:Contribution of Both CD25+ and CD25- T Cells.Contribution of Both CD25+ and CD25- T Cells.Contribution of Both CD25+ and CD25- T Cells.Contribution of Both CD25+ and CD25- T Cells.Contribution of Both CD25+ and CD25- T Cells.D. Cao,1 A.-K. Ulfgren,1 C. Trollmo,1 V. Malmstrom.1 1Dept ofMedicine, Rheumatology Unit, Karolinska Institutet, Stockholm,Sweden.

Sa1.63 - Increased Systemic and Local Expression of TSa1.63 - Increased Systemic and Local Expression of TSa1.63 - Increased Systemic and Local Expression of TSa1.63 - Increased Systemic and Local Expression of TSa1.63 - Increased Systemic and Local Expression of Toll-oll-oll-oll-oll-L ike Receptor 2 and 4 in Spondyloarthropathy IsL ike Receptor 2 and 4 in Spondyloarthropathy IsL ike Receptor 2 and 4 in Spondyloarthropathy IsL ike Receptor 2 and 4 in Spondyloarthropathy IsL ike Receptor 2 and 4 in Spondyloarthropathy IsDownmodulated by TDownmodulated by TDownmodulated by TDownmodulated by TDownmodulated by Tumour Necrosis Factor alpha Blockade.umour Necrosis Factor alpha Blockade.umour Necrosis Factor alpha Blockade.umour Necrosis Factor alpha Blockade.umour Necrosis Factor alpha Blockade.L. De Rycke,1 B. Vandooren,1 E. Kruithof,1 F. De Keyser,1 E. M.Veys,1 D. Baeten.1 1Rheumatology, Ghent University Hospital,Ghent, Belgium.

Sa1.64 - IgM Anti-dsDNA Antibodies Are the Main Anti-Sa1.64 - IgM Anti-dsDNA Antibodies Are the Main Anti-Sa1.64 - IgM Anti-dsDNA Antibodies Are the Main Anti-Sa1.64 - IgM Anti-dsDNA Antibodies Are the Main Anti-Sa1.64 - IgM Anti-dsDNA Antibodies Are the Main Anti-Nuclear Reactivity Induced by Infliximab but Not EtanerceptNuclear Reactivity Induced by Infliximab but Not EtanerceptNuclear Reactivity Induced by Infliximab but Not EtanerceptNuclear Reactivity Induced by Infliximab but Not EtanerceptNuclear Reactivity Induced by Infliximab but Not EtanerceptTTTTTreatment: Biological and Clinical Implications.reatment: Biological and Clinical Implications.reatment: Biological and Clinical Implications.reatment: Biological and Clinical Implications.reatment: Biological and Clinical Implications.L. De Rycke,1 D. Baeten,1 E. Kruithof,1 E. M. Veys,1 F. De Keyser.11Rheumatology, Ghent University Hospital, Ghent, Belgium.

Sa1.65 - High Serum Levels of Chemokines but Low Expres-Sa1.65 - High Serum Levels of Chemokines but Low Expres-Sa1.65 - High Serum Levels of Chemokines but Low Expres-Sa1.65 - High Serum Levels of Chemokines but Low Expres-Sa1.65 - High Serum Levels of Chemokines but Low Expres-sion of Chemokine Receptors of Peripheral Blood Mono-sion of Chemokine Receptors of Peripheral Blood Mono-sion of Chemokine Receptors of Peripheral Blood Mono-sion of Chemokine Receptors of Peripheral Blood Mono-sion of Chemokine Receptors of Peripheral Blood Mono-nuclear Cells in Juvenile Systemic Lupus Ernuclear Cells in Juvenile Systemic Lupus Ernuclear Cells in Juvenile Systemic Lupus Ernuclear Cells in Juvenile Systemic Lupus Ernuclear Cells in Juvenile Systemic Lupus Erythematosus.ythematosus.ythematosus.ythematosus.ythematosus.J.-L. Huang,1 C.-J. Lin,2,3 C.-L. Liu,4 T.-C. Yao,1 H.-Y. Chang,2 G.-W. Chen,2 C.-R. Shen.2 1Division of Rheumatology, Chang GungChildren Hospital, Kweishan, Taoyuan, Taiwan; 2Graduate In-stitute of Medical Biotechnology, Chang Gung University,Kweishan, Taoyuan, Taiwan; 3Department of Loaboratory Medi-cine, Mackay Memorial Hospital, Taipei, Taipei, Taiwan;4Graduate Institute of Engineering and Department of Biochemi-cal Engineering, Ming-Chi University of Technology, Taishan,Taipei, Taiwan.

Sa1.66 - Modulation of Murine Lupus by an InhibitorSa1.66 - Modulation of Murine Lupus by an InhibitorSa1.66 - Modulation of Murine Lupus by an InhibitorSa1.66 - Modulation of Murine Lupus by an InhibitorSa1.66 - Modulation of Murine Lupus by an InhibitoryyyyyGpG Oligonucleotide.GpG Oligonucleotide.GpG Oligonucleotide.GpG Oligonucleotide.GpG Oligonucleotide.K. L. Graham,1 L. Y. Lee,2 P. Teo,1 L. Steinman,2 P. J. Utz,1 P. P.Ho.2 1Department of Medicine, Division of Immunology andRheumatology, Stanford University School of Medicine, Stanford,CA, USA; 2Department of Neurology, Stanford University Schoolof Medicine, Stanford, CA, USA.

Sa1.67 - The Phosphodiesterase Inhibitor Rolipram FacilitatesSa1.67 - The Phosphodiesterase Inhibitor Rolipram FacilitatesSa1.67 - The Phosphodiesterase Inhibitor Rolipram FacilitatesSa1.67 - The Phosphodiesterase Inhibitor Rolipram FacilitatesSa1.67 - The Phosphodiesterase Inhibitor Rolipram Facilitatesthe Suppression of Antigen-Induced Arthritis in Mice by Oralthe Suppression of Antigen-Induced Arthritis in Mice by Oralthe Suppression of Antigen-Induced Arthritis in Mice by Oralthe Suppression of Antigen-Induced Arthritis in Mice by Oralthe Suppression of Antigen-Induced Arthritis in Mice by OralAdministration of the Inducing Antigen.Administration of the Inducing Antigen.Administration of the Inducing Antigen.Administration of the Inducing Antigen.Administration of the Inducing Antigen.Shin Yoshino,1 Kouya Yamaki,1 Yoshiki Harada.1 1Departmentof Pharmacology, Kobe Pharmaceutical University, Kobe, Hyogo,Japan.

Sa1.68 - Therapeutic Response of Rituximab in a Patient withSa1.68 - Therapeutic Response of Rituximab in a Patient withSa1.68 - Therapeutic Response of Rituximab in a Patient withSa1.68 - Therapeutic Response of Rituximab in a Patient withSa1.68 - Therapeutic Response of Rituximab in a Patient withAmyopathic DerAmyopathic DerAmyopathic DerAmyopathic DerAmyopathic Dermatomyositis Refractormatomyositis Refractormatomyositis Refractormatomyositis Refractormatomyositis Refractory to Methotrexate andy to Methotrexate andy to Methotrexate andy to Methotrexate andy to Methotrexate andCyclosporin.Cyclosporin.Cyclosporin.Cyclosporin.Cyclosporin.S. M. Fung, R. Herzog, Y. Padeh, A. Rubenstein. 1Division ofAllergy and Immunology, Albert Einstein College of Medicine,Bronx, NY, USA.

Sa1.69 - Azathioprine Use but Not Hydroxycholorquine orSa1.69 - Azathioprine Use but Not Hydroxycholorquine orSa1.69 - Azathioprine Use but Not Hydroxycholorquine orSa1.69 - Azathioprine Use but Not Hydroxycholorquine orSa1.69 - Azathioprine Use but Not Hydroxycholorquine orPrednisone Use Is Associated with Lower CoronarPrednisone Use Is Associated with Lower CoronarPrednisone Use Is Associated with Lower CoronarPrednisone Use Is Associated with Lower CoronarPrednisone Use Is Associated with Lower Coronary Ary Ary Ary Ary ArterterterterteryyyyyCalcification DeterCalcification DeterCalcification DeterCalcification DeterCalcification Determined by Electron Beam Computed Tmined by Electron Beam Computed Tmined by Electron Beam Computed Tmined by Electron Beam Computed Tmined by Electron Beam Computed Tomog-omog-omog-omog-omog-raphy (EBCT) in SLE Patients.raphy (EBCT) in SLE Patients.raphy (EBCT) in SLE Patients.raphy (EBCT) in SLE Patients.raphy (EBCT) in SLE Patients.E. R. Gehrie,1 A. J. Cucchiara,1 E. Nackos,1 J. M. Von Feldt.11Department of Rheumatology, University of Pennsylvania, Phila-delphia, PA, USA.

Sa1.70 - Proteomic Analysis of Secreted Proteins Defines Sub-Sa1.70 - Proteomic Analysis of Secreted Proteins Defines Sub-Sa1.70 - Proteomic Analysis of Secreted Proteins Defines Sub-Sa1.70 - Proteomic Analysis of Secreted Proteins Defines Sub-Sa1.70 - Proteomic Analysis of Secreted Proteins Defines Sub-types of Rheumatoid Arthritis.types of Rheumatoid Arthritis.types of Rheumatoid Arthritis.types of Rheumatoid Arthritis.types of Rheumatoid Arthritis.W. Hueber,1,2 B. H. Tomooka,1,2 W. J. van Venrooij,3 P. J. Utz,1M. C. Genovese,1 W. H. Robinson.1,2 1Division of Immunologyand Rheumatology, Stanford University School of Medicine,Stanford, CA, USA; 2GRECC, VA Palo Alto Heath Care System,Palo Alto, CA, USA; 3Department of Biocehmistry, RadboudUniversity Nijmegen, Nijmegen, Netherlands.

Sa1.71 - Death Receptor 5 as a Therapeutic TSa1.71 - Death Receptor 5 as a Therapeutic TSa1.71 - Death Receptor 5 as a Therapeutic TSa1.71 - Death Receptor 5 as a Therapeutic TSa1.71 - Death Receptor 5 as a Therapeutic Target: Increasedarget: Increasedarget: Increasedarget: Increasedarget: IncreasedExpression in B and T Cell Subsets in SLE.Expression in B and T Cell Subsets in SLE.Expression in B and T Cell Subsets in SLE.Expression in B and T Cell Subsets in SLE.Expression in B and T Cell Subsets in SLE.R. H. Carter,1 S. Pandey,1 T. Zhou.1 1Dept. of Medicine, Univer-sity of Alabama at Birmingham, Birmingham, AL, USA.

20052005200520052005ANNUAL MEETING

85



Sa1.72 - Immune Response to a Citrullinated Peptide of Fi-Sa1.72 - Immune Response to a Citrullinated Peptide of Fi-Sa1.72 - Immune Response to a Citrullinated Peptide of Fi-Sa1.72 - Immune Response to a Citrullinated Peptide of Fi-Sa1.72 - Immune Response to a Citrullinated Peptide of Fi-brinogen in DR4 tg Mice Following Intra-Articular Injectionbrinogen in DR4 tg Mice Following Intra-Articular Injectionbrinogen in DR4 tg Mice Following Intra-Articular Injectionbrinogen in DR4 tg Mice Following Intra-Articular Injectionbrinogen in DR4 tg Mice Following Intra-Articular Injectionof Streptococcal Cell Wof Streptococcal Cell Wof Streptococcal Cell Wof Streptococcal Cell Wof Streptococcal Cell Wall Antigen.all Antigen.all Antigen.all Antigen.all Antigen.W. Brintnell,1 J. A. Hill,1 C. Nadasdy,1 D. A. Bell,1 E. Cairns.1

1Department of Medicine, Division of Rheumatology and De-partment of Microbiology and Immunology, London Health Sci-ences Centre, University of Western Ontario, London, ON,Canada.

Sa1.73 - Homozygous TSa1.73 - Homozygous TSa1.73 - Homozygous TSa1.73 - Homozygous TSa1.73 - Homozygous Type I C2 Deficiency and Immunoglo-ype I C2 Deficiency and Immunoglo-ype I C2 Deficiency and Immunoglo-ype I C2 Deficiency and Immunoglo-ype I C2 Deficiency and Immunoglo-bulin Deficiencies in a HLA-B27 Positive Ybulin Deficiencies in a HLA-B27 Positive Ybulin Deficiencies in a HLA-B27 Positive Ybulin Deficiencies in a HLA-B27 Positive Ybulin Deficiencies in a HLA-B27 Positive Young Girl Present-oung Girl Present-oung Girl Present-oung Girl Present-oung Girl Present-ing with an Antinuclear Antibody-Positive Juvenile Rheuma-ing with an Antinuclear Antibody-Positive Juvenile Rheuma-ing with an Antinuclear Antibody-Positive Juvenile Rheuma-ing with an Antinuclear Antibody-Positive Juvenile Rheuma-ing with an Antinuclear Antibody-Positive Juvenile Rheuma-toid Arthritis.toid Arthritis.toid Arthritis.toid Arthritis.toid Arthritis.G. Hauptmann,1 A. Meyer,2 B. Uring-Lambert,1 J. Goetz,2 I.Jahn,2 S. Finck,3 B. Cribier,4 D. Lipsker.4 1Centre de Recherched’Immunologie, Faculte de Medecine, Strasbourg, France;2Laboratoire d’Immunologie, Hopitaux Universitaires, Strasbourg,France; 3Service de Pediatrie, Centre Hospitalier, Haguenau,France; 4Service de Dermatologie, Hopitaux Universitaires,Strasbourg, France.

Sa1.74 - The Combination of Complement Deficiency andSa1.74 - The Combination of Complement Deficiency andSa1.74 - The Combination of Complement Deficiency andSa1.74 - The Combination of Complement Deficiency andSa1.74 - The Combination of Complement Deficiency andCigarette Smoking as Risk Factor for Cutaneous Lupus ErCigarette Smoking as Risk Factor for Cutaneous Lupus ErCigarette Smoking as Risk Factor for Cutaneous Lupus ErCigarette Smoking as Risk Factor for Cutaneous Lupus ErCigarette Smoking as Risk Factor for Cutaneous Lupus Erythe-ythe-ythe-ythe-ythe-matosus (CLE) in Men; a Focus on Combined C2/C4 Defi-matosus (CLE) in Men; a Focus on Combined C2/C4 Defi-matosus (CLE) in Men; a Focus on Combined C2/C4 Defi-matosus (CLE) in Men; a Focus on Combined C2/C4 Defi-matosus (CLE) in Men; a Focus on Combined C2/C4 Defi-ciencyciencyciencyciencyciency.....G. Hauptmann,1 P. Boeckler,2 M. Milea,2 A. Meyer,3 B. Uring-Lambert,1 J. Goetz,3 B. Cribier,2 D. Lipsker.2 1Centre de Recher-che d’Immunologie, Faculte de Medecine, Strasbourg, France;2Service de Dermatologie, Hopitaux Universitaires, Strasbourg,France; 3Laboratoire d’Immunologie, Hopitaux Universitaires,Strasbourg, France.

Sa1.75 - Pregnancy Outcomes in TSa1.75 - Pregnancy Outcomes in TSa1.75 - Pregnancy Outcomes in TSa1.75 - Pregnancy Outcomes in TSa1.75 - Pregnancy Outcomes in Ten Japanese Wen Japanese Wen Japanese Wen Japanese Wen Japanese Women withomen withomen withomen withomen withMixed Connective Tissue Disease.Mixed Connective Tissue Disease.Mixed Connective Tissue Disease.Mixed Connective Tissue Disease.Mixed Connective Tissue Disease.K. Abe, R. Matudaira, Y. Takasaki, H. Hashimoto. 1InternalMedicine and Rheumatology, Juntendo University School ofMedicine, Tokyo, Japan.

Sa1.76 - Characteristics of Patients with Clinical Manifesta-Sa1.76 - Characteristics of Patients with Clinical Manifesta-Sa1.76 - Characteristics of Patients with Clinical Manifesta-Sa1.76 - Characteristics of Patients with Clinical Manifesta-Sa1.76 - Characteristics of Patients with Clinical Manifesta-tions of APS with Anti-betations of APS with Anti-betations of APS with Anti-betations of APS with Anti-betations of APS with Anti-beta22222-Glycoprotein-I but Not-Glycoprotein-I but Not-Glycoprotein-I but Not-Glycoprotein-I but Not-Glycoprotein-I but NotAnticardiolipin Antibodies or Any Other Autoimmune Condi-Anticardiolipin Antibodies or Any Other Autoimmune Condi-Anticardiolipin Antibodies or Any Other Autoimmune Condi-Anticardiolipin Antibodies or Any Other Autoimmune Condi-Anticardiolipin Antibodies or Any Other Autoimmune Condi-tion.tion.tion.tion.tion.D. Micheloud,1 J. Carbone,1 S. Sanchez-Ramon,1 J. Lopez-Longo,2 A. Velastegui,1 J. Ruiz-Tiscar,1 E. Sarmiento,1 E.Fernandez-Cruz,1 M. Rodriguez-Mahou.1 1Autoimmunity Sec-tion, Immunology Department, University Hospital GregorioMaranon, Madrid, Spain; 2Rheumatology Department, Univer-sity Hospital Gregorio Maranon, Madrid, Spain.

Sa1.77 - TSa1.77 - TSa1.77 - TSa1.77 - TSa1.77 - Transcriptional Regulation of Fli1 and Lupus.ranscriptional Regulation of Fli1 and Lupus.ranscriptional Regulation of Fli1 and Lupus.ranscriptional Regulation of Fli1 and Lupus.ranscriptional Regulation of Fli1 and Lupus.J. D. Fulton,1 G. Gilkeson,1 T. Nowling.1 1Medicine, Rheuma-tology Div., Medical University of South Carolina, Charleston,SC, USA.

Sa1.78 - Chronic GVH-Like Disease in a Man Exposed toSa1.78 - Chronic GVH-Like Disease in a Man Exposed toSa1.78 - Chronic GVH-Like Disease in a Man Exposed toSa1.78 - Chronic GVH-Like Disease in a Man Exposed toSa1.78 - Chronic GVH-Like Disease in a Man Exposed toOrganic Solvents: Evidence for a Role of Microchimeric CellsOrganic Solvents: Evidence for a Role of Microchimeric CellsOrganic Solvents: Evidence for a Role of Microchimeric CellsOrganic Solvents: Evidence for a Role of Microchimeric CellsOrganic Solvents: Evidence for a Role of Microchimeric Cellsof Maternal Origin.of Maternal Origin.of Maternal Origin.of Maternal Origin.of Maternal Origin.A. de Lavareille,1 O. Michel,2 P. Heimann,3 E. Cogan,4 M.Goldman,1 F. Roufosse.1,4 1Clinical Immunology Unit, Institutefor Medical Immunology, Erasme Hospital, Brussels, Belgium;2Department of Internal Medicine, Saint Pierre Hospital, Brus-sels, Belgium; 3Department of Medical Genetics, Erasme Hospi-tal, Brussels, Belgium; 4Department of Internal Medicine, ErasmeHospital, Brussels, Belgium.

Sa1.79 - IgG Fc Receptor Polymorphisms Influence Suscepti-Sa1.79 - IgG Fc Receptor Polymorphisms Influence Suscepti-Sa1.79 - IgG Fc Receptor Polymorphisms Influence Suscepti-Sa1.79 - IgG Fc Receptor Polymorphisms Influence Suscepti-Sa1.79 - IgG Fc Receptor Polymorphisms Influence Suscepti-bility to Collagen-Induced Arthritis.bility to Collagen-Induced Arthritis.bility to Collagen-Induced Arthritis.bility to Collagen-Induced Arthritis.bility to Collagen-Induced Arthritis.M. Andren,1 B. Johanneson,2 M. Alarcon-Riquelme,2 S. Kleinau.11Department of Cell and Molecular Biology, Uppsala Univer-sity, Uppsala, Sweden; 2Department of Genetics and Pathol-ogy, Uppsala University, Uppsala, Sweden.



Sa1.80 - Outcome of a National Israeli Cohort of PediatricSa1.80 - Outcome of a National Israeli Cohort of PediatricSa1.80 - Outcome of a National Israeli Cohort of PediatricSa1.80 - Outcome of a National Israeli Cohort of PediatricSa1.80 - Outcome of a National Israeli Cohort of PediatricSystemic Lupus ErSystemic Lupus ErSystemic Lupus ErSystemic Lupus ErSystemic Lupus Erythematosus.ythematosus.ythematosus.ythematosus.ythematosus.Natalia Gorodnitsky,1 Pinhas Hashkes,2 Masza Mukamel,3 ShaiPadeh,4 Riva Brik,5 Judith Barash,6 Dror Mevorach,7 YakovBerkun,7 Tzvia Tauber,8 Joseph Press,9 Liora Harel,3 PninaNavon,10 Yakov Naparstek,7 Yosef Uziel.1 1Pediatric MedicalCenter, Meir Hospital, Kfar-Saba, Israel; 2Rheumatology, Cleve-land Clinik, Cleveland, USA; 3Pediatric Medical Center,Schneider, Petach-Tikva, Israel; 4Pediatric Medical Center, Tel-Ha Shomer Hospital, Ramat-Gan, Israel; 5Pediatric MedicalCenter, Rambam Hospital, Haifa, Israel; 6Pediatric, KaplanHospital, Rechovot, Israel; 7Rheumatology Center, Hadasa Hos-pital, Jerusalem, Israel; 8Pediatric Medical Center, Asaf-Ha-RofeHospital, Lood, Israel; 9Pediatric Medical Center, Soroca Hospi-tal, Beer-Sheva, Israel; 10Pediatric, Hadasa, Mt Scopus, Jerusa-lem, Israel.

Sa1.81 - Dyslipoproteinemia in the Active Course of SLE: ASa1.81 - Dyslipoproteinemia in the Active Course of SLE: ASa1.81 - Dyslipoproteinemia in the Active Course of SLE: ASa1.81 - Dyslipoproteinemia in the Active Course of SLE: ASa1.81 - Dyslipoproteinemia in the Active Course of SLE: AContributorContributorContributorContributorContributory Role for Anti-Double Stranded DNA Antibod-y Role for Anti-Double Stranded DNA Antibod-y Role for Anti-Double Stranded DNA Antibod-y Role for Anti-Double Stranded DNA Antibod-y Role for Anti-Double Stranded DNA Antibod-ies.ies.ies.ies.ies.Sara Kashef,1 Mohammad Mehdi Ghaedian,2 Akbar Rajaee,3

Abbas Ghaderi.4 1Allergy Research Center, Pediatric Immunol-ogy & Allergy, Shiraz University of Medical Sciences, Shiraz,Fars, Islamic Republic of Iran; 2Shiraz Medical School, ShirazUniversity of Medical Sciences, Shiraz, Fars, Islamic Republic ofIran; 3Department of Rheumatology, Shiraz University of Medi-cal Sciences, Shiraz, Fars, Islamic Republic of Iran; 4Depart-ment of Immunology, Shiraz University of Medical Sciences,Shiraz, Fars, Islamic Republic of Iran.

Sa1.82 - Mutations in Gene TSa1.82 - Mutations in Gene TSa1.82 - Mutations in Gene TSa1.82 - Mutations in Gene TSa1.82 - Mutations in Gene Transcripts of Systemic Lupusranscripts of Systemic Lupusranscripts of Systemic Lupusranscripts of Systemic Lupusranscripts of Systemic LupusErErErErErythematosus (SLE) T Lythematosus (SLE) T Lythematosus (SLE) T Lythematosus (SLE) T Lythematosus (SLE) T Lymphocytes.ymphocytes.ymphocytes.ymphocytes.ymphocytes.Dama Laxminarayana.1 1Section on Rheumatology and Clini-cal Immunology, Department of Internal Medicine, Wake ForestUniversity School of Medicine, Winston Salem, NC, USA.

Sa1.83 - The Mechanism of Nasal TSa1.83 - The Mechanism of Nasal TSa1.83 - The Mechanism of Nasal TSa1.83 - The Mechanism of Nasal TSa1.83 - The Mechanism of Nasal Tolerance in Lupus Proneolerance in Lupus Proneolerance in Lupus Proneolerance in Lupus Proneolerance in Lupus ProneMice Is T Cell Anergy Induced by Immature B Cells That LackMice Is T Cell Anergy Induced by Immature B Cells That LackMice Is T Cell Anergy Induced by Immature B Cells That LackMice Is T Cell Anergy Induced by Immature B Cells That LackMice Is T Cell Anergy Induced by Immature B Cells That LackB7 Expression.B7 Expression.B7 Expression.B7 Expression.B7 Expression.Henry Yim Wu, Alon Monsonego, Howard L. Weiner. 1Centerfor Neurologic Diseases, Brigham and Women’s Hospital &Harvard Medical School, Boston, MA, USA.

Sa1.84 - Synovial Fluid and InflammatorSa1.84 - Synovial Fluid and InflammatorSa1.84 - Synovial Fluid and InflammatorSa1.84 - Synovial Fluid and InflammatorSa1.84 - Synovial Fluid and Inflammatory Response in Rheu-y Response in Rheu-y Response in Rheu-y Response in Rheu-y Response in Rheu-matoid Arthritis.matoid Arthritis.matoid Arthritis.matoid Arthritis.matoid Arthritis.Lj D. Petrovic-Rackov. 1Clinic for Rheumatology and ClinicalImmunology, Military Medical Academy, Belgrade, Belgrade,Serbia, Yugoslavia.

Sa1.85 - Glycopeptides from TSa1.85 - Glycopeptides from TSa1.85 - Glycopeptides from TSa1.85 - Glycopeptides from TSa1.85 - Glycopeptides from Type II Collagen Incorporatingype II Collagen Incorporatingype II Collagen Incorporatingype II Collagen Incorporatingype II Collagen IncorporatingGalactosylated Hydroxylysine Mimetics TGalactosylated Hydroxylysine Mimetics TGalactosylated Hydroxylysine Mimetics TGalactosylated Hydroxylysine Mimetics TGalactosylated Hydroxylysine Mimetics To Study the Fineo Study the Fineo Study the Fineo Study the Fineo Study the FineSpecificity of Arthritogenic T Cells.Specificity of Arthritogenic T Cells.Specificity of Arthritogenic T Cells.Specificity of Arthritogenic T Cells.Specificity of Arthritogenic T Cells.J. Marin,1 M.-A. Blaton,2 J.-P. Briand,1 G. Chiocchia,2 C. Fournier,2G. Guichard.1 1Immunologie et Chimie Therapeutiques (ICT),UPR 9021 CNRS, Institut de Biologie Moleculaire et Cellulaire(IBMC), Strasbourg, France; 2Departement d’Immunologie,Institut Cochin, INSERM U567, CNRS UMR8104, Universite Paris5, Paris, France.

Sa1.86 - CD8Sa1.86 - CD8Sa1.86 - CD8Sa1.86 - CD8Sa1.86 - CD8ααααα on Monocytes May Aggravate Immune-Com- on Monocytes May Aggravate Immune-Com- on Monocytes May Aggravate Immune-Com- on Monocytes May Aggravate Immune-Com- on Monocytes May Aggravate Immune-Com-plex Mediate Disease by Binding MHC Clacc I and Enhanc-plex Mediate Disease by Binding MHC Clacc I and Enhanc-plex Mediate Disease by Binding MHC Clacc I and Enhanc-plex Mediate Disease by Binding MHC Clacc I and Enhanc-plex Mediate Disease by Binding MHC Clacc I and Enhanc-ing TNF Production.ing TNF Production.ing TNF Production.ing TNF Production.ing TNF Production.D. J. Gibbings,1 A. D. Befus.1 1Medicine, University of Alberta,Edmonton, AB, Canada.

Sa1.87 - Anti-Cyclic Citrullinated Peptide and Anti-Sa Anti-Sa1.87 - Anti-Cyclic Citrullinated Peptide and Anti-Sa Anti-Sa1.87 - Anti-Cyclic Citrullinated Peptide and Anti-Sa Anti-Sa1.87 - Anti-Cyclic Citrullinated Peptide and Anti-Sa Anti-Sa1.87 - Anti-Cyclic Citrullinated Peptide and Anti-Sa Anti-bodies for the Diagnosis of Rheumatoid Arthritis in an Out-bodies for the Diagnosis of Rheumatoid Arthritis in an Out-bodies for the Diagnosis of Rheumatoid Arthritis in an Out-bodies for the Diagnosis of Rheumatoid Arthritis in an Out-bodies for the Diagnosis of Rheumatoid Arthritis in an Out-Patient Clinic of Chronic InflammatorPatient Clinic of Chronic InflammatorPatient Clinic of Chronic InflammatorPatient Clinic of Chronic InflammatorPatient Clinic of Chronic Inflammatory Connective Ty Connective Ty Connective Ty Connective Ty Connective TissueissueissueissueissueDiseases (CICTD).Diseases (CICTD).Diseases (CICTD).Diseases (CICTD).Diseases (CICTD).J.L. Ruiz-Tiscar,1 S. Sanchez-Ramon,1 D. Micheloud,1 A. Garcia-Segovia,1 B. Santamaria,1 R. Urrea,1 M. Escalona,2 A. Estecha,2J.L. Lopez-Longo,2 E. Fernandez-Cruz,1 M. Rodriguez-Mahou.11Immunology, Gregorio Maranon Hospital, Madrid, Madrid,Spain; 2Rheumatology, Gregorio Maranon Hospital, Madrid,Madrid, Spain.

Sa1.88 - Evaluation of the Effect of Different Modified Extra-Sa1.88 - Evaluation of the Effect of Different Modified Extra-Sa1.88 - Evaluation of the Effect of Different Modified Extra-Sa1.88 - Evaluation of the Effect of Different Modified Extra-Sa1.88 - Evaluation of the Effect of Different Modified Extra-cellular Matrix Proteins in the Inflammation and Extracellularcellular Matrix Proteins in the Inflammation and Extracellularcellular Matrix Proteins in the Inflammation and Extracellularcellular Matrix Proteins in the Inflammation and Extracellularcellular Matrix Proteins in the Inflammation and ExtracellularMatrix TMatrix TMatrix TMatrix TMatrix Turururururnover in Carnover in Carnover in Carnover in Carnover in Cartilage and Synovial Ttilage and Synovial Ttilage and Synovial Ttilage and Synovial Ttilage and Synovial Tissue Co-Culturesissue Co-Culturesissue Co-Culturesissue Co-Culturesissue Co-Culturesfrom Patients with Osteoarthritis (OA) and Rheumatoid Ar-from Patients with Osteoarthritis (OA) and Rheumatoid Ar-from Patients with Osteoarthritis (OA) and Rheumatoid Ar-from Patients with Osteoarthritis (OA) and Rheumatoid Ar-from Patients with Osteoarthritis (OA) and Rheumatoid Ar-thritis (RA).thritis (RA).thritis (RA).thritis (RA).thritis (RA).O. Munoz-Chable,1 J. Alcocer-Varela,1 E. Diaz-Borjon,2 J. Bar-rios,3 R. Hernandez-Pando,3 J. Furuzawa-Carballeda.1

1Inmunologia y Reumatologia, Instituto Nacional de CienciasMedicas y Nutricion Salvador Zubiran, Mexico City, Mexico;2Ortopedia; 3Patologia Experimental, Instituto Nacional deCiencias Medicas y Nutricion Salvador Zubiran, Mexico City,DF, Mexico.

20052005200520052005ANNUAL MEETING

87



Sa1.89 - Anti-alpha-Fodrin Antibodies of IgA Isotype in Pa-Sa1.89 - Anti-alpha-Fodrin Antibodies of IgA Isotype in Pa-Sa1.89 - Anti-alpha-Fodrin Antibodies of IgA Isotype in Pa-Sa1.89 - Anti-alpha-Fodrin Antibodies of IgA Isotype in Pa-Sa1.89 - Anti-alpha-Fodrin Antibodies of IgA Isotype in Pa-tients with Sjögren’tients with Sjögren’tients with Sjögren’tients with Sjögren’tients with Sjögren’s Syndrome (SS).s Syndrome (SS).s Syndrome (SS).s Syndrome (SS).s Syndrome (SS).J.L. Ruiz-Tiscar,1 S. Sanchez-Ramon,1 D. Micheloud,1 B.Santamaria,1 R. Urrea,1 M. Escalona,1 A. Estecha,2 F.J. Lopez-Longo,2 E. Fernandez-Cruz,1 M. Rodriguez-Mahou.1 1Immu-nology, Gregorio Maranon Hospital, Madrid, Madrid, Spain;2Rheumatology, Gregorio Maranon Hospital, Madrid, Madrid,Spain.

Sa1.90 - TSa1.90 - TSa1.90 - TSa1.90 - TSa1.90 - Tumor Necrosis Factor Genetic Polymorphism asumor Necrosis Factor Genetic Polymorphism asumor Necrosis Factor Genetic Polymorphism asumor Necrosis Factor Genetic Polymorphism asumor Necrosis Factor Genetic Polymorphism asPart of Rheumatoid Arthritis Evolution.Part of Rheumatoid Arthritis Evolution.Part of Rheumatoid Arthritis Evolution.Part of Rheumatoid Arthritis Evolution.Part of Rheumatoid Arthritis Evolution.A. Cruzat,1 I. Schiattino,2 M. Cuchacovich,3 J. C. Aguillon.11Disciplinary Program of Immunology, Faculty of Medicine. Uni-versity of Chile, Santiago, Región Metropolitana, Chile; 2HealthPublic School, Faculty of Medicine. University of Chile, Santiago,Región Metropolitana, Chile; 3Rheumatology Section, Universityof Chile Clinical Hospital. University of Chile, Santiago, RegiónMetropolitana, Chile.

Sa1.91 - Mannan Binding Lectin and Complement C4A inSa1.91 - Mannan Binding Lectin and Complement C4A inSa1.91 - Mannan Binding Lectin and Complement C4A inSa1.91 - Mannan Binding Lectin and Complement C4A inSa1.91 - Mannan Binding Lectin and Complement C4A inIcelandic Multicase Families with Systemic Lupus ErIcelandic Multicase Families with Systemic Lupus ErIcelandic Multicase Families with Systemic Lupus ErIcelandic Multicase Families with Systemic Lupus ErIcelandic Multicase Families with Systemic Lupus Erythema-ythema-ythema-ythema-ythema-tosus.tosus.tosus.tosus.tosus.S. Saevarsdottir,1 H. Kristjansdottir,2 G. Grondal,2 T. Vikingsdottir,1K. Steinsson,2 H. Valdimarsson.1 1Department of Immunology,Landspitali University Hospital, Reykjavik, Iceland; 2Center forRheumatology Research, Landspitali University Hospital,Reykjavik, Iceland.

Sa1.92 - Abnormal Dendritic Cell Activation in SLE.Sa1.92 - Abnormal Dendritic Cell Activation in SLE.Sa1.92 - Abnormal Dendritic Cell Activation in SLE.Sa1.92 - Abnormal Dendritic Cell Activation in SLE.Sa1.92 - Abnormal Dendritic Cell Activation in SLE.H. Zhuang,1 D. C. Nacionales,1 S. Narain,1,2 E. Sobel,1,2 P. Y.Lee,1 Jason B. Weinstein,1 K. M. Kelly,1 H. B. Richard,1,2 M.Satoh,1,2 W. H. Reeves.1,2 1Division of Rheumatology & ClinicalImmunology, University of Florida, Gainesville, FL, USA; 2Centerfor Autoimmune Disease, University of Florida, Gainesville, FL,USA.

Sa1.93 - Marginal Zone LSa1.93 - Marginal Zone LSa1.93 - Marginal Zone LSa1.93 - Marginal Zone LSa1.93 - Marginal Zone Lymphoma with Autoantibodies toymphoma with Autoantibodies toymphoma with Autoantibodies toymphoma with Autoantibodies toymphoma with Autoantibodies toRO52 in Sjogren’RO52 in Sjogren’RO52 in Sjogren’RO52 in Sjogren’RO52 in Sjogren’s Syndrome.s Syndrome.s Syndrome.s Syndrome.s Syndrome.R. Lyons,1 M. Rodriguez,1 E.K.L. Chan,1 L. Yang,1 C. Stewart,1

M. Satoh,1 W. H. Reeves.1 1Division of Rheumatology & Clini-cal Immunology, University of Florida, Gainesville, FL, USA.

Sa1.94 - IL-1 Receptor Expression in Muscle Fibre MembraneSa1.94 - IL-1 Receptor Expression in Muscle Fibre MembraneSa1.94 - IL-1 Receptor Expression in Muscle Fibre MembraneSa1.94 - IL-1 Receptor Expression in Muscle Fibre MembraneSa1.94 - IL-1 Receptor Expression in Muscle Fibre Membraneand Muscle Cell Nuclei in Patients with Polymyositis or Der-and Muscle Cell Nuclei in Patients with Polymyositis or Der-and Muscle Cell Nuclei in Patients with Polymyositis or Der-and Muscle Cell Nuclei in Patients with Polymyositis or Der-and Muscle Cell Nuclei in Patients with Polymyositis or Der-matomyositis.matomyositis.matomyositis.matomyositis.matomyositis.I. E. Lundberg,1 C. Grundtman,1 C. Dorph,1 J. Burton,2 U.Andersson,3 S. Salomonsson.1,2 1Rheumatology Unit, Depart-ment of Medicine, Karolinska University Hosptial, Solna,Karolinska Institutet, Stockholm, Sweden; 2Department fo Physi-ology and Pharmacology, Karolinska Institutet, Stockholm, Swe-den; 3Department of Woman and Child Health, KarolinskaUniversity Hosptial, Solna, Karolinska Institutet, Stockholm, Swe-den.

Sa1.95 - Increased Expression and Production of TSa1.95 - Increased Expression and Production of TSa1.95 - Increased Expression and Production of TSa1.95 - Increased Expression and Production of TSa1.95 - Increased Expression and Production of Tumor Ne-umor Ne-umor Ne-umor Ne-umor Ne-crosis Factor-Related Apoptosis Inducing Ligand (TRAIL) by Tcrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) by Tcrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) by Tcrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) by Tcrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) by TCells from Lupus Patients Is a Feature of Active Disease.Cells from Lupus Patients Is a Feature of Active Disease.Cells from Lupus Patients Is a Feature of Active Disease.Cells from Lupus Patients Is a Feature of Active Disease.Cells from Lupus Patients Is a Feature of Active Disease.V. Rus,1 V. Zernetkina,1 R. Puliaev,3 S. Mathai,1 C. Cudrici,2 C.S. Via.3 1Medicine, University of Maryland School of Medi-cine, Baltimore, MD, USA; 2Neurology, University of MarylandSchool of Medicine, Baltimore, MD, USA; 3Pathology, UniformedServices of the University Health Sciences, Bethesda, MD, USA.

Sa1.96 - Intramuscular Administration of Polymerized TSa1.96 - Intramuscular Administration of Polymerized TSa1.96 - Intramuscular Administration of Polymerized TSa1.96 - Intramuscular Administration of Polymerized TSa1.96 - Intramuscular Administration of Polymerized Type Iype Iype Iype Iype ICollagen for the TCollagen for the TCollagen for the TCollagen for the TCollagen for the Treatment of Patients with Rheumatoid Arreatment of Patients with Rheumatoid Arreatment of Patients with Rheumatoid Arreatment of Patients with Rheumatoid Arreatment of Patients with Rheumatoid Arthri-thri-thri-thri-thri-tis. A Double Blind Placebo-Controlled Clinical Ttis. A Double Blind Placebo-Controlled Clinical Ttis. A Double Blind Placebo-Controlled Clinical Ttis. A Double Blind Placebo-Controlled Clinical Ttis. A Double Blind Placebo-Controlled Clinical Trial.rial.rial.rial.rial.J. Furuzawa-Carballeda,1 J. Alcocer-Varela.1 1Immunology andRheumatology, Instituto Nacional de Ciencias Medicas yNutricion Salvador Zubiran, Mexico City, DF, Mexico.

Sa1.97 - Clinical Characteristics of 88 Patients with JuvenileSa1.97 - Clinical Characteristics of 88 Patients with JuvenileSa1.97 - Clinical Characteristics of 88 Patients with JuvenileSa1.97 - Clinical Characteristics of 88 Patients with JuvenileSa1.97 - Clinical Characteristics of 88 Patients with Juvenileor Adult Dermatomyositis.or Adult Dermatomyositis.or Adult Dermatomyositis.or Adult Dermatomyositis.or Adult Dermatomyositis.Tamas Constantin,1 Andrea Ponyi,1,2 Katalin Molnar,3 JuditMuller,1 Zsuzsanna Szalai,3 Gyorgy Fekete,1 Katalin Danko.2

12nd Department of Pediatrics Hungary, Semmelweis Univer-sity, Budapest, Hungary; 23rd Department of Internal Medicine,Division of Clinical Immunology, University of Debrecen,Debrecen, Hungary; 3Department of Dermatology, Heim PalChildren’s Hospital, Budapest, Hungary.

Sa1.98 - Pre-B Cell Colony Enhancing Factor Stimulates Pro-Sa1.98 - Pre-B Cell Colony Enhancing Factor Stimulates Pro-Sa1.98 - Pre-B Cell Colony Enhancing Factor Stimulates Pro-Sa1.98 - Pre-B Cell Colony Enhancing Factor Stimulates Pro-Sa1.98 - Pre-B Cell Colony Enhancing Factor Stimulates Pro-duction of Proinflammatorduction of Proinflammatorduction of Proinflammatorduction of Proinflammatorduction of Proinflammatory Mediators by Human Monocytesy Mediators by Human Monocytesy Mediators by Human Monocytesy Mediators by Human Monocytesy Mediators by Human Monocytesand Is Overexpressed in Systemic Autoimmune Disease.and Is Overexpressed in Systemic Autoimmune Disease.and Is Overexpressed in Systemic Autoimmune Disease.and Is Overexpressed in Systemic Autoimmune Disease.and Is Overexpressed in Systemic Autoimmune Disease.S. Liu,1 C. Lee,1 K. A. Kirou,1 M. K. Crow.1 1Mary KirklandCenter for Lupus Research, Hospital for Special Surgery, NewYork, NY, USA.



Sa1.99 - Mannose-Binding Lectin Polymorphisms in Rheuma-Sa1.99 - Mannose-Binding Lectin Polymorphisms in Rheuma-Sa1.99 - Mannose-Binding Lectin Polymorphisms in Rheuma-Sa1.99 - Mannose-Binding Lectin Polymorphisms in Rheuma-Sa1.99 - Mannose-Binding Lectin Polymorphisms in Rheuma-toid Arthritis and the Associations with Radiological Progres-toid Arthritis and the Associations with Radiological Progres-toid Arthritis and the Associations with Radiological Progres-toid Arthritis and the Associations with Radiological Progres-toid Arthritis and the Associations with Radiological Progres-sion Rate and Serological Markers.sion Rate and Serological Markers.sion Rate and Serological Markers.sion Rate and Serological Markers.sion Rate and Serological Markers.L. De Rycke,1 I. Peene,1 E. Kruithof,1 T. Van De Casteele,2 L.Nuytinck,2 E. M. Veys,1 F. De Keyser.1 1Rheumatology, GhentUniversity Hospital, Ghent, Belgium; 2Innogenetics, Ghent, Bel-gium.

Sa1.100 - Interferon Inducible Proteins Are NovelSa1.100 - Interferon Inducible Proteins Are NovelSa1.100 - Interferon Inducible Proteins Are NovelSa1.100 - Interferon Inducible Proteins Are NovelSa1.100 - Interferon Inducible Proteins Are NovelAutoantigens in Systemic Lupus ErAutoantigens in Systemic Lupus ErAutoantigens in Systemic Lupus ErAutoantigens in Systemic Lupus ErAutoantigens in Systemic Lupus Erythematosus.ythematosus.ythematosus.ythematosus.ythematosus.D. L. Thibault,1 W. Hueber,1 T. Sylvester,1 D. Zeng,1 S. Strober,1

P. J. Utz.1 1Department of Medicine, Division of Rheumatologyand Immunology, Stanford University, Stanford, CA, USA.

Sa1.101 - Estrogen Receptor Effects on the Anti-InflammatorSa1.101 - Estrogen Receptor Effects on the Anti-InflammatorSa1.101 - Estrogen Receptor Effects on the Anti-InflammatorSa1.101 - Estrogen Receptor Effects on the Anti-InflammatorSa1.101 - Estrogen Receptor Effects on the Anti-InflammatoryyyyyAction of PPAction of PPAction of PPAction of PPAction of PPARs in Lupus Mice.ARs in Lupus Mice.ARs in Lupus Mice.ARs in Lupus Mice.ARs in Lupus Mice.J. L. Svenson,1 G. S. Gilkeson.1 1Rheumatology, Medical Univ.of South Carolina, Charleston, SC, USA.

Sa1.102 - Pathogenetic VSa1.102 - Pathogenetic VSa1.102 - Pathogenetic VSa1.102 - Pathogenetic VSa1.102 - Pathogenetic Value of the Disbalance Talue of the Disbalance Talue of the Disbalance Talue of the Disbalance Talue of the Disbalance Trace Ele-race Ele-race Ele-race Ele-race Ele-ments under Systemic Sclerosis.ments under Systemic Sclerosis.ments under Systemic Sclerosis.ments under Systemic Sclerosis.ments under Systemic Sclerosis.Andriy I. Mazepa,1 Mariya A. Mazepa,1 Ivan V. Mazepa.1

1Biochemistry, Medical Academy, Ivano-Frankivsk, Ivano-Frankivsk, Ukraine.

Sa1.103 - Increased Granulopoiesis in Active SLE Blood: NewSa1.103 - Increased Granulopoiesis in Active SLE Blood: NewSa1.103 - Increased Granulopoiesis in Active SLE Blood: NewSa1.103 - Increased Granulopoiesis in Active SLE Blood: NewSa1.103 - Increased Granulopoiesis in Active SLE Blood: NewInsights into SLE Pathogenesis.Insights into SLE Pathogenesis.Insights into SLE Pathogenesis.Insights into SLE Pathogenesis.Insights into SLE Pathogenesis.B. Vega, J. Borvak, A. Caldwell, V. Cantrell, J. Banchereau, V.Pascual. 1Baylor Institute for Immunology Research, Baylor Insti-tute for Immunology Research, Dallas, TX, USA.

Sa1.104 - Rheumatoid Factor Seropositivity in a NormalSa1.104 - Rheumatoid Factor Seropositivity in a NormalSa1.104 - Rheumatoid Factor Seropositivity in a NormalSa1.104 - Rheumatoid Factor Seropositivity in a NormalSa1.104 - Rheumatoid Factor Seropositivity in a NormalPopulation Is Associated with the Use of Oral Contracep-Population Is Associated with the Use of Oral Contracep-Population Is Associated with the Use of Oral Contracep-Population Is Associated with the Use of Oral Contracep-Population Is Associated with the Use of Oral Contracep-tives and Cigarette Smoking.tives and Cigarette Smoking.tives and Cigarette Smoking.tives and Cigarette Smoking.tives and Cigarette Smoking.D. S. Majka,1 S. Pande,2 K. D. Deane,3 L. A. Parrish,3 W. P.Arend,3 V. M. Holers,3 J. M. Norris.2 1Division of Rheumatol-ogy, Northwestern University, Feinberg School of Medicine,Chicago, IL, USA; 2Department of Preventive Medicine and Bio-metrics, University of Colorado Health Sciences Center, Denver,CO, USA; 3Division of Rheumatology, University of ColoradoHealth Sciences Center, Denver, CO, USA.

Sa1.105 - Efficacy of Apratastat, a Novel Dual Inhibitor ofSa1.105 - Efficacy of Apratastat, a Novel Dual Inhibitor ofSa1.105 - Efficacy of Apratastat, a Novel Dual Inhibitor ofSa1.105 - Efficacy of Apratastat, a Novel Dual Inhibitor ofSa1.105 - Efficacy of Apratastat, a Novel Dual Inhibitor ofTNF-TNF-TNF-TNF-TNF-aaaaa Converting Enzyme/Metalloproteinase, in Murine Converting Enzyme/Metalloproteinase, in Murine Converting Enzyme/Metalloproteinase, in Murine Converting Enzyme/Metalloproteinase, in Murine Converting Enzyme/Metalloproteinase, in MurineCollagen-Induced Arthritis Models.Collagen-Induced Arthritis Models.Collagen-Induced Arthritis Models.Collagen-Induced Arthritis Models.Collagen-Induced Arthritis Models.M. Hegen,1 Y. Zhang,1 J. Levin,2 J. Xu,3 T. Cummons,3 K.Harding,4 B. J. Sheppard,5 M. W. Leach,5 L. L. Lin,1 J. Gib-bons,3 J. Skotnicki,2 C. L. Nickerson-Nutter.1 1Inflammation, WyethResearch, Cambridge, MA, USA; 2Medicinal Chemistry, WyethResearch, Pearl River, NY, USA; 3Oncology, Wyeth Research,Pearl River, NY, USA; 4Bioresources, Wyeth Research, Cam-bridge, MA, USA; 5Exploratory Drug Safety, Wyeth Research,Andover, MA, USA.

Sa1.106 - Marginal Zone (MZ) B Cells Are Most SusceptibleSa1.106 - Marginal Zone (MZ) B Cells Are Most SusceptibleSa1.106 - Marginal Zone (MZ) B Cells Are Most SusceptibleSa1.106 - Marginal Zone (MZ) B Cells Are Most SusceptibleSa1.106 - Marginal Zone (MZ) B Cells Are Most Susceptibleto Loss of Tto Loss of Tto Loss of Tto Loss of Tto Loss of Tolerance in the Chronic GVH Model of SLE.olerance in the Chronic GVH Model of SLE.olerance in the Chronic GVH Model of SLE.olerance in the Chronic GVH Model of SLE.olerance in the Chronic GVH Model of SLE.A. Choudhury, P. L. Cohen, R. A. Eisenberg. 1Medicine, Div ofRheumatology, University of Pennsylvania, Philadelphia, PA,USA.

Sa1.107 - Elevated Levels of Anti-Oxidized Low Density Lipo-Sa1.107 - Elevated Levels of Anti-Oxidized Low Density Lipo-Sa1.107 - Elevated Levels of Anti-Oxidized Low Density Lipo-Sa1.107 - Elevated Levels of Anti-Oxidized Low Density Lipo-Sa1.107 - Elevated Levels of Anti-Oxidized Low Density Lipo-protein Autoantibodies Is Correlated with Disease Activity ofprotein Autoantibodies Is Correlated with Disease Activity ofprotein Autoantibodies Is Correlated with Disease Activity ofprotein Autoantibodies Is Correlated with Disease Activity ofprotein Autoantibodies Is Correlated with Disease Activity ofSystemic Lupus ErSystemic Lupus ErSystemic Lupus ErSystemic Lupus ErSystemic Lupus Erythematosus.ythematosus.ythematosus.ythematosus.ythematosus.Ruihua Wu, Guoqiu Shen, Robert Morris, Galina Lummer, JohnSama, Allan Metzger. 1R & D, RDL Reference Laboratory, LosAngeles, CA, USA.

Sa1.108 - Pediatric Systemic Lupus ErSa1.108 - Pediatric Systemic Lupus ErSa1.108 - Pediatric Systemic Lupus ErSa1.108 - Pediatric Systemic Lupus ErSa1.108 - Pediatric Systemic Lupus Erythematosus (SLE) - Lossythematosus (SLE) - Lossythematosus (SLE) - Lossythematosus (SLE) - Lossythematosus (SLE) - Lossof Tof Tof Tof Tof Tolerance to Materolerance to Materolerance to Materolerance to Materolerance to Maternal Microchimerism?nal Microchimerism?nal Microchimerism?nal Microchimerism?nal Microchimerism?A. M. Stevens,1 N. C. Lambert,2 H. M. Hermes,1 T. E. Erickson,2J. L. Nelson.2,3 1Pediatrics, University of Washington, Seattle,WA, USA; 2Immunogenetics, Fred Hutchinson Cancer ResearchInstitute, Seattle, WA, USA; 3Medicine, University of Washing-ton, Seattle, WA, USA.

Sa1.109 - Hypogammaglobulinemia in a Pediatric PatientSa1.109 - Hypogammaglobulinemia in a Pediatric PatientSa1.109 - Hypogammaglobulinemia in a Pediatric PatientSa1.109 - Hypogammaglobulinemia in a Pediatric PatientSa1.109 - Hypogammaglobulinemia in a Pediatric Patientwith Idiopathic Retroperitoneal Fibrosis Twith Idiopathic Retroperitoneal Fibrosis Twith Idiopathic Retroperitoneal Fibrosis Twith Idiopathic Retroperitoneal Fibrosis Twith Idiopathic Retroperitoneal Fibrosis Treated withreated withreated withreated withreated withTTTTTamoxifen.amoxifen.amoxifen.amoxifen.amoxifen.R. Tachdjian,1 R. L. Roberts,1 D. K. McCurdy.1 1Allergy, Immu-nology and Rheumatology, UCLA School of Medicine, Los An-geles, CA, USA.

20052005200520052005ANNUAL MEETING

89



Sa1.110 - Dendritic Cells Pulsed with TSa1.110 - Dendritic Cells Pulsed with TSa1.110 - Dendritic Cells Pulsed with TSa1.110 - Dendritic Cells Pulsed with TSa1.110 - Dendritic Cells Pulsed with Type II Bovine Collagenype II Bovine Collagenype II Bovine Collagenype II Bovine Collagenype II Bovine CollagenModulate the Murine Collagen Induced Arthritis.Modulate the Murine Collagen Induced Arthritis.Modulate the Murine Collagen Induced Arthritis.Modulate the Murine Collagen Induced Arthritis.Modulate the Murine Collagen Induced Arthritis.L. E. Salazar,1 O. A. Aravena,1 P. Abello,2 A. Aguirre,1 D.Catalan,1 C. Llanos,3 F. Sabugo,3 F. Gonzalez,1 C. Gonzalez,2

M. Cuchacovich,3 J. C. Aguillon.1 1Disciplinary Program of Im-munology, University of Chile; 2Program of Anatopatologic inVeterinaria, University of Chile; 3Department of Rheumatologic,Hospital Clinic of University of Chile, Santiago, Chile.

Sa1.111 - IL-12 Regulates Collagen-Induced Arthritis in DQ8Sa1.111 - IL-12 Regulates Collagen-Induced Arthritis in DQ8Sa1.111 - IL-12 Regulates Collagen-Induced Arthritis in DQ8Sa1.111 - IL-12 Regulates Collagen-Induced Arthritis in DQ8Sa1.111 - IL-12 Regulates Collagen-Induced Arthritis in DQ8Mice through STMice through STMice through STMice through STMice through STAAAAAT4-Dependent Mechanisms.T4-Dependent Mechanisms.T4-Dependent Mechanisms.T4-Dependent Mechanisms.T4-Dependent Mechanisms.V. Taneja, M. Behrens, H. S. Luthra, M. M. Griffiths, C. S. David.1Immunology, Mayo Clinic, Rochester, MN, USA; 2Immunology,Mayo Clinic, Rochester, MN, USA; 3Rheumatology, Mayo Clinic,Rochester, MN, USA; 4Medicine, University of Utah, Salt LakeCity, UT, USA; 5Immunology, Mayo Clinic, Rochester, MN, USA.

Sa1.112 - Identification of Genes Participating in Suppres-Sa1.112 - Identification of Genes Participating in Suppres-Sa1.112 - Identification of Genes Participating in Suppres-Sa1.112 - Identification of Genes Participating in Suppres-Sa1.112 - Identification of Genes Participating in Suppres-sion of Murine SLE by CD8sion of Murine SLE by CD8sion of Murine SLE by CD8sion of Murine SLE by CD8sion of Murine SLE by CD8+++++ Ti Cells. Ti Cells. Ti Cells. Ti Cells. Ti Cells.R. P. Singh, F. M. Ebling, D. Elashoff, D. V. Sven, C. Zamber, D.Patel, A. L. Cava, B. H. Hahn. 1Division of Rheumatology/Medicine, David Geffen School of Medicine at UCLA, Los An-geles, CA, USA; 2Dept. of Biosatstics, Haematology/Onccology,David Geffen School of Medicine at UCLA, Los Angeles, CA,USA; 3Research Department, Genome Explorations Inc., Mem-phis, TN, USA.

Sa1.113 - Impact of Gender on Immune Nephritis.Sa1.113 - Impact of Gender on Immune Nephritis.Sa1.113 - Impact of Gender on Immune Nephritis.Sa1.113 - Impact of Gender on Immune Nephritis.Sa1.113 - Impact of Gender on Immune Nephritis.T. Henry, Y. Fu, J. Zhou, C. Mohan. 1Internal Medicine-Rheu-matology, University of Texas Southwestern Medical Center,Dallas, TX, USA.

Sa1.114 - Use of Gene-Expression Profiling in Labial Sali-Sa1.114 - Use of Gene-Expression Profiling in Labial Sali-Sa1.114 - Use of Gene-Expression Profiling in Labial Sali-Sa1.114 - Use of Gene-Expression Profiling in Labial Sali-Sa1.114 - Use of Gene-Expression Profiling in Labial Sali-varvarvarvarvary Glands Using cDNA Microarrays Ty Glands Using cDNA Microarrays Ty Glands Using cDNA Microarrays Ty Glands Using cDNA Microarrays Ty Glands Using cDNA Microarrays To Identify New Patho-o Identify New Patho-o Identify New Patho-o Identify New Patho-o Identify New Patho-genic Pathways in Primargenic Pathways in Primargenic Pathways in Primargenic Pathways in Primargenic Pathways in Primary Sjögren’y Sjögren’y Sjögren’y Sjögren’y Sjögren’s Syndrome.s Syndrome.s Syndrome.s Syndrome.s Syndrome.Jacques-Eric Gotttenberg,1 Carlo Lucchesi,2 Nicolas Cagnard,2

Franck Letourneur,2 Sylvie Mistou,2 Jean Sibilia,3 GillesChiocchia,2 Xavier Mariette.1 1Rheumatology, INSERM E 109,Bicetre Hospital, Le Kremlin Bicetre, France; 2Immunology, InstitutCochin, Paris, France; 3Rheumatology, Strasbourg Hospital,Strasbourg, France.

Sa1.115 - Four Systemic Lupus ErSa1.115 - Four Systemic Lupus ErSa1.115 - Four Systemic Lupus ErSa1.115 - Four Systemic Lupus ErSa1.115 - Four Systemic Lupus Erythematosus Autoantigensythematosus Autoantigensythematosus Autoantigensythematosus Autoantigensythematosus AutoantigensIdentified by HEp-2 LibrarIdentified by HEp-2 LibrarIdentified by HEp-2 LibrarIdentified by HEp-2 LibrarIdentified by HEp-2 Library Screening.y Screening.y Screening.y Screening.y Screening.A. D. Chang,1 L. Q. Tai,1 J. Nguyen,2 R. A. Gatti,2 D. K.McCurdy.1 1Pediatric Allergy, Immunology, Rheumatology, Uni-versity of California,Los Angeles, Los Angeles, CA, USA; 2Pa-thology, University of California,Los Angeles, Los Angeles, CA,USA.

Sa1.116 - Exploration of a Burn Medication for Potential Anti-Sa1.116 - Exploration of a Burn Medication for Potential Anti-Sa1.116 - Exploration of a Burn Medication for Potential Anti-Sa1.116 - Exploration of a Burn Medication for Potential Anti-Sa1.116 - Exploration of a Burn Medication for Potential Anti-InflammatorInflammatorInflammatorInflammatorInflammatory Agent through Extery Agent through Extery Agent through Extery Agent through Extery Agent through External Application.nal Application.nal Application.nal Application.nal Application.Yuching Wu,1 Rany Ly,1 Wenhsiou Wu,1 Abdulrahman Ibrahim.21Immunology, MYC, Inc., Irvine, CA, USA; 2Center for Virus Re-search, The University of California at Irvine, Irvine, CA, USA..ral usage to treat systemic inflammation.

Sa1.117 - Regulation of Autoimmune Arthritis by the Homolo-Sa1.117 - Regulation of Autoimmune Arthritis by the Homolo-Sa1.117 - Regulation of Autoimmune Arthritis by the Homolo-Sa1.117 - Regulation of Autoimmune Arthritis by the Homolo-Sa1.117 - Regulation of Autoimmune Arthritis by the Homolo-gous Dominant Self and Crgous Dominant Self and Crgous Dominant Self and Crgous Dominant Self and Crgous Dominant Self and Cryptic Mycobacterial Hsp65yptic Mycobacterial Hsp65yptic Mycobacterial Hsp65yptic Mycobacterial Hsp65yptic Mycobacterial Hsp65Epitopes.Epitopes.Epitopes.Epitopes.Epitopes.M. Durai,1 H. R. Kim,1 Y. Mia,1 E. Kim,1 K. D. Moudgil.1 1Mi-crobiology and Immunology, University of Maryland School ofMedicine, Baltimore, MD, USA.

Sa1.118 - Both Chlordecone and Estrogen Enhance the Ger-Sa1.118 - Both Chlordecone and Estrogen Enhance the Ger-Sa1.118 - Both Chlordecone and Estrogen Enhance the Ger-Sa1.118 - Both Chlordecone and Estrogen Enhance the Ger-Sa1.118 - Both Chlordecone and Estrogen Enhance the Ger-minal Center B Cell Reaction and Reduce the Splenic B Cellminal Center B Cell Reaction and Reduce the Splenic B Cellminal Center B Cell Reaction and Reduce the Splenic B Cellminal Center B Cell Reaction and Reduce the Splenic B Cellminal Center B Cell Reaction and Reduce the Splenic B CellApoptosis in Ovariectomized (NZB x NZW) F1 Mice.Apoptosis in Ovariectomized (NZB x NZW) F1 Mice.Apoptosis in Ovariectomized (NZB x NZW) F1 Mice.Apoptosis in Ovariectomized (NZB x NZW) F1 Mice.Apoptosis in Ovariectomized (NZB x NZW) F1 Mice.F. Wang,1,2 S. M. Roberts,1,3 E. S. Sobel.2 1Department of Phar-macology and Therapeutics, University of Florida College ofMedicine, Gainesville, FL, USA; 2Department of Medicine, Uni-versity of Florida College of Medicine, Gainesville, FL, USA;3Department of Physiological Sciences, University of FloridaCollege of Veterinary Medicine, Gainesville, FL, USA.

Sa1.119 - IL10 Promoter Polymorphisms in Mexican PatientsSa1.119 - IL10 Promoter Polymorphisms in Mexican PatientsSa1.119 - IL10 Promoter Polymorphisms in Mexican PatientsSa1.119 - IL10 Promoter Polymorphisms in Mexican PatientsSa1.119 - IL10 Promoter Polymorphisms in Mexican Patientswith Spondyloarthropathies.with Spondyloarthropathies.with Spondyloarthropathies.with Spondyloarthropathies.with Spondyloarthropathies.G. Vargas-Alarcon,1 J.M. Rodriguez-Perez,1 G. Hernandez-Pacheco,1 J. Londono,2 C. Pacheco-Tena,3 J. Granados,2 R.Burgos-Vargas.3 1Physiology, Instituto Nacional de CardiologiaIgnacio Chavez, Mexico City, Mexico; 2Immunology and Rheu-matology, Instituto Nacional de Ciencias Medicas y NutricionSalvador Zubiran, Mexico City, Mexico; 3Rheumatology, Hospi-tal General de Mexico, Mexico City, Mexico.



Sa1.120 - Genetic Dissection of Congenital Heart Block in aSa1.120 - Genetic Dissection of Congenital Heart Block in aSa1.120 - Genetic Dissection of Congenital Heart Block in aSa1.120 - Genetic Dissection of Congenital Heart Block in aSa1.120 - Genetic Dissection of Congenital Heart Block in aRat Model.Rat Model.Rat Model.Rat Model.Rat Model.L. S. Horvath,1 S. Salomonsson,1 M. Jagodic,2 K. Becanovic,2

S.-E. Sonesson,3 T. Olsson,2 M. Wahren-Herlenius.1 1Depart-ment of Medicine, Karolinska Institutet, Stockholm, Sweden;2Department of Neuroimmunology, Karolinska Institutet,Stockholm, Sweden; 3Department of Women and Child Health,Karolinska Institutet, Stockholm, Sweden.

Sa1.121 - Identification of Disease Profiles for RheumatoidSa1.121 - Identification of Disease Profiles for RheumatoidSa1.121 - Identification of Disease Profiles for RheumatoidSa1.121 - Identification of Disease Profiles for RheumatoidSa1.121 - Identification of Disease Profiles for RheumatoidArthritis Using Antibody and Antigen Arrays.Arthritis Using Antibody and Antigen Arrays.Arthritis Using Antibody and Antigen Arrays.Arthritis Using Antibody and Antigen Arrays.Arthritis Using Antibody and Antigen Arrays.David L. Hirschberg,1 Anya Tsalenko,1 Mark Westall,1 Bill Fisher,1Bo Curry,1 Wolfgang Hueber, Orr Sharpe,2 Beren Toomoka,2

Dorothy Yang,1 Artie Schleifer,1 Willy McAllister,1 William H.Robinson,2 Viorica Lopez-Avila.1 1Agilent Technologies Inc., PaloAlto, USA; 2. Stanford University School of Medicine, Division ofImmunology and Rheunatology, Stanford, CA, USA.

Sa1.122 - Development and VSa1.122 - Development and VSa1.122 - Development and VSa1.122 - Development and VSa1.122 - Development and Validation of the Simple Mea-alidation of the Simple Mea-alidation of the Simple Mea-alidation of the Simple Mea-alidation of the Simple Mea-sures of Impact of Lupus Ersures of Impact of Lupus Ersures of Impact of Lupus Ersures of Impact of Lupus Ersures of Impact of Lupus Erythematosus in Yythematosus in Yythematosus in Yythematosus in Yythematosus in Youngstersoungstersoungstersoungstersoungsters(SMILEY(SMILEY(SMILEY(SMILEY(SMILEY(c)(c)(c)(c)(c)) Questionnaire.) Questionnaire.) Questionnaire.) Questionnaire.) Questionnaire.L. N. Moorthy,1 M. G. Peterson,2 M. J. Harrison,2 K. B. Onel,3

M. J. Baratelli,1 D. R. Mohan,1 T. Lehman.2 1Robert WoodJohnson University, New Brunswick, NJ; 2Hospital for SpecialSurgery, New York, NY; 3La Rabida Children’s Hospital, Chi-cago, IL.

Sa1.123 - Relationship of School Attendance with Quality ofSa1.123 - Relationship of School Attendance with Quality ofSa1.123 - Relationship of School Attendance with Quality ofSa1.123 - Relationship of School Attendance with Quality ofSa1.123 - Relationship of School Attendance with Quality ofLife, Physical Function, Disease Activity and Damage in Pe-Life, Physical Function, Disease Activity and Damage in Pe-Life, Physical Function, Disease Activity and Damage in Pe-Life, Physical Function, Disease Activity and Damage in Pe-Life, Physical Function, Disease Activity and Damage in Pe-diatric Systemic Lupus Erdiatric Systemic Lupus Erdiatric Systemic Lupus Erdiatric Systemic Lupus Erdiatric Systemic Lupus Erythematosus.ythematosus.ythematosus.ythematosus.ythematosus.L N Moorthy,1 M G Peterson,2 M J Harrison,2 K B Onel,3 D RMohan,1 Thomas Lehman.2 1Robert Wood Johnson University,New Brunswick, NJ, USA; 2Hospital for Special Surgery, NewYork, NY, USA; 3La Rabida Children’s Hospital, Chicago, IL,USA.

Sa1.124 - Development and VSa1.124 - Development and VSa1.124 - Development and VSa1.124 - Development and VSa1.124 - Development and Validation of the Simple Mea-alidation of the Simple Mea-alidation of the Simple Mea-alidation of the Simple Mea-alidation of the Simple Mea-sures of Impact of Lupus Ersures of Impact of Lupus Ersures of Impact of Lupus Ersures of Impact of Lupus Ersures of Impact of Lupus Erythematosus in Yythematosus in Yythematosus in Yythematosus in Yythematosus in Youngstersoungstersoungstersoungstersoungsters(SMILEY©) Questionnaire.(SMILEY©) Questionnaire.(SMILEY©) Questionnaire.(SMILEY©) Questionnaire.(SMILEY©) Questionnaire.L N Moorthy,1 M G Peterson,2 M J Harrison,2 K B Onel,3 M JBaratelli,1 D R Mohan,1 T Lehman.2 1Robert Wood JohnsonUniversity, New Brunswick, NJ, USA; 2Hospital for Special Sur-gery, New York, NY, USA; 3La Rabida Children’s Hospital, Chi-cago, IL, USA.

Diabetes & Other AutoimmuneDiabetes & Other AutoimmuneDiabetes & Other AutoimmuneDiabetes & Other AutoimmuneDiabetes & Other AutoimmuneEndocrine DiseasesEndocrine DiseasesEndocrine DiseasesEndocrine DiseasesEndocrine Diseases

Sa1.125 - A Fractal Analysis of Binding and DissociationSa1.125 - A Fractal Analysis of Binding and DissociationSa1.125 - A Fractal Analysis of Binding and DissociationSa1.125 - A Fractal Analysis of Binding and DissociationSa1.125 - A Fractal Analysis of Binding and DissociationKinetics of Connective Tissue Interstitial Glucose, AdiposeKinetics of Connective Tissue Interstitial Glucose, AdiposeKinetics of Connective Tissue Interstitial Glucose, AdiposeKinetics of Connective Tissue Interstitial Glucose, AdiposeKinetics of Connective Tissue Interstitial Glucose, AdiposeTissue Interstitial Glucose and Related Analytes on BiosensorTissue Interstitial Glucose and Related Analytes on BiosensorTissue Interstitial Glucose and Related Analytes on BiosensorTissue Interstitial Glucose and Related Analytes on BiosensorTissue Interstitial Glucose and Related Analytes on BiosensorSurfaces.Surfaces.Surfaces.Surfaces.Surfaces.A. M. Doke, A. Sadana. 1Chemical Enginnering, University ofMississippi, University, MS, USA; 2Chemical Enginnering, Uni-versity of Mississippi, University, MS, USA.

Sa1.126 - Serum Levels of Interleukin-16 in Patients with NewlySa1.126 - Serum Levels of Interleukin-16 in Patients with NewlySa1.126 - Serum Levels of Interleukin-16 in Patients with NewlySa1.126 - Serum Levels of Interleukin-16 in Patients with NewlySa1.126 - Serum Levels of Interleukin-16 in Patients with NewlyDiagnosed TDiagnosed TDiagnosed TDiagnosed TDiagnosed Type 1 Diabetes Mellitus.ype 1 Diabetes Mellitus.ype 1 Diabetes Mellitus.ype 1 Diabetes Mellitus.ype 1 Diabetes Mellitus.V. V. Popova,1 S. V. Melnichenko,1 T. N. Malinovskaya,1 K. P.Zak,1 B. N. Mankovsky.1 1Diabetes, Institute of Endocrinology,Kiev, Ukraine.

Sa1.127 - Antigen-Based Therapies Utilizing Ignored De-Sa1.127 - Antigen-Based Therapies Utilizing Ignored De-Sa1.127 - Antigen-Based Therapies Utilizing Ignored De-Sa1.127 - Antigen-Based Therapies Utilizing Ignored De-Sa1.127 - Antigen-Based Therapies Utilizing Ignored De-terminants of ß-Cell Antigens Can More Effectively Slow Late-terminants of ß-Cell Antigens Can More Effectively Slow Late-terminants of ß-Cell Antigens Can More Effectively Slow Late-terminants of ß-Cell Antigens Can More Effectively Slow Late-terminants of ß-Cell Antigens Can More Effectively Slow Late-Stage Autoimmune Disease in Diabetes-Prone Mice.Stage Autoimmune Disease in Diabetes-Prone Mice.Stage Autoimmune Disease in Diabetes-Prone Mice.Stage Autoimmune Disease in Diabetes-Prone Mice.Stage Autoimmune Disease in Diabetes-Prone Mice.Angelica P. Olcott,1 Jide Tian,1 Valerie Walker,1 Hoa Dang,1Blake Middleton,1 Luciano Adorini,2 Lorraine Washburn,1 DanielL. Kaufman.1 1Molecular and Medical Pharmacology, DavidGeffen School of Medicine, UCLA, Los Angeles, CA, USA;2BioXell, Milano, Italy.

Sa1.128 - NKT Cel l s May Cont r ibu te to theSa1.128 - NKT Cel l s May Cont r ibu te to theSa1.128 - NKT Cel l s May Cont r ibu te to theSa1.128 - NKT Cel l s May Cont r ibu te to theSa1.128 - NKT Cel l s May Cont r ibu te to theImmunopathogenesis of Non-Alcoholic Steatohepatis.Immunopathogenesis of Non-Alcoholic Steatohepatis.Immunopathogenesis of Non-Alcoholic Steatohepatis.Immunopathogenesis of Non-Alcoholic Steatohepatis.Immunopathogenesis of Non-Alcoholic Steatohepatis.Kazuto Tajiri,1 Yukihiro Shimizu,1 Yoshiharu Tokimitsu,1 YasuhiroNakayama,1 Katsuharu Hirano,1 Masami Minemura,1 KazumiEbata,1 Toshiro Sugiyama,1 Koichi Tsuneyama.2 1Third Depart-ment of Internal Medicine, Toyama Medical and Pharmaceuti-cal University, Toyama, Japan; 2First Department of Pathology,Toyama Medical and Pharmaceutical University, Toyama, Ja-pan.

Sa1.129 - Pro-Apoptotic DNA VSa1.129 - Pro-Apoptotic DNA VSa1.129 - Pro-Apoptotic DNA VSa1.129 - Pro-Apoptotic DNA VSa1.129 - Pro-Apoptotic DNA Vaccination as a Therapyaccination as a Therapyaccination as a Therapyaccination as a Therapyaccination as a Therapyfor Tfor Tfor Tfor Tfor Type 1 Diabetes.ype 1 Diabetes.ype 1 Diabetes.ype 1 Diabetes.ype 1 Diabetes.A. Li, O. Ojogho, E. Franco, P. Baron, W. Concepcion, A. Escher.1Transplantation Institute for Molecular and Translational Medi-cine, Loma Linda University, Loma Linda, CA, USA.

20052005200520052005ANNUAL MEETING

91



Sa1.130 - Increased Sa1.130 - Increased Sa1.130 - Increased Sa1.130 - Increased Sa1.130 - Increased β β β β β Cell Replication with Onset of Dia-Cell Replication with Onset of Dia-Cell Replication with Onset of Dia-Cell Replication with Onset of Dia-Cell Replication with Onset of Dia-betes and after Induction of Immune Tbetes and after Induction of Immune Tbetes and after Induction of Immune Tbetes and after Induction of Immune Tbetes and after Induction of Immune Tolerance in the NODolerance in the NODolerance in the NODolerance in the NODolerance in the NODMouse.Mouse.Mouse.Mouse.Mouse.N. A. Sherry,1 M. Glandt,2 Y. Liu,1 A. M. Brillantes,2 K. Herold.2

1Pediatrics, Columbia University, New York, NY, USA; 2Medi-cine, Columbia University, New York, NY, USA.

Sa1.131 - A Subset of Insulin and Glucagon Positive CellsSa1.131 - A Subset of Insulin and Glucagon Positive CellsSa1.131 - A Subset of Insulin and Glucagon Positive CellsSa1.131 - A Subset of Insulin and Glucagon Positive CellsSa1.131 - A Subset of Insulin and Glucagon Positive CellsSurSurSurSurSurvives Destruction in “Older” Female NOD Mice.vives Destruction in “Older” Female NOD Mice.vives Destruction in “Older” Female NOD Mice.vives Destruction in “Older” Female NOD Mice.vives Destruction in “Older” Female NOD Mice.M. Nakayama,1 N. Babaya,1 T. Still,1 E. Liu,1 R. Gianani.1

1Barbara Davis Center for Childhood Diabetes, University ofColorado Health Science Center, Denver, CO, USA.

Sa1.132 - PDL1 Regulates Autoimmunity by Limiting Ex-Sa1.132 - PDL1 Regulates Autoimmunity by Limiting Ex-Sa1.132 - PDL1 Regulates Autoimmunity by Limiting Ex-Sa1.132 - PDL1 Regulates Autoimmunity by Limiting Ex-Sa1.132 - PDL1 Regulates Autoimmunity by Limiting Ex-pansion of Autoreactive Th1 Cells and Mediates Resistancepansion of Autoreactive Th1 Cells and Mediates Resistancepansion of Autoreactive Th1 Cells and Mediates Resistancepansion of Autoreactive Th1 Cells and Mediates Resistancepansion of Autoreactive Th1 Cells and Mediates Resistanceto Diabetes in NOD Mice.to Diabetes in NOD Mice.to Diabetes in NOD Mice.to Diabetes in NOD Mice.to Diabetes in NOD Mice.I. Guleria,1 S. Eckenrode,2 M. J. Ansari,1 M. Azuma,3 M.Atkinson,4 J. She,2 M. H. Sayegh.1 1Transplantation ResearchCenter, Brigham and Women’s Hospital and Children’s Hospi-tal Boston, Harvard Medical School, Boston, MA, USA; 2Medi-cal College of Georgia, Augusta, GA, USA; 3Tokyo Medicaland Dental University, Tokyo, Japan; 4University of Florida, Col-lege of Medicine, Gainesville, FL.

Sa1.133 - Human HLA-A2 MHC Class 1 Molecule Is Per-Sa1.133 - Human HLA-A2 MHC Class 1 Molecule Is Per-Sa1.133 - Human HLA-A2 MHC Class 1 Molecule Is Per-Sa1.133 - Human HLA-A2 MHC Class 1 Molecule Is Per-Sa1.133 - Human HLA-A2 MHC Class 1 Molecule Is Per-missive for the Development of Diabetes in Experimental Au-missive for the Development of Diabetes in Experimental Au-missive for the Development of Diabetes in Experimental Au-missive for the Development of Diabetes in Experimental Au-missive for the Development of Diabetes in Experimental Au-toimmune Diabetes.toimmune Diabetes.toimmune Diabetes.toimmune Diabetes.toimmune Diabetes.A. Ide,1 E. Melanitou,1,2 E. Liu,1 H. Moriyama,1 D. Miao,1 G. S.Eisenbarth.1 1Barbara Davis Center for Childhood Diabetes,University of Colorado Health Sciences Center, Denver, CO, USA;2Institut Pasteur, Paris, France.

Sa1.134 - Similarities and Differences in Autoimmune Re-Sa1.134 - Similarities and Differences in Autoimmune Re-Sa1.134 - Similarities and Differences in Autoimmune Re-Sa1.134 - Similarities and Differences in Autoimmune Re-Sa1.134 - Similarities and Differences in Autoimmune Re-sponses between Tsponses between Tsponses between Tsponses between Tsponses between Type 1 and Type 1 and Type 1 and Type 1 and Type 1 and Type 1.5 Diabetes Patients.ype 1.5 Diabetes Patients.ype 1.5 Diabetes Patients.ype 1.5 Diabetes Patients.ype 1.5 Diabetes Patients.B. Brooks-Worrell,1,2 H. Chiu,1,2 A. Goel,1,2 J. P. Palmer.1,2 1De-partment of Medicine, University of Washington, Seattle, WA,USA; 2Metabolism and Endocrinology, Puget Sound Health CareSystem, Seattle, WA, USA.

Sa1.135 - The Role of Cytomegalovirus Infection in theSa1.135 - The Role of Cytomegalovirus Infection in theSa1.135 - The Role of Cytomegalovirus Infection in theSa1.135 - The Role of Cytomegalovirus Infection in theSa1.135 - The Role of Cytomegalovirus Infection in theDevelopment of TDevelopment of TDevelopment of TDevelopment of TDevelopment of Type 1 Diabetes-Associated Autoimmunity inype 1 Diabetes-Associated Autoimmunity inype 1 Diabetes-Associated Autoimmunity inype 1 Diabetes-Associated Autoimmunity inype 1 Diabetes-Associated Autoimmunity inHLA-Susceptible Children.HLA-Susceptible Children.HLA-Susceptible Children.HLA-Susceptible Children.HLA-Susceptible Children.J. Aarnisalo,1,2 O. Simell,1,3 M. Knip,1,4 J. Ilonen.1,2 1JDRF Cen-ter for Prevention of Type 1 Diabetes in Finland, Finland; 2De-partment of Virology, University of Turku, Turku, Finland; 3De-partment of Pediatrics, University of Turku, Turku, Finland; 4Hos-pital for Children and Adolescents, University of Helsinki, Helsinki,Finland.

Sa1.136 - Rotavirus-Specific TSa1.136 - Rotavirus-Specific TSa1.136 - Rotavirus-Specific TSa1.136 - Rotavirus-Specific TSa1.136 - Rotavirus-Specific T-Cell Responses and T-Cell Responses and T-Cell Responses and T-Cell Responses and T-Cell Responses and Type 1ype 1ype 1ype 1ype 1Diabetes (T1D): No Evidence for Interrelationship.Diabetes (T1D): No Evidence for Interrelationship.Diabetes (T1D): No Evidence for Interrelationship.Diabetes (T1D): No Evidence for Interrelationship.Diabetes (T1D): No Evidence for Interrelationship.M. Makela,1,2 J. Marttila,1,2 M. Knip,1,3,4 O. Simell,1,5 J. Ilonen.1,2

1JDRF Center for Prevention of Type 1 Diabetes in Finland, Fin-land; 2Department of Virology, University of Turku, Turku, Fin-land; 3Hospital for Children and Adolescents, University ofHelsinki, Helsinki, Finland; 4Department of Pediatrics, TampereUniversity Hospital, Tampere, Finland; 5Department of Pediat-rics, University of Turku, Turku, Finland.

Sa1.137 - The Possible Biochemical TSa1.137 - The Possible Biochemical TSa1.137 - The Possible Biochemical TSa1.137 - The Possible Biochemical TSa1.137 - The Possible Biochemical Targets of Alteredargets of Alteredargets of Alteredargets of Alteredargets of AlteredOpioid Mediated Nocicpetion at Diabetes Conditions.Opioid Mediated Nocicpetion at Diabetes Conditions.Opioid Mediated Nocicpetion at Diabetes Conditions.Opioid Mediated Nocicpetion at Diabetes Conditions.Opioid Mediated Nocicpetion at Diabetes Conditions.Gayane S. Vardanyan,1 Aghadjanov I. Michael,1 AghadjanovaM. Elena,1 Alla L. Shaljyan.1 1Biochemistry, Yerevan State Medi-cal University, Yerevan, Yerevan, Armenia.

Sa1.138 - Combinatorial TSa1.138 - Combinatorial TSa1.138 - Combinatorial TSa1.138 - Combinatorial TSa1.138 - Combinatorial Treatment of Recent-Onset Treatment of Recent-Onset Treatment of Recent-Onset Treatment of Recent-Onset Treatment of Recent-Onset Typeypeypeypeype1 Diabetes by Induction of Islet-Antigen Specific T1 Diabetes by Induction of Islet-Antigen Specific T1 Diabetes by Induction of Islet-Antigen Specific T1 Diabetes by Induction of Islet-Antigen Specific T1 Diabetes by Induction of Islet-Antigen Specific Tregs andregs andregs andregs andregs andAnti-CD3.Anti-CD3.Anti-CD3.Anti-CD3.Anti-CD3.Damien Bresson,1 Lisa Togher,1 Kevan Herold,2 Matthias vonHerrath.1 1La Jolla Institute for Allergy and Immunology, SanDiego, CA, USA; 2Columbia University, New York, NY, USA.

Sa1.139 - De Novo Generation of Antigen-SpecificSa1.139 - De Novo Generation of Antigen-SpecificSa1.139 - De Novo Generation of Antigen-SpecificSa1.139 - De Novo Generation of Antigen-SpecificSa1.139 - De Novo Generation of Antigen-SpecificCD4+CD25+ RegulatorCD4+CD25+ RegulatorCD4+CD25+ RegulatorCD4+CD25+ RegulatorCD4+CD25+ Regulatory T Cells from Human CD4+CD25-y T Cells from Human CD4+CD25-y T Cells from Human CD4+CD25-y T Cells from Human CD4+CD25-y T Cells from Human CD4+CD25-Cells.Cells.Cells.Cells.Cells.M. R. Walker,1,3 B. D. Carson,2,3 S. F. Ziegler,2,3 G. T. Nepom,1,3

J. H. Buckner.1 1Diabetes, Benaroya Research Institute at Vir-ginia Mason, Seattle, WA, USA; 2Immunology, Benaroya Re-search Institute at Virginia Mason, Seattle, WA, USA; 3Immunol-ogy, University of Washington, Seattle, WA, USA.



Sa1.140 - TGF-Sa1.140 - TGF-Sa1.140 - TGF-Sa1.140 - TGF-Sa1.140 - TGF-β β β β β Enhances Autoimmune Diabetes byEnhances Autoimmune Diabetes byEnhances Autoimmune Diabetes byEnhances Autoimmune Diabetes byEnhances Autoimmune Diabetes byIncreasing SurIncreasing SurIncreasing SurIncreasing SurIncreasing Survival of Memorvival of Memorvival of Memorvival of Memorvival of Memory Effector CD8 Ly Effector CD8 Ly Effector CD8 Ly Effector CD8 Ly Effector CD8 Lymphocytes.ymphocytes.ymphocytes.ymphocytes.ymphocytes.Amy E. Juedes,1 Chrystelle Asseman,1 Lisa Togher,1 YufengPeng,2 Allison Green,2 Richard A. Flavell,2 Matthias G. vonHerrath.1 1Developmental Immunology, La Jolla Institute for Al-lergy and Immunology, San Diego, CA, USA; 2Immunobiology,Yale University, New Haven, CT, USA.

Sa1.141 - Protection from TSa1.141 - Protection from TSa1.141 - Protection from TSa1.141 - Protection from TSa1.141 - Protection from Type 1 Diabetes by iNKT Cellsype 1 Diabetes by iNKT Cellsype 1 Diabetes by iNKT Cellsype 1 Diabetes by iNKT Cellsype 1 Diabetes by iNKT CellsMay Require Interactions with CD4+CD25+ RegulatorMay Require Interactions with CD4+CD25+ RegulatorMay Require Interactions with CD4+CD25+ RegulatorMay Require Interactions with CD4+CD25+ RegulatorMay Require Interactions with CD4+CD25+ Regulatory Ty Ty Ty Ty TCells.Cells.Cells.Cells.Cells.D. Ly,1,2 Q. S. Mi,3 T. L. Delovitch.1,2 1Autoimmune/DiabetesGroup, Robarts Research Institute, London, ON, Canada; 2De-partment of Microbiology and Immunology, University of West-ern Ontario, London, ON, Canada; 3Center for Biotechnologyand Genomic Medicine, Medical College of Georgia, Dept ofPathology - Section of Dermatology, Augusta, GA, USA.

Sa1.142 - Immunomodulation in TSa1.142 - Immunomodulation in TSa1.142 - Immunomodulation in TSa1.142 - Immunomodulation in TSa1.142 - Immunomodulation in Type 1 Diabetes by NBI-ype 1 Diabetes by NBI-ype 1 Diabetes by NBI-ype 1 Diabetes by NBI-ype 1 Diabetes by NBI-6024, An Altered Peptide Ligand of the Insulin B6024, An Altered Peptide Ligand of the Insulin B6024, An Altered Peptide Ligand of the Insulin B6024, An Altered Peptide Ligand of the Insulin B6024, An Altered Peptide Ligand of the Insulin B(9-23)(9-23)(9-23)(9-23)(9-23) Epitope. Epitope. Epitope. Epitope. Epitope.D. G. Alleva,1 R. A. Maki,1 A. L. Putnam,2 M. S. Kipnes,3 P.Dandona,4 J. B. Marks,5 D. L. Simmons,6 C. J. Greenbaum,7 R.J. Jimenez,1 P. J. Conlon,1 P. A. Gottlieb.2 1Molecular Medicine,Neurocrine Biosciences, Inc., San Diego, CA, USA; 2BarbaraDavis Center for Childhood Diabetes, University of ColoradoHealth Sciences Center, Denver, CO, USA; 3Diabetes and Glan-dular Disease Clinic, San Antonia, TX, USA; 4Diabetes-Endocri-nology Center of WNY Kaleida Health, Buffalo, NY, USA; 5De-partment of Diabetes, Endocrinology, and Metabolism, Univer-sity of Miami, Miami, FL, USA; 6Division of Endocrinology andMetabolism, University of Arkansas for Med Sciences, Little Rock,AR, USA; 7Diabetes Clinical Research Unit,, Virginia MasonResearch Center, Seattle, WA, USA.

Sa1.143 - A Single Explanation for Three Puzzles in TSa1.143 - A Single Explanation for Three Puzzles in TSa1.143 - A Single Explanation for Three Puzzles in TSa1.143 - A Single Explanation for Three Puzzles in TSa1.143 - A Single Explanation for Three Puzzles in Type 1ype 1ype 1ype 1ype 1Diabetes (T1D).Diabetes (T1D).Diabetes (T1D).Diabetes (T1D).Diabetes (T1D).Zuheir L. Awdeh,1 Edmond J. Yunis,1,2,3 Mark J. Audeh,4 DoloresA. Fici,1 Alberto Pugliese,5 Charles E. Larsen,1,3 Chester A.Alper.1,3 1Immunogenetics Division, The CBR Institute for Bio-medical Research, Boston, MA, USA; 2Department of CancerImmunology and AIDS, The Dana-Farber Cancer Institute, Bos-ton, MA, USA; 3Departments of Pathology, Medicine and Pedi-atrics, Harvard Medical School, Boston, MA, USA; 4Boston Col-lege, Chestnut Hill, MA, USA; 5Diabetes Research Institute, Uni-versity of Miami School of Medicine, Miami, FL, USA.

Sa1.144 - The (Relatively) Simple Genetics of a PolygenicSa1.144 - The (Relatively) Simple Genetics of a PolygenicSa1.144 - The (Relatively) Simple Genetics of a PolygenicSa1.144 - The (Relatively) Simple Genetics of a PolygenicSa1.144 - The (Relatively) Simple Genetics of a PolygenicDisease: TDisease: TDisease: TDisease: TDisease: Type 1 Diabetes (TID).ype 1 Diabetes (TID).ype 1 Diabetes (TID).ype 1 Diabetes (TID).ype 1 Diabetes (TID).Chester A. Alper,1,2 Charles E. Larsen,1,2 Edmond J. Yunis,2,3

Zaheed Husain,1,2 Zuheir L. Awdeh.1 1Immunogenetics Divi-sion, The CBR Institute for Biomedical Research, Boston, MA,USA; 2Departments of Pediatrics, Medicine and Pathology,Harvard Medical School, Boston, MA, USA; 3Department ofCancer Immunology and AIDS, The Dana-Farber Cancer Insti-tute, Boston, MA, USA.

Sa1.145 - An Atypical Case of IPEX Syndrome with MultipleSa1.145 - An Atypical Case of IPEX Syndrome with MultipleSa1.145 - An Atypical Case of IPEX Syndrome with MultipleSa1.145 - An Atypical Case of IPEX Syndrome with MultipleSa1.145 - An Atypical Case of IPEX Syndrome with MultipleFOXP3FOXP3FOXP3FOXP3FOXP3 Mutations. Mutations. Mutations. Mutations. Mutations.E. Gambineri,1 C. Azzari,1 M. Moriondo,1 L. Bianchi,1 A. M.G.Gelli,1 A. Vierucci,1 M. de Martino.1 1Department of Pediatrics,“Anna Meyer” Childrens’ Hospital, University of Florence, Flo-rence, Italy.

Immunology of the EyeImmunology of the EyeImmunology of the EyeImmunology of the EyeImmunology of the Eye

Sa1.146 - Increase of Serum KL-6 Levels In Sera of UveitisSa1.146 - Increase of Serum KL-6 Levels In Sera of UveitisSa1.146 - Increase of Serum KL-6 Levels In Sera of UveitisSa1.146 - Increase of Serum KL-6 Levels In Sera of UveitisSa1.146 - Increase of Serum KL-6 Levels In Sera of UveitisPatients with Sarcoidosis.Patients with Sarcoidosis.Patients with Sarcoidosis.Patients with Sarcoidosis.Patients with Sarcoidosis.N. Kitaichi,1 S. Ohno.1 1Ophthalmology & Visual Sciences,Hokkaido University Graduate School of Medicine, Sapporo,Hokkaido, Japan.

Sa1.147 - Cyto toxic CD8Sa1.147 - Cyto toxic CD8Sa1.147 - Cyto toxic CD8Sa1.147 - Cyto toxic CD8Sa1.147 - Cyto toxic CD8brightbr igh tbr igh tbr igh tbr igh tCD56+ T Cel l s AreCD56+ T Cel l s AreCD56+ T Cel l s AreCD56+ T Cel l s AreCD56+ T Cel l s AreImmunopathogenic Effectors in Patients with Active Behcet’Immunopathogenic Effectors in Patients with Active Behcet’Immunopathogenic Effectors in Patients with Active Behcet’Immunopathogenic Effectors in Patients with Active Behcet’Immunopathogenic Effectors in Patients with Active Behcet’sssssUveitis.Uveitis.Uveitis.Uveitis.Uveitis.Jae Kyoun Ahn,1 Hyeong Gon Yu,1 Hum Chung,1 Sung-pyoPark,1 Young Joo Kim.1 1Ophthalmology, Seoul National Uni-versity College of Medicine, Seoul, Seoul, Republic of Korea.

Sa1.148 - Flt3L-Elicited, In Vitro-Matured Splenic DendriticSa1.148 - Flt3L-Elicited, In Vitro-Matured Splenic DendriticSa1.148 - Flt3L-Elicited, In Vitro-Matured Splenic DendriticSa1.148 - Flt3L-Elicited, In Vitro-Matured Splenic DendriticSa1.148 - Flt3L-Elicited, In Vitro-Matured Splenic DendriticCells (DC) Induce Autoimmune Disease in the Retina.Cells (DC) Induce Autoimmune Disease in the Retina.Cells (DC) Induce Autoimmune Disease in the Retina.Cells (DC) Induce Autoimmune Disease in the Retina.Cells (DC) Induce Autoimmune Disease in the Retina.J. Tang,1 W. Zhu,1 P. B. Sliver,1 S.B. Shu,1 C.C. Chan,2 R. R.Caspi.1 1Section of Immunoregulation, Lab of Immunology,National Eye Institute, NIH, Bethesda, MD, USA; 2Section ofImmunopathology, Lab of Immunology, National Eye Institute,NIH, Bethesda, MD, USA.

20052005200520052005ANNUAL MEETING

93



Sa1.149 - Thrombospondin 1 Mediates a Contact Depen-Sa1.149 - Thrombospondin 1 Mediates a Contact Depen-Sa1.149 - Thrombospondin 1 Mediates a Contact Depen-Sa1.149 - Thrombospondin 1 Mediates a Contact Depen-Sa1.149 - Thrombospondin 1 Mediates a Contact Depen-dent Mechanism by Which Retinal Pigment Epithelial (RPE)dent Mechanism by Which Retinal Pigment Epithelial (RPE)dent Mechanism by Which Retinal Pigment Epithelial (RPE)dent Mechanism by Which Retinal Pigment Epithelial (RPE)dent Mechanism by Which Retinal Pigment Epithelial (RPE)Cells Regulate T Cell Function.Cells Regulate T Cell Function.Cells Regulate T Cell Function.Cells Regulate T Cell Function.Cells Regulate T Cell Function.J. L. Vega,1,2 S. Masli,2 A. W. Taylor,2 H. L. Weiner,1 J. W.Streilein.2 1Neurology, Brigham and Women’s Hospital, HarvardMedical School, Boston, MA, USA; 2Ophthalmology, SchepensEye Research Institute, Harvard Medical School, Boston, MA,USA.

Sa1.150 - Altered Peptide Ligands of a Retinal AntigenSa1.150 - Altered Peptide Ligands of a Retinal AntigenSa1.150 - Altered Peptide Ligands of a Retinal AntigenSa1.150 - Altered Peptide Ligands of a Retinal AntigenSa1.150 - Altered Peptide Ligands of a Retinal AntigenProtect from Anti-Retinal Autoimmunity by Eliciting Active Regu-Protect from Anti-Retinal Autoimmunity by Eliciting Active Regu-Protect from Anti-Retinal Autoimmunity by Eliciting Active Regu-Protect from Anti-Retinal Autoimmunity by Eliciting Active Regu-Protect from Anti-Retinal Autoimmunity by Eliciting Active Regu-latorlatorlatorlatorlatory Mechanisms.y Mechanisms.y Mechanisms.y Mechanisms.y Mechanisms.L. M. Cortes,1 D. Avichezer,1 P. B. Silver,1 C. C. Chan,1 R. R.Caspi.1 1Lab.of Immunology. National Eye Institute, NationalInstitutes of Health, Bethesda, MD, USA.

Sa1.151 - Modulation of Innate Immune Response withSa1.151 - Modulation of Innate Immune Response withSa1.151 - Modulation of Innate Immune Response withSa1.151 - Modulation of Innate Immune Response withSa1.151 - Modulation of Innate Immune Response withGranulocyteapheresis in Behçet’Granulocyteapheresis in Behçet’Granulocyteapheresis in Behçet’Granulocyteapheresis in Behçet’Granulocyteapheresis in Behçet’s Disease: 1 Ys Disease: 1 Ys Disease: 1 Ys Disease: 1 Ys Disease: 1 Year Experience.ear Experience.ear Experience.ear Experience.ear Experience.O. Garcia, R. Lafuente, J. Munoz, A. Vidaller, J. Arruga. 1Oph-thalmology, Hospital Universitari de Bellvitge, Hospitalet,Barcelona, Spain; 2Intensive Care Unit, Hospital General,Hospitalet, Barcelona, Spain; 3Blood Bank, Hospital Universitaride Bellvitge, Hospitalet, Barcelona, Spain; 4Internal Medicine,Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain;5Ophthalmology, Hospital Universitari de Bellvitge, Hospitalet,Barcelona, Spain.

Sa1.152 - Systemic Autoimmune Disease in Patients with Uvei-Sa1.152 - Systemic Autoimmune Disease in Patients with Uvei-Sa1.152 - Systemic Autoimmune Disease in Patients with Uvei-Sa1.152 - Systemic Autoimmune Disease in Patients with Uvei-Sa1.152 - Systemic Autoimmune Disease in Patients with Uvei-tis.tis.tis.tis.tis.J. Carbone,1 E. Sarmiento,1 D. Micheloud,1 R. Mora,1 M.Rodriguez-Mahou,1 R. Cobo,2 J.L. Vicario,3 J.J. Rodriguez-Molina,1 E. Fernandez-Cruz.1 1Clinical Immunology Unit, Im-munology Department, University Hospital Gregorio Maranon,Madrid, Spain; 2Ophthalmology Department, University Hospi-tal Gregorio Maranon, Madrid, Spain; 3Transfusion Center,Community of Madrid.

Sa1.153 - In Silico Prediciton of Binding of Auto-AntigenicSa1.153 - In Silico Prediciton of Binding of Auto-AntigenicSa1.153 - In Silico Prediciton of Binding of Auto-AntigenicSa1.153 - In Silico Prediciton of Binding of Auto-AntigenicSa1.153 - In Silico Prediciton of Binding of Auto-AntigenicPeptides to HLA-DRB1 in VPeptides to HLA-DRB1 in VPeptides to HLA-DRB1 in VPeptides to HLA-DRB1 in VPeptides to HLA-DRB1 in Vogt-Koyanagi-Harada Disease.ogt-Koyanagi-Harada Disease.ogt-Koyanagi-Harada Disease.ogt-Koyanagi-Harada Disease.ogt-Koyanagi-Harada Disease.P. S. Prasad,1 R. D. Levinson.1 1Ophthalmology, David GeffenSchool of Medicine, UCLA, LA, CA, USA.

Sa1.154 - Increased Ratio of Activating:InhibitorSa1.154 - Increased Ratio of Activating:InhibitorSa1.154 - Increased Ratio of Activating:InhibitorSa1.154 - Increased Ratio of Activating:InhibitorSa1.154 - Increased Ratio of Activating:Inhibitory Killer Im-y Killer Im-y Killer Im-y Killer Im-y Killer Im-munoglobulin-Like Receptor Genes in Uveitis.munoglobulin-Like Receptor Genes in Uveitis.munoglobulin-Like Receptor Genes in Uveitis.munoglobulin-Like Receptor Genes in Uveitis.munoglobulin-Like Receptor Genes in Uveitis.R. D. Levinson,1 Z. Du,2 G. N. Holland,1 E. F. Reed,2 R.Rajalingam.1 1Ophthalmology, David Geffen School of Medi-cine, UCLA, LA, CA, USA; 2Immunogenetics, UCLA, LA, CA,USA.

Poster Session 2Poster Session 2Poster Session 2Poster Session 2Poster Session 2SaturdaySaturdaySaturdaySaturdaySaturday, May 14, 2005, May 14, 2005, May 14, 2005, May 14, 2005, May 14, 2005


Immunity and InfectionImmunity and InfectionImmunity and InfectionImmunity and InfectionImmunity and Infection

Sa2.01 - Quality Assurance SurSa2.01 - Quality Assurance SurSa2.01 - Quality Assurance SurSa2.01 - Quality Assurance SurSa2.01 - Quality Assurance Survey (QAS) in the Detection ofvey (QAS) in the Detection ofvey (QAS) in the Detection ofvey (QAS) in the Detection ofvey (QAS) in the Detection ofInfectious Diseases with Outbreak Potential.Infectious Diseases with Outbreak Potential.Infectious Diseases with Outbreak Potential.Infectious Diseases with Outbreak Potential.Infectious Diseases with Outbreak Potential.M. B. Dela Cruz. 1Office of the Secretary-Department of HealthPhilippines (on Leave), Department of Health, Manila, Manila,Philippines.

Sa2.02 - Lack of Association between Interferon-Gamma Re-Sa2.02 - Lack of Association between Interferon-Gamma Re-Sa2.02 - Lack of Association between Interferon-Gamma Re-Sa2.02 - Lack of Association between Interferon-Gamma Re-Sa2.02 - Lack of Association between Interferon-Gamma Re-ceptorceptorceptorceptorceptor-1 Polymorphism and Pulmonar-1 Polymorphism and Pulmonar-1 Polymorphism and Pulmonar-1 Polymorphism and Pulmonar-1 Polymorphism and Pulmonary Ty Ty Ty Ty Tuberculosis in Ira-uberculosis in Ira-uberculosis in Ira-uberculosis in Ira-uberculosis in Ira-nian Population Sample.nian Population Sample.nian Population Sample.nian Population Sample.nian Population Sample.Mehdi Mirsaeidi,1 Masoud Houshmand,2 Payam Tabarsi,1

Mohammad Mehdi Banoei,2 Sonia Zargari,1 Majid Amiri,1

Davood Seyed Mansouri,1 Mohammad Sanati,2 MohammadReza Masjedi,1 Ali Akbar Velayati.1 1Tuberculosis & Respira-tory Infections, National Research Institute of Tuberculosis andLung Disease, Tehran, Tehran, Islamic Republic of Iran; 2Mo-lecular Genetics, The National Research Center for GeneticEngineering and Biotechnology, Tehran, Tehran, Islamic Repub-lic of Iran.

Sa2.03 - The Functional Activity of Specific Antibodies inSa2.03 - The Functional Activity of Specific Antibodies inSa2.03 - The Functional Activity of Specific Antibodies inSa2.03 - The Functional Activity of Specific Antibodies inSa2.03 - The Functional Activity of Specific Antibodies inProgression of HIVProgression of HIVProgression of HIVProgression of HIVProgression of HIV-Infection.-Infection.-Infection.-Infection.-Infection.Irina I. Andreeva.1 1Clinical of Immunology, Rostov State Medi-cal University, Rostov-on Don, Russian Federation.

Sa2.04 - Impairment of Recent Thymic Emigrants in HCV In-Sa2.04 - Impairment of Recent Thymic Emigrants in HCV In-Sa2.04 - Impairment of Recent Thymic Emigrants in HCV In-Sa2.04 - Impairment of Recent Thymic Emigrants in HCV In-Sa2.04 - Impairment of Recent Thymic Emigrants in HCV In-fection.fection.fection.fection.fection.R. Cianci,1 M. Nasi,2 M. Pinti,2 S. Starnino,1 A. Florio,1 G.Cammarota,1 A. De Luca,3 R. Cauda,3 A. Grieco,1 G. Rapaccini,1G. Gasbarrini,1 A. Cossarizza,2 F. Pandolfi.1 1Internal Medi-cine, Catholic University, Rome, Italy; 2Biochemical Sciences,University of Modena, Italy; 3Infectious Diseases, Catholic Uni-versity, Rome, Italy.



Sa2.05 - The Persistence of Allergen-Specific IgE and Long-Sa2.05 - The Persistence of Allergen-Specific IgE and Long-Sa2.05 - The Persistence of Allergen-Specific IgE and Long-Sa2.05 - The Persistence of Allergen-Specific IgE and Long-Sa2.05 - The Persistence of Allergen-Specific IgE and Long-Lived Plasma Cells.Lived Plasma Cells.Lived Plasma Cells.Lived Plasma Cells.Lived Plasma Cells.Elke O. Luger,1 Verena Fokuhl,1 Michael Wegmann,2 HaraldRenz,2 Andreas Radbruch.1 1DRFZ, German Rheumatism Re-search Center, Berlin, Germany; 2Department of Clinical Chem-istry and Molecular Diagnostics, Philipps-University Marburg,Marburg, Germany.

Sa2.06 - TSa2.06 - TSa2.06 - TSa2.06 - TSa2.06 - Transmission Hepatic Electron Microscopic Find-ransmission Hepatic Electron Microscopic Find-ransmission Hepatic Electron Microscopic Find-ransmission Hepatic Electron Microscopic Find-ransmission Hepatic Electron Microscopic Find-ings in Chronic Experimental Schistosomiasis Mansoni afterings in Chronic Experimental Schistosomiasis Mansoni afterings in Chronic Experimental Schistosomiasis Mansoni afterings in Chronic Experimental Schistosomiasis Mansoni afterings in Chronic Experimental Schistosomiasis Mansoni afterPraziquantel and an Antifibrotic.Praziquantel and an Antifibrotic.Praziquantel and an Antifibrotic.Praziquantel and an Antifibrotic.Praziquantel and an Antifibrotic.A. M. Ahour,1 M. A. El khafif,2 S. I. Hassan,3 N. G. Nessim,3N. M. Amer,3 I. M. Ali.3 1Biochemistry Department, Ein ShamsUniveristy, Cairo, Egypt; 2Parasitology Department, Ein ShamsUniversity, Cairo, Egypt; 3Parasitology Department, TheodoreBilharz Research Institute, Guiza, Cairo, Egypt.

Sa2.07 - TSa2.07 - TSa2.07 - TSa2.07 - TSa2.07 - Transmission Hepatic Electron Microscopic Find-ransmission Hepatic Electron Microscopic Find-ransmission Hepatic Electron Microscopic Find-ransmission Hepatic Electron Microscopic Find-ransmission Hepatic Electron Microscopic Find-ings in Acute Experimental Schistosomiasis Mansoni afterings in Acute Experimental Schistosomiasis Mansoni afterings in Acute Experimental Schistosomiasis Mansoni afterings in Acute Experimental Schistosomiasis Mansoni afterings in Acute Experimental Schistosomiasis Mansoni afterPraziquantel and an Antifibrotic.Praziquantel and an Antifibrotic.Praziquantel and an Antifibrotic.Praziquantel and an Antifibrotic.Praziquantel and an Antifibrotic.S. I. Hassan,1 I. M. Ali,1 N. G. Nessim,1 N. M. Amer,1 M. A. ElKhafif,2 Amin M. Ahour,3 M. M. Mohandes.4 1ParasitologyDepartment, Theodore Bilharz Research Institute, Guiza, Cairo,Egypt; 2Biochemistry Department, Ein Shams University, Cairo,Egypt; 3Parasitology Department, Ein Shams University, Cairo,Egypt.

Sa2.08 - Serum TSa2.08 - Serum TSa2.08 - Serum TSa2.08 - Serum TSa2.08 - Serum Transaminase Levels in Murine Schistoso-ransaminase Levels in Murine Schistoso-ransaminase Levels in Murine Schistoso-ransaminase Levels in Murine Schistoso-ransaminase Levels in Murine Schistoso-miasis Mansoni after Giving Praziquantel and an Antifibroticmiasis Mansoni after Giving Praziquantel and an Antifibroticmiasis Mansoni after Giving Praziquantel and an Antifibroticmiasis Mansoni after Giving Praziquantel and an Antifibroticmiasis Mansoni after Giving Praziquantel and an AntifibroticAgent.Agent.Agent.Agent.Agent.A. M. Ashour,1 M. A. El Khafif,2 Soad I. Hassan,3 N. G. Nessim,3I. M. Ali,3 N. M. Amer.3 1Parasitology Department, Ein ShamsUniversity, Cairo, Egypt; 2Biochemistry Departemnt, Ein ShamsUniversity, Cairo, Egypt; 3Parasitology Department, TheodoreBilharz Research Institute, Cairo, Egypt.

Sa2.09 - Effect of a Novel Muramyl Dipeptide Derivative TSa2.09 - Effect of a Novel Muramyl Dipeptide Derivative TSa2.09 - Effect of a Novel Muramyl Dipeptide Derivative TSa2.09 - Effect of a Novel Muramyl Dipeptide Derivative TSa2.09 - Effect of a Novel Muramyl Dipeptide Derivative To-o-o-o-o-gether with Praziquantel in Experimental Schistosomagether with Praziquantel in Experimental Schistosomagether with Praziquantel in Experimental Schistosomagether with Praziquantel in Experimental Schistosomagether with Praziquantel in Experimental SchistosomaMansoni Infection.Mansoni Infection.Mansoni Infection.Mansoni Infection.Mansoni Infection.S. S. Boutros,1 F. A. Ebeid,1 H. A. Ismail,2 N. G. Nessim.3

1Parmacology Department, Theodore Bilharz Research Institute,Guiza, Cairo, Egypt; 2Immunology Department, Theodore BilharzResearch Institute, Guiza, Cairo, Egypt; 3Parasitology Depart-ment, Theodore Bilharz Research Institute, Guiza, Cairo, Egypt.

Sa2.10 - DiscoverSa2.10 - DiscoverSa2.10 - DiscoverSa2.10 - DiscoverSa2.10 - Discovery of Neutralizing CpG ODN from Sero-y of Neutralizing CpG ODN from Sero-y of Neutralizing CpG ODN from Sero-y of Neutralizing CpG ODN from Sero-y of Neutralizing CpG ODN from Sero-type 2 and 5 Adenoviruse Based on the Relationship betweentype 2 and 5 Adenoviruse Based on the Relationship betweentype 2 and 5 Adenoviruse Based on the Relationship betweentype 2 and 5 Adenoviruse Based on the Relationship betweentype 2 and 5 Adenoviruse Based on the Relationship betweenFree Energy and BioactivityFree Energy and BioactivityFree Energy and BioactivityFree Energy and BioactivityFree Energy and Bioactivity.....Zhou Hong,1 Wang Liangxi,1 Zheng Jiang,2 Ding Guofu,1 LiuWei.1 1Department of Pharmacology, Department of Pharma-cology, Chongqing, China; 2Medical Research Center, South-western Hospital, Chongqing, China.

Sa2.11 - Evaluation of IL-10 Serum Level in Visceral Leishma-Sa2.11 - Evaluation of IL-10 Serum Level in Visceral Leishma-Sa2.11 - Evaluation of IL-10 Serum Level in Visceral Leishma-Sa2.11 - Evaluation of IL-10 Serum Level in Visceral Leishma-Sa2.11 - Evaluation of IL-10 Serum Level in Visceral Leishma-niasis.niasis.niasis.niasis.niasis.Abdolvahab Alborzi, Manoochehr Rasouli, Abolfazl Khoshdel,Simin Kiany. 1Clinical Microbiology Research Center, ShirazUniversity of Medical Sciences, Shiraz, Fars, Islamic Republic ofIran; 2Clinical Microbiology Research Center, Shiraz Universityof Medical Sciences, Shiraz, Fars, Islamic Republic of Iran; 3Clini-cal Microbiology Research Center, Shiraz University of MedicalSciences, Shiraz, Fars, Islamic Republic of Iran; 4Clinical Micro-biology Research Center, Shiraz University of Medical Sciences,Shiraz, Fars, Islamic Republic of Iran.

Sa2.12 - IL-10 Gene Polymorphisms and Susceptibility to Bru-Sa2.12 - IL-10 Gene Polymorphisms and Susceptibility to Bru-Sa2.12 - IL-10 Gene Polymorphisms and Susceptibility to Bru-Sa2.12 - IL-10 Gene Polymorphisms and Susceptibility to Bru-Sa2.12 - IL-10 Gene Polymorphisms and Susceptibility to Bru-cellosis.cellosis.cellosis.cellosis.cellosis.Simin Kiany, Manoochehr Rasouli, Mohammad Ali Dehyadegari,Noredin Rafatpour, Abdolvahab Alborzi. 1Immunology of In-fectious Diseases Department- Clinical Microbiology ResearchCenter, Shiraz University of Medical Sciences, Shiraz, Fars, Is-lamic Republic of Iran; 2Immunology of Infectious Diseases De-partment- Clinical Microbiology Research Center, Shiraz Univer-sity of Medical Sciences, Shiraz, Fars, Islamic Republic of Iran;3Clinical Microbiology Research Center, Shiraz University ofMedical Sciences, Shiraz, Fars, Islamic Republic of Iran; 4Clini-cal Microbiology Research Center, Shiraz University of MedicalSciences, Shiraz, Fars, Islamic Republic of Iran; 5Clinical Micro-biology Research Center, Shiraz University of Medical Sciences,Shiraz, Fars, Islamic Republic of Iran.

20052005200520052005ANNUAL MEETING

95



Sa2.13 -Investigation of IFN- Sa2.13 -Investigation of IFN- Sa2.13 -Investigation of IFN- Sa2.13 -Investigation of IFN- Sa2.13 -Investigation of IFN- γ γ γ γ γ Gene Polymorphism inGene Polymorphism inGene Polymorphism inGene Polymorphism inGene Polymorphism inVisceral Leishmaniasis.Visceral Leishmaniasis.Visceral Leishmaniasis.Visceral Leishmaniasis.Visceral Leishmaniasis.Simin Kiany, Manoochehr Rasouli, Abolfazl Khoshdel,Abdolvahab Alborzi. 1Immunology of Infectious Diseases De-partment- Clinical Microbiology Research Center, Shiraz Univer-sity of Medical Sciences, Shiraz, Fars, Islamic Republic of Iran;2Immunology of Infectious Diseases Department- Clinical Micro-biology Research Center, Shiraz University of Medical Sciences,Shiraz, Fars, Islamic Republic of Iran; 3Pediatric Infectious Dis-eases Department, Shiraz University of Medical Sciences, Shiraz,Fars, Islamic Republic of Iran; 4Clinical Microbiology ResearchCenter, Shiraz University of Medical Sciences, Shiraz, Fars, Is-lamic Republic of Iran.

Sa2.14 - Polymorphisms of IL-10 Gene Promoter in PatientsSa2.14 - Polymorphisms of IL-10 Gene Promoter in PatientsSa2.14 - Polymorphisms of IL-10 Gene Promoter in PatientsSa2.14 - Polymorphisms of IL-10 Gene Promoter in PatientsSa2.14 - Polymorphisms of IL-10 Gene Promoter in Patientswith Kala-azarwith Kala-azarwith Kala-azarwith Kala-azarwith Kala-azar.....Manoochehr Rasouli, Simin Kiany, Abdolvahab Alborzi,Abolfazl Khoshdel. 1Immunology of Infectious Diseases Depart-ment-Clinical Microbiology Research Center, Shiraz Universityof Medical Sciences, Shiraz, Fars, Islamic Republic of Iran; 2Im-munology of Infectious Diseases Department-Clinical Microbiol-ogy Research Center, Shiraz University of Medical Sciences,Shiraz, Fars, Islamic Republic of Iran; 3Clinical MicrobiologyResearch Center, Shiraz University of Medical Sciences, Shiraz,Fars, Islamic Republic of Iran; 4Pediatric Infectious Diseases,Shiraz University of Medical Sciences, Shiraz, Fars, Islamic Re-public of Iran.

Sa2.15 - Role of RegulatorSa2.15 - Role of RegulatorSa2.15 - Role of RegulatorSa2.15 - Role of RegulatorSa2.15 - Role of Regulatory CD25+CD4+ Cells during Infec-y CD25+CD4+ Cells during Infec-y CD25+CD4+ Cells during Infec-y CD25+CD4+ Cells during Infec-y CD25+CD4+ Cells during Infec-tion with tion with tion with tion with tion with TTTTTrrrrrypanosoma cruziypanosoma cruziypanosoma cruziypanosoma cruziypanosoma cruzi.....D. Golgher, R. Vasconcelos, R. Arantes, R. T. Gazzinelli.1Departament of Biochemistry and Immunology, UniversidadeFederal de Minas Gerais, Belo Horizonte, Minas Gerais, Bra-zil; 2Departament of Biochemistry and Immunology, UniversidadeFederal de Minas Gerais, Belo Horizonte, Minas Gerais, Bra-zil; 3Departament of Pathology, Universidade Federal de MinasGerais, Belo Horizonte, Minas Gerais, Brazil; 4Departament ofBiochemistry and Immunology, Universidade Federal de MinasGerais, Belo Horizonte, Minas Gerais, Brazil.

Sa2.16 - Dendritic Cell Mediated Immune Response Is Im-Sa2.16 - Dendritic Cell Mediated Immune Response Is Im-Sa2.16 - Dendritic Cell Mediated Immune Response Is Im-Sa2.16 - Dendritic Cell Mediated Immune Response Is Im-Sa2.16 - Dendritic Cell Mediated Immune Response Is Im-paired by the paired by the paired by the paired by the paired by the Mycobacterium tuberculosis Mycobacterium tuberculosis Mycobacterium tuberculosis Mycobacterium tuberculosis Mycobacterium tuberculosis Mannosylated-Mannosylated-Mannosylated-Mannosylated-Mannosylated-LipoArabinoMannan.LipoArabinoMannan.LipoArabinoMannan.LipoArabinoMannan.LipoArabinoMannan.N. Dulphy,1 J.-L. Herrmann,2 J. Nigoux,3 G. Puzo,3 D. Charron,1P. H. Lagrange,2 A. Toubert.1 1INSERM U662, InstitutUniversitaire d’Hematologie; Hopital Saint Louis, Paris, France;2Equipe d’Accueil EA3510, Faculte Lariboisiere-Saint Louis;Universite Paris VII, Paris, France; 3Departement “MecanismesMoleculaires des Infections Mycobacteriennes”, Institut dePharmacologie et de Biologie Structurale, Toulouse, France.

Sa2.17 - InflammatorSa2.17 - InflammatorSa2.17 - InflammatorSa2.17 - InflammatorSa2.17 - Inflammatory Response and Apoptosis of Polymory Response and Apoptosis of Polymory Response and Apoptosis of Polymory Response and Apoptosis of Polymory Response and Apoptosis of Polymor-----phonuclear Neutrophils by Prevalent Strains of phonuclear Neutrophils by Prevalent Strains of phonuclear Neutrophils by Prevalent Strains of phonuclear Neutrophils by Prevalent Strains of phonuclear Neutrophils by Prevalent Strains of Mycobacte-Mycobacte-Mycobacte-Mycobacte-Mycobacte-rium tuberculosisrium tuberculosisrium tuberculosisrium tuberculosisrium tuberculosis.....Pokkali Supriya,1 Rajavelu Priya,1 Das Sulochana.1 1Dept ofImmunology, Tuberculosis Research Centre, Chennai, TamilNadu, India.

Sa2.18 - Comparison of Regional and Systemic Humoral Im-Sa2.18 - Comparison of Regional and Systemic Humoral Im-Sa2.18 - Comparison of Regional and Systemic Humoral Im-Sa2.18 - Comparison of Regional and Systemic Humoral Im-Sa2.18 - Comparison of Regional and Systemic Humoral Im-mune Response to a Parasitic Infection.mune Response to a Parasitic Infection.mune Response to a Parasitic Infection.mune Response to a Parasitic Infection.mune Response to a Parasitic Infection.C. H. Wang,1 S. D. Wagner,1 H. Montalvo, Jr.,1 C. L. Hauschild,1A. M. Vanhoose.1 1Biology, California State University ChannelIslands, Camarillo, CA, USA.

Sa2.19 - Co-Administration of Corticosteroids (CS) with Anti-Sa2.19 - Co-Administration of Corticosteroids (CS) with Anti-Sa2.19 - Co-Administration of Corticosteroids (CS) with Anti-Sa2.19 - Co-Administration of Corticosteroids (CS) with Anti-Sa2.19 - Co-Administration of Corticosteroids (CS) with Anti-TTTTTuberculous Drugs (Auberculous Drugs (Auberculous Drugs (Auberculous Drugs (Auberculous Drugs (ATD) in TTD) in TTD) in TTD) in TTD) in Tuberculous Menangitis Had Notuberculous Menangitis Had Notuberculous Menangitis Had Notuberculous Menangitis Had Notuberculous Menangitis Had NotOnly Reduced the Intra- Cranial Pressure Symptoms, Also HadOnly Reduced the Intra- Cranial Pressure Symptoms, Also HadOnly Reduced the Intra- Cranial Pressure Symptoms, Also HadOnly Reduced the Intra- Cranial Pressure Symptoms, Also HadOnly Reduced the Intra- Cranial Pressure Symptoms, Also HadIncreased Patient’Increased Patient’Increased Patient’Increased Patient’Increased Patient’s Compliance.s Compliance.s Compliance.s Compliance.s Compliance.M. Ishaq, I. M. Sameera. 1Allergy/Pulmonology, Al-JunaidHospital, Nowshera, Pakistan.

Sa2.20 - Relationship Study between the Status of Innate Im-Sa2.20 - Relationship Study between the Status of Innate Im-Sa2.20 - Relationship Study between the Status of Innate Im-Sa2.20 - Relationship Study between the Status of Innate Im-Sa2.20 - Relationship Study between the Status of Innate Im-munology and the Infection of SARS.munology and the Infection of SARS.munology and the Infection of SARS.munology and the Infection of SARS.munology and the Infection of SARS.Wang Haibin.1 1Dept. of Clinic Immunology, 302 Hospital,Beijing, Beijing, China.

Sa2.21 - A Safe Nanoemulsion Adjuvant Produces a Killed-Sa2.21 - A Safe Nanoemulsion Adjuvant Produces a Killed-Sa2.21 - A Safe Nanoemulsion Adjuvant Produces a Killed-Sa2.21 - A Safe Nanoemulsion Adjuvant Produces a Killed-Sa2.21 - A Safe Nanoemulsion Adjuvant Produces a Killed-VVVVVirus Nasal Virus Nasal Virus Nasal Virus Nasal Virus Nasal Vaccine for Smallpox.accine for Smallpox.accine for Smallpox.accine for Smallpox.accine for Smallpox.A. U. Bielinska, K. W. Janczak, J. J. Landers, J. R. Baker, Jr..1Internal Medicine and Center for Biologic Nanotechnology,University of Michigan, Ann Arbor, MI, USA.



Sa2.22 - Novel Pan-DR Binding TSa2.22 - Novel Pan-DR Binding TSa2.22 - Novel Pan-DR Binding TSa2.22 - Novel Pan-DR Binding TSa2.22 - Novel Pan-DR Binding T-Cell Epitopes of Aden--Cell Epitopes of Aden--Cell Epitopes of Aden--Cell Epitopes of Aden--Cell Epitopes of Aden-ovirus Induce a Mixed Profile in Healthy Donors.ovirus Induce a Mixed Profile in Healthy Donors.ovirus Induce a Mixed Profile in Healthy Donors.ovirus Induce a Mixed Profile in Healthy Donors.ovirus Induce a Mixed Profile in Healthy Donors.L. M. Haveman,1,2 M. Bierings,1 M. R. Klein,1,2 S. Albani,2,3 B. J.Prakken.1,2 1Department of Pediatric Immunology, WilhelminaChildren’s Hospital / University Medical Center, Utrecht, Neth-erlands; 2IACOPO Institute, University of California, San Diego,USA; 3Department of Pediatrics, University of California, SanDiego, USA.

Sa2.23 - Naturally Occurring Breakdown Products of Inflam-Sa2.23 - Naturally Occurring Breakdown Products of Inflam-Sa2.23 - Naturally Occurring Breakdown Products of Inflam-Sa2.23 - Naturally Occurring Breakdown Products of Inflam-Sa2.23 - Naturally Occurring Breakdown Products of Inflam-mation, Generated in Inflammatormation, Generated in Inflammatormation, Generated in Inflammatormation, Generated in Inflammatormation, Generated in Inflammatory Sites, Functioned as Down-y Sites, Functioned as Down-y Sites, Functioned as Down-y Sites, Functioned as Down-y Sites, Functioned as Down-Regulator of Inflammation.Regulator of Inflammation.Regulator of Inflammation.Regulator of Inflammation.Regulator of Inflammation.Liora Cahalon,1 Zvi Landau,2 Raanan Margalit,1 Arie Admon,3

Tamar Ziv,3 Alexandra Zanin-Zhorov,1 Ofer Lider.1 1Immunol-ogy, Weizmann, Rehovot, Israel; 2Internal Medicine “D”, KaplanMedical Center, Rehovot, Israel; 3Biology, the Smoler ProteomicCenter, Technion, Haifa, Israel.

Sa2.24 - The InflammatorSa2.24 - The InflammatorSa2.24 - The InflammatorSa2.24 - The InflammatorSa2.24 - The Inflammatory & Immunological Complex Clini-y & Immunological Complex Clini-y & Immunological Complex Clini-y & Immunological Complex Clini-y & Immunological Complex Clini-cal Presentation of Mycoplasmal Infection in School Children.cal Presentation of Mycoplasmal Infection in School Children.cal Presentation of Mycoplasmal Infection in School Children.cal Presentation of Mycoplasmal Infection in School Children.cal Presentation of Mycoplasmal Infection in School Children.M. Ishaq, I. M. Sameera. 1Allergy/Pulmonology, Al-JunaidHospital, Nowshera, Pakistan.

Sa2.25 - YSa2.25 - YSa2.25 - YSa2.25 - YSa2.25 - Yeast Cells Activation Method of Hemaimmune Re-east Cells Activation Method of Hemaimmune Re-east Cells Activation Method of Hemaimmune Re-east Cells Activation Method of Hemaimmune Re-east Cells Activation Method of Hemaimmune Re-action Road Map Experimental System.action Road Map Experimental System.action Road Map Experimental System.action Road Map Experimental System.action Road Map Experimental System.Guo Feng. 1Department of Blood Tansfusion, Changhai Hospi-tal Second Military Medical University, Shanghai, China.

Sa2.26 - Phage Display Epitope Study of TSa2.26 - Phage Display Epitope Study of TSa2.26 - Phage Display Epitope Study of TSa2.26 - Phage Display Epitope Study of TSa2.26 - Phage Display Epitope Study of Two Two Two Two Two Toxins Pro-oxins Pro-oxins Pro-oxins Pro-oxins Pro-duced by Enteroaggregative duced by Enteroaggregative duced by Enteroaggregative duced by Enteroaggregative duced by Enteroaggregative Esherichia coliEsherichia coliEsherichia coliEsherichia coliEsherichia coli That Cause Pe- That Cause Pe- That Cause Pe- That Cause Pe- That Cause Pe-diatric Diarrhea: Identification and Characterization of Anti-diatric Diarrhea: Identification and Characterization of Anti-diatric Diarrhea: Identification and Characterization of Anti-diatric Diarrhea: Identification and Characterization of Anti-diatric Diarrhea: Identification and Characterization of Anti-genic and Immunogenic Mimotopes.genic and Immunogenic Mimotopes.genic and Immunogenic Mimotopes.genic and Immunogenic Mimotopes.genic and Immunogenic Mimotopes.T. G. Gazarian,1 U. Hernandez,1 J. Villaseca,1 K. G. Gazarian,2C. Eslava.1 1Department of Public Health, Faculty ofMedicine,UNAM, Mexico City, DF, Mexico; 2Department ofMolecular Biology and Biotechnology, Institute of Biomedical Re-search, Mexican National University, Mexico City, DF, Mexico.

Sa2.27 - The Combined Modulation of Nicotine and Sa2.27 - The Combined Modulation of Nicotine and Sa2.27 - The Combined Modulation of Nicotine and Sa2.27 - The Combined Modulation of Nicotine and Sa2.27 - The Combined Modulation of Nicotine and Chlamy-Chlamy-Chlamy-Chlamy-Chlamy-dia dia dia dia dia Heat Shock Protein on Cell Proliferation and ApoptosisHeat Shock Protein on Cell Proliferation and ApoptosisHeat Shock Protein on Cell Proliferation and ApoptosisHeat Shock Protein on Cell Proliferation and ApoptosisHeat Shock Protein on Cell Proliferation and Apoptosisin HEp-2 Cells.in HEp-2 Cells.in HEp-2 Cells.in HEp-2 Cells.in HEp-2 Cells.A. I. Hakki, A. Radwan, H. Friedman, S. H. Pross. 1MedicalMicrobiology & Immunology, MDC-10, Collge of Medicine-Uni-versity of South Florida, Tampa, FL, USA.

Sa2.28 - Circulating VSa2.28 - Circulating VSa2.28 - Circulating VSa2.28 - Circulating VSa2.28 - Circulating Vδδδδδ1 and V1 and V1 and V1 and V1 and Vδδδδδ2 T Cells in HIV2 T Cells in HIV2 T Cells in HIV2 T Cells in HIV2 T Cells in HIV-1-Infected-1-Infected-1-Infected-1-Infected-1-InfectedPatients: Response to CXCR3 and CXCR4 Ligands and to HIVPatients: Response to CXCR3 and CXCR4 Ligands and to HIVPatients: Response to CXCR3 and CXCR4 Ligands and to HIVPatients: Response to CXCR3 and CXCR4 Ligands and to HIVPatients: Response to CXCR3 and CXCR4 Ligands and to HIV-----1 T1 T1 T1 T1 Tat.at.at.at.at.A. Poggi,1 D. Fenoglio,2 G. Murdaca,2 M. Setti,2 F. Indiveri,2M. R. Zocchi.3 1Oncogenesis, Laboratory of Immunology, Na-tional Institute for Cancer Research, Genoa, Italy; 2Departmentof Internal Medicine, Laboratory of Clinical Immunology, Uni-versity of Genoa, Genoa, Italy; 3Department of Internal Medi-cine, Laboratory of Tumor Immunology, San Raffaele ScientificInstitute, Milan, Italy.

Sa2.29 - Adenovirus Capsid Hexon Is the Main TSa2.29 - Adenovirus Capsid Hexon Is the Main TSa2.29 - Adenovirus Capsid Hexon Is the Main TSa2.29 - Adenovirus Capsid Hexon Is the Main TSa2.29 - Adenovirus Capsid Hexon Is the Main Target Pro-arget Pro-arget Pro-arget Pro-arget Pro-tein of Adenovirus-Specific CD4tein of Adenovirus-Specific CD4tein of Adenovirus-Specific CD4tein of Adenovirus-Specific CD4tein of Adenovirus-Specific CD4+++++ T T T T T-Cells That Display a Th1-Cells That Display a Th1-Cells That Display a Th1-Cells That Display a Th1-Cells That Display a Th1like Cytokine Profile in Healthy Adults.like Cytokine Profile in Healthy Adults.like Cytokine Profile in Healthy Adults.like Cytokine Profile in Healthy Adults.like Cytokine Profile in Healthy Adults.O. Arbach,1 M. Frentsch,1 B. Chmielewicz,2 M. Kaiser,3 H.Ellerbrok,2 R. Lauster,4 A. Radbruch,1 A. Scheffold,5 A. Thiel.1

1Clinical Immunology Group, German Rheumatism ResearchCenter, Berlin, Germany; 2Robert-Koch-Institute, Berlin, Germany;3GenExpress, Berlin, Germany; 4Molecular Biology, GermanRheumatism Research Center, Berlin, Germany;5Immunomodulation Group, German Rheumatism ResearchCenter, Berlin, Germany.

Sa2.30 - Identification of SARS T Cell Epitopes Using theSa2.30 - Identification of SARS T Cell Epitopes Using theSa2.30 - Identification of SARS T Cell Epitopes Using theSa2.30 - Identification of SARS T Cell Epitopes Using theSa2.30 - Identification of SARS T Cell Epitopes Using theiTiTiTiTiTopia™Epitope Discoveropia™Epitope Discoveropia™Epitope Discoveropia™Epitope Discoveropia™Epitope Discovery System.y System.y System.y System.y System.C. A. Johnson,1 J. Chang,1 C. M. Cameron,2 D. J. Kelvin,2 L. R.Lofaro,1 K. R. Bray.1 1Clinical Research and Development,Beckman Coulter, San Diego, CA, USA; 2Division of Experimen-tal Therapeutics, University Health Network, Toronto, Canada.

Sa2.31 - Sa2.31 - Sa2.31 - Sa2.31 - Sa2.31 - LeishmaniaLeishmaniaLeishmaniaLeishmaniaLeishmania Infection in T Infection in T Infection in T Infection in T Infection in Two Two Two Two Two Twins, Association towins, Association towins, Association towins, Association towins, Association toPerforin Defect.Perforin Defect.Perforin Defect.Perforin Defect.Perforin Defect.M.E. Seoane,1 M.S. Lovillo,2 J.L. Jimenez,1 J.A. Leon,2 M.A.Munoz.1 1Division of Molecular Immuno-Biology, UniversityGeneral Hospital Gregorio Maranon, Madrid, Madrid, Spain;2Department of Paediatrics, University General Hospital Virgendel Rocio, Sevilla, Sevilla, Spain.

Sa2.32 - The Calcium-Promoted Ras Inactivator (CAPRI) LinksSa2.32 - The Calcium-Promoted Ras Inactivator (CAPRI) LinksSa2.32 - The Calcium-Promoted Ras Inactivator (CAPRI) LinksSa2.32 - The Calcium-Promoted Ras Inactivator (CAPRI) LinksSa2.32 - The Calcium-Promoted Ras Inactivator (CAPRI) LinksFcg Receptor to Cdc42 and Rac1 and Is Essential for HostFcg Receptor to Cdc42 and Rac1 and Is Essential for HostFcg Receptor to Cdc42 and Rac1 and Is Essential for HostFcg Receptor to Cdc42 and Rac1 and Is Essential for HostFcg Receptor to Cdc42 and Rac1 and Is Essential for HostInnate Defense.Innate Defense.Innate Defense.Innate Defense.Innate Defense.J. Zhang, I. Dzhagalov, J. Guo, W. Y. He. 1Immunology, DukeUniversity, Durham, NC, USA.

20052005200520052005ANNUAL MEETING

97



Sa2.33 - An 8 YSa2.33 - An 8 YSa2.33 - An 8 YSa2.33 - An 8 YSa2.33 - An 8 Year Old Girl with Recurrent Derear Old Girl with Recurrent Derear Old Girl with Recurrent Derear Old Girl with Recurrent Derear Old Girl with Recurrent Dermatomal Hermatomal Hermatomal Hermatomal Hermatomal Her-----pes Outbreaks.pes Outbreaks.pes Outbreaks.pes Outbreaks.pes Outbreaks.Cecilia P. Mikita,1 Steven M. Holland,2 Michael R. Nelson.1

1Department of Allergy-Immunology, Walter Reed Army Medi-cal Center, Washington, DC, USA; 2Laboratory of Clinical Infec-tious Diseases, National Institute of Allergy and Infectious Dis-eases, Bethesda, MD, USA.

Sa2.34 - Reconstitution of Genetically Determined DeficiencySa2.34 - Reconstitution of Genetically Determined DeficiencySa2.34 - Reconstitution of Genetically Determined DeficiencySa2.34 - Reconstitution of Genetically Determined DeficiencySa2.34 - Reconstitution of Genetically Determined Deficiencyof the Innate Immune Defence with Recombinant Mannan-Bind-of the Innate Immune Defence with Recombinant Mannan-Bind-of the Innate Immune Defence with Recombinant Mannan-Bind-of the Innate Immune Defence with Recombinant Mannan-Bind-of the Innate Immune Defence with Recombinant Mannan-Bind-ing Lectin (MBL).ing Lectin (MBL).ing Lectin (MBL).ing Lectin (MBL).ing Lectin (MBL).J. C. Jensenius,1 M. Axelsen,2 L. Kongerslev,2 S. Thiel.1 1Depart-ment of Medical Microbiology and Immunology, University ofAarhus, Aarhus, Denmark; 2NatImmune A/S, Copenhagen,Denmark.

Sa2.35 - An Active Role for Complement Regulator CD46 inSa2.35 - An Active Role for Complement Regulator CD46 inSa2.35 - An Active Role for Complement Regulator CD46 inSa2.35 - An Active Role for Complement Regulator CD46 inSa2.35 - An Active Role for Complement Regulator CD46 inSignal TSignal TSignal TSignal TSignal Transduction upon Infection.ransduction upon Infection.ransduction upon Infection.ransduction upon Infection.ransduction upon Infection.P. S. Tsang, S. H. Sacks, N. S. Sheerin. 1Department of Neph-rology and Transplantation, King’s College London, London,United Kingdom.

Sa2.36 - Access to the Entire Human Antigen-Specific CD4+Sa2.36 - Access to the Entire Human Antigen-Specific CD4+Sa2.36 - Access to the Entire Human Antigen-Specific CD4+Sa2.36 - Access to the Entire Human Antigen-Specific CD4+Sa2.36 - Access to the Entire Human Antigen-Specific CD4+TTTTT-Cell Response According to Antigen-Reactive CD154 Ex--Cell Response According to Antigen-Reactive CD154 Ex--Cell Response According to Antigen-Reactive CD154 Ex--Cell Response According to Antigen-Reactive CD154 Ex--Cell Response According to Antigen-Reactive CD154 Ex-pression.pression.pression.pression.pression.Marco Frentsch,1 Olga Arbach,1 Dennis Kirchhoff,2 ThomasSchneider,3 Alexander Scheffold,2 Andreas Thiel.1 1Clinical Im-munology, German Arthritis Research Centre, Berlin, Berlin,Germany; 2Immunmodulation, German Arthritis Research Cen-tre, Berlin, Berlin, Germany; 3Gastroenterology and InfectiousDiseases, Charite - Campus Benjamin Franklin, Berlin, Berlin,Germany.

Sa2.37 - Excessive Innate Immune Responses Could PrimeSa2.37 - Excessive Innate Immune Responses Could PrimeSa2.37 - Excessive Innate Immune Responses Could PrimeSa2.37 - Excessive Innate Immune Responses Could PrimeSa2.37 - Excessive Innate Immune Responses Could PrimeMassive Hepatocyte Apoptosis Induced by Lipopolysaccha-Massive Hepatocyte Apoptosis Induced by Lipopolysaccha-Massive Hepatocyte Apoptosis Induced by Lipopolysaccha-Massive Hepatocyte Apoptosis Induced by Lipopolysaccha-Massive Hepatocyte Apoptosis Induced by Lipopolysaccha-ride.ride.ride.ride.ride.Katsuharu Hirano,1 Yukihiro Shimizu,1 Yasuhiro Nakayama,1

Masami Minemura,1 Yoshinari Atarashi,1 Satoshi Yasumura,1

Toshiro Sugiyama.1 1The Third Department of Internal Medi-cine, Toyama Medical and Pharmaceutical University, Toyama,Japan.

Sa2.38 - Evalution CD64 Marker in Neonatal Spesis for RapidSa2.38 - Evalution CD64 Marker in Neonatal Spesis for RapidSa2.38 - Evalution CD64 Marker in Neonatal Spesis for RapidSa2.38 - Evalution CD64 Marker in Neonatal Spesis for RapidSa2.38 - Evalution CD64 Marker in Neonatal Spesis for RapidDiagnosis.Diagnosis.Diagnosis.Diagnosis.Diagnosis.Mino Adib, Farzad Oreizi, Fereshteh Sahebfosul, VajihehOstadi. 1Immunology, Medical School of Science, Isfahan,Isfahan, Islamic Republic of Iran; 2Immunology, Medical Schoolof Science, Isfahan, Isfahan, Islamic Republic of Iran; 3Immunol-ogy, Medical School of Science, Isfahan, Isfahan, Islamic Re-public of Iran; 4Immunology, Medical School of Science, Isfahan,Isfahan, Islamic Republic of Iran.

Sa2.39 - TSa2.39 - TSa2.39 - TSa2.39 - TSa2.39 - T. Whipplei Specific Immune Reactions Are Signifi-. Whipplei Specific Immune Reactions Are Signifi-. Whipplei Specific Immune Reactions Are Signifi-. Whipplei Specific Immune Reactions Are Signifi-. Whipplei Specific Immune Reactions Are Signifi-cantly Reduced in Patients with Whipple’cantly Reduced in Patients with Whipple’cantly Reduced in Patients with Whipple’cantly Reduced in Patients with Whipple’cantly Reduced in Patients with Whipple’s Disease.s Disease.s Disease.s Disease.s Disease.V. Moos,1 D. Kunkel,1 T. Marth,2 B. LaScola,3 M. Zeitz,1 T.Schneider.1 1Medical Clinic I, Charite, Campus BenjaminFranklin, Berlin, Germany; 2Internal Medicine, St Josef Hospital,Zell/ Mosel, Germany; 3Unite de Rickettsies, Faculty of Medi-cine, Marseille, France.

Sa2.40 - Adoptive TSa2.40 - Adoptive TSa2.40 - Adoptive TSa2.40 - Adoptive TSa2.40 - Adoptive Transfer of CFSE-Labeled Autologous PBMCransfer of CFSE-Labeled Autologous PBMCransfer of CFSE-Labeled Autologous PBMCransfer of CFSE-Labeled Autologous PBMCransfer of CFSE-Labeled Autologous PBMCfor the Visualization of T Cell Migration in a Non-Humanfor the Visualization of T Cell Migration in a Non-Humanfor the Visualization of T Cell Migration in a Non-Humanfor the Visualization of T Cell Migration in a Non-Humanfor the Visualization of T Cell Migration in a Non-HumanPrimate Model.Primate Model.Primate Model.Primate Model.Primate Model.D. Kunkel,1 V. Moos,1 C. Stahl-Hennig,2 F. J. Kaup,2 M. Zeitz,1

T. Schneider.1 1Medical Clinic I, Charite - Campus BenjaminFranklin, Berlin, Germany; 2German Primate Center, Gottingen,Germany.

Sa2.41 - The Effect of Post-TSa2.41 - The Effect of Post-TSa2.41 - The Effect of Post-TSa2.41 - The Effect of Post-TSa2.41 - The Effect of Post-Traumatic Stress Syndrome on theraumatic Stress Syndrome on theraumatic Stress Syndrome on theraumatic Stress Syndrome on theraumatic Stress Syndrome on theOutcome of Influenza VOutcome of Influenza VOutcome of Influenza VOutcome of Influenza VOutcome of Influenza Vaccination.accination.accination.accination.accination.E. Kosor,1 A. Gagro,1 V. Folnegovic-Smalc,4 M. Vilibic,4 D.Kozaric-Kovacic,5 M. Grubisic-Ilic,5 V. Drazenovic,2 K. Gotovac,1A. Sabioncello,1 E. Cecuk,3 V. Kerhin-Brkljacic,3 I. Gjenero-Margan,2 B. Kaic,2 S. Rabatic,1 G. Mlinaric-Galinovic,2 D.Dekaris.1 1Research and Development, Institute of Immunology,Zagreb, Croatia; 2Virology, Croatian Institute of Public Health,Zagreb, Croatia; 3National Referal Organ Transplant and Tis-sue Centre, University Hospital Centre Zagreb, Zagreb, Croatia;4University Department of Psychiatry, Psychiatric Hospital Vrapce,Zagreb, Croatia; 5Department of Psychiatry, National Centerfor Psychotrauma Dubrava, Zagreb, Croatia.



Sa2.42 - Cholesterol Loading of T Cells as a Model of T CellSa2.42 - Cholesterol Loading of T Cells as a Model of T CellSa2.42 - Cholesterol Loading of T Cells as a Model of T CellSa2.42 - Cholesterol Loading of T Cells as a Model of T CellSa2.42 - Cholesterol Loading of T Cells as a Model of T CellAging.Aging.Aging.Aging.Aging.A. Larbi,1,2 G. Dupuis,2 C. Fortin,1,2 H. Berrougui,1 A. Khalil,1 T.Fulop.1,2 1Laboratory of Immunology, Research Center on Ag-ing, Sherbrooke, QC, Canada; 2Immunology Program, Facultyof Medicine, Clinical Research Center, Sherbrooke, QC,Canada.

Sa2.43 - The Role of Programmed Death-1 Pathway in a Neu-Sa2.43 - The Role of Programmed Death-1 Pathway in a Neu-Sa2.43 - The Role of Programmed Death-1 Pathway in a Neu-Sa2.43 - The Role of Programmed Death-1 Pathway in a Neu-Sa2.43 - The Role of Programmed Death-1 Pathway in a Neu-trophil Mediated Shock Syndrome.trophil Mediated Shock Syndrome.trophil Mediated Shock Syndrome.trophil Mediated Shock Syndrome.trophil Mediated Shock Syndrome.B. Zhu,1 K. Raddassi,1 M. H. Sayegh,2 S. J. Khoury.1 1Centerfor Neurologic Diseases, Brigham and Women’s Hospital, Bos-ton, MA, USA; 2Transplantation Research Center, Brigham andWomen’s Hospital and Children’s Hospital Boston, Boston, MA,USA.

Sa2.44 - Immune Response Balance on Human CutaneousSa2.44 - Immune Response Balance on Human CutaneousSa2.44 - Immune Response Balance on Human CutaneousSa2.44 - Immune Response Balance on Human CutaneousSa2.44 - Immune Response Balance on Human CutaneousLeishmaniasis.Leishmaniasis.Leishmaniasis.Leishmaniasis.Leishmaniasis.L. Castellano,1 D. Correia Filho,1 L. Argiro,2 H. Dessein,2 A. Prata,1A. Dessein,2 V. Rodrigues.1 1Lab of Immunology, Faculdade deMedicina do Triangulo Mineiro, Uberaba, Minas Gerais, Bra-zil; 2Fac Medecine, INSERM U399, Marseille, France.

Sa2.45 - Investigatin of IL-4 Gene Polymorphism in PatientsSa2.45 - Investigatin of IL-4 Gene Polymorphism in PatientsSa2.45 - Investigatin of IL-4 Gene Polymorphism in PatientsSa2.45 - Investigatin of IL-4 Gene Polymorphism in PatientsSa2.45 - Investigatin of IL-4 Gene Polymorphism in Patientswith Brucellosis.with Brucellosis.with Brucellosis.with Brucellosis.with Brucellosis.Manoochehr Rasouli, Amin Abbasian, Simin Kiany. 1Immunol-ogy of Infectious Diseae Departrment, Clinical Microbiology Re-search Center- Shiraz University of Medical Sciences, Shiraz,Fars, Islamic Republic of Iran; 2Immunology of Infectious DiseaeDepartrment, Clinical Microbiology Research Center- ShirazUniversity of Medical Sciences, Shiraz, Fars, Islamic Republic ofIran; 3Immunology of Infectious Diseae Departrment, ClinicalMicrobiology Research Center- Shiraz University of Medical Sci-ences, Shiraz, Fars, Islamic Republic of Iran.

Sa2.46 - Immunophenotype Characterization of PeripheralSa2.46 - Immunophenotype Characterization of PeripheralSa2.46 - Immunophenotype Characterization of PeripheralSa2.46 - Immunophenotype Characterization of PeripheralSa2.46 - Immunophenotype Characterization of PeripheralBlood T LBlood T LBlood T LBlood T LBlood T Lymphocytes before and after Tymphocytes before and after Tymphocytes before and after Tymphocytes before and after Tymphocytes before and after Treatment in Treatment in Treatment in Treatment in Treatment in Tubercu-ubercu-ubercu-ubercu-ubercu-losis Patients.losis Patients.losis Patients.losis Patients.losis Patients.Fereshteh Sahebfosul, Farzad Oreizi, Zohre Pessaran, AhmadGhavaminejad. 1Immunology, Medical School, Isfahan,Isfahan/Isfahn, Islamic Republic of Iran; 2Immunology, MedicalSchool, Isfahan, Isfahan/Isfahan, Islamic Republic of Iran; 3Im-munology, Medical School, Isfahan, Isfahan/Isfahan, IslamicRepublic of Iran; 4Immunology, Medical School, Isfahan,Isfahan/Isfahan, Islamic Republic of Iran.

Sa2.47 - Class I Restricted Epitopes Highly Represented inSa2.47 - Class I Restricted Epitopes Highly Represented inSa2.47 - Class I Restricted Epitopes Highly Represented inSa2.47 - Class I Restricted Epitopes Highly Represented inSa2.47 - Class I Restricted Epitopes Highly Represented inthe the the the the TTTTTrrrrrypanosoma cruziypanosoma cruziypanosoma cruziypanosoma cruziypanosoma cruzi Genome Are Recognized by CD8+ T Genome Are Recognized by CD8+ T Genome Are Recognized by CD8+ T Genome Are Recognized by CD8+ T Genome Are Recognized by CD8+ TCells from Individuals with Chronic Cells from Individuals with Chronic Cells from Individuals with Chronic Cells from Individuals with Chronic Cells from Individuals with Chronic TTTTT. cruzi. cruzi. cruzi. cruzi. cruzi Infection. Infection. Infection. Infection. Infection.S. A. Laucella,1 B. Weatherly,2 D. Martin,2 M. C. Albareda,1

M. G. Alvarez,3 G. Bertochi,3 A. H. Armenti,3 J. Sidney,4 A.Sette,4 M. Postan,1 R. L. Tarleton.2 1Research Department, InstitutoNacional de Parasitologia, Buenos Aires, Argentina; 2Centerfor Tropical and Emerging Global Diseases, UGA, Athens, GA,USA; 3Hospital Interzonal Eva Peron, Buenos Aires, Argentina;4La Jolla Institute for Allergy and Immunology, San Diego, CA,USA.

Sa2.48 - Sustained Expansion, Activation and Maturation ofSa2.48 - Sustained Expansion, Activation and Maturation ofSa2.48 - Sustained Expansion, Activation and Maturation ofSa2.48 - Sustained Expansion, Activation and Maturation ofSa2.48 - Sustained Expansion, Activation and Maturation ofVVVVVirus-Specific CD8+ T Cells after Acute Parirus-Specific CD8+ T Cells after Acute Parirus-Specific CD8+ T Cells after Acute Parirus-Specific CD8+ T Cells after Acute Parirus-Specific CD8+ T Cells after Acute Parvovirus B19 In-vovirus B19 In-vovirus B19 In-vovirus B19 In-vovirus B19 In-fection.fection.fection.fection.fection.V. O. Kasprowicz,1 A. Isa,2 O. Norbeck,2 T. Tolfvenstam,2 P.Klenerman,3 P. Bowness.1 1Human Immunology Unit, WeatherallInstitute of Molecular Medicine, University of Oxford, Oxford,United Kingdom; 2Department of Virology, Karolinska Institute,Stockholm, Sweden; 3Peter Medawar Building for PathogenResearch, University of Oxford, Oxford, United Kingdom.

Sa2.49 - Defining Putative T Cell Epitopes from PE and PPESa2.49 - Defining Putative T Cell Epitopes from PE and PPESa2.49 - Defining Putative T Cell Epitopes from PE and PPESa2.49 - Defining Putative T Cell Epitopes from PE and PPESa2.49 - Defining Putative T Cell Epitopes from PE and PPEFamilies of Proteins of Families of Proteins of Families of Proteins of Families of Proteins of Families of Proteins of Mycobacterium tuberculosisMycobacterium tuberculosisMycobacterium tuberculosisMycobacterium tuberculosisMycobacterium tuberculosis with V with V with V with V with Vac-ac-ac-ac-ac-cine Potential.cine Potential.cine Potential.cine Potential.cine Potential.G. M. Chaitra,1 Sridhar Hariharaputran,2 Nagasuma R.Chandra,2 S. M. Shaila,1 Rabindranath Nayak.1 1Departmentof Microbiology & Cell Biology, Indian Institute of Science, Ban-galore, Karnataka, India; 2Bioinformatics Center, Indian Insti-tute of Science, Bangalore, Karnataka, India.

Sa2.50 - The Study between the Changes of CD35 ExpressedSa2.50 - The Study between the Changes of CD35 ExpressedSa2.50 - The Study between the Changes of CD35 ExpressedSa2.50 - The Study between the Changes of CD35 ExpressedSa2.50 - The Study between the Changes of CD35 Expressedon Eron Eron Eron Eron Erythrocyte in Patients with Hepatocirrhosis and the Se-ythrocyte in Patients with Hepatocirrhosis and the Se-ythrocyte in Patients with Hepatocirrhosis and the Se-ythrocyte in Patients with Hepatocirrhosis and the Se-ythrocyte in Patients with Hepatocirrhosis and the Se-verity of Liver Function Destroying.verity of Liver Function Destroying.verity of Liver Function Destroying.verity of Liver Function Destroying.verity of Liver Function Destroying.Ma Chi,1 Wang Haibin.2 1Dept. Immunology, Peking UnionMedical College, Beijing, China; 2Dept. Lab of Clinical Immu-nology, Beijing 302 Hospital, Beijing, China.

Sa2.51 - Deficient IgM to IgG Antibody Switch in PatientsSa2.51 - Deficient IgM to IgG Antibody Switch in PatientsSa2.51 - Deficient IgM to IgG Antibody Switch in PatientsSa2.51 - Deficient IgM to IgG Antibody Switch in PatientsSa2.51 - Deficient IgM to IgG Antibody Switch in PatientsUnresponsive TUnresponsive TUnresponsive TUnresponsive TUnresponsive To Conjugate Pneumococcal Polysaccharides.o Conjugate Pneumococcal Polysaccharides.o Conjugate Pneumococcal Polysaccharides.o Conjugate Pneumococcal Polysaccharides.o Conjugate Pneumococcal Polysaccharides.L. E. Leiva, E. J. Saturno, H. Monjure, E. Barr, K. Mason, R. U.Sorensen. 1Pediatrics, LSU Health Sciences Center and Children’sHospital, New Orleans, LA, USA.

20052005200520052005ANNUAL MEETING

99



Sa2.52 - A Delayed Diagnosis of Cystic Fibrosis in a PatientSa2.52 - A Delayed Diagnosis of Cystic Fibrosis in a PatientSa2.52 - A Delayed Diagnosis of Cystic Fibrosis in a PatientSa2.52 - A Delayed Diagnosis of Cystic Fibrosis in a PatientSa2.52 - A Delayed Diagnosis of Cystic Fibrosis in a Patientwith Asthma and Allergic Bronchopulmonarwith Asthma and Allergic Bronchopulmonarwith Asthma and Allergic Bronchopulmonarwith Asthma and Allergic Bronchopulmonarwith Asthma and Allergic Bronchopulmonary Aspergillosis.y Aspergillosis.y Aspergillosis.y Aspergillosis.y Aspergillosis.K. R. Lowe,1 C. P. Mikita.1 1Allergy/Immunology, Walter ReedArmy Medical Center, Washington, DC, USA.

Sa2.53 - Determination of Sa2.53 - Determination of Sa2.53 - Determination of Sa2.53 - Determination of Sa2.53 - Determination of Borrelia burgdorferiBorrelia burgdorferiBorrelia burgdorferiBorrelia burgdorferiBorrelia burgdorferi Outer-Sur- Outer-Sur- Outer-Sur- Outer-Sur- Outer-Sur-face Protein Aface Protein Aface Protein Aface Protein Aface Protein A161-175161-175161-175161-175161-175 Peptide Binding to HLA-DR Molecules Peptide Binding to HLA-DR Molecules Peptide Binding to HLA-DR Molecules Peptide Binding to HLA-DR Molecules Peptide Binding to HLA-DR MoleculesAssociated with Antibiotic-RefractorAssociated with Antibiotic-RefractorAssociated with Antibiotic-RefractorAssociated with Antibiotic-RefractorAssociated with Antibiotic-Refractory or Antibiotic-Respon-y or Antibiotic-Respon-y or Antibiotic-Respon-y or Antibiotic-Respon-y or Antibiotic-Respon-sive Lsive Lsive Lsive Lsive Lyme Aryme Aryme Aryme Aryme Arthritis.thritis.thritis.thritis.thritis.E. E. Drouin,1 B. Falk,2 L. J. Glickstein,1 W. Klitz,3 W. W. Kwok,2G. T. Nepom,2 L.A. Baxter-Lowe,4 A. C. Steere.1 1CIID/Rheu-matology Division, Massachusetts General Hospital / HarvardMedical School, Boston, MA; 2Benaroya Res Inst, Seattle, WA;3UC Berkeley, Oakland, CA; 4Immunogenetics and Transplan-tation Lab, UCSF, San Francisco, CA.

Sa2.54 - Mycobacteria Directly Induces Cytoskeletal Rear-Sa2.54 - Mycobacteria Directly Induces Cytoskeletal Rear-Sa2.54 - Mycobacteria Directly Induces Cytoskeletal Rear-Sa2.54 - Mycobacteria Directly Induces Cytoskeletal Rear-Sa2.54 - Mycobacteria Directly Induces Cytoskeletal Rear-rangements for Macrophage Motility through TLR2-Dependentrangements for Macrophage Motility through TLR2-Dependentrangements for Macrophage Motility through TLR2-Dependentrangements for Macrophage Motility through TLR2-Dependentrangements for Macrophage Motility through TLR2-DependentPI3-K Signaling.PI3-K Signaling.PI3-K Signaling.PI3-K Signaling.PI3-K Signaling.E. B. Lasunskaia,1 M. N. Campos,1 R. da Matta,2 T. L. Kipnis,1

W. D. da Silva.1 1Laboratory of Biology of Recognition,Universidade Estadual do Norte Fluminense, Campos, Rio deJaneiro, Brazil; 2Laboratory of Cell and Tissue Biology,Universidade Estadual do Norte Fluminense, Campos, Rio deJaneiro, Brazil.

Sa2.55 - Sa2.55 - Sa2.55 - Sa2.55 - Sa2.55 - Chlamydia pneumoniaeChlamydia pneumoniaeChlamydia pneumoniaeChlamydia pneumoniaeChlamydia pneumoniae Infection of Human Immune Infection of Human Immune Infection of Human Immune Infection of Human Immune Infection of Human ImmuneCells Modulates Cytokine Production.Cells Modulates Cytokine Production.Cells Modulates Cytokine Production.Cells Modulates Cytokine Production.Cells Modulates Cytokine Production.Y. Mamata,1 C. Newton,1 T. W. Klein,1 Y. Yamamoto,1,2 H. Fried-man.1 1Medical Microbiology and Immunology, University ofSouth Florida College of Medicine, Tampa, FL, USA; 2BasicLabolatory Science, Osaka University, Suita, Osaka, Japan.

Sa2.56 - Homeostatic Chemokines: Organizers of CellularSa2.56 - Homeostatic Chemokines: Organizers of CellularSa2.56 - Homeostatic Chemokines: Organizers of CellularSa2.56 - Homeostatic Chemokines: Organizers of CellularSa2.56 - Homeostatic Chemokines: Organizers of CellularInteractions Required for T Cell Priming in the PulmonarInteractions Required for T Cell Priming in the PulmonarInteractions Required for T Cell Priming in the PulmonarInteractions Required for T Cell Priming in the PulmonarInteractions Required for T Cell Priming in the Pulmonary En-y En-y En-y En-y En-vironment during the Influenza Infection.vironment during the Influenza Infection.vironment during the Influenza Infection.vironment during the Influenza Infection.vironment during the Influenza Infection.J. Rangel-Moreno,1 J. E. Moyron-Quiroz,1 K. Kusser,1 S.Goodrich,1 L. Hartson,1 M. Tighe,1 T. D. Randall.1 1Immunol-ogy, Trudeau Institute, Saranac Lake, NY, USA.

Sa2.57 - Human ‘MemorSa2.57 - Human ‘MemorSa2.57 - Human ‘MemorSa2.57 - Human ‘MemorSa2.57 - Human ‘Memory’ CD4+ T Cells Are Distributed be-y’ CD4+ T Cells Are Distributed be-y’ CD4+ T Cells Are Distributed be-y’ CD4+ T Cells Are Distributed be-y’ CD4+ T Cells Are Distributed be-tween Five Phenotypically and Functionally Distinct Subsets.tween Five Phenotypically and Functionally Distinct Subsets.tween Five Phenotypically and Functionally Distinct Subsets.tween Five Phenotypically and Functionally Distinct Subsets.tween Five Phenotypically and Functionally Distinct Subsets.E. Amyes, A. J. McMichael, M. F.C. Callan. 1Division of Medi-cine, Chelsea and Westminster Hospital Campus, Imperial Col-lege, London, United Kingdom; 2MRC Human Immunology Unit,Weatherall Institute of Molecular Medicine, Oxford, Oxfordshire,United Kingdom.

Sa2.58 - Characterization of the Th Cellular Immune ResponseSa2.58 - Characterization of the Th Cellular Immune ResponseSa2.58 - Characterization of the Th Cellular Immune ResponseSa2.58 - Characterization of the Th Cellular Immune ResponseSa2.58 - Characterization of the Th Cellular Immune ResponseInduced by the Diphtheria TInduced by the Diphtheria TInduced by the Diphtheria TInduced by the Diphtheria TInduced by the Diphtheria Toxin Croxin Croxin Croxin Croxin Cry1A Mutants in Spleeny1A Mutants in Spleeny1A Mutants in Spleeny1A Mutants in Spleeny1A Mutants in SpleenCells from Intranasally Primed BALB/c Mice.Cells from Intranasally Primed BALB/c Mice.Cells from Intranasally Primed BALB/c Mice.Cells from Intranasally Primed BALB/c Mice.Cells from Intranasally Primed BALB/c Mice.Fernando T. Hernandez,1 Gloria G. Guerrero.1 1Escuela deCiencias Biologicas. Unidad Torreon, Universidad Autonoma deCoahuila, Torreon, Coahuila, Mexico.

Sa2.59 - Intranasal VSa2.59 - Intranasal VSa2.59 - Intranasal VSa2.59 - Intranasal VSa2.59 - Intranasal Vaccination with Chlamydial Protease-accination with Chlamydial Protease-accination with Chlamydial Protease-accination with Chlamydial Protease-accination with Chlamydial Protease-Like Activity Factor and Interleukin-12 Promotes the ClearanceLike Activity Factor and Interleukin-12 Promotes the ClearanceLike Activity Factor and Interleukin-12 Promotes the ClearanceLike Activity Factor and Interleukin-12 Promotes the ClearanceLike Activity Factor and Interleukin-12 Promotes the Clearanceof Pulmonarof Pulmonarof Pulmonarof Pulmonarof Pulmonary y y y y C. trachomatisC. trachomatisC. trachomatisC. trachomatisC. trachomatis Infection. Infection. Infection. Infection. Infection.Ashlesh K. Murthy,1 Yu Cong,1 Guangming Zhong,2 Bernard P.Arulanandam.1 1Biology, University of Texas at San Antonio,San Antonio, TX, USA; 2Microbiology and Immunology, Univer-sity of Texas Health Science Center, San Antonio, TX, USA.

Sa2.60 - Identification of ssRNA Sequences That StimulateSa2.60 - Identification of ssRNA Sequences That StimulateSa2.60 - Identification of ssRNA Sequences That StimulateSa2.60 - Identification of ssRNA Sequences That StimulateSa2.60 - Identification of ssRNA Sequences That StimulateInnate Immunity through TLRs.Innate Immunity through TLRs.Innate Immunity through TLRs.Innate Immunity through TLRs.Innate Immunity through TLRs.Alexandra Forsbach,1 Carmen Montino,1 Christian Muller,1 JorgVollmer,1 Stefan Bauer,3 Grayson B. Lipford.2 1&ÿÿ2&ÿÿ3Inst. forMedical Microbiology & Immunology, Technical University ofMunich, Munich, Germany.

Sa2.61 - Mechanism of In Vivo Cytotoxicity Mediated bySa2.61 - Mechanism of In Vivo Cytotoxicity Mediated bySa2.61 - Mechanism of In Vivo Cytotoxicity Mediated bySa2.61 - Mechanism of In Vivo Cytotoxicity Mediated bySa2.61 - Mechanism of In Vivo Cytotoxicity Mediated byCFP10-Specific CD8+ T Cells.CFP10-Specific CD8+ T Cells.CFP10-Specific CD8+ T Cells.CFP10-Specific CD8+ T Cells.CFP10-Specific CD8+ T Cells.S. M. Behar,1 J. Woodworth,1 A. B. Kamath.1 1Division of Rheu-matology, Immunology, and Allergy, Brigham and Women’sHospital, Boston, MA, USA.



Sa2.62 - Characterization of an Lck-Independent Pathway ofSa2.62 - Characterization of an Lck-Independent Pathway ofSa2.62 - Characterization of an Lck-Independent Pathway ofSa2.62 - Characterization of an Lck-Independent Pathway ofSa2.62 - Characterization of an Lck-Independent Pathway ofTTTTT-Cell Activation Used by Bacterial Superantigens: Mecha--Cell Activation Used by Bacterial Superantigens: Mecha--Cell Activation Used by Bacterial Superantigens: Mecha--Cell Activation Used by Bacterial Superantigens: Mecha--Cell Activation Used by Bacterial Superantigens: Mecha-nistic and Therapeutic Implications on Autoimmunitynistic and Therapeutic Implications on Autoimmunitynistic and Therapeutic Implications on Autoimmunitynistic and Therapeutic Implications on Autoimmunitynistic and Therapeutic Implications on Autoimmunity.....C. Bueno,1,2 G. Criado,1,2 M. L. Baroja,1,2 S. S. Ferguson,2,3 C.Tsoukas,5 J. Madrenas.1,2,4 1Immunology, FOCIS Centre for Clini-cal Immunology and Immunotherapeutics; 2Immunology, RobartsResearch Institute; 3Department of Physiology and Pharmacol-ogy; 4Department of Microbiology and Immunology, The Uni-versity of Western Ontario, London, ON, Canada; 5Departmentof Biology, San Diego State University, San Diego, CA, USA.

Sa2.63 - HLA Phenotype and the Production of IFN-Sa2.63 - HLA Phenotype and the Production of IFN-Sa2.63 - HLA Phenotype and the Production of IFN-Sa2.63 - HLA Phenotype and the Production of IFN-Sa2.63 - HLA Phenotype and the Production of IFN-γ γ γ γ γ andandandandandInter leukin-10 in Patients with Chronic UrogenitalInter leukin-10 in Patients with Chronic UrogenitalInter leukin-10 in Patients with Chronic UrogenitalInter leukin-10 in Patients with Chronic UrogenitalInter leukin-10 in Patients with Chronic UrogenitalChlamydiosis.Chlamydiosis.Chlamydiosis.Chlamydiosis.Chlamydiosis.G. N. Drannik,1 V. E. Driyanskaya,1 S. N. Vashchenko,1 A. G.Drannik,2 L. M. DuBuske.3 1Institute of Urology, Academy ofMedical Sciences, Kiev, Ukraine; 2McMaster University, Hamilton,ON, Canada; 3Immunology Research Institute of New England,Gardner, MA, USA.

Sa2.64 - Are Probiotics Essential Adjunctive Therapies for Sa2.64 - Are Probiotics Essential Adjunctive Therapies for Sa2.64 - Are Probiotics Essential Adjunctive Therapies for Sa2.64 - Are Probiotics Essential Adjunctive Therapies for Sa2.64 - Are Probiotics Essential Adjunctive Therapies for CCCCCdifficiledifficiledifficiledifficiledifficile Enteritis? Enteritis? Enteritis? Enteritis? Enteritis?K. D. Karpa,1 N. Trenev,1 M. L. McCann.1 1College of Medi-cine, PSU, Hershey, PA, USA.

Sa2.65 - Alterations in Th1 Subpopulations Correspond toSa2.65 - Alterations in Th1 Subpopulations Correspond toSa2.65 - Alterations in Th1 Subpopulations Correspond toSa2.65 - Alterations in Th1 Subpopulations Correspond toSa2.65 - Alterations in Th1 Subpopulations Correspond toClinical Pathology in Severe TClinical Pathology in Severe TClinical Pathology in Severe TClinical Pathology in Severe TClinical Pathology in Severe Trauma Patients.rauma Patients.rauma Patients.rauma Patients.rauma Patients.A. K. De,1 K. Laudanski,1 R. V. Maier,2 P. E. Bankey,1 J. P. Minei,3C. Elson,4 D. Hayden,4 D. A. Schoenfeld,4 L. L. Moldawer,5 R.G. Tompkins,4 C. L. Miller-Graziano.1 1Surgery, University ofRochester Medical Center, Rochester, NY, USA; 2Surgery, Uni-versity of Washington, Seattle, WA, USA; 3Surgery, Universityof Texas Southwestern, Dallas, TX, USA; 4Surgery and Biostatis-tics, Massachusetts General Hospital, Harvard, Boston, MA,USA; 5Surgery, University of Florida, Gainsville, FL, USA.

Sa2.66 - The Effect of Immunotherapies on In Vivo AntiviralSa2.66 - The Effect of Immunotherapies on In Vivo AntiviralSa2.66 - The Effect of Immunotherapies on In Vivo AntiviralSa2.66 - The Effect of Immunotherapies on In Vivo AntiviralSa2.66 - The Effect of Immunotherapies on In Vivo AntiviralResponses to HIVResponses to HIVResponses to HIVResponses to HIVResponses to HIV.....S. Andjelic,1 Z. Popmihajlov,1 L. Kelly-Rossini,1 P. Bellman,1 B.Boyle,1 M. Lesser,1 J. Ruitenberg,2 C. Waters,2 R. El Habib,3 K.A. Smith.1 1Medicine, Weill Medical College of Cornell Univer-sity, New York, NY, USA; 2Becton Dickinson, San Jose, CA, USA;3Aventis Pasteur, Marcy l’Etoile, France.

Sa2.67 - An Automated Methodology for Evaluation of Den-Sa2.67 - An Automated Methodology for Evaluation of Den-Sa2.67 - An Automated Methodology for Evaluation of Den-Sa2.67 - An Automated Methodology for Evaluation of Den-Sa2.67 - An Automated Methodology for Evaluation of Den-dritic Cells in Whole Blood.dritic Cells in Whole Blood.dritic Cells in Whole Blood.dritic Cells in Whole Blood.dritic Cells in Whole Blood.C. Smith,1 E. Rabellino,1 J. Wilkinson,1 S. D’Costa.1 1Biomedi-cal Research Division, Beckman Coulter Inc., Miami, FL, USA.

Sa2.68 - Ozonetherapy and Quality of Life in HIV PositiveSa2.68 - Ozonetherapy and Quality of Life in HIV PositiveSa2.68 - Ozonetherapy and Quality of Life in HIV PositiveSa2.68 - Ozonetherapy and Quality of Life in HIV PositiveSa2.68 - Ozonetherapy and Quality of Life in HIV PositivePatients.Patients.Patients.Patients.Patients.Osmel Gaspar Guerra Segura, Barbara Elias-Calles Fernadez.1Immunology Lab., Teach.and Gen Hosp. Dr.A. Neto,Guantanamo, Guantanamo, Cuba; 2Ozonetherapy Dept.,Teach.and Gen Hosp. Dr.A. Neto, Guantanamo, Guantanamo,Cuba.

Sa2.69 - Characteristics of Fas Ligand Expression by Hu-Sa2.69 - Characteristics of Fas Ligand Expression by Hu-Sa2.69 - Characteristics of Fas Ligand Expression by Hu-Sa2.69 - Characteristics of Fas Ligand Expression by Hu-Sa2.69 - Characteristics of Fas Ligand Expression by Hu-man Cytomegalovirus Infection.man Cytomegalovirus Infection.man Cytomegalovirus Infection.man Cytomegalovirus Infection.man Cytomegalovirus Infection.Eung-Soo Hwnag,1 Jung Heon Kim,1 Ye Jin Kwon,1 Hye Jin Jung,1Su-Yeon Kim,1 Chung-Gyu Park,1 Chang-Yong Cha.1 1Depart-ment of Microbiology and Immunology, Seoul National Univer-sity College of Medicine, Seoul, Republic of Korea.

Sa2.70 - Characterization of a Th1/TSa2.70 - Characterization of a Th1/TSa2.70 - Characterization of a Th1/TSa2.70 - Characterization of a Th1/TSa2.70 - Characterization of a Th1/Tc1 Tc1 Tc1 Tc1 Tc1 Type Immune Responseype Immune Responseype Immune Responseype Immune Responseype Immune Responseto the Novel Therapeutic Hepatitis C Peptide Vto the Novel Therapeutic Hepatitis C Peptide Vto the Novel Therapeutic Hepatitis C Peptide Vto the Novel Therapeutic Hepatitis C Peptide Vto the Novel Therapeutic Hepatitis C Peptide Vaccine IC41 inaccine IC41 inaccine IC41 inaccine IC41 inaccine IC41 inHumans.Humans.Humans.Humans.Humans.S. Jelovcan,1 H. Wedemeyer,2 V. Buerger,1 E. Tauber,1 C. Klade.11Intercell AG, Campus Vienna, Vienna, Austria; 2MedizinischeHochschule Hannover, Abt. Gastroenterologie, Hepatologie undEndokrinologie, Hannover, Germany.

Sa2.71 - Hepatitis B VSa2.71 - Hepatitis B VSa2.71 - Hepatitis B VSa2.71 - Hepatitis B VSa2.71 - Hepatitis B Virus X and C Protein Induce Tirus X and C Protein Induce Tirus X and C Protein Induce Tirus X and C Protein Induce Tirus X and C Protein Induce Transcrip-ranscrip-ranscrip-ranscrip-ranscrip-tion of hfgl2 Prothrombinase Gene.tion of hfgl2 Prothrombinase Gene.tion of hfgl2 Prothrombinase Gene.tion of hfgl2 Prothrombinase Gene.tion of hfgl2 Prothrombinase Gene.Meifang Han,1 Dong Xi,1 Gary Levy,2 Xiaoping Luo,1 Qin Ning.11Department of Infectious Disease, Tongji Hospital of TongjiMedical University, Huazhong University of Science and Tech-nology, Wuhan, Hubei, China; 2Department of Medicine andSurgery and Multiorgan Transplant Program, The Toronto Hos-pital of the University of Toronto, Toronto, Canada.

Sa2.72 - BCG VSa2.72 - BCG VSa2.72 - BCG VSa2.72 - BCG VSa2.72 - BCG Vaccination of the Human Newboraccination of the Human Newboraccination of the Human Newboraccination of the Human Newboraccination of the Human Newborn Inducesn Inducesn Inducesn Inducesn InducesSpecific RegulatorSpecific RegulatorSpecific RegulatorSpecific RegulatorSpecific Regulatory CD4+ T Cells.y CD4+ T Cells.y CD4+ T Cells.y CD4+ T Cells.y CD4+ T Cells.J. Riley,1 A. Keyser,1 A. Soares,1 H. Fletcher,3 W. Hanekom.1

1Institute of Infectious Diseases, University of Cape Town, CapeTown, South Africa; 2University of Oxford, Oxford, United King-dom.

20052005200520052005ANNUAL MEETING

101



Sa2.73 - Effect of an Anti-InflammatorSa2.73 - Effect of an Anti-InflammatorSa2.73 - Effect of an Anti-InflammatorSa2.73 - Effect of an Anti-InflammatorSa2.73 - Effect of an Anti-Inflammatory Pentapeptide Producedy Pentapeptide Producedy Pentapeptide Producedy Pentapeptide Producedy Pentapeptide Producedby by by by by Entamoeba histolyticaEntamoeba histolyticaEntamoeba histolyticaEntamoeba histolyticaEntamoeba histolytica upon Gene Expression Related to upon Gene Expression Related to upon Gene Expression Related to upon Gene Expression Related to upon Gene Expression Related toInflammation/WInflammation/WInflammation/WInflammation/WInflammation/Woundhealing.oundhealing.oundhealing.oundhealing.oundhealing.R. Silva,1 G. Rico,1 I. Estrada,2 R. Ramos,2 D. Arenas,3 J.Gimenez,1 A. Torres,4 M. Morales,1 R. Kretschmer.1 1UIMInmunologia, IMSS, Mexico, DF, Mexico; 2Inmunologia Molecu-lar, IPN, Mexico, DF, Mexico; 3UIM en Genetica, IMSS, Mexico,DF, Mexico; 4Genetica de Poblaciones, IMSS, Mexico, DF,Mexico.

Sa2.74 - Spectrum of CD1d-Restricted T Cells: Control ofSa2.74 - Spectrum of CD1d-Restricted T Cells: Control ofSa2.74 - Spectrum of CD1d-Restricted T Cells: Control ofSa2.74 - Spectrum of CD1d-Restricted T Cells: Control ofSa2.74 - Spectrum of CD1d-Restricted T Cells: Control ofAnti-VAnti-VAnti-VAnti-VAnti-Viral and Anti-Tiral and Anti-Tiral and Anti-Tiral and Anti-Tiral and Anti-Tumor Responses.umor Responses.umor Responses.umor Responses.umor Responses.R. Wang,1 S. C. Yue,1 P. Ilyinskii,1 J. J. Van der Vliet,1 KazuhikoYanagisawa,1 A. Shaulov,1 Q. He,2 M. J. Koziel,2 S. P. Balk,1M. A. Exley.1 1Cancer Biology, Hematology / Oncology, BethIsrael Deaconess Medical Center, Boston, MA, USA; 2InfectiousDiseases, Beth Israel Deaconess Medical Center, Boston, MA,USA.

Sa2.75 - Establishment of a Substitutive SARS Murine ModelSa2.75 - Establishment of a Substitutive SARS Murine ModelSa2.75 - Establishment of a Substitutive SARS Murine ModelSa2.75 - Establishment of a Substitutive SARS Murine ModelSa2.75 - Establishment of a Substitutive SARS Murine Modeland Its Application in SARS Studyand Its Application in SARS Studyand Its Application in SARS Studyand Its Application in SARS Studyand Its Application in SARS Study.....Weiming Yan,1 Chuanglong Zhu,1 Xiaoping Luo,1 Qin Ning.11Department of Infectious Disease, Tongji Hospital of TongjiMedical College, Wuhan, Hubei, China.

Sa2.76 - Direct Innate Immune Activation by Human Naive BSa2.76 - Direct Innate Immune Activation by Human Naive BSa2.76 - Direct Innate Immune Activation by Human Naive BSa2.76 - Direct Innate Immune Activation by Human Naive BSa2.76 - Direct Innate Immune Activation by Human Naive BCells Via Combined TLR9 and RP105.Cells Via Combined TLR9 and RP105.Cells Via Combined TLR9 and RP105.Cells Via Combined TLR9 and RP105.Cells Via Combined TLR9 and RP105.Kazuko Yamazaki,1 Takashi Yamazaki,2 Takuma Hayashi,1

Kazuo Sugane,1 Kazunaga Agematsu.1 1Department of Infec-tious Immunology, Graduate School of Medicine,Shinshu Uni-versity, Matsumoto, Nagano, Japan; 2Department of Pediatrics,Shinshu University, Matumoto, Nagano, Japan.

Sa2.77 - Evaluacion del Numero de Linfocitos T ReguladoresSa2.77 - Evaluacion del Numero de Linfocitos T ReguladoresSa2.77 - Evaluacion del Numero de Linfocitos T ReguladoresSa2.77 - Evaluacion del Numero de Linfocitos T ReguladoresSa2.77 - Evaluacion del Numero de Linfocitos T Reguladoresen Pacientes Con Ten Pacientes Con Ten Pacientes Con Ten Pacientes Con Ten Pacientes Con Tuberculosis.uberculosis.uberculosis.uberculosis.uberculosis.L. R. Gamez,1,2 M. Rocha,1 R. Gonzalez,2 S. Romano,1 D. P.Portales.1,2 1Inmunologia, Facultad de Ciencias Quimicas dela Universidad Autonoma de San Luis Potosi, San Luis Potosi,San Luis Potosi, Mexico; 2Inmunologia, Facultad de Medicinade la Universidad Autonoma de San Luis Potosi, San Luis Potosi,San Luis Potosi, Mexico.

Sa2.78 - Direct Epitope DiscoverSa2.78 - Direct Epitope DiscoverSa2.78 - Direct Epitope DiscoverSa2.78 - Direct Epitope DiscoverSa2.78 - Direct Epitope Discovery for Yy for Yy for Yy for Yy for Yellow Fever Vellow Fever Vellow Fever Vellow Fever Vellow Fever Virus Asibi-17D.irus Asibi-17D.irus Asibi-17D.irus Asibi-17D.irus Asibi-17D.A. Collymore-Slovak,1 A. Gilb,1 C. Roberts,1 M. Jones,1 W. H.Hildebrand.1 1Microbiology and Immunology, University ofOklahoma Health Sciences Center, Oklahoma City, OK, USA.

Sa2.79 - Clonal Organization of T Cell MemorSa2.79 - Clonal Organization of T Cell MemorSa2.79 - Clonal Organization of T Cell MemorSa2.79 - Clonal Organization of T Cell MemorSa2.79 - Clonal Organization of T Cell Memory: Paradigmy: Paradigmy: Paradigmy: Paradigmy: Paradigmof “Focused Diversity” Contributes to Reperof “Focused Diversity” Contributes to Reperof “Focused Diversity” Contributes to Reperof “Focused Diversity” Contributes to Reperof “Focused Diversity” Contributes to Repertoire Flexibilitytoire Flexibilitytoire Flexibilitytoire Flexibilitytoire Flexibility.....Yuri N. Naumov,1 Shalyn C. Clute,1 Elena N. Naumova,2 JackGorski,3 Liisa K. Selin.1 1Department of Pathology, University ofMassachusetts Medical School, Worcester, MA, USA; 2Depart-ment of Family Medicine and Community Health, Tufts Univer-sity School of Medicine, Boston, MA, USA; 3Blood Research In-stitute, The Blood Center of S.-E. Wisconsin, Milwaukee, WI,USA.

Sa2.80 - Capture and Specific DeliverSa2.80 - Capture and Specific DeliverSa2.80 - Capture and Specific DeliverSa2.80 - Capture and Specific DeliverSa2.80 - Capture and Specific Delivery of Exogenous Lipidy of Exogenous Lipidy of Exogenous Lipidy of Exogenous Lipidy of Exogenous LipidAntigens by Apolipoprotein E.Antigens by Apolipoprotein E.Antigens by Apolipoprotein E.Antigens by Apolipoprotein E.Antigens by Apolipoprotein E.P. van den Elzen,1 S. Garg,2 M. Brigl,2 J. E. Gumperz,2 F. M.Sacks,3 G. S. Besra,4 D. B. Moody,2 M. B. Brenner.2 1Pathol-ogy, Brigham and Women’s Hospital, Harvard Medical School,Boston, MA, United Kingdom; 2Medicine, Division of Rheuma-tology, Immunology and Allergy, Brigham and Women’s Hospi-tal, Harvard Medical School, Boston, MA, USA; 3Nutrition,Harvard School of Public Health, Boston, MA, USA; 4School ofBiosciences, University of Birmingham, Edgbaston, Birmingham,United Kingdom.

Sa2.81 - Supertype Analysis: Definition of Overlapping Pep-Sa2.81 - Supertype Analysis: Definition of Overlapping Pep-Sa2.81 - Supertype Analysis: Definition of Overlapping Pep-Sa2.81 - Supertype Analysis: Definition of Overlapping Pep-Sa2.81 - Supertype Analysis: Definition of Overlapping Pep-tide-Binding Capacities for MHC Class I Molecules.tide-Binding Capacities for MHC Class I Molecules.tide-Binding Capacities for MHC Class I Molecules.tide-Binding Capacities for MHC Class I Molecules.tide-Binding Capacities for MHC Class I Molecules.R. Buchli,1 R. S. VanGundy,1 C. F. Giberson,1 W. H. Hildebrand.21Research Department, Pure Protein L.L.C., Oklahoma City, OK,USA; 2Department of Microbiology and Immunology, Universityof Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Sa2.82 - Development and VSa2.82 - Development and VSa2.82 - Development and VSa2.82 - Development and VSa2.82 - Development and Validation of Fluorescence Polaralidation of Fluorescence Polaralidation of Fluorescence Polaralidation of Fluorescence Polaralidation of Fluorescence Polar-----ization-Based Competitive Peptide Binding Assays - Newization-Based Competitive Peptide Binding Assays - Newization-Based Competitive Peptide Binding Assays - Newization-Based Competitive Peptide Binding Assays - Newization-Based Competitive Peptide Binding Assays - NewScreening TScreening TScreening TScreening TScreening Tools for Epitope Discoverools for Epitope Discoverools for Epitope Discoverools for Epitope Discoverools for Epitope Discoveryyyyy.....R. S. VanGundy,1 R. Buchli,1 C. F. Giberson,1 W. H. Hildebrand.21Research Department, Pure Protein L.L.C., Oklahoma City, OK,USA; 2Department of Microbiology and Immunology, Universityof Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Sa2.83 - Anthrax TSa2.83 - Anthrax TSa2.83 - Anthrax TSa2.83 - Anthrax TSa2.83 - Anthrax Toxins Impair Pulmonaroxins Impair Pulmonaroxins Impair Pulmonaroxins Impair Pulmonaroxins Impair Pulmonary Dendritic Cell Func-y Dendritic Cell Func-y Dendritic Cell Func-y Dendritic Cell Func-y Dendritic Cell Func-tions: Implications in Pathogenesis.tions: Implications in Pathogenesis.tions: Implications in Pathogenesis.tions: Implications in Pathogenesis.tions: Implications in Pathogenesis.A. Cleret,1 A. Quesnel-Hellmann,1 J. Mathieu,1 D. Vidal,1 J.-N.Tournier.1 1Immunology Unit, CRSSA, La Tronche, France.



Sa2.84 - Rheumatic Fever: Development of an Animal ModelSa2.84 - Rheumatic Fever: Development of an Animal ModelSa2.84 - Rheumatic Fever: Development of an Animal ModelSa2.84 - Rheumatic Fever: Development of an Animal ModelSa2.84 - Rheumatic Fever: Development of an Animal ModelUsing Streptococcal M1 Recombinant Protein.Using Streptococcal M1 Recombinant Protein.Using Streptococcal M1 Recombinant Protein.Using Streptococcal M1 Recombinant Protein.Using Streptococcal M1 Recombinant Protein.F. F. Alcantara,1,2,3 E. Postol,1,3 E.R. Alencar,1,3 V. R. Assis,1 L.Demarchi,1 J. Kalil,1,2,3 L. Guilherme.1,3 1Immunology Labora-tory, Heart Institute (InCor), Sao Paulo, Sao Paulo, Brazil; 2Al-lergy and Clinical Immunology, University of Sao Paulo, SaoPaulo, Sao Paulo, Brazil; 3Institute for Immunological Investiga-tions, University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil.

Sa2.85 - Effect of the Zinc in the Viability and DifferentiationSa2.85 - Effect of the Zinc in the Viability and DifferentiationSa2.85 - Effect of the Zinc in the Viability and DifferentiationSa2.85 - Effect of the Zinc in the Viability and DifferentiationSa2.85 - Effect of the Zinc in the Viability and Differentiationin Human and Murine Cells.in Human and Murine Cells.in Human and Murine Cells.in Human and Murine Cells.in Human and Murine Cells.G. B. Vega,1 A. Polo,1 M. E. Morales,2 G. Rico.2 1Coordinacionde Educacion Medica Continua Facultad de Medicina, UNAM,Mexico, DF, Mexico; 2UIM en Inmunologia. Hospital de PediatriaCMN-SXXI, IMSS, Mexico, DF, Mexico.

Sa2.86 - IL-27/WSX-1 Signalling: An Important Role in theSa2.86 - IL-27/WSX-1 Signalling: An Important Role in theSa2.86 - IL-27/WSX-1 Signalling: An Important Role in theSa2.86 - IL-27/WSX-1 Signalling: An Important Role in theSa2.86 - IL-27/WSX-1 Signalling: An Important Role in thePathogenesis of Experimental Septic Peritonitis.Pathogenesis of Experimental Septic Peritonitis.Pathogenesis of Experimental Septic Peritonitis.Pathogenesis of Experimental Septic Peritonitis.Pathogenesis of Experimental Septic Peritonitis.Stefan Wirtz,1 Ingrid Tubbe,1 Mark Birkenbach,2 Richard S.Blumberg,3 Neurath F. Neurath.1 1I. Medical Department,Univesity of Mainz, Mainz, Germany; 2Department of Pathol-ogy and Anatomy, Eastern Virginia Medical School, Norfolk,VA, USA; 3Gastroenterology Division, Brigham and Women’sHospital, Harvard Medical, Boston, MA, USA.

Sa2.87 - Morphine Facilitates TSa2.87 - Morphine Facilitates TSa2.87 - Morphine Facilitates TSa2.87 - Morphine Facilitates TSa2.87 - Morphine Facilitates Transendothelial Migration ofransendothelial Migration ofransendothelial Migration ofransendothelial Migration ofransendothelial Migration ofHIVHIVHIVHIVHIV-1 Infected Monocytes across the Blood Brain Barrier by-1 Infected Monocytes across the Blood Brain Barrier by-1 Infected Monocytes across the Blood Brain Barrier by-1 Infected Monocytes across the Blood Brain Barrier by-1 Infected Monocytes across the Blood Brain Barrier byModulating P-Glycoprotein Expression in Brain Microvascu-Modulating P-Glycoprotein Expression in Brain Microvascu-Modulating P-Glycoprotein Expression in Brain Microvascu-Modulating P-Glycoprotein Expression in Brain Microvascu-Modulating P-Glycoprotein Expression in Brain Microvascu-lar Endothelial Cells.lar Endothelial Cells.lar Endothelial Cells.lar Endothelial Cells.lar Endothelial Cells.S. D. Mahajan,1 S. A. Schwartz,1 R. C. Chawda,1 N.McCulloch,1 M. P. Nair.1 1Medicine, Division ofAllergy,Immunology and Rheumatology, State University of NewYork at Buffalo, Buffalo, NY, USA.

Sa2.88 - Intralesional T Cell Lines Obtained from RheumaticSa2.88 - Intralesional T Cell Lines Obtained from RheumaticSa2.88 - Intralesional T Cell Lines Obtained from RheumaticSa2.88 - Intralesional T Cell Lines Obtained from RheumaticSa2.88 - Intralesional T Cell Lines Obtained from RheumaticHearHearHearHearHeart Disease Lesions Can Be Used as a Tt Disease Lesions Can Be Used as a Tt Disease Lesions Can Be Used as a Tt Disease Lesions Can Be Used as a Tt Disease Lesions Can Be Used as a Tool for Searchingool for Searchingool for Searchingool for Searchingool for Searchingfor Non-Autoimmune M Protein Epitopes for Developing afor Non-Autoimmune M Protein Epitopes for Developing afor Non-Autoimmune M Protein Epitopes for Developing afor Non-Autoimmune M Protein Epitopes for Developing afor Non-Autoimmune M Protein Epitopes for Developing aSafe VSafe VSafe VSafe VSafe Vaccine Against Group A Streptococci.accine Against Group A Streptococci.accine Against Group A Streptococci.accine Against Group A Streptococci.accine Against Group A Streptococci.L. Guilherme,1,3 S. E. Oshiro,1,3 C. Puschel,1,3 W. R. Silva,1,3 F.Higa,1,3 L. Chaves,1,3 A. C. Tanaka,1 G. Spina,1 P. M.A.Pomerantzeff,1 J. Kalil.1,2,3 1Heart Institute, University of SaoPaulo, Sao Paulo, São Paulo, Brazil; 2Clinical Immunology andAllergy, School of Medicine, University of Sao Paulo, Sao Paulo,São Paulo, Brazil; 3Institute for Immunology Investigation, Uni-versity of Sao Paulo, Sao Paulo, São Paulo, Brazil.

Sa2.89 - Is There Any Relation between LSa2.89 - Is There Any Relation between LSa2.89 - Is There Any Relation between LSa2.89 - Is There Any Relation between LSa2.89 - Is There Any Relation between Lymphocyte Subsets,ymphocyte Subsets,ymphocyte Subsets,ymphocyte Subsets,ymphocyte Subsets,NK Activity and Infection in Beta Thalassemia Patients.NK Activity and Infection in Beta Thalassemia Patients.NK Activity and Infection in Beta Thalassemia Patients.NK Activity and Infection in Beta Thalassemia Patients.NK Activity and Infection in Beta Thalassemia Patients.Arezoo Jamali,1 Hossein Hadi nadoushan,2 Mina Izadyar,3Farhad Vaezzadeh,1 Mahroo Mirahmadian,2 Bita Ansaripour.21Medical Laboratory Scienses, Allied Medical School,TehranUniversity of Medical Scienses, Tehran, Tehran, Islamic Repub-lic of Iran; 2Immunology, Tehran University of Medical Scienses,Tehran, Tehran, Islamic Republic of Iran; 3Medical Center ofPeditrics, Tehran University of Medical Scienses, Tehran, Tehran,Islamic Republic of Iran.

Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology

Sa2.90 - Dysregulation of Histone Modification and DNASa2.90 - Dysregulation of Histone Modification and DNASa2.90 - Dysregulation of Histone Modification and DNASa2.90 - Dysregulation of Histone Modification and DNASa2.90 - Dysregulation of Histone Modification and DNAMethylation in Acute Myeloid Leukemia.Methylation in Acute Myeloid Leukemia.Methylation in Acute Myeloid Leukemia.Methylation in Acute Myeloid Leukemia.Methylation in Acute Myeloid Leukemia.M. Ogawa, K. Sakashita, K. Koike. 1Pediatrics, Shinshu Uni-versity School of Medicine, Matsumoto, Nagano, Japan.

Sa2.91 - Immunological and Comparitive Study of Ras Fam-Sa2.91 - Immunological and Comparitive Study of Ras Fam-Sa2.91 - Immunological and Comparitive Study of Ras Fam-Sa2.91 - Immunological and Comparitive Study of Ras Fam-Sa2.91 - Immunological and Comparitive Study of Ras Fam-ily Oncogene Product in Vily Oncogene Product in Vily Oncogene Product in Vily Oncogene Product in Vily Oncogene Product in Various Human Tarious Human Tarious Human Tarious Human Tarious Human Tissues.issues.issues.issues.issues.V. Mehrotra, V. L. Lahiri. 1Biochemistry, Himalayan Institute ofMedical Sciences, Dehradun, Uttranchal, India; 2Pathology, SN Medical College, Agra, Uttar Pradesh, India.

Sa2.92 - Defects in TCR Associated Proteins in Relation toSa2.92 - Defects in TCR Associated Proteins in Relation toSa2.92 - Defects in TCR Associated Proteins in Relation toSa2.92 - Defects in TCR Associated Proteins in Relation toSa2.92 - Defects in TCR Associated Proteins in Relation toImmune Impairment in Oral Cancer Patients.Immune Impairment in Oral Cancer Patients.Immune Impairment in Oral Cancer Patients.Immune Impairment in Oral Cancer Patients.Immune Impairment in Oral Cancer Patients.V. T. Cheriyan,1 S. C. Dutt,2 S. M. Krishna,1 P. Balaram.1 1Divi-sion of Cancer Research, Regional Cancer Centre, Trivandrum,Kerala, India; 2Division of Radiotherapy, Regional Cacner Cen-tre, Trivandrum, Kerala, India.

Sa2.93 - Is the Oncogenesis Epigenetic Induced AlternativeSa2.93 - Is the Oncogenesis Epigenetic Induced AlternativeSa2.93 - Is the Oncogenesis Epigenetic Induced AlternativeSa2.93 - Is the Oncogenesis Epigenetic Induced AlternativeSa2.93 - Is the Oncogenesis Epigenetic Induced AlternativeWWWWWay for Cell Suray for Cell Suray for Cell Suray for Cell Suray for Cell Survival?vival?vival?vival?vival?I. Bubanovic, S. Najman. 1Ob/Gyn, Medica Centre, Nis,Serbia, Yugoslavia; 2Department for Byology, Medical Univer-sity School, Nis, Serbia, Yugoslavia.

Sa2.94 - Anti-Interleukin-10 Strategies in TSa2.94 - Anti-Interleukin-10 Strategies in TSa2.94 - Anti-Interleukin-10 Strategies in TSa2.94 - Anti-Interleukin-10 Strategies in TSa2.94 - Anti-Interleukin-10 Strategies in Treatment of Malig-reatment of Malig-reatment of Malig-reatment of Malig-reatment of Malig-nant Diseases.nant Diseases.nant Diseases.nant Diseases.nant Diseases.I. Bubanovic, S. Najman. 1Ob/Gyn, Medica Centre, Nis,Serbia, Yugoslavia; 2Institute for Biology, Medical UniversitySchool, Nis, Serbia, Yugoslavia.

20052005200520052005ANNUAL MEETING

103



Sa2.95 - Modulation of TNF alpha Effects on Apoptosis In-Sa2.95 - Modulation of TNF alpha Effects on Apoptosis In-Sa2.95 - Modulation of TNF alpha Effects on Apoptosis In-Sa2.95 - Modulation of TNF alpha Effects on Apoptosis In-Sa2.95 - Modulation of TNF alpha Effects on Apoptosis In-duction in PC Cell Line.duction in PC Cell Line.duction in PC Cell Line.duction in PC Cell Line.duction in PC Cell Line.V. Jurisic,1 G. Bogdanovic,2 T. Srdic,2 V. Kojic,2 J. Dimitar,2 N.Kraguljac.3 1Pathophysiology, University of Kragujevac, Schoolof Medicine, Kragujevac, Serbia, Yugoslavia; 2ExperimentalOncology, Institute of Oncology, Novi Sad, Serbia, Yugoslavia;3Institute of Hematology, Belgrade, Serbia, Yugoslavia.

Sa2.96 - Priming of T Cells to Intracranial TSa2.96 - Priming of T Cells to Intracranial TSa2.96 - Priming of T Cells to Intracranial TSa2.96 - Priming of T Cells to Intracranial TSa2.96 - Priming of T Cells to Intracranial Tumor Antigensumor Antigensumor Antigensumor Antigensumor AntigensDoes Not Confer a SurDoes Not Confer a SurDoes Not Confer a SurDoes Not Confer a SurDoes Not Confer a Survival Advantage.vival Advantage.vival Advantage.vival Advantage.vival Advantage.S. Velicu,1 Y. Han,1 I. Ulasov,1 T. Gajewski,1 M. S. Lesniak.1

1Neurosurgery, The University of Chicago, Chicago, IL, USA.

Sa2.97 - An Sa2.97 - An Sa2.97 - An Sa2.97 - An Sa2.97 - An In VIn VIn VIn VIn Vivoivoivoivoivo Role for Role for Role for Role for Role for TTTTTrrrrrypanosoma cruziypanosoma cruziypanosoma cruziypanosoma cruziypanosoma cruzi Calreticulin Calreticulin Calreticulin Calreticulin Calreticulinin Antiangiogenesis.in Antiangiogenesis.in Antiangiogenesis.in Antiangiogenesis.in Antiangiogenesis.M. C. Molina,1 V. Ferreira,1 W. Schwaeble,2 D. Lemus,3 A.Ferreira.1 1Immunology Disciplinary Program, ICBM, Faculty ofMedicine, University of Chile, Santiago, Santiago, Chile; 2Mor-phology Disciplinary Program, ICBM, Faculty of Medicine, Uni-versity of Chile, Santiago, Santiago, Chile; 3Department of Mi-crobiology and Immunology, University of Leicester, Leicester,United Kingdom.

Sa2.98 - Post-TSa2.98 - Post-TSa2.98 - Post-TSa2.98 - Post-TSa2.98 - Post-Transcriptional Control of MICA Expressionranscriptional Control of MICA Expressionranscriptional Control of MICA Expressionranscriptional Control of MICA Expressionranscriptional Control of MICA Expressionby BCR/ABL Oncogene through PI3K/mTOR Pathwayby BCR/ABL Oncogene through PI3K/mTOR Pathwayby BCR/ABL Oncogene through PI3K/mTOR Pathwayby BCR/ABL Oncogene through PI3K/mTOR Pathwayby BCR/ABL Oncogene through PI3K/mTOR Pathway.....N. Boissel,1 D. Rea,3 V. Tieng,1 N. Dulphy,1 M. Brun,1 J.M.Cayuela,4 P. Rousselot,5 R. Tamouza,1 P. Le Bouteiller,6 F.X.Mahon,7 A. Steinle,8 D. Charron,1 H. Dombret,2 A. Toubert.1

1Unite INSERM U396, Laboratoire d’Immunologie etd’Histocompatibilite, Institut Universitaire d’Hematologie, Paris,France; 2Service d’Hematologie Adulte, Hopital Saint-Louis,Paris, France; 3Unite de Therapie Cellulaire et CliniqueTransfusionnelle, Hopital Saint-Louis, Paris, France; 4LaboratoireCentral d’Hematologie, Hopital Saint-Louis, Paris, France; 5Ser-vice d’Onco-Hematologie, Centre Hospitalier de Versailles, LeChesnay, France; 6Unite INSERM U563, Hopital Purpan,Toulouse, France; 7Laboratoire d’Hematologie, CHU de Bor-deaux, Bordeaux, France; 8Institute for Cell Biology, Eberhard-Karls-University, Tuebingen, Germany.

Sa2.99 - Innate Immune Adherence Activity to TSa2.99 - Innate Immune Adherence Activity to TSa2.99 - Innate Immune Adherence Activity to TSa2.99 - Innate Immune Adherence Activity to TSa2.99 - Innate Immune Adherence Activity to Tumor Cellsumor Cellsumor Cellsumor Cellsumor CellsProperProperProperProperProperties of Methotrexate-Loaded Adult and Cord Blood Erties of Methotrexate-Loaded Adult and Cord Blood Erties of Methotrexate-Loaded Adult and Cord Blood Erties of Methotrexate-Loaded Adult and Cord Blood Erties of Methotrexate-Loaded Adult and Cord Blood Eryth-yth-yth-yth-yth-rocytes.rocytes.rocytes.rocytes.rocytes.Wang Xuan. 1Department of Transfusion, Changhai HospitalSecond Military Medical University, Shanghai, China.

Sa2.100 - ErSa2.100 - ErSa2.100 - ErSa2.100 - ErSa2.100 - Erythrocytes Promote the Expression of CXCR4 onythrocytes Promote the Expression of CXCR4 onythrocytes Promote the Expression of CXCR4 onythrocytes Promote the Expression of CXCR4 onythrocytes Promote the Expression of CXCR4 onLeucocyte Membrane Actived by TLeucocyte Membrane Actived by TLeucocyte Membrane Actived by TLeucocyte Membrane Actived by TLeucocyte Membrane Actived by Tumor Cell.umor Cell.umor Cell.umor Cell.umor Cell.Cha Zhanshan. 1Department of Blood Transfusion, ChanghaiHospital Second Military Medical University, Shanghai, China.

Sa2.101 - Cancer Cell Activation Study of Hemaimmune Re-Sa2.101 - Cancer Cell Activation Study of Hemaimmune Re-Sa2.101 - Cancer Cell Activation Study of Hemaimmune Re-Sa2.101 - Cancer Cell Activation Study of Hemaimmune Re-Sa2.101 - Cancer Cell Activation Study of Hemaimmune Re-action Road Map Experimental System.action Road Map Experimental System.action Road Map Experimental System.action Road Map Experimental System.action Road Map Experimental System.Guo Feng. 1Department of Blood Tansfusion, Changhai Hospi-tal Second Military Medical University, Shanghai, China.

Sa2.102 - Apoptosis-Based Therapies for Hematological Ma-Sa2.102 - Apoptosis-Based Therapies for Hematological Ma-Sa2.102 - Apoptosis-Based Therapies for Hematological Ma-Sa2.102 - Apoptosis-Based Therapies for Hematological Ma-Sa2.102 - Apoptosis-Based Therapies for Hematological Ma-lignancies.lignancies.lignancies.lignancies.lignancies.F. Q.B. Alenzi.1 1Department of Medical Laboratory Sciences,King Faisal University, Dammam, Saudi Arabia.

Sa2.103 - The Role of CD4+CD25+ T Cells in Leukemia Re-Sa2.103 - The Role of CD4+CD25+ T Cells in Leukemia Re-Sa2.103 - The Role of CD4+CD25+ T Cells in Leukemia Re-Sa2.103 - The Role of CD4+CD25+ T Cells in Leukemia Re-Sa2.103 - The Role of CD4+CD25+ T Cells in Leukemia Re-lapse after BMTlapse after BMTlapse after BMTlapse after BMTlapse after BMT.....F. Q.B. Alenzi.1 1Department of Medical Laboratory Sciences,King Faisal University, Dammam, Saudi Arabia.

Sa2.104 - The Immunoreactivity of Serum IgA with Gliadin inSa2.104 - The Immunoreactivity of Serum IgA with Gliadin inSa2.104 - The Immunoreactivity of Serum IgA with Gliadin inSa2.104 - The Immunoreactivity of Serum IgA with Gliadin inSa2.104 - The Immunoreactivity of Serum IgA with Gliadin inPatients with Myeloma Multiplex.Patients with Myeloma Multiplex.Patients with Myeloma Multiplex.Patients with Myeloma Multiplex.Patients with Myeloma Multiplex.Zorica D. Juranic,1 Aleksandra I. Konic-Ristic,2 Svetislav Jelic,1

Nenad Milanovic,1 Milica Marinkovic,1 Dusanka Milosevic,1

Jelena Radic,1 Nevenka Stanojevic-Bakic.1 1Experimental On-cology, Institute of Oncology and Radiology of Serbia, Belgrade,Serbia, Yugoslavia; 2Institute of Bromatology, Faculty of Phar-macy, Belgrade, Serbia, Yugoslavia.

Sa2.105 - TSa2.105 - TSa2.105 - TSa2.105 - TSa2.105 - Transcription Factors Abnorranscription Factors Abnorranscription Factors Abnorranscription Factors Abnorranscription Factors Abnormalities Associatedmalities Associatedmalities Associatedmalities Associatedmalities Associatedwith Lwith Lwith Lwith Lwith Lymphoid Malignancies.ymphoid Malignancies.ymphoid Malignancies.ymphoid Malignancies.ymphoid Malignancies.R. Beluzic,1 A. Tomljenovic,1 S. Dzebro,2 M. Dominis,2 M. Antica.11Molecular Medicine, Rudjer Boskovic Institute, Zagreb, Croatia;2Merkur Clinical Hospital, Department of Pathology, Zagreb,Croatia.



Sa2.106 - Generation of Linear and Cyclic Peptides Re-Sa2.106 - Generation of Linear and Cyclic Peptides Re-Sa2.106 - Generation of Linear and Cyclic Peptides Re-Sa2.106 - Generation of Linear and Cyclic Peptides Re-Sa2.106 - Generation of Linear and Cyclic Peptides Re-vealed a Unique Fine Specificity of Rituximab and Its Pos-vealed a Unique Fine Specificity of Rituximab and Its Pos-vealed a Unique Fine Specificity of Rituximab and Its Pos-vealed a Unique Fine Specificity of Rituximab and Its Pos-vealed a Unique Fine Specificity of Rituximab and Its Pos-sible Cross-Reactivity with an Acid Sphingomyelinase-Likesible Cross-Reactivity with an Acid Sphingomyelinase-Likesible Cross-Reactivity with an Acid Sphingomyelinase-Likesible Cross-Reactivity with an Acid Sphingomyelinase-Likesible Cross-Reactivity with an Acid Sphingomyelinase-LikePhosphodiesterase 3B PrecursorPhosphodiesterase 3B PrecursorPhosphodiesterase 3B PrecursorPhosphodiesterase 3B PrecursorPhosphodiesterase 3B Precursor.....Federico Perosa,1 Elvira Favoino,1 Maria Antonietta Caragnano,1Marcella Prete,1 Franco Dammacco.1 1Department of InternalMedicine and Clinical Oncology (DIMO), University of BariMedical School, Bari, Italy.

Sa2.107 - Functional Analysis of Peripheral Blood LSa2.107 - Functional Analysis of Peripheral Blood LSa2.107 - Functional Analysis of Peripheral Blood LSa2.107 - Functional Analysis of Peripheral Blood LSa2.107 - Functional Analysis of Peripheral Blood Lympho-ympho-ympho-ympho-ympho-cytes Subsets in Patients with Cancer-Associated Dermato-cytes Subsets in Patients with Cancer-Associated Dermato-cytes Subsets in Patients with Cancer-Associated Dermato-cytes Subsets in Patients with Cancer-Associated Dermato-cytes Subsets in Patients with Cancer-Associated Dermato-myositis.myositis.myositis.myositis.myositis.A. Ponyi,1,2 M. Aleksza,1 L. Gergely,1 M. Garami,2 T. Constantin,2K. Danko.1 1Division of Clinical Immunology, 3rd Departmentof Internal Medicine, Medical and Health Science Center, Uni-versity of Debrecen, Debrecen, Hungary; 22nd Department ofPediatrics, Faculty of Medicine, Semmelweis University, Budapest,Hungary.

Sa2.108 - Bacteriophage HAP1: Molecular Basis of ItsSa2.108 - Bacteriophage HAP1: Molecular Basis of ItsSa2.108 - Bacteriophage HAP1: Molecular Basis of ItsSa2.108 - Bacteriophage HAP1: Molecular Basis of ItsSa2.108 - Bacteriophage HAP1: Molecular Basis of ItsAntitumour ActivityAntitumour ActivityAntitumour ActivityAntitumour ActivityAntitumour Activity.....K. Dabrowska,1 M. Zembala,2 J. Boratynski,1 M. Kujawa,3 K.Switala-Jelen,1 J. Wietrzyk,1 A. Opolski,1 A. Gorski.1,4 1Instituteof Immunology and Experimental Therapy, Polish Academy ofSciences, Wroclaw, Poland; 2Institute of Catalysis and SurfaceChemistry, Polish Academy of Sciences, Cracow, Poland; 3Cen-ter for Biostructure, Medical University of Warsaw, Warsaw,Poland; 4Transplantation Institute, Medical University of War-saw, Warsaw, Poland.

Sa2.109 - Thy-1Sa2.109 - Thy-1Sa2.109 - Thy-1Sa2.109 - Thy-1Sa2.109 - Thy-1+++++ Immature Natural Killer Cells Suppress Den- Immature Natural Killer Cells Suppress Den- Immature Natural Killer Cells Suppress Den- Immature Natural Killer Cells Suppress Den- Immature Natural Killer Cells Suppress Den-dritic Cell Functions during the Development of Leukemia in adritic Cell Functions during the Development of Leukemia in adritic Cell Functions during the Development of Leukemia in adritic Cell Functions during the Development of Leukemia in adritic Cell Functions during the Development of Leukemia in aMouse Model.Mouse Model.Mouse Model.Mouse Model.Mouse Model.Kazumi Ebata,1 Yukihiro Shimizu,1 Yasuhiro Nakayama,1

Masami Minemura,1 Jun Murakami,1 Tsutomu Kato,1 ToshiroSugiyama,1 Shigeru Saito.2 1Third Department of Internal Medi-cine, Toyama Medical and Pharmaceutical University, Toyama,Toyama, Japan; 2Department of Obstetrics and Gynecology,Toyama Medical and Pharmaceutical University, Toyama,Toyama, Japan.

Sa2.110 - The Application of an Sa2.110 - The Application of an Sa2.110 - The Application of an Sa2.110 - The Application of an Sa2.110 - The Application of an In VitroIn VitroIn VitroIn VitroIn Vitro Viability Assay Fol- Viability Assay Fol- Viability Assay Fol- Viability Assay Fol- Viability Assay Fol-lowed by Subtractive Hybridization for Identification of Prog-lowed by Subtractive Hybridization for Identification of Prog-lowed by Subtractive Hybridization for Identification of Prog-lowed by Subtractive Hybridization for Identification of Prog-lowed by Subtractive Hybridization for Identification of Prog-nostic Markers in Acute Myeloid Leukemia.nostic Markers in Acute Myeloid Leukemia.nostic Markers in Acute Myeloid Leukemia.nostic Markers in Acute Myeloid Leukemia.nostic Markers in Acute Myeloid Leukemia.A. Maha,1 H. F. Seow,1 S. K. Cheong,2 C. F. Leong.2 1ClinicalLaboratory Sciences, Universiti Putra Malaysia, Serdang,Selangor, Malaysia; 2Clinical Haematology & Stem Cell Trans-plantation Services, Hospital University Kebangsaan Malaysia,Bandar Tun Razak, Kuala Lumpur, Malaysia.

Sa2.111 - Expression of Granzyme B and CD86 Is Associ-Sa2.111 - Expression of Granzyme B and CD86 Is Associ-Sa2.111 - Expression of Granzyme B and CD86 Is Associ-Sa2.111 - Expression of Granzyme B and CD86 Is Associ-Sa2.111 - Expression of Granzyme B and CD86 Is Associ-ated with Persistence of Cerated with Persistence of Cerated with Persistence of Cerated with Persistence of Cerated with Persistence of Cervical Cancervical Cancervical Cancervical Cancervical Cancer.....Valeska B. Guzman,1 Andrey Morgun,1 Ismael D.C.G. Silva,2Sylvia M.F. Brenna,2 Carmen R.N. Carvalho,2 Julisa C.L.Ribalta,2 Natalia Shulzhenko,1 Maria Gerbase-de-Lima.1 1Im-munogenetics Division - Pediatrics Department, Federal Univer-sity of Sao Paulo, Sao Paulo, SP, Brazil; 2Gynecology Depart-ment, Federal University of Sao Paulo, Sao Paulo, SP, Brazil.

Sa2.112 - Potent TSa2.112 - Potent TSa2.112 - Potent TSa2.112 - Potent TSa2.112 - Potent Tumoricidal Capacity of Macrophages Ac-umoricidal Capacity of Macrophages Ac-umoricidal Capacity of Macrophages Ac-umoricidal Capacity of Macrophages Ac-umoricidal Capacity of Macrophages Ac-tivated by GcMAF and Therapeutic Use of GcMAF for a Vtivated by GcMAF and Therapeutic Use of GcMAF for a Vtivated by GcMAF and Therapeutic Use of GcMAF for a Vtivated by GcMAF and Therapeutic Use of GcMAF for a Vtivated by GcMAF and Therapeutic Use of GcMAF for a Va-a-a-a-a-riety of Cancers.riety of Cancers.riety of Cancers.riety of Cancers.riety of Cancers.N. Yamamoto,1 M. Urade,2 Y. Koga,1 M. Ueda.1 1MolecularImmunology, Socrates Institute for Therapeutic Immunology, Phila-delphia, PA, USA; 2Oral Surgery, Hyogo College of Medicine,Hyogo, Japan.

Sa2.113 - Clonal B Cells in Blood and Bone Marrow of Pa-Sa2.113 - Clonal B Cells in Blood and Bone Marrow of Pa-Sa2.113 - Clonal B Cells in Blood and Bone Marrow of Pa-Sa2.113 - Clonal B Cells in Blood and Bone Marrow of Pa-Sa2.113 - Clonal B Cells in Blood and Bone Marrow of Pa-tients with a Plasma Cell Dyscrasia- Light Chain Amyloidosis.tients with a Plasma Cell Dyscrasia- Light Chain Amyloidosis.tients with a Plasma Cell Dyscrasia- Light Chain Amyloidosis.tients with a Plasma Cell Dyscrasia- Light Chain Amyloidosis.tients with a Plasma Cell Dyscrasia- Light Chain Amyloidosis.Michelle K. Manske,1 Stephanie Maiden,2 Roshini S. Abraham.11Hematology / Internal Medicine, Mayo Clinic College of Medi-cine, Rochester, MN, USA; 2Department of Biochemistry, Univer-sity of Missouri at Rolla, Rolla, MO, USA.

Sa2.114 - Immunomodulation by Different Forms of a Chi-Sa2.114 - Immunomodulation by Different Forms of a Chi-Sa2.114 - Immunomodulation by Different Forms of a Chi-Sa2.114 - Immunomodulation by Different Forms of a Chi-Sa2.114 - Immunomodulation by Different Forms of a Chi-meric Costimulatormeric Costimulatormeric Costimulatormeric Costimulatormeric Costimulatory Molecule That Selectively Binds to CD28.y Molecule That Selectively Binds to CD28.y Molecule That Selectively Binds to CD28.y Molecule That Selectively Binds to CD28.y Molecule That Selectively Binds to CD28.M. Neighbors,1 J. C.-C. Chang,1 S. Leong,1 R. Ong,1 I. Sipos,1

D. Apt,1 J. Punnonen.1 1Human Therapeutics, Maxygen, Red-wood City, CA, USA.

Sa2.115 - Enhanced Melanoma TSa2.115 - Enhanced Melanoma TSa2.115 - Enhanced Melanoma TSa2.115 - Enhanced Melanoma TSa2.115 - Enhanced Melanoma Tumor Growth in CD28 Defi-umor Growth in CD28 Defi-umor Growth in CD28 Defi-umor Growth in CD28 Defi-umor Growth in CD28 Defi-cient Mice.cient Mice.cient Mice.cient Mice.cient Mice.F. Luhder,1 H. Voigt,2 D. Schrama,2 A. O. Eggert,2 J. C. Becker.2

1Institute for Multiple Sclerosis Research, Georg-August Univer-sity, Gottingen, Germany; 2Department of Dermatology, Julius-Maximilians-University, Wurzburg, Germany.

20052005200520052005ANNUAL MEETING

105



Sa2.116 - ALL and CLL Cells Express Elevated TNF-alpha uponSa2.116 - ALL and CLL Cells Express Elevated TNF-alpha uponSa2.116 - ALL and CLL Cells Express Elevated TNF-alpha uponSa2.116 - ALL and CLL Cells Express Elevated TNF-alpha uponSa2.116 - ALL and CLL Cells Express Elevated TNF-alpha uponStimulation When Compared with Normal B Cells.Stimulation When Compared with Normal B Cells.Stimulation When Compared with Normal B Cells.Stimulation When Compared with Normal B Cells.Stimulation When Compared with Normal B Cells.T. Selvaggi,1 S. Liau,1 M. Michelis,1 G. Mantile-Selvaggi.1 1Spe-cial Diagnostic Immunology Laboratory, Hackensack UniversityMedical Center, Hackensack, NJ, USA.

Sa2.117 - Role of the MAP Kinase Signaling Pathway in theSa2.117 - Role of the MAP Kinase Signaling Pathway in theSa2.117 - Role of the MAP Kinase Signaling Pathway in theSa2.117 - Role of the MAP Kinase Signaling Pathway in theSa2.117 - Role of the MAP Kinase Signaling Pathway in theRegulation of Antigen Expression by Human Melanomas.Regulation of Antigen Expression by Human Melanomas.Regulation of Antigen Expression by Human Melanomas.Regulation of Antigen Expression by Human Melanomas.Regulation of Antigen Expression by Human Melanomas.M. Kono,1 I. S. Dunn,1,2 L. B. Rose,1,2 P. J. Durda,2 J. T. Kurnick.1,2

1Pathology, Massachusetts General Hospital, Boston, MA, USA;2CytoCure, LLC, Beverly, MA, USA.

Sa2.118 - Optimization of a Manufacturing Process of Den-Sa2.118 - Optimization of a Manufacturing Process of Den-Sa2.118 - Optimization of a Manufacturing Process of Den-Sa2.118 - Optimization of a Manufacturing Process of Den-Sa2.118 - Optimization of a Manufacturing Process of Den-dritic Cell Vdritic Cell Vdritic Cell Vdritic Cell Vdritic Cell Vaccine Taccine Taccine Taccine Taccine To To To To To Treat Colorectal Cancerreat Colorectal Cancerreat Colorectal Cancerreat Colorectal Cancerreat Colorectal Cancer.....O. Faure,1 R. Guillermo,1 M. Loudovaris,1 S. M. Lee,1 F. Aono,1

T. Vo,1 L. Ho,1 M. Schilling,1 J. Bender.1 1Product Development/ Manufacturing Departments, IDM, Irvine, CA.

Sa2.119 - Hfgl2 Prothrombinase/Fibroleukin Expression inSa2.119 - Hfgl2 Prothrombinase/Fibroleukin Expression inSa2.119 - Hfgl2 Prothrombinase/Fibroleukin Expression inSa2.119 - Hfgl2 Prothrombinase/Fibroleukin Expression inSa2.119 - Hfgl2 Prothrombinase/Fibroleukin Expression inCancer and Its Potential Clinical Significance.Cancer and Its Potential Clinical Significance.Cancer and Its Potential Clinical Significance.Cancer and Its Potential Clinical Significance.Cancer and Its Potential Clinical Significance.Qin Ning,1 Fang Chen,1 Hanying Sun,1 Weiming Yan,1 WenliLiu.1 1Department of Infectious Disease, Tongji Hospital of TongjiMedical College, Wuhan, Hubei, China.

Sa2.120 - Expression of Stromal Cell-Derived Factor-1 in BrainSa2.120 - Expression of Stromal Cell-Derived Factor-1 in BrainSa2.120 - Expression of Stromal Cell-Derived Factor-1 in BrainSa2.120 - Expression of Stromal Cell-Derived Factor-1 in BrainSa2.120 - Expression of Stromal Cell-Derived Factor-1 in BrainBiopsies from Patients with PrimarBiopsies from Patients with PrimarBiopsies from Patients with PrimarBiopsies from Patients with PrimarBiopsies from Patients with Primary Central Nery Central Nery Central Nery Central Nery Central Nervous Systemvous Systemvous Systemvous Systemvous SystemLLLLLymphoma.ymphoma.ymphoma.ymphoma.ymphoma.J. R. Smith,1 K. M. Falkenhagen,1 R. M. Braziel,2 S. E. Coupland,3J. T. Rosenbaum.1 1Casey Eye Institute, Oregon Health & Sci-ence University, Portland, OR, USA; 2Department of SurgicalPathology, Oregon Health & Science University, Portland, OR,USA; 3Department of Pathology, University Hospital BenjaminFranklin, Berlin, Germany.Sa2.121 - Phase 1-2 Evaluation of Different ImmunotherapySa2.121 - Phase 1-2 Evaluation of Different ImmunotherapySa2.121 - Phase 1-2 Evaluation of Different ImmunotherapySa2.121 - Phase 1-2 Evaluation of Different ImmunotherapySa2.121 - Phase 1-2 Evaluation of Different ImmunotherapyProtocols for GBM.Protocols for GBM.Protocols for GBM.Protocols for GBM.Protocols for GBM.G. A. Moviglia,1 A. Carrizo,1 G. Varela,1 A. Kreutel,1 C. A.Gaeta,1 R. Moya,1 P. Farina,1 H. Costanzo,1 S. Merino,1 M. J.Veloso,1 A. Paes de Lima,1 H. Molina.1 1Immunotherapy, ReginaMater Foundation, Buenos Aires, Argentina.

Sa2.122 - Suppression of Lck Sensitizes Acute LSa2.122 - Suppression of Lck Sensitizes Acute LSa2.122 - Suppression of Lck Sensitizes Acute LSa2.122 - Suppression of Lck Sensitizes Acute LSa2.122 - Suppression of Lck Sensitizes Acute Lymphoblas-ymphoblas-ymphoblas-ymphoblas-ymphoblas-tic T Cells to the Antiproliferative Action of Interferon Alpha.tic T Cells to the Antiproliferative Action of Interferon Alpha.tic T Cells to the Antiproliferative Action of Interferon Alpha.tic T Cells to the Antiproliferative Action of Interferon Alpha.tic T Cells to the Antiproliferative Action of Interferon Alpha.S. M. Chan,1 P. J. Utz.1 1Medicine, Stanford University, Stanford,CA, USA.

Sa2.123 - RegulatorSa2.123 - RegulatorSa2.123 - RegulatorSa2.123 - RegulatorSa2.123 - Regulatory Cells and Human Malignant Gliomas.y Cells and Human Malignant Gliomas.y Cells and Human Malignant Gliomas.y Cells and Human Malignant Gliomas.y Cells and Human Malignant Gliomas.A. Waziri,1 A. T. Ogden,1 R. C.E. Anderson,1 J. N. Bruce,1 D. E.Anderson.2 1Department of Neurological Surgery, ColumbiaUniversity College of Physicians & Surgeons, the Gabriele BartoliBrain Tumor Research Laboratory, the Neurological Institute, NewYork, NY, USA; 2Center for Neurologic Diseases, Harvard Medi-cal School, Boston, MA, USA.

Sa2.124 - TSa2.124 - TSa2.124 - TSa2.124 - TSa2.124 - Transfection of Breast and Lung Cancer Cell Linesransfection of Breast and Lung Cancer Cell Linesransfection of Breast and Lung Cancer Cell Linesransfection of Breast and Lung Cancer Cell Linesransfection of Breast and Lung Cancer Cell Lineswith sHLA-A*0201 and sHLA-B*0702.with sHLA-A*0201 and sHLA-B*0702.with sHLA-A*0201 and sHLA-B*0702.with sHLA-A*0201 and sHLA-B*0702.with sHLA-A*0201 and sHLA-B*0702.M. L. Gonzalez,1 C. M. Roberts,1 A. R. Gilb,1 W. H. Hildebrand.11Microbiology and Immunology, University of Oklahoma HealthSciences Center, Oklahoma City, OK, USA.

Sa2.125 - Serologic Study Using a GSTSa2.125 - Serologic Study Using a GSTSa2.125 - Serologic Study Using a GSTSa2.125 - Serologic Study Using a GSTSa2.125 - Serologic Study Using a GST-Capture ELISA for-Capture ELISA for-Capture ELISA for-Capture ELISA for-Capture ELISA forDeterDeterDeterDeterDetermination of Anti-HPV16 Antibodies in Tmination of Anti-HPV16 Antibodies in Tmination of Anti-HPV16 Antibodies in Tmination of Anti-HPV16 Antibodies in Tmination of Anti-HPV16 Antibodies in Tunisian Wunisian Wunisian Wunisian Wunisian Women.omen.omen.omen.omen.M. Achour, P. Sehr, D. Zeghal, L. Kochbati, F. Zouari, M. Pawlita,R. Oueslati. 1Biology, Faculty of Sciences, Bizerte, Zarzouna,Tunisia; 2DKFZ, Heidelberg, Germany; 3Hospital la Rabta, Tunis,Tunisia; 4Institute Salah Azaiz, Tunis, Tunisia; 5Hospital la Rabta,Tunis, Tunisia; 6DKFZ, Heidelberg, Germany; 7Biology, Facultyof Sciences, Bizerte, Zarzouna, Tunisia.

Immunology of the EyeImmunology of the EyeImmunology of the EyeImmunology of the EyeImmunology of the Eye

Sa2.126 - The Involvement of Autoimmunity Against RetinalSa2.126 - The Involvement of Autoimmunity Against RetinalSa2.126 - The Involvement of Autoimmunity Against RetinalSa2.126 - The Involvement of Autoimmunity Against RetinalSa2.126 - The Involvement of Autoimmunity Against RetinalAntigens in DeterAntigens in DeterAntigens in DeterAntigens in DeterAntigens in Determining Disease Severity in Tmining Disease Severity in Tmining Disease Severity in Tmining Disease Severity in Tmining Disease Severity in Toxoplasmosis.oxoplasmosis.oxoplasmosis.oxoplasmosis.oxoplasmosis.A. L. Vallochi,1 C. Silveira,2 R. Belfort, Jr.,2 L. V. Rizzo.1 1Immu-nology, University of Sao Paulo, Sao Paulo, São Paulo, Brazil;2Ophthalmology, Federal University of Sao Paulo, Sao Paulo,São Paulo, Brazil.

Sa2.127 - Ipsilateral LSa2.127 - Ipsilateral LSa2.127 - Ipsilateral LSa2.127 - Ipsilateral LSa2.127 - Ipsilateral Lymphadenectomy Tymphadenectomy Tymphadenectomy Tymphadenectomy Tymphadenectomy To Inhibit Coro Inhibit Coro Inhibit Coro Inhibit Coro Inhibit CornealnealnealnealnealAllograft Rejection in Rats.Allograft Rejection in Rats.Allograft Rejection in Rats.Allograft Rejection in Rats.Allograft Rejection in Rats.Ling Shiqi, Hu Yanhua. 1Ocular Surface Center, Sun Yat-senUniversity, Guangzhou, Guangdong, China; 2Ophthalmologyof Tongji Medical College, Huazhong University of Science andTechnology.

Sa2.128 - Different Circulating Levels of Endothelin-1 inSa2.128 - Different Circulating Levels of Endothelin-1 inSa2.128 - Different Circulating Levels of Endothelin-1 inSa2.128 - Different Circulating Levels of Endothelin-1 inSa2.128 - Different Circulating Levels of Endothelin-1 inPlasma from Glaucoma Patients.Plasma from Glaucoma Patients.Plasma from Glaucoma Patients.Plasma from Glaucoma Patients.Plasma from Glaucoma Patients.Aida Jimenez-Martinez,1 MaCarmen Jimenez-Martinez,1 VincentKorder.1 1Research Unit, Institute of Opthalmology, Conde deValenciana, Mexico, D.F., Mexico, D.F., Mexico.



Sa2.129 - LPS Stimulation Induce an up Regulation of TLR-4Sa2.129 - LPS Stimulation Induce an up Regulation of TLR-4Sa2.129 - LPS Stimulation Induce an up Regulation of TLR-4Sa2.129 - LPS Stimulation Induce an up Regulation of TLR-4Sa2.129 - LPS Stimulation Induce an up Regulation of TLR-4on Limbal Epithelial Cells without Secretion of TNF-Alpha.on Limbal Epithelial Cells without Secretion of TNF-Alpha.on Limbal Epithelial Cells without Secretion of TNF-Alpha.on Limbal Epithelial Cells without Secretion of TNF-Alpha.on Limbal Epithelial Cells without Secretion of TNF-Alpha.Yonathan Garfias,1 Marisela Linares,1 Raul Suarez,1 AlejandraSanchez-Navarro,1 MaCarmen Jimenez-Martinez.1 1ResearchUnit, Institute of Ophthalmology, Conde de Valenciana, Mexico,D.F., Mexico, D.F., Mexico.

Sa2.130 - CD80 and CD86 Expression on Corneal Epithe-Sa2.130 - CD80 and CD86 Expression on Corneal Epithe-Sa2.130 - CD80 and CD86 Expression on Corneal Epithe-Sa2.130 - CD80 and CD86 Expression on Corneal Epithe-Sa2.130 - CD80 and CD86 Expression on Corneal Epithe-lial Cells Infected with Adenovirus.lial Cells Infected with Adenovirus.lial Cells Infected with Adenovirus.lial Cells Infected with Adenovirus.lial Cells Infected with Adenovirus.MaCarmen Jimenez,1 Herlinda Mejia,1 Marisela Linares,1

Alejandra Sanchez-Navarro,1 Raul Suarez,1 Yonathan Garfias.11Research Unit, Institute of Ophthalmology, Fundacion Condede Valenciana, Mexico, D.F., Mexico, D.F., Mexico.

Sa2.131 - Adamantiades-Behcet’Sa2.131 - Adamantiades-Behcet’Sa2.131 - Adamantiades-Behcet’Sa2.131 - Adamantiades-Behcet’Sa2.131 - Adamantiades-Behcet’s Disease: A Ts Disease: A Ts Disease: A Ts Disease: A Ts Disease: A Trend in Trend in Trend in Trend in Trend in Time.ime.ime.ime.ime.L. I. Kump,1 K. L. Moeller,1 S. Kurup,1 G. F. Reed,1 R. B.Nussenblatt.1 1Laboratory of Immunology, National Eye Insti-tute, NIH, Bethesda, MD, USA.

Sa2.132 - Visual Outcomes in Children with Juvenile Idio-Sa2.132 - Visual Outcomes in Children with Juvenile Idio-Sa2.132 - Visual Outcomes in Children with Juvenile Idio-Sa2.132 - Visual Outcomes in Children with Juvenile Idio-Sa2.132 - Visual Outcomes in Children with Juvenile Idio-pathic Arthritis-Associated Uveitis.pathic Arthritis-Associated Uveitis.pathic Arthritis-Associated Uveitis.pathic Arthritis-Associated Uveitis.pathic Arthritis-Associated Uveitis.L. I. Kump,1,2 R. A. Cervantes Castaneda,1 S. N. Androudi,1 G.F. Reed,2 C. S. Foster.1 1Ocular Immunology and Uveitis Ser-vice, Massachusetts Eye and Ear Infirmary, Boston, MA, USA;2Laboratory of Immunology, National Eye Institute, NIH, Bethesda,MD, USA.Sa2.133 - Increased Expression of ISa2.133 - Increased Expression of ISa2.133 - Increased Expression of ISa2.133 - Increased Expression of ISa2.133 - Increased Expression of IκκκκκBBBBBααααα Per Per Per Per Permits Tmits Tmits Tmits Tmits ToleranceoleranceoleranceoleranceoleranceInduction by TGFInduction by TGFInduction by TGFInduction by TGFInduction by TGFβββββ-T-T-T-T-Treated Antigen Presenting Cells.reated Antigen Presenting Cells.reated Antigen Presenting Cells.reated Antigen Presenting Cells.reated Antigen Presenting Cells.A. P. Ghafoori,1 B. Turpie,2 J. W. Streilein,2 S. Masli.2 1HMS,Harvard Medical School, Boston, MA, USA; 2Department ofOphthalmology, Schepen Eye Research Institute,Harvard Medi-cal School, Boston, MA, USA.

Sa2.134 - CD36 and Thrombospondin Interaction Is Essen-Sa2.134 - CD36 and Thrombospondin Interaction Is Essen-Sa2.134 - CD36 and Thrombospondin Interaction Is Essen-Sa2.134 - CD36 and Thrombospondin Interaction Is Essen-Sa2.134 - CD36 and Thrombospondin Interaction Is Essen-tial for the Ttial for the Ttial for the Ttial for the Ttial for the Tolerance Inducing Properolerance Inducing Properolerance Inducing Properolerance Inducing Properolerance Inducing Properties of TGFties of TGFties of TGFties of TGFties of TGFβββββ-T-T-T-T-TreatedreatedreatedreatedreatedAntigen Presenting Cells.Antigen Presenting Cells.Antigen Presenting Cells.Antigen Presenting Cells.Antigen Presenting Cells.S. Masli,1 B. Turpie,1 J. W. Streilein.1 1Department of Ophthal-mology, Schepens Eye Research Institute, Harvard MedicalSchool, Boston, MA, USA.

Sa2.135 - Sa2.135 - Sa2.135 - Sa2.135 - Sa2.135 - α α α α α Blocking Therapy in Patients with EndogeneousBlocking Therapy in Patients with EndogeneousBlocking Therapy in Patients with EndogeneousBlocking Therapy in Patients with EndogeneousBlocking Therapy in Patients with EndogeneousUveitis.Uveitis.Uveitis.Uveitis.Uveitis.P.M. Van Hagen for the RESCU study group. Erasmus MCRotterdam and, Eye Hospital Rotterdam, The Netherlands

Poster Session 1Poster Session 1Poster Session 1Poster Session 1Poster Session 1SundaySundaySundaySundaySunday, May 15, 2005, May 15, 2005, May 15, 2005, May 15, 2005, May 15, 2005


Cytokines/ChemokinesCytokines/ChemokinesCytokines/ChemokinesCytokines/ChemokinesCytokines/Chemokines

Su1.01 - STSu1.01 - STSu1.01 - STSu1.01 - STSu1.01 - STAAAAATTTTT-1 Mediates the Stimulator-1 Mediates the Stimulator-1 Mediates the Stimulator-1 Mediates the Stimulator-1 Mediates the Stimulatory Effect of IL-10 ony Effect of IL-10 ony Effect of IL-10 ony Effect of IL-10 ony Effect of IL-10 onCD14 Expression in Human Monocytic Cells.CD14 Expression in Human Monocytic Cells.CD14 Expression in Human Monocytic Cells.CD14 Expression in Human Monocytic Cells.CD14 Expression in Human Monocytic Cells.A. A. Rahim Rahimi,1 K. Gee,3 S. Mishra,1 W. Lim,1 A. Kumar.1,2,3

1Departments of Biochemistry, Microbiology and Immunology,University of Ottawa; 2Pathology and Laboratory Medicine,University of Ottawa; 3Division of Virology and Molecular Immu-nology, Research Institute, Children’s Hospital of Eastern Ontario,Ottawa, ON, Canada.

Su1.02 - Altered Cytokine Production and Reduced MembraneSu1.02 - Altered Cytokine Production and Reduced MembraneSu1.02 - Altered Cytokine Production and Reduced MembraneSu1.02 - Altered Cytokine Production and Reduced MembraneSu1.02 - Altered Cytokine Production and Reduced MembraneSignaling through the Antigen Receptor in CD4+ T CellsSignaling through the Antigen Receptor in CD4+ T CellsSignaling through the Antigen Receptor in CD4+ T CellsSignaling through the Antigen Receptor in CD4+ T CellsSignaling through the Antigen Receptor in CD4+ T CellsOverexpressing LOverexpressing LOverexpressing LOverexpressing LOverexpressing Ly-6A.2 Molecule.y-6A.2 Molecule.y-6A.2 Molecule.y-6A.2 Molecule.y-6A.2 Molecule.Anil Bamezai, Jennifer Reed, Abraham Chacko. 1Biology De-partment, Villanova University, Villanova, PA, USA.

Su1.03 - LSu1.03 - LSu1.03 - LSu1.03 - LSu1.03 - Lymphocytes Demonstrate Different Functioningymphocytes Demonstrate Different Functioningymphocytes Demonstrate Different Functioningymphocytes Demonstrate Different Functioningymphocytes Demonstrate Different FunctioningChanges Induced by Exogenous PDGF-AB and TGF-b In VitroChanges Induced by Exogenous PDGF-AB and TGF-b In VitroChanges Induced by Exogenous PDGF-AB and TGF-b In VitroChanges Induced by Exogenous PDGF-AB and TGF-b In VitroChanges Induced by Exogenous PDGF-AB and TGF-b In Vitroat Cerebral and Coronarat Cerebral and Coronarat Cerebral and Coronarat Cerebral and Coronarat Cerebral and Coronary Atherosclerosis: What Is Estab-y Atherosclerosis: What Is Estab-y Atherosclerosis: What Is Estab-y Atherosclerosis: What Is Estab-y Atherosclerosis: What Is Estab-lished?lished?lished?lished?lished?Andrei I. Teplyakov.1 1Resrarch Institute for Ecopathology andOccupational Diseases, Mogilev, Belarus.

Su1.04 - Live Measurement of Chemokine TSu1.04 - Live Measurement of Chemokine TSu1.04 - Live Measurement of Chemokine TSu1.04 - Live Measurement of Chemokine TSu1.04 - Live Measurement of Chemokine Triggered Integrinriggered Integrinriggered Integrinriggered Integrinriggered IntegrinActivation on a Single-Molecule Level.Activation on a Single-Molecule Level.Activation on a Single-Molecule Level.Activation on a Single-Molecule Level.Activation on a Single-Molecule Level.R. H. Eibl.1 1Institute of Pathology, Technical University of Munich,Munich, Germany.

Su1.05 - Sp1 Binding Site of TGF-beta1 Promoter Is the TSu1.05 - Sp1 Binding Site of TGF-beta1 Promoter Is the TSu1.05 - Sp1 Binding Site of TGF-beta1 Promoter Is the TSu1.05 - Sp1 Binding Site of TGF-beta1 Promoter Is the TSu1.05 - Sp1 Binding Site of TGF-beta1 Promoter Is the Tararararar-----get for Tget for Tget for Tget for Tget for Trans-Activation by HPVrans-Activation by HPVrans-Activation by HPVrans-Activation by HPVrans-Activation by HPV-16 E6 and E7 Oncoproteins.-16 E6 and E7 Oncoproteins.-16 E6 and E7 Oncoproteins.-16 E6 and E7 Oncoproteins.-16 E6 and E7 Oncoproteins.O. Peralta-Zaragoza,1 V. Bermudez-Morales,1 M. Bahena-Ro-man,1 J. Alcocer-Gonzalez,2 F. Recillas-Targa,3 V. Madrid-Ma-rina.1 1Division of Pathogens Molecular Biology, National Insti-tute of Public Health from Mexico, Cuernavaca, Morelos, Mexico;2School of Biological Sciences, Autonomous University of NuevoLeon, Monterrey, Nuevo Leon, Mexico; 3Department of Molecu-lar Genetics, Institute of Cellular Physiology, National Autono-mous University of Mexico, Mexico, DF, Mexico.

20052005200520052005ANNUAL MEETING

107



Su1.06 - Orexin-A Has Delayed Reponse to Intestinal Ischemia-Su1.06 - Orexin-A Has Delayed Reponse to Intestinal Ischemia-Su1.06 - Orexin-A Has Delayed Reponse to Intestinal Ischemia-Su1.06 - Orexin-A Has Delayed Reponse to Intestinal Ischemia-Su1.06 - Orexin-A Has Delayed Reponse to Intestinal Ischemia-ReperReperReperReperReperfusion Injurfusion Injurfusion Injurfusion Injurfusion Injuryyyyy.....Ji Lin,1 Guang-Tao Yan,1 Xiu-Hua Hao,1 Lu-Huan Wang,1 KaiZhang.1 1Research Laboratory of Biochemistry, Basic MedicalInstitute,General Hospital of P.L.A, Beijing, Beijing, China.

Su1.07 - Increased Interleukin-6 Serum Levels in Subjects withSu1.07 - Increased Interleukin-6 Serum Levels in Subjects withSu1.07 - Increased Interleukin-6 Serum Levels in Subjects withSu1.07 - Increased Interleukin-6 Serum Levels in Subjects withSu1.07 - Increased Interleukin-6 Serum Levels in Subjects withMetabolic Syndrome.Metabolic Syndrome.Metabolic Syndrome.Metabolic Syndrome.Metabolic Syndrome.I. N. Kondratska,1 B. N. Mankovsky.1 1Diabetes, Institute ofEndocrinology, Kiev, Ukraine.

Su1.08 - LIGHT Regulates CD86 Expression on Dendritic CellsSu1.08 - LIGHT Regulates CD86 Expression on Dendritic CellsSu1.08 - LIGHT Regulates CD86 Expression on Dendritic CellsSu1.08 - LIGHT Regulates CD86 Expression on Dendritic CellsSu1.08 - LIGHT Regulates CD86 Expression on Dendritic Cellsthrough NF-kB, but Neither p44/42 MAPK nor JNK/AP-1 Sig-through NF-kB, but Neither p44/42 MAPK nor JNK/AP-1 Sig-through NF-kB, but Neither p44/42 MAPK nor JNK/AP-1 Sig-through NF-kB, but Neither p44/42 MAPK nor JNK/AP-1 Sig-through NF-kB, but Neither p44/42 MAPK nor JNK/AP-1 Sig-nal Tnal Tnal Tnal Tnal Transduction Pathwayransduction Pathwayransduction Pathwayransduction Pathwayransduction Pathway.....G. M. Zou,1 W. Y. Hu.2 1Bone Marrow Transplantation, RushUniversity Medical Center, Chicago, IL, USA; 2Physiology andBiophysics, University of Illinois at Chicago, Chicago, IL, USA.

Su1.09 - An ImporSu1.09 - An ImporSu1.09 - An ImporSu1.09 - An ImporSu1.09 - An Important Role of Inducible Histamine in Ptant Role of Inducible Histamine in Ptant Role of Inducible Histamine in Ptant Role of Inducible Histamine in Ptant Role of Inducible Histamine in P.acnes-.acnes-.acnes-.acnes-.acnes-Primed and LPS-Induced Hepatitis in Mice.Primed and LPS-Induced Hepatitis in Mice.Primed and LPS-Induced Hepatitis in Mice.Primed and LPS-Induced Hepatitis in Mice.Primed and LPS-Induced Hepatitis in Mice.M. Nishibori,1 H. K. Takahashi,1 M. Yokoyama,1 A. Yokoyama,1T. Yoshino,2 T. Watanabe,3 T. Watanabe,4 H. Ohtsu,5 H. Wake,1S. Mori.1 1Department of Pharmacology, Okayama Univ GradSchl of Med & Dent, Okayama, Okayama, Japan; 2Depart-ment of Pathology, Okayama Univ Grad Schl of Med & Dent,Okayama, Okayama, Japan; 3Department of Mol Immunology,Kyushu Univ, Fukuoka, Fukuoka, Japan; 4Department of Phar-macology, Tohoku Univ Gad Schl Med, Sendai, Miyagi, Ja-pan; 5Department of Appl Quant Med Eng, Tohoku Univ GradSchl Eng, Sendai, Miyagi, Japan.Su1.10 - Receptors for VSu1.10 - Receptors for VSu1.10 - Receptors for VSu1.10 - Receptors for VSu1.10 - Receptors for Vascular Endothelial Growth Factorascular Endothelial Growth Factorascular Endothelial Growth Factorascular Endothelial Growth Factorascular Endothelial Growth Factor(VEGF) on Murine L(VEGF) on Murine L(VEGF) on Murine L(VEGF) on Murine L(VEGF) on Murine Lymphocytes and Macrophages.ymphocytes and Macrophages.ymphocytes and Macrophages.ymphocytes and Macrophages.ymphocytes and Macrophages.Ekaterina P. Kisseleva,1 Andrei V. Krylov,1 Victoria I. Lioudyno.1

1Immunology, Institute for Experimental Medicine, St.Petersburg,Russian Federation.

Su1.11 - Modulation of Suppressor of Cytokine Signalling 3Su1.11 - Modulation of Suppressor of Cytokine Signalling 3Su1.11 - Modulation of Suppressor of Cytokine Signalling 3Su1.11 - Modulation of Suppressor of Cytokine Signalling 3Su1.11 - Modulation of Suppressor of Cytokine Signalling 3(SOCS3) Expression and Stability in Human Neutrophils and(SOCS3) Expression and Stability in Human Neutrophils and(SOCS3) Expression and Stability in Human Neutrophils and(SOCS3) Expression and Stability in Human Neutrophils and(SOCS3) Expression and Stability in Human Neutrophils andin Differentiated PLB-985 Cells by G-CSFin Differentiated PLB-985 Cells by G-CSFin Differentiated PLB-985 Cells by G-CSFin Differentiated PLB-985 Cells by G-CSFin Differentiated PLB-985 Cells by G-CSF, GM-CSF and IL-4., GM-CSF and IL-4., GM-CSF and IL-4., GM-CSF and IL-4., GM-CSF and IL-4.C. Ratthe,1 D. Girard.1 1INRS, Institut Armand-Frappier, Pointe-Claire, QC, Canada.

Su1.12 - Quantification of mRNA Expression of TNF-Su1.12 - Quantification of mRNA Expression of TNF-Su1.12 - Quantification of mRNA Expression of TNF-Su1.12 - Quantification of mRNA Expression of TNF-Su1.12 - Quantification of mRNA Expression of TNF-α α α α α andandandandandTGFTGFTGFTGFTGFβ−β−β−β−β−, Fas, TNFR1 and 2 Using Real-T, Fas, TNFR1 and 2 Using Real-T, Fas, TNFR1 and 2 Using Real-T, Fas, TNFR1 and 2 Using Real-T, Fas, TNFR1 and 2 Using Real-Time Quantitative Rime Quantitative Rime Quantitative Rime Quantitative Rime Quantitative RTTTTT-----PCR.PCR.PCR.PCR.PCR.F. Q.B. Alenzi. 1Department of Medical Laboratory Sciences,King Faisal University, Dammam, Saudi Arabia.

Su1.13 - Role of TWEAK, a Member of the TNFa Family ofSu1.13 - Role of TWEAK, a Member of the TNFa Family ofSu1.13 - Role of TWEAK, a Member of the TNFa Family ofSu1.13 - Role of TWEAK, a Member of the TNFa Family ofSu1.13 - Role of TWEAK, a Member of the TNFa Family ofCytokines, in Arthritis.Cytokines, in Arthritis.Cytokines, in Arthritis.Cytokines, in Arthritis.Cytokines, in Arthritis.S. Perper,1 B. Browning,2 C. Gao,1 K. Giza,1 L. Rajman,3 L.Runkel,3 M. Scott,3 L. C. Burkly,2 T. Zheng,2 H. Hess.1

1Immunopharmacology, Biogen Idec, Cambridge, MA, USA;2Exploratory Science, Biogen Idec, Inc, Cambridge, MA, USA;3Validation Genetics, Biogen Idec, Inc, Cambridge, MA, USA.

Su1.14 - The Anti-Proliferative Effect of Infliximab on TSu1.14 - The Anti-Proliferative Effect of Infliximab on TSu1.14 - The Anti-Proliferative Effect of Infliximab on TSu1.14 - The Anti-Proliferative Effect of Infliximab on TSu1.14 - The Anti-Proliferative Effect of Infliximab on T-Cells Is-Cells Is-Cells Is-Cells Is-Cells IsPrevented by CD28 Induced Co-Stimulation.Prevented by CD28 Induced Co-Stimulation.Prevented by CD28 Induced Co-Stimulation.Prevented by CD28 Induced Co-Stimulation.Prevented by CD28 Induced Co-Stimulation.B. Gunnlaugsdottir,1,2 S. M. Maggadottir,1,2,3 B. R. Ludviksson.1,2,3

1Center for Rheumatology Research, Landspitali - University Hos-pital, Reykjavik, Iceland; 2Institute of Laboratory Medicine, De-partment of Immunology, Landspitali - University Hospital,Reykjavik, Iceland; 3Department of Medicine, University of Ice-land, Reykjavik, Iceland.

Su1.15 - Lack of Linkage between DNA Methylation andSu1.15 - Lack of Linkage between DNA Methylation andSu1.15 - Lack of Linkage between DNA Methylation andSu1.15 - Lack of Linkage between DNA Methylation andSu1.15 - Lack of Linkage between DNA Methylation andInterleukine-10 Gene Expression.Interleukine-10 Gene Expression.Interleukine-10 Gene Expression.Interleukine-10 Gene Expression.Interleukine-10 Gene Expression.Jun Dong,1 Claudia Ivascu,2 Florian Eckhardt,2 Hyun-DongChang,3 Carolina Haefliger,2 Lars Tykocinski,3 Martin Rudwaleit,4Jochiem Sieper,4 Andreas Radbruch,3 Andreas Thiel.1 1ClinicalImmunology, German Rheumatism Research Center, Berlin, Ger-many; 2Epigenomics, Berlin, Germany; 3Cell Biology, GermanRheumatism Research Center, Berlin, Germany; 4Rheumatology,Charite Campus Benjamin Franklin, Berlin, Germany.

Su1.16 - Epigenetic Regulation of TNF alpha in Monocytes/Su1.16 - Epigenetic Regulation of TNF alpha in Monocytes/Su1.16 - Epigenetic Regulation of TNF alpha in Monocytes/Su1.16 - Epigenetic Regulation of TNF alpha in Monocytes/Su1.16 - Epigenetic Regulation of TNF alpha in Monocytes/Macrophages.Macrophages.Macrophages.Macrophages.Macrophages.K. E. Sullivan,1 K. Dietzmann,1 A. R. Suriano,1 A. N. Sanford,1

M. A. Petri, M. Bhatia,2 B. Aramati.1 1Allergy Immunology,Children’s Hospital of Philadelphia, Philadelphia, PA, USA;2Stem Cell Biology, Robarts Research Institute, London, ON,Canada; 3Rheumatology, Johns Hopkins University School ofMedicine, Baltimore, MD, USA.



Su1.17 - A Fast and Robust Multiplexed Immunoassay PanelSu1.17 - A Fast and Robust Multiplexed Immunoassay PanelSu1.17 - A Fast and Robust Multiplexed Immunoassay PanelSu1.17 - A Fast and Robust Multiplexed Immunoassay PanelSu1.17 - A Fast and Robust Multiplexed Immunoassay Panelfor Simultaneously Quantifying 24 Cytokines/Chemokinesfor Simultaneously Quantifying 24 Cytokines/Chemokinesfor Simultaneously Quantifying 24 Cytokines/Chemokinesfor Simultaneously Quantifying 24 Cytokines/Chemokinesfor Simultaneously Quantifying 24 Cytokines/Chemokinesin Rat Serum or Plasma Using Luminex xMAP Tin Rat Serum or Plasma Using Luminex xMAP Tin Rat Serum or Plasma Using Luminex xMAP Tin Rat Serum or Plasma Using Luminex xMAP Tin Rat Serum or Plasma Using Luminex xMAP Technologyechnologyechnologyechnologyechnology.....S. Ji,1 T. Whitehead,1 H. Hwang,1 R. Rick,1 J. Mistry.1 1. R&D,LINCO Research, St. Charles, MO, USA.

Su1.18 - Markers of Inflammation, Vitamin E and PeripheralSu1.18 - Markers of Inflammation, Vitamin E and PeripheralSu1.18 - Markers of Inflammation, Vitamin E and PeripheralSu1.18 - Markers of Inflammation, Vitamin E and PeripheralSu1.18 - Markers of Inflammation, Vitamin E and PeripheralNerNerNerNerNervous System Function. The InCHIANTI Studyvous System Function. The InCHIANTI Studyvous System Function. The InCHIANTI Studyvous System Function. The InCHIANTI Studyvous System Function. The InCHIANTI Study.....R. Paganelli,1 A. Di Iorio,1 L. Ferrucci,2 E. Sparvieri,1 A. Michetti,1C. Franceschi,4 A. Cherubini,3 U. Senin,3 G. Abate.1 1Depart-ment of Medicine and Sciences of Aging, University G.d’Annunzio, Chieti, Italy; 2Longitudinal Studies Section, ClinicalResearch Branch, NIH, Baltimore, MD, USA; 3Institute of Geron-tology and Geriatrics, University of Perugia, Perugia, Italy; 4De-partment of Biomedical Sciences, University of Bologna, Bolo-gna, Italy.

Su1.19 - Protective Effect of Galectins Against the General-Su1.19 - Protective Effect of Galectins Against the General-Su1.19 - Protective Effect of Galectins Against the General-Su1.19 - Protective Effect of Galectins Against the General-Su1.19 - Protective Effect of Galectins Against the General-ized Shwartzman Reaction of Mice.ized Shwartzman Reaction of Mice.ized Shwartzman Reaction of Mice.ized Shwartzman Reaction of Mice.ized Shwartzman Reaction of Mice.Ryusuke Nakagawa,1 Hiroko Abe,1 Mitsuomi Hirashima,2 AkiraYamauchi.1 1Cell Regulation, Kagawa University, School ofMedicine, Kita-gun, Miki-cho, Kagawa, Japan; 2Immunologyand Immunopathplogy, Kagawa University, School of Medicine,Kita-gun, Miki-cho, Kita-gun, Miki-cho, Japan.

Su1.20 - Analysis of Cytokine Network for Initiation of Im-Su1.20 - Analysis of Cytokine Network for Initiation of Im-Su1.20 - Analysis of Cytokine Network for Initiation of Im-Su1.20 - Analysis of Cytokine Network for Initiation of Im-Su1.20 - Analysis of Cytokine Network for Initiation of Im-mune Responses in the Hyperplastic Thymus Associated withmune Responses in the Hyperplastic Thymus Associated withmune Responses in the Hyperplastic Thymus Associated withmune Responses in the Hyperplastic Thymus Associated withmune Responses in the Hyperplastic Thymus Associated withMyasthenia Gravis.Myasthenia Gravis.Myasthenia Gravis.Myasthenia Gravis.Myasthenia Gravis.I. Kamo,1 A. Kikuchi,2 H. Tomoyasu,3 N. Sakuragawa.1 1Re-generative Medicine, School of Medicine, Toho University,Sagamihara, Kanagawa, Japan; 2Ultrastracuture, National In-stitute of Neuroscience, Kodaira, Tokyo, Japan; 3Respiratoy, Ja-pan Red Cross, Ohmori, Tokyo, Japan.Su1.21 - Age-Related Changes in Cytokine Production inSu1.21 - Age-Related Changes in Cytokine Production inSu1.21 - Age-Related Changes in Cytokine Production inSu1.21 - Age-Related Changes in Cytokine Production inSu1.21 - Age-Related Changes in Cytokine Production inCherCherCherCherChernobyl Clean-up Wnobyl Clean-up Wnobyl Clean-up Wnobyl Clean-up Wnobyl Clean-up Workers from Latvia.orkers from Latvia.orkers from Latvia.orkers from Latvia.orkers from Latvia.Natalja Kurjane,1 Natalija Gabrusheva,2 Ruta Bruvere,2 ElviraHagina,3 Tija Zvagule,1 Arija Volrate,4 Guna Feldmane.4 1Cen-tre of Occupational and Radiological Medicine, P.Stradins Uni-versity Hospital, Riga, Latvia; 2Biomedical Research and StudyCentre, University of Latvia, Riga, Latvia; 3Institute of Immunol-ogy, Riga, Latvia; 4Institute of Virology and Microbiology, Riga,Latvia.

Su1.22 - Phosphodiesterase Regulation of TNF-Su1.22 - Phosphodiesterase Regulation of TNF-Su1.22 - Phosphodiesterase Regulation of TNF-Su1.22 - Phosphodiesterase Regulation of TNF-Su1.22 - Phosphodiesterase Regulation of TNF-α α α α α ExpressionExpressionExpressionExpressionExpressionafter Spinal Cord Injurafter Spinal Cord Injurafter Spinal Cord Injurafter Spinal Cord Injurafter Spinal Cord Injuryyyyy.....S. M. Schaal, M. Perez, A. E. Marcillo, W. D. Dietrich, D. D.Pearse. 1Miami Project To Cure Paralysis, Departments of Neu-rological Surgery, Neurology, and Cell Biology and Anatomy,Miller School of Medicine, Miami, FL, USA.

Su1.23 - Analysis of IL-27 (EBI3/p28) Expression in EBVSu1.23 - Analysis of IL-27 (EBI3/p28) Expression in EBVSu1.23 - Analysis of IL-27 (EBI3/p28) Expression in EBVSu1.23 - Analysis of IL-27 (EBI3/p28) Expression in EBVSu1.23 - Analysis of IL-27 (EBI3/p28) Expression in EBV- and- and- and- and- andHTLHTLHTLHTLHTLVVVVV-1-Associated L-1-Associated L-1-Associated L-1-Associated L-1-Associated Lymphomas: Heterogeneous Expression ofymphomas: Heterogeneous Expression ofymphomas: Heterogeneous Expression ofymphomas: Heterogeneous Expression ofymphomas: Heterogeneous Expression ofEBI3 Subunit by TEBI3 Subunit by TEBI3 Subunit by TEBI3 Subunit by TEBI3 Subunit by Tumoral Cells.umoral Cells.umoral Cells.umoral Cells.umoral Cells.F. Larousserie,1,2 E. Bardel,1 S. Pflanz,3 B. Arnulf,4 C. Lome-Maldonado,5 O. Hermine,1 L. Bregeaud,2 M. Perennec,2 N.Brousse,2 R. Kastelein,3 O. Devergne.1 1CNRS UMR 8147,Universite Paris V, IFR Necker, Paris, France; 2UPRES EA 219,Hopital Necker, Paris, France; 3DNAX Research Institute, PaloAlto, CA, USA; 4Service d’Immuno-Hematologie, Hopital Saint-Louis, Paris, France; 5Department of Pathology, Instituto Salva-dor Zubiran, Mexico City, Mexico.

Su1.24 - Pin1 Regulates Cytokine Expression in Human Pe-Su1.24 - Pin1 Regulates Cytokine Expression in Human Pe-Su1.24 - Pin1 Regulates Cytokine Expression in Human Pe-Su1.24 - Pin1 Regulates Cytokine Expression in Human Pe-Su1.24 - Pin1 Regulates Cytokine Expression in Human Pe-ripheral Blood Mononuclear Cells.ripheral Blood Mononuclear Cells.ripheral Blood Mononuclear Cells.ripheral Blood Mononuclear Cells.ripheral Blood Mononuclear Cells.S. J. Esnault,1 Z. J. Shen,1 J. S. Malter.1 1Pathology and Labora-tory Medicine, Waisman Center, University of Wisconsin, Madi-son, WI, USA.

Su1.25 - Cytokine and Enzyme Spectrum in TSu1.25 - Cytokine and Enzyme Spectrum in TSu1.25 - Cytokine and Enzyme Spectrum in TSu1.25 - Cytokine and Enzyme Spectrum in TSu1.25 - Cytokine and Enzyme Spectrum in TracheobronchialracheobronchialracheobronchialracheobronchialracheobronchialAspirate of NewborAspirate of NewborAspirate of NewborAspirate of NewborAspirate of Newborns with Pneumonia Tns with Pneumonia Tns with Pneumonia Tns with Pneumonia Tns with Pneumonia Treated with Recom-reated with Recom-reated with Recom-reated with Recom-reated with Recom-binant IL2.binant IL2.binant IL2.binant IL2.binant IL2.Dilbar Kajumova,1 Leonid Nikulin,1 Oleg Borovikov.2 1PediatricDepartment, Kuban State Medical Academy, Krasnodar, Rus-sian Federation; 2Clinical Immunology and Allergy, Kuban StateMedical Academy, Krasnodar, Russian Federation.

Su1.26 - Cytokines and Anticytokines Therapy in Severe AcuteSu1.26 - Cytokines and Anticytokines Therapy in Severe AcuteSu1.26 - Cytokines and Anticytokines Therapy in Severe AcuteSu1.26 - Cytokines and Anticytokines Therapy in Severe AcuteSu1.26 - Cytokines and Anticytokines Therapy in Severe AcutePancreatitis.Pancreatitis.Pancreatitis.Pancreatitis.Pancreatitis.S. Chooklin,1 A. Perejaslov.1 1Department of Surgery, MedicalUniversity, Lviv, Ukraine.

20052005200520052005ANNUAL MEETING

109



Su1.27 - Cytokine Production by Dendritic Cells StimulatedSu1.27 - Cytokine Production by Dendritic Cells StimulatedSu1.27 - Cytokine Production by Dendritic Cells StimulatedSu1.27 - Cytokine Production by Dendritic Cells StimulatedSu1.27 - Cytokine Production by Dendritic Cells Stimulatedwith Microbial Products Modulated by Epigallocatechinwith Microbial Products Modulated by Epigallocatechinwith Microbial Products Modulated by Epigallocatechinwith Microbial Products Modulated by Epigallocatechinwith Microbial Products Modulated by EpigallocatechinGallate (EGCG).Gallate (EGCG).Gallate (EGCG).Gallate (EGCG).Gallate (EGCG).J. Rogers,1 I. Perkins,1 A. van Olphen,1 N. Burdash,1 T. W. Klein,1H. Friedman.1 1Medical Microbiology and Immunology, Uni-versity of South Florida College of Medicine, Tampa, FL, USA.

Su1.28 - TSG-6 Protein Up-Regulates Cyclooxygenase-2 Ex-Su1.28 - TSG-6 Protein Up-Regulates Cyclooxygenase-2 Ex-Su1.28 - TSG-6 Protein Up-Regulates Cyclooxygenase-2 Ex-Su1.28 - TSG-6 Protein Up-Regulates Cyclooxygenase-2 Ex-Su1.28 - TSG-6 Protein Up-Regulates Cyclooxygenase-2 Ex-pression and Prostaglandin Biosynthesis in Macrophage Cellpression and Prostaglandin Biosynthesis in Macrophage Cellpression and Prostaglandin Biosynthesis in Macrophage Cellpression and Prostaglandin Biosynthesis in Macrophage Cellpression and Prostaglandin Biosynthesis in Macrophage CellLine.Line.Line.Line.Line.C. Mindrescu,1 J. Le,1 H.-G. Wisniewski,1 J. Vilcek.1 1Depart-ment of Microbiology, New York University, School of Medicine,New York, NY, USA.

Su1.29 - The Experimental Study on the Antitumor Effect of 4-Su1.29 - The Experimental Study on the Antitumor Effect of 4-Su1.29 - The Experimental Study on the Antitumor Effect of 4-Su1.29 - The Experimental Study on the Antitumor Effect of 4-Su1.29 - The Experimental Study on the Antitumor Effect of 4-1BBL 1BBL 1BBL 1BBL 1BBL In VivoIn VivoIn VivoIn VivoIn Vivo.....Li Qiaoxia, Shan Baoen. 1Research Center, The Fourth Hospitalof Hebei Medical University, Shijiazhuang, Hebei, China; 2Re-search Center, The Fourth Hospital of Hebei Medical University,Shijiazhuang, Hebei, China.

Su1.30 - Enhanced Immunol Efficacy of mIL-23 Gene Modi-Su1.30 - Enhanced Immunol Efficacy of mIL-23 Gene Modi-Su1.30 - Enhanced Immunol Efficacy of mIL-23 Gene Modi-Su1.30 - Enhanced Immunol Efficacy of mIL-23 Gene Modi-Su1.30 - Enhanced Immunol Efficacy of mIL-23 Gene Modi-fied Tfied Tfied Tfied Tfied Tumor Vumor Vumor Vumor Vumor Vaccine.accine.accine.accine.accine.Shan Banen, H.A.O. Jingsheng. 1Research Center, The FourthHospital of Hebei Medical University, Shijiazhuang, Hebei,China; 2Research Center, The Fourth Hospital of Hebei MedicalUniversity, Shijiazhuang, Hebei, China.

Su1.31 - Expressions of mIL-23 Gene in Murine Colon Carci-Su1.31 - Expressions of mIL-23 Gene in Murine Colon Carci-Su1.31 - Expressions of mIL-23 Gene in Murine Colon Carci-Su1.31 - Expressions of mIL-23 Gene in Murine Colon Carci-Su1.31 - Expressions of mIL-23 Gene in Murine Colon Carci-noma Cells Induces Production of NO and TNF-noma Cells Induces Production of NO and TNF-noma Cells Induces Production of NO and TNF-noma Cells Induces Production of NO and TNF-noma Cells Induces Production of NO and TNF-α α α α α in Murinein Murinein Murinein Murinein MurineMacrophages.Macrophages.Macrophages.Macrophages.Macrophages.H.A.O. Jingsheng, Shan Baoen. 1Research Center, The FourthHospital of Hebei Medical University, China, Hebei, China; 2Re-search Center, The Fourth Hospital of Hebei Medical University,Shijiazhuang, Hebei, China.

Su1.32 - Control of Apoptosis of PrimarSu1.32 - Control of Apoptosis of PrimarSu1.32 - Control of Apoptosis of PrimarSu1.32 - Control of Apoptosis of PrimarSu1.32 - Control of Apoptosis of Primary Human Peripheraly Human Peripheraly Human Peripheraly Human Peripheraly Human PeripheralCD4+ T Cells.CD4+ T Cells.CD4+ T Cells.CD4+ T Cells.CD4+ T Cells.M. Pajusto, J. Tarkkanen, P. S. Mattila. 1Department of Otorhi-nolaryngology, Helsinki University Central Hospital, Helsinki, Fin-land; 2Department of Pathology, Helsinki University Central Hos-pital, Helsinki, Finland; 3Department of Otorhinolaryngology,Helsinki University Central Hospital, Helsinki, Finland.

Su1.33 - Regulation of Inducible Heparanase Gene Expres-Su1.33 - Regulation of Inducible Heparanase Gene Expres-Su1.33 - Regulation of Inducible Heparanase Gene Expres-Su1.33 - Regulation of Inducible Heparanase Gene Expres-Su1.33 - Regulation of Inducible Heparanase Gene Expres-sion in Human Tsion in Human Tsion in Human Tsion in Human Tsion in Human T-Cells by Soluble and Immobilize TNF-Cells by Soluble and Immobilize TNF-Cells by Soluble and Immobilize TNF-Cells by Soluble and Immobilize TNF-Cells by Soluble and Immobilize TNFα.α.α.α.α.Ilya Sotnikov, Liora Cahalon, Oded Vainas, Rinat Eshel, Ben-Zion Katz, Neta Ilan, Israel Vlodavsky, Irun Cohen, Ofer Lider.1Immunology, The Weizmann Institute of Science, Rehovot, Is-rael; 2Bone Marrow Transplantation, The Hematology Institute,Sourasky Medical Center, Tel-Aviv, Israel; 3Oncology, Hadassah-Hebrew University Hospital, Jerusalem, Israel.

Su1.34 - Serum Free PBMC Freezing and TSu1.34 - Serum Free PBMC Freezing and TSu1.34 - Serum Free PBMC Freezing and TSu1.34 - Serum Free PBMC Freezing and TSu1.34 - Serum Free PBMC Freezing and Testing Conditionsesting Conditionsesting Conditionsesting Conditionsesting ConditionsAfford Enhanced Detection of Antigen-Specific T Cells andAfford Enhanced Detection of Antigen-Specific T Cells andAfford Enhanced Detection of Antigen-Specific T Cells andAfford Enhanced Detection of Antigen-Specific T Cells andAfford Enhanced Detection of Antigen-Specific T Cells andStandardization of Immune Monitoring.Standardization of Immune Monitoring.Standardization of Immune Monitoring.Standardization of Immune Monitoring.Standardization of Immune Monitoring.W.J. Zhang,1 S. Gregory,2 M. Ewell,2 W. Lopaczynski,2 T. Watts,2C. Shive,1 N. Sigmund,1 S. Berry,1 O. Targoni,1 J. Lathey,2 P. V.Lehmann.1 1&1ÀŒ-õŒ-õ2BBI Biotech Research Laboratories,A Division of SeraCare Life Sciences, Gaithersburg, MD, USA.

Su1.35 - Serum High Mobility Group B1 [HMGB1] Is a Dam-Su1.35 - Serum High Mobility Group B1 [HMGB1] Is a Dam-Su1.35 - Serum High Mobility Group B1 [HMGB1] Is a Dam-Su1.35 - Serum High Mobility Group B1 [HMGB1] Is a Dam-Su1.35 - Serum High Mobility Group B1 [HMGB1] Is a Dam-age Associated Molecular Pattern [DAMP] Cytokine Elevatedage Associated Molecular Pattern [DAMP] Cytokine Elevatedage Associated Molecular Pattern [DAMP] Cytokine Elevatedage Associated Molecular Pattern [DAMP] Cytokine Elevatedage Associated Molecular Pattern [DAMP] Cytokine Elevatedin Chronic Hepatitis C Patients and Diminishing Followingin Chronic Hepatitis C Patients and Diminishing Followingin Chronic Hepatitis C Patients and Diminishing Followingin Chronic Hepatitis C Patients and Diminishing Followingin Chronic Hepatitis C Patients and Diminishing FollowingOrOrOrOrOrthotopic Liver Tthotopic Liver Tthotopic Liver Tthotopic Liver Tthotopic Liver Transplantation.ransplantation.ransplantation.ransplantation.ransplantation.M. T. Lotze,1 R. Day,2 M. E. DeVera,3 A. J. Demetris,3 R. A.DeMarco,1 O. Shakil.3 1Surgery, Bioengineering, and Molecu-lar Genetics and Biochemistry, University of Pittsburgh Molecu-lar Medicine Institute, Pittsburgh, PA, USA; 2Department of Bio-statistics, University of Pittsburgh, Pittsburgh, PA, USA; 3Surgery,Medicine, and Pathology, Starzl Transplant Institute, Pittsburgh,PA, USA.

Su1.36 - Su1.36 - Su1.36 - Su1.36 - Su1.36 - Ex VEx VEx VEx VEx Vivoivoivoivoivo Pro-Inflammator Pro-Inflammator Pro-Inflammator Pro-Inflammator Pro-Inflammatory Cytokines Expression iny Cytokines Expression iny Cytokines Expression iny Cytokines Expression iny Cytokines Expression inPatients with Aggressive Periodontitis.Patients with Aggressive Periodontitis.Patients with Aggressive Periodontitis.Patients with Aggressive Periodontitis.Patients with Aggressive Periodontitis.F. E. Gonzalez,1,2 D. Catalan,1 J. C. Aguillon.1 1DisciplinaryProgram of Immunology, Faculty of Medicine, University of Chile,Santiago, Región Metropolitana, Chile; 2Dentomaxilofacial Ser-vice, University of Chile Clinical Hospital. University of Chile,Santiago, Región Metropolitana, Chile.



Su1.37 - IL-22 Increases the Innate Immunity of the Skin.Su1.37 - IL-22 Increases the Innate Immunity of the Skin.Su1.37 - IL-22 Increases the Innate Immunity of the Skin.Su1.37 - IL-22 Increases the Innate Immunity of the Skin.Su1.37 - IL-22 Increases the Innate Immunity of the Skin.K. Wolk, S. Kunz, E. Witte, M. Friedrich, K. Asadullah, R. Sabat.1Interdisciplinary Group Molecular Immunopathology, Derma-tology/Medical Immunology, University Hospital Charite, Berlin,Germany; 2Interdisciplinary Group Molecular Immunopathology,Dermatology/Medical Immunology, University Hospital Charite,Berlin, Germany; 3Interdisciplinary Group Molecular Immuno-pathology, Dermatology/Medical Immunology, University Hos-pital Charite, Berlin, Germany; 4Interdisciplinary Group Molecu-lar Immunopathology, Dermatology/Medical Immunology, Uni-versity Hospital Charite, Berlin, Germany; 5CRBA Dermatology,Schering Inc., Berlin, Germany; 6Interdisciplinary Group Mo-lecular Immunopathology, Dermatology/Medical Immunology,University Hospital Charite, Berlin, Germany.

Su1.38 - IL-7 in Human B Cell Development.Su1.38 - IL-7 in Human B Cell Development.Su1.38 - IL-7 in Human B Cell Development.Su1.38 - IL-7 in Human B Cell Development.Su1.38 - IL-7 in Human B Cell Development.Y. K. Parrish,1 E. Sahakian,1 G. M. Crooks,1 E. Zielinska,1 L. W.Barsky,1 K. J. Payne.1 1Research Immunolgy/BMT, ChildrensHospital Los Angeles, Los Angeles, CA, USA.

Su1.39 - An ImporSu1.39 - An ImporSu1.39 - An ImporSu1.39 - An ImporSu1.39 - An Important Role for CXtant Role for CXtant Role for CXtant Role for CXtant Role for CX33333CR1 in VCR1 in VCR1 in VCR1 in VCR1 in Vascular Remodeling.ascular Remodeling.ascular Remodeling.ascular Remodeling.ascular Remodeling.P. Liu,1 S. Patil,2 M. Rojas,3 A. Fong,1 S.S. Smyth,3 D.D. Patel.1

1Thurston Arthritis Research Center and Department of Medi-cine, University of North Carolina at Chapel Hill, Chapel Hill,NC; 2School of Medicine, Duke University, Durham, NC; 3Divi-sion of Cardiology and Carolina Cardiovascular Biology Cen-ter, University of North Carolina at Chapel Hill, Chapel Hill,NC, USA.

Su1.40 - Chromatin Regulation of Interleukin 10 Gene Ex-Su1.40 - Chromatin Regulation of Interleukin 10 Gene Ex-Su1.40 - Chromatin Regulation of Interleukin 10 Gene Ex-Su1.40 - Chromatin Regulation of Interleukin 10 Gene Ex-Su1.40 - Chromatin Regulation of Interleukin 10 Gene Ex-pression at the Allele Level.pression at the Allele Level.pression at the Allele Level.pression at the Allele Level.pression at the Allele Level.D. Calado,1 D. Holmberg,2 H. Matthias.1 1Cellular Differentia-tion, Gulbenkian Institute for Science, Oeiras, Portugal; 2UmeaCenter for Genome Research, Umea University, Umea, Sweden.

Su1.41 - Local Interleukin-1 Immunotherapy Effectiveness De-Su1.41 - Local Interleukin-1 Immunotherapy Effectiveness De-Su1.41 - Local Interleukin-1 Immunotherapy Effectiveness De-Su1.41 - Local Interleukin-1 Immunotherapy Effectiveness De-Su1.41 - Local Interleukin-1 Immunotherapy Effectiveness De-pends on Cytokine Genetic Background.pends on Cytokine Genetic Background.pends on Cytokine Genetic Background.pends on Cytokine Genetic Background.pends on Cytokine Genetic Background.A. S. Simbirtsev,1 A. J. Gromova,1 L. E. Timchuk,1 E. A.Variouchina.1 1Immunopharmacology, Institute of Highly PureBiopreparations, St.Petersburg, Russian Federation.

Su1.42 - Local TSu1.42 - Local TSu1.42 - Local TSu1.42 - Local TSu1.42 - Local T-L-L-L-L-Lymphocytes from Subacute and Chronicymphocytes from Subacute and Chronicymphocytes from Subacute and Chronicymphocytes from Subacute and Chronicymphocytes from Subacute and ChronicHypersensitivity Pneumonitis Show Phenotypic and FunctionalHypersensitivity Pneumonitis Show Phenotypic and FunctionalHypersensitivity Pneumonitis Show Phenotypic and FunctionalHypersensitivity Pneumonitis Show Phenotypic and FunctionalHypersensitivity Pneumonitis Show Phenotypic and FunctionalDifferences.Differences.Differences.Differences.Differences.Felipe Mendoza,1 Lourdes Barrera,1 Emma Melendro,2 AnniePardo,3 Moises Selman.1 1Inmunoquimica, National Institute ofRespiratory Diseases, Mexico City, Mexico; 2Medicina Experi-mental, Universidad Nacional Autonoma de Mexico, MexicoCity, Mexico; 3Facultad de Ciencias, Universidad NacionalAutonoma de Mexico, Mexico City, Mexico.

Su1.43 - Phenotypic and Functional Analysis of MemorSu1.43 - Phenotypic and Functional Analysis of MemorSu1.43 - Phenotypic and Functional Analysis of MemorSu1.43 - Phenotypic and Functional Analysis of MemorSu1.43 - Phenotypic and Functional Analysis of Memory CD4y CD4y CD4y CD4y CD4and CD8 T Land CD8 T Land CD8 T Land CD8 T Land CD8 T Lymphocytes in Subacute and Chronic Hypersen-ymphocytes in Subacute and Chronic Hypersen-ymphocytes in Subacute and Chronic Hypersen-ymphocytes in Subacute and Chronic Hypersen-ymphocytes in Subacute and Chronic Hypersen-sitivity Pneumonitis.sitivity Pneumonitis.sitivity Pneumonitis.sitivity Pneumonitis.sitivity Pneumonitis.L. Barrera,1 F. Mendoza,2 M. Selman.1 1Immunochemistry,National Institute of Respiratory Diseases, Mexico City, MexicoCity, Mexico; 2Sistemas Biologicos, Universidad AutonomaMetropolitana, Mexico, D.F., Mexico.

Su1.44 - Pro-InflammatorSu1.44 - Pro-InflammatorSu1.44 - Pro-InflammatorSu1.44 - Pro-InflammatorSu1.44 - Pro-Inflammatory and Anti-Inflammatory and Anti-Inflammatory and Anti-Inflammatory and Anti-Inflammatory and Anti-Inflammatory Cytokinesy Cytokinesy Cytokinesy Cytokinesy CytokinesTTTTTrack with KIR Haplotypes A and B in Octo/Nonagenarianrack with KIR Haplotypes A and B in Octo/Nonagenarianrack with KIR Haplotypes A and B in Octo/Nonagenarianrack with KIR Haplotypes A and B in Octo/Nonagenarianrack with KIR Haplotypes A and B in Octo/NonagenarianSubjects.Subjects.Subjects.Subjects.Subjects.I. M. Rea,1 L. D. Maxwell,2 O. A. Ross,2 C. A. Rea-Lyon,1 H. D.Alexander,3 D. Middleton.2 1Geriatric Medicine, Queens Uni-versity Belfast, Belfast, Northern Ireland, United Kingdom; 2NIRegional Histocompatability and Immunogenetics Laboratory,Belfast City Hospital, Belfast, Northern Ireland, United Kingdom;3Haematology Laboratory, Belfast City Hospital, Belfast, North-ern Ireland, United Kingdom.

Su1.45 - Evaluation of TSu1.45 - Evaluation of TSu1.45 - Evaluation of TSu1.45 - Evaluation of TSu1.45 - Evaluation of THHHHH1/T1/T1/T1/T1/THHHHH2 Cytokine Modulations in2 Cytokine Modulations in2 Cytokine Modulations in2 Cytokine Modulations in2 Cytokine Modulations inChronically HIVChronically HIVChronically HIVChronically HIVChronically HIV-Infected Adults Who Received Therapeutic-Infected Adults Who Received Therapeutic-Infected Adults Who Received Therapeutic-Infected Adults Who Received Therapeutic-Infected Adults Who Received TherapeuticVVVVVaccination and Interaccination and Interaccination and Interaccination and Interaccination and Intermittent HAARmittent HAARmittent HAARmittent HAARmittent HAART Following an Initial HAART Following an Initial HAART Following an Initial HAART Following an Initial HAART Following an Initial HAARTTTTTIntensification (CTN-140 Pilot TIntensification (CTN-140 Pilot TIntensification (CTN-140 Pilot TIntensification (CTN-140 Pilot TIntensification (CTN-140 Pilot Trial).rial).rial).rial).rial).Sardar Sindhu,1,2,3 Maude Loignon,1 Jose Menezes,2,3 EmilToma.1,3 1Microbiology & Infectious Diseases, CHUM-Hotel DieuHospital, Montreal, QC, Canada; 2Immunovirology Lab andViral & Immune Diseases Program, CHUM-Ste Justine Hospital,Montreal, QC, Canada; 3Microbiology & Immunology, Univer-sity of Montreal, Montreal, QC, Canada.

20052005200520052005ANNUAL MEETING

111



Su1.46 - Cytokine Expression in CD4+ Cells Exposed to Su1.46 - Cytokine Expression in CD4+ Cells Exposed to Su1.46 - Cytokine Expression in CD4+ Cells Exposed to Su1.46 - Cytokine Expression in CD4+ Cells Exposed to Su1.46 - Cytokine Expression in CD4+ Cells Exposed to thethethethetheMonocyte Locomotion InhibitorMonocyte Locomotion InhibitorMonocyte Locomotion InhibitorMonocyte Locomotion InhibitorMonocyte Locomotion Inhibitory Factory Factory Factory Factory Factor Produced by Produced by Produced by Produced by Produced by E.E.E.E.E.histolyticahistolyticahistolyticahistolyticahistolytica.....S. Rojas,1 G. Rico,1 J. Perez,2 J. Velazquez,1 R. Kretschmer.1

1UIM en Inmunologia, Hospital de Pediatria CMN S-XXI, IMSS,Mexico, DF, Mexico; 2Division de Ciencias Biologicas y de laSalud, Universidad Autonoma Metropolitana, Mexico, DF,Mexico.

Su1.47 - Interleukin 21 Modulates Cytokine Pathways ThatSu1.47 - Interleukin 21 Modulates Cytokine Pathways ThatSu1.47 - Interleukin 21 Modulates Cytokine Pathways ThatSu1.47 - Interleukin 21 Modulates Cytokine Pathways ThatSu1.47 - Interleukin 21 Modulates Cytokine Pathways ThatContribute to the Pathology of Arthritis.Contribute to the Pathology of Arthritis.Contribute to the Pathology of Arthritis.Contribute to the Pathology of Arthritis.Contribute to the Pathology of Arthritis.L. Lowe,1 M. Senices,1 M. Hegen,1 J. C. Keith, Jr.,1 J. Lamothe,1

P. Wu,1 M. Whitters,1 C. Nickerson-Nutter,1 D. Young,1 M.Collins.1 1Inflammation, Wyeth Research, Cambridge, MA, USA.

Su1.48 - Critical Role of STSu1.48 - Critical Role of STSu1.48 - Critical Role of STSu1.48 - Critical Role of STSu1.48 - Critical Role of STAAAAAT1 on Self-Renewal Capacity ofT1 on Self-Renewal Capacity ofT1 on Self-Renewal Capacity ofT1 on Self-Renewal Capacity ofT1 on Self-Renewal Capacity ofCNS Stem Cells by an Inducible Interferon-gCNS Stem Cells by an Inducible Interferon-gCNS Stem Cells by an Inducible Interferon-gCNS Stem Cells by an Inducible Interferon-gCNS Stem Cells by an Inducible Interferon-gJ. Imitola, R. Fryer, Y. Wang, S. Rasmussen, R. V. Jensen, S. J.Khoury. 1Neurology, Brigham and Women’s Hospital, Boston,MA, USA.

Su1.49 - Role of CXCL1/CXCR2 in Promotion of Glial Sur-Su1.49 - Role of CXCL1/CXCR2 in Promotion of Glial Sur-Su1.49 - Role of CXCL1/CXCR2 in Promotion of Glial Sur-Su1.49 - Role of CXCL1/CXCR2 in Promotion of Glial Sur-Su1.49 - Role of CXCL1/CXCR2 in Promotion of Glial Sur-vival during Experimental Demyelination.vival during Experimental Demyelination.vival during Experimental Demyelination.vival during Experimental Demyelination.vival during Experimental Demyelination.L. T. Remington,1 S. P. Zehntner,1 C. A. Hollmann,1 T. Owens.1

1Neuroimmunology, Montreal Neurological Institute, Montreal,QC, Canada.

Su1.50 - Standardizing Multiparameter Flow CytometrSu1.50 - Standardizing Multiparameter Flow CytometrSu1.50 - Standardizing Multiparameter Flow CytometrSu1.50 - Standardizing Multiparameter Flow CytometrSu1.50 - Standardizing Multiparameter Flow Cytometry fory fory fory fory forEvaluation of Cytokine-Secreting Activity in T Cells Via Auto-Evaluation of Cytokine-Secreting Activity in T Cells Via Auto-Evaluation of Cytokine-Secreting Activity in T Cells Via Auto-Evaluation of Cytokine-Secreting Activity in T Cells Via Auto-Evaluation of Cytokine-Secreting Activity in T Cells Via Auto-mation of Sample Preparation and Analysis.mation of Sample Preparation and Analysis.mation of Sample Preparation and Analysis.mation of Sample Preparation and Analysis.mation of Sample Preparation and Analysis.J. Wilkinson,1 C. Smith,1 S. D’Costa,1 E. Rabellino.1 1Biomedi-cal Research Division, Beckman Coulter Inc., Miami, FL, USA.

Su1.51 - LSu1.51 - LSu1.51 - LSu1.51 - LSu1.51 - LTTTTTβββββR Expressed, Functional, and Regulated on En-R Expressed, Functional, and Regulated on En-R Expressed, Functional, and Regulated on En-R Expressed, Functional, and Regulated on En-R Expressed, Functional, and Regulated on En-dothelial Cells during Contact Sensitization.dothelial Cells during Contact Sensitization.dothelial Cells during Contact Sensitization.dothelial Cells during Contact Sensitization.dothelial Cells during Contact Sensitization.S. Liao,1 N. H. Ruddle.1 1Epidemiology and Public Health,Yale University School of Medicine, New Haven, CT, USA.

Su1.52 - Interferon-að Inducing TLR9 Agonists.Su1.52 - Interferon-að Inducing TLR9 Agonists.Su1.52 - Interferon-að Inducing TLR9 Agonists.Su1.52 - Interferon-að Inducing TLR9 Agonists.Su1.52 - Interferon-að Inducing TLR9 Agonists.E. R. Kandimalla, D. Yu, T. Sullivan, S. Agrawal. 1Discovery,Hybridon, Inc., Cambridge, MA, USA.

Su1.53 - TGF-Su1.53 - TGF-Su1.53 - TGF-Su1.53 - TGF-Su1.53 - TGF-ααααα in Foxp3 Expression and Development of in Foxp3 Expression and Development of in Foxp3 Expression and Development of in Foxp3 Expression and Development of in Foxp3 Expression and Development ofPeripheral CD4+CD25+ TPeripheral CD4+CD25+ TPeripheral CD4+CD25+ TPeripheral CD4+CD25+ TPeripheral CD4+CD25+ Treg.reg.reg.reg.reg.W.J. Chen, Y. Liu. 1Mucosal Immunology Unit, OIIB, NIDCR,NIH, Bethesda, MD, USA.

Su1.54 - Osteoprotegerin Synthesis by Circulating T Cells IsSu1.54 - Osteoprotegerin Synthesis by Circulating T Cells IsSu1.54 - Osteoprotegerin Synthesis by Circulating T Cells IsSu1.54 - Osteoprotegerin Synthesis by Circulating T Cells IsSu1.54 - Osteoprotegerin Synthesis by Circulating T Cells IsRelated to Osteoporosis in HIVRelated to Osteoporosis in HIVRelated to Osteoporosis in HIVRelated to Osteoporosis in HIVRelated to Osteoporosis in HIV-Infected Patients.-Infected Patients.-Infected Patients.-Infected Patients.-Infected Patients.A. Chakravarti,1 L. Flamand,1 R. Lalonde,2 P. E. Poubelle.1 1De-partment of Medicine, Centre de Recherche en Rhumatologie etImmunologie,Universite Laval, Quebec, QC, Canada; 2Divisionof Infectious Diseases, Royal Victoria Hospital, McGill Univer-sity, Montreal, QC, Canada.

Su1.55 - Detection of Cytokines in Patients with Hypersensi-Su1.55 - Detection of Cytokines in Patients with Hypersensi-Su1.55 - Detection of Cytokines in Patients with Hypersensi-Su1.55 - Detection of Cytokines in Patients with Hypersensi-Su1.55 - Detection of Cytokines in Patients with Hypersensi-tivity to Metals.tivity to Metals.tivity to Metals.tivity to Metals.tivity to Metals.Z. Venclikova,1 J. Bartova,1 L. Mrklas.1 1Clinical Department,The Institute of Dental Research, 1st Medical Faculty and GUH,Charles University, Prague 2, Prague, Czech Republic.

Su1.56 - SCYSu1.56 - SCYSu1.56 - SCYSu1.56 - SCYSu1.56 - SCYA4L Polymorphism Genotyping by FluorescentA4L Polymorphism Genotyping by FluorescentA4L Polymorphism Genotyping by FluorescentA4L Polymorphism Genotyping by FluorescentA4L Polymorphism Genotyping by FluorescentResonance Emission (FRET) Probes in Real-Time PCR.Resonance Emission (FRET) Probes in Real-Time PCR.Resonance Emission (FRET) Probes in Real-Time PCR.Resonance Emission (FRET) Probes in Real-Time PCR.Resonance Emission (FRET) Probes in Real-Time PCR.Roger Colobran,1 Rosa Faner,1 Carles Llop,1 Ricardo Pujol,1Manel Juan.1 1LIRAD (Laboratori d’Immunobiologia per a laRecerca i Aplicacions Diagnostiques) / IICSGTIP (Institutd’Investigacio en Ciencies de la Salut Germans Trias i Pujol),CTBT (Centre de Transfusio i Banc de Teixits) / UAB (UniversitatAut.

Su1.57 - Correlation of Interleukin-4 and Chronic Periodonti-Su1.57 - Correlation of Interleukin-4 and Chronic Periodonti-Su1.57 - Correlation of Interleukin-4 and Chronic Periodonti-Su1.57 - Correlation of Interleukin-4 and Chronic Periodonti-Su1.57 - Correlation of Interleukin-4 and Chronic Periodonti-tis.tis.tis.tis.tis.Mandana Sattari,1 Saeed Khalili,1 Leili Mehrdad.1 1Immunol-ogy, Shaheed Beheshti University Medical School, Tehran, Is-lamic Republic of Iran.

Su1.58 - Interleukin-21 Maintains T Cells in a Naive Pheno-Su1.58 - Interleukin-21 Maintains T Cells in a Naive Pheno-Su1.58 - Interleukin-21 Maintains T Cells in a Naive Pheno-Su1.58 - Interleukin-21 Maintains T Cells in a Naive Pheno-Su1.58 - Interleukin-21 Maintains T Cells in a Naive Pheno-type.type.type.type.type.S. Ferrari-Lacraz,1 D. C. Foster,2 R. Chicheportiche.1 1Immunol-ogy and Allergy, University Hospital, Geneva, Geneva, Swit-zerland; 2Cytokine Biology, Zymogenetics, Seattle, WA, USA.



Su1.59 - Osteopontin, a Th1 Cytokine, Promotes Cell Sur-Su1.59 - Osteopontin, a Th1 Cytokine, Promotes Cell Sur-Su1.59 - Osteopontin, a Th1 Cytokine, Promotes Cell Sur-Su1.59 - Osteopontin, a Th1 Cytokine, Promotes Cell Sur-Su1.59 - Osteopontin, a Th1 Cytokine, Promotes Cell Sur-vival and Inhibits Programmed Cell Death of Activated T Cells.vival and Inhibits Programmed Cell Death of Activated T Cells.vival and Inhibits Programmed Cell Death of Activated T Cells.vival and Inhibits Programmed Cell Death of Activated T Cells.vival and Inhibits Programmed Cell Death of Activated T Cells.E. M. Hur,1 L. Steinman.2 1Program in Immunology, StanfordUniversity, School of Medicine, Stanford, CA, USA; 2Neurologyand Neurological Sciences, Stanford University, Medical School,Stanford, CA, USA.

Su1.60 - Comparison of RNA Preparation Methods and TheirSu1.60 - Comparison of RNA Preparation Methods and TheirSu1.60 - Comparison of RNA Preparation Methods and TheirSu1.60 - Comparison of RNA Preparation Methods and TheirSu1.60 - Comparison of RNA Preparation Methods and TheirEffect on Cytokine/Chemokine Gene Expression.Effect on Cytokine/Chemokine Gene Expression.Effect on Cytokine/Chemokine Gene Expression.Effect on Cytokine/Chemokine Gene Expression.Effect on Cytokine/Chemokine Gene Expression.A. L. Asare,1 S. A. Kolchinsky,1 P. Wood,2 V. L. Seyfert-Margolis.11Immune Tolerance Network, University of California, San Fran-cisco, San Francisco, CA, USA; 2Center for Human Geneticsand Integrated Biology, University of Pittsburgh, Pittsburgh, PA,USA.

Su1.61 - Regulation of InterSu1.61 - Regulation of InterSu1.61 - Regulation of InterSu1.61 - Regulation of InterSu1.61 - Regulation of Interferon Gamma Expression by Tferon Gamma Expression by Tferon Gamma Expression by Tferon Gamma Expression by Tferon Gamma Expression by Tu-u-u-u-u-mor Necrosis Factor Receptor Tmor Necrosis Factor Receptor Tmor Necrosis Factor Receptor Tmor Necrosis Factor Receptor Tmor Necrosis Factor Receptor Type 1 Signaling.ype 1 Signaling.ype 1 Signaling.ype 1 Signaling.ype 1 Signaling.L. M. Kelly,1 R. D. Wheeler,1 T. Owens.1,2 1NeuroimmunologyUnit, Montreal Neurological Institute, Montreal, QC, Canada;2Medical Biotechnology Center, University of Southern Denmark,Odense, Denmark.

General AutoimmunityGeneral AutoimmunityGeneral AutoimmunityGeneral AutoimmunityGeneral Autoimmunity

Su1.62 - Bacterial HSP70 Immunization Inhibits Proteoglycan-Su1.62 - Bacterial HSP70 Immunization Inhibits Proteoglycan-Su1.62 - Bacterial HSP70 Immunization Inhibits Proteoglycan-Su1.62 - Bacterial HSP70 Immunization Inhibits Proteoglycan-Su1.62 - Bacterial HSP70 Immunization Inhibits Proteoglycan-Induced Arthritis.Induced Arthritis.Induced Arthritis.Induced Arthritis.Induced Arthritis.S. E. Berlo,1 C. B. ten Brink,1 P. J. van Kooten,1 R. van der Zee,1M. Singh,2 B. J. Prakken,3 T. T. Glant,4 W. van Eden,1 C. P.Broeren.1 1Department of Infectious Diseases and Immunology,University of Utrecht, Utrecht, Netherlands; 2German NationalResearch Institute for Biotechnology, Braunscheig, Germany;3Department of Pediatric Immunology, UMCU, Utrecht, Nether-lands; 4Department of Orthopedic Surgery, Rush University,Chicago, Netherlands.

Su1.63 - Characterization of Functionally Important RegionsSu1.63 - Characterization of Functionally Important RegionsSu1.63 - Characterization of Functionally Important RegionsSu1.63 - Characterization of Functionally Important RegionsSu1.63 - Characterization of Functionally Important Regionsof CD200:CD200R for Immunoregulation Using Blocking Syn-of CD200:CD200R for Immunoregulation Using Blocking Syn-of CD200:CD200R for Immunoregulation Using Blocking Syn-of CD200:CD200R for Immunoregulation Using Blocking Syn-of CD200:CD200R for Immunoregulation Using Blocking Syn-thetic Peptides and/or mAbs.thetic Peptides and/or mAbs.thetic Peptides and/or mAbs.thetic Peptides and/or mAbs.thetic Peptides and/or mAbs.R. M. Gorczynski, D. X. Chen. 1Transplant Research Division,University Health Network (UHN), Toronto, ON, Canada.

Su1.64 - Gene Identification of Single Chain FormatSu1.64 - Gene Identification of Single Chain FormatSu1.64 - Gene Identification of Single Chain FormatSu1.64 - Gene Identification of Single Chain FormatSu1.64 - Gene Identification of Single Chain FormatVVVVVariable(scFv) Anti-ßariable(scFv) Anti-ßariable(scFv) Anti-ßariable(scFv) Anti-ßariable(scFv) Anti-ß22222-Glycoprotein-I (aß-Glycoprotein-I (aß-Glycoprotein-I (aß-Glycoprotein-I (aß-Glycoprotein-I (aß22222GP-I) and Anti-Pro-GP-I) and Anti-Pro-GP-I) and Anti-Pro-GP-I) and Anti-Pro-GP-I) and Anti-Pro-thrombin (aPt) Antibodies Obtained from a Primarthrombin (aPt) Antibodies Obtained from a Primarthrombin (aPt) Antibodies Obtained from a Primarthrombin (aPt) Antibodies Obtained from a Primarthrombin (aPt) Antibodies Obtained from a Primary Anti-Phos-y Anti-Phos-y Anti-Phos-y Anti-Phos-y Anti-Phos-pholipid Syndrome (Ppholipid Syndrome (Ppholipid Syndrome (Ppholipid Syndrome (Ppholipid Syndrome (PAPS) Patient by Phage DisplayAPS) Patient by Phage DisplayAPS) Patient by Phage DisplayAPS) Patient by Phage DisplayAPS) Patient by Phage Display.....J. Cabiedes,1 M. Languren,1 B. Becerril,2 L. E. Fernandez-Altuna,2D. F. Hernandez-Ramirez,1 V. Pascual,1 A. R. Cabral.1 1Immu-nology and Reumathology, Instituto Nacional de CienciasMedicas y Nutricion Salvador Zubiran, Mexico City, Mexico;2Biotecnologia y Bioprocesos, Instituto de Biotecnologia. UNAM.,Cuernavaca, Morelos, Mexico, Malta.

Su1.65 - A Novel Network of Human B Cell Effector CytokinesSu1.65 - A Novel Network of Human B Cell Effector CytokinesSu1.65 - A Novel Network of Human B Cell Effector CytokinesSu1.65 - A Novel Network of Human B Cell Effector CytokinesSu1.65 - A Novel Network of Human B Cell Effector CytokinesIs Implicated in Autoimmunity: Dysregulation in Patients withIs Implicated in Autoimmunity: Dysregulation in Patients withIs Implicated in Autoimmunity: Dysregulation in Patients withIs Implicated in Autoimmunity: Dysregulation in Patients withIs Implicated in Autoimmunity: Dysregulation in Patients withMultiple Sclerosis and Potential as Therapeutic TMultiple Sclerosis and Potential as Therapeutic TMultiple Sclerosis and Potential as Therapeutic TMultiple Sclerosis and Potential as Therapeutic TMultiple Sclerosis and Potential as Therapeutic Target.arget.arget.arget.arget.A. Bar-Or,1 M. Niino,1 M. Duddy,1 F. Adatia,1 S. Hebert,1 H.J.Kim.1 1Neuroimmunology Unit, Montreal Neurological Institute,McGill University, Montreal, QC, Canada.

Su1.66 - Class Switch Recombination in B-LSu1.66 - Class Switch Recombination in B-LSu1.66 - Class Switch Recombination in B-LSu1.66 - Class Switch Recombination in B-LSu1.66 - Class Switch Recombination in B-Lymphopoiesis Isymphopoiesis Isymphopoiesis Isymphopoiesis Isymphopoiesis Isa Novel Pathway for Development of Autoimmune B Cells.a Novel Pathway for Development of Autoimmune B Cells.a Novel Pathway for Development of Autoimmune B Cells.a Novel Pathway for Development of Autoimmune B Cells.a Novel Pathway for Development of Autoimmune B Cells.Doron Melamed.1 1Immunology, Technion, Faculty of Medicine,Haifa, Israel.

Su1.67 - The Role of VCAM-1 in Self-Reactive T Cell Fate.Su1.67 - The Role of VCAM-1 in Self-Reactive T Cell Fate.Su1.67 - The Role of VCAM-1 in Self-Reactive T Cell Fate.Su1.67 - The Role of VCAM-1 in Self-Reactive T Cell Fate.Su1.67 - The Role of VCAM-1 in Self-Reactive T Cell Fate.Jonathan A. Abbas,1 Pandelakis A. Koni.1 1Program in Mo-lecular Immunology, Institute of Molecular Medicine and Genet-ics, Medical College of Georgia, Augusta, GA, USA.

Su1.68 - The Autoimmune Response to Modified Human Low-Su1.68 - The Autoimmune Response to Modified Human Low-Su1.68 - The Autoimmune Response to Modified Human Low-Su1.68 - The Autoimmune Response to Modified Human Low-Su1.68 - The Autoimmune Response to Modified Human Low-Density Lipoprotein.Density Lipoprotein.Density Lipoprotein.Density Lipoprotein.Density Lipoprotein.G. Virella,1 M. B. Derrick,1 C. Chassereau,1 S. R. Thorpe,3 M. F.Lopes-Virella.1,2 1Depts. of Microbiology & Immunology andMedicine, Medical University of South Carolina, Charleston, SC;2Ralph H. Johnson VAMC, Charleston, Charleston, SC; 3Depart-ment of Chemistry and Biochemistry, University of South Caro-lina, Columbia, SC.

Su1.69 - Studies on Signal TSu1.69 - Studies on Signal TSu1.69 - Studies on Signal TSu1.69 - Studies on Signal TSu1.69 - Studies on Signal Transduction Pathways Downstreamransduction Pathways Downstreamransduction Pathways Downstreamransduction Pathways Downstreamransduction Pathways Downstreamof CD28/IL-2 That Regulate the E3 Ligase, GRAIL.of CD28/IL-2 That Regulate the E3 Ligase, GRAIL.of CD28/IL-2 That Regulate the E3 Ligase, GRAIL.of CD28/IL-2 That Regulate the E3 Ligase, GRAIL.of CD28/IL-2 That Regulate the E3 Ligase, GRAIL.L. X. Wu,1 L. Soares,1 C. G. Fathman.1 1Department of Medi-cine, Division of Immunology and Rheumatology, Stanford Uni-versity, Stanford, CA, USA.

20052005200520052005ANNUAL MEETING

113



Su1.70 - Immune Monitoring the Effects of hOKT3Su1.70 - Immune Monitoring the Effects of hOKT3Su1.70 - Immune Monitoring the Effects of hOKT3Su1.70 - Immune Monitoring the Effects of hOKT3Su1.70 - Immune Monitoring the Effects of hOKT3γγγγγ1 Ala-Ala1 Ala-Ala1 Ala-Ala1 Ala-Ala1 Ala-Alain a patient with New Onset Tin a patient with New Onset Tin a patient with New Onset Tin a patient with New Onset Tin a patient with New Onset Type 1 Diabetes Mellitus.ype 1 Diabetes Mellitus.ype 1 Diabetes Mellitus.ype 1 Diabetes Mellitus.ype 1 Diabetes Mellitus.W. H. Liu,1 G. Szot,1 K. E. Earle,1,2 K. C. Herold,3 U. Masharani,1,2

S. E. Gitelman,4 J. A. Bluestone.1,2 1Diabetes Center, Universityof California at San Francisco, San Francisco, CA; 2Departmentof Medicine, University of California at San Francisco, San Fran-cisco, CA; 3Department of Medicine, Division of Endocrinology,and the Naomi Berrie Diabetes, Columbia University, New York,NY; 4Department of Pediatrics, University of California at SanFrancisco, San Francisco, CA.

Su1.71 - Essential Role of the Co-Receptor CD72 in B CellSu1.71 - Essential Role of the Co-Receptor CD72 in B CellSu1.71 - Essential Role of the Co-Receptor CD72 in B CellSu1.71 - Essential Role of the Co-Receptor CD72 in B CellSu1.71 - Essential Role of the Co-Receptor CD72 in B CellPeripheral TPeripheral TPeripheral TPeripheral TPeripheral Tolerance.olerance.olerance.olerance.olerance.Daniel H. Li,1 Albert Chen,1 James Tung,2 Paulo Fontoura,3 LarrySteinman,3 Jane R. Parnes.1 1Department of Medicine, StanfordUniversity, Stanford, CA, USA; 2Department of Genetics, StanfordUniversity, Stanford, CA, USA; 3Department of Neurology &Neurological Sciences, Stanford University, Stanford, CA, USA.

Su1.72 - Identification of the TSu1.72 - Identification of the TSu1.72 - Identification of the TSu1.72 - Identification of the TSu1.72 - Identification of the Target Self-Antigens in Ischemia/arget Self-Antigens in Ischemia/arget Self-Antigens in Ischemia/arget Self-Antigens in Ischemia/arget Self-Antigens in Ischemia/ReperReperReperReperReperfusion Injurfusion Injurfusion Injurfusion Injurfusion Injuryyyyy.....M. Zhang,1 E. M. Alicot,5 I. Chiu,1 N. Verna,2 T. Vorup-Jensen,1

B. Kessler,3 M. Shimaoka,1 R. Chan,2 D. Friend,2 L. H. Michael,4M. L. Entman,4 F. D. Moore,2 M. C. Carroll.1 1CBR Institute ofBiomedical Research, Harvard Medical School, Boston, MA,USA; 2Surgery-Brigham & Women’s Hospital, Harvard MedicalSchool, Boston, MA, USA; 3Pathology, Harvard Medical School,Boston, MA, USA; 4DeBakey Heart Center and Department ofMedicine, Baylor College of Medicine and the Methodist Hos-pital, Houston, MA, USA; 5DecImmune Therapeutics, Boston,MA, USA.

Su1.73 - Shared Epitopes among HLA Class II Molecules inSu1.73 - Shared Epitopes among HLA Class II Molecules inSu1.73 - Shared Epitopes among HLA Class II Molecules inSu1.73 - Shared Epitopes among HLA Class II Molecules inSu1.73 - Shared Epitopes among HLA Class II Molecules inCommon Autoimmune Diseases.Common Autoimmune Diseases.Common Autoimmune Diseases.Common Autoimmune Diseases.Common Autoimmune Diseases.Elissaveta J. Naumova,1 Milena I. Ivanova,1 Snejina M.Mihaylova,1 Antoaneta P. Nedialkova,1 Anastassia P.Mihaylova.1 1Central Laboratory for Clinical Immunology, Uni-versity Hospital Alexandrovska, Sofia, Bulgaria.

Su1.74 - Su1.74 - Su1.74 - Su1.74 - Su1.74 - In VivoIn VivoIn VivoIn VivoIn Vivo Blockade of Human IL-2 Receptor (IL-2R) In- Blockade of Human IL-2 Receptor (IL-2R) In- Blockade of Human IL-2 Receptor (IL-2R) In- Blockade of Human IL-2 Receptor (IL-2R) In- Blockade of Human IL-2 Receptor (IL-2R) In-duces Expansion of CD56duces Expansion of CD56duces Expansion of CD56duces Expansion of CD56duces Expansion of CD56brightbrightbrightbrightbright Regulator Regulator Regulator Regulator Regulatory NK Cells in Pa-y NK Cells in Pa-y NK Cells in Pa-y NK Cells in Pa-y NK Cells in Pa-tients with Active Uveitis.tients with Active Uveitis.tients with Active Uveitis.tients with Active Uveitis.tients with Active Uveitis.Zhuqing Li,1 Wee Kiak Lim,1,2 Sankaranarayana P. Mahesh,1

Robert B. Nussenblatt.1 1Laboratory of Immunology, NationalEye Institute, NIH, Bethesda, MD, USA; 2Singapore NationalEye Center, Singapore, Singapore.

Su1.75 - Premature Senescence of the Immune System in Rheu-Su1.75 - Premature Senescence of the Immune System in Rheu-Su1.75 - Premature Senescence of the Immune System in Rheu-Su1.75 - Premature Senescence of the Immune System in Rheu-Su1.75 - Premature Senescence of the Immune System in Rheu-matoid Arthritis and Multiple Sclerosis Patients.matoid Arthritis and Multiple Sclerosis Patients.matoid Arthritis and Multiple Sclerosis Patients.matoid Arthritis and Multiple Sclerosis Patients.matoid Arthritis and Multiple Sclerosis Patients.M. M. Thewissen, L. Linsen, P. Geusens, J. Raus, P. Stinissen.1Biomedisch Onderzoeksinstituut (BIOMED), Limburgs UniversitairCentrum (LUC)/Transnational University Limburg (tUL),Diepenbeek, Belgium.

Su1.76 - Histamine Release and Autoantbodies in ChronicSu1.76 - Histamine Release and Autoantbodies in ChronicSu1.76 - Histamine Release and Autoantbodies in ChronicSu1.76 - Histamine Release and Autoantbodies in ChronicSu1.76 - Histamine Release and Autoantbodies in ChronicIdiopathic Urticaria and Cough.Idiopathic Urticaria and Cough.Idiopathic Urticaria and Cough.Idiopathic Urticaria and Cough.Idiopathic Urticaria and Cough.Francesca Gibellino,1 Stefania Stella,2 Michele Massimino,2Manuela Di Stefano,3 Anna M. Longo,1 Costantino Sipione,4

Angelo Messina.1 1Respiratory Pathophisiology Service,Cannizzaro Hospital, Catania, Italy; 2Biomedical Sciences, Uni-versity of Catania, Catania, Italy; 3Endoscopic Service,Cannizzaro Hospital, Catania, Italy; 4Endocrinology and Dia-betes Unit, Cannizzaro Hospital, Catania, Italy.

Su1.77 - A Polymorphism of the InhibitorSu1.77 - A Polymorphism of the InhibitorSu1.77 - A Polymorphism of the InhibitorSu1.77 - A Polymorphism of the InhibitorSu1.77 - A Polymorphism of the Inhibitory Receptory Receptory Receptory Receptory Receptor, Fc, Fc, Fc, Fc, FcγγγγγRIIb,RIIb,RIIb,RIIb,RIIb,Prevents It’Prevents It’Prevents It’Prevents It’Prevents It’s Access to Lipid Rafts and Alters Macrophages Access to Lipid Rafts and Alters Macrophages Access to Lipid Rafts and Alters Macrophages Access to Lipid Rafts and Alters Macrophages Access to Lipid Rafts and Alters MacrophageResponses to Immune Complexes and Opsonized Bateria.Responses to Immune Complexes and Opsonized Bateria.Responses to Immune Complexes and Opsonized Bateria.Responses to Immune Complexes and Opsonized Bateria.Responses to Immune Complexes and Opsonized Bateria.R. A. Floto,1 M. R. Clatworthy,1 P. A. McAry,1 E. U. Walker,1 K.R. Heilbronn,1 A. Rankin,2 J. M. Allen,3 N. A. Watkins,2 K. G.C.Smith.1 1Cambridge Institute for Medical Research and Depart-ment of Medicine, University of Cambridge School of ClinicalMedicine, Cambridge, Cambs, United Kingdom; 2Division ofTransfusion Medicine, University of Cambridge School of Clini-cal Medicine, Cambridge, Cambs, United Kingdom; 3Discov-ery Biology, Inpharmatica, London, United Kingdom.

Su1.78 - On the Role of Th1 Cytokines (gIFN, IL18) and GrowthSu1.78 - On the Role of Th1 Cytokines (gIFN, IL18) and GrowthSu1.78 - On the Role of Th1 Cytokines (gIFN, IL18) and GrowthSu1.78 - On the Role of Th1 Cytokines (gIFN, IL18) and GrowthSu1.78 - On the Role of Th1 Cytokines (gIFN, IL18) and GrowthFactor TGFbFactor TGFbFactor TGFbFactor TGFbFactor TGFb1 1 1 1 1 in Autoimmune Thyroid Disease.in Autoimmune Thyroid Disease.in Autoimmune Thyroid Disease.in Autoimmune Thyroid Disease.in Autoimmune Thyroid Disease.Roman Khanferyan,1 Ljudmila Ravovaya.1 1Clinical Immunol-ogy and Allergy, Kuban State Medical Academy, Krasnodar,Russian Federation.

Su1.79 - Autoimmunity: Common Origin for Diverse Diseases.Su1.79 - Autoimmunity: Common Origin for Diverse Diseases.Su1.79 - Autoimmunity: Common Origin for Diverse Diseases.Su1.79 - Autoimmunity: Common Origin for Diverse Diseases.Su1.79 - Autoimmunity: Common Origin for Diverse Diseases.G. J. Tobon,1,2 P. Vega,1,2 R. Pineda-Tamayo,1,2 J. M. Anaya.1,2

1Rheumatology, Clinica Universitaria Bolivariana, Medellin,Colombia; 2Cellular Biology and Immunogenetics Unit,Corporacion para Investigaciones Biologicas, Medellin, Colom-bia.



Su1.80 - Selective Unresponsiveness of TNFR1Su1.80 - Selective Unresponsiveness of TNFR1Su1.80 - Selective Unresponsiveness of TNFR1Su1.80 - Selective Unresponsiveness of TNFR1Su1.80 - Selective Unresponsiveness of TNFR1-/--/--/--/--/- Macroph- Macroph- Macroph- Macroph- Macroph-ages to IFN-gages to IFN-gages to IFN-gages to IFN-gages to IFN-gC. J. Calder,1 A. D. Dick,2 L. B. Nicholson.1,2 1Pathology &Microbiology, University of Bristol; 2Clinical Sciences, Universityof Bristol, Bristol, United Kingdom.

Su1.81 - Suppressor Potency among RegulatorSu1.81 - Suppressor Potency among RegulatorSu1.81 - Suppressor Potency among RegulatorSu1.81 - Suppressor Potency among RegulatorSu1.81 - Suppressor Potency among Regulatory T Cells Isy T Cells Isy T Cells Isy T Cells Isy T Cells IsDiscriminated by Functionally Active CD44.Discriminated by Functionally Active CD44.Discriminated by Functionally Active CD44.Discriminated by Functionally Active CD44.Discriminated by Functionally Active CD44.M. Firan,1 P. Estess,1 M. Siegelman.1 1Pathology, University ofTexas Southwestern Medical Center, Dallas, TX, USA.

Su1.82 - Characterization of Immune Response in Su1.82 - Characterization of Immune Response in Su1.82 - Characterization of Immune Response in Su1.82 - Characterization of Immune Response in Su1.82 - Characterization of Immune Response in β−β−β−β−β−TTTTTubulinubulinubulinubulinubulinIndiced Murine Autoimmune Hearing Loss.Indiced Murine Autoimmune Hearing Loss.Indiced Murine Autoimmune Hearing Loss.Indiced Murine Autoimmune Hearing Loss.Indiced Murine Autoimmune Hearing Loss.B. Zhou, J. Glickstein, J. Lee, M. H. Kermany, T. J. Yoo. 1Depart-ment of Medicine, University of Tennessee, Memphis, TN, USA.

Su1.83 - Endogenous Expression of IRBP Is Dispensable forSu1.83 - Endogenous Expression of IRBP Is Dispensable forSu1.83 - Endogenous Expression of IRBP Is Dispensable forSu1.83 - Endogenous Expression of IRBP Is Dispensable forSu1.83 - Endogenous Expression of IRBP Is Dispensable forGeneration of CD4+CD25+ RegulatorGeneration of CD4+CD25+ RegulatorGeneration of CD4+CD25+ RegulatorGeneration of CD4+CD25+ RegulatorGeneration of CD4+CD25+ Regulatory T Cells That Protecty T Cells That Protecty T Cells That Protecty T Cells That Protecty T Cells That ProtectAgainst IRBP-Induced Retinal AutoimmunityAgainst IRBP-Induced Retinal AutoimmunityAgainst IRBP-Induced Retinal AutoimmunityAgainst IRBP-Induced Retinal AutoimmunityAgainst IRBP-Induced Retinal Autoimmunity.....R. S. Grajewski,1 P. B. Silver,1 R. K. Agarwal,1 S. B. Su,1 C. C.Chan,1 G. I. Liou,2 R. R. Caspi.1 1Laboratory of Immunology,NEI, NIH, Bethesda, MD, USA; 2Department of Ophthalmol-ogy, Medical College of Georgia, Augusta, GA, USA;3Bethesda, MD, USA.

Su1.84 - Prevention and TSu1.84 - Prevention and TSu1.84 - Prevention and TSu1.84 - Prevention and TSu1.84 - Prevention and Treatment of Experimental Autoim-reatment of Experimental Autoim-reatment of Experimental Autoim-reatment of Experimental Autoim-reatment of Experimental Autoim-mune Myocarditis with Altered Peptide Ligand (APL).mune Myocarditis with Altered Peptide Ligand (APL).mune Myocarditis with Altered Peptide Ligand (APL).mune Myocarditis with Altered Peptide Ligand (APL).mune Myocarditis with Altered Peptide Ligand (APL).D. Cihakova,1 M. Kimura,1 M. Talor,1 J. Barin,1 E. Talor,2 D.Zimmerman,2 N. Rose.1 1Pathology, Johns Hopkins MedicalInstitutions, Baltimore, MD, USA; 2Research and Development,CEL-SCI Corporation, Baltimore, MD, USA.

Su1.85 - T Cell Responses Induced by Myelin Oligodendro-Su1.85 - T Cell Responses Induced by Myelin Oligodendro-Su1.85 - T Cell Responses Induced by Myelin Oligodendro-Su1.85 - T Cell Responses Induced by Myelin Oligodendro-Su1.85 - T Cell Responses Induced by Myelin Oligodendro-cyte Glycoprotein Are Suppressed by CD4cyte Glycoprotein Are Suppressed by CD4cyte Glycoprotein Are Suppressed by CD4cyte Glycoprotein Are Suppressed by CD4cyte Glycoprotein Are Suppressed by CD4+++++CD25CD25CD25CD25CD25+ + + + + FOXP3FOXP3FOXP3FOXP3FOXP3+++++

RegulatorRegulatorRegulatorRegulatorRegulatory T Cells from Thymus and Cord Blood.y T Cells from Thymus and Cord Blood.y T Cells from Thymus and Cord Blood.y T Cells from Thymus and Cord Blood.y T Cells from Thymus and Cord Blood.K. Wing,1 P. Larsson,1 K. Sandstrom,2 S. Lundin,3 E. Suri-Payer,4A. Rudin.1 1Rheumatology and Inflammation Research,Gothenburg University, Gothenburg, Sweden; 2Paediatric Ana-esthesia and Intensive Care at, The Queen Silvia Children’sHospital, Gothenburg, Sweden; 3Medical Microbiology andImmunology, Gothenburg University, Gothenburg, Sweden; 4Di-vision of Immunogenetics, German Cancer Research Center,Heidelberg, Germany.

Su1.86 - Pinocytosis by Human Dendritic Cells TSu1.86 - Pinocytosis by Human Dendritic Cells TSu1.86 - Pinocytosis by Human Dendritic Cells TSu1.86 - Pinocytosis by Human Dendritic Cells TSu1.86 - Pinocytosis by Human Dendritic Cells Targets Exog-argets Exog-argets Exog-argets Exog-argets Exog-enous Material Selectively to Intracellular Cathepsin S.enous Material Selectively to Intracellular Cathepsin S.enous Material Selectively to Intracellular Cathepsin S.enous Material Selectively to Intracellular Cathepsin S.enous Material Selectively to Intracellular Cathepsin S.Michael Reich,1 Stella Erfurth,2 Marianne Kraus,1 HermanOverkleeft,3 Christoph Driessen.1 1Medicine II, University ofTubingen, Germany; 2Microbiology, University of Tubingen,Germany; 3Organic Chemistry, University of Leiden, Netherlands.

Su1.87 - Induction of CD4Su1.87 - Induction of CD4Su1.87 - Induction of CD4Su1.87 - Induction of CD4Su1.87 - Induction of CD4+++++CD25CD25CD25CD25CD25+++++ T T T T Treg Suppressive Activityreg Suppressive Activityreg Suppressive Activityreg Suppressive Activityreg Suppressive Activityand IL-10 Production by IL-2.and IL-10 Production by IL-2.and IL-10 Production by IL-2.and IL-10 Production by IL-2.and IL-10 Production by IL-2.Susan Brandenburg,1 Maurus De La Rosa,1 Gabriela Karsten,1

Heike Dorninger,1 Sascha Rutz,1 Alexander Scheffold.1

1Immunomodulation, German Rheumatism Research Center,Berlin, Germany.

Su1.88 - Comparison of Anti- DNA Antibodies for Their Abil-Su1.88 - Comparison of Anti- DNA Antibodies for Their Abil-Su1.88 - Comparison of Anti- DNA Antibodies for Their Abil-Su1.88 - Comparison of Anti- DNA Antibodies for Their Abil-Su1.88 - Comparison of Anti- DNA Antibodies for Their Abil-ity Tity Tity Tity Tity To Restore Mesenteric Ischemia/Repero Restore Mesenteric Ischemia/Repero Restore Mesenteric Ischemia/Repero Restore Mesenteric Ischemia/Repero Restore Mesenteric Ischemia/Reperfusion-Induced In-fusion-Induced In-fusion-Induced In-fusion-Induced In-fusion-Induced In-jurjurjurjurjury and Remote Ty and Remote Ty and Remote Ty and Remote Ty and Remote Tissue Damage in issue Damage in issue Damage in issue Damage in issue Damage in Rag 1Rag 1Rag 1Rag 1Rag 1 Deficient Mice. Deficient Mice. Deficient Mice. Deficient Mice. Deficient Mice.C. Moratz,1/4 S. Fleming,2 M. Monestier,3 G. Tsokos.1/4 1De-partment of Medicine, Uniformed Services University of the HealthSciences, Bethesda, MD, USA; 2Department of Biology, KansasState Universtiy, Manhattan, KS, USA; 3Department of Microbi-ology and Immunology, School of Medicine, Temple Universtiy,Philladelphia, PA, USA; 4Department of Cellular Injury, WalterReed Army Institute of Research, Silver Spring, MD, USA.

Su1.89 - The Functional Role of CD48-Related Pathways inSu1.89 - The Functional Role of CD48-Related Pathways inSu1.89 - The Functional Role of CD48-Related Pathways inSu1.89 - The Functional Role of CD48-Related Pathways inSu1.89 - The Functional Role of CD48-Related Pathways inAutoimmunityAutoimmunityAutoimmunityAutoimmunityAutoimmunity.....A. Tamir,1 C. Arancibia,2 M. Ali,1 A. Sharpe,2 Y. Latchman.1

1Department of Immunology, Puget Sound Blood Center andProgram, Seattle, WA, USA; 2Department of Pathology, HarvardMedical School, Boston, MA, USA.

Su1.90 - The L i fecyc le o f In Vi t ro GeneratedSu1.90 - The L i fecyc le o f In Vi t ro GeneratedSu1.90 - The L i fecyc le o f In Vi t ro GeneratedSu1.90 - The L i fecyc le o f In Vi t ro GeneratedSu1.90 - The L i fecyc le o f In Vi t ro GeneratedCD4+CD25+FoxP3+ Human TCD4+CD25+FoxP3+ Human TCD4+CD25+FoxP3+ Human TCD4+CD25+FoxP3+ Human TCD4+CD25+FoxP3+ Human TRRRRR: Generation, Expansion, and: Generation, Expansion, and: Generation, Expansion, and: Generation, Expansion, and: Generation, Expansion, andPersistence.Persistence.Persistence.Persistence.Persistence.M. R. Walker,1,3 B. D. Carson,2,3 S. F. Ziegler,2,3 J. H. Buckner.11Diabetes, Benaroya Research Institute at Virginia Mason, Se-attle, WA, USA; 2Immunology, Benaroya Research Institute atVirginia Mason, Seattle, WA, USA; 3Immunology, University ofWashington, Seattle, WA, USA.

20052005200520052005ANNUAL MEETING

115



Su1.91 - siRNA TSu1.91 - siRNA TSu1.91 - siRNA TSu1.91 - siRNA TSu1.91 - siRNA Targeted Reduction of IL-23 Production byargeted Reduction of IL-23 Production byargeted Reduction of IL-23 Production byargeted Reduction of IL-23 Production byargeted Reduction of IL-23 Production byHuman Dendritic Cells Increases IL-10 Production and De-Human Dendritic Cells Increases IL-10 Production and De-Human Dendritic Cells Increases IL-10 Production and De-Human Dendritic Cells Increases IL-10 Production and De-Human Dendritic Cells Increases IL-10 Production and De-creases Antigen Presentation Capacitycreases Antigen Presentation Capacitycreases Antigen Presentation Capacitycreases Antigen Presentation Capacitycreases Antigen Presentation Capacity.....A. Vaknin-Dembinsky, H. L. Weiner. 1Neurology, Center forNeurological Diseases, Boston, MA, USA.

Su1.92 - Opposite Effect of IL-4 and IL-13 in ExperimentalSu1.92 - Opposite Effect of IL-4 and IL-13 in ExperimentalSu1.92 - Opposite Effect of IL-4 and IL-13 in ExperimentalSu1.92 - Opposite Effect of IL-4 and IL-13 in ExperimentalSu1.92 - Opposite Effect of IL-4 and IL-13 in ExperimentalAutoimmune Myocarditis (EAM).Autoimmune Myocarditis (EAM).Autoimmune Myocarditis (EAM).Autoimmune Myocarditis (EAM).Autoimmune Myocarditis (EAM).Daniela Cihakova,1 Marina Afanasyeva,1,2 Miho Kimura,1

Monica Talor,1 Jobert Barin,1 Noel R. Rose.1 1Department ofPathology, The Johns Hopkins Medical Institutions, Baltimore, MD,USA; 2Department of Medicine, University of Calgary, Calgary,AB, Canada.

Su1.93 - CTLA4-Ig Inhibts IL-2 Production and Su1.93 - CTLA4-Ig Inhibts IL-2 Production and Su1.93 - CTLA4-Ig Inhibts IL-2 Production and Su1.93 - CTLA4-Ig Inhibts IL-2 Production and Su1.93 - CTLA4-Ig Inhibts IL-2 Production and In-VivoIn-VivoIn-VivoIn-VivoIn-Vivo Expan- Expan- Expan- Expan- Expan-sion of Antigen-Stimulated Memorsion of Antigen-Stimulated Memorsion of Antigen-Stimulated Memorsion of Antigen-Stimulated Memorsion of Antigen-Stimulated Memory CD4 T Cells.y CD4 T Cells.y CD4 T Cells.y CD4 T Cells.y CD4 T Cells.M. P. Ndejembi, D. S. Patke, A. W. Bingaman, D. L. Farber.1Surgery, University of Maryland, Baltimore, MD.

Su1.94 - Both FcSu1.94 - Both FcSu1.94 - Both FcSu1.94 - Both FcSu1.94 - Both FcγγγγγR and C5a Are Indispensable in AntibodyR and C5a Are Indispensable in AntibodyR and C5a Are Indispensable in AntibodyR and C5a Are Indispensable in AntibodyR and C5a Are Indispensable in AntibodyDependent Autoimmune Disease.Dependent Autoimmune Disease.Dependent Autoimmune Disease.Dependent Autoimmune Disease.Dependent Autoimmune Disease.Varsha Kumar,1 Syed R. Ali,1 Olga Felda,1 Jorg Zwirner,2 JosefS. Verbeek,3 Reinhold E. Schmidt,1 Johannes E. Gessner.1 1De-partment of Clinical Immunology, Hannover Medical School,Hannover, Lower Saxony, Germany; 2Department of Immunol-ogy, Georg-August-University Gottingen, Gottingen, Germany;3Department of Human Genetics, Leiden University MedicalCenter, Al Leiden, Netherlands.

Su1.95 - RegulatorSu1.95 - RegulatorSu1.95 - RegulatorSu1.95 - RegulatorSu1.95 - Regulatory T Cells: Differential Requirement for In-y T Cells: Differential Requirement for In-y T Cells: Differential Requirement for In-y T Cells: Differential Requirement for In-y T Cells: Differential Requirement for In-nate and Adaptive Immune Cells Inhibition nate and Adaptive Immune Cells Inhibition nate and Adaptive Immune Cells Inhibition nate and Adaptive Immune Cells Inhibition nate and Adaptive Immune Cells Inhibition In VitroIn VitroIn VitroIn VitroIn Vitro.....S. Zelenay,1 I. Caramalho,1 J. Demengeot.1 1Lymphocyte Physi-ology Unit, Instituto Gulbenkian de Ciencia, Oeiras, Portugal.

Su1.96 - CCR6 Expression Defines RegulatorSu1.96 - CCR6 Expression Defines RegulatorSu1.96 - CCR6 Expression Defines RegulatorSu1.96 - CCR6 Expression Defines RegulatorSu1.96 - CCR6 Expression Defines Regulatory Effector/y Effector/y Effector/y Effector/y Effector/MemorMemorMemorMemorMemory-Like Cells within the CD25+CD4+ T Cell Subset.y-Like Cells within the CD25+CD4+ T Cell Subset.y-Like Cells within the CD25+CD4+ T Cell Subset.y-Like Cells within the CD25+CD4+ T Cell Subset.y-Like Cells within the CD25+CD4+ T Cell Subset.Markus Kleinewietfeld,1 Fabiola Puentes,1 Giovanna Borsellino,2Luca Battistini,2 Olaf Rotzschke,1 Kirsten Falk.1 1Cellular Immu-nology of Autoimmune Reactions, Max-Delbruck-Center for Mo-lecular Medicine (MDC), Berlin, Berlin, Germany; 2Laboratoryof Neuroimmunology, IRCCS Santa Lucia, Rome, Rome, Italy.

Su1.97 - Small Molecules TSu1.97 - Small Molecules TSu1.97 - Small Molecules TSu1.97 - Small Molecules TSu1.97 - Small Molecules Trigger Peptide Loading of HLA-DRrigger Peptide Loading of HLA-DRrigger Peptide Loading of HLA-DRrigger Peptide Loading of HLA-DRrigger Peptide Loading of HLA-DRby Allele-Specific Induction of a Peptide-Receptive State.by Allele-Specific Induction of a Peptide-Receptive State.by Allele-Specific Induction of a Peptide-Receptive State.by Allele-Specific Induction of a Peptide-Receptive State.by Allele-Specific Induction of a Peptide-Receptive State.Heiko Kramer,1 Katharina Dickhaut,1 Maria Hofstaatter,1 SabineHopner,1 Dominik Ruckerl,1 Arvid Soderhall,2 Viviana Marin-Esteban,1 Ronald Kuhne,2 Christian Freund,2 Gunther Jung,3

Kirsten Falk,1 Olaf Rotzschke.1 1Celluar Immunology of Autoim-mune Reactions, Max-Delbruck-Center for Molecular Medicine(MDC), Berlin, Berlin, Germany; 2NMR Supported Structural Bi-ology, Forschungsinstitut for Molecular Pharmacy (FMP), Berlin,Berlin, Germany; 3Organic Chemistry, Eberhard Karls Universitat,Tubingen, Tubingen, Baden Wurtenberg, Germany.

Su1.98 - B Cell Receptor Editing Begins in the Bone MarrowSu1.98 - B Cell Receptor Editing Begins in the Bone MarrowSu1.98 - B Cell Receptor Editing Begins in the Bone MarrowSu1.98 - B Cell Receptor Editing Begins in the Bone MarrowSu1.98 - B Cell Receptor Editing Begins in the Bone Marrow.....Elahna Paul,1 Thomas J. Schneider,2 Michael C. Carroll.2 1Pe-diatric Nephrology, Massachusetts General Hospital, Boston,MA, USA; 2CBR Institute for Biomedical Research, HarvardMedical School, Boston, MA, USA.

SSSSSu1.99 - The Macrophage C5a:C5aR-Gau1.99 - The Macrophage C5a:C5aR-Gau1.99 - The Macrophage C5a:C5aR-Gau1.99 - The Macrophage C5a:C5aR-Gau1.99 - The Macrophage C5a:C5aR-Gai2i2i2i2i2-FcgRIIB/FcgRIII-Axis-FcgRIIB/FcgRIII-Axis-FcgRIIB/FcgRIII-Axis-FcgRIIB/FcgRIII-Axis-FcgRIIB/FcgRIII-AxisDefines the InflammatorDefines the InflammatorDefines the InflammatorDefines the InflammatorDefines the Inflammatory Response in the Ary Response in the Ary Response in the Ary Response in the Ary Response in the Arthus Reaction.thus Reaction.thus Reaction.thus Reaction.thus Reaction.S. R. Ali,1 J. Skokowa,1 O. Felda,2 V. Kumar,1 S. Konrad,1 R. E.Schmidt,1 R. P. Pierkorz,2 B. Nunberg,2 K. Spicher,3 L.Birnbaumer,4 J. Zwirner,5 N. Rooijen,6 J. E. Gessner.1 1ClinicalImmunology, Hannover Medical School, Hannover, Germany;2Biochemistry and Molecular Biology, Heinrich-Heine-University,Dusseldorf, Germany; 3Institute of Pharmacology, Berlin FreeUniversity, Berlin, Germany; 4Laboratory of Signal Transduction,NIEHS, NIH, USA; 5Department of Immunology, Georg AugustUniversity, Gottingen, Germany; 6Department of Molecular CellBiology, Vrije University, Amsterdam, Netherlands.

Su1.100 - T Cells and Autoimmunity: Immunoregulation bySu1.100 - T Cells and Autoimmunity: Immunoregulation bySu1.100 - T Cells and Autoimmunity: Immunoregulation bySu1.100 - T Cells and Autoimmunity: Immunoregulation bySu1.100 - T Cells and Autoimmunity: Immunoregulation byCD40 Expressed on CD4CD40 Expressed on CD4CD40 Expressed on CD4CD40 Expressed on CD4CD40 Expressed on CD4+++++ T L T L T L T L T Lymphocytes.ymphocytes.ymphocytes.ymphocytes.ymphocytes.M. E. Munroe,1 G. A. Bishop.1,2 1Departments of Microbiologyand Internal Medicine, University of Iowa, Iowa City, IA, USA;2VAMC.

Su1.101 - Induction of TSu1.101 - Induction of TSu1.101 - Induction of TSu1.101 - Induction of TSu1.101 - Induction of Tolerance by Gene Therapy with B-olerance by Gene Therapy with B-olerance by Gene Therapy with B-olerance by Gene Therapy with B-olerance by Gene Therapy with B-Cells Expressing Ig Fusion Proteins: Mechanisms and Pre-Cells Expressing Ig Fusion Proteins: Mechanisms and Pre-Cells Expressing Ig Fusion Proteins: Mechanisms and Pre-Cells Expressing Ig Fusion Proteins: Mechanisms and Pre-Cells Expressing Ig Fusion Proteins: Mechanisms and Pre-Clinical Success in Naïve and Immune Hemophilia A Mice.Clinical Success in Naïve and Immune Hemophilia A Mice.Clinical Success in Naïve and Immune Hemophilia A Mice.Clinical Success in Naïve and Immune Hemophilia A Mice.Clinical Success in Naïve and Immune Hemophilia A Mice.D. W. Scott,1 T. C. Lei,1 Y. Su,1 N. Soukhareva.1 1Surgery, Uni-versity of Maryland School of Medicine, Rockville, MD, USA.



Su1.102 - Increase in Pancreatic NK Cells at Early Onset ofSu1.102 - Increase in Pancreatic NK Cells at Early Onset ofSu1.102 - Increase in Pancreatic NK Cells at Early Onset ofSu1.102 - Increase in Pancreatic NK Cells at Early Onset ofSu1.102 - Increase in Pancreatic NK Cells at Early Onset ofAutoimmune Diabetes in IFNAutoimmune Diabetes in IFNAutoimmune Diabetes in IFNAutoimmune Diabetes in IFNAutoimmune Diabetes in IFNβ β β β β TTTTTransgenic NOD Mice.ransgenic NOD Mice.ransgenic NOD Mice.ransgenic NOD Mice.ransgenic NOD Mice.A. Alba,1 R. Planas,1 J. Carrillo,1 M. C. Puertas,1 R. Ampudia,1

X. Pastor,1 M. A. Fernandez,1 R. Pujol-Borrell,1 J. Verdaguer,1

M. Vives-Pi.1 1Immunobiology for Research and DiagnosticApplications, Transfusion Centre and Tissue Bank, Fundacio Institutd’Investigacio en Ciencies de la Salut Germans Trias i Pujol,Badalona, Barcelona, Spain.

Su1.103 - Rapid Protocol TSu1.103 - Rapid Protocol TSu1.103 - Rapid Protocol TSu1.103 - Rapid Protocol TSu1.103 - Rapid Protocol To Generate To Generate To Generate To Generate To Generate Tolerogenic Dendriticolerogenic Dendriticolerogenic Dendriticolerogenic Dendriticolerogenic DendriticCells Using Microbial Lipopeptide (BLP).Cells Using Microbial Lipopeptide (BLP).Cells Using Microbial Lipopeptide (BLP).Cells Using Microbial Lipopeptide (BLP).Cells Using Microbial Lipopeptide (BLP).O. A. Aravena,1 L. Salazar,1 C. Mass,1 A. Aguirre,1 D. Catalan,1M. Hermoso,1 J. C. Aguillon.1 1Disciplinary Program of Immu-nology, ICBM, University of Chile, Santiago, Chile.

Su1.104 - Mucosal Administration of Anti-CD3 Antibody Sup-Su1.104 - Mucosal Administration of Anti-CD3 Antibody Sup-Su1.104 - Mucosal Administration of Anti-CD3 Antibody Sup-Su1.104 - Mucosal Administration of Anti-CD3 Antibody Sup-Su1.104 - Mucosal Administration of Anti-CD3 Antibody Sup-presses EAE, Collagen Arthritis, Diabetes and Prolongs Car-presses EAE, Collagen Arthritis, Diabetes and Prolongs Car-presses EAE, Collagen Arthritis, Diabetes and Prolongs Car-presses EAE, Collagen Arthritis, Diabetes and Prolongs Car-presses EAE, Collagen Arthritis, Diabetes and Prolongs Car-diac Allograft Surdiac Allograft Surdiac Allograft Surdiac Allograft Surdiac Allograft Survival.vival.vival.vival.vival.H. L. Weiner,1 H. Ochi,1 M. Abraham,1 H. Ishikawa,1 H. Wu,1

R. Maron,1 D. Frenkel,1 R. Gandi,1 M. L. Chen,1 A. Izawa,1 I.Guleria,1 M. H. Sayegh.1 1Brigham and Women’s Hospital,Harvard Medical School, Boston, MA, USA.

Su1.105 - The Role of Ultralarge Complexes (ULC) in Hep-Su1.105 - The Role of Ultralarge Complexes (ULC) in Hep-Su1.105 - The Role of Ultralarge Complexes (ULC) in Hep-Su1.105 - The Role of Ultralarge Complexes (ULC) in Hep-Su1.105 - The Role of Ultralarge Complexes (ULC) in Hep-arin Induced Thrombocytopenia (HIT).arin Induced Thrombocytopenia (HIT).arin Induced Thrombocytopenia (HIT).arin Induced Thrombocytopenia (HIT).arin Induced Thrombocytopenia (HIT).L. Rauova,1 D. B. Cines,2 B. B. Sachais,2 M. Poncz.1 1Divisionof Hematology, Children’s Hospital of Philadelphia, Philadel-phia, PA, USA; 2Department of Pathology and Laboratory Medi-cine, University of Pennsylvania, Philadelphia, PA, USA.

Su1.106 - Effect of Freezing/Thawing Conditions and TheirSu1.106 - Effect of Freezing/Thawing Conditions and TheirSu1.106 - Effect of Freezing/Thawing Conditions and TheirSu1.106 - Effect of Freezing/Thawing Conditions and TheirSu1.106 - Effect of Freezing/Thawing Conditions and TheirOptimization for Quality Control of PBMC Viability and Func-Optimization for Quality Control of PBMC Viability and Func-Optimization for Quality Control of PBMC Viability and Func-Optimization for Quality Control of PBMC Viability and Func-Optimization for Quality Control of PBMC Viability and Func-tional Assays.tional Assays.tional Assays.tional Assays.tional Assays.Khadir Raddassi,1,2 Kasia Bourcier,2 Jose Estevam,1,2 David A.Hafler,1 Vicki Seyfert-Margolis.2 1Neurology, Harvard MedicalSchool, Boston, MA, USA; 2Immune Tolerance Network, Univ.California San Francisco, San Francisco, CA, USA.

Su1.107 - MBLA/C Deficienct Mice Display DefectiveSu1.107 - MBLA/C Deficienct Mice Display DefectiveSu1.107 - MBLA/C Deficienct Mice Display DefectiveSu1.107 - MBLA/C Deficienct Mice Display DefectiveSu1.107 - MBLA/C Deficienct Mice Display DefectiveApoptotic Cell Clearance but No Autoimmune Phenotype.Apoptotic Cell Clearance but No Autoimmune Phenotype.Apoptotic Cell Clearance but No Autoimmune Phenotype.Apoptotic Cell Clearance but No Autoimmune Phenotype.Apoptotic Cell Clearance but No Autoimmune Phenotype.L. M. Stuart,1,2 K. Takahshi,1 L. Shi,1 J. Savill,2 R. A. Ezekowitz.11Laboratory of Developmental Immunology, Massachusetts Gen-eral Hospital, Boston, MA, USA; 2MRC Center for InflammationResearch, University of Edinburgh, Edinburgh, United Kingdom.

Su1.108 - Study of the Thymic Function in Patients with Au-Su1.108 - Study of the Thymic Function in Patients with Au-Su1.108 - Study of the Thymic Function in Patients with Au-Su1.108 - Study of the Thymic Function in Patients with Au-Su1.108 - Study of the Thymic Function in Patients with Au-toimmune Thyroiditis.toimmune Thyroiditis.toimmune Thyroiditis.toimmune Thyroiditis.toimmune Thyroiditis.M. P. Armengol,1 M. A. Fernandez,2 L. Sabater,1 M. Juan,1 R.Pujol-Borrell.1 1Laboratory of Immunobiology for Research andDiagnosis (LIRAD). Centre for Transfusion and Tissue Bank (CTBT),Institut per a la Recerca Biomedica Germans Trias i Pujol.,Badalona, Barcelona, Spain; 2Cytometry Unit, Institut per a laRecerca Biomedica Germans Trias i Pujol., Badalona, Barcelona,Spain.

Su1.109 - A Novel Low-Calcemic Vitamin D Analog as a Po-Su1.109 - A Novel Low-Calcemic Vitamin D Analog as a Po-Su1.109 - A Novel Low-Calcemic Vitamin D Analog as a Po-Su1.109 - A Novel Low-Calcemic Vitamin D Analog as a Po-Su1.109 - A Novel Low-Calcemic Vitamin D Analog as a Po-tential Therapeutic Ttential Therapeutic Ttential Therapeutic Ttential Therapeutic Ttential Therapeutic Treatment for Autoimmune Diseases.reatment for Autoimmune Diseases.reatment for Autoimmune Diseases.reatment for Autoimmune Diseases.reatment for Autoimmune Diseases.N. Chouinard,1 A. H. Collop,1 K. A. Ryder,1 S. P. Tabash,1 G.H. Posner,2 B. Korczak,1 S. S. Chuang.1 1Research and Devel-opment, Cytochroma Inc., Markham, ON, Canada; 2Depart-ment of Chemistry, The Johns Hopkins University, Baltimore, MD,USA.

Su1.110 - SP-A May Be a Candidate of “Qi” Molecule TSu1.110 - SP-A May Be a Candidate of “Qi” Molecule TSu1.110 - SP-A May Be a Candidate of “Qi” Molecule TSu1.110 - SP-A May Be a Candidate of “Qi” Molecule TSu1.110 - SP-A May Be a Candidate of “Qi” Molecule Trig-rig-rig-rig-rig-gers Some Autoimmune Diseases.gers Some Autoimmune Diseases.gers Some Autoimmune Diseases.gers Some Autoimmune Diseases.gers Some Autoimmune Diseases.J. Luo,1 Y. Wan.2 1Orthopaedics, Rhode Island Hospital/BrownMedical School, Providence, RI, USA; 2Biology, Providence Col-lege, Providence, RI, USA.

Su1.111 - The Inhibitions of Autoreactive TSu1.111 - The Inhibitions of Autoreactive TSu1.111 - The Inhibitions of Autoreactive TSu1.111 - The Inhibitions of Autoreactive TSu1.111 - The Inhibitions of Autoreactive T-Cell Functions by-Cell Functions by-Cell Functions by-Cell Functions by-Cell Functions bya Peptide Based on the Complementarity Determining Region-a Peptide Based on the Complementarity Determining Region-a Peptide Based on the Complementarity Determining Region-a Peptide Based on the Complementarity Determining Region-a Peptide Based on the Complementarity Determining Region-1 of an Anti-DNA Autoantibody Is Via TGF1 of an Anti-DNA Autoantibody Is Via TGF1 of an Anti-DNA Autoantibody Is Via TGF1 of an Anti-DNA Autoantibody Is Via TGF1 of an Anti-DNA Autoantibody Is Via TGFβ β β β β Mediated Sup-Mediated Sup-Mediated Sup-Mediated Sup-Mediated Sup-pression of LFpression of LFpression of LFpression of LFpression of LFA-1 and CD44 Expression and Function.A-1 and CD44 Expression and Function.A-1 and CD44 Expression and Function.A-1 and CD44 Expression and Function.A-1 and CD44 Expression and Function.Uri Sela,1 Nora Mauermann,1 Rami Hershkoviz,2 Edna Mozes,1Liora Cahalon,1 Ofer Lider.1 1Immunology Department, TheWeizmann Institute of Science, Rehovot, Israel; 2Internal Depart-ment D, Assaf-Harofeh Medical Center and the Sakler Facultyof Medicine, Tel-Aviv University, Zerifin, Israel.

Su1.112 - Fas Ligand (CD95L)-TSu1.112 - Fas Ligand (CD95L)-TSu1.112 - Fas Ligand (CD95L)-TSu1.112 - Fas Ligand (CD95L)-TSu1.112 - Fas Ligand (CD95L)-Transduced Monocyte-Derivedransduced Monocyte-Derivedransduced Monocyte-Derivedransduced Monocyte-Derivedransduced Monocyte-DerivedKiller-DC Are Protected from CTL-Induced Cytotoxicity andKiller-DC Are Protected from CTL-Induced Cytotoxicity andKiller-DC Are Protected from CTL-Induced Cytotoxicity andKiller-DC Are Protected from CTL-Induced Cytotoxicity andKiller-DC Are Protected from CTL-Induced Cytotoxicity andDelete Antigen-Specific CD8+ T Cells.Delete Antigen-Specific CD8+ T Cells.Delete Antigen-Specific CD8+ T Cells.Delete Antigen-Specific CD8+ T Cells.Delete Antigen-Specific CD8+ T Cells.Ch. Schuetz,1 A. Mackensen,2 H. Herfarth,1 D. Halbritter,1 M.Fleck.1 1Department of Internal Medicine I, University ofRegensburg, Regensburg, Bavaria, Germany; 2Division of He-matology, University of Regensburg, Regensburg, Bavaria, Ger-many.

20052005200520052005ANNUAL MEETING

117



InflammatorInflammatorInflammatorInflammatorInflammatory Bowel Diseasesy Bowel Diseasesy Bowel Diseasesy Bowel Diseasesy Bowel Diseases

Su1.113 - The Peripheral Cannabinoid Receptor CB2 Is Re-Su1.113 - The Peripheral Cannabinoid Receptor CB2 Is Re-Su1.113 - The Peripheral Cannabinoid Receptor CB2 Is Re-Su1.113 - The Peripheral Cannabinoid Receptor CB2 Is Re-Su1.113 - The Peripheral Cannabinoid Receptor CB2 Is Re-quired for the Normal Formation of B and T Cell Subsets.quired for the Normal Formation of B and T Cell Subsets.quired for the Normal Formation of B and T Cell Subsets.quired for the Normal Formation of B and T Cell Subsets.quired for the Normal Formation of B and T Cell Subsets.D. A. Ziring,1 B. Wei,2 P. Velazquez,2 M. Schrage,2 N. Buckley,3J. Braun.2 1Division of Pediatric Gastroenterology, UCLA DavidGeffen School of Medicine, Los Angeles, CA, USA; 2Depart-ment of Pathology and Laboratory Medicine, UCLA DavidGeffen School of Medicine, Los Angeles, CA, USA; 3Depart-ment of Biological Sciences, California State Polytechnic Univer-sity, Pomona, CA, USA.

Su1.114 - The Effect of Bifidobacterium on Murine Experi-Su1.114 - The Effect of Bifidobacterium on Murine Experi-Su1.114 - The Effect of Bifidobacterium on Murine Experi-Su1.114 - The Effect of Bifidobacterium on Murine Experi-Su1.114 - The Effect of Bifidobacterium on Murine Experi-mental Colitis.mental Colitis.mental Colitis.mental Colitis.mental Colitis.Aiping Bai, Qin Ouyang, Renwei Hu. 1Department of Gastro-enterology, The First Affiliated Hospital, Sun Yat-sen University,Guangzhou, Guangdong, China; 2Department of Gastroenter-ology, Westchina Hospital, Sichuan University, Chengdu,Sichuan, China; 3Department of Gastroenterology, WestchinaHospital, Sichuan University, Chengdu, Sichuan, China.

Su1.115 - Anti-Murine TNF-alpha Reverses TNBS Colitis inSu1.115 - Anti-Murine TNF-alpha Reverses TNBS Colitis inSu1.115 - Anti-Murine TNF-alpha Reverses TNBS Colitis inSu1.115 - Anti-Murine TNF-alpha Reverses TNBS Colitis inSu1.115 - Anti-Murine TNF-alpha Reverses TNBS Colitis inMice but Not Oxazolone Colitis: Potential Role of ApoptosisMice but Not Oxazolone Colitis: Potential Role of ApoptosisMice but Not Oxazolone Colitis: Potential Role of ApoptosisMice but Not Oxazolone Colitis: Potential Role of ApoptosisMice but Not Oxazolone Colitis: Potential Role of ApoptosisInduction.Induction.Induction.Induction.Induction.Chong Shen,1 Philippe Maerten,1 Gert VanAssche,2 KarelGeboes,3 Paul Rutgeerts,2 Jan L. Ceuppens.1 1Laboratory ofExperimental Immunology, Campus Gasthuisberg, Catholic Uni-versity Leuven, Leuven, Vlaams-Brabant, Belgium; 2Departmentof Gastroenterology, Campus Gasthuisberg, Catholic UniversityLeuven, Leuven, Vlaams-Brabant, Belgium; 3Department of Pa-thology, Campus Gasthuisberg, Catholic University Leuven,Leuven, Vlaams-Brabant, Belgium.

Su1.116 - Evaluation of 5 vs 10 Granulocyteapheresis TSu1.116 - Evaluation of 5 vs 10 Granulocyteapheresis TSu1.116 - Evaluation of 5 vs 10 Granulocyteapheresis TSu1.116 - Evaluation of 5 vs 10 Granulocyteapheresis TSu1.116 - Evaluation of 5 vs 10 Granulocyteapheresis Treat-reat-reat-reat-reat-ments in Patients with Moderate Active Steroid Dependentments in Patients with Moderate Active Steroid Dependentments in Patients with Moderate Active Steroid Dependentments in Patients with Moderate Active Steroid Dependentments in Patients with Moderate Active Steroid DependentUlcerative Colitis: A Prospective Multicenter Randomized TUlcerative Colitis: A Prospective Multicenter Randomized TUlcerative Colitis: A Prospective Multicenter Randomized TUlcerative Colitis: A Prospective Multicenter Randomized TUlcerative Colitis: A Prospective Multicenter Randomized Trial.rial.rial.rial.rial.E. Ricart,1 D. Monfort,1 J. Panes,2 M. Esteve,3 R. Lafuente,4 M.Andreu,5 F. Casellas,6 M. Sans.2 1Gastroenterology, Hospitalde la Santa Creu i Sant Pau, Barcelona, Spain; 2Gastroenterol-ogy, Hospital Clinic i Provincial, Barcelona, Spain; 3Gastroen-terology, Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain;4Intensive Care Unit, Hospital General de L´Hospitalet, Hospitaletde Llobregat, Barcelona, Spain; 5Gastroenterology, Hospital Valld´Hebron, Barcelona, Spain.

Su1.117 - Cytokine and Chemokine TSu1.117 - Cytokine and Chemokine TSu1.117 - Cytokine and Chemokine TSu1.117 - Cytokine and Chemokine TSu1.117 - Cytokine and Chemokine Transcript Profiles inranscript Profiles inranscript Profiles inranscript Profiles inranscript Profiles inAcute Pouchitis.Acute Pouchitis.Acute Pouchitis.Acute Pouchitis.Acute Pouchitis.A. Stallmach,1 T. Giese,2 C. Schmidt,3 B. Ludwig,3 S. Meuer.2

1Gastroenterology, Catholic Clinics Essen-Nord, Essen, Germany;2Immunology, University of Heidelberg, Heidelberg, Germany;3Internal Medicine II, Saarland University, Homburg, Germany.

Su1.118 - InflammatorSu1.118 - InflammatorSu1.118 - InflammatorSu1.118 - InflammatorSu1.118 - Inflammatory Ty Ty Ty Ty Transcript Profiles Reflect Onset ofranscript Profiles Reflect Onset ofranscript Profiles Reflect Onset ofranscript Profiles Reflect Onset ofranscript Profiles Reflect Onset ofClinical Remission in Patients with Steroid RefractorClinical Remission in Patients with Steroid RefractorClinical Remission in Patients with Steroid RefractorClinical Remission in Patients with Steroid RefractorClinical Remission in Patients with Steroid Refractory Crohn’y Crohn’y Crohn’y Crohn’y Crohn’sssssDisease after TDisease after TDisease after TDisease after TDisease after Treatment with Cyclophosphamide or Infliximab.reatment with Cyclophosphamide or Infliximab.reatment with Cyclophosphamide or Infliximab.reatment with Cyclophosphamide or Infliximab.reatment with Cyclophosphamide or Infliximab.A. Stallmach,1 T. Giese,2 B. Ludwig,3 M. Zeitz,4 S. Zeuzem,3 S.Meuer.2 1Gastroenterology, Catholic Clinics Essen-Nord, Essen,Germany; 2Immunology, University of Heidelberg, Heidelberg;3Internal Medicine II, Saarland University, Homburg, Germany;4Internal Medicine I, Charite, Berlin, Germany.

Su1.119 - Long TSu1.119 - Long TSu1.119 - Long TSu1.119 - Long TSu1.119 - Long Terererererm Follow-Up of Ulcerative Colitis (UC)m Follow-Up of Ulcerative Colitis (UC)m Follow-Up of Ulcerative Colitis (UC)m Follow-Up of Ulcerative Colitis (UC)m Follow-Up of Ulcerative Colitis (UC)TTTTTreated with a Probiotic Containing the Pingel/BM Non-Patho-reated with a Probiotic Containing the Pingel/BM Non-Patho-reated with a Probiotic Containing the Pingel/BM Non-Patho-reated with a Probiotic Containing the Pingel/BM Non-Patho-reated with a Probiotic Containing the Pingel/BM Non-Patho-genic Strain of genic Strain of genic Strain of genic Strain of genic Strain of E coliE coliE coliE coliE coli.....M. L. McCann, R. Buck.2; 2Microbiology, Kaiser Permanente,Cleveland, OH, USA.

Su1.120 - Blockade of Interleukin 21 with Soluble IL21RFcSu1.120 - Blockade of Interleukin 21 with Soluble IL21RFcSu1.120 - Blockade of Interleukin 21 with Soluble IL21RFcSu1.120 - Blockade of Interleukin 21 with Soluble IL21RFcSu1.120 - Blockade of Interleukin 21 with Soluble IL21RFcReduces InflammatorReduces InflammatorReduces InflammatorReduces InflammatorReduces Inflammatory Cytokines and Correlates with Sup-y Cytokines and Correlates with Sup-y Cytokines and Correlates with Sup-y Cytokines and Correlates with Sup-y Cytokines and Correlates with Sup-pression of Disease in Mice Adoptively Tpression of Disease in Mice Adoptively Tpression of Disease in Mice Adoptively Tpression of Disease in Mice Adoptively Tpression of Disease in Mice Adoptively Transplanted withransplanted withransplanted withransplanted withransplanted withCD45RBCD45RBCD45RBCD45RBCD45RBhi hi hi hi hi CD4CD4CD4CD4CD4+++++ T Cells. T Cells. T Cells. T Cells. T Cells.M. Senices,1 L. Lowe,1 C. Groves,1 S. Benoit,1 X. Li,1 M. Leach,1C. Nickerson-Nutter,1 M. Collins,1 D. Young.1 1Inflammation,Wyeth Research, Cambridge, MA, USA.

Su1.121 - Role of ICOS in Regulating Mucosal TSu1.121 - Role of ICOS in Regulating Mucosal TSu1.121 - Role of ICOS in Regulating Mucosal TSu1.121 - Role of ICOS in Regulating Mucosal TSu1.121 - Role of ICOS in Regulating Mucosal Tolerance.olerance.olerance.olerance.olerance.C. V. Arancibia, A. H. Sharpe. 1Department of Pathology,Harvard Medical School, Boston, MA, USA.

Su1.122 - A Critical RegulatorSu1.122 - A Critical RegulatorSu1.122 - A Critical RegulatorSu1.122 - A Critical RegulatorSu1.122 - A Critical Regulatory Role of Th2-Like Ty Role of Th2-Like Ty Role of Th2-Like Ty Role of Th2-Like Ty Role of Th2-Like Transcrip-ranscrip-ranscrip-ranscrip-ranscrip-tion Factor c-Maf in Th1-Mediated Experimental Colitis.tion Factor c-Maf in Th1-Mediated Experimental Colitis.tion Factor c-Maf in Th1-Mediated Experimental Colitis.tion Factor c-Maf in Th1-Mediated Experimental Colitis.tion Factor c-Maf in Th1-Mediated Experimental Colitis.B. Weigmann,1 A. Nemetz,1 C. Becker,1 H.-A. Lehr,2 D. Strand,1P. R. Galle,1 I.-C. Ho,3 M. Neurath.1 1Laboratory of Immunol-ogy, I. Medical Clinic, Johannes Gutenberg University, Mainz,Germany; 2Institute of Pathology, Johannes Gutenberg Univer-sity, Mainz, Germany; 3Harvard School of Public Health andHarvard Medical School, Boston, MA.



Su1.123 - Dual Immune Suppressive Activity of 4AZA1378Su1.123 - Dual Immune Suppressive Activity of 4AZA1378Su1.123 - Dual Immune Suppressive Activity of 4AZA1378Su1.123 - Dual Immune Suppressive Activity of 4AZA1378Su1.123 - Dual Immune Suppressive Activity of 4AZA1378Alleviates TNBS-Induced Colitis in Mice.Alleviates TNBS-Induced Colitis in Mice.Alleviates TNBS-Induced Colitis in Mice.Alleviates TNBS-Induced Colitis in Mice.Alleviates TNBS-Induced Colitis in Mice.Chong Shen,1 Yuan Lin,2 Gavin Clydesdale,2 Ilse Sienaert,2

Steven De Jonghe,2 Karel Geboes,3 Louis Boon,2 Paul Rutgeerts,4Jan L. Ceuppens.1 1Laboratory of Experimental Immunology,Campus Gasthuiberg, Catholic University Leuven, Leuven,Vlaams-Brabant, Belgium; 24AZA Biosciences, Leuven, Vlaams-Brabant, Belgium; 3Department of Pathology, CampusGasthuiberg, Catholic University Leuven, Leuven, Vlaams-Brabant, Belgium; 4Department of Gastroenterology, CampusGasthuiberg, Catholic University Leuven, Leuven, Vlaams-Brabant, Belgium.

Su1.124 - Immunohistochemical Localization of Interleukin-6Su1.124 - Immunohistochemical Localization of Interleukin-6Su1.124 - Immunohistochemical Localization of Interleukin-6Su1.124 - Immunohistochemical Localization of Interleukin-6Su1.124 - Immunohistochemical Localization of Interleukin-6in Pancreatitis and Normal Pancreas.in Pancreatitis and Normal Pancreas.in Pancreatitis and Normal Pancreas.in Pancreatitis and Normal Pancreas.in Pancreatitis and Normal Pancreas.M. Jablonowska,1 H. Milnerowicz,1 J. Rabczynski,2 S.Milnerowicz.3 1Departament of Biomedical and EnvironmentalAnalyses, Wroclaw University of Medicine, Wroclaw, Poland;2Department of Pathological Anatomy, Wroclaw University ofMedicine, Wroclaw, Poland; 3Department and Clinic ofGastointestinal and General Surgery, Wroclaw University ofMedicine, Wroclaw, Poland.

Su1.125 - TSu1.125 - TSu1.125 - TSu1.125 - TSu1.125 - Tumor Derived TGF-beta Suppresses Inflamma-umor Derived TGF-beta Suppresses Inflamma-umor Derived TGF-beta Suppresses Inflamma-umor Derived TGF-beta Suppresses Inflamma-umor Derived TGF-beta Suppresses Inflamma-tion Dependent Colon Cancer Development by Inducingtion Dependent Colon Cancer Development by Inducingtion Dependent Colon Cancer Development by Inducingtion Dependent Colon Cancer Development by Inducingtion Dependent Colon Cancer Development by InducingFoxP3 in TFoxP3 in TFoxP3 in TFoxP3 in TFoxP3 in Tumor Infiltrating CD4+ T Cells.umor Infiltrating CD4+ T Cells.umor Infiltrating CD4+ T Cells.umor Infiltrating CD4+ T Cells.umor Infiltrating CD4+ T Cells.C. Becker,1 M. C. Fantini,1 C. Schramm,1 A. Nikolaev,1 P. R.Galle,1 M. F. Neurath.1 1I. Dept. of Medicine, University ofMainz, Mainz, Germany.

Su1.126 - Cross-Linking of Lipid Rafts on CD4Su1.126 - Cross-Linking of Lipid Rafts on CD4Su1.126 - Cross-Linking of Lipid Rafts on CD4Su1.126 - Cross-Linking of Lipid Rafts on CD4Su1.126 - Cross-Linking of Lipid Rafts on CD4+++++ T Cells T Cells T Cells T Cells T Cellsby an Epithelial Lectin, Galectin-4, Contributes to theby an Epithelial Lectin, Galectin-4, Contributes to theby an Epithelial Lectin, Galectin-4, Contributes to theby an Epithelial Lectin, Galectin-4, Contributes to theby an Epithelial Lectin, Galectin-4, Contributes to theExacerbation of Intestinal Inflammation.Exacerbation of Intestinal Inflammation.Exacerbation of Intestinal Inflammation.Exacerbation of Intestinal Inflammation.Exacerbation of Intestinal Inflammation.K. Shirane,1 A. Hokama,1 Y. Shimomura,1 A. Ogawa,1 M.Yoshida,2 S. T. Rietdijk,3 S. B. Snapper,4 C. Terhorst,3 R. S.Blumberg,2 A. Mizoguchi.1 1Department of Pathology,Massachusetts General Hospital, Boston, MA, USA; 2Divisionof Gastroenterology, Brigham and Women’s Hospital, Boston,MA, USA; 3Department of Immunology, Beth Israel DeaconessMedical Center, Boston, MA, USA; 4Department of Medicine,Massachusetts General Hospital, Boston, MA, USA.

Su1.127 - Immunohistochemical Localization of Copper/Su1.127 - Immunohistochemical Localization of Copper/Su1.127 - Immunohistochemical Localization of Copper/Su1.127 - Immunohistochemical Localization of Copper/Su1.127 - Immunohistochemical Localization of Copper/Zinc-Containing Superoxide Dismutase in Normal Pan-Zinc-Containing Superoxide Dismutase in Normal Pan-Zinc-Containing Superoxide Dismutase in Normal Pan-Zinc-Containing Superoxide Dismutase in Normal Pan-Zinc-Containing Superoxide Dismutase in Normal Pan-creas and in Pancreatitis.creas and in Pancreatitis.creas and in Pancreatitis.creas and in Pancreatitis.creas and in Pancreatitis.H. Milnerowicz,1 M. Jablonowska,1 J. Rabczynski,2 K.Grabowski.3 1Departament of Biomedical and EnvironmentalAnalyses, Wroclaw University of Medicine, Wroclaw, Poland;2Department of Pathological Anatomy, Wroclaw University ofMedicine, Wroclaw, Poland; 3Department and Clinic ofGastointestinal and General Surgery, Wroclaw University ofMedicine, Wroclaw, Poland.

Su1.128 - The Response of Blood Monocytes of CoeliacSu1.128 - The Response of Blood Monocytes of CoeliacSu1.128 - The Response of Blood Monocytes of CoeliacSu1.128 - The Response of Blood Monocytes of CoeliacSu1.128 - The Response of Blood Monocytes of CoeliacPatients to Gliadin.Patients to Gliadin.Patients to Gliadin.Patients to Gliadin.Patients to Gliadin.L. Palova-Jelinkova,1 J. Cinova,1 B. Pecharova,1 M. Cerna,2 L.Tuckova,1 H. Tlaskalova-Hogenova.1 1Department of Immu-nology, Czech Academy of Sciences, Prague, Czech Repub-lic; 23rd Medical Faculty, Charles University, Prague, CzechRepublic.

Su1.129 - Eosinophilic Esophagitis (EE): Improved ClinicalSu1.129 - Eosinophilic Esophagitis (EE): Improved ClinicalSu1.129 - Eosinophilic Esophagitis (EE): Improved ClinicalSu1.129 - Eosinophilic Esophagitis (EE): Improved ClinicalSu1.129 - Eosinophilic Esophagitis (EE): Improved ClinicalResponses without a Concomitant Reduction in EsophagealResponses without a Concomitant Reduction in EsophagealResponses without a Concomitant Reduction in EsophagealResponses without a Concomitant Reduction in EsophagealResponses without a Concomitant Reduction in EsophagealEosinophilic Infiltration.Eosinophilic Infiltration.Eosinophilic Infiltration.Eosinophilic Infiltration.Eosinophilic Infiltration.F. M. Schaffer, R. B. Pillai, K. A. Hetherington, R. Shannon, T.C. Hulsey, D. Lewin, S. N. Khubchandani, V. Tolia. 1PediatricPulmonary, Allergy, and Immunology, MUSC, Charleston, SC,USA; 2Pediatric Gastroenterology, MUSC, Charleston, SC,USA; 3Pediatrics, MUSC, Charleston, SC, USA; 4PediatricGastroenterology, MUSC, Charleston, SC, USA; 5PediatricEpidimiology, MUSC, Charleston, SC, USA; 6Pathology,MUSC, Charleston, SC, USA; 7Gastroenterology, Wayne StateSchool of Medicine, Detroit, MI, USA; 8Gastroenterology,Wayne State School of Medicine, Detroit, MI, USA.

20052005200520052005ANNUAL MEETING

119



Poster Session 2Poster Session 2Poster Session 2Poster Session 2Poster Session 2SundaySundaySundaySundaySunday, May 15, 2005, May 15, 2005, May 15, 2005, May 15, 2005, May 15, 2005


Immunodeficiency: PrimarImmunodeficiency: PrimarImmunodeficiency: PrimarImmunodeficiency: PrimarImmunodeficiency: Primary or Acquiredy or Acquiredy or Acquiredy or Acquiredy or Acquired

Su2.01 - Rheumatic Manifestations in a South Italy Popula-Su2.01 - Rheumatic Manifestations in a South Italy Popula-Su2.01 - Rheumatic Manifestations in a South Italy Popula-Su2.01 - Rheumatic Manifestations in a South Italy Popula-Su2.01 - Rheumatic Manifestations in a South Italy Popula-tion HIV Positive: Correlation with CD4 Count.tion HIV Positive: Correlation with CD4 Count.tion HIV Positive: Correlation with CD4 Count.tion HIV Positive: Correlation with CD4 Count.tion HIV Positive: Correlation with CD4 Count.A. Caliri,1 L. G. De Filippis,1 G. Scibilia,1 C. Romano,1 G. F.Bagnato.1 1Rheumatology Unit, Policlinico Universitario GMartino, Messina, ME, Italy.

Su2.02 - Quality Control of siRNA, Optimizing It’Su2.02 - Quality Control of siRNA, Optimizing It’Su2.02 - Quality Control of siRNA, Optimizing It’Su2.02 - Quality Control of siRNA, Optimizing It’Su2.02 - Quality Control of siRNA, Optimizing It’s Ts Ts Ts Ts Transfec-ransfec-ransfec-ransfec-ransfec-tion Efficiency and Monitoring CD4 Gene Silencing Effecttion Efficiency and Monitoring CD4 Gene Silencing Effecttion Efficiency and Monitoring CD4 Gene Silencing Effecttion Efficiency and Monitoring CD4 Gene Silencing Effecttion Efficiency and Monitoring CD4 Gene Silencing Effectwith a Microfluidic Chip Device.with a Microfluidic Chip Device.with a Microfluidic Chip Device.with a Microfluidic Chip Device.with a Microfluidic Chip Device.T. Preckel,1 C. Buhlmann,1 M. Valer.1 1Liquid Phase Analysis,Agilent Technologies, Waldbronn, BW, Germany.

Su2.03 - Cardiac Thrombus in Omenn Syndrome.Su2.03 - Cardiac Thrombus in Omenn Syndrome.Su2.03 - Cardiac Thrombus in Omenn Syndrome.Su2.03 - Cardiac Thrombus in Omenn Syndrome.Su2.03 - Cardiac Thrombus in Omenn Syndrome.S. S. Kilic.1 1Pediatric Immunology, Uludag University School ofMedicine, Bursa, Turkey.

Su2.04 - The Frequency and Effects of Vitamin A DeficiencySu2.04 - The Frequency and Effects of Vitamin A DeficiencySu2.04 - The Frequency and Effects of Vitamin A DeficiencySu2.04 - The Frequency and Effects of Vitamin A DeficiencySu2.04 - The Frequency and Effects of Vitamin A Deficiencyin Common Vin Common Vin Common Vin Common Vin Common Variable Immunodeficiency Patients.ariable Immunodeficiency Patients.ariable Immunodeficiency Patients.ariable Immunodeficiency Patients.ariable Immunodeficiency Patients.S. S. Kilic.1 1Pediatric Immunology, Uludag University School ofMedicine, Bursa, Turkey.

Su2.05 - PulmonarSu2.05 - PulmonarSu2.05 - PulmonarSu2.05 - PulmonarSu2.05 - Pulmonary Abscess Due to Aspergillus spp. in Pa-y Abscess Due to Aspergillus spp. in Pa-y Abscess Due to Aspergillus spp. in Pa-y Abscess Due to Aspergillus spp. in Pa-y Abscess Due to Aspergillus spp. in Pa-tients with Chronic Granulomatous Disease.tients with Chronic Granulomatous Disease.tients with Chronic Granulomatous Disease.tients with Chronic Granulomatous Disease.tients with Chronic Granulomatous Disease.S. S. Kilic.1 1Pediatric Immunology, Uludag University School ofMedicine, Bursa, Turkey.

Su2.06 - Hodgkin’Su2.06 - Hodgkin’Su2.06 - Hodgkin’Su2.06 - Hodgkin’Su2.06 - Hodgkin’s Ls Ls Ls Ls Lymphoma Developing in a 4.5-Yymphoma Developing in a 4.5-Yymphoma Developing in a 4.5-Yymphoma Developing in a 4.5-Yymphoma Developing in a 4.5-Yearearearearear-Old-Old-Old-Old-OldGirl with Hyper-IgE Syndrome.Girl with Hyper-IgE Syndrome.Girl with Hyper-IgE Syndrome.Girl with Hyper-IgE Syndrome.Girl with Hyper-IgE Syndrome.Mohammad Amin Kashef,1 Sara Kashef,2 Farhad Hanjani,3

Mehran Karimi.4 1Allergy Research Center, Shiraz University ofMedical Sciences, Shiraz, Fars, Islamic Republic of Iran; 2Immu-nology and Allergy, Shiraz University of Medical Sciences, Shiraz,Fars, Islamic Republic of Iran; 3Dermatology, Shiraz Universityof Medical Sciences, Shiraz, Fars, Islamic Republic of Iran; 4Pe-diatric Oncology, Shiraz University of Medical Sciences, Shiraz,Fars, Islamic Republic of Iran.

Su2.07 - The Prognostic ImporSu2.07 - The Prognostic ImporSu2.07 - The Prognostic ImporSu2.07 - The Prognostic ImporSu2.07 - The Prognostic Importance of Vtance of Vtance of Vtance of Vtance of Variants of Allele Genesariants of Allele Genesariants of Allele Genesariants of Allele Genesariants of Allele GenesHLA DRB1 and IL-4 in HIVHLA DRB1 and IL-4 in HIVHLA DRB1 and IL-4 in HIVHLA DRB1 and IL-4 in HIVHLA DRB1 and IL-4 in HIV-Infection.-Infection.-Infection.-Infection.-Infection.Loudmila P. Sizyakina, Julia V. Sokolova. 1Center of ClinicalImmunology, State Medical University, Rostov-on-Don, RussianFederation; 2Russian Federation.

Su2.08 - Recurrent Infections and Cytokine Imbalance inSu2.08 - Recurrent Infections and Cytokine Imbalance inSu2.08 - Recurrent Infections and Cytokine Imbalance inSu2.08 - Recurrent Infections and Cytokine Imbalance inSu2.08 - Recurrent Infections and Cytokine Imbalance inHyperHyperHyperHyperHyper-IgE Syndrome Are Not Due to a Defect in T-IgE Syndrome Are Not Due to a Defect in T-IgE Syndrome Are Not Due to a Defect in T-IgE Syndrome Are Not Due to a Defect in T-IgE Syndrome Are Not Due to a Defect in Toll-Like Re-oll-Like Re-oll-Like Re-oll-Like Re-oll-Like Re-ceptor Pathways.ceptor Pathways.ceptor Pathways.ceptor Pathways.ceptor Pathways.E. D. Renner,1 F. Hoffmann,1 I. Pawlita,1 V. Hornung,2 D. Hartl,1

M. Albert,1 A. Jansson,1 S. Endres,2 G. Hartmann,2 B. H.Belohradsky,1 S. Rothenfusser.2 1University Children’s Hospital,Dr. von Haunersches Kinderspital, Ludwig-Maximilians-Univer-sity, Munich, Germany; 2Department of Internal Medicine, Divi-sion of Clinical Pharmacology, Ludwig-Maximilians-University,Munich, Germany.

Su2.09 - Defective Functioning of Dendritic Cells in CommonSu2.09 - Defective Functioning of Dendritic Cells in CommonSu2.09 - Defective Functioning of Dendritic Cells in CommonSu2.09 - Defective Functioning of Dendritic Cells in CommonSu2.09 - Defective Functioning of Dendritic Cells in CommonVVVVVariable Immuno Deficiency (CVID): A Common Denomina-ariable Immuno Deficiency (CVID): A Common Denomina-ariable Immuno Deficiency (CVID): A Common Denomina-ariable Immuno Deficiency (CVID): A Common Denomina-ariable Immuno Deficiency (CVID): A Common Denomina-tor for the Multiple Symptoms Displayed by CVID Patients.tor for the Multiple Symptoms Displayed by CVID Patients.tor for the Multiple Symptoms Displayed by CVID Patients.tor for the Multiple Symptoms Displayed by CVID Patients.tor for the Multiple Symptoms Displayed by CVID Patients.Jagadeesh Bayry, Olivier Hermine, Eric Oksenhendler, MichelD. Kazatchkine, Srini V. Kaveri. 1Memory Group, The EdwardJenner Institute for Vaccine Research; INSERM U681, Compton,Nr Newbury, Berkshire, United Kingdom; 2CNRS – UMR 8147,Necker Hospital, Paris, France; 3Department of Clinical Immu-nopathology, Saint Louis Hospital, Paris, France; 4INSERM U681,Institut des Cordeliers, Paris, France; 5INSERM U681, Institut desCordeliers, Paris, France.

Su2.10 - Clinical Profile of PrimarSu2.10 - Clinical Profile of PrimarSu2.10 - Clinical Profile of PrimarSu2.10 - Clinical Profile of PrimarSu2.10 - Clinical Profile of Primary Immunodeficiencies Dis-y Immunodeficiencies Dis-y Immunodeficiencies Dis-y Immunodeficiencies Dis-y Immunodeficiencies Dis-eases Patientes Followed up at Hospital das Clínicas daeases Patientes Followed up at Hospital das Clínicas daeases Patientes Followed up at Hospital das Clínicas daeases Patientes Followed up at Hospital das Clínicas daeases Patientes Followed up at Hospital das Clínicas daUniversidade Federal de Minas Gerais.Universidade Federal de Minas Gerais.Universidade Federal de Minas Gerais.Universidade Federal de Minas Gerais.Universidade Federal de Minas Gerais.L. A.O. Cunha,1 D. B. Greco,2 J. A. Pinto.1 1Paediatrics,Faculdade de Medicina da Universidade Federal de MinasGerais, Belo Horizonte, Minas Gerais, Brazil; 2Infectious andContagious Diseases, Faculdade de Medicina da UniversidadeFederal de Minas Gerais, Belo Horizonte, Minas Gerais, Bra-zil.



Su2.11 - New Single Nucleotide Polymorphisms in the GeneSu2.11 - New Single Nucleotide Polymorphisms in the GeneSu2.11 - New Single Nucleotide Polymorphisms in the GeneSu2.11 - New Single Nucleotide Polymorphisms in the GeneSu2.11 - New Single Nucleotide Polymorphisms in the GeneEncoding the Phagocyte Oxidase 67 kDa Protein.Encoding the Phagocyte Oxidase 67 kDa Protein.Encoding the Phagocyte Oxidase 67 kDa Protein.Encoding the Phagocyte Oxidase 67 kDa Protein.Encoding the Phagocyte Oxidase 67 kDa Protein.L. Gomez-Restrepo,1 M. T. Rugeles,2 P. J. Patino,2 A. Condino-Neto.1,3 1Pediatrics, State University of Campinas MedicalSchool, Campinas, SP, Brazil; 2Immunology, University ofAntioquia Medical School, Medellin, Colombia; 3Immunology -Institute of Biomedical Sciences, University of Sao Paulo, SaoPaulo, Brazil.

Su2.12 - Chronic Granulomatous Disease in Latin AmericanSu2.12 - Chronic Granulomatous Disease in Latin AmericanSu2.12 - Chronic Granulomatous Disease in Latin AmericanSu2.12 - Chronic Granulomatous Disease in Latin AmericanSu2.12 - Chronic Granulomatous Disease in Latin AmericanPatients: Clinical Spectrum and Molecular Genetics.Patients: Clinical Spectrum and Molecular Genetics.Patients: Clinical Spectrum and Molecular Genetics.Patients: Clinical Spectrum and Molecular Genetics.Patients: Clinical Spectrum and Molecular Genetics.P. Agudelo-Florez,1 C. Prando-Andrade,1 J. A. Lopez,1 B. T. Costa-Carvalho,2 A. Quezada,3 F. J. Espinosa,4 M. A. Souza-Paiva,5

P. Roxo,6 M. M.S. Carneiro-Sampaio,7 P. E. Newburger,8 A.Condino-Neto.1,7 1Pediatrics, State University of CampinasMedical School, Campinas, SP, Brazil; 2Pediatrics - Allergy, Im-munology & Rheumatology, Federal University of Sao PauloMedical School, Sao Paulo, Brazil; 3Pediatrics, University of ChileMedical School, Santiago, Chile; 4Immunology, National Insti-tute of Pediatrics, Mexico, Mexico; 5Pediatrics, Rio de JaneiroState Employees Hospital, Rio de Janeiro, Brazil; 6Pediatrics,Ribeirao Preto Medical School - University of Sao Paulo, RibeiraoPreto, SP, Brazil; 7Immunology, Institute of Biomedical Sciences -University of Sao Paulo, Sao Paulo, Brazil; 8Pediatrics, Univer-sity of Massachusetts Medical School, Worcester, MA, USA.

Su2.13 - HereditarSu2.13 - HereditarSu2.13 - HereditarSu2.13 - HereditarSu2.13 - Hereditary Angioedema in Childhood - A Practicey Angioedema in Childhood - A Practicey Angioedema in Childhood - A Practicey Angioedema in Childhood - A Practicey Angioedema in Childhood - A PracticeGuideline.Guideline.Guideline.Guideline.Guideline.R. J. Boyle,1 M. L.K. Tang.1 1Immunology, Royal Children’s Hos-pital, Parkville, Victoria, Australia.

Su2.14 - AbnorSu2.14 - AbnorSu2.14 - AbnorSu2.14 - AbnorSu2.14 - Abnormal Neutrophil’mal Neutrophil’mal Neutrophil’mal Neutrophil’mal Neutrophil’s Chemotactic Activity ins Chemotactic Activity ins Chemotactic Activity ins Chemotactic Activity ins Chemotactic Activity inChildren with Congenital Insensitivity to Pain with AnhidrosisChildren with Congenital Insensitivity to Pain with AnhidrosisChildren with Congenital Insensitivity to Pain with AnhidrosisChildren with Congenital Insensitivity to Pain with AnhidrosisChildren with Congenital Insensitivity to Pain with Anhidrosis(CIP(CIP(CIP(CIP(CIPA): The Role of NerA): The Role of NerA): The Role of NerA): The Role of NerA): The Role of Nerve Growth Factor in Chemotactic Ac-ve Growth Factor in Chemotactic Ac-ve Growth Factor in Chemotactic Ac-ve Growth Factor in Chemotactic Ac-ve Growth Factor in Chemotactic Ac-tivitytivitytivitytivitytivity.....A. Beigelman,1 J. Levy,1 N. Hadad,2 V. Pinsk,1 R. Levy.2 1De-partment of Pediatrics, Soroka Medical Center, Beer Sheva, Is-rael; 2Infectious Disease Laboratory, Soroka Medical Center, BeerSheva, Israel.

Su2.15 - The IgG 2F5-Like Antibody in Serum of MexicanSu2.15 - The IgG 2F5-Like Antibody in Serum of MexicanSu2.15 - The IgG 2F5-Like Antibody in Serum of MexicanSu2.15 - The IgG 2F5-Like Antibody in Serum of MexicanSu2.15 - The IgG 2F5-Like Antibody in Serum of MexicanPatients with AIDS Progression Prior to and after the HighlyPatients with AIDS Progression Prior to and after the HighlyPatients with AIDS Progression Prior to and after the HighlyPatients with AIDS Progression Prior to and after the HighlyPatients with AIDS Progression Prior to and after the HighlyActive Anti-Retroviral TherapyActive Anti-Retroviral TherapyActive Anti-Retroviral TherapyActive Anti-Retroviral TherapyActive Anti-Retroviral Therapy.....Y. Palacios-Rodriguez,1 T. G. Gazarian,2 A. Majluf-Cruz,3 K.G. Gazarian.1 1Department of Molecular Biology and Biotech-nology, Institute of Biomedical Research, Mexican NationalUniversity(UNAM), Mexico-City, DF, Mexico; 2Department ofPublic Health, Faculty of Medicine, Mexican NationalUniversity(UNAM), Mexico-City, DF, Mexico; 3AIDS Clinic, Re-gional Hoospital “Gabriel Mancera”, Mexico-City, DF, Mexico.

Su2.16 - Genetically Determined Deficiency of the InnateSu2.16 - Genetically Determined Deficiency of the InnateSu2.16 - Genetically Determined Deficiency of the InnateSu2.16 - Genetically Determined Deficiency of the InnateSu2.16 - Genetically Determined Deficiency of the InnateImmune Defence Protein, MBL-Associated Serine Protease-2Immune Defence Protein, MBL-Associated Serine Protease-2Immune Defence Protein, MBL-Associated Serine Protease-2Immune Defence Protein, MBL-Associated Serine Protease-2Immune Defence Protein, MBL-Associated Serine Protease-2(MASP-2).(MASP-2).(MASP-2).(MASP-2).(MASP-2).S. Thiel,1 J. C. Jensenius,1 L. Truedsson,2 M. Carlsson,2 W. K.Ip,3 Y. C. Lau.3 1Medical Microbiology and Immunology, Uni-versity of Aarhus, Aarhus, Denmark; 2Clinical Microbiology andImmunology, Lund University Hospital, Lund, Sweden; 3Paediat-rics and Adolescent Medicine, The University of Hong Kong,Hong Kong, China.

Su2.17 - Phenotypic Analysis of Peripheral Blood and TissueSu2.17 - Phenotypic Analysis of Peripheral Blood and TissueSu2.17 - Phenotypic Analysis of Peripheral Blood and TissueSu2.17 - Phenotypic Analysis of Peripheral Blood and TissueSu2.17 - Phenotypic Analysis of Peripheral Blood and TissueMemorMemorMemorMemorMemory B Cells in Common Vy B Cells in Common Vy B Cells in Common Vy B Cells in Common Vy B Cells in Common Variable Immunodeficiencyariable Immunodeficiencyariable Immunodeficiencyariable Immunodeficiencyariable Immunodeficiency(CVID).(CVID).(CVID).(CVID).(CVID).A. P. Williams,1 C. Stephens,1 L. Hedges,1 A. Mani,1 E. Hodges,1J. Smith.1 1Department of Clinical Immunology, SouthamptonGeneral Hospital, Southampton, United Kingdom.

Su2.18 - Plasma Interleukin-7 Levels before Highly ActiveSu2.18 - Plasma Interleukin-7 Levels before Highly ActiveSu2.18 - Plasma Interleukin-7 Levels before Highly ActiveSu2.18 - Plasma Interleukin-7 Levels before Highly ActiveSu2.18 - Plasma Interleukin-7 Levels before Highly ActiveAntiretroviral Therapy May Predict CD4+ TAntiretroviral Therapy May Predict CD4+ TAntiretroviral Therapy May Predict CD4+ TAntiretroviral Therapy May Predict CD4+ TAntiretroviral Therapy May Predict CD4+ T-Cells Recover-Cells Recover-Cells Recover-Cells Recover-Cells Recovery iny iny iny iny inHIVHIVHIVHIVHIV-Children.-Children.-Children.-Children.-Children.A. Perez,1 S. Resino,1 A.A. Meca,1 M.D. Gurbindo,2 M.AMunoz-Fernandez.1 1Laboratorio de Immunobiologia Molecu-lar, Hospital “Gregorio Maranon”, Madrid, Spain; 2Servicio deInmuno-Pediatria, Hospital “Gregorio Maranon”, Madrid, Spain.

Su2.19 - Different Profiles of Immune Reconstitution in Chil-Su2.19 - Different Profiles of Immune Reconstitution in Chil-Su2.19 - Different Profiles of Immune Reconstitution in Chil-Su2.19 - Different Profiles of Immune Reconstitution in Chil-Su2.19 - Different Profiles of Immune Reconstitution in Chil-dren and Adults with HIVdren and Adults with HIVdren and Adults with HIVdren and Adults with HIVdren and Adults with HIV-Infection after HAAR-Infection after HAAR-Infection after HAAR-Infection after HAAR-Infection after HAARTTTTT.....S. Resino,1 E. Seoane,1 A. Perez,1 E. Ruiz-Mateos,2 M. Leal,2M.A. Munoz-Fernadez.1 1Laboratorio de Inmuno-Biologia Mo-lecular, Hospital General Universitario “Gregorio Maranon”,Madrid, Spain; 2Grupo de Estudio Hepatitis Virica y SIDA, Hos-pital Universitario “Virgen del Rocio”, Sevilla, Spain.

20052005200520052005ANNUAL MEETING

121



Su2.20 - Understanding HIV Infection through DynamicalSu2.20 - Understanding HIV Infection through DynamicalSu2.20 - Understanding HIV Infection through DynamicalSu2.20 - Understanding HIV Infection through DynamicalSu2.20 - Understanding HIV Infection through DynamicalModeling: VModeling: VModeling: VModeling: VModeling: Vaccines Waccines Waccines Waccines Waccines Won’on’on’on’on’t Wt Wt Wt Wt Work, What Work, What Work, What Work, What Work, What Will?ill?ill?ill?ill?I. Kramer.1 1Physics, Univ. of MD, Catonsville, MD.

Su2.21 - Model for the Repopulating Capacity of TSu2.21 - Model for the Repopulating Capacity of TSu2.21 - Model for the Repopulating Capacity of TSu2.21 - Model for the Repopulating Capacity of TSu2.21 - Model for the Repopulating Capacity of TransplantedransplantedransplantedransplantedransplantedT Cells.T Cells.T Cells.T Cells.T Cells.Sebastian Newrzela,1 Sanaz Taromi,1 Roland Zahn,1 DorotheeVon Laer.1 1Georg-Speyer-Haus (ChemotherapeutischesForschungszentrum), Georg-Speyer-Haus (ChemotherapeutischesForschungszentrum), Frankfurt AM Main, Hessen, Germany.

Su2.22 - Apoptosis and the Emergence of Clonal Dual Posi-Su2.22 - Apoptosis and the Emergence of Clonal Dual Posi-Su2.22 - Apoptosis and the Emergence of Clonal Dual Posi-Su2.22 - Apoptosis and the Emergence of Clonal Dual Posi-Su2.22 - Apoptosis and the Emergence of Clonal Dual Posi-tive CD4CD8 Cells in a Ytive CD4CD8 Cells in a Ytive CD4CD8 Cells in a Ytive CD4CD8 Cells in a Ytive CD4CD8 Cells in a Young Boy with CD4 Loung Boy with CD4 Loung Boy with CD4 Loung Boy with CD4 Loung Boy with CD4 Lymphopenia.ymphopenia.ymphopenia.ymphopenia.ymphopenia.M. T. Krishna,1 E. Hodges,1 S. Harris,1 S. M. Morgan,1 J. O.Warner,2 J. Hourihane,2 J. L. Smith.1 1Wessex Immunology Ser-vice, Southampton University Hospitals NHS Trust, Southampton,Hampshire, United Kingdom; 2Division of Infection, Inflamma-tion and Repair, School of Medicine, Southampton UniversityHospitals NHS Trust, Southampton, Hampshire, United Kingdom.

Su2.23-Hypogammaglobulinemia andSu2.23-Hypogammaglobulinemia andSu2.23-Hypogammaglobulinemia andSu2.23-Hypogammaglobulinemia andSu2.23-Hypogammaglobulinemia andLLLLLymphoproliferation in Tymphoproliferation in Tymphoproliferation in Tymphoproliferation in Tymphoproliferation in Two Patients with Heterozygouswo Patients with Heterozygouswo Patients with Heterozygouswo Patients with Heterozygouswo Patients with HeterozygousDeleterious Mutation of the Caspase-9 Gene.Deleterious Mutation of the Caspase-9 Gene.Deleterious Mutation of the Caspase-9 Gene.Deleterious Mutation of the Caspase-9 Gene.Deleterious Mutation of the Caspase-9 Gene.A. Chiocchetti,1 R. Mesturini,1 T. Bensi,1 A. Biava,1 M. Ferretti,1

C. Santoro,1 C. Pignata,2 F. Rieux-Laucat,3 I. Dianzani,1 U.Ramenghi,4 L. D. Notarangelo,5 U. Dianzani.1 1IRCAD andDepartment of Medical Sciences, University of Eastern Piedmont,Novara, Italy; 2Department of Pediatrics, University of Naples,Naples, Italy; 3INSERM Unite 429, Hopital Necker-EnfantsMalades, Paris, France; 4Department of Pediatrics, University ofTurin, Turin, Italy; 5Department of Pediatrics, University of Brescia,Brescia, Italy.

Su2.24 - Haplotypes, Mutations and Phenotype GenotypeSu2.24 - Haplotypes, Mutations and Phenotype GenotypeSu2.24 - Haplotypes, Mutations and Phenotype GenotypeSu2.24 - Haplotypes, Mutations and Phenotype GenotypeSu2.24 - Haplotypes, Mutations and Phenotype GenotypeCorrelation in TCorrelation in TCorrelation in TCorrelation in TCorrelation in Turkish A-T Patients.urkish A-T Patients.urkish A-T Patients.urkish A-T Patients.urkish A-T Patients.O. Sanal,1 B. Behjatnia,2 M. Mitsui,2 F. Ersoy,1 I. Tezcan,1 A. I.Berkel,1 R. A. Gatti.2 1Pediatric Immunology, Hacettepe Univer-sity Scool of Medicine, Ankara, Turkey; 2Pathology and Labora-tory Medicine, UCLA School of Medicine, Los Angeles, CA, USA.

Su2.25 - Mechanisms of Immunotoxicity of Mycotoxins.Su2.25 - Mechanisms of Immunotoxicity of Mycotoxins.Su2.25 - Mechanisms of Immunotoxicity of Mycotoxins.Su2.25 - Mechanisms of Immunotoxicity of Mycotoxins.Su2.25 - Mechanisms of Immunotoxicity of Mycotoxins.Elena Dorofeeva,1 Roman Khanferyan.1 1Immunoregulation,Institute of Allergy and Asthma, Krasnodar, Russian Federation.

Su2.26 - Immunotherapy by Cytogenes in Patients with Ac-Su2.26 - Immunotherapy by Cytogenes in Patients with Ac-Su2.26 - Immunotherapy by Cytogenes in Patients with Ac-Su2.26 - Immunotherapy by Cytogenes in Patients with Ac-Su2.26 - Immunotherapy by Cytogenes in Patients with Ac-quired Neutropenia.quired Neutropenia.quired Neutropenia.quired Neutropenia.quired Neutropenia.Vardan Sergey Aprikyan, Nata Adolf Otieva.1Neuroimmunology, Inst. of Biochemistry, Yerevan, Armenia;2Pharmacology, State University, Yerevan, Armenia.

Su2.27 - Evaluation of Humoral Immune Responsein ChildrenSu2.27 - Evaluation of Humoral Immune Responsein ChildrenSu2.27 - Evaluation of Humoral Immune Responsein ChildrenSu2.27 - Evaluation of Humoral Immune Responsein ChildrenSu2.27 - Evaluation of Humoral Immune Responsein Childrenwith Otitis Media and Control Group.with Otitis Media and Control Group.with Otitis Media and Control Group.with Otitis Media and Control Group.with Otitis Media and Control Group.Farzad Oreizi, Maryam Saleminik, Ahmad GhavamiNejad,Fereshteh Sahebfosul. 1Immunology, Isfahan University of Medi-cal Science, Isfahan, Isfahan, Islamic Republic of Iran;2Flowcytometry, BD Company, San Francisco, CA, USA; 3Immu-nology, Isfahan University of Medical Sciences, Isfahan, Isfahan,Islamic Republic of Iran; 4Immunology, Isfahan University ofMedical Sciences, Isfahan, Isfahn, Islamic Republic of Iran.

Su2.28 - New Composition Immunotherapy in TSu2.28 - New Composition Immunotherapy in TSu2.28 - New Composition Immunotherapy in TSu2.28 - New Composition Immunotherapy in TSu2.28 - New Composition Immunotherapy in Treatment ofreatment ofreatment ofreatment ofreatment ofSecondarSecondarSecondarSecondarSecondary Immunodeficiency Accompanied by Vy Immunodeficiency Accompanied by Vy Immunodeficiency Accompanied by Vy Immunodeficiency Accompanied by Vy Immunodeficiency Accompanied by Viral Infec-iral Infec-iral Infec-iral Infec-iral Infec-tious Syndrome.tious Syndrome.tious Syndrome.tious Syndrome.tious Syndrome.Nesterova V. Irina. 1Department of Family Medicine, Educa-tional-Scientific Centre of Medical Centre of MD of Russian Presi-dent, Moscow, Russian Federation.

Su2.29 - Therapeutic Efficacy of Gc Protein-Derived Mac-Su2.29 - Therapeutic Efficacy of Gc Protein-Derived Mac-Su2.29 - Therapeutic Efficacy of Gc Protein-Derived Mac-Su2.29 - Therapeutic Efficacy of Gc Protein-Derived Mac-Su2.29 - Therapeutic Efficacy of Gc Protein-Derived Mac-rophage Activating Factor for HIVrophage Activating Factor for HIVrophage Activating Factor for HIVrophage Activating Factor for HIVrophage Activating Factor for HIV-Infected/AIDS Patients.-Infected/AIDS Patients.-Infected/AIDS Patients.-Infected/AIDS Patients.-Infected/AIDS Patients.N. Yamamoto,1 M. Ueda.1 1Molecular Immunology, SocratesInstitute for Therapeutic Immunology, Philadelphia, PA, USA.

Su2.30 - Pathogenic Significance ofSu2.30 - Pathogenic Significance ofSu2.30 - Pathogenic Significance ofSu2.30 - Pathogenic Significance ofSu2.30 - Pathogenic Significance ofααααα-N-Acetylgalactosaminidase Activity Found in the Fusion-N-Acetylgalactosaminidase Activity Found in the Fusion-N-Acetylgalactosaminidase Activity Found in the Fusion-N-Acetylgalactosaminidase Activity Found in the Fusion-N-Acetylgalactosaminidase Activity Found in the FusionProtein gp160 of Human Immunodeficiency VProtein gp160 of Human Immunodeficiency VProtein gp160 of Human Immunodeficiency VProtein gp160 of Human Immunodeficiency VProtein gp160 of Human Immunodeficiency Virus Tirus Tirus Tirus Tirus Type 1.ype 1.ype 1.ype 1.ype 1.N. Yamamoto. 1Molecular Immunology, Socrates Institute forTherapeutic Immunology, Philadelphia, PA, USA.

Su2.31 - Clinical and LaboratorSu2.31 - Clinical and LaboratorSu2.31 - Clinical and LaboratorSu2.31 - Clinical and LaboratorSu2.31 - Clinical and Laboratory Findings in Ty Findings in Ty Findings in Ty Findings in Ty Findings in Twenty Eightwenty Eightwenty Eightwenty Eightwenty EightPatients with a PrimarPatients with a PrimarPatients with a PrimarPatients with a PrimarPatients with a Primary Immunoglobulin Deficiency Associ-y Immunoglobulin Deficiency Associ-y Immunoglobulin Deficiency Associ-y Immunoglobulin Deficiency Associ-y Immunoglobulin Deficiency Associ-ated with Lated with Lated with Lated with Lated with Lymphadenopathyymphadenopathyymphadenopathyymphadenopathyymphadenopathy, Hepatosplenomegaly and Pul-, Hepatosplenomegaly and Pul-, Hepatosplenomegaly and Pul-, Hepatosplenomegaly and Pul-, Hepatosplenomegaly and Pul-monarmonarmonarmonarmonary Infiltrates.y Infiltrates.y Infiltrates.y Infiltrates.y Infiltrates.W. Ding,1 C. R. Weiler.1 1Internal Medicine, Mayo Clinic Col-lege of Medicine, Rochester, MN, USA.



Su2.32 - ThirSu2.32 - ThirSu2.32 - ThirSu2.32 - ThirSu2.32 - Thirteen Yteen Yteen Yteen Yteen Years of ears of ears of ears of ears of M. bovis-BCGM. bovis-BCGM. bovis-BCGM. bovis-BCGM. bovis-BCG Culture-Positive In- Culture-Positive In- Culture-Positive In- Culture-Positive In- Culture-Positive In-fection in an IL-12Rfection in an IL-12Rfection in an IL-12Rfection in an IL-12Rfection in an IL-12Rβββββ1 Deficient Patient: T1 Deficient Patient: T1 Deficient Patient: T1 Deficient Patient: T1 Deficient Patient: Treatment and Out-reatment and Out-reatment and Out-reatment and Out-reatment and Out-come.come.come.come.come.Sergio D. Rosenzweig,1 Judith Yancoski,1 Andrea Bernasconi,1

Silvia Krasovec,1 Beatriz E. Marciano,1 Lidia Casimir,1 NorbertoSimboli,2 Griselda Berberian,1 Marcela Russeau,1 GracielaCalle.1 1Hospital Nacional de Pediatria, “J. P. Garrahan”,Buenos Aires, Argentina; 2Servicio de Micobacterias, INEI ANLIS“Dr. C. G. Malbran”, Buenos Aires, Argentina.

Su2.33 - Equivalent PerSu2.33 - Equivalent PerSu2.33 - Equivalent PerSu2.33 - Equivalent PerSu2.33 - Equivalent Perforforforforformance of Vmance of Vmance of Vmance of Vmance of VACUTACUTACUTACUTACUTAINER® CPT™toAINER® CPT™toAINER® CPT™toAINER® CPT™toAINER® CPT™toFicoll-Hypaque Gradient Separation in Maintaining the Qual-Ficoll-Hypaque Gradient Separation in Maintaining the Qual-Ficoll-Hypaque Gradient Separation in Maintaining the Qual-Ficoll-Hypaque Gradient Separation in Maintaining the Qual-Ficoll-Hypaque Gradient Separation in Maintaining the Qual-ity and Function of PBMC from HIV Seropositive Bloodity and Function of PBMC from HIV Seropositive Bloodity and Function of PBMC from HIV Seropositive Bloodity and Function of PBMC from HIV Seropositive Bloodity and Function of PBMC from HIV Seropositive BloodSamples.Samples.Samples.Samples.Samples.J. J. Ruitenberg,1 C. B. Mulder,2 V. C. Maino,1 A. L. Landay,2 S.A. Ghanekar.1 1&1pGL2Immunology and Microbiology, RUSHUniversity Medical Center, Chicago, IL, USA.

Su2.34 - B inding of the Green TSu2.34 - B inding of the Green TSu2.34 - B inding of the Green TSu2.34 - B inding of the Green TSu2.34 - B inding of the Green Tea Po lyphenol ,ea Po lyphenol ,ea Po lyphenol ,ea Po lyphenol ,ea Po lyphenol ,Epigallocatechin Gallate, to the CD4 Receptor on HumanEpigallocatechin Gallate, to the CD4 Receptor on HumanEpigallocatechin Gallate, to the CD4 Receptor on HumanEpigallocatechin Gallate, to the CD4 Receptor on HumanEpigallocatechin Gallate, to the CD4 Receptor on HumanCD4+T Cells Resulting in Inhibition of HIVCD4+T Cells Resulting in Inhibition of HIVCD4+T Cells Resulting in Inhibition of HIVCD4+T Cells Resulting in Inhibition of HIVCD4+T Cells Resulting in Inhibition of HIV-1-gp120 Binding.-1-gp120 Binding.-1-gp120 Binding.-1-gp120 Binding.-1-gp120 Binding.C. L. Nance,1 M. P. Williamson,2 T. G. McCormick,1 W. T.Shearer.1 1Pediatrics/Allergy and Immunology, Baylor Collegeof Medicine, Houston, TX, USA; 2Biochemistry, University ofSheffield, Sheffield, England, United Kingdom.

Su2.35 - Defect in CRAC Ca2+ Channel Function AssociatedSu2.35 - Defect in CRAC Ca2+ Channel Function AssociatedSu2.35 - Defect in CRAC Ca2+ Channel Function AssociatedSu2.35 - Defect in CRAC Ca2+ Channel Function AssociatedSu2.35 - Defect in CRAC Ca2+ Channel Function Associatedwith Altered K+ Channel Gating Properties in T Cells fromwith Altered K+ Channel Gating Properties in T Cells fromwith Altered K+ Channel Gating Properties in T Cells fromwith Altered K+ Channel Gating Properties in T Cells fromwith Altered K+ Channel Gating Properties in T Cells fromImmunodeficient Patients.Immunodeficient Patients.Immunodeficient Patients.Immunodeficient Patients.Immunodeficient Patients.S. Feske,1 M. Prakriya,2 R. S. Lewis,2 A. Rao.1 1CBR Institute forBiomedical Research, Harvard Medical School, Boston, MA,USA; 2Dept Molecular and Cellular Physiology, Stanford Uni-versity, Stanford, CA, USA.

Su2.36 - Proposal for Diagnostic Criteria for Immunodefi-Su2.36 - Proposal for Diagnostic Criteria for Immunodefi-Su2.36 - Proposal for Diagnostic Criteria for Immunodefi-Su2.36 - Proposal for Diagnostic Criteria for Immunodefi-Su2.36 - Proposal for Diagnostic Criteria for Immunodefi-ciency Associated with DiGeorge Syndrome.ciency Associated with DiGeorge Syndrome.ciency Associated with DiGeorge Syndrome.ciency Associated with DiGeorge Syndrome.ciency Associated with DiGeorge Syndrome.A. Sediva,1 A. Janda.1 1Institute of Immunology, University Hos-pital Motol, Prague, Czech Republic.

Su2.37 - Immunological Characterization of Children withSu2.37 - Immunological Characterization of Children withSu2.37 - Immunological Characterization of Children withSu2.37 - Immunological Characterization of Children withSu2.37 - Immunological Characterization of Children withTTTTTransient Hypogammaglobulinemia of Infancy (THI): In Vransient Hypogammaglobulinemia of Infancy (THI): In Vransient Hypogammaglobulinemia of Infancy (THI): In Vransient Hypogammaglobulinemia of Infancy (THI): In Vransient Hypogammaglobulinemia of Infancy (THI): In VitroitroitroitroitroImmunoglobulin Production Is a Candidate Predictive MarkerImmunoglobulin Production Is a Candidate Predictive MarkerImmunoglobulin Production Is a Candidate Predictive MarkerImmunoglobulin Production Is a Candidate Predictive MarkerImmunoglobulin Production Is a Candidate Predictive Marker.....V. Moschese,1 S. Graziani,1 M.A. Avanzini,2 R. Carsetti,3 I.Quinti,4 A. Plebani,5 A. Soresina,5 S. Di Cesare,1 L. Chini,1 M.Marconi,2 G. Bossi,6 M. La Rocca,1 R. Maccario,2 P. Rossi,1,3

A.G. Ugazio.3 1Pediatrics, Policlinico Tor Vergata, University ofTor Vergata, Rome, Italy; 2Laboratorio Area Trapianti, IRCCS,Policlinico San Matteo, Pavia, Italy; 3Ospedale PediatricoBambino Gesu, Rome, Holy See (Vatican City State); 4UniversityLa Sapienza, Rome, Italy; 5Pediatrics, University of Brescia,Brescia, Italy; 6Scienze Pediatriche, Policlinico San Matteo, Pavia,Italy.

Su2.38 - Health-Related Quality of Life in Patients with Pri-Su2.38 - Health-Related Quality of Life in Patients with Pri-Su2.38 - Health-Related Quality of Life in Patients with Pri-Su2.38 - Health-Related Quality of Life in Patients with Pri-Su2.38 - Health-Related Quality of Life in Patients with Pri-marmarmarmarmary Immunodeficiencies in Nory Immunodeficiencies in Nory Immunodeficiencies in Nory Immunodeficiencies in Nory Immunodeficiencies in North America Receiving Home-th America Receiving Home-th America Receiving Home-th America Receiving Home-th America Receiving Home-Based Subcutaneous Immunologlobulin Replacement TherapyBased Subcutaneous Immunologlobulin Replacement TherapyBased Subcutaneous Immunologlobulin Replacement TherapyBased Subcutaneous Immunologlobulin Replacement TherapyBased Subcutaneous Immunologlobulin Replacement Therapy.....Uwe Nicolay,1 Peter Kiessling,2 Ann Gardulf,1 Hans D. Ochs.3

1Department of Laboratory Medicine, Section of Clinical Immu-nology, Karolinska Institutet at Karolinska University Hospital,Stockholm, Sweden; 2Clinical Research & Development, ZLBBehring GmbH, Marburg, Germany; 3Department of Pediat-rics, University of Washington, Seattle, WA, USA.

Su2.39 - Host MHC Influences Susceptibility to Hypersensi-Su2.39 - Host MHC Influences Susceptibility to Hypersensi-Su2.39 - Host MHC Influences Susceptibility to Hypersensi-Su2.39 - Host MHC Influences Susceptibility to Hypersensi-Su2.39 - Host MHC Influences Susceptibility to Hypersensi-tivity Reactions to Ttivity Reactions to Ttivity Reactions to Ttivity Reactions to Ttivity Reactions to Two Drugs Commonly Used in HIV Therapywo Drugs Commonly Used in HIV Therapywo Drugs Commonly Used in HIV Therapywo Drugs Commonly Used in HIV Therapywo Drugs Commonly Used in HIV Therapy.....F. T. Christiansen,1 A. M. Martin,1 D. A. Nolan,1 S. Gaudieri,1C. A. Almeida,1 E. Phillips,1 P. U. Cameron,1 C. B. Moore,1 I.James,1 S. A. Mallal.1 1Department of Clinical Immunology &Biochemical Genetics & Centre for Clinical Immunology & Bio-medical Statistics, Royal Perth Hospital, Perth, Western Austra-lia, Australia.

Su2.40 - Multisystem Disease in CAEBV Infection.Su2.40 - Multisystem Disease in CAEBV Infection.Su2.40 - Multisystem Disease in CAEBV Infection.Su2.40 - Multisystem Disease in CAEBV Infection.Su2.40 - Multisystem Disease in CAEBV Infection.A. P. Williams,1 J. O’B Hourihane,2 E. Hodges,1 H. B. Gaspar,3J. Smith.1 1Department of Clinical Immunology, SouthamptonGeneral Hospital, Southampton, United Kingdom; 2Departmentof Child Health, Southampton General Hospital, Southampton,United Kingdom; 3Molecular Immunology Unit, Institute of ChildHealth, London, United Kingdom.

20052005200520052005ANNUAL MEETING

123



Su2.41 - Infants with Recurrent Infections and Low Immuno-Su2.41 - Infants with Recurrent Infections and Low Immuno-Su2.41 - Infants with Recurrent Infections and Low Immuno-Su2.41 - Infants with Recurrent Infections and Low Immuno-Su2.41 - Infants with Recurrent Infections and Low Immuno-globulins: Analysis of Immunoglobluin Normalization.globulins: Analysis of Immunoglobluin Normalization.globulins: Analysis of Immunoglobluin Normalization.globulins: Analysis of Immunoglobluin Normalization.globulins: Analysis of Immunoglobluin Normalization.M. A. Whelan,1 S. J. Kung,1 S. J. McGeady.2 1Allergy/Immu-nology, Thomas Jefferson University Hospital, Philadelphia, PA,USA; 2Allergy/Immunology, AI duPont Hospital for Children,Wilmington, DE, USA.

Su2.42 - The Role of Wiskott Aldrich Syndrome Protein in TSu2.42 - The Role of Wiskott Aldrich Syndrome Protein in TSu2.42 - The Role of Wiskott Aldrich Syndrome Protein in TSu2.42 - The Role of Wiskott Aldrich Syndrome Protein in TSu2.42 - The Role of Wiskott Aldrich Syndrome Protein in THelper Cell Function.Helper Cell Function.Helper Cell Function.Helper Cell Function.Helper Cell Function.J. Aoki,1 A. Konno,2 D. Jankovic,3 J. Cannons,1 F. Candotti,2 P.Schwartzberg.1 1Genetic Disease Research Branch, NationalHuman Genome Research Institute, Bethesda, MD, USA; 2Ge-netics and Molecular Biology Branch, National Human GenomeResearch Institute, Bethesda, MD, USA; 3Laboratory of ParasiticDiseases, National Institute of Allergy and Infectious Diseases,Bethesda, MD, USA.

Su2.43 - Cyclic CD4 LSu2.43 - Cyclic CD4 LSu2.43 - Cyclic CD4 LSu2.43 - Cyclic CD4 LSu2.43 - Cyclic CD4 Lymphopenia and Absence Interleukin-ymphopenia and Absence Interleukin-ymphopenia and Absence Interleukin-ymphopenia and Absence Interleukin-ymphopenia and Absence Interleukin-2: A Novel Immunodeficiency Presentation.2: A Novel Immunodeficiency Presentation.2: A Novel Immunodeficiency Presentation.2: A Novel Immunodeficiency Presentation.2: A Novel Immunodeficiency Presentation.Ronit Herzog, Joan Berman, Shirley Fung, Arye Rubinstein. 1Al-lergy and Immunology, Albert Einstein College of Medicine,Bronx, NY, USA.

Su2.44 - Novel Severe TSu2.44 - Novel Severe TSu2.44 - Novel Severe TSu2.44 - Novel Severe TSu2.44 - Novel Severe T-Cell Immunodeficiency Syndrome-Cell Immunodeficiency Syndrome-Cell Immunodeficiency Syndrome-Cell Immunodeficiency Syndrome-Cell Immunodeficiency SyndromeInvolving Absent Thymus, Coloboma, Bullous Dermatitis, Eosi-Involving Absent Thymus, Coloboma, Bullous Dermatitis, Eosi-Involving Absent Thymus, Coloboma, Bullous Dermatitis, Eosi-Involving Absent Thymus, Coloboma, Bullous Dermatitis, Eosi-Involving Absent Thymus, Coloboma, Bullous Dermatitis, Eosi-nophilia, and Elevated IgE.nophilia, and Elevated IgE.nophilia, and Elevated IgE.nophilia, and Elevated IgE.nophilia, and Elevated IgE.K. P. Shanks,1 L. M. Noroski,1 C. Langston,2 E. M. McKay,2 M.L. Levy,3 S. L. Abramson.1 1Department of Pediatrics, BaylorCollege of Medicine, Houston, TX, USA; 2Department of Pathol-ogy, USA; 3Department of Dermatology, USA.

Su2.45 - Isolated PCP Infection in Children – A Systemic orSu2.45 - Isolated PCP Infection in Children – A Systemic orSu2.45 - Isolated PCP Infection in Children – A Systemic orSu2.45 - Isolated PCP Infection in Children – A Systemic orSu2.45 - Isolated PCP Infection in Children – A Systemic orSpecific Immunodeficiency?Specific Immunodeficiency?Specific Immunodeficiency?Specific Immunodeficiency?Specific Immunodeficiency?A. P. Williams,1 J. O’B Hourihane,2 E. Hodges,1 G. Davies,3 J.Smith.1 1Department of Clinical Immunology, SouthamptonGeneral Hospital, Southampton, United Kingdom; 2Departmentof Child Health, Southampton General Hospital, Southampton,United Kingdom; 3Molecular Immunology Unit, Institute of ChildHealth, London, United Kingdom.

Su2.46 - Combined Immunodeficiency with Defective Expres-Su2.46 - Combined Immunodeficiency with Defective Expres-Su2.46 - Combined Immunodeficiency with Defective Expres-Su2.46 - Combined Immunodeficiency with Defective Expres-Su2.46 - Combined Immunodeficiency with Defective Expres-sion in MHC Class II Genes.sion in MHC Class II Genes.sion in MHC Class II Genes.sion in MHC Class II Genes.sion in MHC Class II Genes.Anastassia P. Mihaylova,1 Kalina L. Penkova,1 Danilela N.Baltadzhieva,1 Milena I. Ivanova,1 Elissaveta J. Naumova.1

1Central Laboratory for Clinical Immunology, University HospitalAlexandrovska, Sofia, Bulgaria.

Su2.47 - E f f icacy and Safe ty o f SubcutaneousSu2.47 - E f f icacy and Safe ty o f SubcutaneousSu2.47 - E f f icacy and Safe ty o f SubcutaneousSu2.47 - E f f icacy and Safe ty o f SubcutaneousSu2.47 - E f f icacy and Safe ty o f SubcutaneousImmunologlobulin Replacement Therapy at Home in PatientsImmunologlobulin Replacement Therapy at Home in PatientsImmunologlobulin Replacement Therapy at Home in PatientsImmunologlobulin Replacement Therapy at Home in PatientsImmunologlobulin Replacement Therapy at Home in Patientswith Primarwith Primarwith Primarwith Primarwith Primary Immunodeficiency Diseases: Combined Analy-y Immunodeficiency Diseases: Combined Analy-y Immunodeficiency Diseases: Combined Analy-y Immunodeficiency Diseases: Combined Analy-y Immunodeficiency Diseases: Combined Analy-sis of Tsis of Tsis of Tsis of Tsis of Two Clinical Studies, One in Norwo Clinical Studies, One in Norwo Clinical Studies, One in Norwo Clinical Studies, One in Norwo Clinical Studies, One in North America and Oneth America and Oneth America and Oneth America and Oneth America and Onein Europe.in Europe.in Europe.in Europe.in Europe.Hans D. Ochs & Clinical Investigators,1 Ann Gardulf,2 MichaelaPraus,3 Peter Kiessling.4 1Department of Pediatrics, Universityof Washington, Seattle, WA, USA; 2Department of LaboratoryMedicine, Section of Clinical Immunology, Karolinska Intitutet atKarolinska University Hospital, Stockholm, Sweden; 3Biostatis-tics, Accovion GmbH, Marburg, Germany; 4ZLB Behring GmbH,Marburg, Germany.

Su2.48 – Abstract WithdrawnSu2.48 – Abstract WithdrawnSu2.48 – Abstract WithdrawnSu2.48 – Abstract WithdrawnSu2.48 – Abstract Withdrawn

Su2.49 - Association of IgA Deficiency and CiliarSu2.49 - Association of IgA Deficiency and CiliarSu2.49 - Association of IgA Deficiency and CiliarSu2.49 - Association of IgA Deficiency and CiliarSu2.49 - Association of IgA Deficiency and Ciliary Dyskine-y Dyskine-y Dyskine-y Dyskine-y Dyskine-sia: Report of a Familiar Case.sia: Report of a Familiar Case.sia: Report of a Familiar Case.sia: Report of a Familiar Case.sia: Report of a Familiar Case.D. Strozzi,1,3 M. Toledo-Barros,1,3 L. V. Rizzo,1,3 P. H.N. Saldiva,2E. G. Caldini,2 J. Kalil,1,3 C. M. Kokron.1,3 1Division of ClinicalImmunology and Allergy, Department of Medicine, University ofSao Paulo Medical School, Sao Paulo, São Paulo, Brazil; 2De-partment of Pathology, University of Sao Paulo Medical School,Sao Paulo, São Paulo, Brazil; 3Institute for Investigation in Immu-nology (iii), Sao Paulo, São Paulo, Brazil.

Su2.50 - Atypical Mycobacterial Infection and ChronicSu2.50 - Atypical Mycobacterial Infection and ChronicSu2.50 - Atypical Mycobacterial Infection and ChronicSu2.50 - Atypical Mycobacterial Infection and ChronicSu2.50 - Atypical Mycobacterial Infection and ChronicGranulomatous Disease: Experience of One CenterGranulomatous Disease: Experience of One CenterGranulomatous Disease: Experience of One CenterGranulomatous Disease: Experience of One CenterGranulomatous Disease: Experience of One Center.....G. Uzel,1 H. L. Malech,2 S. M. Holland.1 1NIAID, Laboratoryof Clinical Infectious Diseases, NIH, Bethesda, MD, USA;2NIAID, Laboratory of Host Defenses, NIH, Bethesda, MD.

Su2.51 - Use of Subcutaneous Immunoglobulin for TSu2.51 - Use of Subcutaneous Immunoglobulin for TSu2.51 - Use of Subcutaneous Immunoglobulin for TSu2.51 - Use of Subcutaneous Immunoglobulin for TSu2.51 - Use of Subcutaneous Immunoglobulin for Treatmentreatmentreatmentreatmentreatmentof Chronic Wof Chronic Wof Chronic Wof Chronic Wof Chronic Warararararts in Patient with Common Vts in Patient with Common Vts in Patient with Common Vts in Patient with Common Vts in Patient with Common Variable Immuno-ariable Immuno-ariable Immuno-ariable Immuno-ariable Immuno-deficiencydeficiencydeficiencydeficiencydeficiency.....J. H. Lin,1 R. L. Roberts.1 1Department of Pediatric Allergy, Im-munology, Rheumatology, University of California Los Angeles,Los Angeles, CA, USA.



Su2.52 - Distribution and Clinical Aspects of Pediactir Pri-Su2.52 - Distribution and Clinical Aspects of Pediactir Pri-Su2.52 - Distribution and Clinical Aspects of Pediactir Pri-Su2.52 - Distribution and Clinical Aspects of Pediactir Pri-Su2.52 - Distribution and Clinical Aspects of Pediactir Pri-marmarmarmarmary Immunodeficiencies in Ty Immunodeficiencies in Ty Immunodeficiencies in Ty Immunodeficiencies in Ty Immunodeficiencies in Taiwan.aiwan.aiwan.aiwan.aiwan.Wen-I. Lee,1 Jing-Long Huang,1 Ming-Ling Kuo,2 Syh-Jae Lin,1

Cheng-Jang Wu.2 1Department of Pediatric Allergy, Immunol-ogy and Rheumatology, Chang Gung University and Children’sHospital, Kwei-Shan, Taoyuan, Taiwan; 2Department of Micro-biology and Immunology, Graduate Institute of Basic MedicalSciences, Chang Gung University, Kwei-Shan, Taoyuan, Taiwan.

Su2.53 - Experimental Study of the Complex Bi-DirectionalSu2.53 - Experimental Study of the Complex Bi-DirectionalSu2.53 - Experimental Study of the Complex Bi-DirectionalSu2.53 - Experimental Study of the Complex Bi-DirectionalSu2.53 - Experimental Study of the Complex Bi-DirectionalInteractions between Human Immunodeficiency VInteractions between Human Immunodeficiency VInteractions between Human Immunodeficiency VInteractions between Human Immunodeficiency VInteractions between Human Immunodeficiency Virus Tirus Tirus Tirus Tirus Type 1ype 1ype 1ype 1ype 1(HIV(HIV(HIV(HIV(HIV-1) and the Protozoan Parasite -1) and the Protozoan Parasite -1) and the Protozoan Parasite -1) and the Protozoan Parasite -1) and the Protozoan Parasite LeishmaniaLeishmaniaLeishmaniaLeishmaniaLeishmania.....Chenqi Zhao,1 Michel J. Tremblay.2 1Microbiology-Immunology,Centre de Recherche en Infectiologie, Ste-Foy, QC, Canada;2Microbiology-Immunology, Centre de Recherche en Infectiologie,Ste-Foy, QC, Canada.

Su2.54 - HereditarSu2.54 - HereditarSu2.54 - HereditarSu2.54 - HereditarSu2.54 - Hereditary Angioedema: A New Mutation and ay Angioedema: A New Mutation and ay Angioedema: A New Mutation and ay Angioedema: A New Mutation and ay Angioedema: A New Mutation and aSearch of Gravity Factor?Search of Gravity Factor?Search of Gravity Factor?Search of Gravity Factor?Search of Gravity Factor?Kamel Djenouhat, Veronique Fremeaux-Bacchi, Jacques Blouin,Marie Therese Guinnepin, Jerome Laurent, Mario Tosi, MohamedCherif Abbadi. 1Immunology, Institut Pasteur d’Alger, ElHamma,Alger, Algeria; 2Immunology, Hopital Europeen GeorgesPompidou, Paris, Paris, France; 3Immunology, Hopital EuropeenGeorges Pompidou, Paris, Paris, France; 4Allergy, Institut Pas-teur de Paris, Paris, Paris, France; 5Allergy, Institut Pasteur deParis, Paris, Paris, France; 6Immunogenetic, Faculte de Medecineet de Pharmacie, Rouen, Rouen, France; 7Immynology, I.P.ALGER,Alger, Alger, France.

Immuno-dermatologyImmuno-dermatologyImmuno-dermatologyImmuno-dermatologyImmuno-dermatology

Su2.55 - Bexarotene Gel 1% vs. VSu2.55 - Bexarotene Gel 1% vs. VSu2.55 - Bexarotene Gel 1% vs. VSu2.55 - Bexarotene Gel 1% vs. VSu2.55 - Bexarotene Gel 1% vs. Vehicle Gel in Combinationehicle Gel in Combinationehicle Gel in Combinationehicle Gel in Combinationehicle Gel in Combinationwith Narrow-Band Ultraviolet B Phototherapy for Moderatewith Narrow-Band Ultraviolet B Phototherapy for Moderatewith Narrow-Band Ultraviolet B Phototherapy for Moderatewith Narrow-Band Ultraviolet B Phototherapy for Moderatewith Narrow-Band Ultraviolet B Phototherapy for Moderateto Severe Psoriasis Vto Severe Psoriasis Vto Severe Psoriasis Vto Severe Psoriasis Vto Severe Psoriasis Vulgaris.ulgaris.ulgaris.ulgaris.ulgaris.M. A. Magliocco,1 K. Pandya,1 V. Dombrovskiy,1 Y. Wong,1 L.Christiansen,1 A. B. Gottlieb.1 1Clinical Research Center, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

Su2.56 - The Higher pH Level Present in the Skin of PatientsSu2.56 - The Higher pH Level Present in the Skin of PatientsSu2.56 - The Higher pH Level Present in the Skin of PatientsSu2.56 - The Higher pH Level Present in the Skin of PatientsSu2.56 - The Higher pH Level Present in the Skin of Patientswith Atopic Eczema Stimulates the Release of with Atopic Eczema Stimulates the Release of with Atopic Eczema Stimulates the Release of with Atopic Eczema Stimulates the Release of with Atopic Eczema Stimulates the Release of MalasseziaMalasseziaMalasseziaMalasseziaMalasseziasympodialissympodialissympodialissympodialissympodialis Allergens. Allergens. Allergens. Allergens. Allergens.Annika Scheynius,1 Christine Selander,1 Omid Rasool,1 RetoCrameri,2 Arezou Zargari.1 1Department of Medicine, ClinicalAllergy Research Unit, Karolinska Institutet and University Hospi-tal, Stockholm, Sweden; 2Swiss Institute of Allergy and AsthmaResearch (SIAF), Davos, Switzerland.

Su2.57 - TSu2.57 - TSu2.57 - TSu2.57 - TSu2.57 - Tuberculin Skin Tuberculin Skin Tuberculin Skin Tuberculin Skin Tuberculin Skin Testing Westing Westing Westing Westing Widely Used as a Dianosticidely Used as a Dianosticidely Used as a Dianosticidely Used as a Dianosticidely Used as a DianosticAid for TAid for TAid for TAid for TAid for Tuberculosis, False Negative Outcome Has Ques-uberculosis, False Negative Outcome Has Ques-uberculosis, False Negative Outcome Has Ques-uberculosis, False Negative Outcome Has Ques-uberculosis, False Negative Outcome Has Ques-tioned Its Specificity & Sensitivity Inspite of Ttioned Its Specificity & Sensitivity Inspite of Ttioned Its Specificity & Sensitivity Inspite of Ttioned Its Specificity & Sensitivity Inspite of Ttioned Its Specificity & Sensitivity Inspite of Tuberculous In-uberculous In-uberculous In-uberculous In-uberculous In-fection.fection.fection.fection.fection.M. Ishaq, I. M. Sameera, K. M. Miraj. 1Allergy/Pulmonology,Al-Junaid Hospital, Nowshera, NWFP, Pakistan.

Su2.58 - Absence of Draining LSu2.58 - Absence of Draining LSu2.58 - Absence of Draining LSu2.58 - Absence of Draining LSu2.58 - Absence of Draining Lymph Nodes Results in Th2ymph Nodes Results in Th2ymph Nodes Results in Th2ymph Nodes Results in Th2ymph Nodes Results in Th2Immune Deviation and Loss of Resistance to Immune Deviation and Loss of Resistance to Immune Deviation and Loss of Resistance to Immune Deviation and Loss of Resistance to Immune Deviation and Loss of Resistance to Leishmania ma-Leishmania ma-Leishmania ma-Leishmania ma-Leishmania ma-jorjorjorjorjor Infection. Infection. Infection. Infection. Infection.T. W. Spahn,1,2 W. Domschke,1 J. Roth,3 C. Sorg,3 T. Kucharzik,1J. M. Ehrchen.3 1Department of Medicine B, Muenster Univer-sity Hospital, Muenster, NRW, Germany; 2Department of Inter-nal Medicine and Gastroenterology, MarienhospitalOsnabrueck, Osnabrueck, Niedersachsen, Germany; 3Depart-ment of Experimental Dermatology, Muenster University Hospi-tal, Muenster, NRW, Germany.

Su2.59 - Dissociation of TSu2.59 - Dissociation of TSu2.59 - Dissociation of TSu2.59 - Dissociation of TSu2.59 - Dissociation of Transactivation from Transactivation from Transactivation from Transactivation from Transactivation from TransrepressionransrepressionransrepressionransrepressionransrepressionActivity by a Selective Glucocorticoid Receptor AgonistActivity by a Selective Glucocorticoid Receptor AgonistActivity by a Selective Glucocorticoid Receptor AgonistActivity by a Selective Glucocorticoid Receptor AgonistActivity by a Selective Glucocorticoid Receptor Agonist(SEGRA) Leads to Separation of Therapeutic Effects from Side(SEGRA) Leads to Separation of Therapeutic Effects from Side(SEGRA) Leads to Separation of Therapeutic Effects from Side(SEGRA) Leads to Separation of Therapeutic Effects from Side(SEGRA) Leads to Separation of Therapeutic Effects from SideEffects.Effects.Effects.Effects.Effects.H. Schaecke,1 A. Schottelius,1 W.D. Doecke,1 P. Strehlke,2 S.Jaroch,2 N. Schmees,2 H. Rehwinkel,2 H. Hennekes,3 K.Asadullah.1 1RBA Dermatology, Schering AG, Berlin, Germany;2Medicinal Chemistry, Schering AG, Berlin, Germany; 3Corpo-rate Project Management SBU Specialized Therapeutics,Schering AG, Berlin, Germany.

20052005200520052005ANNUAL MEETING

125



Su2.60 - The Effect of BurSu2.60 - The Effect of BurSu2.60 - The Effect of BurSu2.60 - The Effect of BurSu2.60 - The Effect of Burn Tn Tn Tn Tn Trauma in Rats on Neutrophil Re-rauma in Rats on Neutrophil Re-rauma in Rats on Neutrophil Re-rauma in Rats on Neutrophil Re-rauma in Rats on Neutrophil Re-cruitment and Antioxidant Enzymes Activity in Epidermis.cruitment and Antioxidant Enzymes Activity in Epidermis.cruitment and Antioxidant Enzymes Activity in Epidermis.cruitment and Antioxidant Enzymes Activity in Epidermis.cruitment and Antioxidant Enzymes Activity in Epidermis.E. V. Mikhal’chik,1 S. M. Titkova,2 M. V. Anurov,2 A. P. Oettinger,2L. G. Korkina.1 1Department of Molecular Biology, Russian StateMedical University, Moscow, Russia, Russian Federation; 2De-partment of Physiology, Russian State Medical University, Mos-cow, Russia, Russian Federation; 3Deparment of Physiology,Russian State Medical University, Moscow, Russia, Russian Fed-eration; 4Department of Physiology, Russian State Medical Uni-versity, Moscow, Russia, Russian Federation; 5Department of Mo-lecular Biology, Russian State Medical University, Moscow, Rus-sia, Russian Federation.

Su2.61 - Quantitative Changes of Mast Cells Following TSu2.61 - Quantitative Changes of Mast Cells Following TSu2.61 - Quantitative Changes of Mast Cells Following TSu2.61 - Quantitative Changes of Mast Cells Following TSu2.61 - Quantitative Changes of Mast Cells Following Topi-opi-opi-opi-opi-cal Application of Honey on Third Degree Burns in Rats.cal Application of Honey on Third Degree Burns in Rats.cal Application of Honey on Third Degree Burns in Rats.cal Application of Honey on Third Degree Burns in Rats.cal Application of Honey on Third Degree Burns in Rats.Mohammad Bayat,1 Mojtaba Karimipour,1 MohammadaliAlmasieh.1 1Anatomy, Shaheed Beheshti University of MedicalSiences, Tehran, Tehran, Islamic Republic of Iran.

Su2.62 - Anti-IFN-gamma as a Universal TSu2.62 - Anti-IFN-gamma as a Universal TSu2.62 - Anti-IFN-gamma as a Universal TSu2.62 - Anti-IFN-gamma as a Universal TSu2.62 - Anti-IFN-gamma as a Universal Treatment for Th1reatment for Th1reatment for Th1reatment for Th1reatment for Th1Mediated Skin Diseases.Mediated Skin Diseases.Mediated Skin Diseases.Mediated Skin Diseases.Mediated Skin Diseases.S. Skurkovich,1 B. Skurkovich,2 N. Korotky,3 N. Sharova,3 G.Lukina,4 Y. Sigidin.4 1R&D, Adv Biotherapy, Inc., Rockville, MD,USA; 2Brown Med School, Providence, RI, USA; 3Dept of SkinDis, Russian St Med U, Moscow, Russian Federation; 4Clinic,Rheumatol Inst, Moscow, Russian Federation.

Su2.63 - Buschke’Su2.63 - Buschke’Su2.63 - Buschke’Su2.63 - Buschke’Su2.63 - Buschke’s Scleredema: Atypical Onset and Evolu-s Scleredema: Atypical Onset and Evolu-s Scleredema: Atypical Onset and Evolu-s Scleredema: Atypical Onset and Evolu-s Scleredema: Atypical Onset and Evolu-tion. Case Report.tion. Case Report.tion. Case Report.tion. Case Report.tion. Case Report.Victor Cristea,1 Monica Crisan,1 Claudia Magurici,1 RamonaBologa,1 Nicolae Miron.1 1Immunology, Iuliu Hatieganu Uni-versity of Medicine and Pharmacy, Cluj Napoca, Cluj, Roma-nia.

Su2.64 - The Characteristics of Mucosal Immunity in ChronicSu2.64 - The Characteristics of Mucosal Immunity in ChronicSu2.64 - The Characteristics of Mucosal Immunity in ChronicSu2.64 - The Characteristics of Mucosal Immunity in ChronicSu2.64 - The Characteristics of Mucosal Immunity in ChronicAdult Periodontitis Patients.Adult Periodontitis Patients.Adult Periodontitis Patients.Adult Periodontitis Patients.Adult Periodontitis Patients.I. Kaidashev,1 V. Shinkevich,1 L. M. DuBuske.2 1Ukrainian Medi-cal Stomatological Academy, Poltava, Ukraine; 2ImmunologyResearch Institute of New England, Gardner, MA, USA.

Su2.65 - Acquired Angioedema and Coagulopathy SeveralSu2.65 - Acquired Angioedema and Coagulopathy SeveralSu2.65 - Acquired Angioedema and Coagulopathy SeveralSu2.65 - Acquired Angioedema and Coagulopathy SeveralSu2.65 - Acquired Angioedema and Coagulopathy SeveralYYYYYears after Syphilis.ears after Syphilis.ears after Syphilis.ears after Syphilis.ears after Syphilis.Soheil F. Chegini, Michael J. Davies, Timothy J. Craig. 1Medi-cine, Division of Pulmonary, Allergy & Critical Care, Penn StateCollege of Medicine, Hershey, PA, USA.

Su2.66 - Expression of the CostimulatorSu2.66 - Expression of the CostimulatorSu2.66 - Expression of the CostimulatorSu2.66 - Expression of the CostimulatorSu2.66 - Expression of the Costimulatory Molecules on Anti-y Molecules on Anti-y Molecules on Anti-y Molecules on Anti-y Molecules on Anti-gen-Presenting Cells in Atopic Dermatitis.gen-Presenting Cells in Atopic Dermatitis.gen-Presenting Cells in Atopic Dermatitis.gen-Presenting Cells in Atopic Dermatitis.gen-Presenting Cells in Atopic Dermatitis.G. N. Drannik,1 A. I. Kurchenko,1 L. M. DuBuske.2 1Dept. Clini-cal Immunology and Allergology, National Medical University,Kiev, Ukraine; 2Immunology Research Institute of New England,Gardner, MA, USA.

Su2.67 - Differential Distribution of LSu2.67 - Differential Distribution of LSu2.67 - Differential Distribution of LSu2.67 - Differential Distribution of LSu2.67 - Differential Distribution of Lymphocyte Subpopula-ymphocyte Subpopula-ymphocyte Subpopula-ymphocyte Subpopula-ymphocyte Subpopula-tions in Peripheral Blood and Muscle Biopsies in Untreatedtions in Peripheral Blood and Muscle Biopsies in Untreatedtions in Peripheral Blood and Muscle Biopsies in Untreatedtions in Peripheral Blood and Muscle Biopsies in Untreatedtions in Peripheral Blood and Muscle Biopsies in UntreatedJuvenile Dermatomyositis (JDM).Juvenile Dermatomyositis (JDM).Juvenile Dermatomyositis (JDM).Juvenile Dermatomyositis (JDM).Juvenile Dermatomyositis (JDM).C. Chuu,1 M. O’Gorman,1 L. M. Pachman.1 1Pediatrics, FeinbergCollege of Medicine, Northwestern University, Chicago, IL, USA.

Su2.68 - Thalidomide, an Anti-InflammatorSu2.68 - Thalidomide, an Anti-InflammatorSu2.68 - Thalidomide, an Anti-InflammatorSu2.68 - Thalidomide, an Anti-InflammatorSu2.68 - Thalidomide, an Anti-Inflammatory Medication. In-y Medication. In-y Medication. In-y Medication. In-y Medication. In-hibits the Induction of Thibits the Induction of Thibits the Induction of Thibits the Induction of Thibits the Induction of Tumor Necrosis Factorumor Necrosis Factorumor Necrosis Factorumor Necrosis Factorumor Necrosis Factor-----ααααα (TNF (TNF (TNF (TNF (TNFααααα) in) in) in) in) inUltraviolet B (UVB)-Irradiated Human Keratinocytes by Desta-Ultraviolet B (UVB)-Irradiated Human Keratinocytes by Desta-Ultraviolet B (UVB)-Irradiated Human Keratinocytes by Desta-Ultraviolet B (UVB)-Irradiated Human Keratinocytes by Desta-Ultraviolet B (UVB)-Irradiated Human Keratinocytes by Desta-bilizing the TNFbilizing the TNFbilizing the TNFbilizing the TNFbilizing the TNFα α α α α mRNA.mRNA.mRNA.mRNA.mRNA.J. H. Lin,1 M. M. Bashir,1 W. Zhang,1 V. P. Werth.1,2 1Dermatol-ogy, U. of Penn., Phila., PA, USA; 2Dermatology, Phila. VAMedical Center, Phila., PA, USA.

Su2.69 - Gene TSu2.69 - Gene TSu2.69 - Gene TSu2.69 - Gene TSu2.69 - Gene Transcripts as Potential Diagnostic Markersranscripts as Potential Diagnostic Markersranscripts as Potential Diagnostic Markersranscripts as Potential Diagnostic Markersranscripts as Potential Diagnostic Markersfor Allergic Contact Dermatitis.for Allergic Contact Dermatitis.for Allergic Contact Dermatitis.for Allergic Contact Dermatitis.for Allergic Contact Dermatitis.M. B. Hansen,1 L. Skov,1 T. Menne,1 J. Olsen.2 1Department ofDermatology, Gentofte Hospital, Hellerup, Denmark; 2Depart-ment of Medical Biochemistry and Genetics, University ofCopenhagen, Copenhagen, Denmark.

Su2.70 - Potent Anti-InflammatorSu2.70 - Potent Anti-InflammatorSu2.70 - Potent Anti-InflammatorSu2.70 - Potent Anti-InflammatorSu2.70 - Potent Anti-Inflammatory Effect of Ty Effect of Ty Effect of Ty Effect of Ty Effect of Topical Nuclearopical Nuclearopical Nuclearopical Nuclearopical NuclearFactor kappa B Decoy in Skin Inflammation.Factor kappa B Decoy in Skin Inflammation.Factor kappa B Decoy in Skin Inflammation.Factor kappa B Decoy in Skin Inflammation.Factor kappa B Decoy in Skin Inflammation.B. Schryver,1 T. Muchamuel,1 A. Oo,1 J. Alleman,1 M. Dajee,1L. M. McEvoy,1 R. Ehrhardt.1 1Research, Corgentech.Inc, SouthSan Francisco, CA, USA.

Su2.71 - Dual Diagnosis of Pemphigus VSu2.71 - Dual Diagnosis of Pemphigus VSu2.71 - Dual Diagnosis of Pemphigus VSu2.71 - Dual Diagnosis of Pemphigus VSu2.71 - Dual Diagnosis of Pemphigus Vulgaris and Connec-ulgaris and Connec-ulgaris and Connec-ulgaris and Connec-ulgaris and Connec-tive Tissue Disease.tive Tissue Disease.tive Tissue Disease.tive Tissue Disease.tive Tissue Disease.Mohsin Malik,1 A. Razzaque Ahmed.1 1Oral Medicine, Infec-tion and Immunity, Harvard School of Dental Medicine, Boston,MA, USA.



Su2.72 - Production and Characterization of Human Mono-Su2.72 - Production and Characterization of Human Mono-Su2.72 - Production and Characterization of Human Mono-Su2.72 - Production and Characterization of Human Mono-Su2.72 - Production and Characterization of Human Mono-clonal Antibody Against Desmoglein 3 from Pemphigus Vclonal Antibody Against Desmoglein 3 from Pemphigus Vclonal Antibody Against Desmoglein 3 from Pemphigus Vclonal Antibody Against Desmoglein 3 from Pemphigus Vclonal Antibody Against Desmoglein 3 from Pemphigus Vul-ul-ul-ul-ul-garis Patient.garis Patient.garis Patient.garis Patient.garis Patient.Shih Wei Yeh,1 Kailash C. Bhol,1 Mukesh Kumar,2 Lisa A.Cavacini,2 Marshall Posner,2 A. Razzaque Ahmed.1 1OralMedicine, Infection and Immunity, Harvard School of DentalMedicine, Boston, MA, USA; 2Beth Israel Deaconess MedicalCenter, Boston, MA, USA.

Su2.73 - Identification of Epitope for Autoantibody and ItsSu2.73 - Identification of Epitope for Autoantibody and ItsSu2.73 - Identification of Epitope for Autoantibody and ItsSu2.73 - Identification of Epitope for Autoantibody and ItsSu2.73 - Identification of Epitope for Autoantibody and ItsRole in Basement Membrane Separation in Oral Pemphig-Role in Basement Membrane Separation in Oral Pemphig-Role in Basement Membrane Separation in Oral Pemphig-Role in Basement Membrane Separation in Oral Pemphig-Role in Basement Membrane Separation in Oral Pemphig-oid.oid.oid.oid.oid.Khwaja Aftab Rashid,1 Adnan Q. Usman,1 Shih Wei Yeh,1 JoelN.H. Stern,1 Kailash C. Bhol,1 A. Razzaque Ahmed.1 1OralMedicine, Infection and Immunity, Harvard School of DentalMedicine, Boston, MA, USA.

Su2.74 - Effects of Electrical Microcurrent on Open SkinSu2.74 - Effects of Electrical Microcurrent on Open SkinSu2.74 - Effects of Electrical Microcurrent on Open SkinSu2.74 - Effects of Electrical Microcurrent on Open SkinSu2.74 - Effects of Electrical Microcurrent on Open SkinWWWWWound Healing in Rabbit.ound Healing in Rabbit.ound Healing in Rabbit.ound Healing in Rabbit.ound Healing in Rabbit.Mohammad Bayat,1 Zahra Asgari-Moghadam,1 MohammadRakhshan,1 Fateme-sadat Rezai,1 Mohammadali Almasieh.1

1Anatomy, Shaheed Beheshti University of Medical Sciences,Tehran, Tehran, Islamic Republic of Iran.

Su2.75 - Morphometric Assessment of Nitrofurazone Oint-Su2.75 - Morphometric Assessment of Nitrofurazone Oint-Su2.75 - Morphometric Assessment of Nitrofurazone Oint-Su2.75 - Morphometric Assessment of Nitrofurazone Oint-Su2.75 - Morphometric Assessment of Nitrofurazone Oint-ment on Healing of Infectous Second Degree Burns of Rat.ment on Healing of Infectous Second Degree Burns of Rat.ment on Healing of Infectous Second Degree Burns of Rat.ment on Healing of Infectous Second Degree Burns of Rat.ment on Healing of Infectous Second Degree Burns of Rat.Mohammad Bayat,1 Hasan Bagheri-Yazdi,1 MohammadaliAlmasieh.1 1Anatomy, Shaheed Beheshti University of MedicalSciences, Tehran, Tehran, Islamic Republic of Iran.

Su2.76 - Effect of Low-Power Gallium Aluminum Arsenide LaserSu2.76 - Effect of Low-Power Gallium Aluminum Arsenide LaserSu2.76 - Effect of Low-Power Gallium Aluminum Arsenide LaserSu2.76 - Effect of Low-Power Gallium Aluminum Arsenide LaserSu2.76 - Effect of Low-Power Gallium Aluminum Arsenide LaserRadiation on Mast Cells of Open Skin WRadiation on Mast Cells of Open Skin WRadiation on Mast Cells of Open Skin WRadiation on Mast Cells of Open Skin WRadiation on Mast Cells of Open Skin Wound Bed of Rats.ound Bed of Rats.ound Bed of Rats.ound Bed of Rats.ound Bed of Rats.Mohammad Bayat,1 Mohammadghasem Golmohammadi,1

Mohammadali Almasieh.1 1Anatomy, Shaheed Beheshti Uni-versity of Medical Sciences, Tehran, Tehran, Islamic Republic ofIran.

LaboratorLaboratorLaboratorLaboratorLaboratory Immunologyy Immunologyy Immunologyy Immunologyy Immunology

Su2.77 - Influence of Atopic HistorSu2.77 - Influence of Atopic HistorSu2.77 - Influence of Atopic HistorSu2.77 - Influence of Atopic HistorSu2.77 - Influence of Atopic History on Cord Blood IgE.y on Cord Blood IgE.y on Cord Blood IgE.y on Cord Blood IgE.y on Cord Blood IgE.Mohammad Amin Kashef,1 Sara Kashef,2 Narjes Pishva,3

Mozhgan Afshari, Zahra Amirgofran,4 Hamed Jalaeian.1 1Al-lergy Research Center, Shiraz University of Medical Sciences,Shiraz, Fars, Islamic Republic of Iran; 2Immunology and Allergy,Shiraz University of Medical Sciences, Shiraz, Fars, Islamic Re-public of Iran; 3Neonatalogy, Shiraz University of Medical Sci-ences, Shiraz, Fars, Islamic Republic of Iran; 4Immunology, ShirazUniversity of Medical Sciences, Shiraz, Fars, Islamic Republic ofIran.

Su2.78 - LSu2.78 - LSu2.78 - LSu2.78 - LSu2.78 - Lymphocyte Adenosine Deaminase Activity in Chil-ymphocyte Adenosine Deaminase Activity in Chil-ymphocyte Adenosine Deaminase Activity in Chil-ymphocyte Adenosine Deaminase Activity in Chil-ymphocyte Adenosine Deaminase Activity in Chil-dren with Idiopathic Nephrotic Syndrome.dren with Idiopathic Nephrotic Syndrome.dren with Idiopathic Nephrotic Syndrome.dren with Idiopathic Nephrotic Syndrome.dren with Idiopathic Nephrotic Syndrome.Om P. Mishra, Jayant K. Ghosh, Ziledar Ali, Malay R. Sen,Rajniti Prasad. 1Dept of Pediatrics, Institute of Medical Sciences,Varanasi, Uttar Pradesh, India; 2Dept of Pediatrics, Institute ofMedical Sciences, Varanasi, Uttar Pradesh, India; 3Dept of Bio-chemistry, Institute of Medical Sciences, Varanasi, Uttar Pradesh,India; 4Dept of Microbiology, Institute of Medical Sciences,Varanasi, Uttar Pradesh, India; 5Dept of Pediatrics, Institute ofMedical Sciences, Varanasi, Uttar Pradesh, India.

Su2.79 - ESN: A Potent Natural Inhibitor of ProliferationgSu2.79 - ESN: A Potent Natural Inhibitor of ProliferationgSu2.79 - ESN: A Potent Natural Inhibitor of ProliferationgSu2.79 - ESN: A Potent Natural Inhibitor of ProliferationgSu2.79 - ESN: A Potent Natural Inhibitor of Proliferationgand Inducer of Apoptosis on K562 Cells.and Inducer of Apoptosis on K562 Cells.and Inducer of Apoptosis on K562 Cells.and Inducer of Apoptosis on K562 Cells.and Inducer of Apoptosis on K562 Cells.Yang Ping Niu. 1School of Pharmacology, Zhejiang Univerisityof Technology, Hangzhou, Zhejiang, China.

Su2.80 - An Automatic System for the Image Analysis andSu2.80 - An Automatic System for the Image Analysis andSu2.80 - An Automatic System for the Image Analysis andSu2.80 - An Automatic System for the Image Analysis andSu2.80 - An Automatic System for the Image Analysis andInterpretation of HEp-2 Image Pattern.Interpretation of HEp-2 Image Pattern.Interpretation of HEp-2 Image Pattern.Interpretation of HEp-2 Image Pattern.Interpretation of HEp-2 Image Pattern.Petra Perner,1 Horst Perner.1 1Research Dept., ImageInterpretGmbH, Leipzig, Germany.

Su2.81 - Determination of ANA Autoantibodies with Multi-Su2.81 - Determination of ANA Autoantibodies with Multi-Su2.81 - Determination of ANA Autoantibodies with Multi-Su2.81 - Determination of ANA Autoantibodies with Multi-Su2.81 - Determination of ANA Autoantibodies with Multi-plexed Immunoassays.plexed Immunoassays.plexed Immunoassays.plexed Immunoassays.plexed Immunoassays.J. L. Hadley,1 D. O. Onley,1 G. J. Harradence,1 N. F. Cahir,1 C.Garey,1 P. A. Swarbrick.1 1R&D, SmartBead Technologies, Cam-bridge, United Kingdom.

Su2.82 - Distribution of Killer Cell Immunoglogulin-Like Re-Su2.82 - Distribution of Killer Cell Immunoglogulin-Like Re-Su2.82 - Distribution of Killer Cell Immunoglogulin-Like Re-Su2.82 - Distribution of Killer Cell Immunoglogulin-Like Re-Su2.82 - Distribution of Killer Cell Immunoglogulin-Like Re-ceptors Genes in Chinese Han Population.ceptors Genes in Chinese Han Population.ceptors Genes in Chinese Han Population.ceptors Genes in Chinese Han Population.ceptors Genes in Chinese Han Population.K. Jiang, F. M. Zhu, Q. F. Lv, L. X. Yan. 1HLA Typing Laboratory,Blood Center of Zhejiang Province, Hangzhou, Zhejiang, China.

20052005200520052005ANNUAL MEETING

127



Su2.83 - Problems of Immunodiagnostics of Hepatitis C inSu2.83 - Problems of Immunodiagnostics of Hepatitis C inSu2.83 - Problems of Immunodiagnostics of Hepatitis C inSu2.83 - Problems of Immunodiagnostics of Hepatitis C inSu2.83 - Problems of Immunodiagnostics of Hepatitis C inSenior Patients.Senior Patients.Senior Patients.Senior Patients.Senior Patients.A. A. Potapova, P. G. Bogush, E. B. Redchenko. 1Laboratory ofHIV-Detection, Urban Sexually Transmitted Diseases Clinic N 1of Moscow Health Care Department, Moscow, Russian Federa-tion.

Su2.84 - The Novel Docosatriene, Protectin D1, Produced bySu2.84 - The Novel Docosatriene, Protectin D1, Produced bySu2.84 - The Novel Docosatriene, Protectin D1, Produced bySu2.84 - The Novel Docosatriene, Protectin D1, Produced bySu2.84 - The Novel Docosatriene, Protectin D1, Produced byTTTTTHHHHH2-Polarization Promotes Human T Cell Apoptosis Via Lipid-2-Polarization Promotes Human T Cell Apoptosis Via Lipid-2-Polarization Promotes Human T Cell Apoptosis Via Lipid-2-Polarization Promotes Human T Cell Apoptosis Via Lipid-2-Polarization Promotes Human T Cell Apoptosis Via Lipid-Raft Clustering.Raft Clustering.Raft Clustering.Raft Clustering.Raft Clustering.Amiram Ariel,1 Pin-Lan Li,1,2 Wei Wang,1 Wang-Xian Tang,1,2

Song Hong,1 Katherine H. Gotlinger,1 Charles N. Serhan.1

1Center for Experimental Therapeutics and Reperfusion Injury,Department of Anesthesiology, Perioperative and Pain Medi-cine, Brigham and Women’s Hospital and Harvard MedicalSchool, Boston, MA, USA; 2Department of Pharmacology andToxicology, Medical College of Wisconsin, Milwaukee, WI, USA.

Su2.85 - FSu2.85 - FSu2.85 - FSu2.85 - FSu2.85 - FACS-Based Method TACS-Based Method TACS-Based Method TACS-Based Method TACS-Based Method To Evaluate Inhibitoro Evaluate Inhibitoro Evaluate Inhibitoro Evaluate Inhibitoro Evaluate Inhibitory Antibod-y Antibod-y Antibod-y Antibod-y Antibod-ies in Patients Receiving Enzyme Replacement Therapyies in Patients Receiving Enzyme Replacement Therapyies in Patients Receiving Enzyme Replacement Therapyies in Patients Receiving Enzyme Replacement Therapyies in Patients Receiving Enzyme Replacement Therapy.....K. Seiger,1 L. Cherry,1 V. Theobald,1 S. Richards.1 1ClinicalLaboratory Science, Genzyme Corporation, Framingham, MA,USA.

Su2.86 - Experimental (war) TSu2.86 - Experimental (war) TSu2.86 - Experimental (war) TSu2.86 - Experimental (war) TSu2.86 - Experimental (war) Type System of Hemaimmuneype System of Hemaimmuneype System of Hemaimmuneype System of Hemaimmuneype System of HemaimmuneReaction Road Map.Reaction Road Map.Reaction Road Map.Reaction Road Map.Reaction Road Map.Guo Feng. 1Department of Blood Transfusion, Chang Hai Hos-pital Second Military Medical University, Shanghai, China.

Su2.87 - Activation of Red Blood Cell Innate Immune Reac-Su2.87 - Activation of Red Blood Cell Innate Immune Reac-Su2.87 - Activation of Red Blood Cell Innate Immune Reac-Su2.87 - Activation of Red Blood Cell Innate Immune Reac-Su2.87 - Activation of Red Blood Cell Innate Immune Reac-tion Main Road by Antigen.tion Main Road by Antigen.tion Main Road by Antigen.tion Main Road by Antigen.tion Main Road by Antigen.Guo Feng. 1Department of Blood Tansfusion, Changhai Hospi-tal Second Military Medical University, Shanghai, China.

Su2.88 - Evaluation of the Effects of Different Freezing Proce-Su2.88 - Evaluation of the Effects of Different Freezing Proce-Su2.88 - Evaluation of the Effects of Different Freezing Proce-Su2.88 - Evaluation of the Effects of Different Freezing Proce-Su2.88 - Evaluation of the Effects of Different Freezing Proce-dures on the Function and Composition of Ldures on the Function and Composition of Ldures on the Function and Composition of Ldures on the Function and Composition of Ldures on the Function and Composition of Lymphocyte Sub-ymphocyte Sub-ymphocyte Sub-ymphocyte Sub-ymphocyte Sub-populations from Blood and Synovial Fluid.populations from Blood and Synovial Fluid.populations from Blood and Synovial Fluid.populations from Blood and Synovial Fluid.populations from Blood and Synovial Fluid.Mona Widhe,1 Nimrod Kiss,1 Therese Wallerskog,1 AndreasFasth,1 Vivianne Malmstrom,1 Christina Trollmo.1 1Rheumatol-ogy Research Unit, Dep of Medicine at Solna, KarolinskaInstitutet, Stockholm, Sweden.

Su2.89 - Does the CD203c Basophil Marker Improve the Flow-Su2.89 - Does the CD203c Basophil Marker Improve the Flow-Su2.89 - Does the CD203c Basophil Marker Improve the Flow-Su2.89 - Does the CD203c Basophil Marker Improve the Flow-Su2.89 - Does the CD203c Basophil Marker Improve the Flow-CytometrCytometrCytometrCytometrCytometry Diagnosis of Immediate Allergy?y Diagnosis of Immediate Allergy?y Diagnosis of Immediate Allergy?y Diagnosis of Immediate Allergy?y Diagnosis of Immediate Allergy?A. Ocmant,1 A. Michils,2 Y. Peignois,1 L. Schandene.1 1Depart-ment of Immunology, Erasme Hospital, Brussels, Belgium; 2De-partment of Chest Medecine, Erasme Hospital, Brussels, Belgium.

Su2.90 - Prospective Comparison of ELISA and ImmunodiffusionSu2.90 - Prospective Comparison of ELISA and ImmunodiffusionSu2.90 - Prospective Comparison of ELISA and ImmunodiffusionSu2.90 - Prospective Comparison of ELISA and ImmunodiffusionSu2.90 - Prospective Comparison of ELISA and Immunodiffusionfor Detection of Antibodies to Extractable Nuclear Antigens.for Detection of Antibodies to Extractable Nuclear Antigens.for Detection of Antibodies to Extractable Nuclear Antigens.for Detection of Antibodies to Extractable Nuclear Antigens.for Detection of Antibodies to Extractable Nuclear Antigens.J. L. Schmitz,1 K. Freeman,1 S. Orton,1 J. D. Folds.1 1McLendonClinical Laboratories, UNC Hospitals, Chapel Hill, NC, USA.

Su2.91 - A Novel Proteomics Assay Employing AmplificationSu2.91 - A Novel Proteomics Assay Employing AmplificationSu2.91 - A Novel Proteomics Assay Employing AmplificationSu2.91 - A Novel Proteomics Assay Employing AmplificationSu2.91 - A Novel Proteomics Assay Employing Amplificationof Oligonucleotide Tof Oligonucleotide Tof Oligonucleotide Tof Oligonucleotide Tof Oligonucleotide Tags from Monoclonal Antibodies.ags from Monoclonal Antibodies.ags from Monoclonal Antibodies.ags from Monoclonal Antibodies.ags from Monoclonal Antibodies.M. G. Kattah,1 J. Coller,2 P. J. Utz.1 1Division of Immunologyand Rheumatology, Stanford University, Stanford, CA, USA;2Stanford Functional Genomics Facility (SFGF), Stanford Univer-sity, Stanford, CA, USA.

Su2.92 - Identification of Major Histocompatibility ComplexSu2.92 - Identification of Major Histocompatibility ComplexSu2.92 - Identification of Major Histocompatibility ComplexSu2.92 - Identification of Major Histocompatibility ComplexSu2.92 - Identification of Major Histocompatibility Complex(MHC) Class I-Realted Genes in Cattle.(MHC) Class I-Realted Genes in Cattle.(MHC) Class I-Realted Genes in Cattle.(MHC) Class I-Realted Genes in Cattle.(MHC) Class I-Realted Genes in Cattle.C. De Juan Sanjuan,1 S. A. Ellis.1 1Immunopathology, Institutefor Animal Health, Compton, Berkshire, United Kingdom.

Su2.93 - an of Influenza Virus.Su2.93 - an of Influenza Virus.Su2.93 - an of Influenza Virus.Su2.93 - an of Influenza Virus.Su2.93 - an of Influenza Virus.N. Yamamoto,1 M. Urade,2 M. Ueda.1 1Molecular Immunol-ogy, Socrates Institute for Therapeutic Immunology, Philadelphia,PA, USA; 2Oral Surgery, Hyogo College of Medicine, Hyogo,Japan.

Su2.94 - Role of L-Arginine TSu2.94 - Role of L-Arginine TSu2.94 - Role of L-Arginine TSu2.94 - Role of L-Arginine TSu2.94 - Role of L-Arginine Transporransporransporransporransporterterterterter, Solute Carrier 7A2, Solute Carrier 7A2, Solute Carrier 7A2, Solute Carrier 7A2, Solute Carrier 7A2(SLC7A2), in the Immune System.(SLC7A2), in the Immune System.(SLC7A2), in the Immune System.(SLC7A2), in the Immune System.(SLC7A2), in the Immune System.R. M. Sanchez-Munoz,1 J. Kleeman,1 C. L. MacLeod,1 L. G.Ellies.1 1Cancer Center, University of California San Diego, SanDiego, CA, USA.

Su2.95 - Improved Immunological Methods Using Peptides:Su2.95 - Improved Immunological Methods Using Peptides:Su2.95 - Improved Immunological Methods Using Peptides:Su2.95 - Improved Immunological Methods Using Peptides:Su2.95 - Improved Immunological Methods Using Peptides:WWWWWesteresteresteresterestern Blots, Peptide Arrays, Kinase Assays and ELISAs.n Blots, Peptide Arrays, Kinase Assays and ELISAs.n Blots, Peptide Arrays, Kinase Assays and ELISAs.n Blots, Peptide Arrays, Kinase Assays and ELISAs.n Blots, Peptide Arrays, Kinase Assays and ELISAs.I. Ghosh,1 L. Sun,1 M.-Q. Xu.1 1Research and Development,New England Biolabs, Beverly, MA, USA.



Su2.96 - Characterization of Assay VSu2.96 - Characterization of Assay VSu2.96 - Characterization of Assay VSu2.96 - Characterization of Assay VSu2.96 - Characterization of Assay Variability in Real-Tariability in Real-Tariability in Real-Tariability in Real-Tariability in Real-Timeimeimeimeimeand Batch Assays of Sequential Samples from the Same Do-and Batch Assays of Sequential Samples from the Same Do-and Batch Assays of Sequential Samples from the Same Do-and Batch Assays of Sequential Samples from the Same Do-and Batch Assays of Sequential Samples from the Same Do-nors.nors.nors.nors.nors.J. L. Lathey,1 K. Martinez,1 S. Gregory,1 P. D’Souza,2 W.Lopaczynski.1 1Virology/Immunology, BBI Biotech, a Division ofSeraCare Life Sciences, Gaithersburg, MD, USA; 2Vaccine,NIAID, Bethesda, MD, USA.

Su2.97 - HLA-TSu2.97 - HLA-TSu2.97 - HLA-TSu2.97 - HLA-TSu2.97 - HLA-Typed PBMC Samples with Established Anti-yped PBMC Samples with Established Anti-yped PBMC Samples with Established Anti-yped PBMC Samples with Established Anti-yped PBMC Samples with Established Anti-gen/Peptide Reactivity for Accelerating and Standardizinggen/Peptide Reactivity for Accelerating and Standardizinggen/Peptide Reactivity for Accelerating and Standardizinggen/Peptide Reactivity for Accelerating and Standardizinggen/Peptide Reactivity for Accelerating and StandardizingHuman Immunological Research.Human Immunological Research.Human Immunological Research.Human Immunological Research.Human Immunological Research.P. V. Lehmann,1 S. Gregory,2 M. Ewell,2 W. Lopaczynski,2 T.Watts,2 C. Shive,1 N. Sigmund,1 O. Targoni,1 J. Lathey,2 W.J.Zhang.1 1&2BBI Biotech Research Laboratories, A Division ofSeraCare Life Sciences, Gaithersburg, MD, USA.

Su2.98 - Cell Proliferation Index. A Reliable and VSu2.98 - Cell Proliferation Index. A Reliable and VSu2.98 - Cell Proliferation Index. A Reliable and VSu2.98 - Cell Proliferation Index. A Reliable and VSu2.98 - Cell Proliferation Index. A Reliable and ValidatedalidatedalidatedalidatedalidatedMethod That Quantifies Cell Proliferation According to CFSEMethod That Quantifies Cell Proliferation According to CFSEMethod That Quantifies Cell Proliferation According to CFSEMethod That Quantifies Cell Proliferation According to CFSEMethod That Quantifies Cell Proliferation According to CFSEDilution.Dilution.Dilution.Dilution.Dilution.J. C. Crispin,1 M. I. Vargas-Rojas,1 J. Alcocer-Varela.1 1Depart-ment of Immunology and Rheumatology, Instituto Nacional deCiencias Medicas y Nutricion Salvador Zubiran, Mexico City,Mexico.

Su2.99 - Evaluation of CellPrep, an Automated Cell WSu2.99 - Evaluation of CellPrep, an Automated Cell WSu2.99 - Evaluation of CellPrep, an Automated Cell WSu2.99 - Evaluation of CellPrep, an Automated Cell WSu2.99 - Evaluation of CellPrep, an Automated Cell WashingashingashingashingashingInstrument for Analysis of Surface Markers on Leukocyte Sub-Instrument for Analysis of Surface Markers on Leukocyte Sub-Instrument for Analysis of Surface Markers on Leukocyte Sub-Instrument for Analysis of Surface Markers on Leukocyte Sub-Instrument for Analysis of Surface Markers on Leukocyte Sub-populations Vpopulations Vpopulations Vpopulations Vpopulations Via Flow Cytometria Flow Cytometria Flow Cytometria Flow Cytometria Flow Cytometryyyyy.....J. G. Wilkinson,1 C. Aparicio,1 C. Smith,1 E. Rabellino,1 S.D’Costa.1 1Biomedical Research Division, Beckman Coulter Inc.,Miami, FL, USA.

Su2.100 - Optimization of the Aspiration Dose of IL-1ra Prepa-Su2.100 - Optimization of the Aspiration Dose of IL-1ra Prepa-Su2.100 - Optimization of the Aspiration Dose of IL-1ra Prepa-Su2.100 - Optimization of the Aspiration Dose of IL-1ra Prepa-Su2.100 - Optimization of the Aspiration Dose of IL-1ra Prepa-ration Tration Tration Tration Tration To Stop an Inflammation in the Mouse Respiratoro Stop an Inflammation in the Mouse Respiratoro Stop an Inflammation in the Mouse Respiratoro Stop an Inflammation in the Mouse Respiratoro Stop an Inflammation in the Mouse Respiratory Ty Ty Ty Ty Tract.ract.ract.ract.ract.A. M. Ischenko,1 B. P. Nikolaev,2 E. V. Vorobeychikov,2 L. YuYakovleva,2 T. V. Kotova,2 L. Ya Soloviova,1 V. G. Konusova.3

1Protein Biochemistry, Institute of Highly Pure Biopreparations,Saint-Petersburg, Russian Federation; 2New Drug Formulations,Institute of Highly Pure Biopreparations, Saint-Petersburg, Rus-sian Federation; 3Immunopharmacology, Institute of Highly PureBiopreparations, Saint-Petersburg, Russian Federation.

Su2.101 - The Use of Arginine-Rich Peptide ConjugatedSu2.101 - The Use of Arginine-Rich Peptide ConjugatedSu2.101 - The Use of Arginine-Rich Peptide ConjugatedSu2.101 - The Use of Arginine-Rich Peptide ConjugatedSu2.101 - The Use of Arginine-Rich Peptide ConjugatedAntisense Oligomers TAntisense Oligomers TAntisense Oligomers TAntisense Oligomers TAntisense Oligomers To Alter Immune Function.o Alter Immune Function.o Alter Immune Function.o Alter Immune Function.o Alter Immune Function.N. B. Marshall,1 D. V. Mourich,1 H. M. Moulton,1 P. L. Iversen.1

1Biology, AVI BioPharma Inc., Corvallis, OR, USA.

Su2.102 - A Multi-Level Approach to Analyzing Immune Re-Su2.102 - A Multi-Level Approach to Analyzing Immune Re-Su2.102 - A Multi-Level Approach to Analyzing Immune Re-Su2.102 - A Multi-Level Approach to Analyzing Immune Re-Su2.102 - A Multi-Level Approach to Analyzing Immune Re-sponses in Tsponses in Tsponses in Tsponses in Tsponses in Targeted Cells by Combining Cytomic andargeted Cells by Combining Cytomic andargeted Cells by Combining Cytomic andargeted Cells by Combining Cytomic andargeted Cells by Combining Cytomic andProteomic TProteomic TProteomic TProteomic TProteomic Techniques of Cell Sorechniques of Cell Sorechniques of Cell Sorechniques of Cell Sorechniques of Cell Sorting and Protein Fraction-ting and Protein Fraction-ting and Protein Fraction-ting and Protein Fraction-ting and Protein Fraction-ation.ation.ation.ation.ation.S. D’Costa,1 E. Betgovargez,1 C. Snow,1 M. Simonian.1 1Bio-medical Research Division, Beckman Coulter Inc., Miami, FL,USA.

Su2.103 - Notch Modulation of Peripheral Immunity: A NovelSu2.103 - Notch Modulation of Peripheral Immunity: A NovelSu2.103 - Notch Modulation of Peripheral Immunity: A NovelSu2.103 - Notch Modulation of Peripheral Immunity: A NovelSu2.103 - Notch Modulation of Peripheral Immunity: A NovelApproach to Antigen-Specific ImmunotherapyApproach to Antigen-Specific ImmunotherapyApproach to Antigen-Specific ImmunotherapyApproach to Antigen-Specific ImmunotherapyApproach to Antigen-Specific Immunotherapy.....B. R. Champion,1 S. Ballantyne,1 A. Rust,1 L. Perry,1 H. Beacock-Sharp,1 C. Howard,1 L. Green,1 A. Watkins,1 R. Bartram,1 G.Martin,1 E. Briend,1 H. Harper,1 T. Tugal,1 S. Ragno,1 L. L. Young.11Discovery Research, Lorantis Ltd, Cambridge, United Kingdom.

Su2.104 - Serum Heat-Inactivation and Granulocyte PresenceSu2.104 - Serum Heat-Inactivation and Granulocyte PresenceSu2.104 - Serum Heat-Inactivation and Granulocyte PresenceSu2.104 - Serum Heat-Inactivation and Granulocyte PresenceSu2.104 - Serum Heat-Inactivation and Granulocyte PresenceExerts a Differential Effect on the Antigen-Induced Prolifera-Exerts a Differential Effect on the Antigen-Induced Prolifera-Exerts a Differential Effect on the Antigen-Induced Prolifera-Exerts a Differential Effect on the Antigen-Induced Prolifera-Exerts a Differential Effect on the Antigen-Induced Prolifera-tion of Ltion of Ltion of Ltion of Ltion of Lymphoid Subsets.ymphoid Subsets.ymphoid Subsets.ymphoid Subsets.ymphoid Subsets.N. J. Andersen,1 D. A. Lawrence.1 1Wadsworth Center, NewYork State Dept of Health, Albany, NY, USA.

Su2.105 - Provision and Integration of HLA Alleles into Sci-Su2.105 - Provision and Integration of HLA Alleles into Sci-Su2.105 - Provision and Integration of HLA Alleles into Sci-Su2.105 - Provision and Integration of HLA Alleles into Sci-Su2.105 - Provision and Integration of HLA Alleles into Sci-entific Research.entific Research.entific Research.entific Research.entific Research.S. J. Cate,1 R. Tian,1 M. Jones,1 S. Chandrasekaran,1 W. H.Hildebrand.1 1Microbiology, University of Oklahoma, OklahomaCity, OK, USA.

Su2.106 - Potassium Channels IR, Kv1.5, and Kv1.3 Are Ex-Su2.106 - Potassium Channels IR, Kv1.5, and Kv1.3 Are Ex-Su2.106 - Potassium Channels IR, Kv1.5, and Kv1.3 Are Ex-Su2.106 - Potassium Channels IR, Kv1.5, and Kv1.3 Are Ex-Su2.106 - Potassium Channels IR, Kv1.5, and Kv1.3 Are Ex-pressed on Human Dendritic Cells and Have a Functionalpressed on Human Dendritic Cells and Have a Functionalpressed on Human Dendritic Cells and Have a Functionalpressed on Human Dendritic Cells and Have a Functionalpressed on Human Dendritic Cells and Have a FunctionalRole in Maturation.Role in Maturation.Role in Maturation.Role in Maturation.Role in Maturation.K. M. Mullen,1 M. Rozycka,2 L. Hu,1 H. Rus,2 J. Graber,1 M. W.Pennington,3 D. C. Johns,4 S. I. Judge,2 P. A. Calabresi.1 1Neu-rology, Johns Hopkins University, Baltimore, MD, USA; 2Neurol-ogy, University of Maryland, Baltimore, MD, USA; 3Bachem Bio-science, Inc, King of Prussia, PA, USA; 4Neurosurgery, JohnsHopkins Hospital, Baltimore, MD, USA.

Su2.107 - Monitoring the Effects of Immuno-Modulating Thera-Su2.107 - Monitoring the Effects of Immuno-Modulating Thera-Su2.107 - Monitoring the Effects of Immuno-Modulating Thera-Su2.107 - Monitoring the Effects of Immuno-Modulating Thera-Su2.107 - Monitoring the Effects of Immuno-Modulating Thera-pies.pies.pies.pies.pies.J. B. Woodcock, J. A. Britz, D. R. Post, R. J. Kowalski.1 1ProductDevelopment, Cylex Incorporated, Columbia, MD, USA.

20052005200520052005ANNUAL MEETING

129



Su2.108 - Development of a VSu2.108 - Development of a VSu2.108 - Development of a VSu2.108 - Development of a VSu2.108 - Development of a Versatile Murine T Cell Expanderersatile Murine T Cell Expanderersatile Murine T Cell Expanderersatile Murine T Cell Expanderersatile Murine T Cell ExpanderBead: Combining Quality with PracticalityBead: Combining Quality with PracticalityBead: Combining Quality with PracticalityBead: Combining Quality with PracticalityBead: Combining Quality with Practicality.....E. Leung,1 A. Aas-Eng,2 G. Okern,2 A. M. Rasmussen,2 O.Amellem,2 A. Simonsen,2 O. A. Garden.1 1MolecularImmunoregulation Team, Dep. of Immunology, Imperial CollegeLondon, London, United Kingdom; 2Immunosystems, DynalBiotech ASA, Oslo, Norway.

Su2.109 - Characterization of Endogenously Loaded RhesusSu2.109 - Characterization of Endogenously Loaded RhesusSu2.109 - Characterization of Endogenously Loaded RhesusSu2.109 - Characterization of Endogenously Loaded RhesusSu2.109 - Characterization of Endogenously Loaded RhesusMacaque MHC Class I Peptides.Macaque MHC Class I Peptides.Macaque MHC Class I Peptides.Macaque MHC Class I Peptides.Macaque MHC Class I Peptides.A. R. Gilb,1 H. D. Hickman-Miller,1 W. Bardet,1 A. D. Luis,1 D. I.Watkins,2 K. Jackson,1 W. H. Hildebrand.1 1Microbiology andImmunology, University of Oklahoma Health Sciences Center,Oklahoma City, OK, USA; 2Wisconsin Regional Primate Center,University of Wisconsin, Madison, WI, USA.

Su2.110 - NUSE and RLE: Quality Assessment of Oligonucle-Su2.110 - NUSE and RLE: Quality Assessment of Oligonucle-Su2.110 - NUSE and RLE: Quality Assessment of Oligonucle-Su2.110 - NUSE and RLE: Quality Assessment of Oligonucle-Su2.110 - NUSE and RLE: Quality Assessment of Oligonucle-otide Microarray Data Totide Microarray Data Totide Microarray Data Totide Microarray Data Totide Microarray Data To Quantify Systemic Vo Quantify Systemic Vo Quantify Systemic Vo Quantify Systemic Vo Quantify Systemic Variation.ariation.ariation.ariation.ariation.F. Collin,1 A. L. Asare,1 S. A. Kolchinsky,1 T. P. Speed,2 V. L.Seyfert-Margolis.1 1Immune Tolerance Network, University ofCalifornia, San Francisco, Bethesda, MD, USA; 2Department ofStatistics, University of California, Berkeley, CA, USA.

Su2.111 - High Resolution HLA TSu2.111 - High Resolution HLA TSu2.111 - High Resolution HLA TSu2.111 - High Resolution HLA TSu2.111 - High Resolution HLA Typing for Vyping for Vyping for Vyping for Vyping for Vaccine and Au-accine and Au-accine and Au-accine and Au-accine and Au-toimmune Studies.toimmune Studies.toimmune Studies.toimmune Studies.toimmune Studies.R.Y. Tian,1 S. J. Cate,1 M. M. Jones,1 W. H. Hildebrand.1 1Mi-crobiology and Immunology, University of Oklahoma HealthScience Center, Oklahoma City, OK, USA.

Organ TOrgan TOrgan TOrgan TOrgan Transplantationransplantationransplantationransplantationransplantation

Su2.112 - On the Possibility of Oral TSu2.112 - On the Possibility of Oral TSu2.112 - On the Possibility of Oral TSu2.112 - On the Possibility of Oral TSu2.112 - On the Possibility of Oral Tolerance Tolerance Tolerance Tolerance Tolerance To Be Used ino Be Used ino Be Used ino Be Used ino Be Used inGraft TGraft TGraft TGraft TGraft Transplantation.ransplantation.ransplantation.ransplantation.ransplantation.Xiao-Bin Zheng. 1Research and Development, BeijingZhongbangyumin Sci-trade Company Co.Ltd., Beijing, China.

Su2.113 - Evidence for Naturally Occurring and InducedSu2.113 - Evidence for Naturally Occurring and InducedSu2.113 - Evidence for Naturally Occurring and InducedSu2.113 - Evidence for Naturally Occurring and InducedSu2.113 - Evidence for Naturally Occurring and InducedRegulatorRegulatorRegulatorRegulatorRegulatory Ty Ty Ty Ty T-Cells in Non-Human Primates.-Cells in Non-Human Primates.-Cells in Non-Human Primates.-Cells in Non-Human Primates.-Cells in Non-Human Primates.K. G. Haanstra,1 J. A.M. Wubben,1 M. Jonker.1 1Immunobiology,Biomedical Primate Research Centre, Rijswijk, ZH, Netherlands.

Su2.114 - Phenotypically and Functionally Distinct CD8+ LSu2.114 - Phenotypically and Functionally Distinct CD8+ LSu2.114 - Phenotypically and Functionally Distinct CD8+ LSu2.114 - Phenotypically and Functionally Distinct CD8+ LSu2.114 - Phenotypically and Functionally Distinct CD8+ Lym-ym-ym-ym-ym-phocyte Populations in Long-Tphocyte Populations in Long-Tphocyte Populations in Long-Tphocyte Populations in Long-Tphocyte Populations in Long-Terererererm Drug-Free Tm Drug-Free Tm Drug-Free Tm Drug-Free Tm Drug-Free Tolerance in Hu-olerance in Hu-olerance in Hu-olerance in Hu-olerance in Hu-man Kidney Graft Recipients.man Kidney Graft Recipients.man Kidney Graft Recipients.man Kidney Graft Recipients.man Kidney Graft Recipients.D. Baeten,1 S. Louis,1 C. Braud,1 C. Braudeau,1 A. Pallier,1 M.Giral,1 S. Brouard,1 J.P. Soulillou.1 1INSERM U643, ITERT,Nantes, France.

Su2.115 - Could Early Posttransplant Allosensitivity PredictSu2.115 - Could Early Posttransplant Allosensitivity PredictSu2.115 - Could Early Posttransplant Allosensitivity PredictSu2.115 - Could Early Posttransplant Allosensitivity PredictSu2.115 - Could Early Posttransplant Allosensitivity PredictPatients at High Risk for Rejection and Graft Loss in KidneyPatients at High Risk for Rejection and Graft Loss in KidneyPatients at High Risk for Rejection and Graft Loss in KidneyPatients at High Risk for Rejection and Graft Loss in KidneyPatients at High Risk for Rejection and Graft Loss in KidneyTTTTTransplantation.ransplantation.ransplantation.ransplantation.ransplantation.Petia P. Boneva,1 Anastassia P. Mihaylova,1 Daniela N.Baltadzhieva,1 Kalina L. Penkova,1 Daniela L. Jordanova,1 PepiK. Angelova,1 Elissaveta J. Naumova.1 1Central Laboratory forClinical Immunology, University Hospital Alexandrovska, Sofia,Bulgaria.

Su2.116 - Humoral and Cellular Response to Influenza VSu2.116 - Humoral and Cellular Response to Influenza VSu2.116 - Humoral and Cellular Response to Influenza VSu2.116 - Humoral and Cellular Response to Influenza VSu2.116 - Humoral and Cellular Response to Influenza Vac-ac-ac-ac-ac-cination in Human Recipients Naturally Tcination in Human Recipients Naturally Tcination in Human Recipients Naturally Tcination in Human Recipients Naturally Tcination in Human Recipients Naturally Tolerant to a Kidneyolerant to a Kidneyolerant to a Kidneyolerant to a Kidneyolerant to a KidneyAllograft.Allograft.Allograft.Allograft.Allograft.G. Roussey-Kesler,1 C. Ballet,1 J. T. Aubin,2 S. Brouard,1 J. P.Soulillou.1 1ITERT, INSERM U643, Nantes, France; 2CentreNational de Reference du Virus Influenza, Institut Pasteur, Paris,France.

Su2.117 - Pharmacodynamic Monitoring of Calcineurin In-Su2.117 - Pharmacodynamic Monitoring of Calcineurin In-Su2.117 - Pharmacodynamic Monitoring of Calcineurin In-Su2.117 - Pharmacodynamic Monitoring of Calcineurin In-Su2.117 - Pharmacodynamic Monitoring of Calcineurin In-hibitors by Quantitative Analysis of NFhibitors by Quantitative Analysis of NFhibitors by Quantitative Analysis of NFhibitors by Quantitative Analysis of NFhibitors by Quantitative Analysis of NFAAAAATTTTT-Regulated Gene Ex--Regulated Gene Ex--Regulated Gene Ex--Regulated Gene Ex--Regulated Gene Ex-pression.pression.pression.pression.pression.T. Giese,1 M. Schoels,1 T. Dengler,2 M. Zeier,3 S. Meuer.1 1Im-munology, University of Heidelberg, Heidelberg, Germany; 2Car-diology, University of Heidelberg, Heidelberg, Germany; 3Neph-rology, University of Heidelberg, Heidelberg, Germany.

Su2.118 - Profiling of “Operationally TSu2.118 - Profiling of “Operationally TSu2.118 - Profiling of “Operationally TSu2.118 - Profiling of “Operationally TSu2.118 - Profiling of “Operationally Tolerant” Kidney Re-olerant” Kidney Re-olerant” Kidney Re-olerant” Kidney Re-olerant” Kidney Re-cipients Using SELDI-TOF Mass Spectroscopycipients Using SELDI-TOF Mass Spectroscopycipients Using SELDI-TOF Mass Spectroscopycipients Using SELDI-TOF Mass Spectroscopycipients Using SELDI-TOF Mass Spectroscopy.....Christophe Braud,1 Alexandre DuPont,1 Magali Giral,1 Jean-Paul Soulillou,1 Sophie Brouard.1 1INSERM U643, ITERT-CHUHotel Dieu Nantes, Nantes, France.



Su2.119 - Mega Dose Allogeneic Hematopoietic Stem CellSu2.119 - Mega Dose Allogeneic Hematopoietic Stem CellSu2.119 - Mega Dose Allogeneic Hematopoietic Stem CellSu2.119 - Mega Dose Allogeneic Hematopoietic Stem CellSu2.119 - Mega Dose Allogeneic Hematopoietic Stem CellTTTTTransplantation, Natural Suppressor Cell Chimerism and Transplantation, Natural Suppressor Cell Chimerism and Transplantation, Natural Suppressor Cell Chimerism and Transplantation, Natural Suppressor Cell Chimerism and Transplantation, Natural Suppressor Cell Chimerism and Tol-ol-ol-ol-ol-erance in Clinic- Ahmedabad Experience.erance in Clinic- Ahmedabad Experience.erance in Clinic- Ahmedabad Experience.erance in Clinic- Ahmedabad Experience.erance in Clinic- Ahmedabad Experience.H. L. Trivedi, A. V. Vanikar, P. R. Modi, V. R. Shah, J. M. Vakil, S.I. Khemchandani, V. B. Trivedi. 1Department of TransplantationMedicine, Institute of Transplantaion Sciences and Institute ofKidney Diseases & Research Centre, Ahmedabad, Gujarat, In-dia; 2Department of Pathology, Lab Medicine and TransfusionServices and Dept. of Immunohematology, Institute ofTransplantaion Sciences and Institute of Kidney Diseases & Re-search Centre, Ahmedabad, Gujarat, India; 3Department ofUrology, Institute of Transplantaion Sciences and Institute of Kid-ney Diseases & Research Centre, Ahmedabad, Gujarat, India;4Department of Anesthesia, Institute of Transplantaion Sciencesand Institute of Kidney Diseases & Research Centre, Ahmedabad,Gujarat, India; 5Department of Transplantation Medicine, Insti-tute of Transplantaion Sciences and Institute of Kidney Diseases& Research Centre, Ahmedabad, Gujarat, India; 6Departmentof Urology, Institute of Transplantaion Sciences and Institute ofKidney Diseases & Research Centre, Ahmedabad, Gujarat, In-dia; 7Department of Pathology, Lab Medicine and TransfusionServices and Dept. of Immunohematology, Institute ofTransplantaion Sciences and Institute of Kidney Diseases & Re-search Centre, Ahmedabad, Gujarat, India.

Su2.120 - Analysis of HLA Class One Alloantibodies in theSu2.120 - Analysis of HLA Class One Alloantibodies in theSu2.120 - Analysis of HLA Class One Alloantibodies in theSu2.120 - Analysis of HLA Class One Alloantibodies in theSu2.120 - Analysis of HLA Class One Alloantibodies in theSera of Sensitized Patients on Hemodialisis.Sera of Sensitized Patients on Hemodialisis.Sera of Sensitized Patients on Hemodialisis.Sera of Sensitized Patients on Hemodialisis.Sera of Sensitized Patients on Hemodialisis.Minoo K. Adib,1 Edna Abkarshahnazar.2 1Immunology, Medi-cal School, Isfahan, Isfahan, Islamic Republic of Iran; 2Immunol-ogy, Medical School., Isfahan, Isfahan, Islamic Republic of Iran.

Su2.121 - IgG Monitoring Can Predict the Development ofSu2.121 - IgG Monitoring Can Predict the Development ofSu2.121 - IgG Monitoring Can Predict the Development ofSu2.121 - IgG Monitoring Can Predict the Development ofSu2.121 - IgG Monitoring Can Predict the Development ofInfection in HearInfection in HearInfection in HearInfection in HearInfection in Heart Tt Tt Tt Tt Transplantation.ransplantation.ransplantation.ransplantation.ransplantation.E. Sarmiento,1 J.J. Rodriguez-Molina,1 J. Fernandez-Yanez,2 J.Palomo,2 P. Munoz,3 E. Fernandez-Cruz,4 E. Bouza,1 J. Carbone.11Immunology Department, University Hospital GregorioMaranon, Madrid, Spain; 2Cardiology Department, UniversityHospital Gregorio Maranon, Madrid, Spain; 3MicrobiologyDepartment, University Hospital Gregorio Maranon, Madrid,Spain.

Su2.122 - New Insights in Mechanisms of Action of DifferentSu2.122 - New Insights in Mechanisms of Action of DifferentSu2.122 - New Insights in Mechanisms of Action of DifferentSu2.122 - New Insights in Mechanisms of Action of DifferentSu2.122 - New Insights in Mechanisms of Action of DifferentImmunosuppressive Drug Therapies by Assessing the Phar-Immunosuppressive Drug Therapies by Assessing the Phar-Immunosuppressive Drug Therapies by Assessing the Phar-Immunosuppressive Drug Therapies by Assessing the Phar-Immunosuppressive Drug Therapies by Assessing the Phar-macodynamics in Hearmacodynamics in Hearmacodynamics in Hearmacodynamics in Hearmacodynamics in Heart Tt Tt Tt Tt Transplant Recipients.ransplant Recipients.ransplant Recipients.ransplant Recipients.ransplant Recipients.M. J. Barten,1 A. Rahmel,1 M. Richter,1 J. Garbade,1 H. B. Bittner,1S. Dhein,1 F. W. Mohr,1 J. F. Gummert.1 1Cardiac Surgery, Uni-versity Leipzig, Heart Center Leipzig, Leipzig, Germany.

Su2.123 - Assessment of Peripheral Blood Dendritic Cell Sub-Su2.123 - Assessment of Peripheral Blood Dendritic Cell Sub-Su2.123 - Assessment of Peripheral Blood Dendritic Cell Sub-Su2.123 - Assessment of Peripheral Blood Dendritic Cell Sub-Su2.123 - Assessment of Peripheral Blood Dendritic Cell Sub-sets and Their Functions Tsets and Their Functions Tsets and Their Functions Tsets and Their Functions Tsets and Their Functions To Monitor Immunosuppression af-o Monitor Immunosuppression af-o Monitor Immunosuppression af-o Monitor Immunosuppression af-o Monitor Immunosuppression af-ter Hearter Hearter Hearter Hearter Heart Tt Tt Tt Tt Transplantation.ransplantation.ransplantation.ransplantation.ransplantation.M. J. Barten,1 A. Rahmel,1 M. Richter,1 J. Garbade,1 H. B. Bittner,1S. Dhein,1 F. W. Mohr,1 J. F. Gummert.1 1Cardiac Surgery, Uni-versity Leipzig, Heart Center Leipzig, Leipzig, Germany.

Su2.124 - T Helper Cells Produced Increased IL-6 and TNF-Su2.124 - T Helper Cells Produced Increased IL-6 and TNF-Su2.124 - T Helper Cells Produced Increased IL-6 and TNF-Su2.124 - T Helper Cells Produced Increased IL-6 and TNF-Su2.124 - T Helper Cells Produced Increased IL-6 and TNF-αααααLevels in Human HearLevels in Human HearLevels in Human HearLevels in Human HearLevels in Human Heart Tt Tt Tt Tt Transplant Recipients.ransplant Recipients.ransplant Recipients.ransplant Recipients.ransplant Recipients.M. J. Barten,1 A. Rahmel,1 M. Richter,1 J. Garbade,1 H. B. Bittner,1S. Dhein,1 F. W. Mohr,1 J. F. Gummert.1 1Cardiac Surgery, Uni-versity Leipzig, Heart Center Leipzig, Leipzig, Germany.

Su2.125 - The Expression of SurSu2.125 - The Expression of SurSu2.125 - The Expression of SurSu2.125 - The Expression of SurSu2.125 - The Expression of Survivin in T Cells and Its Pos-vivin in T Cells and Its Pos-vivin in T Cells and Its Pos-vivin in T Cells and Its Pos-vivin in T Cells and Its Pos-sible Significance.sible Significance.sible Significance.sible Significance.sible Significance.Ning Zeng, Bicheng Chen, Zhonghua Klause Chen, Li Tang,Shang Chang, Dunfeng Du. 1Key Laboratory of Organ Trans-plantation Ministry of Education, Key Laboratory of Organ Trans-plantation Ministry of Health, Institute of Organ TransplantationTongji Hospital, Wuhan, Hu Bei, China.

Su2.126 - Anti-CD132 Monoclonal Antibodies Inducing Acti-Su2.126 - Anti-CD132 Monoclonal Antibodies Inducing Acti-Su2.126 - Anti-CD132 Monoclonal Antibodies Inducing Acti-Su2.126 - Anti-CD132 Monoclonal Antibodies Inducing Acti-Su2.126 - Anti-CD132 Monoclonal Antibodies Inducing Acti-vated T Cells Apoptosis after Alloantigen Stimulation.vated T Cells Apoptosis after Alloantigen Stimulation.vated T Cells Apoptosis after Alloantigen Stimulation.vated T Cells Apoptosis after Alloantigen Stimulation.vated T Cells Apoptosis after Alloantigen Stimulation.Fu-li Xiang,1 Chang Sheng,1 Bicheng Chen,1 Dunfeng Du,1

Zhonghua Clause Chen.1 1Organ Transplantation, Tongji Hos-pital, Tongji Medical College, HUST, Wuhan, Hubei, China.

Su2.127 - Cytomegalovirus-Specific CD4 TSu2.127 - Cytomegalovirus-Specific CD4 TSu2.127 - Cytomegalovirus-Specific CD4 TSu2.127 - Cytomegalovirus-Specific CD4 TSu2.127 - Cytomegalovirus-Specific CD4 T-Cell Immunity Is-Cell Immunity Is-Cell Immunity Is-Cell Immunity Is-Cell Immunity IsAssociated with Protection from Human Cardiac AllograftAssociated with Protection from Human Cardiac AllograftAssociated with Protection from Human Cardiac AllograftAssociated with Protection from Human Cardiac AllograftAssociated with Protection from Human Cardiac AllograftRejection and Negative CoronarRejection and Negative CoronarRejection and Negative CoronarRejection and Negative CoronarRejection and Negative Coronary-Ary-Ary-Ary-Ary-Artertertertertery Remodeling.y Remodeling.y Remodeling.y Remodeling.y Remodeling.W. Tu,1 L. Potena,2 P. Stepick-Biek,1 L. Liu,1 K. Y. Dionis,1 L.Bashyam,3 W. Fearon,2 H. A. Valantine,2 E. S. Mocarski,3 D. B.Lewis.1 1Department of Pediatrics, Stanford University School ofMedicine, Stanford, CA, USA; 2Department of Medicine, StanfordUniversity School of Medicine, Stanford, CA, USA; 3Deaprtmentof Microbiology and Immunology, Stanford University School ofMedicine, Stanford, CA, USA.

20052005200520052005ANNUAL MEETING

131



Su2.128 - Immunological Evaluation of LSu2.128 - Immunological Evaluation of LSu2.128 - Immunological Evaluation of LSu2.128 - Immunological Evaluation of LSu2.128 - Immunological Evaluation of Lymphocyte Activa-ymphocyte Activa-ymphocyte Activa-ymphocyte Activa-ymphocyte Activa-tion, Cytokines and Apoptosis on Ttion, Cytokines and Apoptosis on Ttion, Cytokines and Apoptosis on Ttion, Cytokines and Apoptosis on Ttion, Cytokines and Apoptosis on Tacrolimus-Sirolimus-In-acrolimus-Sirolimus-In-acrolimus-Sirolimus-In-acrolimus-Sirolimus-In-acrolimus-Sirolimus-In-duced Long-Tduced Long-Tduced Long-Tduced Long-Tduced Long-Terererererm Allograft Surm Allograft Surm Allograft Surm Allograft Surm Allograft Survival in Nonhuman Primates.vival in Nonhuman Primates.vival in Nonhuman Primates.vival in Nonhuman Primates.vival in Nonhuman Primates.MA/Anlun,1 Qi/Shijie,1 Xu/Dasheng,1 Daloze/Pierre,1 Chen/Huifang.1 1Laboratory of Experimental Surgery, Research Cen-tre Hospitilier de l’University de Montreal (CHUM), Hopital Notre-Dame, Universite de Montreal, Montreal, QC, Canada.

Su2.129 - Baohuoside-1, a Novel Immunosuppressive Mol-Su2.129 - Baohuoside-1, a Novel Immunosuppressive Mol-Su2.129 - Baohuoside-1, a Novel Immunosuppressive Mol-Su2.129 - Baohuoside-1, a Novel Immunosuppressive Mol-Su2.129 - Baohuoside-1, a Novel Immunosuppressive Mol-ecule, Inhibits Lecule, Inhibits Lecule, Inhibits Lecule, Inhibits Lecule, Inhibits Lymphocyte Activation ymphocyte Activation ymphocyte Activation ymphocyte Activation ymphocyte Activation In VIn VIn VIn VIn Vitroitroitroitroitro and and and and and In VIn VIn VIn VIn Vivoivoivoivoivo.....MA/Anlun,1 Qi/Shijie,1 Xu/Dasheng,1 Daloze/Pierre,1 Chen/Huifang.1 1CHUM, Notre-Dame Hospital, University of Montreal,Montreal, QC, Canada.

Su2.130 - Cellular Reactivity to Human Hsp60 in Murine SkinSu2.130 - Cellular Reactivity to Human Hsp60 in Murine SkinSu2.130 - Cellular Reactivity to Human Hsp60 in Murine SkinSu2.130 - Cellular Reactivity to Human Hsp60 in Murine SkinSu2.130 - Cellular Reactivity to Human Hsp60 in Murine Skinand Hearand Hearand Hearand Hearand Heart Tt Tt Tt Tt Transplantation.ransplantation.ransplantation.ransplantation.ransplantation.Veronica Coelho,1,2,3 Ernesto Luna,1,2 Luiz A. Benvenuti,1 Luiz R.Mundel,1 Valquiria Bueno,4 Leo K. Iwai,1 Cristina Caldas,1 JorgeKalil.1,2,3 1Heart Institute (Incor), University of Sao Paulo, SaoPaulo, Sao Paulo, Brazil; 2Division of Allergy and Clinical Im-munology, Internal Medicine Department, University of Sao Paulo,Sao Paulo, Sao Paulo, Brazil; 3Institute for Investigation in Immu-nology-Millenium Institute, CNPq, Brazil; 4Nephrology Division,Department of Medicine, Paulista School of Medicine, PaulistaSchool of Medicine UNIFESP, Sao Paulo, Sao Paulo, Brazil.

Su2.131 - Evaluation of Skin Graft SurSu2.131 - Evaluation of Skin Graft SurSu2.131 - Evaluation of Skin Graft SurSu2.131 - Evaluation of Skin Graft SurSu2.131 - Evaluation of Skin Graft Survival Using the Encap-vival Using the Encap-vival Using the Encap-vival Using the Encap-vival Using the Encap-sulated Hsp60 Peptide (p277) in a Murine Model of Minorsulated Hsp60 Peptide (p277) in a Murine Model of Minorsulated Hsp60 Peptide (p277) in a Murine Model of Minorsulated Hsp60 Peptide (p277) in a Murine Model of Minorsulated Hsp60 Peptide (p277) in a Murine Model of MinorAntigen Disparities.Antigen Disparities.Antigen Disparities.Antigen Disparities.Antigen Disparities.Ernesto Luna,1,2 Edilberto Postol,1 Luiz A. Benvenuti,1 Jose M.Rodrigues,4 Karla M. Lima,4 Cristina Caldas,1 Jorge Kalil,1,2,3

Veronica Coelho.1,2,3 1Heart Institute (Incor), University of SaoPaulo, Sao Paulo, Sao Paulo, Brazil; 2Division of Allergy andClinical Immunology, Dep.Internal Medicine, University of SaoPaulo, Sao Paulo, Sao Paulo, Brazil; 3Institute for Investigationin Immunology, Millenium-Institute, Brazil; 4Center for Tuberculo-sis Research, School of Medicine of Ribeirao Preto, RibeiraoPreto, Sao Paulo, Brazil.

Su2.132 - The Role of Indoleamine 2,3-Dioxygenase (IDO) inSu2.132 - The Role of Indoleamine 2,3-Dioxygenase (IDO) inSu2.132 - The Role of Indoleamine 2,3-Dioxygenase (IDO) inSu2.132 - The Role of Indoleamine 2,3-Dioxygenase (IDO) inSu2.132 - The Role of Indoleamine 2,3-Dioxygenase (IDO) ina Murine CTLA4Ig-Based Mixed Chimerism Model.a Murine CTLA4Ig-Based Mixed Chimerism Model.a Murine CTLA4Ig-Based Mixed Chimerism Model.a Murine CTLA4Ig-Based Mixed Chimerism Model.a Murine CTLA4Ig-Based Mixed Chimerism Model.I. Pree,1 S. Bigenzahn,1 P. Nierlich,1 Z. Koporc,1 P. Blaha,1 F.Langer,1 E. Selzer,2 D. Fuchs,3 C. Winkler,3 G. Brandacher,4 M.Sykes,5 F. Muehlbacher,1 T. Wekerle.1 1Dept. of Surgery, Div. ofTransplantation, Medical University of Vienna; 2Dept. of Radio-therapy and Radiobiology, Vienna Gernal Hospital; 3Inst. ofMedical Chemistry and Biochemistry; 4Dept. of General andTransplant Surgery, University of Innsbruck, Austria; 5Transplan-tation Biology Research Center, MGH/Harvard Medical School,Boston, USA.

Su2.133 - Evaluation of Su2.133 - Evaluation of Su2.133 - Evaluation of Su2.133 - Evaluation of Su2.133 - Evaluation of ImmuknowImmuknowImmuknowImmuknowImmuknow-Immune Cell Function As--Immune Cell Function As--Immune Cell Function As--Immune Cell Function As--Immune Cell Function As-say as a New Parameter of Net State of Immunosuppresionsay as a New Parameter of Net State of Immunosuppresionsay as a New Parameter of Net State of Immunosuppresionsay as a New Parameter of Net State of Immunosuppresionsay as a New Parameter of Net State of Immunosuppresionin Monitoring Renal Tin Monitoring Renal Tin Monitoring Renal Tin Monitoring Renal Tin Monitoring Renal Transplant Recipients.ransplant Recipients.ransplant Recipients.ransplant Recipients.ransplant Recipients.Alex Yussim,1 Moshe Israeli,2 Eytan Mor,1 Dan Krest,2 Tirza Klein.21Department of Transplantation, Research Unit, Rabin MedicalCentre, Affil. to Tel Aviv University School of Medicine, PetachTikva, Israel; 2Tissue Typing Laboratory.

Su2.134 - CD80 but Not CD86 CostimulatorSu2.134 - CD80 but Not CD86 CostimulatorSu2.134 - CD80 but Not CD86 CostimulatorSu2.134 - CD80 but Not CD86 CostimulatorSu2.134 - CD80 but Not CD86 Costimulatory Molecules Sup-y Molecules Sup-y Molecules Sup-y Molecules Sup-y Molecules Sup-presses Xenogeneic Humoral Rejection by Regulation ofpresses Xenogeneic Humoral Rejection by Regulation ofpresses Xenogeneic Humoral Rejection by Regulation ofpresses Xenogeneic Humoral Rejection by Regulation ofpresses Xenogeneic Humoral Rejection by Regulation ofComplement C3dg Generation.Complement C3dg Generation.Complement C3dg Generation.Complement C3dg Generation.Complement C3dg Generation.K. A. Hosiawa,1,2 H. Wang,3 B. Garcia,3 R. Zhong,2,3 D. J.Kelvin.1,2,4 1Division of Experimental Therapeutics, UniversityHealth Network-Toronto General Research Institute, Toronto, ON,Canada; 2Microbiology and Immunology, University of WesternOntario, London, ON, Canada; 3Surgery, University of WesternOntario, London, ON, Canada; 4Immunology, University ofToronto, Toronto, ON, Canada.

Su2.135 - Lack of Correlation between the Presence of Anti-Su2.135 - Lack of Correlation between the Presence of Anti-Su2.135 - Lack of Correlation between the Presence of Anti-Su2.135 - Lack of Correlation between the Presence of Anti-Su2.135 - Lack of Correlation between the Presence of Anti-Human Panel Reactive Antibodies (PRA) and Anti-Swine Non-Human Panel Reactive Antibodies (PRA) and Anti-Swine Non-Human Panel Reactive Antibodies (PRA) and Anti-Swine Non-Human Panel Reactive Antibodies (PRA) and Anti-Swine Non-Human Panel Reactive Antibodies (PRA) and Anti-Swine Non-Galactose-Galactose-Galactose-Galactose-Galactose-ααααα1,3-Galactose (NonGal) Cytotoxic Antibodies in1,3-Galactose (NonGal) Cytotoxic Antibodies in1,3-Galactose (NonGal) Cytotoxic Antibodies in1,3-Galactose (NonGal) Cytotoxic Antibodies in1,3-Galactose (NonGal) Cytotoxic Antibodies inPatients APatients APatients APatients APatients Awaiting Life-Saving Organ Twaiting Life-Saving Organ Twaiting Life-Saving Organ Twaiting Life-Saving Organ Twaiting Life-Saving Organ Transplantation.ransplantation.ransplantation.ransplantation.ransplantation.B. S. Wong,1 P. E. O’Malley,1 Y.-L. Tseng,1 F. J.M.F. Dor,1 S. L.Saidman,2 K. Yamada,1 D. H. Sachs.1 1Transplantation Biol-ogy Research Center, Massachusetts General Hospital/HarvardMedical School, Boston, MA, USA; 2Department of Pathology,Massachusetts General Hospital/Harvard Medical School, Bos-ton, MA, USA.



Su2.136 - TIRC7 Is Expressed upon Immune Activation EarlySu2.136 - TIRC7 Is Expressed upon Immune Activation EarlySu2.136 - TIRC7 Is Expressed upon Immune Activation EarlySu2.136 - TIRC7 Is Expressed upon Immune Activation EarlySu2.136 - TIRC7 Is Expressed upon Immune Activation Earlyin Peripheral Blood Lin Peripheral Blood Lin Peripheral Blood Lin Peripheral Blood Lin Peripheral Blood Lymphocytes and Remains Induced in In-ymphocytes and Remains Induced in In-ymphocytes and Remains Induced in In-ymphocytes and Remains Induced in In-ymphocytes and Remains Induced in In-flammatorflammatorflammatorflammatorflammatory Cells during Rejection after Kidney Ty Cells during Rejection after Kidney Ty Cells during Rejection after Kidney Ty Cells during Rejection after Kidney Ty Cells during Rejection after Kidney Transplanta-ransplanta-ransplanta-ransplanta-ransplanta-tion as Wtion as Wtion as Wtion as Wtion as Well as in Joints from Patients with Established Rheu-ell as in Joints from Patients with Established Rheu-ell as in Joints from Patients with Established Rheu-ell as in Joints from Patients with Established Rheu-ell as in Joints from Patients with Established Rheu-matoid Arthritis.matoid Arthritis.matoid Arthritis.matoid Arthritis.matoid Arthritis.S. G. Tullius,1 H. D. Volk,2 A. Tamura,2,3 M. Winter,2 P. Fraser,5

R. S. Blumberg,5 N. Utku.2,4 1Department of General and Trans-plantation Surgery, Charite-Campus Virchow Clinic, Humboldt-University, Berlin, Germany; 2Institute of Medical Immunology,Humboldt-University of Berlin, Berlin, Germany; 3School of Medi-cine, Keio University, Tokyo, Japan; 4GenPat77 Pharmacoge-netics AG, Berlin, Germany; 5Department of Medicine, Rheu-matology and Gastroenterology, Brigham and Women’s Hospi-tal, Harvard Medical School, Boston, MA, USA.

Su2.137 - Peripheral and Graft Infiltrating T Cell ResponsesSu2.137 - Peripheral and Graft Infiltrating T Cell ResponsesSu2.137 - Peripheral and Graft Infiltrating T Cell ResponsesSu2.137 - Peripheral and Graft Infiltrating T Cell ResponsesSu2.137 - Peripheral and Graft Infiltrating T Cell Responsesto Self Heat Shock Protein 60 in Renal Tto Self Heat Shock Protein 60 in Renal Tto Self Heat Shock Protein 60 in Renal Tto Self Heat Shock Protein 60 in Renal Tto Self Heat Shock Protein 60 in Renal Transplant Patients.ransplant Patients.ransplant Patients.ransplant Patients.ransplant Patients.C. Caldas,1 M. Spadafora-Ferreira,1 S. E. Oshiro,1 J. A. Fonseca,2E. Luna,1,5 P. L. Ho,3 J. Kalil,1,4,5 V. Coelho.1,4,5 1Heart Institute(InCor), University of Sao Paulo Medical School; 2Renal Trans-plantation Unit, University of Sao Paulo Medical School;3Butantan Institute; 4Institute for Investigation in Immunology-Millenium Institute; 5Clinical Immunology and Allergy,Departament of Clinical Medicine, University of Sao Paulo Medi-cal School, Sao Paulo, SP, Brazil.

20052005200520052005ANNUAL MEETING

133


PLEASE NOTE:PLEASE NOTE:PLEASE NOTE:PLEASE NOTE:PLEASE NOTE: that this information willbe used to issue CME certificates. Yourname will be printed on your certificate theway it appears in this box.

CME Self-ReporterCME Self-ReporterCME Self-ReporterCME Self-ReporterCME Self-Reporter

SELF-REPORTING SYSTEM:SELF-REPORTING SYSTEM:SELF-REPORTING SYSTEM:SELF-REPORTING SYSTEM:SELF-REPORTING SYSTEM:The 5th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS) will offerContinuing Medical Education (CME) credits for physicians jointly sponsored by the Clinical Immu-nology Society (CIS) and FOCIS. Please note that not all FOCIS sessions and activities offer CMEcredit. The amount of credit offered for each session is included on the back of this form. Pleasecircle the corresponding CME credits (other side) and total at the bottom of the CME form.Base credit will not be offered at the FOCIS meeting. Each delegate will be required to completethis Self-Reporter Form in order to receive a certificate of credit. This form lists all sessions offeredfor credit, as well as the amount of credit available per session from the Clinical ImmunologySociety (CIS) and FOCIS.

PLEASE FOLLOW THESE INSTRUCTIONS TO RECEIVE YOUR CERPLEASE FOLLOW THESE INSTRUCTIONS TO RECEIVE YOUR CERPLEASE FOLLOW THESE INSTRUCTIONS TO RECEIVE YOUR CERPLEASE FOLLOW THESE INSTRUCTIONS TO RECEIVE YOUR CERPLEASE FOLLOW THESE INSTRUCTIONS TO RECEIVE YOUR CERTIFICATIFICATIFICATIFICATIFICATE OF CREDITTE OF CREDITTE OF CREDITTE OF CREDITTE OF CREDIT:::::1. Complete this Self-Report Form, tear it out of the final meeting program and return it to the

FOCIS Information Booth, 3rd floor of the Westin Copley Place. Certificates will be issued onlyupon completion of this form.

OR

2. Mail your completed Self-Report Form to the FOCIS office(555 East Wells Street, Suite 1100, Milwaukee, WI 53202)

3. Please print your name and address in the box below:

4. Please transfer the TOTAL NUMBER OF CME CREDITS from the bottom of the other side to thespace below.

________________________ TOTTOTTOTTOTTOTAL CME CREDITSAL CME CREDITSAL CME CREDITSAL CME CREDITSAL CME CREDITS

5. Signature: ____________________________________________ Date: ________________

*PLEASE NOTE: *PLEASE NOTE: *PLEASE NOTE: *PLEASE NOTE: *PLEASE NOTE: Delegates must complete this Self-Report Form in order to receive their certificateof credit for the 5th Annual Meeting of the Federation of Clinical Immunology Societies. Delegatesnot completing this form will not be issued a certificate.


134

THURSDATHURSDATHURSDATHURSDATHURSDAYYYYY, MA, MA, MA, MA, MAY 11, 2005Y 11, 2005Y 11, 2005Y 11, 2005Y 11, 2005 CREDITS CREDITS CREDITS CREDITS CREDITSSociety Satellite SessionsSociety Satellite SessionsSociety Satellite SessionsSociety Satellite SessionsSociety Satellite Sessions8:30am-12:30 pmCIS: Emerging Lab Technologies ......................................... 4

8:00am-5:00 pmCIS: Primary Immune Deficiency Disease Conference ............ 8

8:00am-5:00 pmFOCIS: Basic Immunology for Clinicians: Update 2005 ........ 8

FRIDAFRIDAFRIDAFRIDAFRIDAYYYYY, MA, MA, MA, MA, MAY 13, 2005Y 13, 2005Y 13, 2005Y 13, 2005Y 13, 2005Plenary SessionPlenary SessionPlenary SessionPlenary SessionPlenary Session8:30-10:00 amRegulation of T Cell and Differentiation ............................. 1.5

Thematic SymposiaThematic SymposiaThematic SymposiaThematic SymposiaThematic Symposia10:30 am-12:30 pm ................................................................Regulatory T Cells in Transplant and Autoimmunity ............... 2 FCR and Complement ........................................................ 2 Dendritic Cells .................................................................. 2 Antibodies in Disease Pathogensis and Therapy .................... 2

Industry SymposiumIndustry SymposiumIndustry SymposiumIndustry SymposiumIndustry Symposium1:30-3:00 pmBiogen IDEC Symposium: ................................................ 1.5

Concurrent Oral Abstract SessionsConcurrent Oral Abstract SessionsConcurrent Oral Abstract SessionsConcurrent Oral Abstract SessionsConcurrent Oral Abstract Sessions3:30-5:30 pmAntibodies and B Cells ...................................................... 2 Innate Immune System Regulating Disease ............................ 2 T Regs and Regulations of Immunes Responses ..................... 2 New Pathways of Immune Regulation .................................. 2 NK and NKT Cells ............................................................ 2

SASASASASATURDATURDATURDATURDATURDAYYYYY, MA, MA, MA, MA, MAY 14, 2005Y 14, 2005Y 14, 2005Y 14, 2005Y 14, 2005Plenary SessionPlenary SessionPlenary SessionPlenary SessionPlenary Session8:30-10:00 amGenetics and Gene Therapy ............................................ 1.5

Thematic SymposiaThematic SymposiaThematic SymposiaThematic SymposiaThematic Symposia10:30 am-12:30 pmGenetics of Immune Mediated Diseases & Transplantation ..... 2 TLR, NK, Innate Immunity ................................................... 2 Immunodysregulation and Immunoreconstitution .................... 2 Disease Regulation: Role of Antigens, Cytokines, Chemokines 2

Industry SymposiumIndustry SymposiumIndustry SymposiumIndustry SymposiumIndustry Symposium1:30-3:00 pmCentocor Symposium: ..................................................... 1.5

Oral Abstract SessionsOral Abstract SessionsOral Abstract SessionsOral Abstract SessionsOral Abstract Sessions3:30-5:30 pmGenetics and Genomics ..................................................... 2 Immunodiagnosis ............................................................... 2 Tolerance ......................................................................... 2 Dendritic Cells and Regulation of Disease ............................ 2 Immunodeficiency .............................................................. 2

SUNDASUNDASUNDASUNDASUNDAYYYYY, MA, MA, MA, MA, MAY 15, 2005Y 15, 2005Y 15, 2005Y 15, 2005Y 15, 2005 CREDITS CREDITS CREDITS CREDITS CREDITSPlenary SessionPlenary SessionPlenary SessionPlenary SessionPlenary Session8:30-10:00amTracking Pathogenic & Therapeutic Immune Responses ....... 1.5

Thematic SymposiaThematic SymposiaThematic SymposiaThematic SymposiaThematic Symposia10:30 am-12:30 pmIn Vivo Imaging ................................................................ 2 Costimulation and Tolerance .............................................. 2 Mast Cell, Eosinophils, Allergic Reactions ........................... 2 Living with the Bugs: Good or Bad ..................................... 2

Industry SymposiumIndustry SymposiumIndustry SymposiumIndustry SymposiumIndustry Symposium1:30-3:00 pmGenentech Symposium .................................................... 1.5

Oral Abstract SessionsOral Abstract SessionsOral Abstract SessionsOral Abstract SessionsOral Abstract Sessions3:30-5:30 pmNew Animal Models: Defining Antigens Recognition by Animal Models .............. 2 Costimulation .................................................................... 2 Immunotherapy .................................................................. 2 Trafficking and Adhesion .................................................... 2 Cytokine Mediated Immunoregulation .................................. 2

MONDAMONDAMONDAMONDAMONDAYYYYY, MA, MA, MA, MA, MAY 16, 2005Y 16, 2005Y 16, 2005Y 16, 2005Y 16, 2005Plenary SessionPlenary SessionPlenary SessionPlenary SessionPlenary Session8:30-10:00amGenetics and Genomics .................................................. 1.5

Thematic SymposiaThematic SymposiaThematic SymposiaThematic SymposiaThematic Symposia10:30am-12:30 pmTherapeutic Vaccines ......................................................... 2 Development of Immune-Based Therapeutics ......................... 2 Roles of Interferons in Defense and Disease .......................... 2 Immunodiagnostic Disease Predictors .................................. 2

TOTTOTTOTTOTTOTAL CREDITSAL CREDITSAL CREDITSAL CREDITSAL CREDITS (T(T(T(T(Transfer Credits to Forransfer Credits to Forransfer Credits to Forransfer Credits to Forransfer Credits to Form on Page): m on Page): m on Page): m on Page): m on Page): _____________________________________________

NOTESNOTESNOTESNOTESNOTES

Take your research to the next level.

Discover how Beckman Coulter

helps you innovate, simplify and

automate your immune monitoring

processes. Learn more by visiting us

at booth #20, and join us for these

revolutionary Industry Tutorials:

Your ImmuneMonitoring Partner

Your ImmuneMonitoring Partner

From Epitope DiscoveryTo Patient Monitoring

From Epitope DiscoveryTo Patient Monitoring

www.beckmancoulter.com/immunomics

Advances in Immune Monitoring: A SARS Case Study

Kurtis Bray, Ph.D., Director, Research and Development, Beckman Coulter, Inc. Saturday, May 14, 7:00 a.m. – 8:00 a.m. Breakfast served.

Multiplex Serum Cytokine Analysis for Immunogenicity and Immune Competence

Meeta Patnaik, MD, Vice President, Pathway Diagnostics Saturday, May 14, 12:45 p.m. – 1:45 p.m. Lunch served.

Monitoring Vaccine Response: Standardization of Functional Cell Assays

Enrique Rabellino, MD, Medical Officer, Beckman Coulter, Inc.Sunday, May 15, 7:00 a.m. – 8:00 a.m. Breakfast Served.

Visit us at booth #20!

focis program may 2005

Documents